{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Read the csv file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import re\n",
    "from tqdm import tqdm\n",
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "import pickle\n",
    "import torch"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "> This is for initial analysis you can go to \"Process stage 1 results and go to stage 2.\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "csv_file_name = 'elasticsearch_files/test_yn_large_mod_which_scispacy.csv' \n",
    "trials_df = pd.read_csv(csv_file_name, \n",
    "                 dtype={'#ncd_id':str, \n",
    "                        'title':str, \n",
    "                        'has_us_facility':bool, \n",
    "                        'conditions': str, \n",
    "                        'eligibility_criteria': str, \n",
    "                        'gender':str, \n",
    "                        'minimum_age':str, \n",
    "                        'maximum_age':str},\n",
    "                 )\n",
    "\n",
    "trials_df = trials_df.rename(columns={'#ncd_id':'nct_id'})\n",
    "trials_df.index = trials_df.iloc[:,0] # index by nct_icds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total clinical trials: 451538\n"
     ]
    }
   ],
   "source": [
    "print(f'Total clinical trials: {len(trials_df)}')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Index(['nct_id', 'title', 'has_us_facility', 'conditions',\n",
      "       'eligibility_criteria', 'gender', 'minimum_age', 'maximum_age', 'no',\n",
      "       'yes'],\n",
      "      dtype='object')\n"
     ]
    }
   ],
   "source": [
    "print(trials_df.columns)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Stage 1 Results (used to get stub results for stage 2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "disorders_cui = [{\n",
    "    'condition': 'rheumatoid arthritis', # topic 26-30\n",
    "    'condition_cui': 'C0003873'}]\n",
    "\n",
    "def compile_queries_for_stage_1_ranking():\n",
    "    \"\"\"return trials if disorder present in both the 'condition' column and disorder CUI in 'yes'  \n",
    "    i.e. (negated concept in exclusion + concept in inclusion)\n",
    "    \n",
    "    returns: Tuple(condition, query)\n",
    "    \"\"\"\n",
    "\n",
    "    for item in disorders_cui:\n",
    "        yield (item['condition'], f\"yes.str.contains('{item['condition_cui']}') &  \\\n",
    "            conditions.str.lower().str.contains('{item['condition']}')\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "stage1_query_tuples = list(compile_queries_for_stage_1_ranking())\n",
    "\n",
    "def search_queries(df,query_tuples):\n",
    "    for query in query_tuples:\n",
    "        cond,q = query\n",
    "        yield {'condition':cond, 'relevant_nct_ids': df.query(q).iloc[:,0].tolist()}\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# we only have 1 query for now,\n",
    "\n",
    "results = list(search_queries(trials_df,stage1_query_tuples))\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "def itemize(criteria: str):\n",
    "    \"\"\"Split the inclusion/exclusion criteria into individual items\"\"\"\n",
    "    if criteria is None:\n",
    "        return None\n",
    "    else:\n",
    "        # Regex spliting rules:\n",
    "        # {1 or more blank space}{'-' character}{1 or 2 blank space}\n",
    "        # OR\n",
    "        # {1 or more blank space}{1 or 2 digit/letter}{'.' character}{one or more blank space}\n",
    "        items = re.split(r'\\s+-\\s{1,2}|\\s+\\w{1,2}\\.\\s+', criteria)[1:]\n",
    "        # strip leading and trailing space and remove extra spaces for each item.\n",
    "        clean_items = [re.sub('\\s+', ' ', item.strip()) for item in items]\n",
    "        return clean_items\n",
    "\n",
    "\n",
    "def itemize_criteria(eligibility: str):\n",
    "    \"\"\"Important: We assume for a trial both inclusion and exclusion are given, \n",
    "    If any trail does not include both inclusion and exclusion both it is returned as NONE.\n",
    "\n",
    "    The total number of criteria w/o inclusion and exclusion is considered to be minimal and \n",
    "    should not effect the outcome much.\n",
    "    \"\"\"\n",
    "\n",
    "    regex = 'inclusion criteria([.\\w\\W]*)exclusion criteria([.\\w\\W]*)'\n",
    "    match = re.search(regex, eligibility, flags=re.IGNORECASE)\n",
    "    inc, exc = match.groups() if match else (None, None)\n",
    "\n",
    "    return {'inclusion': itemize(inc), 'exclusion': itemize(exc)}\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_relevant_trials_inclusion_exclusion(trials_df,stage1_results):\n",
    "    for output in stage1_results:\n",
    "        \n",
    "        relevant_ids = output['relevant_nct_ids']\n",
    "        relavant_trial = trials_df.loc[relevant_ids]\n",
    "        relevant_trials = relavant_trial.apply(lambda x: {'nct_id':x.nct_id}|itemize_criteria(x.eligibility_criteria),axis=1)\n",
    "        \n",
    "        return relevant_trials.tolist()\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "expected_output_stage1 = get_relevant_trials_inclusion_exclusion(trials_df,results)\n",
    "expected_output_stage1 = list(filter(lambda x: x['inclusion'] is not None and len(x['inclusion']) > 0 ,expected_output_stage1))\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Expected output format from stage 1 of retrieval for each topic."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[{'nct_id': 'NCT04227535',\n",
       "  'inclusion': ['Age ≥18 years',\n",
       "   'RA diagnosis according to ACR (classification of rheumatoid arthritis) 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist',\n",
       "   'ILD diagnosis based on typical High-Resolution Computed-Tomography (HCRT) patterns and pulmonary function tests (PFT), validated by a senior pulmonologist Exclusion Criteria:',\n",
       "   'Lack of signed informed consent SELECTION OF CONTROLS: Inclusion Criteria:',\n",
       "   'Age ≥18 years',\n",
       "   'RA diagnosis according to ACR 1987 and/or ACR/EULAR 2010 criteria, validated by a senior rheumatologist'],\n",
       "  'exclusion': ['Lack of signed informed consent']},\n",
       " {'nct_id': 'NCT04226131',\n",
       "  'inclusion': ['Rheumatoid arthritis participants will all be seropositive (positive rheumatoid factor or anti-citrullinated protein antibody) or with erosions typical of RA on radiographs.',\n",
       "   'Meet 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria for',\n",
       "   '- Early RA defined as duration of disease/symptoms of less than 6 months (where \"duration\" denotes the length of time the patient has had symptoms/disease, not the length of time since RA diagnosis) AND prior to starting biologic DMARD therapy.',\n",
       "   'Participants will not be engaging in regular exercise (According to 2018 US guidelines): not more than 150 minutes per week of moderate intensity exercise or 75 minutes per week of vigorous intensity exercise) for at least three months prior to consent.'],\n",
       "  'exclusion': ['Early RA participants will be excluded if they have already started bDMARD therapy.',\n",
       "   'The investigators will exclude persons using non-aspirin anticoagulants that would complicate the biopsy. There will be a wash-out period of seven days for anti-platelet agents, and three days for NSAIDs prior to biopsies.',\n",
       "   'Uncontrolled thyroid diseases',\n",
       "   'Chronic obstructive lung disease',\n",
       "   \"Parkinson's disease\",\n",
       "   'Ankylosing spondylitis',\n",
       "   'Congestive Heart Failure Class III and above will be excluded based on recognized effects on skeletal muscle.',\n",
       "   'Patients with absolute or relative contraindications to exercise will be excluded: recent (<6 months) acute cardiac event, unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism or acute systemic infection, left main coronary stenosis, moderate stenotic valvular heart disease, outflow tract obstruction, high degree atrioventricular (AV) block, ventricular aneurysm.',\n",
       "   'Uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis, myxoedema)',\n",
       "   'Uncontrolled pulmonary disease (e.g. severe COPD or pulmonary fibrosis)',\n",
       "   'Mental or physical impairment leading to inability to exercise adequately',\n",
       "   'Pregnant women will be excluded as determined via menstrual history/self-reporting.']},\n",
       " {'nct_id': 'NCT04222920',\n",
       "  'inclusion': ['Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010',\n",
       "   'Treated for at least 28 weeks with adalimumab',\n",
       "   'Adalimumab trough concentration >5mg/L',\n",
       "   'Who has agreed to participate (written informed consent);',\n",
       "   'Age 18 years or older.'],\n",
       "  'exclusion': ['scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation',\n",
       "   'life expectancy shorter than follow-up period of the study;',\n",
       "   'other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease']},\n",
       " {'nct_id': 'NCT04227366',\n",
       "  'inclusion': ['Signed informed consent form (ICF).',\n",
       "   'Men and women aged 18 years or older on the day of signing the ICF.',\n",
       "   'Verified rheumatoid arthritis according to the ACR 2010 criteria diagnosed at least 24 weeks before signing the ICF .',\n",
       "   'Use of methotrexate for the last 12 weeks before signing the ICF.',\n",
       "   'Use of a stable dose of methotrexate for the last 4 weeks before signing the ICF (the dose of methotrexate should be 15 to 25 mg per week). Methotrexate can be used at a dose of 10 mg in the case of intolerability/toxicity of higher doses.',\n",
       "   'Inefficacy of methotrexate used for the last 12 weeks before signing the ICF (in the opinion of the Investigator).',\n",
       "   'Active rheumatoid arthritis at randomization in the study.',\n",
       "   \"The ability of the patient (in the Investigator's opinion) to follow the Protocol procedures.\",\n",
       "   'Patients and their sexual partners of childbearing potential agree to use reliable contraceptive methods starting from signing the ICF, during the study and for 8 weeks from the last injection of the investigational product. This requirement does not apply to patients and their partners who underwent surgical sterilization and to women who are post-menopausal for at least 2 years. Reliable contraceptive methods include one barrier method in combination with one of the following: spermicides, intrauterine device/oral contraceptives.'],\n",
       "  'exclusion': ['Previous exposure to tocilizumab or other anti-IL6 or anti-IL-6R monoclonal antibodies.',\n",
       "   'Previous exposure to JAK inhibitors.',\n",
       "   'Previous exposure to rituximab or other B-cell depleting/suppressing agents.',\n",
       "   \"Felty's syndrome (regardless of clinical form).\",\n",
       "   \"Patient's functional status: class IV according to the ACR 1991 classification.\",\n",
       "   'Known allergy to or intolerance of any ingredients of BCD-089 or placebo.',\n",
       "   'Use of any of the following concomitant therapies:',\n",
       "   'Oral prednisolone or its equivalent in a dose more than 10 mg/day;',\n",
       "   'Need in oral prednisolone (or its equivalent) ≤ 10 mg if its dose was not stable during the last 4 weeks before signing the ICF (patients who used topical glucocorticoids are allowed to participate in the study);',\n",
       "   'Need in NSAIDs if the dose was not stable during the last 4 weeks before signing the ICF (patients who have occasionally used NSAIDs for fever or allergy syndrome associated with an intercurrent disease can be included in the study);',\n",
       "   'Use of alkylating agents any time within 12 months before signing the ICF.',\n",
       "   'Intra-articular use of corticosteroids within 4 weeks before signing the ICF.',\n",
       "   'Vaccination with live or attenuated vaccines any time within 8 weeks before signing the ICF.',\n",
       "   'Use of leflunomide within 8 weeks before signing the ICF.',\n",
       "   'Use of TNFα inhibitors or T-cell costimulation blockers within 8 weeks before signing the ICF.',\n",
       "   'Any of the following laboratory values at screening:',\n",
       "   'Hemoglobin level < 80 g/L;',\n",
       "   'Leukocyte count < 3.0 × 109/L;',\n",
       "   'Platelet count < 100 × 109/L;',\n",
       "   'Neutrophil count < 2 × 109/L;',\n",
       "   'AST and ALT ≥ 1.5×ULN (based on the reference limits used by the laboratory);',\n",
       "   'Serum creatinine ≥ 1.7 × ULN (based on the reference limits used by the laboratory).',\n",
       "   'Positive pregnancy urine test in female subjects at screening (no test is required in women who are post-menopausal for at least 2 years and in surgically sterile women).',\n",
       "   'Current diagnosis or a history of a severe immunodeficiency of any other origin.',\n",
       "   'Diagnosed HIV, hepatitis B, hepatitis C, or syphilis ;',\n",
       "   'Tuberculosis now or in the past.',\n",
       "   'Latent TB forms (positive Diaskintest®, QuantiFERON®-TB Gold or T-SPOT.TB test with no radiographic signs of pulmonary TB).',\n",
       "   'Herpes zoster infection now or in the past .',\n",
       "   'Documented chickenpox within 30 days before signing the ICF.',\n",
       "   \"Definite diagnosis of any other chronic infection (e.g. sepsis, invasive mycoses, histoplasmosis, etc.) that, in the Investigator's opinion, can increase the risk of infectious complications.\",\n",
       "   \"Any acute infection or aggravation of a chronic infection within 30 days before signing the ICF if this condition may, in the Investigator's opinion, increase the risk of infectious complications.\",\n",
       "   'Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF.',\n",
       "   'Systemic antibacterial/antimycotic/antiprotozoal treatments used within 8 weeks before the signing the ICF.',\n",
       "   'More than 4 episodes of respiratory infections within 6 months before signing the ICF.',\n",
       "   'A major surgery within 30 days before signing the ICF or a major surgery scheduled at any time during the study.',\n",
       "   'History of epileptic attacks or seizures.',\n",
       "   'History of severe depression, suicidal thoughts or suicide attempts .',\n",
       "   'Diverticulosis and/or diverticulitis .',\n",
       "   'Alcohol, drug or psychoactive substance dependence or medication abuse now or in the past, signs of alcohol/drug dependence.',\n",
       "   'Other documented medical conditions that can increase a risk of adverse events during the study treatment, affect the assessment of the main disease severity, mask, aggravate, affect symptoms of the main disease, or result in the same clinical and laboratory instrumental symptoms as those of rheumatoid arthritis:',\n",
       "   'Diabetes mellitus with inadequate glycemic control ;',\n",
       "   'Severe treatment-resistant hypertension ;',\n",
       "   \"Current or a history of inflammatory joint diseases other than rheumatoid arthritis (including ankylosing spondylitis, gout, psoriatic arthritis, Lyme disease etc. ) or other systemic autoimmune diseases (including systemic lupus erythematosus, Crohn's disease, non-specific ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, fibromyalgia etc.);\",\n",
       "   'Malignant neoplasms except for cured basal-cell carcinoma and cancer of the cervix in situ (complete remission ≥ 5 years); cured basal-cell carcinoma of the skin (complete remission ≥ 5 years); cured ductal breast cancer (complete remission ≥ 5 years);',\n",
       "   'Decompensated liver or kidney diseases;',\n",
       "   'Unstable angina;',\n",
       "   'Chronic heart failure of NYHA class III-IV;',\n",
       "   'Myocardial infarction within 1 year before signing the ICF;',\n",
       "   'History of organ transplantation;',\n",
       "   'History of angioedema;',\n",
       "   'Respiratory system disorders with decompensated respiratory insufficiency;',\n",
       "   \"Definite diagnosis of multiple sclerosis, Devic's disease, or Guillain-Barre syndrome;\",\n",
       "   'Nervous system disorders with motor and/or sensitivity abnormalities.',\n",
       "   'Pregnancy , planned pregnancy less than 8 weeks after the last injection of the investigational product; lactation.',\n",
       "   'Current participation in other clinical studies; previous participation in other clinical studies within 3 calendar months before signing the ICF (except for screenouts); previous participation in this study (except for screenouts).']},\n",
       " {'nct_id': 'NCT04649697',\n",
       "  'inclusion': ['Patient who agreed to sign the informed consent.',\n",
       "   'Age: 20-70 years old.',\n",
       "   'Gender: males and females',\n",
       "   'RA patients treated with MTX and suffering from MTX-induced oral ulceration.'],\n",
       "  'exclusion': ['Patients refused to sign the informed consent.',\n",
       "   'Pregnant or lactating females in their child bearing age group.',\n",
       "   'patients with known or suspected history of hypersensitivity to any of the ingredients of the preparation of the drugs used.',\n",
       "   'Systemic disease: such as uncontrolled diabetes mellitus, auto-immune diseases known to cause oral ulceration, renal or liver dysfunction or any other condition considered risky by the clinician.',\n",
       "   'Patients treated with any medication for the condition at the time of setting.',\n",
       "   'Salivary gland diseases.',\n",
       "   'Malignancy.']},\n",
       " {'nct_id': 'NCT04066803',\n",
       "  'inclusion': ['According to the revised 1987 American Academy of Rheumatology (ACR) RA classification criteria, subjects must be diagnosed as rheumatoid arthritis ≥6 months.',\n",
       "   'MTX was given 10 mg/week（not the maximum dose of MTX (calculated as 0.3 mg/kg)) for ≥3 months before admission.',\n",
       "   'At the screening and baseline phases, the number of swollen joints (SJC) should be ≥1 (counting 66 joints), and the number of tender joints (TJC) should be ≥ 1 (counting 66 joints); the ESR should be ≥20 mm/h, and/or the CRP should be ≥ 10 mg/l;',\n",
       "   'The age of the subjects ranged from 18 to 70 years.',\n",
       "   'The following RA drugs can be used in combination within 3 months before admission; oral glucocorticoid (prednisone ≤10 mg/d or its equivalent), non-steroidal anti-inflammatory drugs (≤ the maximum recommended dose), leflunomide, hydroxychloroquine, sulfasalazine, total paeoniflorin, Tripterygium glycoside, azathioprine, and MTX. The stable dose of DMARDs should be at least 4 weeks before baseline, and the combined dose of DMARDs beside MTX could not reach the full dose.',\n",
       "   'Women of childbearing age should agree to take effective contraceptive measures during the trial period;',\n",
       "   'The urinary pregnancy test of women of childbearing age was negative at screening time.',\n",
       "   'Understand the steps and contents of the experiment and sign the informed consent to participate in the experiment.'],\n",
       "  'exclusion': ['Those who underwent major surgery (including joint surgery) within 8 weeks before screening or who planned major surgery within 6 months after random selection;',\n",
       "   'Patients with autoimmune diseases except RA include SLE, MCTD, scleroderma and polymyositis. But subjects with RA and secondary Sjogren syndrome were allowed to participate in the trial.',\n",
       "   'Inflammatory arthritis (such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) .',\n",
       "   'Intra-articular injection or other injection of corticosteroids within 4 weeks before baseline;',\n",
       "   'Those who had been vaccinated with live/inactivated vaccine within 4 weeks before baseline;',\n",
       "   'Three months before admission, the following drugs were used: cyclophosphamide, biological agents and folic acid.',\n",
       "   'DMARDs dose reached maximum dosage in 3 months before admission， or DMARDs≥3 were used in 3 months before admission',\n",
       "   'Subjects with severe uncontrolled diseases including cardiovascular disease, nervous system disease, pulmonary disease (including obstructive pulmonary disease and interstitial lung disease), nephropathy, liver disease, endocrine disease (including uncontrolled diabetes mellitus) and gastrointestinal diseases;',\n",
       "   'known history of active or recurrent bacterial, viral, fungal, Mycobacterium or other infections (including, but not limited to, tuberculosis and atypical mycobacterium diseases, chest X-rays showing granulomatous diseases, hepatitis B and C, HIV infection, herpes zoster, but excluding Onychomycosis) ，any infection requiring hospitalization and intravenous antibiotic therapy within 4 weeks before screening ，or oral antibiotic therapy within 2 weeks before screening; active hepatitis B refers to HBsAg-positive patients without antiviral drugs and HBV-DNA > 10^4; active hepatitis C refers to anti-HCV-positive patients without antiviral drugs and HCV-RNA > 10^4;',\n",
       "   'Subjects with a history of malignant tumors, including solid tumors and hematological malignancies (except excised or cured skin basal cell carcinomas);',\n",
       "   'Pregnant or lactating women (breastfeeding);',\n",
       "   'Subjects with neuropathy and other painful diseases may interfere with pain assessment.',\n",
       "   'Serum creatinine > 1.5 mg/dl (equivalent to 133 umol/L);',\n",
       "   'Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times of the upper limit of normal value (if ALT or AST is greater than 2 times of the upper limit of normal value for the first time, it should be sampled again during the screening period), or total bilirubin is greater than the upper limit of normal value (if total bilirubin is greater than the upper limit of normal value for the first time at the screening, sampling should be done again during the selection period).',\n",
       "   'Platelet count < 100 x 10^9/L, or white blood cells < 3 x 10^9/L;']},\n",
       " {'nct_id': 'NCT04068246',\n",
       "  'inclusion': ['Patients with active rheumatoid arthritis based on DAS28 score. Patients received the standard therapy (i.e. one or more conventional DMARDs) for at least three months.'],\n",
       "  'exclusion': ['Known hypersensitivity to metformin.',\n",
       "   'Patients who have a prior diagnosis with diabetes mellitus.',\n",
       "   'Patients receive metformin for any other indications.',\n",
       "   'Patients with congestive heart failure.',\n",
       "   'Patients with a history of myocardial infarction.',\n",
       "   'Patients with severe anemia.',\n",
       "   'Patients with active infections or other inflammatory diseases.',\n",
       "   'Patients receiving biological therapy.',\n",
       "   'Pregnancy or lactation.',\n",
       "   'Patients with impaired liver functions.',\n",
       "   'Patients with impaired kidney functions (serum creatinine concentrations ≥1.5 and ≥1.4 mg/dL in males and females respectively).',\n",
       "   'Patients with malignancies.']},\n",
       " {'nct_id': 'NCT04065958',\n",
       "  'inclusion': ['Subject is 18 years of age or older',\n",
       "   'Subject has a diagnosis of either rheumatoid arthritis or psoriatic arthritis',\n",
       "   'Subject has a total score on SIQR above 33',\n",
       "   'Subject has not changed anti-rheumatic or analgetic treatment strategies during the three months preceding study inclusion (dose changes of ongoing treatments are accepted)'],\n",
       "  'exclusion': ['Subject has another medical condition that might prevent the subjects full participation in the interventions',\n",
       "   'Subject has more than four swollen joints',\n",
       "   'Subject has a C-Reactive Protein more than 20 mg/L',\n",
       "   'Subject is currently practicing yoga or has practiced yoga regularly during the last six months prior to study inclusion',\n",
       "   'Subject does not speak Swedish',\n",
       "   'Subject is unwilling to comply with the study protocol',\n",
       "   'Subject is considered, by the investigator, to be an unsuitable candidate for the study']},\n",
       " {'nct_id': 'NCT04204603',\n",
       "  'inclusion': ['Diagnosis of RA for at least 6 months prior to Screening, currently meet the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for RA, and are ACR functional class I-III.',\n",
       "   'Have active RA',\n",
       "   'Ongoing treatment with a stable dose of MTX as described below:',\n",
       "   'Use of oral or injectable MTX on a continuous basis for at least 12 weeks prior to Baseline and on a stable dose and route of administration between 15 mg and 25 mg/weekly for at least 8 weeks prior to Baseline and planned during the study.',\n",
       "   'Subjects should be on an adequate and stable dose of folic acid for at least 4 weeks prior to first administration of study treatment and planned during the study.',\n",
       "   'Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study treatment.',\n",
       "   'Women of childbearing potential must have a negative serum pregnancy test at Screening and urine pregnancy test at Baseline',\n",
       "   'Sexually active men, if not surgically sterile, must agree to use a medically acceptable form of contraception during the study and continue its use for at least 12 weeks after the last dose of study treatment.'],\n",
       "  'exclusion': ['Treatments for RA as follows: JAK inhibitors at any time; use of any currently licensed biologics with DMARD properties at any time.',\n",
       "   'Use of oral steroids at a dose >10 mg/day of prednisone or prednisone equivalent or at a dose that has not been stable for at least 4 weeks prior to Screening.',\n",
       "   'Use of nonsteroidal anti-inflammatory drugs (NSAIDs) which have not been at a stable dose or route of administration for at least 2 weeks prior to Baseline and planned during the study.',\n",
       "   'History of tuberculosis (TB) infection.',\n",
       "   'Positive serology for human immunodeficiency virus 1 or 2, hepatitis B virus or hepatitis C virus.',\n",
       "   'Currently active infection or history of infection within the last 2 weeks of Screening or Baseline']},\n",
       " {'nct_id': 'NCT04201886',\n",
       "  'inclusion': ['Adult RA Patients who fulfilled the 2010 ACR/European league against rheumatism (EULAR) criteria for the classification of RA',\n",
       "   'Adult osteoarthritis patients who fulfilled 2016 ACR revised Criteria for early diagnosis of knee OA'],\n",
       "  'exclusion': [\"Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis, behcet's disease, psoriasis and inflammatory bowel disease).\",\n",
       "   'RA patients with interstitial lung disease (IPF).',\n",
       "   'Patients with malignancy.',\n",
       "   'Patients with end stage organ failure.',\n",
       "   'Other conditions that may affect the serum level of calprotectin as diabetes mellitus, coronary artery disease, hepatitis and concomitant inflammatory disease as acute infection or chronic inflammatory status.']},\n",
       " {'nct_id': 'NCT04758689',\n",
       "  'inclusion': ['Patients referred from physician (immunologist) diagnosed with rheumatoid arthritis.'],\n",
       "  'exclusion': ['Patients having the disease overlapping with other connective tissue diseases, such as systematic lupus erythromatosus and systematic sclerosis.',\n",
       "   'History of malignancies.']},\n",
       " {'nct_id': 'NCT04754087',\n",
       "  'inclusion': ['Patient must be a legal adult who has reached full skeletal maturity.',\n",
       "   'Patient must be treated for one of the following indications:',\n",
       "   'Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Correction of functional deformity',\n",
       "   'Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques',\n",
       "   'Revision procedures where other treatment or devices have failed',\n",
       "   'Patient must be able and willing to complete the protocol required follow-up visits.',\n",
       "   'Patient must be able and willing to sign the Institutional Review Board or Ethics Committee (IRB/EC) approved informed consent.'],\n",
       "  'exclusion': [\"Patient presents with osteoporosis, which in the opinion of the Principal Investigator, may limit the subject's ability to support total hip arthroplasty using the study device.\",\n",
       "   'Patient has a metabolic disorder that may impair bone formation.',\n",
       "   'Patient has osteomalacia.',\n",
       "   'Patient has distant foci of infections which may spread to the implant site or patient with infection, sepsis or osteomyelitis.',\n",
       "   'Patient has rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram.',\n",
       "   'Patient has a vascular insufficiency, muscular atrophy, or neuromuscular disease',\n",
       "   'Patient is a prisoner.',\n",
       "   'Patient is a current alcohol or drug abuser.',\n",
       "   'Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions.',\n",
       "   'Patient is pregnant.']},\n",
       " {'nct_id': 'NCT04752748',\n",
       "  'inclusion': ['early rheumatoid arthritis fulfilment of the 2010 ACR/EULAR RA classification criteria;',\n",
       "   'age between 18-65 years;',\n",
       "   'female gender,',\n",
       "   'naive for treatment.'],\n",
       "  'exclusion': ['use of oral > 10 mg/d glucocorticoid in the previous three weeks;',\n",
       "   'serum aspartate aminotransferase or alanine aminotransferase level > 3 times the upper limit of normal;',\n",
       "   'bone marrow, auto-imune, lymphoproliferative or infectious diseases;',\n",
       "   'pregnancy.']},\n",
       " {'nct_id': 'NCT04755127',\n",
       "  'inclusion': ['Male and female patients with age ≥ 18 years',\n",
       "   'Subjects able and willing to give written informed consent (or legally acceptable representative or impartial witness when applicable) and is available for entire study',\n",
       "   'Patients meet the criteria of either group below: Group',\n",
       "   'Inclusion criteria RA patients:',\n",
       "   'Patients that are diagnosed with RA according to the revised 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Rheumatoid Arthritis Classification Criteria (table 1)',\n",
       "   'Patients are experiencing an exacerbation defined as an increase in DAS28 > 1.2 or > 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)',\n",
       "   \"The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)\",\n",
       "   'Wrist arthritis, that is diagnosed clinically, is the predominant symptom Group',\n",
       "   'Inclusion criteria PsA patients:',\n",
       "   'Patients that are diagnosed with PsA according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria (table 3)',\n",
       "   'Patients are experiencing an exacerbation defined as an increase in DAS28 > 1.2 or > 0.6 if DAS28 ≥ 3.2 compared to last DAS28 measurement (maximum six months before)',\n",
       "   \"The exacerbation is refractory to systemic cDMARDs for at least three months, defined as 'no response' according to the EULAR response criteria (table 2)\",\n",
       "   'Wrist arthritis, that is diagnosed clinically, is the predominant symptom'],\n",
       "  'exclusion': ['Previous or current treatment with biological (b) DMARDs',\n",
       "   'Current inflammatory joint disease other than RA or PsA (e.g. gout, reactive arthritis, Lyme disease)',\n",
       "   'Subjects who are pregnant or intend to become pregnant during the study',\n",
       "   'Intra-articular corticosteroids injection in the wrist in the last 6 months',\n",
       "   'Previous wrist surgery',\n",
       "   'Severe osteoarthritis with malformations of the wrist',\n",
       "   'Congenital abnormalities of wrist function or motion']},\n",
       " {'nct_id': 'NCT04078191',\n",
       "  'inclusion': ['The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) or equivalent authorization before the initiation of any study-related procedures.',\n",
       "   'Women and men of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) for the duration of the study.',\n",
       "   'The subject is at least 18 years of age and was ≥ 18 years of age at the time of RA diagnosis.',\n",
       "   'The subject has RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of ≥ 6/10 at or before screening).',\n",
       "   'The subject has a 28-joint disease activity score (DAS28) of ≥ 3.2 (includes the C-reactive protein [CRP] test and visual analog scale [VAS]).',\n",
       "   'Subjects receiving traditional DMARDs must have been on therapy for ≥ 90 days and at a stable dose for ≥ 30 days prior to the first imaging visit (Day 0).',\n",
       "   'If the subject is receiving biologic disease-modifying antirheumatic drug (bDMARD) or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 180 days prior to the first imaging visit (Day 0).',\n",
       "   'If the subject is receiving NSAIDs (nonsteroidal anti-inflammatory drug) or oral corticosteroids, the dose has been at a stable dose for ≥ 28 days prior to imaging. The corticosteroid dose should be ≤ 10 mg/day of prednisone or an equivalent steroid dose.',\n",
       "   'The subject has a hand or wrist joint with a minimum ultrasound gray-scale synovitis score of 2 (range 0 to 3).'],\n",
       "  'exclusion': ['The subject is pregnant or lactating.',\n",
       "   'The subject size or weight is not compatible with imaging per the investigator.',\n",
       "   'The subject has had or is currently receiving radiation therapy or chemotherapy.',\n",
       "   'The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.',\n",
       "   'The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the upper limit of normal.',\n",
       "   'The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.',\n",
       "   'The subject has a known allergy to or has had an adverse reaction to dextran exposure.',\n",
       "   'The subject has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration (Day 0).',\n",
       "   'The subject has received intra-articular corticosteroids ≤ 8 weeks prior to imaging (Day 0).',\n",
       "   'The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept (Day 0).',\n",
       "   'The subject has an intolerance to anesthetic and antiseptic agents indicated for the synovial biopsy procedure.',\n",
       "   'The subject is currently receiving anticoagulants (oral anti-platelet agents are permitted) or has a condition that is contraindicated with ultrasound-guided synovial biopsy e.g., needle phobia.']},\n",
       " {'nct_id': 'NCT04079920',\n",
       "  'inclusion': ['Adult subjects with moderately to severely active rheumatoid arthritis who start treatment with tofacitinib in usual clinical practice conditions in compliance with the label',\n",
       "   'Patients aged ≥ 18 years',\n",
       "   'Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist',\n",
       "   'Patients with moderate to severe RA diagnosed according to local practice who have already been started on treatment with tofacitinib, for at most seven working days .',\n",
       "   'Patients eligible for tofacitinib treatment according to current approved Summary of Product Characteristics (SmPC).',\n",
       "   'Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria:',\n",
       "   'Patients meeting any of the following criteria will not be included in the study:',\n",
       "   ''],\n",
       "  'exclusion': ['Contraindications to Xeljanz® according to SmPC.',\n",
       "   'Hypersensitivity to the active substance (tofacitinib) or to any of the excipients.',\n",
       "   'Active tuberculosis (TB), serious infections, such as sepsis, or opportunistic infections.',\n",
       "   'Receipt of any investigational drug within 3 months before study inclusion as well as currently not participating in an interventional clinical trial.',\n",
       "   'Subjects who have received any previous treatment with tofacitinib or other JAK inhibitors.',\n",
       "   'Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.']},\n",
       " {'nct_id': 'NCT04076202',\n",
       "  'inclusion': ['Patients scheduled to undergo primary total knee replacement:',\n",
       "   'with painful and disabled knee joint resulting from any of the following diagnoses:',\n",
       "   'Osteoarthritis,',\n",
       "   'Traumatic arthritis,',\n",
       "   'Rheumatoid arthritis with one or more compartments involved.',\n",
       "   'Correction of varus, valgus, or posttraumatic deformity.',\n",
       "   'Correction or revision of unsuccessful osteotomy or arthrodesis.',\n",
       "   'Need to obtain pain relief and improve function.',\n",
       "   'Ability and willingness to follow instructions, including control of weight and activity level, and to return for follow-up evaluations.',\n",
       "   'A good nutritional state of the patient.',\n",
       "   'Full skeletal maturity of the patient, patients who are at least 18 years of age.',\n",
       "   'Patients of either sex.',\n",
       "   'Consent form read, understood, and signed by patient.'],\n",
       "  'exclusion': ['Absolute contraindications include the following diagnoses:',\n",
       "   'Infection',\n",
       "   'Osteomyelitis',\n",
       "   'Previous partial or total prosthetic knee replacement on the operative side',\n",
       "   'Skeletal immaturity of the patient',\n",
       "   'Sepsis',\n",
       "   'Patients who are less than 18 years of age',\n",
       "   'Relative contraindications include:',\n",
       "   'uncooperative patient or patient with neurologic disorders who are incapable of following directions,',\n",
       "   'osteoporosis,',\n",
       "   'metabolic disorders which may impair bone formation,',\n",
       "   'osteomalacia,',\n",
       "   'distant foci of infections which may spread to the implant site,',\n",
       "   'rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,',\n",
       "   'vascular insufficiency, muscular atrophy, neuromuscular disease,',\n",
       "   'incomplete or deficient soft tissue surrounding the knee']},\n",
       " {'nct_id': 'NCT04079374',\n",
       "  'inclusion': ['patients of both sexes, from 18 to 75 years old;',\n",
       "   'body weight > 45 kg;',\n",
       "   'patients diagnosed with: rheumatoid arthritis (RA) of moderate and high activity, according to the classification of RA criteria of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) of 2010;',\n",
       "   'functional class I, II or III according to the Classification of the Functional Class of the RA of the American College of Rheumatology (ACR);',\n",
       "   'number of painful joints (NPJ) ≥ 6 (68 joints examined), number of swollen joints (NSJ) ≥6 (66 joints examined);',\n",
       "   'ESR (Erythrocyte sedimentation rate)≥ 28 mm/hour or СRP (C',\n",
       "   'reactive protein) > 7.0 mg/dl;',\n",
       "   'patient who receive methotrexate for at least 12 weeks at doses of 7.5-20 mg/week (orally or parenterally), and the dose and route of administration of methotrexate was not changed for 4 weeks before randomization;',\n",
       "   'patient who stopped therapy with other basic antirheumatic drugs, except methotrexate, and completed the wash-out period for these drugs of at least five half-life periods, but not less than 2 weeks (whichever is longer);',\n",
       "   'if a patient takes NSAIDs (Nonsteroidal anti-inflammatory drugs), the dose of the drug should be stable within 2 weeks before randomization;',\n",
       "   'if a patient takes oral glucocorticosteroids, the dose should be ≤10 mg/day of prednisolone (or equivalent) and be stable for 2 weeks before randomization;',\n",
       "   'women of childbearing age and men who have partners, who have agreed to use reliable contraceptive methods during the entire study period and within 3 months after its termination. Reliable methods of contraception include: intrauterine devices, double-barrier method or state after surgical sterilization and vasectomy;',\n",
       "   'signed informed consent of participants to participate in this study, which was obtained before any screening procedures, including discontinuation of forbidden-drugs.'],\n",
       "  'exclusion': ['known hypersensitivity to Etanercept or other components of the study drugs;',\n",
       "   'other rheumatic diseases, autoimmune diseases, connective tissue diseases, immunodeficiency (e.g. psoriasis, psoriatic arthritis, primary Sjogren syndrome, systemic lupus erythematosus or demyelinating diseases such as multiple sclerosis);',\n",
       "   'septic arthritis within 12 months before screening; purulent arthritis of prosthetic joints;',\n",
       "   'acute or frequent recurrent chronic, local or generalized infections (bacterial/fungal/viral) or sepsis, or history of recurrent infections, or increased risk of developing infections or sepsis;',\n",
       "   'an active form of tuberculosis; the history of the ineffective treatment of tuberculosis; latent tuberculosis or risk of developing tuberculosis (e.g., contact with patients who have an active form of tuberculosis, shortly before screening);',\n",
       "   'severe interstitial lung diseases (bronchial asthma, chronic obstructive pulmonary disease, bronchiectasis, fibrosis);',\n",
       "   'malignant diseases, including history (except successfully treated non-metastatic basal cell or squamous cell skin cancer or cervical cancer);',\n",
       "   'congestive heart failure of class III or IV, according to New York Heart Association criteria, or unstable angina;',\n",
       "   'uncontrolled diabetes mellitus, uncontrolled arterial hypertension;',\n",
       "   'abnormal laboratory parameters at screening:',\n",
       "   'haemoglobin < 100.0 g/L;',\n",
       "   'platelets < 125 *10^9 cell/L;',\n",
       "   'leukocytes < 3.5 *10^9 cell/L,',\n",
       "   'absolute neutrophil count < 1.5 *10^9 cell/L;',\n",
       "   'absolute lymphocyte count < 0.8 *10^9 cell/L;',\n",
       "   'ASТ (Aspartate aminotransferase), АLТ (Alanine aminotransferase) 3 and more times higher than the upper limit of normal and serum total bilirubin 2 and more times higher than the upper limit of normal;',\n",
       "   'serum creatinine 2 times or higher than the upper limit of normal;',\n",
       "   'history of clinically significant or uncontrolled diseases of the respiratory system, liver, kidney, blood, gastrointestinal tract, endocrine system, immune system, skin, nervous system (including demyelinating disorders), cardiovascular system, or history of an autoimmune or mental disorder, or any condition which, in the opinion of the Investigator, can pose a threat to the safety of a patient, affect the study results or prevent a patient from completing the study;',\n",
       "   'hepatitis В, С;',\n",
       "   'scheduled surgical intervention including joint replacement during the study;',\n",
       "   'recent chickenpox;',\n",
       "   'oral and gastrointestinal ulcers;',\n",
       "   'pregnancy, breastfeeding;',\n",
       "   'history of alcohol or drug abuse;',\n",
       "   'vaccination with live or attenuated vaccines within 4 weeks before the screening, or scheduled vaccination during the study, or within 3 months after the last dose of the study/reference drug;',\n",
       "   'previous treatment with any other GEBD (genetically engineered biological drugs) (GEBD) for rheumatoid arthritis (including, tocilizumab, adalimumab, anakinra, abatacept, infliximab, rituximab, golimumab, Etanercept, certolizumab) or tofacitinib;',\n",
       "   'use of systemic or intraarticular corticosteroids, except prednisolone at a dose of≤10 mg/day orally, or equivalent to GCS (Glucocorticosteroids) within 2 weeks before randomization;',\n",
       "   'use of alkylating agents (e.g. cyclophosphamide, chlorambucil) within 6 months before randomization;',\n",
       "   'use of intravenous or oral antimicrobial agents 4 weeks before randomization; simultaneous participation in any other clinical study, or participation in a clinical study within 3 months before screening.']},\n",
       " {'nct_id': 'NCT04961853',\n",
       "  'inclusion': ['Adult-onset disease.',\n",
       "   'Patients who fulfill the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis.'],\n",
       "  'exclusion': ['Any patient with any collagen disease rather than Rheumatoid arthritis.',\n",
       "   'Patients with joints deformities.',\n",
       "   \"Patient's with implanted metal clips or wires or artificial pacemaker.\"]},\n",
       " {'nct_id': 'NCT04740814',\n",
       "  'inclusion': ['Participant must be 18 to 69 years of age inclusive, at the time of signing the informed consent',\n",
       "   'Participant must have a diagnosis of moderately-to-severely active rheumatoid arthritis (RA)',\n",
       "   'Participant must have had an inadequate response to, or intolerance to, at least 1 disease modifying antirheumatic drug (DMARD) (nonbiologic or biologic)',\n",
       "   'Participant has a negative interferon-gamma release assay (IGRA) at Screening',\n",
       "   'Participant has a body mass index within the range 18.0 kg/m2 to 35.0 kg/m2 (inclusive)',\n",
       "   'Male or female',\n",
       "   'A female participant is eligible to participate if: i) she is not pregnant, ii) not breastfeeding, iii) at least one of the following conditions applies:',\n",
       "   'Not a woman of childbearing potential (WOCBP) OR',\n",
       "   'A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and until the Safety Follow-up (SFU) Visit'],\n",
       "  'exclusion': ['Participant has a known hypersensitivity to any components of the study medication(including polyethylene glycol) or comparative drugs (and/or an investigational device) as stated in this protocol',\n",
       "   'Participant has clinically significant electrocardiogram (ECG) abnormalities at Screening',\n",
       "   'Participant has previously been exposed to certolizumab pegol (CZP)',\n",
       "   'Participant has failed treatment with ≥1 tumor necrosis factor (TNF) α inhibitor or was a primary failure for any TNFα antagonist. A primary failure is defined as no clinical disease improvement within the first 12 weeks of treatment (study participants who demonstrated clinical response within 12 weeks of treatment and subsequently lost response after 12 weeks of treatment are eligible)',\n",
       "   'Participant has received a live vaccination within 6 weeks prior to Screening or intends to have a live vaccination during the course of the study or within 3 months following CZP treatment in the study',\n",
       "   'Participant has received any investigational drug or experimental procedure within 90 days prior to the first dose of IMPinvestigational medicinal product (IMP)',\n",
       "   'Participant has a laboratory abnormality at Screening, including any of the following:',\n",
       "   \">3.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP); or >ULN total bilirubin (>1.5x ULN total bilirubin if the participant has a documented pre-study diagnosis of Gilbert's syndrome)\",\n",
       "   'white blood cell count <3.00x103/μL',\n",
       "   'absolute neutrophil count (ANC) <1.5x103/μL',\n",
       "   'lymphocyte count <500 cells/μL',\n",
       "   'hemoglobin <8.5 g/dL',\n",
       "   'Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent the study participant from completing the study or will interfere with the interpretation of the study results']},\n",
       " {'nct_id': 'NCT04749160',\n",
       "  'inclusion': ['Social security affiliation',\n",
       "   'Signed informed consent',\n",
       "   'Adult patient (over 18 years old)',\n",
       "   'RA according to ACR/EULAR 2010 criteria since less than 6 months',\n",
       "   'DAS28 ≥ 3.2 despite methotrexate therapy and initiating for the first time a bDMARD or a tsDMARD',\n",
       "   'Having an internet access at home and using an email address'],\n",
       "  'exclusion': ['Other arthritis than RA',\n",
       "   'To participate to a blind-randomized study to assess RA treatment',\n",
       "   'Pregnancy or breastfeeding',\n",
       "   'Patient unable to understand the study, unable to give consent',\n",
       "   'Patient deprived of liberty or patient under guardianship',\n",
       "   'Patient refusing to participate in the study',\n",
       "   'Patients having difficulty using connected objects']},\n",
       " {'nct_id': 'NCT04210817',\n",
       "  'inclusion': ['Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study',\n",
       "   'Male or female patients of any age (interest is given to children to compare with mothers).',\n",
       "   'Diagnosis of Rheumatoid Arthritis'],\n",
       "  'exclusion': ['Refusal to sign informed consent form',\n",
       "   'History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.',\n",
       "   'Postoperative stoma, ostomy, or ileoanal pouch',\n",
       "   'Participation in any experimental drug protocol within the past 12 weeks',\n",
       "   'Treatment with total parenteral nutrition',\n",
       "   \"Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial\",\n",
       "   'Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study']},\n",
       " {'nct_id': 'NCT04449224',\n",
       "  'inclusion': ['19 years or olders',\n",
       "   'Patients who satisfy the 1987 American College of Rheumatology (ACR) or 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria for RA',\n",
       "   'Patients having moderately to severely active RA who are intolerant to csDMARDs including methotrexate and those who have never been exposed to bDMARDs or small molecular inhibitors before',\n",
       "   'Patients who provide written consent to participate in this study'],\n",
       "  'exclusion': ['Patients who are contraindicated to bDMARDs or small molecule inhibitor',\n",
       "   'Patients who have plans for pregnancy or elective surgery',\n",
       "   'Patients who had ever diagnosed with any malignancy or are treated for malginancy',\n",
       "   'Patients who cannot voluntarily provie a written consent to participate in this study',\n",
       "   'Patients who did not provide a written consent to participate in this study']},\n",
       " {'nct_id': 'NCT04464096',\n",
       "  'inclusion': ['Adults with Rheumatoid arthritis.'],\n",
       "  'exclusion': ['patients aged < 18 years',\n",
       "   'Patients with lower limb disability preventing the participant from performing the mobility tests,',\n",
       "   'Patients who were using antidepressants and sedatives.',\n",
       "   'Patients with severe comorbidities, severe vision impairment, or hearing loss or neurological diseases that interferes with the mobility as stroke or neuropathy, were also excluded.']},\n",
       " {'nct_id': 'NCT04464642',\n",
       "  'inclusion': ['patients fulfill the ACR-EULAR classification criteria for RA 3.DAS-28 CRP more than 5.1',\n",
       "   ''],\n",
       "  'exclusion': ['systemic infection',\n",
       "   'hemoglobin less than 9 mg/dl',\n",
       "   'WBC <4000, neutrophil <1000, platelet <100000/mm',\n",
       "   'live vaccine within 3 months',\n",
       "   'GFR < 50 ml/min',\n",
       "   'ALT > 2 times ULN',\n",
       "   'pregnancy']},\n",
       " {'nct_id': 'NCT04839081',\n",
       "  'inclusion': ['Being diagnosed with RA according to the 1987 ACR Criteria',\n",
       "   'Visual Analogue Scale hand pain score ≥ 3'],\n",
       "  'exclusion': ['Diabetes mellitus, renal insufficiency, hypothyroidism',\n",
       "   'Carpal tunnel syndrome, postherpetic neuralgia, cervical spinal cord compression',\n",
       "   'Cervical radiculopathy',\n",
       "   'Fibromyalgia',\n",
       "   'Malignancy',\n",
       "   'Hand muscle weakness of even one grade on Medical Research Council Manual Muscle Testing scale',\n",
       "   'Upper motor neuron sign on physical examination of hands',\n",
       "   'Pregnancy',\n",
       "   'In the last three months medical treatment leading to neuropathy (colchicine etc.)',\n",
       "   'In the last three months drug use for the treatment of fibromyalgia, depression or anxiety']},\n",
       " {'nct_id': 'NCT04834557',\n",
       "  'inclusion': ['Diagnosed with rheumatoid arthritis according to the ACR/EULAR 2010 criteria.',\n",
       "   'Having active rheumatoid arthritis disease activity (the 28-joint disease activity score [DAS28] according to the CRP formula > 2.6).',\n",
       "   'Aged between 18 and 80 years.',\n",
       "   'With clear consciousness and able to cooperate with this study.',\n",
       "   'Personal willingness and ability to comply with the study follow-up schedule and other requirements of the study protocol.',\n",
       "   'Both male and female will be included',\n",
       "   'All patients receiving non-biological drugs will be also included.',\n",
       "   'Sign an informed consent for the clinical study.'],\n",
       "  'exclusion': ['Pregnant or planning to be pregnant and breast-feeding women',\n",
       "   'Patients suffering from any chronic diseases',\n",
       "   \"Patients with other autoimmune diseases, such as systemic lupus erythematosus, Sjogren's syndrome and mixed connective tissue disease.\",\n",
       "   'Patients who have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis).',\n",
       "   'Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis).',\n",
       "   'Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease.',\n",
       "   'Patients treated with biological therapy such as TNF-α or IL-1β antagonists.',\n",
       "   'Patients with infectious or inflammatory diseases, endocrine disorders, any past or current psychiatric or neurological diseases.',\n",
       "   'Patients with cardiovascular diseases such as arrhythmias and acute myocardial infarction.',\n",
       "   'Patients with electrolyte disturbances (such as hypokalemia, hypomagnesemia, and hypercalcemia) could potentially elevate the risk of digoxin toxicity.',\n",
       "   'Patients with clinically significant hepatic and renal dysfunction or impairment.',\n",
       "   'Alcohol abuse',\n",
       "   'Patients with evidence of viral (HBV or HCV), autoimmune hepatitis, and decompensated liver disease.',\n",
       "   'Patients with cancer currently diagnosed or in medical history, if no recovery was achieved.',\n",
       "   'Patients who are allergic to digoxin or Ursodeoxycholic acid (UDCA)',\n",
       "   'Patients who are unconscious and unable to complete the study.',\n",
       "   'Patients with acute inflammation of the gall bladder or the biliary tract, frequent episodes of biliary colic, and impaired contractility of the gall bladder, will be excluded.',\n",
       "   'Patients with cholestasis, primary biliary cirrhosis, or biliary obstruction will also be excluded.',\n",
       "   'Patients who have received an organ transplant.']},\n",
       " {'nct_id': 'NCT04454034',\n",
       "  'inclusion': ['The patients who fulfilled the 1987 ACR（American College of Rheumatology) or 2010 ACR/EULAR（European League Against Rheumatism） RA classification criteria.',\n",
       "   'The age is more than 18 years old and less than 60 years old.',\n",
       "   'They received stable traditional DMARDs (including Chrysopidae, leflunomide, sulfasalazine, hydroxychloroquine, eilamod) or biological dmrads (including tumor necrosis factor antagonists, IL(Interleukin)-6 receptor antagonists, CD20 monoclonal antibodies) for at least 6 months.',\n",
       "   'The disease is still in the active stage, which means the disease activity score (DAS28) is more than 3.2, and the elbow joint function is obviously limited.',\n",
       "   'The patient agreed to undergo arthroscopic synovectomy.',\n",
       "   'No contraindications were found.'],\n",
       "  'exclusion': ['The disease is in remission.',\n",
       "   'The patient has contraindications.',\n",
       "   'Arthroscopic synovectomy was performed in different patients.']},\n",
       " {'nct_id': 'NCT04457856',\n",
       "  'inclusion': ['Subjects must be ≥ 18 and ≤70 years old when signing the informed consent, with no limitation of gender.',\n",
       "   'Established Rheumatoid arthritis patients, diagnosed by ACR/EULAR criteria 2010 at least 6 months prior to randomisation.',\n",
       "   'Single Ascending Dose: DAS28 score≤3.2. Multiple Ascending Dose: DAS28 score≤5.1 and >3.2.',\n",
       "   'Allowed one or more standard treatments, but the start date should no later than 12 weeks(84 days) before the randomisation and should take at a stable dose more than 4 weeks(28 days) before the randomisation. The combination taken of Methotrexate (MTX) and leflunomide was not allowed within 4 weeks (28 days) before randomization.',\n",
       "   'Subjects must agree to attendance the study and signed the inform concent by themselves.',\n",
       "   \"Subjects(include subjects's wife) are no pregnancy plan during the sceering and 3 months after complete the study and agree to use contraceptives that protocol suggest.\"],\n",
       "  'exclusion': ['Employees of the hospital or any other person that paticipant in the study and their immedidte family members.',\n",
       "   \"A documented history of an autoimmune disease other than RA (other than secondary Sjögren's syndrome) .\",\n",
       "   'Previous received Any biologic DMARD therapy including tsDMARD. •A positive hepatitis B (HBsAg, anti-HBc, and/or IgM anti-HBc), hepatitis C or HIV test at screening, indicative of a current or past infection.',\n",
       "   'A history of active tuberculosis (TB) or positive serological test for TB (Quantiferon TB Gold or T-SPOT).',\n",
       "   'Female patients who are pregnant during the study, or are breastfeeding. •Malignancy, or prior malignancy, with a disease free interval of <5 years after diagnosis and intervention except curative treatment for basal and squamous cell skin cancer.']},\n",
       " {'nct_id': 'NCT04577781',\n",
       "  'inclusion': ['A body mass index (BMI) between 18-32 kg/m^2, inclusive.',\n",
       "   'Diagnosis of RA ≥6 months prior to screening AND meeting the 2010 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria of RA AND ACR functional class I-III.',\n",
       "   'Have ≥6 swollen joints (from a swollen joint count evaluated in 66 joints [SJC66]) AND ≥8 tender joints (from a tender joint count evaluated in 68 joints [TJC68]) at screening and at the baseline visit (Visit 1) prior to the first investigational product (IP) dosing.',\n",
       "   'DAS28 (CRP) >3.2 (moderate disease) at screening.',\n",
       "   'Screening serum high sensitivity C-reactive protein (hsCRP) > upper limit of normal (ULN, central laboratory reference: ≤ 5.0 mg/L).',\n",
       "   'Inadequate response to MTX, i.e. treatment-experienced participants who demonstrated inadequate clinical response during treatment with MTX.',\n",
       "   'Have received MTX for ≥6 months and on stable dose (10 to 20 mg/week) of MTX for at least 4 weeks prior to screening and willing to continue on their current stable dose and dosing regimen for the duration of the study.',\n",
       "   'If taking systemic steroids, prednisone equivalent at a dose of ≤10 mg/day and stable for at least 4 weeks prior to the first IP dosing. Key Exclusion Criteria:',\n",
       "   'Current therapy with any conventional disease-modifying antirheumatic drug (DMARD) other than MTX, including',\n",
       "   'oral or injectable gold, sulfasalazine, antimalarials, azathioprine, or D-penicillamine within 4 weeks prior to screening,',\n",
       "   'cyclosporine within 8 weeks prior to screening, and',\n",
       "   'leflunomide within 3 months prior to screening or a minimum 4 weeks prior to screening if after 11 days of standard cholestyramine therapy.',\n",
       "   'Current or previous treatment with a biologic DMARD (bDMARD). Except for participants who received bDMARDs only in a single clinical study setting:',\n",
       "   'For whom the last dose of bDMARD ≥6 months prior to screening (12 months for rituximab or other lymphocyte depleting agents), AND;',\n",
       "   'For whom the bDMARD was effective, without being discontinued due to lack of efficacy.',\n",
       "   'Participants who received an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening.',\n",
       "   'Participants who received a prior surgical intervention within 12 weeks prior to screening or likely requirement for surgery during the study.',\n",
       "   'Participant has a history of tuberculosis (TB) diagnosis or evidence of active or latent infection with Mycobacterium tuberculosis as defined by one of the following assessments:',\n",
       "   'Positive QuantiFERON-TB Gold test result at screening, OR',\n",
       "   'Chest radiograph (posterior anterior view) taken within 12 weeks prior to screening, read by a qualified radiologist or pulmonologist, with evidence of current active TB or old inactive',\n",
       "   '6. Participant has any active systemic infection within the last 2 weeks prior to first IP dosing, or poorly controlled chronic cardiac, pulmonary or renal disease.',\n",
       "   'Participant has a known or suspected history of or a current immunosuppressive condition, or a history of invasive opportunistic infections (e.g. human immunodeficiency virus [HIV] infection, histoplasmosis, listeriosis, coccidiodmycosis, pneumocystosis, aspergillosis).',\n",
       "   'Participant has a chronic hepatitis B virus (HBV) infection, as defined by persistent HBV surface antigen (HBsAg) positivity. Participant has hepatitis C virus (HCV) infection, as defined by positive HCV antibody at screening and detectable HCV viremia. Participants with positive HCV antibody must undergo reflex HCV ribonucleic acid (RNA) testing, and participants with HCV RNA positivity will be excluded. Participants with positive HCV antibody and negative HCV RNA are eligible.',\n",
       "   'Participant testing positive at screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection as detected by real time polymerase chain reaction (RT-PCR), participants presenting any signs or symptoms as detected at baseline following careful physical examination (e.g. cough, fever, headaches, fatigue, dyspnea, myalgia, anosmia, dysgeusia, anorexia, sore throat, others) or reporting any signs and symptoms for the 2 preceding weeks, or participants who have been exposed to individuals with confirmed or suspected diagnosis of SARS-CoV-2 within 2 weeks prior to baseline. In addition, any other locally applicable standard diagnostic criteria may also apply to rule out SARS-CoV-2 infection. Note: Other protocol-defined Inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04570280',\n",
       "  'inclusion': ['Romatoid Arthritis diagnosed for> 1 year',\n",
       "   'Female gender',\n",
       "   'The patient has been in remission or low disease activity for at least 3 months',\n",
       "   '20-50 years'],\n",
       "  'exclusion': ['Patient with active arthritis or high disease activity',\n",
       "   'Significant deformity and inability to ambulate in the lower extremity joints',\n",
       "   'Pregnant patient',\n",
       "   'Patient with menopause',\n",
       "   'The presence of malignancy',\n",
       "   'A patient with a serious psychiatric disorder and difficulty in cooperation',\n",
       "   'Presence of cardiovascular and pulmonary comorbidity that may prevent exercise',\n",
       "   'Male gender']},\n",
       " {'nct_id': 'NCT04574492',\n",
       "  'inclusion': ['Diagnosis of moderate to severe Rheumatoid Arthritis (RA) according to the investigator.',\n",
       "   \"Decision to initiate UPA treatment by investigator according to the local product label independent of the participant's participation in the study.\",\n",
       "   'Has been previously treated with Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and corresponds to one of the following subgroups:',\n",
       "   'Has not been previously exposed to any Biologic Disease-Modifying Antirheumatic Drugs (bDMARD) or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (tsDMARD).',\n",
       "   'Has not been previously exposed to tsDMARD and has been previously exposed to <= 2 bDMARDs.',\n",
       "   'Has been previously treated with one tsDMARD and <=1 bDMARD prior to treatment with that tsDMARD.'],\n",
       "  'exclusion': ['Presence of any condition that, in the opinion of the treating physician, prohibits the participant from participating in the study or obscures the assessment of the treatment of',\n",
       "   '- Diagnosis of rheumatic disease other than',\n",
       "   '- Diagnosis of juvenile',\n",
       "   '- Currently participating in an investigational clinical trial.',\n",
       "   'Has prior exposure to a bDMARD after exposure to a tsDMARD.',\n",
       "   'Has prior exposure to tsDMARD in an investigational clinical trial.']},\n",
       " {'nct_id': 'NCT04817969',\n",
       "  'inclusion': ['Patient is of legal age and skeletally mature',\n",
       "   'Patient is willing and able to provide written Informed Consent by signing and dating the IRB-approved Informed Consent document',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations as defined in the study protocol',\n",
       "   'Patient qualifies for total knee arthroplasty based upon physical exam and medical history, and meets the approved indications for use of the Persona Ti-Nidium Knee System and Vivacit-E polyethylene articulating surface',\n",
       "   'Independent of study participation, patient is a candidate for the commercially available Persona Ti-Nidium Knee and Vivacit-E polyethylene articulating surface, implanted in accordance with product labeling Study Device Inclusion Criteria: The Persona Ti-Nidium Total Knee is intended for patients with severe pain and disability due to the following:',\n",
       "   'Rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis.',\n",
       "   'Collagen disorders, and/or avascular necrosis of the femoral condyle.',\n",
       "   'Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy.',\n",
       "   'Moderate valgus, varus, or flexion deformities. Exclusion Criteria:',\n",
       "   'Patient is unwilling to sign the Informed Consent',\n",
       "   'Patient is currently participating in any other surgical intervention or pain management study',\n",
       "   'Patient is pregnant or considered a member of a protected (vulnerable) population whose inclusion in the study is inappropriate (e.g. prisoner, mentally incompetent)',\n",
       "   'Patient has a mental or neurologic condition who is unwilling or incapable of following postoperative care instructions',\n",
       "   'Patient has a condition which would, in the judgement of the Investigator, place the patient at undue risk or interfere with the conduct of the study',\n",
       "   'Patient is institutionalized or is a known drug abuser, a known alcoholic or cannot understand the requirements of study participation Study Device'],\n",
       "  'exclusion': ['Previous history of infection in the affected joint and/or other local/systematic infection that may affect the prosthetic joint',\n",
       "   'Insufficient bone stock on femoral or tibial surfaces',\n",
       "   'Skeletal immaturity',\n",
       "   'Neuropathic arthropathy',\n",
       "   'Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb',\n",
       "   'A stable, painless arthrodesis in a satisfactory functional position',\n",
       "   'Severe instability secondary to the absence of collateral ligament integrity',\n",
       "   'Rheumatoid arthritis (RA) accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin',\n",
       "   'The kinematic alignment surgical technique is contraindicated for patients with greater than 5° valgus deformity with medial collateral ligament (MCL) insufficiency']},\n",
       " {'nct_id': 'NCT04815148',\n",
       "  'inclusion': ['Phase Ia: Adults, age 18',\n",
       "   '45 years old, inclusive, at time of screening. Phase Ib: Adults, age 18',\n",
       "   '70 years old, inclusive, at time of screening.',\n",
       "   'Willing and able to understand and sign an informed consent form and to comply with all aspects of the protocol.',\n",
       "   'Participants whose body mass index (BMI) at screening is within a range of ≥ 18.5 kg/m2 and <35 kg/m2. (BMI = Body Weight (kg) / [Height (m) × Height (m)])',\n",
       "   'Has abstained from smoking or use of tobacco products from 6 months prior to study drug administration and for the entire duration of the study.',\n",
       "   \"Participant's medical history shows no contraindication to JAK inhibitors.\",\n",
       "   'Participants judged to be in good health by the Investigator based upon the results of physical examinations (PEs), 12-lead electrocardiogram (ECG) test, and all items of routine laboratory tests, including serum biochemistry, hematology and urinalysis, are within normal range, or if outside normal range they are deemed not clinically significant as judged by the Investigator. Assessment items of blood biochemistry include albumin, total protein, total bilirubin, ALP, SGOT, SGPT, BUN, serum creatinine, CK and fasting lipid profile (total cholesterol, LDL, HDL and triglycerides). Assessment items of hematology tests include RBC count, WBC with differential counts, hemoglobin, hematocrit and platelet count. Assessment items of urinalysis include pH, colour, appearance, gravity, erythrocyte, leukocyte, glucose, protein, ketones and nitrite. For the ECG test, QTcF must be ≤450msec for females or males, and PR interval <120msec and no evidence of bundle branch block.',\n",
       "   'Willingness of men and women of reproductive potential to observe conventional and highly effective birth control from the beginning of the study screening until 6 months after receiving the last treatment of investigational product. A highly effective method of contraception is defined as follows: Highly Effective Methods That Have Low User Dependency',\n",
       "   'Implantable progestogen-only hormone contraception associated with inhibition of ovulation.',\n",
       "   'Intrauterine device (IUD).',\n",
       "   'Intrauterine hormone-releasing system (IUS).',\n",
       "   'Bilateral tubal occlusion.',\n",
       "   'Vasectomized partner (is a highly effective contraceptive method provided that the partner is the sole sexual partner of the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used. The spermatogenesis cycle is approximately 90 days. Highly Effective Methods That Are User Dependent (must be used in combination with a male or female condom)',\n",
       "   'Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal, injectable.',\n",
       "   'Progestogen-only hormone contraception associated with inhibition of ovulation: oral, injectable.',\n",
       "   'WOCBP must have a negative pregnancy test at Screening and Day 1 and be willing to have additional pregnancy tests as required throughout the study.',\n",
       "   'Males must not donate sperm for at least 90 days after the last dose of study drug.',\n",
       "   'Participants are a current non-smoker (and has not smoked in the 6 months prior to baseline) and will not smoke throughout the course of the study. Screening cotinine test must be negative. Additional Inclusion criteria for Phase Ib (Study 2-1, AD participants):',\n",
       "   'Participants who are diagnosed with mild to moderate atopic dermatitis for ≥3 months prior to screening based on the Hanifin and Rajka Criteria. Mild to moderate AD is defined as BSA 2-20%; EASI 3-16; IGA 2',\n",
       "   '3 at both the screening and Day 1 visit.',\n",
       "   'Participants with a Target Area of Atopic Dermatitis of approx. 10 x 10cm on any part of the body other than the scalp, face, palms of hands, soles of feet, buttocks or groin to apply the Study Drug. The Target Lesion Area score needs to be between mild (2) to moderate (3) on the Disease Affected Eczema Area and Severity Indices (EASI) at screening and Day',\n",
       "   '13. Participant is able to apply the study drug to the Target Lesion Area; or if the Target Lesion is not easily reached (i.e. on their back), has someone who is willing and able to apply the study drug as prescribed during the treatment period.',\n",
       "   'Participants who agree to discontinue all treatment used for their AD, such as topical antihistamines, topical antimicrobials, topical or oral corticosteroid, systemic immune modulating agents and light treatments, as well as bleach baths and avoid prolonged sun exposure during the study period for/on the affected site(s) (except the standard medication oral antihistamine levocetirizine and rescue medication prescribed by the study Investigator(s)). Participants who are taking oral antihistamines need to be on a stable dose for at least 2 months.',\n",
       "   'Participants are required to stop using prohibited topical treatments for at least 14 days before the first investigational drug dose administration (or longer if the treatment half-life requires so 5 half-lives should have elapsed) and prohibited systemic treatment drugs for 28 days before the first investigational drug dose administration (or longer if the treatment half-life requires so 5 half-lives should have elapsed). Additional Inclusion criteria for Phase Ib (Study 2-2, RA participants):',\n",
       "   'Diagnosed with Rheumatoid arthritis (RA) prior to screening who fulfil the 2010 ACR/EULAR classification for',\n",
       "   '17. Mild to moderate disease activity at screening (DAS 28-CRP ≤ 4.5 and ≥ 2.6).',\n",
       "   'Active RA in one Target Joint of either hand or wrist at screening and baseline where both swelling and tenderness/pain is present. Exclusion Criteria: Phase Ia and Ib:',\n",
       "   'Participants with conditions at the study drug application site(s) that would interfere with the study drug administration, skin assessment, or reaction to study drug. For example: presence of open sores; obvious differences in skin color between applications sites/discolouration such as vitiligo; excessive hair; scar tissue; tattoo.',\n",
       "   'Participants with any unstable health status, defined as having newly diagnosed medical conditions or symptoms of a medical condition that is not yet diagnosed within 30 days prior to the first dose of the study drug.',\n",
       "   'Healthy participants and RA participants only (i.e. does not apply to AD participants): Participants with any diagnosed dermatological condition within 180 days prior to the first study dose.',\n",
       "   'History of anaphylaxis.',\n",
       "   'Participants with any clinically significant (as judged by the Investigator) hematological, endocrine, cardiovascular, hepatic, renal, gastrointestinal, and/or pulmonary disorder.',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids.',\n",
       "   'Participants with any predisposing condition that might interfere with the absorption, distribution, metabolism and excretion of the study medication. This includes a screening eGFR <60mL/min/1.73m2 or screening transaminases > 1.5 x ULN.',\n",
       "   'Participant had participated in any investigational drug trial and took any investigational drug within 60 days prior to the first study dose.',\n",
       "   'Participant had blood donation of more than 250 mL within 60 days or 500 mL within 90 days prior to the first study drug dose.',\n",
       "   'Participant has current drug abuse or alcohol abuse per Investigator judgement. Participants must have a negative drug and alcohol test at screening and day',\n",
       "   '11. Participants who are inappropriate to participate in this study, as judged by the Investigator.',\n",
       "   'Participants with any history of or current unstable mental health condition or any lifetime history of suicidal behaviour, as per Investigator judgement.',\n",
       "   'Participants who have known hypersensitivity to the study medication.',\n",
       "   'Participants who are pregnant or breast-feeding or intend to become pregnant during the course of the treatment and follow-up periods.',\n",
       "   'Any history of malignancy of any organ system (other than cervical carcinoma in situ or non-melanoma skin cancers that have been excised) within 5 years prior to study entry.',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or during the course of the study.',\n",
       "   'Known active current, or recent history within 3 months, requiring treatment of bacterial, viral, fungal, mycobacterial or other infections.',\n",
       "   'Vaccinated or exposed to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or is expected to be vaccinated or to have household exposure to these vaccines during treatment or up until the follow-up visit.',\n",
       "   'A history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent (more than one episode of) localized, dermatomal herpes zoster.',\n",
       "   'Any history of any blood clots or clotting disorders (e.g. Deep Vein Thrombosis, Pulmonary Embolism, coagulopathy).',\n",
       "   'Any known immunodeficiency disorder.',\n",
       "   'Mycobacterium tuberculosis (TB) infection as follows:',\n",
       "   'A positive QuantiFERON TB test within the 12 weeks prior to screening or during screening.',\n",
       "   'Any chest imaging (e.g. x-ray, CT) taken at screening or within the 12 weeks prior to screening with changes suggestive of active',\n",
       "   '- Been treated or is currently being treated for active or latent TB infection.',\n",
       "   'A history of either untreated or inadequately treated latent or active TB infection. Participants with an indeterminate QuantiFERON TB test can have the test repeated and if a negative result is obtained, enrollment may proceed. If the repeat is indeterminate again, the participant will be excluded.',\n",
       "   'Participants who have been tested positive for the following tests:',\n",
       "   'Human immunodeficiency virus (HIV)',\n",
       "   'Hepatitis B virus (HBV): HBsAg or anti-HBc',\n",
       "   'Hepatitis C virus (HCV) Additional exclusion criteria for Phase Ib (Study 2-1, AD participants):',\n",
       "   'Participants with active forms of dermatological conditions such as contact dermatitis, seborrheic, discoid, gravitational, asteatotic and dyshidrotic eczema) or other inflammatory skin diseases that are not AD, such as psoriasis, viral infection, fungal infection or bacterial infection.',\n",
       "   'Participants who are inevitable to engage in activities involving excessive or prolonged exposure to sunlight.',\n",
       "   'Treatment with a biologic agent or JAK inhibitor at any time prior to baseline. Additional'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than rheumatoid arthritis.',\n",
       "   'Functional class IV American College of Rheumatology (ACR) Classification.',\n",
       "   \"Prior history of or current inflammatory joint disease other than rheumatoid arthritis (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondylarthritis, reactive arthritis, overlap connective tissue disease). History of secondary Sjogren's syndrome is permitted.\",\n",
       "   'Treatment with a biologic agent or JAK inhibitor at any time prior to baseline. Note: Treatment with traditional DMARDs is allowed provided that the dose is stable for ≥3 months prior to baseline. Oral corticosteroids (e.g. Prednisolone) are allowed if the dose is ≤10mg per day and has been stable for two weeks prior to baseline. NSAIDs and other low-potency analgesics are allowed if the dose has been stable for two weeks prior to baseline. High potency analgesics are excluded.',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline.',\n",
       "   'Previous treatment with tocilizumab.',\n",
       "   'History of or currently active primary or secondary immunodeficiency.']},\n",
       " {'nct_id': 'NCT04813549',\n",
       "  'inclusion': ['diagnosed with rheumatoid arthritis,',\n",
       "   'who can read and write in Turkish,',\n",
       "   \"participant's admission participating in the study,\",\n",
       "   'participants who do not have exclusion criteria'],\n",
       "  'exclusion': [\"participant's refusal to participate in the study,\",\n",
       "   'lack of cooperation due to cognitive impairment,',\n",
       "   \"participant's who have a neurological disease,\",\n",
       "   'presence of drug abuse,',\n",
       "   'presence of malignancy in any organ or system,',\n",
       "   'serious psychiatric problems (psychosis, etc.),',\n",
       "   'the presence of another rheumatological disease other than Rheumatoid Arthritis,',\n",
       "   'serious and unstable metabolic disease.']},\n",
       " {'nct_id': 'NCT04529902',\n",
       "  'inclusion': ['1. No prior use of tumor necrosis factor inhibitors or abatacept anytime prior to cohort entry date',\n",
       "   '2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date'],\n",
       "  'exclusion': ['1. Prior history of dementia measured anytime prior to cohort entry date',\n",
       "   '2. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort entry date',\n",
       "   '3. Prior history of nursing home admission in the 365 days prior to the cohort entry date']},\n",
       " {'nct_id': 'NCT04529863',\n",
       "  'inclusion': ['1. No prior use of tocilizumab or abatacept anytime prior to cohort entry date',\n",
       "   '2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date'],\n",
       "  'exclusion': ['1. Prior history of dementia measured anytime prior to cohort entry date',\n",
       "   '2. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort entry date',\n",
       "   '3. Prior history of nursing home admission in the 365 days prior to the cohort entry date']},\n",
       " {'nct_id': 'NCT04529876',\n",
       "  'inclusion': ['1. No prior use of tofacitinib or abatacept anytime prior to cohort entry date',\n",
       "   '2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date'],\n",
       "  'exclusion': ['1. Prior history of dementia measured anytime prior to cohort entry date',\n",
       "   '2. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort entry date',\n",
       "   '3. Prior history of nursing home admission in the 365 days prior to the cohort entry date']},\n",
       " {'nct_id': 'NCT04047121',\n",
       "  'inclusion': ['first pharmacy claim for Tofacitinib and then Etanercept or Adalimumab between Jan 2014 and Sep 2016 represents the index claim',\n",
       "   'First, select patients receiving ≥1 Tofacitinib pharmacy claim (Jan 2014-Sep 2016) who did not have a Tofacitinib claim anytime prior to index',\n",
       "   'Patients do have >1 advanced therapy filled on index date',\n",
       "   'Physician diagnosis of Rheumatoid Arthritis (in any position) during the 1-year pre-index period, or on the index date',\n",
       "   'Age 18+ years at index'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04482335',\n",
       "  'inclusion': ['Subject ≥ 18 years of age',\n",
       "   'Is capable of understanding and signing an informed consent form',\n",
       "   'Falls into one of the following:',\n",
       "   'Pre-RA',\n",
       "   'Any musculoskeletal symptom (inflammatory and/or non-inflammatory) AND either RF and/orACPA positive.',\n",
       "   'UA',\n",
       "   'Inflammatory joint symptoms (including joint pain, significant early morning stiffness and joint swelling) not fulfilling any classification criteria',\n",
       "   'ERA',\n",
       "   'recent clinical diagnosis of RA EstRA',\n",
       "   'known diagnosis of RA supported by evidence of established inflammatory arthritis including but not limited to synovitis, erosion, tenosynovitis.'],\n",
       "  'exclusion': ['Age less than 18 years',\n",
       "   'Lack of capacity to give informed consent']},\n",
       " {'nct_id': 'NCT04488497',\n",
       "  'inclusion': ['Have RA',\n",
       "   'Age between 40 and 75 years (inclusive)',\n",
       "   'Provide a date of their next appointment with their rheumatologist',\n",
       "   'Willing to work with a peer coach',\n",
       "   'No recollection of having a cholesterol test within the past 2 years OR talking with a physician about cholesterol test results',\n",
       "   'Speaks English',\n",
       "   'Have a phone',\n",
       "   'Has access to the internet',\n",
       "   'Resides or lives in the US'],\n",
       "  'exclusion': ['Do not have rheumatoid arthritis',\n",
       "   'Younger than age 40 or older than age 75',\n",
       "   'Taking a statin',\n",
       "   'History of known cardiovascular disease']},\n",
       " {'nct_id': 'NCT04057118',\n",
       "  'inclusion': ['Patients must provide written, signed, informed consent.',\n",
       "   'Patients must have a diagnosis of Rheumatoid Arthritis (RA) according to American College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against Rheumatism classification, for at least 6 months prior to first administration of study drug.',\n",
       "   'Patients must have active RA at screening and baseline (Day 1 of the study).',\n",
       "   'Patients who have active disease despite csDMARD (conventional synthetic disease-modifying antirheumatic drugs) therapy for at least 3 months prior to Day 1 of the study.',\n",
       "   'Patients must have had an inadequate response to previous anti-TNF⍺ (anti-tumor necrosis factor alpha) biological agent(s) for the treatment of RA and meet the washout period prior to Day 1 of the study. Exclusion Criteria:',\n",
       "   'Patients receiving oral agents, except for medications listed in inclusion criteria for the treatment of',\n",
       "   '- Patients who have previously received any other or biological agent for the treatment of RA, other than anti-TNF⍺ inhibitor(s).',\n",
       "   'Patients who have a current or past history of hepatitis B virus (HBV) infection; positive test for hepatitis C virus (HCV) antibody; positive test for human immunodeficiency virus (HIV); history of or concurrent interstitial pneumonia; acute infection requiring oral antibiotics within 2 weeks, or parenteral injection of antibiotics within 4 weeks prior to first administration of the study drug; other serious infection within 6 months prior to first administration of study drug; recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to first administration of the study drug; past or current granulomatous infections or other severe or chronic infection; positive test for tuberculosis (TB) or other evidence of',\n",
       "   '- Patients with uncontrolled diabetes mellitus, or uncontrolled hypertension (systolic blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg).',\n",
       "   'Patients with any other inflammatory or rheumatic diseases that could impact the evaluation of the effect of the study drug.',\n",
       "   'Patients with a history of malignancy within 5 years prior to first administration of the study drug, except completely excised and cured squamous cell carcinoma, carcinoma of the cervix in situ, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.',\n",
       "   'New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled cardiac disease or heart attack within 6 months prior to first administration of the study drug.',\n",
       "   'Female patients who are currently pregnant, breastfeeding or planning to become pregnant or breastfeed within 6 months of the last dose of the study drug. Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04056234',\n",
       "  'inclusion': ['patients presenting with RA according to ACR87 and ACR/EULAR 2010 criteria',\n",
       "   'patients presenting with RA anti-citrullinated peptide antibodies positive',\n",
       "   'patients presenting with active RA, characterized by at least one synovitis',\n",
       "   'patients presenting with an arthritis requiring arthrocentesis and synovial fluid collection for diagnostic or therapeutic purpose',\n",
       "   'patients giving agreement to participate to the study and to sign informed consent.'],\n",
       "  'exclusion': ['patients suffering from osteoarthritis',\n",
       "   'patients presenting with joint effusion justifying an arthrocentesis and synovial fluid collection for diagnostic of therapeutic purpose',\n",
       "   'patients giving agreement to participate to the study and to sign informed consent',\n",
       "   'Patients presenting with another arthropathy than anti-citrullinated peptide antibodies positive RA or osteoarthritis',\n",
       "   'Patients not requiring arthrocentesis for medical reasons',\n",
       "   'Patients refusing to sign informed consent',\n",
       "   'Patients presenting with understanding problems due to language or cognitive reasons.']},\n",
       " {'nct_id': 'NCT04559412',\n",
       "  'inclusion': ['Provides written informed consent',\n",
       "   'Has rheumatoid arthritis (RA) as defined by having a score of 6 or higher on the 2010 ACR-EULAR classification criteria',\n",
       "   'Is currently on Enbrel therapy and has received once-weekly Enbrel injections for at least 12 weeks with no more than 1 missed dose in the 12 weeks prior to Screening.',\n",
       "   'Must meet the following disease criteria: Have a DAS28(CRP) score > 2.9 at Screening Have a DAS28(ESR) score > 3.2 at Screening Swollen joint count ≥ 3 (28-joint count) and Tender joint count ≥ 3 (28-joint count) at Screening and Baseline',\n",
       "   'If on oral or subcutaneous MTX (up to 25 mg/week) or other permitted oral conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) (i.e., leflunomide, up to 20 mg/day; hydroxychloroquine, up to 400 mg/day; or sulfasalazine, up to 3 g/day), must be on stable dose (MTX ≥ 12 weeks and other permitted DMARDs ≥ 8 weeks) within the specified ranges prior to Baseline. Note: if on methotrexate (MTX), subjects must be on a stable dose of folic acid (total ≥ 5 mg per week for ≥ 12 weeks) prior to Baseline and must continue a stable dose during the course of the study.',\n",
       "   'If taking regular nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) inhibitors, paracetamol/acetaminophen, or oral glucocorticoids for treatment of RA symptoms, must be on stable dose and route of administration for at least 2 weeks before Baseline',\n",
       "   'Females of childbearing potential must agree to use acceptable method(s) of contraception for the duration of the study and for 3 months after the last dose of study drug'],\n",
       "  'exclusion': ['Has participated in a clinical trial with a drug or device within 30 days prior to Screening',\n",
       "   'Prior treatment with investigational therapy within 30 days or 5 half-lives before Screening (whichever is longer)',\n",
       "   'History of hypersensitivity to any recombinant protein drugs or any of the excipients used in Enbrel',\n",
       "   'Has skin contact sensitivities (due to SOFUSA device adhesive) or allergies to iodine (due to the iodine in ICG)',\n",
       "   \"Lack of any clinical response to Enbrel in the Investigator's opinion\",\n",
       "   'Treatment with other biologic agents (e.g., interleukin [IL] 6, IL17, IL12/23 inhibitors; abatacept, tumor necrosis factor [TNF] inhibitors) besides Enbrel within 24 weeks before Baseline',\n",
       "   'Previous treatment with more than 2 other tumor necrosis factor (TNF) inhibitor therapies (besides Enbrel), more than 2 targeted therapies with different mechanisms of action (e.g., Janus kinase inhibitors, T cell costimulation inhibitor, IL-6 receptor antagonist), or any cell depleting agents (e.g., anti-CD20)',\n",
       "   'Use of chlorambucil or cyclophosphamide within 24 weeks of Baseline',\n",
       "   'Use of leflunomide within 8 weeks of Baseline, if washing out of leflunomide, unless a cholestyramine washout has been performed, then use of leflunomide within 4 weeks of Baseline',\n",
       "   'Use of MTX, hydroxychloroquine, or sulfasalazine within 4 weeks of Baseline, if washing out of MTX, hydroxychloroquine, or sulfasalazine',\n",
       "   'Any systemic nonbiologic DMARD (e.g., Janus kinase inhibitor, cyclosporine, azathioprine) within 4 weeks of Baseline',\n",
       "   \"History of or ongoing inflammatory, autoimmune, or painful musculoskeletal diseases (except for Sjogren's syndrome or fibromyalgia) which could interfere with the RA assessments as determined by the Investigator\",\n",
       "   'Functional RA status of class IV according to the ACR 1991 revised criteria at Screening or Baseline',\n",
       "   'Oral glucocorticoids > 10 mg/day prednisone equivalent within 4 weeks prior to Baseline',\n",
       "   'Opioid tolerant: defined as the use of opiate analgesics at a dose of > 30 mg/day of oral morphine equivalent on 4 of the last 7 days prior to Baseline',\n",
       "   'Use of intramuscular, intravenous, or intraarticular corticosteroid therapy within 4 weeks prior to Baseline',\n",
       "   'Treatment with any intra-articular hyaluronic acid preparation within 12 weeks prior to Baseline',\n",
       "   'Chronic arthritis diagnosis before the age of 17 years',\n",
       "   'Presence of any extra-articular manifestations of RA, except for rheumatoid nodules',\n",
       "   'Joint surgery within the preceding 8 weeks before Screening',\n",
       "   'History of, or presence of cancer (if < 5 years from successful treatment even with no evidence of recurrent disease) or lymphoproliferative or hematologic disease, other than a successfully and completely treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix and/or removed non-invasive colon or bladder polyps, with no evidence of recurrence',\n",
       "   'History of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (New York Heart Association III-IV), active peptic ulcer disease, recent stroke, myocardial infarction, or thromboembolism (within 6 months), or any other condition which, in the opinion of the Investigator, would put the patient at risk by participation in the study',\n",
       "   'Previous diagnosis or signs of demyelinating disease',\n",
       "   'History of clinically significant hematologic (e.g. severe anemia, leukopenia, thrombocytopenia), renal or liver disease (e.g. glomerulonephritis, fibrosis, cirrhosis, hepatitis) or abnormal clinical laboratory tests at Screening',\n",
       "   'Receipt of any blood products within 12 weeks of Baseline',\n",
       "   'History of persistent chronic infection; recurrent infection (more than 3 infections requiring antimicrobial therapy within the last 12 months); or active infections requiring hospitalization or treatment with systemic anti-infective therapy within 4 weeks before Screening (counted from anti-infective therapy stop date), except for fungal infection of nails or nail beds',\n",
       "   'History of or current active tuberculosis or presence of latent tuberculosis as detected by imaging (e.g., chest radiograph) and/ or QuantiFERON®-TB Gold Plus test (QFT) NOTE: Positive QFT (or 2 or more tests that are indeterminate) and/or positive imaging result (within 12 weeks prior to Screening or at Screening) excludes a patient from participation in the study (except for patients who have documentation of completing an acceptable regimen for treatment of latent tuberculosis with no known re-exposure to tuberculosis since treatment completion)',\n",
       "   'History or evidence of opportunistic infections (eg, histoplasmosis, listeriosis, legionellosis)',\n",
       "   'Known immune deficiency, known human immunodeficiency virus (HIV) positive or positive at Screening, or immunocompromised for other reasons',\n",
       "   'Serology positive for hepatitis B virus (HBV) surface antigen (HBsAg) or core antibody (HBcAb) or hepatitis C virus (HCV) antibody (HCV-Ab) or ribonucleic acid (HCV RNA). Patients treated for HCV and considered cured (negative HCV RNA) may participate in the study',\n",
       "   'Positive RT-PCR or the equivalent COVID-19 test at Screening',\n",
       "   'History or evidence of ongoing significant drug or alcohol abuse',\n",
       "   \"Known depression or other psychiatric condition, which in the Investigator's opinion may decrease likelihood of participant adherence to the study protocol requirements\",\n",
       "   'History of vaccination with live vaccines within the preceding 8 weeks prior to Baseline or known to require vaccination with live vaccines during the study period',\n",
       "   'For female participants, currently breastfeeding (lactating) or less than 12 weeks from cessation of lactation',\n",
       "   'Pregnant woman where pregnancy is defined as the state of a woman after conception and until the termination of gestation, confirmed by a positive serum pregnancy test at Screening or positive urine pregnancy test at Baseline',\n",
       "   'Patient is considered by the Investigator, for any reason, to be an unsuitable candidate for the study']},\n",
       " {'nct_id': 'NCT04550884',\n",
       "  'inclusion': ['Adults aged ≥ 18 years.',\n",
       "   'RA patients who fulfilled the 2010 ACR/European league against Rheumatism(EULAR) criteria for the classification of RA',\n",
       "   'RA patients complaining of foot and ankle pain'],\n",
       "  'exclusion': ['Presence of other autoimmune disorders',\n",
       "   'Presence of any comorbidities causing neuropathy as Diabetes Mellitus, disc prolapse']},\n",
       " {'nct_id': 'NCT04558905',\n",
       "  'inclusion': ['Patients with RA diagnosis according to their primary rheumatologist',\n",
       "   'With at least six months of follow-up (up to March 2020) at the outpatient clinic',\n",
       "   'Who agree to participate'],\n",
       "  'exclusion': ['Patients lost to follow-up from the outpatient clinic before March 2020',\n",
       "   'Patients with no access to a mobile device during their study participation',\n",
       "   'Patients with severe cognitive, visual and hearing impairment',\n",
       "   'Patients on palliative care because of comorbid condition']},\n",
       " {'nct_id': 'NCT04662359',\n",
       "  'inclusion': [\"Patients must meet the American College of Rheumatology's 2010 criteria for rheumatoid arthritis. They must be undergoing treatment with a disease-modifying anti-rheumatic drug, and their Clinical Disease Activity Index (CDAI) must be greater than 10 while their swollen joint count must be less than or equal to two.\"],\n",
       "  'exclusion': ['Patients with evidence of large joint (knee, hip, shoulder, elbow) disease activity, including warmth and swelling, and patients who have had a joint MRI or musculoskeletal ultrasound in the past 3 months will not be eligible to participate in the study.']},\n",
       " {'nct_id': 'NCT04606810',\n",
       "  'inclusion': ['age ≥ 18 years and had a diagnosis of RA,',\n",
       "   'with active disease as per rheumatologist evaluation,',\n",
       "   'having received a trial of two traditional nbDMARDs therapy, and',\n",
       "   'who requires the addition or change of a biological agent'],\n",
       "  'exclusion': ['patient unable to consent,',\n",
       "   'patient unable to answer questionnaires,',\n",
       "   'patient unable to view a DVD at home',\n",
       "   'patient unable to participate in a teleconference']},\n",
       " {'nct_id': 'NCT04301622',\n",
       "  'inclusion': ['Has previously undergone or currently has determined to undergo a primary TKA with the specified combination of components: EVOLUTION® CS/CR Porous Femur, EVOLUTION® CS Tibial Insert, and EVOLUTION® BIOFOAM® Tibia and modular keel',\n",
       "   'Has previously undergone or currently has determined to undergo a primary TKA for any of the following:',\n",
       "   'non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;',\n",
       "   'inflammatory degenerative joint disease including rheumatoid arthritis;',\n",
       "   'correction of functional deformity;',\n",
       "   'willing and able to complete required study visits and assessments through the 10 year postoperative follow-up visit.',\n",
       "   'Previously implanted subjects must be enrolled within 3 years (+6 months) of their primary TKA implantation'],\n",
       "  'exclusion': ['Skeletally immature (less than 21 years of age) at time of implantation',\n",
       "   'Has or had an overt infection at the time of implantation',\n",
       "   'Has or had a distant foci of infections (which may cause hematogenous spread to the implant site) at the time of implantation',\n",
       "   'Has or had a rapid disease progression as manifested by joint destruction or bone absorption apparent on roentgenogram at the time of implantation',\n",
       "   'Has or had inadequate neuromuscular status (e.g., prior paralysis, fusion, and/or inadequate abductor strength), poor bone stock, poor skin coverage around the joint which would make the procedure unjustifiable',\n",
       "   'Has had a revision procedure(s) where other treatments or devices have failed; and treatment of fractures that are unmanageable using other techniques',\n",
       "   'Currently enrolled in another clinical investigation which could affect the endpoints of this protocol',\n",
       "   'Unwilling or unable to sign the Informed Consent document',\n",
       "   'Has documented substance abuse issues',\n",
       "   'Has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study',\n",
       "   'Currently incarcerated or has impending incarceration',\n",
       "   \"Has a medical condition, as judged by the Investigator, that would interfere with the subject's ability to comply with the requirements of the protocol\"]},\n",
       " {'nct_id': 'NCT04306744',\n",
       "  'inclusion': ['Be between 18 and 80 years of age at the time of enrollment',\n",
       "   'Diagnosis of rheumatoid arthritis based on the 2010 EULAR/ACR criteria',\n",
       "   'Diagnosis present for ≥3 months',\n",
       "   'Have evidence of active disease, as defined by having at least 4 tender and 4 swollen joints in the TJC68 and SJC66, respectively',\n",
       "   'Presence of rheumatoid factor or anti-CCP antibody at enrollment',\n",
       "   'Must have an inadequate response to the maximum tolerated dose of 15-25 mg/week (unless lower dose is needed to due toxicity or physician discretion) of csDMARD/s for at least 12 weeks with a stable dose for at least 4 weeks prior to Baseline visit and have not been previously treated with a biologic',\n",
       "   'Participants receiving a nonsteroidal anti-inflammatory drug (NSAID), prednisone or prednisone equivalent (10mg or less/day) or methotrexate must be on stable doses of these agents for more than 30 days prior to Baseline and remain stable for the duration of the study',\n",
       "   'Able to operate the device appropriately and use it as per the protocol requirements',\n",
       "   'Be willing and capable of giving informed consent',\n",
       "   'Be willing and able to comply with research-related requirements, procedures, assessments and visits'],\n",
       "  'exclusion': ['Previously treated with any approved or investigational biologic agent (including TNF-, IL-1, IL-6, T-cell or B-cell targeted therapies) or tsDMARD',\n",
       "   \"History of any arthritis with onset prior to age 17 years or current diagnosis, inflammatory joint disease other than RA (including but not limited to gout, systemic lupus erythematosus, psoriatic arthritis, axial spondyloarthritis including ankylosing spondylitis and non-radiographic axial spondyloarthritis, reactive arthritis, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, fibromyalgia. Current diagnosis of secondary Sjogren's Syndrome is permitted.\",\n",
       "   'Participants receiving intraarticular, intramuscular, or intravenous glucocorticoids within 4 weeks prior to Baseline (unless participant is on stable dose of prednisone as per inclusion above) or if it is anticipated that the participant will need glucocorticoids at some point during the expected study duration',\n",
       "   'Have active disease involving the auricle or ear canal (e.g. otitis media, tinnitus, infection, perforated tympanic membrane, vestibular and/or balance, excessive cerumen production), unwilling to remove a piercing (e.g. daith or tragus), or use a device (e.g. hearing aid, cochlear implant) that would preclude daily use of the earpiece',\n",
       "   'History of any clinically significant (as deemed by PI) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, neurologic, gastrointestinal, immunologic, or other major diseases',\n",
       "   'History of unilateral or bilateral vagotomy',\n",
       "   'History of recurrent vasovagal syncope episodes',\n",
       "   'Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the research or confounds the ability to interpret data from the research in the opinion of the Investigator',\n",
       "   'Previously implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)',\n",
       "   'Be pregnant or breast feeding (if female and sexually active, participant must be using a reliable form of birth control, be surgically sterile or be at least 2 years post-menopausal)',\n",
       "   'Have symptomatic osteoarthritic knee issues within 30 days of enrollment',\n",
       "   'Diagnosis of cancer (other than non-invasive skin cancer or carcinoma in-situ of the cervix) within the 5 years prior to research initiation',\n",
       "   'Significant ECG findings (as determined by the Investigator), defined by:',\n",
       "   'Ischemic changes (defined as >1mm of down-sloping ST segment depression in at least two contiguous leads)',\n",
       "   'Q-waves in at least two contiguous leads',\n",
       "   'Clinically significant intra-ventricular conduction abnormalities (left bundle branch block or Wolf-Parkinson-White syndrome)',\n",
       "   'Clinically significant arrhythmias (e.g., current atrial fibrillation)',\n",
       "   'Bradyarrhythmias (e.g. Type I or type II block)',\n",
       "   'Have been hospitalized for psychiatric disorder or attempted suicide within the last 12 months',\n",
       "   'History of concurrent illness that requires hospitalization within 30 days prior to Baseline',\n",
       "   'Have skin and vascular problems such as infected areas of skin, skin eruptions, dermatological conditions, open wounds or damaged or broken skin in the area where stimulation is planned',\n",
       "   'Have uncontrolled hypertension or hypotension',\n",
       "   'History or current abuse of or dependence on alcohol or drugs that would interfere with the results or adherence to research requirements based on the judgement of the Investigator',\n",
       "   'Any clinically relevant abnormal findings in the physical exam, vital signs or laboratory tests that, in the opinion of the Investigator, may put the participant at risk',\n",
       "   'Any language barrier that, in the opinion of the Investigator, would preclude communication and compliance with the research requirements',\n",
       "   'Participation in another investigational trial during the 30 days prior to research initiation or during this study',\n",
       "   'Any other household member currently participating in Vorso research or relative of site staff member',\n",
       "   'If the investigator believes there is any reason that the participant will not be compliant with the study requirements and completion of evaluations']},\n",
       " {'nct_id': 'NCT04300465',\n",
       "  'inclusion': ['Stable rheumatoid arthritis (RA). Rheumatoid arthritis as diagnosed by a rheumatologist. Stable meaning that there was no escalation of disease modifying antirheumatic drugs OR escalation in steroid dose/frequency within the previous 6 months. Patients on a stable dose of chronic steroids are eligible for inclusion.',\n",
       "   'Stable chronic kidney disease (CKD). CKD can be of any cause. Stable meaning that there was no significant change in renal function over a period of 3 months Stage of CKD is based on the 2012 KDIGO guidelines:19',\n",
       "   'Stage 3 CKD: GFR 30-59ml/min/1.73m2',\n",
       "   'Stage 4 CKD: GFR of 15-29ml/min/1.73m2. GFR will be calculated based on CKD-EPI equation.',\n",
       "   'At least 2 of the 5 following uncontrolled cardiovascular risk factors:',\n",
       "   'Hypertension (BP ≥130/80mmHg)',\n",
       "   'Active smokers',\n",
       "   'BMI ≥30kg/m2',\n",
       "   'Dyslipidemia (LDL ≥1.4mmol/L in very high risk, ≥1.8mmol/L with high risk, LDL',\n",
       "   '2.6mmol/L with moderate risk or ≥3.0mmol/L in low risk)',\n",
       "   'Poor glycemic control (Defined as: HbA1c ≥53mmol/mol OR ≥48mmol/mol in patients with a long-life expectancy or type 2 diabetes controlled by diet alone) All patients with RA/CKD must have a partner to be included in the study. Partners do not need to have any particular underlying diagnosis and can in theory be completely healthy. The partners must not meet any of the exclusion criteria. Both the patient and the partner must freely sign informed consent.'],\n",
       "  'exclusion': ['Known unstable angina, symptomatic severe aortic stenosis, pregnant patients, severe cognitive impairment, physical impairment leading to inability to exercise, currently enrolled in another lifestyle program, currently awaiting organ transplant, previous renal transplant, patients with End Stage Renal Disease (Stage 5 CKD) or those expected to commence dialysis within the next 6 months, acute pulmonary embolus or pulmonary infarction']},\n",
       " {'nct_id': 'NCT04309227',\n",
       "  'inclusion': ['diagnosis from LSUHSC-SHreveport Rheumatologist of rheumatoid arthritis (RA), osteoarthritis (OA), or myositis',\n",
       "   'stable medication for at least 3 months',\n",
       "   'OA in weightbearing joints, and limited to non-advanced OA per Kellgren Lawrence grading',\n",
       "   'cleared by rheumatologist for participation in high intensity training and blood flow restriction training'],\n",
       "  'exclusion': ['cardiovascular or other disease preventing exercise participation',\n",
       "   'within past 6 months, have performed regular physical activity training or physical therapy',\n",
       "   'one or more arthroplasty in weight-bearing joints',\n",
       "   'taking more then 5mg of prednisone in past 3 months',\n",
       "   'unable to perform timed up and go test, 10 meter walk test, or 6 minute walk test without more than supervision assistance; assistive devices can be used']},\n",
       " {'nct_id': 'NCT04402554',\n",
       "  'inclusion': ['Rheumatoid Arthritis (ACR 2010 Criteria)',\n",
       "   'Ankylosing Spondylitis (New york or ASAS criteria)',\n",
       "   'Psoriatic Arthritis (CASPAR criteria)'],\n",
       "  'exclusion': ['Patient unable to complete questionnaires or unable to express informed consent',\n",
       "   'Guardianship, trusteeship, deprivation of liberties, safeguard of justice']},\n",
       " {'nct_id': 'NCT04402086',\n",
       "  'inclusion': [\"Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\",\n",
       "   'Receiving clinical care at Yale Rheumatology clinics Exclusion Criteria for Rheumatology Patients:',\n",
       "   'Unable to provide informed consent',\n",
       "   'No patients will be excluded based on gender or ethnicity or pregnancy status.',\n",
       "   'Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.',\n",
       "   'Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy. Inclusion Criteria for Healthy Volunteers:',\n",
       "   'Age ≥ 18 years old',\n",
       "   'No chronic skin conditions',\n",
       "   'No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)',\n",
       "   'Normal BMI'],\n",
       "  'exclusion': ['Unable to provide informed consent.',\n",
       "   'Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.',\n",
       "   'Allergies to lidocaine or epinephrine (skin biopsies).',\n",
       "   'A history of impaired wound healing (skin biopsies).']},\n",
       " {'nct_id': 'NCT04407559',\n",
       "  'inclusion': ['Samples from a pre-July 2019 RA patient biobank to ensure true negativity of Covid -19 (patients over 18 years old)'],\n",
       "  'exclusion': ['Patients who have traveled to China or Saudi Arabia and therefore may have encountered other coronaviruses.']},\n",
       " {'nct_id': 'NCT04324892',\n",
       "  'inclusion': ['fulfilled the 2010 ACR/EULAR classification criteria for RA',\n",
       "   'have symptoms onset of less than 2 years,',\n",
       "   'have active disease (SDAI >3.3)'],\n",
       "  'exclusion': ['have severe clinical deformity at the 2nd, 3rd or 4th MCP joint which precluded a reliable HR-pQCT examination and resulted in motion artefacts influencing the scanning accuracy',\n",
       "   'are pregnant or breast feeding']},\n",
       " {'nct_id': 'NCT04321291',\n",
       "  'inclusion': ['Age 18 and over (no upper age limit)',\n",
       "   'All adult patients seen in rheumatology consultation at the Montpellier Hospital',\n",
       "   'With inflammatory rheumatism (rheumatoid arthritis or spondyloarthritis).',\n",
       "   'Treated (or in the process of being treated at the end of the consultation) by etanercept or adalimumab',\n",
       "   'In whom the biomedical treatment already used should in principle be renewed without modification (patient deemed good responder and well tolerant of the treatment)',\n",
       "   'Or where biomedical initiation has just been indicated during the consultation',\n",
       "   'Member of a social security scheme',\n",
       "   'Informed and written consent'],\n",
       "  'exclusion': ['Unable to understand information (not fluent in the French language, severe cognitive impairment, etc.)',\n",
       "   'Known intolerance to one of the proposed biosimilar excipients',\n",
       "   'Vulnerable persons: pregnant woman, minor patient, deprived of liberty, under guardianship or under curatorship']},\n",
       " {'nct_id': 'NCT04297475',\n",
       "  'inclusion': ['The patients were above 18 years-old;',\n",
       "   'The patients were diagnosed with RA according to the American College of Rheumatology (ACR) criteria, and the current clinical state was in-active or relapse;',\n",
       "   'The patients were consent to receive examinations of photoacoustic imaging. The'],\n",
       "  'exclusion': ['The patients had mental disease or other severe diseases, and were not capable of receiving imaging examinations;',\n",
       "   'The patients had strong reaction to laser light.']},\n",
       " {'nct_id': 'NCT04380129',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA)', 'Over 18 years of age'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04389320',\n",
       "  'inclusion': ['rheumatoid arthritis recieving hydroxychloroquine chest infection'],\n",
       "  'exclusion': ['patients not used hydroxychloroquine']},\n",
       " {'nct_id': 'NCT04311567',\n",
       "  'inclusion': ['Diagnosis of seropositive (i.e., presence of RF and/or anti-CCP antibodies) rheumatoid arthritis (RA) according to the ACR/EULAR 2010 criteria within 24 months.',\n",
       "   'No previous treatment with disease modifying anti-rheumatic drugs (DMARDs). History of prednisone use is allowed but should have been discontinued 2 weeks before baseline measurement.',\n",
       "   'Active disease with ≥2 painful and ≥2 swollen joints in 66/68 joints and CRP ≥2.0 mg/L',\n",
       "   'Aged 18-80 years',\n",
       "   'The subject has given written consent to participate in the study. Exclusion Criteria:',\n",
       "   'Current active inflammatory joint disease other than',\n",
       "   \"2. Significant and/or uncontrolled cardiac, pulmonary disease, nervous system, renal, hepatic, endocrine or gastrointestinal disorders or severe RA which in the investigator's opinion would preclude patient participation.\",\n",
       "   'Malignancy within the past 5 years, except for successfully treated cervical carcinoma in situ, basal cell and squamous cell carcinoma of the skin, with no evidence of recurrence or metastatic disease for at least 3 years.',\n",
       "   'Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection.',\n",
       "   'Pregnant or lactating women. For subjects in part II the following'],\n",
       "  'exclusion': ['Women of childbearing potential not willing or able to use highly effective methods of birth control per ICH M3 (R2) for 28 days prior and 3 months after end of study.',\n",
       "   'Active infection (excluding fungal infections of nail beds) requiring i.v. anti-infectives within 4 weeks, or oral anti-infectives within 2 weeks prior to baseline.',\n",
       "   'Positive tests for hepatitis B (HBsAg or HBV DNA),hepatitis C serology or SARS-CoV2',\n",
       "   'History of herpes zoster infection during last 10 years.',\n",
       "   'History or risk of venous thromboembolism or diverticulitis.',\n",
       "   'Positive tuberculosis history and/or positive Quantiferon test.',\n",
       "   'Hemoglobin <90 g/L.',\n",
       "   'Absolute neutrophil count < 1500 cells/uL.',\n",
       "   'ASAT or ALAT >2.0 times the upper limit of normal.',\n",
       "   'High or very high risk (≥ 5%) of cardiovascular death within 10 years by SCOREx1,5.',\n",
       "   'Multiple incidental solid/subsolid lung nodules of size ≥6 mm, single incidental solid lung nodules ≥8',\n",
       "   '']},\n",
       " {'nct_id': 'NCT04315818',\n",
       "  'inclusion': ['Any patient aged 18 or older',\n",
       "   'satisfying 2010 ACR/ EULAR Rheumatoid Arthritis classification criteria will be included .'],\n",
       "  'exclusion': ['Any patient with arthritis other than Rheumatoid Arthritis',\n",
       "   'Individuals with other autoimmune diseases']},\n",
       " {'nct_id': 'NCT04312815',\n",
       "  'inclusion': ['Adult patients 18-75 years of age.',\n",
       "   'Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria, or 2010 ACR/EULAR for the classification of rheumatoid arthritis.',\n",
       "   'Moderate to severe active RA with swollen joint count (SJC) ≥ 6(66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.',\n",
       "   'At screening, either High sensitivity C-Reactive Protein (hs-CRP) ≥ 1.5 UNL, or Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or Morning stiffness of joint for ≥ 45 minutes.',\n",
       "   'Inadequate response to methotrexate, having received and tolerated at a dose of 7.5-20 mg/week for ≥ 12 weeks, at a stable dose over the past 4 weeks.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than',\n",
       "   '- Use of any biological DMARDs for',\n",
       "   '- Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate',\n",
       "   \"Active infection, or history of serious or chronic infection The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT04157010',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis (2010 ACR/EULAR RA classification criteria)',\n",
       "   'Symptom duration ≤12months',\n",
       "   'No previous disease modifying antirheumatic drug (DMARD) therapy',\n",
       "   'Active RA at baseline (defined as: DAS28 ≥ 3.2)',\n",
       "   'Active hand and/or wrist joint evaluable by US and MRI (with no planned surgery during the study period)',\n",
       "   'Patients without any contraindication to MRI'],\n",
       "  'exclusion': ['Patients unwilling or unable to receive MTX for the duration of the study.',\n",
       "   \"Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter's syndrome, psoriatic arthritis, systemic lupus erythematosis, or any arthritis with onset prior to 16 years of age.\",\n",
       "   \"Suspicion of diagnosis of tuberculosis (TB): positive quantiferon +/abnormal chest x-ray, as per clinician judgement. Prior history of TB with confirmed full chemotherapy +/latent TB adequately treated may be included as per physician's discretion.\",\n",
       "   'Intramuscular, oral or intraarticular (of non-target joint) corticosteroid within 28 days of the screening visit; intra-articular steroid of the chosen target joint within 12 weeks of screening.',\n",
       "   'Patients with serious infections within 3 month of enrolment (screening) or persistent infections.',\n",
       "   'Patients at significant risk of infection (e.g. leg ulceration, indwelling urinary catheter, septic joint within 1 year (or ever if prosthetic joint still in situ).',\n",
       "   'Known positive serology for hepatitis B or C, or HIV']},\n",
       " {'nct_id': 'NCT04910048',\n",
       "  'inclusion': ['End-stage knee or hip osteoarthritis, avascular necrosis, or rheumatoid arthritis with recommended primary, unilateral total joint arthroplasty by orthopaedic surgeons at the University of Arkansas for Medical Sciences (Jeffrey Stambough,',\n",
       "   'C. Lowry Barnes,',\n",
       "   'Simon Mears, and',\n",
       "   'Benjamin Stronach)',\n",
       "   'BMI between 41.00-48.00 kg/m2 at time of enrollment',\n",
       "   'Over the age of 18 years',\n",
       "   'Would consider undergoing a total joint arthroplasty if eligible',\n",
       "   'Owns a smartphone or tablet with Bluetooth capability, cell signal or WIFI connection',\n",
       "   'Willing to comply with the requirements of the study and provide informed consent prior to enrollment.'],\n",
       "  'exclusion': ['Patients with a BMI less than 41.00 or greater than 48.00',\n",
       "   'Pregnancy',\n",
       "   'Breastfeeding',\n",
       "   'History of a major organ transplant or other health issue requiring immunosuppressant drugs',\n",
       "   'Strict vegetarian diet',\n",
       "   'Diagnosis of and/or are taking medication for psychiatric conditions including schizophrenia, bipolar disorder or manic depression',\n",
       "   'Patients scheduled for, or those who have previously undergone, bariatric surgery',\n",
       "   'Patients unable to understand and speak English',\n",
       "   'Patients requiring a revision or bilateral TJA',\n",
       "   'Patients unwilling or unable to use a bluetooth-enabled smartphone with cell service or home internet access',\n",
       "   'Incarceration']},\n",
       " {'nct_id': 'NCT04911127',\n",
       "  'inclusion': ['Meet the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 Classification Criteria for Rheumatoid Arthritis',\n",
       "   'Disease activity score (DAS28) >= 3.2',\n",
       "   'Age >= 18',\n",
       "   'Stable RA therapy for 12 weeks prior to baseline',\n",
       "   'Power Doppler Score >= 5 (for the PDUS 34 joint score)',\n",
       "   'Must use at least one highly effective method of contraception',\n",
       "   'Written informed consent'],\n",
       "  'exclusion': ['Prior exposure to cannabis <= 28 days prior to baseline',\n",
       "   'Current diagnosed substance use disorders (including Alcohol Use Disorder)',\n",
       "   'Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment',\n",
       "   'Chronic infections',\n",
       "   '>10mg of prednisone daily use',\n",
       "   'Daily use of central nervous system (CNS) depressant medications (e.g. sedatives, hypnotics [zolpidem, temazepam, alprazolam, lorazepam, diphenhydramine etc.])',\n",
       "   'Women who are pregnant, planning to become pregnant, or breast feeding',\n",
       "   'Sexually active subjects and their partners who are of childbearing potential (ie, neither surgically sterile nor postmenopausal) and not agreeing to use adequate contraception',\n",
       "   'Deemed unsafe by the investigator',\n",
       "   'History of an allergic reaction or adverse reaction to cannabis is exclusionary.']},\n",
       " {'nct_id': 'NCT04286789',\n",
       "  'inclusion': ['≥18 years of age or older, males or females.',\n",
       "   'Diagnosed rheumatoid arthritis per the American Rheumatism Association 1987 classification criteria of at least 6 months duration.',\n",
       "   'Disease activity defined as:',\n",
       "   'erythrocyte sedimentation rate (ESR) > 24 mm or serum C-reactive protein level ≥ 1.2 times (X) the upper limit of normal (ULN), and',\n",
       "   'DAS28-CRP score ≥ 2.6 and < 5.1',\n",
       "   'Current regimen of DMARDs that may include methotrexate, sulfasalazine, hydroxychloroquine, leflunomide and/or azathioprine, alone or in combination.',\n",
       "   'No change in DMARD dose(s) within 4 weeks prior to Screening.',\n",
       "   'May be receiving a stable regimen (of at least 4 weeks duration) of concomitant NSAIDs.',\n",
       "   'Women of child-bearing potential (WOCBP), defined as a sexually mature woman not surgically sterilized, or not post-menopausal for at least 12 consecutive months. Female subjects must:',\n",
       "   'Not be lactating; not be pregnant upon enrollment.',\n",
       "   'Agree to use highly effective methods of birth control throughout the study. Highly effective methods of contraception include combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation by oral, intravaginal, or transdermal administration; progestogen-only hormonal contraception associated with inhibition of ovulation by oral, injectable, or implantable administration; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; partner vasectomy; or total abstinence (only if total abstinence is an established method and lifestyle of the subject).',\n",
       "   'Patients already using hormonal contraception at the time of screening will be eligible but will not initiate hormonal contraception in order to participate in the study.',\n",
       "   'Agree to use highly effective methods of birth control for at least 6 months after the last dose of investigational product.',\n",
       "   'Male subjects must refrain from donating sperm or fathering a child during the study.',\n",
       "   'Male subjects must use barrier contraception throughout the course of the study.',\n",
       "   'Signed and dated informed consent.'],\n",
       "  'exclusion': ['Prior therapy with any biologic therapeutic within 3 months prior to enrollment, or in the case of Rituxan (rituximab), this period must be at least 12 months.',\n",
       "   'History of or current clinical fibromyalgia or Juvenile Idiopathic Arthritis (JIA).',\n",
       "   'Positive diagnosis of SLE.',\n",
       "   'Patients with Type 1 or Type 2 Diabetes Mellitus.',\n",
       "   'Patients with psoriasis.',\n",
       "   'Patients with skin condition(s) or visible abnormalities at or near potential sites of injection (right and left abdomen; right and left thigh) that could mask the assessment of safety.',\n",
       "   'Acute illness including current or chronic infections requiring antibiotics, or symptoms of a resolving illness, within 2 weeks prior to study.',\n",
       "   'Any investigational drug within 3 months prior to study.',\n",
       "   'Patients may not be receiving systemic corticosteroid therapy with the exception of inhaled corticosteroids for the treatment of asthma.',\n",
       "   'Any clinically relevant abnormality as assessed by the Investigator, on screening history, physical exam, clinical laboratory, chest X-ray, or ECG, other than values consistent with rheumatoid arthritis, with the exception that liver function tests (ALP, ALT, AST) may be up to 1.5 times (X) the upper limit of normal (ULN).',\n",
       "   'Positive serological test for HCV, HBsAg, HBcAg, HIV.',\n",
       "   'QuantiFERON-positive patients may be enrolled with documented evidence that they have completed a prescribed course of antituberculous therapy.',\n",
       "   'History of cardiovascular disease with New York Heart Association (NYHA) functional class II or greater; or history of stroke, or uncontrolled hypertension.',\n",
       "   'History of lymphoproliferative disease, or organ allograft.',\n",
       "   'Pregnancy or lactation, or WOCBP not currently using contraceptives or male partners of WOCBP not currently using contraceptives.',\n",
       "   'History of cancer (except for in situ cancer, or limited stage cancer of the cervix, head and neck (squamous cell), thyroid, or skin (non-melanomatous) curatively treated with no sign of disease for > 5 years).',\n",
       "   'Any physical or psychological condition that might prevent complete participation in the study, in the view of the investigator.']},\n",
       " {'nct_id': 'NCT04284735',\n",
       "  'inclusion': ['Subject aged ≥ 18 and ≤ 70 years',\n",
       "   'Patient with RA with ACPA in the state phase, meeting ACR / EULAR 2010 criteria',\n",
       "   'For female subjects:',\n",
       "   'Likely to procreate: negative pregnancy test at the inclusion visit and use of an effective method of contraception (hormonal contraceptives, intrauterine devices, vasectomized partner, abstinence) started at least 1 month before inclusion and continued during the entire study.',\n",
       "   'Inability to procreate: menopause (absence of a rule for at least 1 year) or hysterectomy or bilateral oophorectomy or tubal ligation.',\n",
       "   'Subject having given written consent to participate in the study',\n",
       "   'Subject affiliated to the Social Security scheme or benefiting from an equivalent scheme Additional inclusion criteria for cases (RA patients with PID):',\n",
       "   'PID is defined as damage compatible with the thoracic scanner in thin sections according to international criteria with or without associated clinical signs. Additional inclusion criteria for control patients (RA patients without symptomatology without PID)',\n",
       "   'No functional lung complaints Exclusion Criteria: General'],\n",
       "  'exclusion': ['Vulnerable patient within the meaning of current French legislation (deprived of liberty by judicial or administrative decision, under guardianship or curatorship or under the protection of justice)',\n",
       "   'Patient not fluent in French',\n",
       "   'Woman breastfeeding or planning a pregnancy for the duration of the study',\n",
       "   'Patient in exclusion period after participating in another clinical trial or in the process of participating in another clinical trial involving an experimental product',\n",
       "   'Patient with occupational exposure to particles known to be responsible for PID (silica, etc.)',\n",
       "   'Patient with an autoimmune disease other than RA or an auto-inflammatory disease Non-inclusion criteria for cases (RA patients with PID):',\n",
       "   'Patient with a history of asthma, COPD or any other pulmonary pathology or pulmonary symptom unrelated to PID Non-inclusion criteria for control patients (RA patients without PID)',\n",
       "   'Patient with a history of asthma, COPD, any other pulmonary pathology, any pulmonary symptom or any pulmonary CT abnormality.']},\n",
       " {'nct_id': 'NCT04281602',\n",
       "  'inclusion': ['Adult patients suffering from rheumatoid arthritis diagnosed according to American College of Rheumatology/European League Against Rheumatism 2010 criteria and requiring an anti-IL-6 therapy by intravenous or subcutaneous injection',\n",
       "   'Non-opposition of the patient Inclusion Criteria for healthy controls:',\n",
       "   'Adult patients not suffering from acute or chronic inflammatory disease at inclusion (normal C-reactive protein and fibrinogen levels)',\n",
       "   'Non-opposition of the subject Exclusion Criteria for patients:',\n",
       "   'Patient is already treated with anti-IL-6 therapy',\n",
       "   'Pregnancy or breastfeeding women',\n",
       "   'Person under judicial protection, guardianship',\n",
       "   'Patient suffering from another chronic inflammatory disease',\n",
       "   'Patient suffering from another acute inflammatory disease at inclusion',\n",
       "   'Person not beneficiaries of the social security system'],\n",
       "  'exclusion': ['Pregnancy or breastfeeding women',\n",
       "   'Person under judicial protection, guardianship',\n",
       "   'Patient suffering from acute or chronic inflammatory disease at inclusion',\n",
       "   'Previous history of chronic inflammatory disease',\n",
       "   'Ongoing anti-inflammatory or immunosuppressive treatment, except aspirin and derivatives at anti-platelet aggregation dose, non-steroidal anti-inflammatory drugs stopped for 10 days or systemic steroids stopped for 1 month',\n",
       "   'Person not beneficiaries of the social security system']},\n",
       " {'nct_id': 'NCT04772248',\n",
       "  'inclusion': ['Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and Medicare fee-for-service',\n",
       "   'A minimum of 365 days of continuous enrollment in health plan prior to (and including) the cohort entry date',\n",
       "   'Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis codes between 7 and 365 days apart)',\n",
       "   'Exclusion Criteria',\n",
       "   'Index drug in 365 days prior to cohort entry date (prevalent users)',\n",
       "   'Missing data on age or gender',\n",
       "   'Admission to nursing facility or hospice on or prior to cohort entry date (ever look-back)',\n",
       "   'TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib, or baricitinib) (ever look-back period)',\n",
       "   'TNFi users initiating with more than one TNFi on same date',\n",
       "   'Tofacitinib users with a prescription of baricitinib, upadacitinib (ever look-back period)',\n",
       "   'Tofacitinib users initiating treatment on multiple JAK inhibitors on same day (tofacitinib and baricitinib, tofacitinib and upadacitinib) Exclusion criteria specific to RWE cohorts:',\n",
       "   'Patients less than 18 years of age (MarketScan and Optum) and 65 years of age (Medicare) at cohort entry Inclusion criteria specific to RCT-duplicate cohorts:',\n",
       "   'Patients with at least one methotrexate dispensation (six months look-back period)',\n",
       "   'Patients with at least one cardiovascular risk factor (including smoking, hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history of ischemic heart disease) (one-year look-back period)'],\n",
       "  'exclusion': ['Patients less than 50 years of age (MarketScan and Optum) and 65 years',\n",
       "   'Patients recently hospitalized with infections (30-day look-back period)',\n",
       "   'Pregnant patients (one year look-back period)']},\n",
       " {'nct_id': 'NCT04779983',\n",
       "  'inclusion': ['18 to 65 years old',\n",
       "   'patients with rheumatoid arthritis according to 2010 ACR/EULAR criteria who have one of the following conditions:',\n",
       "   'Subjects with active RA (DAS28> 3.6) who have failed methotrexate treatement and with a standard medical care for which an indication for biotherapy is retained or',\n",
       "   'Subjects with remission of RA (DAS28<2.6) for which a biotherapy delay (anti-TNF or anti-IL6R or JAKi) is proposed.'],\n",
       "  'exclusion': ['Age under 18 years old']},\n",
       " {'nct_id': 'NCT04549857',\n",
       "  'inclusion': ['Diagnosed by a doctor as rheumatoid arthritis.',\n",
       "   'Over 20 years old.',\n",
       "   'No history of allergy to essential oils in the past.',\n",
       "   'A person with clear consciousness and able to communicate in Mandarin or Taiwanese.',\n",
       "   'Those who are willing to participate in this research after the explanation.',\n",
       "   'The main part of the pain in the past month is the joints of the hand.',\n",
       "   'Have equipment that can watch movies.'],\n",
       "  'exclusion': ['There is a history of wounds or surgery around the wrist or finger joints.',\n",
       "   'Those who are contraindicated in aromatherapy and those with high risk such as asthma, epilepsy, and pregnant.',\n",
       "   'Receive physical therapy or complementary therapy during the study period.']},\n",
       " {'nct_id': 'NCT04806113',\n",
       "  'inclusion': ['Adults ages 18 years and older;',\n",
       "   'For the cases, established diagnosis of:',\n",
       "   'RA done by a rheumatologist according to the 2010 American College of Rheumatology (ACR) /European League Against Rheumatism (EULAR) criteria, OR',\n",
       "   'SLE done by a rheumatologist according to the 1997 revised ACR criteria and/or the 2013 SLICC lupus classification criteria and/or the 2019 EULAR/ACR criteria;',\n",
       "   'For the cases, stable treatment (≥3 months prior to enrollment for biologics/small molecules and MMF; >3 weeks of a specific dose in case of steroids);',\n",
       "   'For the controls, people without a diagnosis of a chronic rheumatic disease who can have comorbidities as in patients with rheumatic diseases;',\n",
       "   'Able to comprehend the investigational nature of the protocol and provide informed consent;',\n",
       "   'Male or non-pregnant female;',\n",
       "   'Women of childbearing potential must agree to use at least one acceptable primary form of contraception.'],\n",
       "  'exclusion': ['Positive pregnancy test either at screening or just prior to each vaccine administration.',\n",
       "   'Any medical disease or condition that, in the opinion of the site Principal Investigator (PI) or appropriate sub-investigator, precludes study participation.',\n",
       "   'Acute illness, as determined by the site PI or appropriate sub-investigator, with or without fever [oral temperature >38.0°C (100.40F)] within 72 hours prior to each vaccination.',\n",
       "   'Diagnosis of hepatitis B, hepatitis C virus, or human immunodeficiency virus (HIV).',\n",
       "   'History of hypersensitivity or severe allergic reaction (e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction) to any previous licensed or unlicensed vaccines.',\n",
       "   'Participation in another clinical trial or plan to do so during the study. If a patient was on a drug trial, recruitment could occur following 2 half-lives of the study drug.',\n",
       "   'Vaccines within the 2 weeks prior to any dose of COVID-19 vaccine or until 30 days after any dose of COVID-19 vaccine.',\n",
       "   'Lactating female.',\n",
       "   'Immunoglobulin therapy or blood products within the past month.',\n",
       "   'Prior diagnosis of COVID-19 in the past 3 months.',\n",
       "   'Planned changes in baseline drug treatments (except prednisone) for rheumatic diseases prior to D57.',\n",
       "   'For patients required to be on cohort 8: Planned reduction of prednisone dose below 10 mg prior to D21.']},\n",
       " {'nct_id': 'NCT04804462',\n",
       "  'inclusion': ['Patients with a history of rheumatoid arthritis'],\n",
       "  'exclusion': ['Individuals with a past medical history of uncorrectable visual or auditory impairment, history of seizure disorder or seizure caused by technology use, extensive motion sickness, vestibular dysfunction, severe neck immobility, or excessive face or scalp sensitivity to pressure. These criteria were chosen as immersion and presence necessitate sufficient vision and hearing, technology use may cause side effects in persons with seizure history, severe motion sickness or vestibular dysfunction, neck immobility may decrease immersion and presence, and scalp sensitivity may inhibit use of a head-mounted device (HMD).']},\n",
       " {'nct_id': 'NCT04798287',\n",
       "  'inclusion': ['Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and Medicare fee-for-service',\n",
       "   'A minimum of 365 days of continuous enrollment in health plan prior to (and including) the cohort entry date',\n",
       "   'Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis codes between 7 and 365 days apart)',\n",
       "   'Exclusion Criteria',\n",
       "   'Index drug in 365 days prior to cohort entry date (prevalent users)',\n",
       "   'Missing data on age or gender',\n",
       "   'Admission to nursing facility or hospice on or prior to cohort entry date (ever look-back)',\n",
       "   'Diagnosis of malignant cancer prior to cohort entry date (ever look-back period)',\n",
       "   'TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib, or baricitinib) (ever look-back period)',\n",
       "   'TNFi users initiating with more than one TNFi on same date',\n",
       "   'Tofacitinib users with a prescription of baricitinib, upadacitinib (ever look-back period)',\n",
       "   'Tofacitinib users initiating treatment on multiple JAK inhibitors on same day (tofacitinib and baricitinib, tofacitinib and upadacitinib) Exclusion criteria specific to RWE cohorts:',\n",
       "   'Patients less than 18 years of age (MarketScan and Optum) and 65 years of age (Medicare) at cohort entry Inclusion criteria specific to RCT-duplicate cohorts:',\n",
       "   'Patients with at least one methotrexate dispensation (six months look-back period)',\n",
       "   'Patients with at least one cardiovascular risk factor (including smoking, hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history of ischemic heart disease) (one-year look-back period)'],\n",
       "  'exclusion': ['Patients less than 50 years of age (MarketScan and Optum) and 65 years',\n",
       "   'Patients recently hospitalized with infections (30-day look-back period)',\n",
       "   'Pregnant patients (one year look-back period)']},\n",
       " {'nct_id': 'NCT04798625',\n",
       "  'inclusion': ['An established clinical diagnosis of one of the following immune-mediated diseases: rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA), ulcerative colitis (UC,) Crohns disease (CD), autoimmune hepatitis (AIH) or patients who have undergone a liver transplantation',\n",
       "   'Treatment with relevant immunosuppressive and/or immunomodulating medication *',\n",
       "   'Adult patients (> 18 years)',\n",
       "   'Patient intends to obtain vaccination against COVID-19 during the next 6 months',\n",
       "   '* The following drugs are considered relevant immunosuppressants and/or immunomodulators and patients using them may be eligible for this study: Rituximab, infliximab, adalimumab, golimumab, certolizumab, etanercept, tocilizumab, abatacept, secukinumab, vedolizumab, ustekinumab, risankizumab, methotrexate, sulfasalazine, leflunomide, azathioprine, 6-mercaptopurine, tofacitinib, filgotinib, baricitinib, upadacitinib, tacrolimus, mycophenolate, prednisolone'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT04586933',\n",
       "  'inclusion': ['Patients must be diagnosed with one of the following diagnoses: rheumatoid arthritis, according to the ACR / EULAR 2010 criteria, psoriatic arthritis, according to the CASPAR criteria, axial spondylarthritis, including ankylosing spondylarthritis and non-radiographic spondylarthritis, according to the ASAS criteria',\n",
       "   'Duration of illness ≥0.5 years',\n",
       "   'Between 18 and 75 years',\n",
       "   'Understand Norwegian',\n",
       "   'The patient has given informed consent to participate',\n",
       "   'No change in medication the last 12 weeks before inclusion'],\n",
       "  'exclusion': ['Conditions or use of medications where omega-3 is contraindicated',\n",
       "   'Pregnancy / lactation',\n",
       "   'Allergy to soy or fish',\n",
       "   'Severe liver disease',\n",
       "   'Severe mental or physical illnesses, such as insulin-requiring diabetes']},\n",
       " {'nct_id': 'NCT04584541',\n",
       "  'inclusion': ['Patient with spondyloarthritis fulfilling the ASAS criteria',\n",
       "   'Patients with rheumatoid arthritis fulfilling the ACR/EULAR criteria and',\n",
       "   'Immunosuppressive therapy: Methotrexate, leflunomide, anti-TNF, Anti-IL6R, abatacept, rituximab, Jak inhibitors (tofacitinib or baricitinib) And',\n",
       "   'infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan) Controls:',\n",
       "   'Family cluster member confined to the same location as the index subject',\n",
       "   'Infected with the SarS-Cov-2 (positive PCR and/or serology and/or CT-scan)'],\n",
       "  'exclusion': ['Pregnant woman',\n",
       "   'Breastfeeding woman',\n",
       "   'Immunosuppressed subject for members of the familiar cluster of the index subject',\n",
       "   'Patient with no social security',\n",
       "   'Patients whose freedom is limited by the judicial or administrative authority',\n",
       "   'Patients under legal protection']},\n",
       " {'nct_id': 'NCT04585711',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA) according to the 2010 American College of Rheumatology Classification Criteria (patients greater than or equal to 16 years of age at screening)',\n",
       "   'Diagnosis of Juvenile Idiopathic Arthritis (JIA) according to the International League Against Rheumatism Classification Criteria (children less than 16 years of age at screening)',\n",
       "   \"Initiating treatment with etanercept as standard of care by a patient's primary rheumatologist\",\n",
       "   'Obese at baseline, defined as a body mass index (BMI) greater than or equal to 30 kg/m2 in subjects greater than or equal to 18 years of age, and a BMI greater than or equal to 95th percentile for age and sex in subjects less than18 years of age',\n",
       "   'Active disease at screening, defined as a DAS28 > 3.2 in adults and JADAS27 > 3.8 in children',\n",
       "   'Patients using oral corticosteroids (<10 mg) or DMARDs must be on a stable dose for at least 4 weeks prior to screening'],\n",
       "  'exclusion': ['Receipt of any investigational medical product within the past 12 months',\n",
       "   'Positive urine pregnancy test at screening or planned pregnancy during the study period',\n",
       "   'Prior exposure to etanercept or any other biologic agent within 5 drug half-lives',\n",
       "   'Contraindication to etanercept (e.g., allergy, current or chronic infection [positive tuberculosis screening test, positive hepatitis B surface antigen, positive hepatitis C antibody])',\n",
       "   'Personal history of ever having malignancy, lymphoproliferative disease, or demyelinating disease',\n",
       "   'Screening safety labs with a hemoglobin of ≤ 9 g/dL, white blood cell count <3.0x109L, platelets <125,000 x109L, AST/ALT more than 2x the upper limit of normal, or creatinine > 2 mg/dL for adults and >1 mg/dL for children',\n",
       "   'Evidence of erosive osteoarthritis on plain films (if available at time of screening), or severe osteoarthritis (defined as any anticipated need for joint replacement within the next year) as judged by the primary rheumatologist',\n",
       "   'History of any opportunistic infections, or recent severe infection in the 3 months prior to screening (e.g., hepatitis, pneumonia, pyelonephritis, bacteremia)',\n",
       "   'Heart failure with NYHA classification 3 or more',\n",
       "   'Severe functional impairment status, defined as HAQ >2 and CHAQ >1.75']},\n",
       " {'nct_id': 'NCT04582084',\n",
       "  'inclusion': ['Adults with the diagnosis of rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis receiving biosimilar etanercept (either 25 mg or 50 mg) for their medical condition. Exclusion Criteria:',\n",
       "   'No strict'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04955899',\n",
       "  'inclusion': ['Adult-onset RA of at least six months duration',\n",
       "   'Male or female participants, 22-75 years of age',\n",
       "   'Active RA',\n",
       "   'Inadequate Response to at least 2 biologic DMARDs and/or JAK- inhibitors (JAKis)',\n",
       "   'Have an appropriate washout from previously used biological DMARDs or JAKi',\n",
       "   'A female participant should have no child-bearing potential'],\n",
       "  'exclusion': ['Inability to provide informed consent.',\n",
       "   'Significant psychiatric disease or substance abuse.',\n",
       "   'History of unilateral or bilateral vagotomy.',\n",
       "   'Active or latent tuberculosis',\n",
       "   'Known infection with human immunodeficiency virus (HIV); current acute or chronic hepatitis B or hepatitis C; previous hepatitis',\n",
       "   '- Currently implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators).',\n",
       "   'Previous splenectomy',\n",
       "   'Any investigational small molecule drug or biological within 2 weeks or 2 half-lives whichever is longer, before surgery.',\n",
       "   'Uncontrolled other inflammatory diseases',\n",
       "   'Current/recurrent infections that in the opinion of the PI risk>benefit.',\n",
       "   'History of cancer within the past 5 years, except non-malignant skin cancer.',\n",
       "   'Chronic use of morphine or oxicodone']},\n",
       " {'nct_id': 'NCT04136223',\n",
       "  'inclusion': ['Consecutive adult patients (aged >18 years) meeting RA diagnostic criteria in accordance with ACR 2010',\n",
       "   'Presence of interstitial lung disease 2.1 ILD Definition: presence of interstitial alterations in HRCT associated to functional derangements and/or symptoms',\n",
       "   'Patient agrees with having follow-up visits every 6 months for 2 years'],\n",
       "  'exclusion': ['Pregnancy or intending to become pregnant',\n",
       "   'Overlap with other diseases that occurs with ILD (other collagenoses, vasculitis, inflammatory bowel disease)',\n",
       "   'Presence of advanced ILD, characterized by:',\n",
       "   'Dyspnea rated as modified Medical Research Council 4 (mMRC4) on routine visit',\n",
       "   'Presence of significant Arterial Pulmonary Hypertension:',\n",
       "   'Evidence of Right ventricular failure evidence by echocardiography',\n",
       "   'Previous right chamber catheterism showing cardiac index < 2 liters/min/m²',\n",
       "   'Significant co-morbidity impacting respiratory system (e.g., congestive heart failure, lung neoplasm, active tuberculosis)']},\n",
       " {'nct_id': 'NCT04130178',\n",
       "  'inclusion': ['Rheumatoid arthritis patient according to ACR/EULAR criteria',\n",
       "   'age >18',\n",
       "   'bilateral hand affection'],\n",
       "  'exclusion': ['peripheral neuropathy',\n",
       "   'other chronic arthritis',\n",
       "   'patient who did mastectomy or any other hand operation']},\n",
       " {'nct_id': 'NCT04136262',\n",
       "  'inclusion': ['postmenopausal women, postmenopausal defined as 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy;',\n",
       "   'diagnosed with RA as determined by meeting the 2010 ACR/EULAR classification criteria and having had RA for at least 6 weeks;',\n",
       "   'active disease at the time of enrollment as indicated by 28-joint Disease Activity Score (DAS28) greater than 3.2;',\n",
       "   'no prior exposure to oral glucocorticoids at a daily dose greater than 10 mg or to any biologic agents.'],\n",
       "  'exclusion': ['RA combined with other autoimmune disease, such as adjuvant arthritis, lupus arthritis, or osteoarthritis;',\n",
       "   'RA combined with abnormal liver and kidney function;',\n",
       "   'severe chronic or acute disease interfering with attendance for therapy;',\n",
       "   'patients who had received DMARDs or biological therapy within one months before participating in this study.']},\n",
       " {'nct_id': 'NCT04397237',\n",
       "  'inclusion': ['Age > 18 years;',\n",
       "   \"Patients fitting classification criteria for each IMID (i.e., Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, axial spondyloarthritis or giant cell arteritis);\",\n",
       "   'Willingness to participate;',\n",
       "   'There are no specific inclusion criteria based on IMID previous activity, treatment or known COVID-19.'],\n",
       "  'exclusion': ['Patients who refuse to participate;',\n",
       "   \"Patients who don't speak or read the local language,\",\n",
       "   'Patients unable to perform a routine blood collection during the study period']},\n",
       " {'nct_id': 'NCT04393233',\n",
       "  'inclusion': ['Rheumatoid arthritis satisfying ACR/EULAR criteria',\n",
       "   'Ongoing DMARD therapy'],\n",
       "  'exclusion': ['Inhability to consent']},\n",
       " {'nct_id': 'NCT04909931',\n",
       "  'inclusion': ['Age > 18 yrs old',\n",
       "   'RA diagnosed by ACR/EULAR 2010',\n",
       "   'low to moderate disease activity',\n",
       "   'on stable NSAIDs and DMARDs for at least 1 month',\n",
       "   'Received Prednisolone less than or equal to 7.5 mg/day',\n",
       "   'serum calcium, phosphorus and ALP are within normal limit.'],\n",
       "  'exclusion': ['Chronic kidney disease stage 3 or higher',\n",
       "   'History of TB',\n",
       "   'History of Chronic liver disease',\n",
       "   'Pregnancy or breast-feeding',\n",
       "   'adjustment of immuno-suppressive drugs, steroid',\n",
       "   'other connective tissue disease',\n",
       "   'Vitamin D allergy',\n",
       "   'received other drugs which have vitamin D component',\n",
       "   'serum Vitamin D less than 10 ng/mL']},\n",
       " {'nct_id': 'NCT04909801',\n",
       "  'inclusion': ['Early rheumatoid arthritis (RA), defined as symptoms of RA that started ≤ 12 months prior to screening and satisfied the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria for the classification of RA at some point during the 12-month period',\n",
       "   'Naïve to any targeted (biologic or nonbiologic) disease-modifying antirheumatic drugs (DMARDs), conventional synthetic DMARDs other than methotrexate (MTX), or investigational therapies for RA',\n",
       "   'Treated with MTX for at least 12 weeks, with a stable dose of oral or parenteral MTX for at least 4 weeks prior to randomization',\n",
       "   'Anti-cyclic citrullinated peptide-2 (Anti-CCP-2) test that is > 3× the upper limit of normal and are positive for rheumatoid factor (RF) according to central lab testing during screening',\n",
       "   'At least a Disease Activity Score 28-joint count calculated using C-reactive protein (DAS28-CRP) ≥ 3.2 at screening',\n",
       "   'At least 3 tender and at least 3 swollen joints at screening and at randomization Exclusion Criteria:',\n",
       "   'Women who are breastfeeding',\n",
       "   \"Autoimmune disease other than RA (e.g., psoriasis, systemic lupus erythematosus [SLE], vasculitis, seronegative spondyloarthritis, inflammatory bowel disease, Sjogren's syndrome) or currently active fibromyalgia\",\n",
       "   'History of or current inflammatory joint disease other than RA (e.g., psoriatic arthritis, gout, reactive arthritis, Lyme disease)',\n",
       "   'At risk for tuberculosis',\n",
       "   'Recent acute infection',\n",
       "   'History of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis)',\n",
       "   'History of infection of a joint prosthesis or artificial joint',\n",
       "   'History of systemic fungal infections (such as histoplasmosis, blastomycosis, or coccidiomycosis)',\n",
       "   'History of primary immunodeficiency',\n",
       "   'Current clinical findings or a history of a demyelinating disorder',\n",
       "   '5 or more joints cannot be assessed for tenderness or swelling Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04416997',\n",
       "  'inclusion': ['Adult RA Patients who fulfilled the 2010 European league against rheumatism criteria for the classification of RA'],\n",
       "  'exclusion': ['RA patients with anemia, pregnancy, postpartum, diabetes, obesity hypertension.',\n",
       "   'Patients with age less than 18 years',\n",
       "   'Patients with end stage organ failure.',\n",
       "   'Patients with liver diseases.',\n",
       "   'Patients with hematological disorders.',\n",
       "   'Patients with malignancies']},\n",
       " {'nct_id': 'NCT04413617',\n",
       "  'inclusion': ['Male or female participants between the ages of 18 and 70 years.',\n",
       "   'Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.',\n",
       "   'Diagnosis of RA and meeting the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA with a Total Score ≥6/10.',\n",
       "   'The participant has active disease at both Screening and Randomization, as defined by both: ≥6 joints tender or painful on motion, AND ≥6 joints swollen; and fulfills 1 of the following 2 criteria: High sensitivity C reactive protein (hsCRP) >7 mg/L at Screening (Visit 1) as performed by the central laboratory OR Erythrocyte sedimentation rate (ESR) (Westergren method) >28 mm',\n",
       "   ''],\n",
       "  'exclusion': ['Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.',\n",
       "   'Participants with a known immunodeficiency disorder or a first degree relative with a hereditary immunodeficiency.',\n",
       "   'Participants with any active or latent infections.',\n",
       "   'Participants with positive hepatitis B surface antigen (HBsAg).',\n",
       "   'Participants with positive HCV Ab tests will be reflex tested for HCV ribonucleic acid (HCV RNA).',\n",
       "   'Any history of either untreated or inadequately treated latent or active tuberculosis (TB) infection, current treatment for active or latent TB infection or evidence of currently active TB,',\n",
       "   'History of a major organ transplant (eg, heart, lung, kidney and liver) or hematopoietic stem cell/marrow transplant.',\n",
       "   'History of severe allergic or anaphylactoid reaction to kinase inhibitors, or corticosteroid preparations.',\n",
       "   'Known history of diverticulitis or symptomatic diverticulosis, perineal abscess or fistulae.',\n",
       "   'Participants with malignancy or history of malignancy (including lymphoma, leukemia, or lymphoproliferative disease).',\n",
       "   'Pre-existing chronic autoimmune disease (eg, inflammatory bowel disease, systemic lupus erythematosus, moderate-severe atopic dermatitis, dermatomyositis) other than',\n",
       "   \"Secondary Sjogren's Syndrome (due to RA) may be included.\",\n",
       "   'Participants with fibromyalgia will be excluded.',\n",
       "   'Previous treatment with total lymphoid irradiation.',\n",
       "   'Participants with an oral, tympanic, or temporal temperature of 38°C (100.4°F) or higher at baseline.',\n",
       "   'Participants may not receive any live/attenuated vaccine from 30 days prior to randomization during the course of the study, or for 30 days after the last dose of study medication. Participants who have current routine household contact with children who have received varicella or oral polio vaccine within 2 months of first study dose are also excluded.',\n",
       "   'History of any lymphoproliferative disorder.',\n",
       "   'Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease.',\n",
       "   'History of any prior deep vein thrombosis (DVT) or pulmonary embolism [PE].',\n",
       "   'Recent (within 6 months of screening) myocardial infarction, coronary revascularization, or percutaneous angioplasty with or without placement of a coronary artery stent; acute coronary syndrome; chronic uncompensated heart failure or New York Heart Association Functional Class III or IV; left ventricular assist devices; implanted defibrillators.',\n",
       "   'Current severe chronic renal insufficiency or renal failure as defined by persistent (on repeated measurements) eGFR <60 mL/min per 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) calculation.',\n",
       "   'Any known coagulopathy or hypercoagulant syndrome.',\n",
       "   \"Presence of any of the following laboratory abnormalities at screening or within the 3 months prior to first study dose: Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels ≥1.5 x the upper limit of normal (ULN); Participants with a history of Gilbert's syndrome may have a direct bilirubin measured and would be eligible for this study provided the direct bilirubin is ≤ ULN and other liver function assessments are normal; Absolute neutrophil count of <1.5 x 109/L (<1500/mm3). Participants with cyclic (benign ethnic) neutropenia will be excluded; Absolute lymphocyte count of <0.5 x 109/L (<500/mm3); Absolute white blood cell (WBC) count of <3.0 x 109/L (<3000/mm3); Hemoglobin <9.0 g/dL (90 g/L); Platelet count ≤100 x 109/L (100,000 cells/mm3) or ≥1000 x 109/L (1,000,000 cells/mm3); Thrombocytopenia, as defined by a platelet count <100 x 109/L (<100,000/mm3) at screening visit or within the 3 months prior to first study dose. [Screening laboratory tests with abnormal results may be repeated once to confirm abnormal results. If results return to normal protocol acceptable limits within the 4-week screening period, the participant may enter the study].\",\n",
       "   'Grade 3 or greater laboratory abnormality based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 toxicity scale, except for the following that are allowed: Grade 3 prothrombin time (PT) secondary to warfarin treatment; Grade 3 partial thromboplastin time (PTT) due to lupus anticoagulant and not related to liver disease or anti-coagulant therapy.',\n",
       "   'Participants previously treated with a biologic DMARD (except for up to 25% of participants who may have been treated with 1, and only 1 prior TNF inhibitor) or any other recent DMARD treatment (eg, a JAK inhibitor), or participants currently treated with any other prohibited medications will be excluded.',\n",
       "   'Prior use of tofacitinib or other JAK inhibitor in the context of a clinical trial is excluded. Concomitant use of tofacitinib (other than as prescribed by the randomization scheme) or other JAK inhibitor is prohibited.',\n",
       "   'Participants who have previously been treated with other, non-TNFa inhibiting biologic DMARDs [including, abatacept (Orencia®), tocilizumab (Actemra®), Sarilumab (Kevzara®), anakinra (Kineret®), rituximab (Rituxan®) or other selective B lymphocyte depleting agents, or other lymphocyte depleting agents/therapies (such as alemtuzab [CamPath®], natalizumab (Tysabri®), alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation) are excluded from participation in the study.',\n",
       "   'Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of IP used in this study (whichever is longer).',\n",
       "   'Any 12-lead electrocardiogram (ECG) performed prior to randomization that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.']},\n",
       " {'nct_id': 'NCT04415502',\n",
       "  'inclusion': ['patients diagnosed as RA', 'age more than 18 years'],\n",
       "  'exclusion': ['other rheumatological diseases Malignancies Hepatic diseases']},\n",
       " {'nct_id': 'NCT04679272',\n",
       "  'inclusion': ['Confirmed COVID-19 diagnosis (positive PCR or serology) in RA patients or healthy controls.'],\n",
       "  'exclusion': ['Age under 18 years old',\n",
       "   'Suspected COVID-19 diagnosis (typical symptoms without a positive PCR or serology)']},\n",
       " {'nct_id': 'NCT04251741',\n",
       "  'inclusion': ['rheumatoid arthritis patient, according to American College of Rheumatology (ACR) 1987 and/or EULAR/ACR 2010 criteria;',\n",
       "   'recently failed treatment with adalimumab (defined as DAS28-CRP >2.9) and not treated with a subsequent bDMARD or target synthetic DMARD (tsDMARD)',\n",
       "   'Received adalimumab for at least 10 weeks in standard dosing (40mg subcutaneously every other week, either in monotherapy or combined with methotrexate or leflunomide)',\n",
       "   'Stop adalimumab due to inefficacy, either alone or combined with side effects',\n",
       "   'who has agreed to participate (written informed consent);',\n",
       "   'age 16 years or older.'],\n",
       "  'exclusion': ['Treatment with another TNF-inhibitor prior to adalimumab',\n",
       "   'Treatment with all non-TNFi options (abatacept, rituximab, sarilumab and tocilizumab) prior to adalimumab',\n",
       "   'scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation',\n",
       "   'life expectancy shorter than follow-up period of the study;',\n",
       "   'no possibility to safely receive an TNF-inhibitor or a non TNF-inhibitor']},\n",
       " {'nct_id': 'NCT04255134',\n",
       "  'inclusion': ['Active rheumatoid arthritis causing pain and functional impairment with DAS28 >5.1 -Has already received usual care for inflammatory arthritis including conventional DMARD therapy e.g. methotrexate, sulfasalazine, leflunomide, hydroxychloroquine on stable dose of csDMARD for at least 4 weeks prior to study drug initiation',\n",
       "   'Willing to participate in the study over a 12-month period',\n",
       "   'Desirably to have positive antibodies to cyclic citrullinated peptide (ACPA/CCP)',\n",
       "   'Between 18 and 75 years of age'],\n",
       "  'exclusion': ['Pregnancy or pregnancy planned over next 12 months',\n",
       "   'Current or previous unsuccessful use of the biologics abatacept or adalimumab',\n",
       "   \"Co-existing other autoimmune condition, e.g. systemic lupus erythematosus, -Sjogren's syndrome, connective tissue disease, fibromyalgia, osteoarthritis, gout\",\n",
       "   'Recent surgery in the last 3 months or imminent surgery in the next 12 months',\n",
       "   'Unable to give informed consent',\n",
       "   'Previous history of cancer in the last 5 years',\n",
       "   'Previous history of multiple sclerosis',\n",
       "   'Uncontrolled heart failure, hypertension or diabetes mellitus',\n",
       "   'Known history of fibromyalgia or other chronic pain disorder']},\n",
       " {'nct_id': 'NCT04255394',\n",
       "  'inclusion': [\"Patients who are capable of understanding the doctor's explanations, following his instructions and are able to participate in the follow-up program\",\n",
       "   'Patient who gave verbal consent to take part in the study at study commencement and written consent retrospectively at 10 years follow-up by signing the informed consent form according to the General data protection Regulation (GDPR) Patient Consent Form\"',\n",
       "   'Age: => 18 years',\n",
       "   'Male and Female',\n",
       "   'Non- inflammatory degenerative joint disease including osteoarthritis, avascular necrosis & post traumatic arthritis',\n",
       "   'Rheumatoid arthritis,',\n",
       "   'Correction of functional deformity',\n",
       "   'Revision of failed joint reconstruction or treatment',\n",
       "   'Treatment of femoral neck and trochanteric fractures of the proximal femur with femoral head involvement and which are unmanageable using other techniques'],\n",
       "  'exclusion': ['Infection, sepsis, and osteomyelitis',\n",
       "   'Patients who are unwilling or unable to give consent, or to comply with the follow-up program',\n",
       "   'The patient is known to be pregnant or breastfeeding',\n",
       "   'Any vulnerable subjects (= individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate)',\n",
       "   'Uncooperative patient or patient with neurologic disorders who are incapable of fol-lowing instruction',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorder which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Local and distant foci of infection',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roent-genogram',\n",
       "   'Vascular insufficiency, muscular atrophy, or neuromuscular disease',\n",
       "   'Skeletal immaturity',\n",
       "   'Morbid obesity',\n",
       "   'Foreign body sensitivity. Where suspected, material sensitivity tests are to be made prior to implantation',\n",
       "   \"Any condition that may interfere with the survival of the implant such as Paget's disease, Charcot's disease, sickle cell anaemia or traits, lower extremity muscular atrophy or neuromuscular disease'\"]},\n",
       " {'nct_id': 'NCT04194827',\n",
       "  'inclusion': ['Rheumatoid arthritis patient, according to ACR 1987 or ACR/EULAR 2010 criteria;',\n",
       "   'Starting adalimumab as the first biological therapy',\n",
       "   'Who has agreed to participate (written informed consent);',\n",
       "   'Age 18 years or older.'],\n",
       "  'exclusion': ['Scheduled surgery during the follow-up of the study or other pre-planned reasons for treatment discontinuation;',\n",
       "   'Life expectancy shorter than follow-up period of the study;',\n",
       "   'Other disease that might flare if adalimumab is tapered like psoriasis, inflammatory bowel disease.']},\n",
       " {'nct_id': 'NCT04195789',\n",
       "  'inclusion': ['Men and women over the age of 18',\n",
       "   'With rheumatoid arthritis meeting the criteria ACR (American College of Rheumatology)/ EULAR (EUropean League Against Rheumatism) 2010',\n",
       "   'Never received any biotherapy or targeted therapy',\n",
       "   'Having an indication of introduction of biotherapy or therapy targeted (JAK inhibitors) (JAK : Janus kinase)'],\n",
       "  'exclusion': ['Refusal to participate in the study',\n",
       "   'Known pulmonary disease that can alter lung interstitium: cardiac decompensation, COPD (chronic obstructive pulmonary disease), thoracic surgery, infection pulmonary',\n",
       "   'Patient with respiratory functional signs suggestive of PID (Diffuse interstitial lung disease)',\n",
       "   'Patient with signs of cardiac decompensation',\n",
       "   'Patient with pulmonary auscultation suggestive of PID',\n",
       "   'Pregnant or lactating woman',\n",
       "   'Psychiatric pathology seriously hindering understanding',\n",
       "   'Difficulty understanding oral French',\n",
       "   'Person deprived of liberty or under legal protection']},\n",
       " {'nct_id': 'NCT04190758',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis (RA) meeting the classification criteria of American College of Rheumatology (ACR) and/or European League Against Rheumatism (EULAR) från 2010',\n",
       "   'Patients with psoriatic arthritis (PsA) meeting the classification criteria of Classification for Psoriatic Arthritis (CASPAR) PsA',\n",
       "   'Patients with undifferentiated arthritis defined as a patients with a clear arthritis, but not meeting with established classifications criteria of any now known rheumatic disease',\n",
       "   'Patients with psoriasis diagnosed at a dermatology department. The patients should not have any history of joint complaints with a duration of more than 6 weeks',\n",
       "   'General population controls, matched for age, sex and residence of living to the included patients.'],\n",
       "  'exclusion': ['Inability to follow study protocol',\n",
       "   'Swedish language difficulties',\n",
       "   'Having other concomitant rheumatic diagnose (Sjögrens syndrome is not an exclusion criteria)']},\n",
       " {'nct_id': 'NCT04192617',\n",
       "  'inclusion': ['Adult patients 18-75 years of age.',\n",
       "   'Rheumatoid arthritis (RA) for ≥ 12 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.',\n",
       "   'Moderate to severe active RA with swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.',\n",
       "   'At screening, either C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or Morning stiffness of joint for ≥ 45 minutes',\n",
       "   'Inadequate response to methotrexate, having received and tolerated at a dose of 7.5-20 mg/week for ≥ 12 weeks, at a stable dose over the past 4 weeks.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than',\n",
       "   '- Use of any biological DMARDs for RA within past 6 months.',\n",
       "   'Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate',\n",
       "   'Active infection, or history of serious or chronic infection']},\n",
       " {'nct_id': 'NCT04267536',\n",
       "  'inclusion': ['Diagnosis of moderate to severe active rheumatoid arthritis (RA) upon judgment of the treating physician.',\n",
       "   'Swollen Joint Count (SJC) >= 3 of 28 joints of the Disease Activity Score (DAS)28.',\n",
       "   'Measurement of C-Reactive Protein (CRP)-level at Baseline (BL) or <= 4 weeks prior to BL at a timepoint when the Prednisolone equivalent dose of Glucocorticoid treatment was <= 10 mg/day for at least 7 days.',\n",
       "   'Upadacitinib treatment is indicated as per local Summary of Product characteristics (SmPC).',\n",
       "   'Decision on the treatment with Upadacitinib was made prior to any decision to approach the patient to participate in this study.'],\n",
       "  'exclusion': ['Participants who cannot be treated with Upadacitinib according to the local Upadacitinib SmPC.',\n",
       "   'Prior treatment with Upadacitinib.',\n",
       "   'Treatment with Sarilumab or Tocilizumab within the last 8 weeks before the CRP level for inclusion was measured.',\n",
       "   'Participants currently participating in interventional research.',\n",
       "   'Participants who are unwilling or unable to complete the patient reported questionnaires.']},\n",
       " {'nct_id': 'NCT04264494',\n",
       "  'inclusion': ['patients diagnosed as RA regarding 2010 new criteria of RA, both sex,aged20-60 years old.'],\n",
       "  'exclusion': ['Patients with Local abscess,',\n",
       "   'systemic illness as (diabetes mellitus, malignancy),',\n",
       "   'patients on opioids analgesics.',\n",
       "   'pregnancy, blood disorders(coagulopathy, thrombocytopenia),']},\n",
       " {'nct_id': 'NCT04262505',\n",
       "  'inclusion': ['Age ≥ 18 year',\n",
       "   'Definite diagnosis of rheumatoid arthritis according to ACR or EULAR criteria',\n",
       "   'Full access to Internet/smartphone',\n",
       "   'English speaking'],\n",
       "  'exclusion': ['Age <18 years',\n",
       "   'Breastfeeding, pregnant or trying to get pregnant.',\n",
       "   'Patients who have commenced nutritional supplements or a new dietary regime in the month prior to study enrolment.',\n",
       "   'Patients who do not have access to the Internet/smartphone']},\n",
       " {'nct_id': 'NCT04269993',\n",
       "  'inclusion': ['current RA or PA diagnosis with active arthritis not adequately controlled by standard medication',\n",
       "   'if taking prescribed steroid, non-steroidal anti-inflammatory (NSAID), and/or disease-modifying anti-rheumatic drug (DMARDS; e.g., tumor necrosis factor inhibitors), must be stable use for at least 1 month prior to enrollment (all must be maintained throughout the study)',\n",
       "   'English-speaking or Spanish-speaking',\n",
       "   'negative urine toxicology screen',\n",
       "   'negative pregnancy test',\n",
       "   'not nursing',\n",
       "   'use of highly effective birth control during the study for both males and females',\n",
       "   'prior history of vaping or smoking cannabis'],\n",
       "  'exclusion': ['greater than zero breath alcohol concentration',\n",
       "   'presence of psychosis, panic disorder, or suicidal ideation or intent',\n",
       "   'self-report of serious adverse reaction to cannabis in the past year',\n",
       "   'smoking more than 20 tobacco cigarettes per day',\n",
       "   'body mass index below 18.0 or above 33.0 kg/m2 range confirmed during medical exam',\n",
       "   'all current asthma conditions (i.e., active symptomatic asthma within the last week) or current or past history of asthma triggered by smoking or vaping',\n",
       "   \"current diagnosis of dementia or Parkinson's disease\",\n",
       "   'below cut-off on mental status exam',\n",
       "   'current diagnosis of moderate to severe traumatic brain injury',\n",
       "   'current diagnosis of epilepsy',\n",
       "   'individuals who are immunocompromised (i.e., post-organ transplant, those with an immune deficiency disorder such as HIV, individuals taking immunosuppressant steroids such as continuous prednisone use, and those with lupus)',\n",
       "   'past kidney disease (e.g., glomerular nephritis, polycystic kidney disease) and/or presence of elevated creatinine',\n",
       "   'cardiac disease confirmed via clinically significant abnormal findings on an EKG (e.g., arrhythmia, conduction abnormalities, ischemia, or evidence of past myocardial infarction), as well as diagnoses of congestive heart failure or cardiomyopathy',\n",
       "   'abnormal vital signs',\n",
       "   'taking any exclusionary medications',\n",
       "   'presence of any severe cardiovascular, renal, or hepatic disorder',\n",
       "   'below 18 or above 65 years of age',\n",
       "   'use of cannabis in the past 1 month before commencement of study participation and throughout the study as confirmed via urine toxicology screening aa) below minimum self-reported pain level on a visual analog scale (VAS) pre-study enrollment via telephone and at baseline due to potential variability in pain level']},\n",
       " {'nct_id': 'NCT04263974',\n",
       "  'inclusion': ['Hand Osteoarthritis (OA) patients:',\n",
       "   'Subjects with hand osteoarthritis according to the American College of Rheumatology (ACR) classification criteria for clinical OA; hand pain, aching or stiffness and 3 of the following points;',\n",
       "   'Hard tissue enlargement of 2 or more of 10 hand joints.',\n",
       "   'Hard tissue enlargement of 2 or more interphalangeal joints.',\n",
       "   'Fewer than 3 swollen Metacarpal joints.',\n",
       "   'Deformity of 1 or more of 10 hand joints.',\n",
       "   'Pain and dysfunction in the joints of the hands and/or wrists',\n",
       "   'Possession of a smartphone with internet.',\n",
       "   'Rheumatoid Arthritis (RA) Hand patients:',\n",
       "   'Subjects with hand arthritis according to the American College of Rheumatology (ACR) clinical and immunological criteria for clinical',\n",
       "   'Patients must meet 4 of the following seven criteria:',\n",
       "   'Morning stiffness in and around joints lasting at least 1 hour.',\n",
       "   'Swelling in three or more joints.',\n",
       "   'Swelling in hand or wrist joints,',\n",
       "   'Symmetrical joint swelling.',\n",
       "   'erosions or decalcification on radiographs of hand and/or wrist.',\n",
       "   'Rheumatoid nodules.',\n",
       "   'Abnormal serum rheumatoid factor.',\n",
       "   'Pain and dysfunction in the joints of the hands and/or wrists.',\n",
       "   'Possession of a smartphone with internet'],\n",
       "  'exclusion': ['Hand Osteoarthritis Patients:',\n",
       "   'Age under 18 years',\n",
       "   'People with cognitive impairment',\n",
       "   'Surgery on any upper limb joint or fracture in the upper limb within the previous 6 months',\n",
       "   'People on the waiting list for upper limb surgery.',\n",
       "   'Persons who have received steroid injections into the joints of their hands in the two months prior to recruitment.',\n",
       "   'People with inflammatory rheumatic disease (arthritis, spondylitis or cancer)',\n",
       "   'Rheumatoid Arthritis Hand Patients',\n",
       "   'Age under 18 years',\n",
       "   'People with cognitive impairment',\n",
       "   'Surgery on any upper limb joint or fracture in the upper limb within the previous 6 months',\n",
       "   'People on the waiting list for upper limb surgery.',\n",
       "   'Pregnancy.']},\n",
       " {'nct_id': 'NCT04268771',\n",
       "  'inclusion': ['Male or female subjects aged 18 years or older who have provided valid written informed consent.',\n",
       "   'Subjects with a diagnosis of active RA who are eligible for the subsequent treatment course with US-rituximab or EU-rituximab according to the clinical judgment of the investigator.',\n",
       "   'Documented evidence that subject has received at least 1 full course comprising two 1000 mg infusions of either US-rituximab at least 16 weeks prior to the randomization visit or EU-rituximab at least 24 weeks prior to the day of randomization visit.',\n",
       "   'Subjects receiving a stable dose of weekly methotrexate (MTX) for at least 4 weeks prior to randomization (between 7.5 mg and 25 mg) and folic acid (at least 5 mg per week.'],\n",
       "  'exclusion': ['Subjects with RA in functional Class IV',\n",
       "   'Subjects with human immunodeficiency virus (positive HIV1Ab or HIV2Ab), hepatitis B virus and/or hepatitis C virus infection, including those with positive results in the viral disease screening.',\n",
       "   'Subjects with active tuberculosis. Subjects with evidence of latent TB or a history of TB must have completed treatment or have initiated treatment for at least 1 month before the first dose of study treatment (Day 1). TB testing is required only if it is required by local regulations or practice.',\n",
       "   'Active systemic infection.',\n",
       "   'Severely immunocompromised.',\n",
       "   'History of severe hypersensitivity to either US-rituximab or EU-rituximab or any of its excipients requiring drug discontinuation.',\n",
       "   'Any serious illness or uncontrolled medical condition, including but not limited to severe infections, significant hepatic or renal disease, uncontrolled hypertension despite treatment (defined as blood pressure ≥160/95 mmHg), congestive heart failure (New York Heart Association [NYHA] Class III or IV), or other severe, uncontrolled cardiac disease or uncontrolled diabetes with immediate risk of acute complications.',\n",
       "   'Any condition that in the opinion of the investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for subjects.',\n",
       "   'Requires treatment with any biological medicinal product during the study other than the study treatment.',\n",
       "   'Previous treatment with B-cell modulating or cell depleting biologic therapy except US-rituximab or EU-rituximab.',\n",
       "   'Prior participation in this clinical trial or prior participation in any clinical trial with any monoclonal antibody within 12 months of screening or prior participation in any clinical trial within 3 months of screening or within 5 half-lives of the investigational drug or until the expected PD effect has returned to baseline, whichever is longer.',\n",
       "   'Treatment with other biologic disease-modifying anti-rheumatic drugs, or Janus kinase (JAK) inhibitors administered within 12 weeks before the first dose of rituximab of the prior treatment course onwards till the date of randomization.',\n",
       "   'Subjects with the following laboratory abnormalities:',\n",
       "   'Subjects with screening total white blood cell count <3000/μL, platelets <100,000/μL, neutrophils <1,500/μL, or hemoglobin <8.5 g/dL',\n",
       "   \"Abnormal liver function tests such as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase >2 × upper limit of normal (ULN). A single parameter >2 × ULN can be re-checked as soon as possible, at least prior to randomization, if required as per the investigator's discretion.\",\n",
       "   'Creatinine clearance (Cockcroft & Gault formula) of less than 50 mL/min.',\n",
       "   'History of vaccination with live vaccines within 4 weeks of the first dose of study treatment (Day 1) or known to require live vaccines during the study.',\n",
       "   'Lactating or pregnant female.',\n",
       "   'Women of childbearing potential who do not consent to use highly effective methods of birth control (e.g., barrier contraceptives, oral contraceptives, intrauterine devices, true abstinence if it allowed as per the country specific regulatory requirement [periodic abstinence {e.g., calendar ovulation, symptothermal, post-ovulation methods} and withdrawal are not acceptable methods of contraception], or sterilization) during treatment and for at least 12 months after the last administration of study treatment.',\n",
       "   'For men involved in any sexual intercourse that could lead to pregnancy, subjects must agree to use 1 of the highly effective methods of birth control listed in Exclusion Criterion #16 during treatment and for at least 12 months after the last administration of study treatment.',\n",
       "   'Subject with serum IgG < lower limit of normal.']},\n",
       " {'nct_id': 'NCT04033809',\n",
       "  'inclusion': ['RA patients according to the American College of Rheumatology (ACR)',\n",
       "   'Moderate (DAS 28 = 3.2',\n",
       "   '5.1) and severe (DAS 28 > 5.1) RA manifestation',\n",
       "   'Chronological age: 21 years and above',\n",
       "   'Stable RA patients who are receiving NSAIDs, glucocorticoids/DMARDs (for example leflunomide, methotrexate, sulfasalazine and hydroxychloroquine) for at least 3 months prior to entering the study',\n",
       "   'Not taking antioxidant/antiinflammatory supplements (Example of antioxidant: vitamin C, vitamin E, grape seed extract, garlic capsule, ginkgo biloba) (Example of anti-inflammatory supplement: fish oil, curcumin extract, ginger extract, spirulina)'],\n",
       "  'exclusion': ['Having liver (chronic liver failure, cirrhosis, all types of hepatitis), kidney (chronic kidney disease, haemodialysis) or haematological (anaemia, thalassemia, haemophilia) disorders',\n",
       "   'Active gastric/duodenal ulcer',\n",
       "   'Psychiatric disease/mental retardation (bipolar disorder, depression, schizophrenia)',\n",
       "   \"Cancer (all types), Diabetes Mellitus (Type I and II), uncontrolled hypertension (BP at 140/90 mmHg for the past 3 months), and endocrine disorders (Cushing's disease, gigantism and hyperthyroidism).\",\n",
       "   'Alcohol and drug abuse (self-mentioned or as recorded in the medical card)',\n",
       "   'Other autoimmune/inflammatory diseases (systemic lupus erythematosus, multiple sclerosis, gout, psoriasis, chronic inflammatory demyelinating polyneuropathy)',\n",
       "   'Pregnancy/lactation',\n",
       "   'Hormone replacement therapy (for at least 3 months prior to entering the study)',\n",
       "   'Herbal remedies (any parts from the plants such as flowers, rhizome, seeds, roots, leaves, fruits, stems)',\n",
       "   'Vegetarian patient (pure vegan)',\n",
       "   'Gluten intolerance',\n",
       "   'Participations from another supplementary program']},\n",
       " {'nct_id': 'NCT04037111',\n",
       "  'inclusion': ['Age 18-65 years old, in accordance with DSM-5 diagnostic criteria for major depressive disorder, or meet the diagnostic criteria for rheumatoid arthritis. The major depressive disorder is first or at least not used in the 5 half-life of the drug. Antidepressants, antipsychotics or anticonvulsants.',\n",
       "   'Hamilton Depression Rating Scale (HAMD) 17 scores over 17 points.'],\n",
       "  'exclusion': ['Brain organic lesions (such as cerebral hemorrhage, large area cerebral infarction, encephalitis, epilepsy); cardiac QTc interval > 450ms;',\n",
       "   'Currently or have been diagnosed with other major diseases (such as coronary heart disease, pulmonary heart disease, etc.)',\n",
       "   'Those who are currently or have been diagnosed with other mental disorders other than major depressive disorder (except for anxiety disorder);',\n",
       "   'Patients who have a serious risk of suicide or who have had suicide attempts;',\n",
       "   'Those who are using or have been treated with escitalopram oxalate are not effective;',\n",
       "   'Those who are participating in or have participated in vagus nerve or transcranial electrical stimulation for less than 3 months;',\n",
       "   'MRI scan taboos and high-risk groups;',\n",
       "   'Pregnancy, breastfeeding or planning for pregnancy during the trial;',\n",
       "   'Refusal to sign informed consent.']},\n",
       " {'nct_id': 'NCT04033588',\n",
       "  'inclusion': ['Male and female subjects aged between 18 years and 75 years.',\n",
       "   'Subjects who require unilateral knee prosthesis and have been evaluated as appropriate candidates for a total knee replacement by the investigator.',\n",
       "   'Subjects suffering from severe knee joint pain and loss of mobility due to rheumatoid arthritis, osteoarthritis or post-traumatic osteoarthritis.',\n",
       "   'Subjects, who in the opinion of the investigator are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow ups.',\n",
       "   'Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.'],\n",
       "  'exclusion': ['Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.',\n",
       "   'Subjects who are known drug or alcohol abuse or with psychological disorders that could affect follow-up care or treatment outcomes.',\n",
       "   'Subject with a known sensitivity to device materials.',\n",
       "   'Subjects with other significant disabling problems from the muscular-skeletal system other than in the knees (i.e muscular dystrophy, polio, neuropathic joints).',\n",
       "   'Subjects with a BMI of 40 or above.',\n",
       "   \"Subjects with a current or active history of malignancy, active or suspected infection, Paget's disease, renal osteodystrophy, immunologically suppressed or have any other significant medical illness judged by investigator to exclude from study.\",\n",
       "   'Subject with neuromuscular or neurosensory deficiency that may limit ability of the patient to evaluate the safety and efficacy of the device.',\n",
       "   'Female subjects who are pregnant or lactating.',\n",
       "   'Subjects who have previously undergone total or unicondylar knee replacement, high tibial osteotomy, ligament reconstruction, open reduction internal fixation (ORIF) or with previous fracture in the ipsilateral knee joint.']},\n",
       " {'nct_id': 'NCT04036669',\n",
       "  'inclusion': ['patients who diagnosed with Rheumatoid arthritis according to American Rheumatology Association criteria and radiographic analysis for at least 10 years previously were randomly involved in this study',\n",
       "   'Not receiving any drugs affecting the data obtained',\n",
       "   'had Normal daily diets'],\n",
       "  'exclusion': ['Subjects with obvious ischemic heart disease (angina, myocardial infarction, and lead electrocardiogram abnormalities),',\n",
       "   'HCV, HBV, chronic liver and kidney diseases, hypothyroidism.',\n",
       "   'Drugs (diuretics; oral contraceptives).']},\n",
       " {'nct_id': 'NCT04038970',\n",
       "  'inclusion': ['The patient must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of rheumatoid arthritis (RA) by satisfying at least four of the seven criteria;',\n",
       "   'Patients must have been taking methotrexate for at least 3 months with at least a weekly dose of 7.5-25 mg, and a stable dose for 28 days prior to treatment (Day 1)',\n",
       "   'The patient must have active disease at both screening and baseline, as defined by having both: 6 tender/painful joints on motion (out of 68 joints assessed); and; 6 swollen joints (out of 66 joints assessed); CRP ≥ 7 mg/L, or ESR ≥28 mm/h Key'],\n",
       "  'exclusion': ['Pregnant or lactating females.',\n",
       "   'History of any other autoimmune rheumatic disease.',\n",
       "   'Patients who have previously received CTLA4-Ig therapy for any reason.']},\n",
       " {'nct_id': 'NCT04092244',\n",
       "  'inclusion': ['All RA patients must fulfill the 2010 ACR/EULAR criteria for',\n",
       "   '- Healthy individual must be without a prior history of chronic inflammation or any form of arthritis.'],\n",
       "  'exclusion': ['- Patients with solid tumors.']},\n",
       " {'nct_id': 'NCT04652791',\n",
       "  'inclusion': ['Subject has a diagnosis of RA as defined by the ACR/EULAR 2010 classification criteria',\n",
       "   'Patients older than 18',\n",
       "   'Syndrome of insufficiency of liver and kidney or syndrome of cold and dampness defined by traditional Chinese medicine'],\n",
       "  'exclusion': ['Patients who are pregnant or breast feeding at enrolment',\n",
       "   'History of malignancy prior to screening',\n",
       "   'Patients with severe or poorly controlled chronic diseases such as hypertension, diabetes and coronary heart disease',\n",
       "   'Patients taking biological agents, > 10mg prednisone (or equivalent amount of other glucocorticoids) ，more than 2 kinds of DMARDs or similar TCM drug like Wangbi Capsule']},\n",
       " {'nct_id': 'NCT04658615',\n",
       "  'inclusion': ['age ≥ 18 years old; diagnosis of RA according to the American College of Rheumatology with DAS-28 score ≥ 3.2 and no change in RA medication in the previous 3 months;',\n",
       "   'at least 15 teeth excluding third molars;',\n",
       "   '≥2 non-adjacent teeth interproximal sites with loss of periodontal attachment level (PAL) ≥ 2 mm; or buccal or oral PAL ≥3 mm with pocketing >3 mm is detectable at ≥2 teeth.',\n",
       "   'Patients without RA met the same criteria except for the diagnosis of',\n",
       "   'Exclusion Criteria:',\n",
       "   'periodontal treatment or use of antibiotics in the previous 3 months.',\n",
       "   'diabetes, liver disease, head and neck radiation therapy.',\n",
       "   'pregnancy',\n",
       "   'HIV',\n",
       "   'use of cyclosporine.',\n",
       "   'Smoking, use of hypertension and hyperlipidemia medication were not'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04655612',\n",
       "  'inclusion': ['Patient with chronic inflammatory rheumatic disease (i.e. rheumatoid arthritis, psoriatic rheumatism, axial spondyloarthritis), Coming for consultation or hospitalization as part of the usual follow-up of his condition'],\n",
       "  'exclusion': ['Adult patient under legal protection (guardianship, curatorship)']},\n",
       " {'nct_id': 'NCT04474392',\n",
       "  'inclusion': ['Adults between 18 and 100 years;',\n",
       "   'At-Risk for RA, RA diagnosed, and Healthy Control subjects will be included in the study until recruitment goals are met for each group. At-Risk:',\n",
       "   'No evidence of inflammatory arthritis on clinical examination AND',\n",
       "   'At elevated risk for RA based on familial or serologic risk',\n",
       "   'Familial risk includes having a first degree relatives (FDRs) with RA',\n",
       "   'Serologic risk includes asymptomatic serum ACPA positivity Healthy Controls :',\n",
       "   'No history of RA',\n",
       "   'No FDRs with RA',\n",
       "   'No systemic use of immunosuppressants for autoimmune disease RA Diagnosis:',\n",
       "   'Classified RA by 1987 ACR and/or 2010 ACR/EULAR RA classification criteria (confirmed by medical chart review) OR',\n",
       "   'Diagnosed with RA by a board-certified rheumatologist (confirmed by medical chart review)'],\n",
       "  'exclusion': ['Currently pregnant or planning to become pregnant during the sample collection period of the study',\n",
       "   'Exacerbation of underlying obstructive lung disease within the past 1 month',\n",
       "   'Known FEV1 <1 liter',\n",
       "   'Oxygen requirement >2 liters at rest',\n",
       "   'Participants with health acuity or behavioral health concerns leaving them unable to participate in the current research Note: If a subject temporarily does not meet inclusion criteria but is interested in participating, he/she may participate once inclusion criteria have been met. If interested, please take a few minutes to complete the screening questionnaire for this study opportunity. You may open the survey in your web browser by clicking the link below: https://is.gd/SPAROscreen If the link above does not work, try copying the link below into your web browser: https://redcap.ucdenver.edu/surveys/?s=3WM8WH3WKK']},\n",
       " {'nct_id': 'NCT04476875',\n",
       "  'inclusion': ['Disease duration of at least 1 year.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04474912',\n",
       "  'inclusion': ['A patient is considered having definite RA if he/she scores at least 6 points in the established classification system',\n",
       "   'A patient is considered having Hand OA if he /she Hand pain, aching, or stiffness plus 3 or 4 of hard tissue enlargement of 2 or more of 10 selected joints or hard tissue enlargement of 2 or more DIP joints or fewer than 3 swollen MCP joints, or deformity of at least 1 of 10 selected joints which are are the second and third distal interphalangeal (DIP), the second and third proximal interphalangeal, and the first carpometacarpal joints of both hands'],\n",
       "  'exclusion': ['Any subject with liver diseases, coronary artery diseases, kidney diseases or other inflammatory conditions was excluded from the study.']},\n",
       " {'nct_id': 'NCT04472481',\n",
       "  'inclusion': ['disease duration less than 3 years from the time of diagnosis, age more than 18 years, a diagnosis of RA according to the 2010 ACR/ EULAR Classification criteria for RA diagnosis , active disease according to DAS-28, for those receiving nonsteroidal anti-inflammatory drugs and corticosteroids, the dosage had to be stable for at least 2 weeks before screening.'],\n",
       "  'exclusion': ['Patients with allergic, and infectious diseases, patients receiving steroids for the first time within 2 weeks before the study, patients with hypercalcemia, hypercalciuria, nephrolithiasis, or neoplastic diseases were excluded from the study. We also excluded patients on any biologic therapy and patients with prior use of leflunomide, hydroxychloroquine, or sulphasalazine for more than 2 months.']},\n",
       " {'nct_id': 'NCT04470453',\n",
       "  'inclusion': ['Age > 18 years and have social security affiliation.',\n",
       "   'Patients followed in the Rheumatology Department at the hospital of St Etienne.',\n",
       "   'Rheumatoid Arthritis patients in remission (Disease Activity Score 28<2.6) with methotrexate (MTX) treatment for at least 6months, and with a stable dose for 3months.',\n",
       "   'Patients with a High Disease Activity Rheumatoid Arthritis activity (Disease Activity Score 28>3.2) with methotrexate (MTX) treatment (≥ 15 mg/week), taking MTX treatment for at least 6months with a stable subcutaneous weekly MTX injection (≥ 15 mg/week) treatment during the previous 3 months.',\n",
       "   'Signed informed consent.'],\n",
       "  'exclusion': ['Patients treated with another conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARD)',\n",
       "   'Another diagnostic than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT04472390',\n",
       "  'inclusion': ['2017/4/30 Dose reduction or discontinuation use of TNF-α inhibitors (2011/1/1-2019/4/30)'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04230213',\n",
       "  'inclusion': ['Diagnosis of RA based on 2010 ACR/EULAR for RA for at least a 4 month duration.',\n",
       "   'Moderately to severely active RA based on local standard of care.'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT04022525',\n",
       "  'inclusion': ['Rheumatoid arthritis patients already receiving leflunomide with or without Hydroxychloroquine but without other Disease modifying agents'],\n",
       "  'exclusion': ['Those diagnosed with other rheumatic diseases or Rheumatoid patients receiving disease modifying agents other than leflunomide']},\n",
       " {'nct_id': 'NCT04970550',\n",
       "  'inclusion': ['Ambulatory patients',\n",
       "   'Men or women of any age',\n",
       "   'Follow-ups for chronic inflammatory rheumatism such as rheumatoid arthritis or spondyloarthritis',\n",
       "   'Treated with methotrexate or biotherapy.'],\n",
       "  'exclusion': ['Patients not treated with biotherapy or methotrexate.',\n",
       "   'Patients in whom the assessment could not be performed reliably']},\n",
       " {'nct_id': 'NCT04971980',\n",
       "  'inclusion': ['Male or female patients aged 18 to 65 (inclusive)',\n",
       "   'Patients who are diagnosed with rheumatoid arthritis following the 2010 ACR/EULAR classification criteria',\n",
       "   'Patients who still remain moderate-to-high disease activity, i.e. DAS28>3.2 at screening and study baseline, after standard csDMARDs therapy',\n",
       "   'Patients who are positive for rheumatoid factors (RF) and/or anti-CCP antibody',\n",
       "   'Patients who are clinically stable with no significant changes in physical condition from screening to study baseline',\n",
       "   'Patients who are available and willing to comply with all study procedures',\n",
       "   'Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines'],\n",
       "  'exclusion': ['Infections of hepatitis B, hepatitis C, active or latent tuberculosis, or positive for human immunodeficiency virus (HIV)1 or HIV2',\n",
       "   'Any history of ongoing, significant infections or recent serious infection, i.e., requiring hospitalization and or IV antimicrobial treatment in the 3 months prior to screening',\n",
       "   'Any active inflammatory diseases other than RA',\n",
       "   'Serum aminotransferase (ALT or AST) levels ≥ 2x upper limits of normal',\n",
       "   'Creatinine clearance rate (Ccr) < 45 ml/min calculated by Cockcroft-Gault formula',\n",
       "   'Severe chronic obstructive pulmonary disease or known lung disease except for mild asthma treated with bronchodilators',\n",
       "   \"Any coexistent active major medical diagnosis of clinically significant cardiovascular, neurological psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), or hematological abnormalities that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion\",\n",
       "   'History of cerebrovascular accident (stroke) within 1 year before screening',\n",
       "   'Clinically significant heart disease (New York Heart Association, class III and class IV)',\n",
       "   \"Surgery or trauma (e.g. contusions, abrasions, stab wounds, cutting wounds, crush injuries, impact injuries, and firearm injuries etc.) within 14 days before enrollment that are not approporiate to participate in study in investigators' opinion\",\n",
       "   'Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study and for twelve months after completing the study infusion, unless surgically sterilized or postmenopausal during the study',\n",
       "   'Corticosteroid usage at a high dose (i.e., IV or IM corticosteroids or use of oral prednisone equivalent >10 mg/day) or not at a stable dose for the treatment of RA or other diseases within 28 days prior to randomization.',\n",
       "   \"Known allergies or had a history of allergy to minor molecular heparinum and human serum albumin that are likely to interfere with patient compliance or study assessments/procedures in the investigators' opinion\",\n",
       "   'Already participating in another interventional clinical trial or participated in another interventional clinical trial within 3 months before screening',\n",
       "   'Clinical history of malignancy with the exception of adequately treated cervical carcinoma in situ or basal cell carcinomas',\n",
       "   \"Other situations that are not approporiate to participate in study in investigators' opinion\"]},\n",
       " {'nct_id': 'NCT04680962',\n",
       "  'inclusion': ['Male or female, age 18',\n",
       "   '80 years',\n",
       "   'Body Surface Area (BSA) between 1.5 and 2.2 m2',\n",
       "   'Confirmed diagnosis of RA diagnosed according to the revised (2010) ACR/EULAR classification criteria, with a disease duration minimum of 6 months prior to the Screening Visit',\n",
       "   'Currently moderate to severe RA despite ongoing administration of an adequate MTX regimen. Moderate to severe disease is defined here as the presence of the following two criteria:',\n",
       "   'Six or more swollen joints and ≥6 tender/painful joints, verified by a physician during the screening and re-confirmed at baseline visit (Day 1)',\n",
       "   'DAS28 score ≥3.2 at screening',\n",
       "   'No history of treatment with TNF-α inhibitor (innovative or biosimilar, authorized or investigational) at any time before the screening i.e. TNF-α inhibitor naive population.',\n",
       "   'Receiving MTX treatment at a dosage of 7.5-25 mg/week for at least 12 weeks prior to screening, with the last 4 weeks at a stable dose, and willing to remain at this dose for the entire study duration',\n",
       "   'Male or WOCBP must consent to use highly effective contraception, from the Screening Visit, during the intervention period, and for at least 12 months after the last dose of study intervention',\n",
       "   'Female participants must not be pregnant or lactating (negative baseline serum test)'],\n",
       "  'exclusion': ['History of or current inflammatory joint disease other than RA',\n",
       "   'History of or current systemic autoimmune disorder',\n",
       "   'ACR functional class IV disease',\n",
       "   'History of psychiatric disorder that would interfere with normal participation in the study',\n",
       "   'Evidence of HBV, HCV, HIV infection',\n",
       "   'Evidence of laboratory-confirmed or clinically suspected SARS-CoV-2 infection within 14 days before the study drug administration and a documented positive RT-PCR test within 72 hours before the first infusion or positive antigen test within 24 hours before the first infusion.',\n",
       "   \"Serious and/or uncontrolled coexisting diseases which are recognized as major contraindications to the administration of rituximab, methotrexate or any of the pre-medication components or as important risk factors for the development of severe or life-threatening SARS-CoV-2 infection or other factors, which in the Investigator's opinion, would preclude patients participation. This category includes severe pulmonary, cardiovascular, neurologic, renal and hepatic diseases, severe and inadequately controlled type 1 or 2 diabetes.\",\n",
       "   'Recent history or current evidence of bacterial, viral or fungal infection (excluding infections of nailbeds)',\n",
       "   'History of or current active tuberculosis, with typical symptoms of',\n",
       "   'tuberculosis infection confirmed by positive results of TB screening test or documented diagnosis prior to screening',\n",
       "   \"Latent tuberculosis, as documented in subject's medical records or shown by a positive or indeterminate QuantiFERON test performed at screening, in absence of typical symptoms of tuberculosis. However, a patient with latent tuberculosis may become eligible for the study if he/she meets the following criteria:\",\n",
       "   'Patient completed a standard TB prophylaxis prior to the screening and had no active TB or contact with active TB case after completion of the most recent prophylactic regimen OR received at least four weeks of standard TB prophylactic regimen prior to the screening visit and is capable and willing to continue on this regimen while participating in the study.',\n",
       "   'Patient has no active TB at the time of screening, which must be confirmed through referral to a TB specialist if > 1 year has passed since the completion of the last prophylaxis or if the prophylaxis is still being received by the time of screening',\n",
       "   'Patient had no positive findings on chest X-ray examination at screening and within three months prior to screening',\n",
       "   'History of cancer (solid tumors, hematologic malignancies and other) within 5 years of the screening',\n",
       "   'History of significant cytopenia or other disorder of the hematopoietic system',\n",
       "   'Primary or secondary immunodeficiency',\n",
       "   'Any other condition that is listed as a contraindication to receive rituximab or methotrexate therapy',\n",
       "   'Recent use of biologic DMARDs or non-biologic DMARDs other than MTX within the washout periods specified in the study protocol',\n",
       "   'Treatment with any of the authorized or investigational TNF-α inhibitors at any time before the screening (regardless if innovative or biosimilar).',\n",
       "   'History of prior treatment with a B cell modulating or B cell depleting therapy such as, but not limited to, rituximab or other anti CD20 mAb (ocrelizumab, ofatumumab, obinutuzumab), belimumab, atacicept, tabalumab, epratuzumab and other experimental treatments',\n",
       "   'Use of systemic glucocorticoids at a dose higher than 10 mg prednisolone daily or equivalent, within 2 weeks prior to Screening or between screening and Day 1',\n",
       "   'Use of intraarticular hyaluronic acid injection within 28 days before the screening or between screening and Day',\n",
       "   '20. Use of any drug that has not received regulatory approval for any indication within 4 weeks or a minimum of 5 half-lives, whichever is longer, prior to the Screening Visit or planned receipt of unauthorized drug or vaccine during the study.',\n",
       "   'History of prior allergic or anaphylactic reaction to rituximab therapy (or to any excipient contained in the study IMP)',\n",
       "   'Serious abnormal laboratory findings, specifically:',\n",
       "   'White blood cell count <3,000/μL OR neutrophil count <1,500/μL.',\n",
       "   'Platelet count <75,000/μL.',\n",
       "   'Aspartate aminotransferase or alanine aminotransferase >2.5 times ULN.',\n",
       "   'Hemoglobin <8.0 g/dL.',\n",
       "   'IgG below 5.0 mg/mL or IgM below 0.4 mg/mL.',\n",
       "   'Any other clinically significant laboratory abnormality.',\n",
       "   'Intolerance or contraindications to administration of MTX therapy, i.v. glucocorticoids, or to any other component of the premedication',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to Screening or planned surgery within 12 months after baseline',\n",
       "   'Recent vaccination with inactivated/non-live vaccine (<4 weeks prior to study intervention infusion on Day 1) or live vaccine (<6 weeks prior to study intervention infusion on Day 1) vaccine',\n",
       "   'Planned vaccination with live vaccine during the follow-up.',\n",
       "   'Chronic intake of narcotic analgesics (e.g. morphine, fentanyl, hydrocodone, oxycodone, codeine).',\n",
       "   'Participation in a clinical study during the 2 months prior to enrolment in the study (exemption',\n",
       "   'previously failed screening procedures in MabionCD20-003RA study).',\n",
       "   'Female patients breastfeeding, pregnant or planning of pregnancy within 12 months after the last infusion of the study intervention.',\n",
       "   'Blood donation or other blook loss of more than 500 ml within the last two months prior to Screening Visit.',\n",
       "   'Lack of peripheral venous access.',\n",
       "   'History of drug, alcohol or chemical abuse within 2 years prior to screening.']},\n",
       " {'nct_id': 'NCT04684693',\n",
       "  'inclusion': ['Meeting the criteria of ACR classification for rheumatoid arthritis',\n",
       "   'Meeting the criteria of EULAR classification for rheumatoid arthritis'],\n",
       "  'exclusion': ['Having malignancy',\n",
       "   'Having connective tissue disease',\n",
       "   'Smokers']},\n",
       " {'nct_id': 'NCT04084223',\n",
       "  'inclusion': ['Patient ≥18 years',\n",
       "   '2010 (American College of Rheumatology) ACR-EULAR classification criteria for RA for ≥3 months',\n",
       "   'Inadequate response to MTX (or other csDMARD) for ≥3 months, at stable dosage for ≥1 month',\n",
       "   'Active disease defined by DAS28>3,2 AND presence of ≥2 US synovitis with Power-Doppler≥2,',\n",
       "   'Starting a treatment with JAKi (baricitinib or tofacitinib),',\n",
       "   'Patients previously treated with biologic (stopped for inadequate response or safety) could be included. Biologics will be stopped before entering in the study: Abatacept and all TNF (tumor necrosis factor) inhibitors: no use within 4 weeks before baseline visit; Rituximab: no use within 6 months before baseline visit.',\n",
       "   'Informed signed consent Exclusion Criteria:',\n",
       "   'Patient not treated before by MTX (or other csDMARD). Patients with a contraindication or in whom MTX was stopped due to safety issue could be included. Patients treated by MTX will have MTX during the follow-up, others will be treated by JAKi monotherapy,',\n",
       "   'Patients with a contraindication to baricitinib or tofacitinib (current infection, recent attenuated vaccine injection, cancer <5 years…) or treated previously with baricitinib or tofacitinib,',\n",
       "   'Patients treated by glucocorticoids ≥10 mg/day and unstable dosage for <1 month or with ≥1 glucocorticoids injection <1 month.',\n",
       "   'RA with Steinbrocker class IV damage status',\n",
       "   'General'],\n",
       "  'exclusion': ['Refusal to participate in the study']},\n",
       " {'nct_id': 'NCT04085471',\n",
       "  'inclusion': ['-Patients diagnosed as',\n",
       "   '- Patients ( >18)who are age and sex matched with the controls'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04144101',\n",
       "  'inclusion': ['Diagnosis as Rheumatoid Arthritis'],\n",
       "  'exclusion': ['1. Pregnant or breast-feeding women.',\n",
       "   'Chemotherapy or radiation therapy in cancer patients']},\n",
       " {'nct_id': 'NCT04821050',\n",
       "  'inclusion': ['18-65 years of age at screening',\n",
       "   'Met the American College of Rheumatology criteria (2010) for RA',\n",
       "   'Active mild to moderate RA (defined as 3.2 < DAS28-CRP< 5.1) naïve to any medication; or refractory RA who demonstrated an inadequate response or loss of response to 2 or more conventional synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) after treatment for at least 6 months.'],\n",
       "  'exclusion': ['Any severe chronic or uncontrolled comorbid disease, such as important organ failure, degree II and III heart block, clinically significant cardiovascular disease, severe infection, tumor, etc;',\n",
       "   'Combined with other connective tissue diseases',\n",
       "   \"Cognitive impairment and can't cooperate\",\n",
       "   'Pregnancy or breastfeeding',\n",
       "   'Bleeding or coagulation disorders',\n",
       "   'Localized skin infections',\n",
       "   'Intra-articular corticosteroid or pulse steroid within 2 weeks preceding the study']},\n",
       " {'nct_id': 'NCT04820426',\n",
       "  'inclusion': ['diagnosed with rheumatoid arthritis,',\n",
       "   'who can read and write in Turkish,',\n",
       "   \"participant's admission participating in the study,\",\n",
       "   'participants who do not have exclusion criteria'],\n",
       "  'exclusion': [\"participant's refusal to participate in the study,\",\n",
       "   'lack of cooperation due to cognitive impairment,',\n",
       "   \"participant's who have a neurological disease,\",\n",
       "   'presence of drug abuse,',\n",
       "   'presence of malignancy in any organ or system,',\n",
       "   'serious psychiatric problems (psychosis, etc.),',\n",
       "   'the presence of another rheumatological disease other than Rheumatoid Arthritis,',\n",
       "   'serious and unstable metabolic disease.']},\n",
       " {'nct_id': 'NCT04933097',\n",
       "  'inclusion': ['Rheumatoid arthritis defined according to ACR/EULAR 2010 criteria,',\n",
       "   'Follow-up at the University Hospital of Reims,',\n",
       "   'Signed consent'],\n",
       "  'exclusion': ['Inability to perform a functional test (walking test)',\n",
       "   'Patient under legal protection',\n",
       "   'Patients not affiliated to the social security system',\n",
       "   'Pregnant women']},\n",
       " {'nct_id': 'NCT04937140',\n",
       "  'inclusion': ['Inclusion criteria:',\n",
       "   'Patients with RA classified according to the revised American College of Rheumatology (ACR)/EULAR RA classification criteria 2010 for',\n",
       "   '2. Age ≥ 18 years.',\n",
       "   'Patients who are able and willing to give written informed consent.',\n",
       "   'Disease duration more than one year'],\n",
       "  'exclusion': ['Any other autoimmune disease rather than',\n",
       "   '2. Patients with any disease affecting the cardiovascular system other than',\n",
       "   '3. Patients with known risk factors for atherosclerosis as diabetes, hypertension, hyperlipidemia and obesity.']},\n",
       " {'nct_id': 'NCT04115423',\n",
       "  'inclusion': ['Individuals who had a diagnosis of rheumatoid arthritis (ICD-10 codes: M05-06) between 2013 and 2018'],\n",
       "  'exclusion': ['Individuals less than 18 years of age',\n",
       "   'Having no records of prescription of tocilizumab or TNFi at least once between 2013 and 2018']},\n",
       " {'nct_id': 'NCT04246762',\n",
       "  'inclusion': ['Subjects willing and able to give voluntary informed consent and sign an Informed Consent Form (ICF)',\n",
       "   'Male subjects and their female partners and female subjects of childbearing potential must agree to adhere to the contraceptive requirements for the study Female subjects of non-childbearing potential must be: • Surgically sterile (i.e. bilateral tubal ligation or removal of both ovaries and/or uterus at least 6 months prior to first dosing), or • Naturally postmenopausal (spontaneous cessation of menses) for at least 24 consecutive months prior to first dosing, with a follicle stimulating hormone level at screening of ≥40 mIU/mL.',\n",
       "   'Body mass index of 18 kg/m2 to 29.9 kg/m2, inclusive, and body weight of 55 kg to 110 kg, inclusive, if male, and 45 kg to 100 kg, inclusive, if female.',\n",
       "   'Subjects must have a diagnosis of adult onset RA classified by the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 revised classification criteria for RA (Aletaha et al, 2010) for at least 12 weeks prior to Screening. If the subject was previously diagnosed according to ACR 1987 criteria, the Investigator may classify the subject per ACR 2010 retrospectively, based on medical history, and using available source data.',\n",
       "   \"Subjects must have received Methotrexate (MTX), sulfasalazine, or hydroxychloroquine for at least 12 weeks prior to Day 1 and in stable dose for at least 6 weeks prior to Day 1 without significant Adverse events (AEs). Stable doses of MTX should be 10 mg to 25 mg weekly with folic acid (at least 5 mg weekly or equivalent). No significant side effects based on the Investigator's judgment should be observed during treatment by these agents. The maximum allowed doses of sulfasalazine and hydroxychloroquine are:\",\n",
       "   'Sulfasalazine: 3 g per day',\n",
       "   'Hydroxychloroquine: 400 mg per day Note: The doses should remain stable and not be changed from the time of signing the ICF until the end of the treatment period (EOT, Day 29).',\n",
       "   'Subjects must have an increased CRP at Screening (of ≥1.2 × ULN).',\n",
       "   'Female subjects of childbearing potential must have negative pregnancy test at Screening and throughout the study until the end of study (EOS, Day 161).'],\n",
       "  'exclusion': [\"Diagnosis of any other inflammatory arthritis or systemic inflammatory disease (e.g., gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile idiopathic arthritis, or systemic lupus erythematosus). Osteoarthritis is classified as a degenerative disease rather than an inflammatory disease.\",\n",
       "   'Subjects with Steinbrocker Class III or IV functional capacity (incapacitated, largely, or wholly bed ridden, or confined to a wheelchair, with little, or no self-care).',\n",
       "   'Prior exposure to any licensed or investigational compound directly or indirectly targeting IL-6 or IL-6R within 12 months of Day',\n",
       "   '4. Treatment with DMARDs other than MTX, hydroxychloroquine, or sulfasalazine. Treatment with the following DMARDs are not allowed within the specified time period prior to Day 1:',\n",
       "   '4 weeks for azathioprine, cyclosporine, chloroquine, gold, penicillamine, minocycline, or doxycycline.',\n",
       "   '12 weeks for leflunomide unless the subject has completed the following elimination procedure at least 4 weeks prior to Day 1: Cholestyramine at a dosage of 8 grams 3 times daily for at least 24 hours or activated charcoal at a dosage of 50 grams 4 times a day for at least 24 hours.',\n",
       "   '24 weeks for cyclophosphamide.',\n",
       "   'Treatment with any cell-depleting therapies including anti-cluster of differentiation (CD)20 or investigational agents (eg, CAMPATH®, anti-CD4, anti-CD5, anti-CD3, and anti-CD19) with the exception of rituximab. Treatment with rituximab is not allowed within 6 months of Day',\n",
       "   '6. Treatment with Tumor necrosis factor alpha inhibitor (TNFi) (including investigational proposed or licensed biosimilars) or any other biologic therapy for the treatment of RA within 12 weeks of Day',\n",
       "   '7. Use of parenteral or intra-articular glucocorticoids within 4 weeks prior to Day',\n",
       "   '8. Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or change in dosage within 4 weeks prior to Day',\n",
       "   '9. Use of indomethacin and ketorolac; other nonsteroidal anti-inflammatory drugs (NSAIDs) (with the exception of aspirin, see below) must be taken at a stable dose and route of administration for at least 2 weeks prior to Day',\n",
       "   '10. Female subjects of nonchildbearing potential taking hormone replacement therapy within 4 weeks prior to Day',\n",
       "   '11. Vaccination with live vaccines in the 6 weeks prior to Day 1 or planned vaccination with live vaccines during the study.',\n",
       "   'Participation in any other investigational drug study within 30 days or 5 times the t1/2 of the investigational drug, whichever is longer, prior to Day',\n",
       "   '13. Use of aspirin or other antiplatelet agents and anticoagulants including warfarin in the 4 weeks prior to Day',\n",
       "   '14. Has received any prescription or nonprescription drugs or other products (eg, herbal preparations, food products) known to be inhibitors/inducers of CYP3A4, CYP2C9, CYP2C19, or CYP1A2 within 4 weeks prior to Day 1 and for the duration of the study up to the EOT (Day 29) Visit. The use of MTX, as described in inclusion criterion #5, is permitted.',\n",
       "   'Use of any herbal preparations (including foods or beverages containing herbal preparations), dietary supplements, or natural medications within 14 days of Day',\n",
       "   '16. Has received midazolam and/or omeprazole (or esomeprazole) within 14 days of Day',\n",
       "   '17. Excessive intake of caffeine (more than 5 cups of coffee or equivalent per day) and the inability to abstain from caffeine-containing drinks and foods from 2 days prior to each cocktail administration and while inpatient (Day -1 to Day 2 and Day 21 to Day 23, respectively).',\n",
       "   'Poor metabolizers of CYP2C9 (genotype *2/*2, *2/*3, *3/*3) or CYP2C19 (genotype *2/*2, *2/*3, *3/*3), ultra-rapid metabolizers of CYP2C19 (*17/*17), or high sensitivity to warfarin (VKORCI genotype AA).',\n",
       "   'Previous participation (enrolled) in this study or another study of OKZ in case of receiving at least one OKZ dose.',\n",
       "   'Abnormal laboratory values as defined below. If, in the opinion of the Investigator, exclusionary results are due to laboratory error or a transient condition, these tests may be repeated once during Screening.',\n",
       "   'Creatinine level ≥1.5 mg/dL (132 µmol/L) for females or ≥2.0 mg/dL (177 µmol/L) for males.',\n",
       "   'Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) level ≥1.5 × ULN.',\n",
       "   'Platelets <150 × 10^9/L (<150,000/mm3).',\n",
       "   'White blood cell count <3.0 × 10^9/L.',\n",
       "   'Neutrophil count <2.0 × 10^9/L (<2000 mm3).',\n",
       "   'Hemoglobin level ≤95 g/L.',\n",
       "   'Glycosylated hemoglobin (HbA1c) level ≥8%.',\n",
       "   'International normalized ratio above the ULN (Normal range: 0.80 or 0.90 to 1.20, males and females of all ages).',\n",
       "   'Subjects with concurrent viral hepatitis B or C infection as detected by blood tests at Screening (eg, positive for hepatitis B surface antigen (HBsAg), hepatitis B DNA (HBV DNA) or hepatitis C virus antibody (HCV Ab)).',\n",
       "   'HBV DNA to be tested only in anti-hepatitis B core antigen (anti-HBc) positive subjects.',\n",
       "   'Subject who is positive for hepatitis B surface antibody (anti-HBs) and total antiHBc but negative for HBsAg and HBV DNA, will be eligible upon qualified specialist (i.e. hepatologist) consultation with documented conclusion no additional risk is suspected for the subject.',\n",
       "   'Subject who is positive for hepatitis B surface antibody (anti-HBs) but negative for HBsAg and total anti-HBc, will be eligible with no additional consultation.',\n",
       "   'Subjects with human immunodeficiency virus (HIV) infection.',\n",
       "   'Subjects with:',\n",
       "   'Suspected or confirmed current active tuberculosis (TB) disease or a history of active TB disease.',\n",
       "   'Close contact (ie, sharing the same household or other enclosed environment, such as a social gathering place, workplace or facility, for extended periods during the day) with an individual with active TB within 1.5 years prior to Screening.',\n",
       "   'History of untreated latent TB infection (LTBI), regardless of QuantiFERON-TB Gold Plus interferon-gamma release assay (IGRA) result at Screening.',\n",
       "   'Positive IGRA result at Screening. If indeterminate, the IGRA can be repeated once during Screening. If there is a second indeterminate result, the subject will be excluded.',\n",
       "   'Concurrent malignancy or a history of malignancy within the last 5 years (with the exception of successfully treated carcinoma of the cervix in situ or successfully treated basal cell carcinoma or squamous cell carcinoma not less than 1 year prior to Screening [and no more than 3 excised nonmelanoma skin cancers within the last 5 years prior to Screening]).',\n",
       "   \"Subjects with a history of major bleeding, bleeding tendencies (such as any prior gastrointestinal bleeding and recent ulceration of gastrointestinal track, congenital and acquired disorders by hemostasis), or other clinically significant predisposition to bleeding according to the physician's judgment.\",\n",
       "   'Subjects with a history or presence of severe cardiovascular conditions such as stroke, transient ischemic attack, or myocardial infarction in medical history.',\n",
       "   'Uncompensated congestive heart failure, or Class III or IV heart failure defined by the New York Heart Association classification.',\n",
       "   'Untreated, uncontrolled, or resistant arterial hypertension Grade 2 to 3 (systolic blood pressure (BP) >160 mm Hg and/or diastolic BP >100 mm Hg, based on the mean of 3 readings). If hypertension is not controlled, subjects should be excluded, and not allowed for rescreening.',\n",
       "   \"Uncontrolled diabetes mellitus (based on the Investigator's judgment).\",\n",
       "   \"Subjects with a history or presence of any other cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, hematological, or immunologic/immunodeficiency disorder(s) or any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate subject participation in the clinical study, or clinically significant enough in the opinion of the Investigator to alter the disposition of the study treatment, or constitute a possible confounding factor for assessment of safety of the study treatment..\",\n",
       "   'Subjects with gastrointestinal (GI) resection (eg, partial or total gastrectomy) likely to interfere with absorption of study treatment.',\n",
       "   'Subjects with any infection requiring any anti-infective therapy (eg, antibiotic, antiviral, or antifungal therapy) in the 4 weeks prior to Day 1, or serious or recurrent infection with history of hospitalization in the 6 months prior to Day 1 or active infection at Day',\n",
       "   '33. Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis, meningitis, or other nonself-limited herpes zoster infections in the 6 months prior to Day',\n",
       "   '34. Subjects with planned surgery during the study (up to and including the EOT Visit,[Day 29]) or surgery ≤4 weeks prior to Screening and from which the subject has not fully recovered, as judged by the Investigator.',\n",
       "   'Subjects with diverticulitis or other symptomatic GI conditions that might predispose the subject to perforations, including subjects with a history of such predisposing conditions (eg, diverticulitis, GI perforation, or ulcerative colitis).',\n",
       "   'History of chronic alcohol or drug abuse or consumption of more than 21 units (male subjects) or 14 units (female subjects) of alcohol a week (unit = 1 glass of wine [125 mL] = 1 measure of spirits = ½ pint of beer) as judged by the Investigator.',\n",
       "   'Current smokers or those who have smoked or used nicotine products within the previous 3 months prior to Screening.',\n",
       "   'Subjects with a known hypersensitivity or contraindication to any component of the cocktail drugs or OKZ.',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.',\n",
       "   'Any self-reported symptoms of influenza-like or COVID-19 like illness in the 14 days preceding Screening OR Day 1 as per the Investigators assessment. Symptoms related to COVID-19 include, but are not limited to:',\n",
       "   'Respiratory symptoms (eg, sore throat, nasal congestion, post-nasal discharge, wheezing, cough, dyspnea, and bronchial breath sounds);',\n",
       "   'Non-respiratory symptoms, such as gastrointestinal symptoms (eg, nausea, vomiting, and diarrhea), neurologic symptoms (eg, anosmia, ageusia, headache), myalgia or fatigue.',\n",
       "   'Active SARS-CoV-2 infection as confirmed by reverse transcription polymerase chain reaction (RT-PCR) or/and positive serology at Screening.',\n",
       "   'Known exposure to an individual with confirmed COVID-19 or SARS-CoV-2 infection within 2 weeks before Screening OR Day',\n",
       "   '43. History of COVID-19 infection in the previous 3 months before Day 1 or with sever or critical illness ever. Note: The subject can be enrolled if all of the following criteria are fulfill:',\n",
       "   'had non-sever or non-critical COVID-19 infection more than 3 months before Day 1;',\n",
       "   'fully recovered as per official medical records which should be documented as a source document (mild sequalae of the previous infection such as dry cough, weakness should be resolved by the time of Screening);',\n",
       "   'there are no any concerns that the subject is infections to others;',\n",
       "   'there are no any other local guidelines/requirements with regards of this group of subjects.',\n",
       "   'Those subjects who have been at high risk of exposure before Screening, including but not limited to: Close contacts of confirmed COVID-19 cases, anyone who had to self-isolate as a result of a symptomatic household member, frontline healthcare professionals working in accident and emergency (A&E), ICU and other higher risk areas.',\n",
       "   'Individuals currently working with high risk of exposure to SARS-CoV-2 (eg, active healthcare workers or emergency response personnel having direct interactions with or providing direct care to patients).',\n",
       "   'Pregnancy and breastfeeding.',\n",
       "   \"Other medical or psychiatric conditions or laboratory abnormalities that may increase potential risk associated with study participation and administration of study treatment, or that may affect study results interpretation and, as per the Investigator's judgment.\",\n",
       "   \"Subject's unwillingness or inability to follow the procedures outlined in the protocol.\",\n",
       "   'Employees or relatives of the Sponsor, Contract Research Organization, or the study center personnel.']},\n",
       " {'nct_id': 'NCT04247815',\n",
       "  'inclusion': ['Diagnosis of adult-onset RA as defined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria.',\n",
       "   'DAS28-CRP ≥3.2 defined as moderate to high disease activity.',\n",
       "   'Have moderately to severely active RA defined by at least 4/28 tender and 4/28 swollen joints.',\n",
       "   'hsCRP ≥5 mg/L at screening.',\n",
       "   'Patients must have definitive intra-articular synovitis or osteitis defined as a score of 1 or greater on a Hand-Wrist MRI as assessed by central imaging reader (using RAMRIS).',\n",
       "   'On a stable MTX dose and a stable dose of folic or folinic acid prior to the screening visit.'],\n",
       "  'exclusion': ['Patient has a current acute or chronic immunoinflammatory disease other than RA which may impact the course or assessment of',\n",
       "   '- Patient has an uncontrolled non-immunoinflammatory disease that may place the patient at increased risk during the study or impact the interpretation of results.',\n",
       "   'History or evidence of active or latent tuberculosis.',\n",
       "   'Active infection requiring treatment with antibiotics.',\n",
       "   'Blood pressure levels (in supine position after at least 5 minutes rest): <90 mmHg or >140 mmHg for systolic blood pressure or <40 mmHg or >90 mmHg for diastolic blood pressure.',\n",
       "   'Are currently receiving corticosteroids at doses greater than 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of the screening visit.',\n",
       "   'Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of the screening visit.',\n",
       "   'Patients with history of stroke.',\n",
       "   'Any joint procedure in the past 90 days prior to screening.']},\n",
       " {'nct_id': 'NCT04246827',\n",
       "  'inclusion': ['had RA for at least one year',\n",
       "   'were 18 to 85 years of age',\n",
       "   'were obese according to established RA obesity criteria (RA-BMI > 28)',\n",
       "   'had experienced RA pain in the last two weeks.'],\n",
       "  'exclusion': ['Subjects were excluded if they 1) have a significant rheumatic disorder other than RA or another organic disease that would significantly affect functioning (e.g., COPD, cancer)',\n",
       "   'had a significant medical condition that would expose them to increased risk of a significantly adverse experience during the course of the study (e.g., a recent myocardial infarction)',\n",
       "   'they were already involved in a regular exercise program and/or pain coping skills training program',\n",
       "   'they had an abnormal cardiac response to exercise such as exercise-induced VT, abnormal blood pressure response, etc.,',\n",
       "   'are pregnant at enrollment or at the initiation of intervention',\n",
       "   'are younger than 18 years of age or older than 85 years of age',\n",
       "   'are known or judged by the physician to be cognitively impaired (dementia, retardation, psychosis)']},\n",
       " {'nct_id': 'NCT04163991',\n",
       "  'inclusion': ['Male or female adults, >= 18 years of age at time of informed consent.',\n",
       "   'Diagnosed with RA according to the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2010 criteria >= 6 months prior to screening.',\n",
       "   'Disease Activity Score in 28 Joints (DAS 28) using C-reactive Protein (DAS28-CRP) > 3.2 at screening with >= 4 tender joint count (TJC) and >= 4 swollen joint count (SJC) out of the 28 joints assessed for DAS28 present at screening and confirmed present at visit 2 prior to randomization.',\n",
       "   'Positive for rheumatoid factor (RF) and/or anti-citrullinated protein antibodies (ACPA) at screening, in accordance with criteria at the central laboratory.',\n",
       "   'Treated with methotrexate (MTX), with or without a concomitant conventional disease-modifying anti-rheumatic drug (cDMARD).',\n",
       "   'Agreeing to use of protocol defined contraception methods. Principal'],\n",
       "  'exclusion': ['Prior or current inflammatory joint disease other than',\n",
       "   '2. Severe interstitial lung disease.',\n",
       "   'Prior receipt of any biologic B-cell-depleting therapy.',\n",
       "   'Receipt of any anti',\n",
       "   'tumor necrosis factor alpha (TNF-α) biologic agent < 8 weeks prior to screening.',\n",
       "   'Receipt of any biologic disease-modifying anti-rheumatic drug (bDMARD) with a mechanism of action other than direct TNF-α blockade, < 12 weeks or < 5 half-lives of the drug prior to screening.',\n",
       "   'Injectable corticosteroids or treatment with > 10 mg/day dose of oral prednisolone or equivalent within 4 weeks prior to screening.',\n",
       "   'Previous treatment with anti-cluster of differentiation 40 ligand (CD40L) compounds at any time before randomization.',\n",
       "   'Hepatitis B, hepatitis C, or human immunodeficiency virus infection.',\n",
       "   'Pregnant or lactating or planning to get pregnant during the duration of the study.',\n",
       "   'Evidence of active tuberculosis (TB) or being at high risk for',\n",
       "   '11. History of more than one episode of herpes zoster in the 12 months prior to screening or any opportunistic infection in the 12 months prior to screening, excluding localized mucocutaneous candidiasis.',\n",
       "   'Receipt of live vaccine or live therapeutic infectious agent within the 4 weeks prior to screening.']},\n",
       " {'nct_id': 'NCT04175886',\n",
       "  'inclusion': [\"Adult patient's ≥18 years old with moderately to severely active Rheumatoid Arthritis (RA) (ACR/EULAR criteria )\",\n",
       "   'Previously untreated with Janus Kinase (JAK) inhibitors',\n",
       "   'With an indication for tofacitinib will be eligible.',\n",
       "   'All patients will have to be treated with tofacitinib either alone or with methotrexate. -Healthy volunteers should be ≥18 years old.'],\n",
       "  'exclusion': ['• treatment with more than three anti-Tumor Necrosis Factor alpha (TNFα). Patients who were receiving anti-TNFα will be required a washout period lasting at least five-half-lives before to start tofacitinib,',\n",
       "   'previously exposed to JAK inhibitors,',\n",
       "   'patients who were receiving non-anti-TNFα biologics (abatacept, tocilizumab, sarilumab or rituximab) will be required a washout period lasting at least five-half-lives before to start tofacitinib',\n",
       "   'Concomitant methotrexate (MTX) will be permitted if started ≥3 months prior to study start and at a stable dose (≤25 mg/week) for ≥4 weeks.',\n",
       "   'history or discovery of an osteoporotic fracture AND/OR T-score≤-3 if ≥50 years AND/OR Z-score ≤-3 if <50 years during the screening phase,',\n",
       "   'current treatment with oral corticosteroids higher than 10 mg prednisone/day,',\n",
       "   'pathologies or treatments that could affect the bone metabolism (breast cancer with aromatase inhibitors, gastrointestinal malabsorption, stomach cancer, primary hyperparathyroidism, uncontrolled hyperthyroidism…),',\n",
       "   'weight> 160 kg,',\n",
       "   'patients on restrictive diets or considering such a diet during the study period,',\n",
       "   'patients with an intense exercise program or planning to benefit from it during the study period,']},\n",
       " {'nct_id': 'NCT04170504',\n",
       "  'inclusion': ['Subject has had a confirmed diagnosis of rheumatoid arthritis according to 2010 ACR/EULAR RA classification criteria.',\n",
       "   'Subject has a DAS28 CRP disease activity score of >3.2 at screening.',\n",
       "   'Subject also experienced the following signs and symptoms: swelling, joint pain, and heat in the joints.',\n",
       "   'Subject has had no prior exposure to oral glucocorticoids at a daily dose greater than 10 mg or to any biologic agents.',\n",
       "   'Subject may has had previous exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) prior to screening and must be on stable dose.'],\n",
       "  'exclusion': ['History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.',\n",
       "   'Subject has inflammatory, rheumatological disorders other than RA, where arthritis may be a prominent feature.',\n",
       "   'Subject has received treatment with the prohibited therapies listed in the protocol, or changes to those treatments, within the prescribed timeframe.',\n",
       "   'Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant.']},\n",
       " {'nct_id': 'NCT04178850',\n",
       "  'inclusion': ['Aged 18 to 75 years, males or females;',\n",
       "   'Subjects who have confirmed rheumatoid arthritis for at least 3 months according to 2010 American College of Rheumatology Classification Criteria (amendment);',\n",
       "   'The active stage is met at screening: the following 3 items should be met (based on 28 joints): Swelling of 4 or more joints; tenderness of 6 or more joints; Tenderness of 6 or more joints; At least one of the following criteria is met: erythrocyte sedimentation rate >28mm/h or C-reactive protein >10mg/L (1mg/dl);',\n",
       "   'Subjects who have been treated with MTX treatment for at least 3 months before the before the use of invesetigational products and the dose remains stable (10~15mg/week) for at least 4 weeks;',\n",
       "   'The following DMARDs except MTX (including but not limited to chloroquine, hydroxychloroquine, gold preparation, penicillamine, sulfasalazine, azathioprine, cyclophosphamide, cyclosporin A, glucosinolate, auranofin etc.) are discontinued at least 4 weeks before the use of invesetigational products. Should any leflunomide is previously used, the subjects can be enrolled after 4 weeks after washout with cholestyramine (8g, three times per day) for 11 days. If leflunomide is discontinued 12 weeks ago, the patients can be enrolled without washout with cholestyramine.',\n",
       "   'If glucocorticoids are being administered before the use of invesetigational products, the dose must be stable and remains ≤10mg/d (equivalent to the dose of prednisone) for at least 4 weeks; if no glucocorticoids is used, no oral administration is given at least 4 weeks ago or no local injection is given at least 12 weeks ago.',\n",
       "   'The Chinese traditional patent medicine or Chinese herbal medicine for RA treatment, physical therapy, inoculation with live (attenuated) viral/ bacterial vaccines, or intravenous injection of immunoglobulin (IgG) should be discontinued at least 4 weeks before the use of the use of invesetigational products;',\n",
       "   'If other biological preparations are used, or the subjects participated in clinical trials of other investigational products or marketed drugs before the use of invesetigational products, an interval of at least 3 months is required.',\n",
       "   'Female patients of child-bearing potential have negative pregnancy test at screening; both males and females agree to adopt medically confirmed effective contraceptive measures during the entire study period and within 6 months after the end of this study.',\n",
       "   'Voluntarily participate in the clinical trial and sign the informed consent form;',\n",
       "   'Be able to understand and complete assessment forms;',\n",
       "   'Patients can well communicate with the investigators and complete the study as required by the study.'],\n",
       "  'exclusion': ['The subjects received similar biological preparations (TNF inhibitors) for RA treatment within 3 months before randomization or were treated with TNF inhibitors 3 months ago, which are assessed as ineffective by the investigator.',\n",
       "   'Be allergic to any exicipent of the investigational products or any other murine or human-derived protein, hypersensitivity to immunoglobulin products, known to have medical history of allergic diseases or allergic constitution;',\n",
       "   'Body weight >100kg;',\n",
       "   'Subjects with rheumatoid arthritis with joint function classification of grade IV or subjects who combined to chair or bed (refer to appendix 9 for details of joint function classification);',\n",
       "   'Treatment with interferon within 4 weeks before the use of invesetigational products;',\n",
       "   'Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and anti-treponema pallidum antibody (TP-Ab);',\n",
       "   'Patients with known tuberculosis infection and patients with high risks for tuberculosis infection should be excluded. If patients with latent tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies (appendix 5) during the study period, they can be enrolled. Or, they will be excluded.1) Known tuberculosis infection (any of the following criteria is met):',\n",
       "   'Active tuberculosis infection or presence of clinical signs and symptoms of suspected tuberculosis (pulmonary or extrapulmonary);B. Presence of active tuberculosis infection involved any organ system, or symptoms of other organ systems corresponding to tuberculosis infection;C. The radiology test or other imaging tests showing evidence of previous infection at screening or within the previous 3 months (obsolete tuberculosis evidence: scars of lung and/or pleural fiber; calcification of apex of lung or other sites; pulmonary hilus and /or mediastinal lymph node lesions; decreased volume of upper lobe of lung; pulmonary cavity).2) High risks for tuberculosis infection (any of the following criteria is met):',\n",
       "   'Known to be in close contact with active tuberculosis patients within 3 months before screening;',\n",
       "   'Subjects with low immunologic function and with evidence showing any latent tuberculosis infection (LTBI);',\n",
       "   'Long stay with individuals infected with tuberculosis or long stay in medical service environment or institutions with high risks for tuberculosis transmission and infection;3) If patients with latent tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies (appendix 5) during the study period, they can be enrolled. Or, they will be excluded. LTBI is defined as no evidence showing signs or symptoms of tuberculosis infection or abnormal physical examination, and chest X-ray test (other imaging tests) results showing no evidence of tuberculosis infection, however, interferon gamma release assay (IGRA) is positive or the results of two IGRA tests are not clear;',\n",
       "   'Previous opportunistic infection (herpes zoster, cytomegalovirus, mycoplasma, pneumocystis carinii, histoplasma capsulatum, candida, aspergillus, mycobacterium other than mycobacterium tuberculosis etc.) within 6 months before screening;',\n",
       "   'Medical history of chronic infection (e.g., chronic hepatitis, chronic renal infection etc.), serious or life-threatening infection (e.g., hepatitis, pneumonitis and pyelonephritis etc.) or any current symptoms or signs indicating possible presence of infection (e.g., pyrexia, cough, urgent micturition, urodynia, abdominal pain, diarrhea, cutaneous infected wound etc.)',\n",
       "   'Patients who are in high risk for infection (e.g., leg ulcer, retention catheterization, persistent or recurrent chest infection and bedridden or wheelchair-bound for a long term);',\n",
       "   'Medical history of lymphoproliferative disorder (including lymphoma, or signs or symptoms reflecting lymphoproliferative disorders at any time); or splenomegaly;',\n",
       "   'Patients who previously or currently have malignant tumors within 5 years before screening (excluding adequately treated and completely cured skin basal cell carcinoma or squamous cell carcinoma, cervical in situ carcinoma);',\n",
       "   'Current or previous presence of congestive heart failure or medical history of congestive heart failure;',\n",
       "   'Current presence of interstitial lung disease or medical history of previous interstitial lung disease;',\n",
       "   'Current or previous presence of multiple sclerosis or other demyelinating diseases of the central nervous system or corresponding medical history of these diseases;',\n",
       "   'There is evidence showing that the patients have serious, progressive and uncontrolled cardiovascular, renal, hepatic, hemopoietic, gastrointestinal, endocrine, pulmonary, nervous system disorders; and other conditions who are considered unsuitable for participating in this study at the discretion of the investigator;',\n",
       "   'The following abnormal laboratory variables should be excluded: white blood cells (WBC) <3.0×109/L, neutrophil count (ANC)<1.5×109/L, platelet count (PLT) <100×109/L, hemoglobin (HGB) <85g/L, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of normal (ULN), alkaline phosphatase (ALP)> 2 times the upper limit of normal (ULN), serum creatinine (Cr) > 1.5 times ULN;',\n",
       "   'Current or previous presence of other systemic immune diseases (e.g., systemic lupus erythematosus etc.), or inflammatory joint disease other than rheumatoid arthritis (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy and Lyme disease etc.); Patients with rheumatoid arthritis complicated with secondary Sjogren syndrome which will not affect drug evaluation at the discretion of the investigator are allowed to be enrolled.',\n",
       "   'Subjects with medical history of prosthetic joint infection and the artificial joints are still in the body;',\n",
       "   'Subjects who received arthroplasty for more than 3 times;',\n",
       "   'Subjects who received organ transplantation within 6 months before screening;',\n",
       "   'Lactating women;',\n",
       "   'Subjects who have medical history of long-term alcohol abuse or drug abuse;',\n",
       "   \"Subjects who have insufficient communication, understanding and cooperation, or subjects who have low education level, cannot understand and correctly complete corresponding forms, subjects who have history of noncompliance with doctor's instructions to receive administration, or subjects who have other conditions which may interfere with protocol compliance of subjects (e.g., subjects who have psychiatric disorders or usually travel, and lack of motivation to participate in the study);\",\n",
       "   'Subjects who have other diseases (e.g., clinically significant symptoms or abnormal laboratory variables) which are considered unsuitable for participating in this clinical study at the discretion of the investigator; This study allows repeated screening at screening. The most recent test results prior to the first dose of all items are regarded as the baseline values.']},\n",
       " {'nct_id': 'NCT04179513',\n",
       "  'inclusion': ['Understand the study procedures and contents, voluntarily participate in the clinical trial and sign the informed consent form;',\n",
       "   'Aged 18 to 75 years, males or females;',\n",
       "   'Subjects who have confirmed rheumatoid arthritis for at least 3 months according to 2010 American College of Rheumatology Classification Criteria (amendment);',\n",
       "   'The active stage is met at screening: the following 3 items should be met (based on 28 joints): swelling of 4 or more joints; tenderness of 6 or more joints; at least one of the following criteria is met: erythrocyte sedimentation rate >28mm/h or C-reactive protein >10mg/L (1.0mg/dL);',\n",
       "   'Subjects who have been treated with MTX treatment for at least 12 weeks before the before the use of investigational products and the dose remains stable (10~15mg/week) for at least 4 weeks;',\n",
       "   'The following DMARDs except MTX (including but not limited to chloroquine, hydroxychloroquine, gold preparation, penicillamine, sulfasalazine, azathioprine, cyclophosphamide, cyclosporin A, glucosinolate, auranofin etc.) are discontinued at least 4 weeks before the use of investigational products. Should any leflunomide is previously used, the subjects can be enrolled after washout with cholestyramine (8g, three times per day) for 11 days. If leflunomide is discontinued 12 weeks ago, the patients can be enrolled without washout with cholestyramine.',\n",
       "   'Use of TNF-α antagonists (approved orexploratory new agents) is allowed before the use of investigational products, however, it should be discontinued at least 4 weeks before administration of investigational products due to inadequate response, intolerability or economic reasons. If similar biological preparations (IL-6/IL-6R antagonists) were given before the use of investigational products, inadequate response and intolerability should be not observed and the drug should be discontinued at least 3 months ago.',\n",
       "   'If glucocorticoids are being administered before the use of investigational products, the dose must be stable and remains ≤10mg/d (equivalent to the dose of prednisone) for at least 4 weeks; if no glucocorticoids are used, no oral administration is given at least 4 weeks ago.',\n",
       "   'If the non-steroidal anti-inflammatory drugs (NSAIDs) are being administered before the use of investigational products, the dose should be stable for at least 2 weeks.',\n",
       "   'Female subjects of child-bearing potential have negative pregnancy test at screening; both males and females agree to adopt medically confirmed effective contraceptive measures during the entire study period and within 6 months after the end of this study.',\n",
       "   'Be able to understand and complete assessment forms;',\n",
       "   'Subjects can well communicate with the investigators and complete the study as required by the study.'],\n",
       "  'exclusion': ['Be allergic to any exicipent of the investigational products or any other animal-derived protein, or hypersensitivity to immunoglobulin products; Subjects who are known to have medical history of allergic diseases or allergic constitution;',\n",
       "   'Subjects with rheumatoid arthritis with joint function classification of grade IV or subjects who combined to chair or bed;',\n",
       "   'Use of intramuscular injection, intravenous injection or intra-articular injection of glucocorticoids (including intramuscular injection of ACTH) within 4 weeks before the use of investigational products.',\n",
       "   'Inoculation with live (attenuated) vaccine within 4 weeks before the use of investigational products;',\n",
       "   'Treatment with interferon within 4 weeks before the use of investigational products;',\n",
       "   'Participation in clinical trials of other drugs within 3 months before the use of investigational products;',\n",
       "   'Any of the following is positive at screening: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and anti-treponema pallidum antibody (TP-Ab);',\n",
       "   'Patients with known tuberculosis infection and patients with high risks for tuberculosis infection should be excluded. If patients with obsolete tuberculosis and latent tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies (appendix 5) during the study period, they can be enrolled. Or, they will be excluded. (1) Known tuberculosis infection (any of the following criteria is met): active tuberculosis infection or presence of clinical signs and symptoms of suspected tuberculosis (pulmonary or extrapulmonary), presence of active tuberculosis infection involved any organ system, or symptoms of other organ systems corresponding to tuberculosis infection; (2) High risks for tuberculosis infection (any of the following criteria is met): known to be in close contact with active tuberculosis patients within 3 months before screening; subjects with low immunoligic function and with evidence showing any latent tuberculosis infection (LTBI); long stay with individuals infected with tuberculosis or long stay in medical service environment or institutions with high risks for tuberculosis transmission and infection; If patients with obsolete tuberculosis and latent tuberculosis infection (LTBI) agree to receive preventive anti-tuberculosis therapies (refer to appendix 5) during the study period and have received anti-tuberculosis monotherapy for at least 4 weeks, they can be enrolled. Or, they will be excluded. Obsolete tuberculosis: the radiology test or other imaging tests showing evidence of previous infection at screening or within the previous 3 months (obsolete tuberculosis evidence: scars of lung and/or pleural fiber; calcification of apex of lung or other sites; pulmonary hilus and /or mediastinal lymph node lesions; decreased volume of upper lobe of lung; pulmonary cavity). LTBI is defined as no evidence showing signs or symptoms of tuberculosis infection or abnormal physical examination, and chest X-ray test (other imaging tests) results showing no evidence of current tuberculosis infection, however, interferon gamma release assay (IGRA) is positive or the results of two IGRA tests are not clear.',\n",
       "   'Previous opportunistic infection (herpes zoster, cytomegalovirus, mycoplasma, pneumocystis carinii, histoplasma capsulatum, candida, aspergillus, mycobacterium other than mycobacterium tuberculosis etc.) within 6 months before screening;',\n",
       "   'Medical history of chronic infection (e.g., chronic hepatitis, chronic renal infection etc.), serious or life-threatening infection (e.g., hepatitis, pneumonitis and pyelonephritis etc.) or any current symptoms or signs indicating possible presence of infection (e.g., pyrexia, cough, urgent micturition, urodynia, abdominal pain, diarrhea, cutaneous infected wound etc.)',\n",
       "   'Subjects who are in high risk for infection (e.g., leg ulcer, retention catheterization, persistent or recurrent chest infection and bedridden or wheelchair-bound for a long term)',\n",
       "   'Medical history of lymphoproliferative disorder (including lymphoma, or signs or symptoms reflecting lymphoproliferative disorders at any time); or splenomegaly',\n",
       "   'Patients who previously or currently have malignant tumors within 5 years before screening (excluding adequately treated and completely cured skin basal cell carcinoma or squamous cell carcinoma, cervical in situ carcinoma);',\n",
       "   'Current or previous presence of congestive heart failure or medical history of congestive heart failure;',\n",
       "   'Current presence of interstitial lung disease or medical history of previous interstitial lung disease;',\n",
       "   'Current or previous presence of multiple sclerosis or other demyelinating diseases of the central nervous system or corresponding medical history of these diseases;',\n",
       "   'There is evidence showing that the subjects have serious, progressive and uncontrolled cardiovascular, renal, hepatic, hemopoietic, gastrointestinal, endocrine, pulmonary, nervous system disorders; and other conditions who are considered unsuitable for participating in this study at the discretion of the investigator;',\n",
       "   'The following abnormal laboratory variables should be excluded: white blood cells (WBC) <3.5×109/L, neutrophil count (ANC)<1.5×109/L, platelet count (PLT) <100×109/L, hemoglobin (HGB) <85g/L, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 times the upper limit of normal (ULN), alkaline phosphatase (ALP)> 2 times the upper limit of normal (ULN), serum creatinine (Cr) > 1.5 times ULN, triglycerides (TG)> 2 times ULN;',\n",
       "   'Subjects who currently or previously have other immune diseases (e.g., systemic lupus erythematosus, psoriasis or ankylosing spondylitis) which are considered unsuitable for participating in this study at the discretion of the investigator or subjects who have symptoms and signs of other diseases which are expected to affect the evaluation of investigational product;',\n",
       "   'Subjects with medical history of prosthetic joint infection and the artificial joints are still in the body;',\n",
       "   'Subjects who received arthroplasty for more than 3 times;',\n",
       "   'Subjects who received organ transplantation within 6 months before screening;',\n",
       "   'Lactating women;',\n",
       "   'Subjects who have medical history of long-term alcohol abuse or drug abuse;',\n",
       "   \"Subjects who have insufficient communication, understanding and cooperation, or subjects who have low education level, cannot understand and correctly complete corresponding forms, subjects who have history of noncompliance with doctor's instructions to receive administration, or subjects who have other conditions which may interfere with protocol compliance of subjects (e.g., subjects who have psychiatric disorders or usually travel, and lack of motivation to participate in the study);\",\n",
       "   'Subjects who have other diseases (e.g., clinically significant symptoms or abnormal laboratory variables) which are considered unsuitable for participating in this clinical study at the discretion of the investigator.']},\n",
       " {'nct_id': 'NCT04170426',\n",
       "  'inclusion': ['Must pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C Consistent with American Rheumatism Association-European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis classification criteria',\n",
       "   'Active Rheumatoid Arthritis, see RA functional status of class I-IV',\n",
       "   'Patients must meet at least one of the following: > 6 swollen joints and ≥ 6 involved joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and morning stiffness ≥ 45 minutes based on 68 joint count.',\n",
       "   'Patients must also meet at least one of the following: rheumatoid factor (RF) > 15 IU/mL or > 1:16, C-reactive protein (CRP) > 2.0 mg/dL, Erythrocyte Sedimentation Rate (ESR) > 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) > 20 U/mL, TNFα > 2.8 pg/mL.',\n",
       "   'Patients must have failed anti-rheumatoid drug due to adverse event or inefficacy for at least 12 week and at least 4 weeks on stable dose of methotrexate ≤ 25 mg/week, or leflunomide ≤ 20 mg/day, or sulfasalazine ≤ 3 g/day, or steroids (Prednisone <10 mg/day).',\n",
       "   'For other medications, patients must be on the stable dose for at least 4 weeks prior to study entry in order to preclude changes to patient medication while participating on the study to ensure that a medication change could become a confounding factor in data interpretation.',\n",
       "   'All patients must be clinically stable with no significant changes in health status a minimum of at least 4 weeks prior to randomization and confirming patient eligibility'],\n",
       "  'exclusion': ['Current or prior to treatment',\n",
       "   'Participation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start',\n",
       "   'Evidence of immune suppression related to prior/current therapy',\n",
       "   '> 10% change in delivered monthly dose of anti-rheumatoid medications within 4 weeks prior to this stem cell infusion',\n",
       "   'Use of a new or additional anti-rheumatoid medication within 6 weeks prior to this stem cell infusion',\n",
       "   'Use of other stem cell therapy within 12 weeks prior to this stem cell therapy',\n",
       "   'Unwillingness or inability to comply with study procedures',\n",
       "   'Concurrent Conditions',\n",
       "   'Clinically active malignant disease',\n",
       "   'Severe bladder or thrombotic disorder',\n",
       "   'History of known pulmonary embolism or known secondary anti-phospholipid syndrome',\n",
       "   'Known or suspected hypersensitivity to any components used to culture or store the AdMSCs, e.g. sulfur or sulfonamide',\n",
       "   'Known or suspected antibodies to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO)',\n",
       "   'Active infection at time of planned study treatment start',\n",
       "   'Age related pathology likely to inhibit study participation or completion',\n",
       "   'Major trauma or surgery within 14 days of study treatment start',\n",
       "   \"Mental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study\",\n",
       "   'Alcohol, drug, or medication abuse within one year before study treatment start',\n",
       "   \"Any condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\",\n",
       "   'Irreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure',\n",
       "   'Heavy smokers, bed-bound patients, patients or family history with hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.',\n",
       "   'Laboratory Parameters',\n",
       "   'Hepatic impairment, defined as any of ALT, AST, LDH or bilirubin > 2 x the upper limit of normal (ULN) range according to local laboratory standards',\n",
       "   'Renal impairment, defined as serum creatinine > 133 mmol/L (1.5 mg/dL)',\n",
       "   'Positive virology/serology for human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), hepatitis C and/or syphilis',\n",
       "   'Pregnancy / contraception',\n",
       "   'Pregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study']},\n",
       " {'nct_id': 'NCT04870203',\n",
       "  'inclusion': ['Male or female;',\n",
       "   'Age between 18 and 75 years-old;',\n",
       "   'Adult patient with a diagnosis of RA as defined by the ACR/EULAR 2010 criteria for the classification of RA;',\n",
       "   'Patient who presents an inadequate response to one to four bDMARDs or tsDMARDs for at least 12 weeks prior to study entry at a dose that is considered acceptable to assess clinical response adequately;',\n",
       "   'Patient affected by active RA (DAS28-ESR > 3.2 or sDAI > 11 or cDAI > 10) eligible to receive a bDMARD or tsDMARD according to the French Society of Rheumatology guidelines;',\n",
       "   'Patient treated by prednisone dosage ≤ 10mg per day. The corticosteroids dosage will be decreased to 7,5 mg/day at the beginning of the study (W0);',\n",
       "   'Person affiliated with or beneficiary of the French social security scheme;',\n",
       "   'Free, informed and written consent signed by the participant and the investigator (on the day of inclusion at the latest and before any examination required by the research project).'],\n",
       "  'exclusion': ['Patient previously treated with baricitinib or adalimumab for RA;',\n",
       "   'Patient affected by another form of inflammatory arthritis with the exception of secondary Sjögren syndrome;',\n",
       "   'Patient who presents contraindications to the study treatments;',\n",
       "   'Patient who is currently receiving glucocorticosteroids at doses >10 mg of prednisone per day (or equivalent) or has been receiving an unstable dosing regimen of corticosteroids within 4 weeks of study entry;',\n",
       "   'Patient who is currently receiving more than 1 concomitant csDMARD (MTX, leflunomide, hydroxychloroquine or sulfasalazine) at the time of study entry;',\n",
       "   'Patient who is currently receiving or has received csDMARDs (eg, gold salts, cyclosporine, azathioprine, or any other immunosuppressives) other than MTX (up to 25 mg/week), leflunomide (up to 20 mg/day), hydroxychloroquine (up to 400 mg/day), or sulfasalazine (up to 3000 mg/day) within 4 weeks prior to study entry.',\n",
       "   'Doses of hydroxychloroquine or sulfasalazine should be stable for at least 4 weeks prior to study entry; if either has been recently discontinued, the patient must not have taken any dose within 4 weeks prior to study entry.',\n",
       "   'Immunosuppression related to organ transplantation is not permitted;',\n",
       "   'Patient who has received any parenteral corticosteroid administered by intramuscular or intravenous injection within 4 weeks prior to study entry, or is anticipated to require parenteral injection of corticosteroids during the study;',\n",
       "   'Patient who had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 4 weeks prior to study entry. Joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization cannot be counted in the TJC and SJC for entry or enrollment purposes;',\n",
       "   'Patient with haemoglobin less than 80 g/L, absolute lymphocyte count lower than 0.5×109/L, absolute neutrophil count less than 1×109/L, or platelet count less than 100×109/L; clearance creatinine less than 60 mL/min; total bilirubin more than 1.5 times the upper limit of normal (ULN) at screening, aspartate aminotransferase, or alanine amino-transferase more than 2 times the upper limit of normal (ULN) at screening.',\n",
       "   'Patient with co-administration with OAT3 inhibitors (such as probenecid);',\n",
       "   'Patient who has a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data;',\n",
       "   'Patient with an history of Moderate to severe heart failure (NYHA classes III/IV);',\n",
       "   'Patient with an history of Major Adverse Cardiovascular Events (non-fatal myocardial infarction or non-fatal stroke);',\n",
       "   'Patient who has a history of Venous Thromboembolic Event (VTE) (DVT/PE) within 12 weeks prior to randomization or have a history of recurrent (>1) VTE (DVT/PE). Prior DVT with PE where events overlapped in time (i.e., with PE considered resulting from DVT) is not considered recurrent DVT/PE for the purpose of this criterion.',\n",
       "   'Patient who has been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination). Investigators should review the vaccination status of their patients and follow the local guidelines for adult vaccination with nonlive vaccines intended to prevent infectious disease prior to entering patients into the study;',\n",
       "   'Patient with an active cancer;',\n",
       "   'Patient with malignancy or history of malignancy in the past 5 years, with the exception of adequately treated or excised non-metastatic basal-cell or squamous-cell cancer of the skin or cervical carcinoma in situ;',\n",
       "   'Patient who has a current or recent (<30 days prior to study entry) clinically serious viral, bacterial, fungal, or parasitic infection;',\n",
       "   'Patient who is immunocompromised and, in the opinion of the investigator, is at an unacceptable risk for participating in the study;',\n",
       "   'Patient with a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV);',\n",
       "   'Patient who had household contact with a person with active tuberculosis (TB) and did not receive appropriate and documented prophylaxis for TB;',\n",
       "   'Patient who has evidence of active TB or has previously had evidence of active TB and did not receive appropriate and documented treatment;',\n",
       "   'Patient who has evidence of latent TB (as documented by a positive Purified Protein Derivative (PPD), no clinical symptoms consistent with active TB, and a normal chest x-ray at screening) unless patient completes at least 3 weeks of appropriate treatment prior to study entry and agrees to complete the remainder of treatment while in the trial',\n",
       "   'Patient who had any major surgery within 8 weeks prior to study entry or will require major surgery during the study that, in the opinion of the investigator, would pose an unacceptable risk to the patient;',\n",
       "   'Pregnant or breastfeeding woman, or woman who refuses to use an effective contraception during the study course;',\n",
       "   'Patient governed by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).']},\n",
       " {'nct_id': 'NCT04876781',\n",
       "  'inclusion': ['Xeljanz® XR is administered according to indications on the approved labeling',\n",
       "   'Treatment of moderate to severe active RA in adult patients (18 years of age or older) who have had an inadequate response or are intolerant to methotrexate',\n",
       "   'In combination with methotrexate, treatment of active psoriatic arthritis (PsA) in adult patients (18 years of age or older) who have had an inadequate response or who have been intolerant to a prior DMARD therapy.',\n",
       "   'Treatment of active ankylosing spondylitis (AS) in adult patients (18 years of age or older) who have responded inadequately to conventional therapy',\n",
       "   'In the following patients, Xeljanz® XR should be used only for patients who have had an inadequate response or are intolerant to the existing treatment.',\n",
       "   'Patients aged 65 or older',\n",
       "   'Cardiovascular high-risk patients',\n",
       "   'Patients at risk for malignancy',\n",
       "   'Patients who have previously been given Xeljanz 5mg, who have changed Xeljanz® XR, are also eligible for registration in the study',\n",
       "   'Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study'],\n",
       "  'exclusion': ['Patients with a history of hypersensitivity to any ingredients of this product.',\n",
       "   'Patients with serious infection (sepsis, etc.) or active infection including localized infection.',\n",
       "   'Patients with active tuberculosis.',\n",
       "   'Patients with severe hepatic function disorder.',\n",
       "   'Patients with an absolute neutrophil count (ANC) <1,000 cells/mm3. *',\n",
       "   'Patients with a lymphocyte count <500 cells/mm3. *',\n",
       "   'Patients with a hemoglobin level <9 g/dL. *',\n",
       "   'Pregnant or possibly pregnant women. * Do not initiate Xeljanz XR in the following cases: ANC; absolute neutrophil count <1,000 cells/mm3 ALC; absolute lymphocyte count <500 cells/mm3 Hemoglobin<9 g/dL']},\n",
       " {'nct_id': 'NCT04871919',\n",
       "  'inclusion': ['Patients aged ≥ 18 years with a diagnosis of moderate to severe active RA being prescribed filgotinib in accordance with the local standard of care and product label for the first time.',\n",
       "   'Patients must be willing and able to use an electronic device to complete the study patient-reported outcome (PRO).'],\n",
       "  'exclusion': ['Participation in any other interventional or non-interventional study without prior approval from the Medical Monitor. This does not preclude inclusion of patients enrolled to national registries.']},\n",
       " {'nct_id': 'NCT04345159',\n",
       "  'inclusion': [\"History of Systemic Lupus Erythematosus, Rheumatoid arthritis, Sjogren's Syndrome or Psoriatic Arthritis.\"],\n",
       "  'exclusion': ['beginning, or end, of an hydroxychloroquine treatment between Jan 1, 2020 and day of the phone call.',\n",
       "   'Bad treatment compliance']},\n",
       " {'nct_id': 'NCT04348968',\n",
       "  'inclusion': ['Patient received a Maxera Cup with an outer diameter of 64 mm or 66',\n",
       "   '- The Zimmer Maxera Cup is indicated for non-cemented use in skeletally mature individuals undergoing primary surgery for rehabilitating hips damaged as a result of non-inflammatory degenerative joint disease (NIDJD) including but not limited to osteoarthritis, avascular necrosis, post-traumatic arthritis, congenital hip dysplasia, and inflammatory joint disease (IJD), e.g. rheumatoid arthritis if bone quality is adequate.'],\n",
       "  'exclusion': ['Active, old, or remote infection of the hip.',\n",
       "   'Osteoradionecrosis.',\n",
       "   'Local bone tumors and/or cysts.',\n",
       "   'Patients with poor bone quality, where there is inadequate bone to support the implant(s).',\n",
       "   'Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation.',\n",
       "   'Allergy to the implanted material.',\n",
       "   \"Patient's physical conditions that would eliminate or tend to eliminate adequate implant support or prevent the use of an appropriately sized implant, e.g. previous surgery, insufficient quality or quantity of bone resulting from conditions such as cancer or congenital dislocation, metabolic bone disease of the upper femur or pelvis, femoral osteotomy revision, girdle stone revision, osteoporosis, osteomyelitis, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to render the procedure unjustifiable (e.g. absence of musculoligamentous supporting structures, joint neuropathy) or other conditions that may lead to inadequate skeletal fixation\",\n",
       "   'Do not use ceramic femoral heads which are not BIOLOX delta or BIOLOX OPTION with Maxera components.',\n",
       "   'Use of this device when a less invasive procedure would be sufficient.',\n",
       "   'Skeletal immaturity.',\n",
       "   'Any nerve or muscle disease that may have a negative effect on gait or weight bearing',\n",
       "   'Loss of abductor musculature in the affected limb.',\n",
       "   'Poor skin coverage around the hip joint.',\n",
       "   'Rapid disease progression as obvious by joint destruction or bone absorption seen on x-ray.']},\n",
       " {'nct_id': 'NCT04349046',\n",
       "  'inclusion': ['Primary or secondary osteoarthritis',\n",
       "   'Inflammatory impairment of the hip, rheumatoid arthritis, etc.',\n",
       "   'Fracture of the neck of the femur',\n",
       "   'Avascular necrosis of the femoral head',\n",
       "   'Sequelae from previous operations on the hip, osteotomies, etc.',\n",
       "   'Congenital hip dysplasia.',\n",
       "   'Patient is older than 18 years old',\n",
       "   'Patient had consented to the original data collection after his/her surgery At the time of surgery, the'],\n",
       "  'exclusion': ['Local or systemic infections.',\n",
       "   'Serious muscular, neurological or vascular deficiencies in the limb concerned.',\n",
       "   \"Bone destruction or poor quality bone likely to affect the stability of the implant (Paget's disease, osteoporosis, etc.)\",\n",
       "   'Any concomitant disorder likely to affect the function of the implant.',\n",
       "   'Allergy to one of the implant components.',\n",
       "   'Patients weighing more than 110',\n",
       "   '- Patient incapable of following the recommendations of the surgeon']},\n",
       " {'nct_id': 'NCT04343378',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA) patients (> pr = 18 years) fulfilling the 2010 ACR/EULAR criteria',\n",
       "   'Associated to high levels (> 3 x upper limit of normal in UA/ml) of ACPA measured by the usual anti-CCP(cyclic citrullinated proteins)2 test at the start of abatacept treatment',\n",
       "   'Receiving IV (intravenous) or SC (subcutaneous) abatacept alone or in combination with a conventional Disease Modyfying AntiRheumatic Drugs (cDMARD) (methotrexate, leflunomide, sulfasalasin in monotherapy or in combination) according to the usual scheme or in tapering phase',\n",
       "   'Without intra-articular injections of corticosteroids during the last 6 months prior to down-titration of abatacept',\n",
       "   'Having discontinued corticosteroids at he time of entrance in the study',\n",
       "   'In deep remission (Disease Activity Score (DAS) 28 ESR (or CRP) < 2.6 without clinical synovitis) since at least 1 year',\n",
       "   'In sonographic remission at the time of enrollment (absence of PD (Power Doppler)-positive synovitis on 28 joints defined by a score < 2 on a 0-3 semi-quantitative scale for each joint)'],\n",
       "  'exclusion': ['Age < 18 years',\n",
       "   'RA negative for ACPA (anti-citrullinated proteins antibodies) or not fulfilling ACR/EULAR criteria',\n",
       "   'Abatacept discontinuation due to serious adverse event, loss of efficacy or pregnancy project']},\n",
       " {'nct_id': 'NCT04120831',\n",
       "  'inclusion': ['Understand and voluntarily sign an informed consent form',\n",
       "   'Male or female, age ≥ 18 years at time of consent',\n",
       "   'Able to adhere to the study visits and protocol',\n",
       "   'Satisfy the ACR-EULAR criteria of Rheumatoid Arthritis at diagnosis',\n",
       "   'SDAI≥11 at Screening',\n",
       "   'ACPA positive (anti CCP2 antibody compulsory at screening) (+/- rheumatoid factor)(≥ 40 RE/ml for CCP2 )',\n",
       "   'Completed vaccination for pneumococcus pneumoniae according to local guidelines at Baseline',\n",
       "   'Inadequate treatment response with highest tolerated dose after 3 months therapy and/or intolerance to cDMARDs specifically Methotrexate, Sulfasalazine, Hydroxychloroquine and Leflunomide or bDMARDs specifically TNF-alpha inhibitors or IL-6 receptor blockers.',\n",
       "   'Sulfasalazin, Hydroxychloroquine and Leflunomide must be stopped during screening phase and be replaced by Methotrexate. Leflunomide must be washed out until Baseline (Colestyramine 3x/day 8g/day for 11 days).',\n",
       "   'Only simultaneous therapy with Methotrexate',\n",
       "   'Maximum Glucocorticoid dose at Baseline: 20mg Prednisolone equivalent daily',\n",
       "   'JC-Virus antibody IgG and IgM in Serum negative at screening Main'],\n",
       "  'exclusion': ['Planned or ongoing pregnancy status or breast-feeding',\n",
       "   'Ongoing or previously treatment with Abatacept or Rituximab',\n",
       "   'Hypersensitivity to the active substance, mouse proteins (Rituximab), chinese hamster ovary cells (Abatacept) or other components',\n",
       "   'Use of any other biologic immunomodulatory agent (monoclonal antibody) except insulin.',\n",
       "   'Active ongoing inflammatory diseases other than RA that might confound the evaluation of the benefit of the therapy (including SLE, PSS, MCTD, SpA, Behcet disease, vasculitis or autoimmune hepatitis)',\n",
       "   'History of ongoing, chronic or recurrent infectious disease or evidence of tuberculosis infection as defined by a positive QuantiFERON TB-Gold test. If presence of latent tuberculosis is established then treatment according to local country guidelines must have been initiated but patient cannot take part in the study.',\n",
       "   'Known active or past infection with hepatitis B or hepatitis C at screening or baseline as defined by Antibody positivity and/or positive DNA/RNA levels of hepatitis B/C',\n",
       "   'Uncontrolled severe concomitant disease (including diabetes with plasma glucose >11.1 mmol/l rsp. 200 mg/dl, heart insufficiency >= NYHA III, COPD with severity >= GOLD 3, asthma according to GINA classification >= step 3)',\n",
       "   'Patients with weakened immune system defined as diagnosis of CVID, HIV and or total IgG levels lower than 600 mg/dl)',\n",
       "   'Requirement for immunization with live vaccine during the study period or within 4 weeks preceding baseline.',\n",
       "   'Contraindication for Rituximab or Abatacept treatment according to their SmPCs']},\n",
       " {'nct_id': 'NCT04536844',\n",
       "  'inclusion': ['>18 years',\n",
       "   'Fulfilling the European League against Rheumatism (EULAR) / American College of Rheumatology (ACR) 2010 classification criteria for RA',\n",
       "   'Being in remission (RAPID 3 score <=3)',\n",
       "   'Able to use the electronic app',\n",
       "   'Able to give informed consent'],\n",
       "  'exclusion': ['<18 years', 'Severe cognitive failure']},\n",
       " {'nct_id': 'NCT04530305',\n",
       "  'inclusion': ['Patients with RA fulfilling American College of Rheumatology (ACR)/ European league against rheumatism (EULAR) 2010 criteria',\n",
       "   'Patients with inadequate response to MTX',\n",
       "   'Patients receiving MTX as adjuvant therapy or will receive UPA as monotherapy'],\n",
       "  'exclusion': ['Patients with contraindication to upadacitinib',\n",
       "   'Patients previously treated with biological DMARDs or JAK inhibitors',\n",
       "   'Patients treated with ≥ 10 mg/day of glucocorticoids',\n",
       "   'Use of IV glucocorticoids in the previous month',\n",
       "   'Previous use of biological DMARDs (TNF inhibitors, rituximab, abatacept, tocilizumab) or JAK inhibitors',\n",
       "   'Absence of informed consent',\n",
       "   'Pregnancy planned for the duration of the study, Women pregnant or breastfeeding women',\n",
       "   'Major protected by law or patient under guardianship']},\n",
       " {'nct_id': 'NCT04539964',\n",
       "  'inclusion': ['22-75 years of age at screening',\n",
       "   'Active moderate or severe RA, defined as at least 4/28 tender and 4/28 swollen joints',\n",
       "   'Demonstrated an inadequate response, loss of response, or intolerance to 1 or more approved for rheumatoid arthritis biologic or targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs), including Janus kinase inhibitors (JAKi)',\n",
       "   'Receiving treatment with at least 1 conventional synthetic DMARD for at least 12 weeks and on a continuous non-changing dose and route of administration for at least 4 weeks prior to Screening and able to continue the same stable dose through Week 12'],\n",
       "  'exclusion': ['Untreated or poorly controlled psychiatric illness or history of substance abuse',\n",
       "   'Significant immunodeficiency due to underlying illness',\n",
       "   'History of stroke or transient ischemic attack, or diagnosis of cerebrovascular fibromuscular dysplasia',\n",
       "   'Clinically significant cardiovascular disease',\n",
       "   \"Neurological syndromes, including multiple sclerosis, Alzheimer's disease, or Parkinson's disease\",\n",
       "   'Uncontrolled fibromyalgia',\n",
       "   'History of left or right carotid surgery',\n",
       "   'History of unilateral or bilateral vagotomy, partial or complete splenectomy',\n",
       "   'Recurrent vasovagal syncope episodes',\n",
       "   'Current, regular use of tobacco products',\n",
       "   'Hypersensitivity/allergy to MRI contrast agents and/or unable to perform MRI']},\n",
       " {'nct_id': 'NCT04530461',\n",
       "  'inclusion': ['Age over 18 years old',\n",
       "   \"One of the following conditions: systemic lupus, Sjögren's syndrome, rheumatoid arthritis, inflammatory myopathies, spondyloarthritis, sarcoidosis and Behçet's disease.\",\n",
       "   'Informed consent obtained and signed'],\n",
       "  'exclusion': ['Refusal to repeat blood sampling if the first one was badly performed',\n",
       "   'Informed consent not obained']},\n",
       " {'nct_id': 'NCT04535427',\n",
       "  'inclusion': ['Chinese RA patients who are between 18 and 45 years old (inclusive) when signing the consent form, with a body mass index between 19 and 29 kg/m2 (inclusive), and weigh between 60 and 90',\n",
       "   '- The subject must be diagnosed with RA, and the judgment standard meets the 2010 American College of Rheumatology (ACR)/European Alliance Against Rheumatism (EULAR) RA classification standard;',\n",
       "   'Active RA is defined as having ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline (based on 66/68 joints, excluding distal interphalangeal joints), and at least one of the following conditions occurs during screening: ESR ≥ 28 mm/hr, or serum CRP> 10 mg/L;',\n",
       "   'Positive rheumatoid factor or anti-cyclic citrulline peptide (CCP) during screening;',\n",
       "   'Before using the study drug, the subject must have used MTX continuously for ≥ 12 weeks and have been stable for at least 8 weeks.',\n",
       "   '10-15mg/week dose and willing to use a stable dose throughout the study;',\n",
       "   'Patients with moderate to severe disease activity after the current treatment of DMARDs, DAS28-ESR/CRP>3.2;',\n",
       "   'Subjects taking oral corticosteroids (≤ 10 mg of prednisone or equivalent) should use a stable dose for ≥ 4 weeks before screening;',\n",
       "   'If subjects are taking non-steroidal anti-inflammatory drugs (NSAIDs) or low-efficiency analgesics, such as tramadol, neuronal cell compounds, they must use a stable dose for ≥ 2 weeks before screening.',\n",
       "   'Considered as eligible subjects based on the following tuberculosis screening criteria:',\n",
       "   'The subject has no history of latent or active tuberculosis before screening,',\n",
       "   'No signs or symptoms of active tuberculosis in the history and/or physical examination,',\n",
       "   'Have not had close contact with patients with active tuberculosis recently,',\n",
       "   'One chest radiograph (including anteroposterior and lateral views) taken within three months before the administration of the study drug, and qualified radiologists have confirmed that there are no active tuberculosis foci or old inactivated tuberculosis foci.',\n",
       "   'Non-smokers, or agree to smoke no more than 10 cigarettes or no more than 2 cigars per day during the entire study period. Note: According to the rules and regulations of the research center, smoking may be prohibited during hospitalization;',\n",
       "   'Agree to abstain from alcohol within 48 hours before the administration of the study drug and during the study hospitalization, and agree to drink no more than 10g of alcohol per day during the rest of the study;',\n",
       "   'Agree to limit caffeine intake, with a daily limit of five cups of tea, or three cups of coffee or six cans of cola. Do not take caffeine within 4 hours before receiving the electrocardiogram;',\n",
       "   'Agree to fully use birth control measures to prevent pregnancy (such as birth control pills, uterine contraceptive devices, or protective measures using spermicides) for at least six months after receiving study drug treatment;',\n",
       "   'Except for taking acetaminophen and previously taken multivitamins at the recommended dose, as well as the drugs approved by the investigator and medical monitor, the subject agreed to not use prescription drugs for 14 days before receiving the study drug treatment until the end of the study , Over-the-counter medicines, herbal medicines, proprietary Chinese medicines or \"natural\" medicines;',\n",
       "   'Demonstrate a clear understanding of the research and sign an informed consent (ICF);',\n",
       "   'Personal willingness and ability to comply with the study follow-up schedule and other requirements of the study protocol.'],\n",
       "  'exclusion': ['RA patients combined with hypotension.',\n",
       "   'RA patients combined with renal tubular acidosis and electrolyte imbalance.',\n",
       "   'RA patients with significant gastrointestinal symptoms.',\n",
       "   'According to the judgment of the main investigator, the subject is in a latent physical or psycho-medical state and will not be able to complete the study.',\n",
       "   'Have had major surgery or traumatic surgery within 12 weeks before screening.',\n",
       "   'Have received an organ transplant (except for corneal transplantation for more than three months before administration).',\n",
       "   'Donated blood within 56 days before screening (the blood donation volume is not less than 500 mL).',\n",
       "   'Currently suffering from malignant tumors or a history of malignant tumors.',\n",
       "   'A history of known lymphoproliferative diseases, including lymphoma or possible signs and symptoms of lymphoproliferative diseases, such as lymphadenopathy and/or splenomegaly.',\n",
       "   'Have a recent history of alcohol or drug abuse (within the previous 6 months).',\n",
       "   'Positive urine toxicology screening for drugs of abuse include: cocaine, cannabidiol, phencyclidine, amphetamine, methamphetamine, benzodiazepines, barbiturates, opioids, and C Oxyphene, methaqualone, methadone and tricyclic antidepressants.',\n",
       "   'When admitted to the research center before the study drug was administered, the urine alcohol screening or breath alcohol test results were positive.',\n",
       "   'Have a history of latent or active granulomatous infection before screening, including histoplasmosis or coccidioidomycosis.',\n",
       "   'Have a history of known or suspected intolerance or hypersensitivity to any biological drug treatment.',\n",
       "   'Chest x-ray pictures taken within 3 months before the first administration of the study drug showed abnormalities suggesting malignant tumors or current active infections (including TB).',\n",
       "   'Have nontuberculous mycobacteria or opportunistic infections (such as cytomegalovirus, pneumocystis disease, aspergillosis) within 6 months before screening.',\n",
       "   'Have or have had a serious infection (such as sepsis, pneumonia, or pyelonephritis) or were hospitalized for infection or received fourth-generation antibiotic treatment within 2 months before screening.',\n",
       "   'A history of chronic or recurrent infectious diseases, including but not limited to the following diseases: chronic kidney infection, chronic chest infection (for example, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic non-dilated bladder) Inflammation), or open, draining or infectious skin wounds or ulcers.',\n",
       "   'Serum was positive for HIV-1 or HIV-2, hepatitis B virus (HBV) or hepatitis C virus (HCV) during screening.',\n",
       "   'Syphilis (Treponema pallidum) test (qualitative test) was positive at screening.',\n",
       "   'The staff of the main researcher or research center and directly participate in the research or other research of the main researcher or research center, including the staff or the family members of the main researcher.']},\n",
       " {'nct_id': 'NCT04850183',\n",
       "  'inclusion': ['To be female',\n",
       "   '18 years of age and older',\n",
       "   'Diagnosed with Rheumatoid Arthritis who reached the 2010 American College of Rheumatology (ACR) criterion',\n",
       "   'Had a disease period of at least 6 months'],\n",
       "  'exclusion': ['Other serious and chronic mental disorders',\n",
       "   'Communication difficulties',\n",
       "   'Illiteracy']},\n",
       " {'nct_id': 'NCT04888585',\n",
       "  'inclusion': ['Clinical diagnosis of rheumatoid arthritis(RA) with fulfillment of the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for',\n",
       "   '- Participant has >= 6 swollen joints (based on 66 joint count) and >=6 tender joints (based on 68 joint count) at baseline.',\n",
       "   'Participant must have had an inadequate response to at least one prior biologic and/or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) treatment for',\n",
       "   '- Participants must be on stable dose of methotrexate (MTX).'],\n",
       "  'exclusion': ['Participant discontinued prior adalimumab therapy due to intolerability or toxicity.']},\n",
       " {'nct_id': 'NCT04885751',\n",
       "  'inclusion': ['Men and women who were adults at the time of receipt of written consent (age 19-70)',\n",
       "   'Those with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, or other musculoskeletal diseases that require continuous administration of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral steroids for more than 8 weeks.',\n",
       "   'At screening (before baseline) endoscopy results Modified Lanza Score (MLS) 0~2',\n",
       "   'Those who have not had severe gastrointestinal symptoms in the previous 3 months[Excluding mild abdominal distention, abdominal pain, diarrhea, dyspepsia, nausea, and vomiting]',\n",
       "   'A person who agrees to participate in this clinical trial and voluntarily signs a written consent form'],\n",
       "  'exclusion': ['Those with a history of gastrointestinal surgery (excluding appendectomy)',\n",
       "   'Those who have a history of esophageal cancer, liver cancer, pancreatic cancer, gastric cancer, colon cancer, small intestine tumor or other malignant disease within 5 years from the time of screening',\n",
       "   \"Gastrointestinal diseases that are clinically significant by upper gastrointestinal endoscopy, namely active peptic ulcer, reflux esophagitis, gastroesophageal varices, Barrett's esophagus, Barrett's esophagitis, esophageal stenosis, inflammatory bowel disease (Those diagnosed with inflammatory bowel disease, IBD), gastrointestinal bleeding, etc.\",\n",
       "   'Those with a history of recurrent gastrointestinal ulcer/perforation',\n",
       "   'Those with cerebrovascular bleeding or confirmed systemic bleeding disorder',\n",
       "   'Persons with severe uncontrolled heart failure (NYHA Class III-IV), high blood pressure (above 160/100 mmHg)',\n",
       "   'Those who have plans for surgical operation during the clinical trial period',\n",
       "   'Persons with a history of chronic pancreatitis, chronic renal diseases, chronic liver diseases, or other serious comorbid diseases',\n",
       "   'Those with clinically significant abnormal values (AST, ALT, BUN, Cr exceeding 2.5 times or Hb<10g/dL) by laboratory examination',\n",
       "   'Those with a history of alcohol or drug abuse/dependence',\n",
       "   'Pregnant and lactating women',\n",
       "   'Those who participated in other clinical trials within 30 days prior to participation in this clinical trial and received investigational drugs or received procedures',\n",
       "   'Patients who are difficult to perform this clinical trial by other investigators or who are judged to have medical findings that are not suitable for the clinical trial',\n",
       "   'Those who received celecoxib and prednisolone (or methylprednisolone) within 30 days prior to participation in this clinical trial']},\n",
       " {'nct_id': 'NCT04880720',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis (RA) meeting the 2010 ACR/EULAR diagnostic criteria',\n",
       "   'Patients in inflammatory flare of RA (DAS28 > 3.2)',\n",
       "   'Patients who have been off biological disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic antirheumatic drugs (tsDMARDs) for RA for at least 2 weeks (except for rituximab, where a delay of at least 12 months is required)',\n",
       "   'Conventional synthetic DMARDs (Methotrexate, Hydroxychloroquine, Leflunomide, Sulfasalazine) are allowed',\n",
       "   'Beneficiary of a social security system',\n",
       "   'Informed consent Inclusion Criteria for Healthy Controls:',\n",
       "   'Absence of chronic diseases and current infection',\n",
       "   'Beneficiary of a social security system',\n",
       "   'Informed consent Inclusion Criteria for COVID-19+ Patients:',\n",
       "   'Patients with ongoing SARS-Cov-2 infection (PCR+)',\n",
       "   'Patients hospitalized at D7-D14 of symptoms onset',\n",
       "   'Patients with two or more SARS-Cov-2 symptoms (including fever, cough, dyspnea, sore throat, chest pain, anosmia, diarrhea)',\n",
       "   'Membership in or beneficiary of a social security scheme',\n",
       "   'Collection of free and informed consent'],\n",
       "  'exclusion': ['Subjects under 18 years of age',\n",
       "   'HIV positive patients',\n",
       "   'Diabetic patients',\n",
       "   'Morbidly obese patients (BMI > 40kg/m2)',\n",
       "   'Use of senolytic drugs in the week prior to inclusion (azithromycin, metformin, cyclosporine, JAK inhibitors)',\n",
       "   'Use of steroids in doses greater than 10 mg/day in the week prior to inclusion',\n",
       "   'Subjects unable to give consent',\n",
       "   'Pregnant, breastfeeding, or non-menopausal women not taking effective contraception',\n",
       "   'Vulnerable subjects protected by law',\n",
       "   'Subjects under guardianship or curatorship']},\n",
       " {'nct_id': 'NCT04948775',\n",
       "  'inclusion': ['Having been diagnosed with RA according to the ACR 2010 Criteria',\n",
       "   'Being between 18 and 65 years old',\n",
       "   'To be able to understand the given commands'],\n",
       "  'exclusion': ['Refusing to participate in the study',\n",
       "   'History of trauma involving the neck',\n",
       "   'Having an orthopedic disorder concerning the neck',\n",
       "   'History of spine surgery',\n",
       "   'Having a disease that affects vestibular system',\n",
       "   'Upper extremity involvement due to a disorder other than RA',\n",
       "   'Being pregnant']},\n",
       " {'nct_id': 'NCT04947137',\n",
       "  'inclusion': ['The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.',\n",
       "   'The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion. HEALTHY CONTROL SUBJECTS',\n",
       "   'The subject is 30 years of age or greater at the time of consent.',\n",
       "   'The subject is deemed to be clinically free of any inflammatory disease(s), autoimmune disease(s), or arthropathies and has not experienced joint pain for at least 28 days prior to the consent date.',\n",
       "   'The subject is not currently on anti-inflammatory drugs (including non-steroidal anti-inflammatory drugs [NSAIDs]) and has not taken any anti-inflammatories for at least 28 days prior to the consent date.',\n",
       "   'For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date. CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS',\n",
       "   'The subject is at least 18 years of age and was ≥ 18 years of age at the time of RA diagnosis.',\n",
       "   'The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of ≥ 6/10).',\n",
       "   'The subject has a 28-joint disease activity score (DAS28) of ≥ 3.2 (includes the Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scale [VAS]).',\n",
       "   'Subjects receiving traditional DMARDs must have been on therapy for ≥ 90 days and at a stable dose for ≥ 30 days prior to the imaging visit (Day 0).',\n",
       "   'If the subject is receiving bDMARD or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 60 days prior to the imaging visit (Day 0).',\n",
       "   'If the subject is receiving NSAIDs or oral corticosteroids, the dose has been stable for ≥ 28 days prior to the imaging visit (Day 0). The corticosteroid dose must be ≤ 10 mg/day of prednisone or an equivalent steroid dose.'],\n",
       "  'exclusion': ['The subject is pregnant or lactating.',\n",
       "   'The subject size or weight is not compatible with imaging per the investigator.',\n",
       "   'The subject is currently receiving radiation therapy or chemotherapy or has received radiation therapy or chemotherapy in the past six months.',\n",
       "   'The subject has had a finger, hand, and/or wrist amputation or hand or wrist joint arthroplasty.',\n",
       "   'The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.',\n",
       "   'The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 2 times the upper limit of normal.',\n",
       "   'The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation or compromise the safety of the subject or the quality of the data.',\n",
       "   'The subject has any unstable medical illnesses, including hepatic, renal, gastroenterologic, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.',\n",
       "   'The subject has a known allergy to or has had an adverse reaction to dextran exposure.',\n",
       "   'The subject has received an investigational product within 30 days prior to Tc 99m tilmanocept administration (Day 0).',\n",
       "   'The subject has received intra-articular corticosteroid injections ≤ 8 weeks prior to Tc 99m tilmanocept administration (Day 0).',\n",
       "   'The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to Tc 99m tilmanocept administration (Day 0).',\n",
       "   'Healthy Controls only: The subject has a positive rheumatoid factor and an elevated ESR or CRP.']},\n",
       " {'nct_id': 'NCT04941729',\n",
       "  'inclusion': [\"Subject is a suitable candidate for implanting the OR3O™ Dual Mobility System or single-bearing design Total Hip System in primary total hip replacement in the Investigator's judgement.\",\n",
       "   \"Subject is skeletally mature in the Investigator's judgement.\",\n",
       "   'Subject is 18',\n",
       "   '80 years old (inclusive).',\n",
       "   'Subject is receiving total hip replacement for the first time on the affected hip.',\n",
       "   'Subject has any of the following conditions:',\n",
       "   'Advanced degeneration of the hip joint as a result of degenerative, post-traumatic, or rheumatoid arthritis(RA);',\n",
       "   'Fracture or avascular necrosis of the femoral head;',\n",
       "   'All forms of osteoarthritis(OA);',\n",
       "   'Patients with hips at risk of dislocation;',\n",
       "   'Femoral neck fracture or proximal hip joint fracture.',\n",
       "   'Subject provides written informed consent for study participation using an Ethical Committee (EC) approved consent form before any study procedures are performed, including pre-operative data review and/or collection of data on electronic Case Report Forms (eCRFs).',\n",
       "   'Subject is willing and able to participate in required follow-up visits and is able to complete study activities.',\n",
       "   'Subjects with preoperative HHS ≤ 79 (fair or worse category).'],\n",
       "  'exclusion': ['Subject has conditions that would eliminate or tend to eliminate adequate implant support or prevent the use of an appropriately-sized implant, e.g.:',\n",
       "   'blood supply limitations;',\n",
       "   'insufficient quantity or quality of bone support, e.g., osteoporosis, metabolic disorders which may impair bone formation, radioactive bone disease, tumor around hip joint, and osteomalacia;',\n",
       "   'infections or other conditions which may lead to increased bone resorption.',\n",
       "   'Subject has dysplasia of hip joint with CROWE Grade III,',\n",
       "   '- Subject has weak constitution or failing to endure the surgery due to other diseases of the body.',\n",
       "   'Subject has bodily disease(s) that may interfere with THA survival or outcome.',\n",
       "   'Subject has life expectancy of less than 2 years.',\n",
       "   \"Subject has mental or neurological conditions which impair the subject's ability or willingness to restrict activities that may put the affected limb at risk.\",\n",
       "   'Subject has physical conditions or activities which tend to place extreme loads on implants, e.g., Charcot joints, muscle deficiencies, multiple joint disabilities.',\n",
       "   'Subject has neuromuscular dysfunctions (paralysis, myolysis and abductor muscle weakness) which will cause unstable hip joint or abnormal gait after surgery.',\n",
       "   'Subject has a mental or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, drug or alcohol abuse.',\n",
       "   'Subject has an active infection',\n",
       "   'systemic or at the site of intended surgery.',\n",
       "   'Subject has a Body Mass Index ≥ 40.0 kg/m².',\n",
       "   'Subject has a known allergy to any component of the devices used in the study.',\n",
       "   'Subject is pregnant or breast feeding.',\n",
       "   'Subject is entered in another investigational drug, biologic, or device study within 30 days of active study participation.',\n",
       "   'Subjects that are expected with poor compliance.',\n",
       "   'Subjects with complications of other diseases are limited to participate in the research, not able to comply with the follow-up or have impact on scientific integrity.',\n",
       "   'Subjects with preoperative HHS ≥ 80 (good to excellent category).',\n",
       "   'Subject has other diseases or conditions that investigator considers not appropriate to participate in the study.']},\n",
       " {'nct_id': 'NCT04638426',\n",
       "  'inclusion': ['Male or Female, 19 years ≤ age ≤ 80 years',\n",
       "   'In the case of women of childbearing age, those who have a negative pregnancy test before randomization',\n",
       "   'Patients who agree to use a medically accepted method of contraception during the clinical trial',\n",
       "   'Patients corresponding to ACR functional class Ⅰ,Ⅱ,Ⅲ',\n",
       "   'Patients with active rheumatoid arthritis with DAS28-ESR > 3.2 in the evaluation of DAS28-ESR identified at the screening',\n",
       "   'Patients who were diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria at least 3 months prior to the screening, and showed insufficient response or refractory to treatment with one or more DMARDs.',\n",
       "   'Among the subjects who have previously been continuously administering the following rheumatoid arthritis drugs without stopping, those who have used them according to the conditions before randomization and can maintain the current administration regimen and dose during the clinical trial.',\n",
       "   'cDMARDs : Patients who received the same cDMARDs for 12 weeks or more continuously and did not change the dosage and administration of the cDMARDs for 4 weeks or more until the 2nd visit(ex. methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, bucillamine etc.)',\n",
       "   'Prednisolone : Patients who received corticosteroids with a daily dose of 10mg or less of oral prednisolone equivalent continuously, and did not change the dosage and administration for more than 2 weeks until the 2nd visit.',\n",
       "   'Tramadol or NSAIDs : Patients who did not change the dosage and administration for more than 2 weeks consecutively until the 2nd visit',\n",
       "   'Patients who have completed the wash-out period as follows until the 2nd visit including the screening period (each period refers to the case where it continues consecutively, and these drugs are contraindicated from the screening).',\n",
       "   'bDMARDs abatacept, adalimumab, certolizumab pegol, golimumab : 10 weeks or more anakinra : 10 days or more etanercept : 3 weeks or more infliximab : 8 weeks or more tocilizumab : 5 weeks or more rituximab : 6 months or more',\n",
       "   'JAK inhibitors tofacitinib, baricitinib : 2 weeks or more',\n",
       "   'immunosuppressants tacrolimus, cyclosporin, azathioprine, cyclophosphamide mizoribine etc : 4 weeks or more',\n",
       "   'tramadol, analgesics and anti-inflammatory analgesic other than NSAIDs : 4 days or more',\n",
       "   'Volunteer, be willing and able to provide written informed consent for the trial',\n",
       "   'Patients who can read and understand written instructions'],\n",
       "  'exclusion': ['Patients corresponding to ACR functional class Ⅳ',\n",
       "   'Patients with acquired immune deficiency syndrome or autoimmune diseases other than rheumatoid arthritis',\n",
       "   'Severe heart failure, congestive heart failure (NYHA II～IV), ischemic heart disease, peripheral artery disease and/or cerebrovascular disease',\n",
       "   'Patients with a history of gastrointestinal bleeding or perforation due to treatment of nonsteroidal anti-inflammatory drugs',\n",
       "   'Patients with bleeding or a current history of blood coagulation disorder',\n",
       "   'Patients suffering from infectious disease (including tuberculosis, shingles, etc.) at the time of screening or undergoing treatment with the medical history',\n",
       "   'Patients with a history of malignant tumors within 5 years prior to screening',\n",
       "   'Patients with peptic ulcer confirmed by endoscopy or radiographic examination within 6 months prior to screening',\n",
       "   'Patients with a history of gastric or duodenal perforation or obstruction, patients with a history of gastrointestinal surgery (except appendicitis), and patients with a history of upper or lower gastrointestinal bleeding (excluding simple hemorrhoids) within the past year',\n",
       "   'Patients with symptoms or signs of pyloric obstruction',\n",
       "   'Patients diagnosed with malabsorption within 12 weeks prior to the screening',\n",
       "   'Patients with hypersensitive reaction or history of clinically significant hypersensitive reaction to investigational product or its excipients',\n",
       "   'Patients with aspirin asthma (asthma attacks caused by nonsteroidal anti-inflammatory drugs) or a history of the same',\n",
       "   \"Patients with inflammatory bowel disease such as crohn's disease or ulcerative colitis\",\n",
       "   'Pregnant or breast-feeding',\n",
       "   'Patients administered intraarticular, intramuscular, intravenous corticosteroids within 4 weeks priro to the screening.',\n",
       "   'Patients with significant psychiatric disorders or taking antidepressants, anticonvulsants, or sedatives',\n",
       "   'Patients with substance or alcohol abuse or dependence',\n",
       "   'Patients who participate in other clinical trials within 12 weeks prior to the screening and administer investigational drugs or apply clinical trial medical devices',\n",
       "   'Patients expected to inevitably administer contraindicated drugs during the clinical trial',\n",
       "   'Patients with severe renal dysfuntion(seurum creatinine is 2.0 times higher than the upper limit of normal (based on the institution))',\n",
       "   'Patients with severe liver dysfuntion(ALT, AST or total bilirubin is 2.0 times higher than the upper limit of normal (based on the institution))',\n",
       "   'Patients that the investigator deems unsuitable for participation in the clinical trial']},\n",
       " {'nct_id': 'NCT04634253',\n",
       "  'inclusion': ['Have a diagnosis of adult onset RA as defined by the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 3 months prior to screening',\n",
       "   'Have moderately to severely active RA defined by the presence of ≥6 swollen joints (based on 66 joint count) and ≥6 tender joints (based on 68 joint count) at screening and baseline. The distal interphalangeal joint should be evaluated but not included in the total count to determine eligibility',\n",
       "   'Have at least 1 of the following:',\n",
       "   'positive test results for rheumatoid factor or anti-citrullinated peptide antibodies at screening, OR',\n",
       "   'previous radiographs documenting bony erosions in hands or feet consistent with RA',\n",
       "   'Have C-reactive protein (CRP) >1.2 times upper limit of normal (ULN) per the central laboratory at screening',\n",
       "   'Demonstrated an inadequate response to, or loss of response or intolerance to:',\n",
       "   'at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) treatment OR',\n",
       "   'at least 1 biologic DMARD/tsDMARD treatment'],\n",
       "  'exclusion': ['Class IV RA according to ACR revised response criteria',\n",
       "   'Have a diagnosis or history of malignant disease within 5 years prior to baseline, with the exceptions of:',\n",
       "   'basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years, or',\n",
       "   'cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline',\n",
       "   'Have presence of confirmed cervical dysplasia',\n",
       "   'Have had various types of infection within 3 months of screening or develops any of these infections before the randomization visit.',\n",
       "   'Have any of the following:',\n",
       "   'Human immunodeficiency virus (HIV) infection',\n",
       "   'Current infection with hepatitis B virus (HBV) (i.e., positive for hepatitis B surface antigen and/or polymerase chain reaction (PCR) positive for HBV DNA',\n",
       "   'Current infection with hepatitis C virus (HCV) (i.e., positive for HCV RNA)',\n",
       "   'Active tuberculosis (TB)',\n",
       "   'Have failed more than 2 biologic DMARDs (bDMARDs) or tsDMARDs (e.g. excluded if have received 2 bDMARDs and 1 tsDMARD)']},\n",
       " {'nct_id': 'NCT04434118',\n",
       "  'inclusion': ['Data of all definite cases of RA were collected and reviewed from complete medical records of patients by a team that included 2 trained physicians using a pretested data collection form. Exclusion Criteria:',\n",
       "   'The'],\n",
       "  'exclusion': ['Patients with acute lethal organ injury (e.g., acute myocardial infarction, acute coronary syndrome, acute pulmonary embolism, or acute stroke)',\n",
       "   'Patients with decompensated or end stage chronic organ dysfunction (e.g., decompensated cirrhosis, decompensated chronic renal insufficiency, or severe congestive heart failure), diabetes mellitus, data of pregnant females, acquired immune deficiency syndrome (aids), and leukemia or other malignancies.']},\n",
       " {'nct_id': 'NCT04186871',\n",
       "  'inclusion': ['Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification',\n",
       "   \"Diagnosed with SLE more than 24 weeks before screening visit Sub-study for primary Sjögren's Syndrome (pSS)\",\n",
       "   'Moderate to severe pSS, meeting ACR-EULAR classification criteria Sub-study for active Rheumatoid Arthritis (RA)',\n",
       "   'Moderate to severe adult-onset RA',\n",
       "   'ACR global functional status class I to III Women and men must agree to follow instructions for methods of contraception. Exclusion Criteria: Sub-study for SLE',\n",
       "   'Certain other autoimmune diseases and overlap syndromes Sub-study for pSS',\n",
       "   'Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions Sub-study for RA',\n",
       "   'Diagnosis with juvenile arthritis or idiopathic arthritis before age 16 For all sub-studies:',\n",
       "   'History of any significant drug allergy',\n",
       "   'Active infection, significant concurrent medical condition, or clinically significant abnormalities Other protocol defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04429776',\n",
       "  'inclusion': ['Patients must have RA according to the American College of Rheumatology (ACR) 1987 or 2010 criteria',\n",
       "   'Patients must be willing and able to participate in the study (including follow up visits and providing blood samples) after providing informed consent.',\n",
       "   'Patients must currently be on stable treatment a one of the following single anti-TNF agents Adalimumab, Etanercept or Certolizumab. They must have been taking this biologic/ biosimilar therapy for a minimum of 12 months',\n",
       "   'Patients must be in remission with a DAS28 CRP of less than or equal to 2.6.',\n",
       "   'A DAS28 score must be provided at baseline. This must have been taken within the month before study recruitment. If this DAS score is not available, the patient is not eligible to take part.',\n",
       "   \"Consultant must be looking to taper patient's standard care medication\",\n",
       "   'Aged 18 years or over'],\n",
       "  'exclusion': ['Anyone who has switched anti-TNF agent in the last 12 months',\n",
       "   'Anyone without a recent DAS score (within the previous month)',\n",
       "   \"Anyone taking any anti-TNF therapy that isn't Adalimumab, Etanercept or Certolizumab.\",\n",
       "   'Anyone who has received steroids within past 3 months (enteral, parenteral or intra-articular)',\n",
       "   'Anyone who is currently pregnancy, or pregnancy planned within next 6 months',\n",
       "   'Anyone with any planned major surgery',\n",
       "   'Anyone with the inability to provide informed consent']},\n",
       " {'nct_id': 'NCT04426279',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis on conventional synthetic DMARD (csDMARDs) +/- biological DMARD (bDMARDs) or targeted synthetic DMARD (tsDMARDs) +/- corticosteroid therapy meeting ACR/EULAR 2010 classification criteria',\n",
       "   'Patients with spondylarthritison biological DMARD or targeted synthetic DMARD +/- conventional synthetic DMARD +/- non-steroidal anti-inflammatory drugs meeting ASAS classification criteria',\n",
       "   'Patients with systemic lupus erythematosus on hydroxychloroquine +/- conventional synthetic DMARD +/- corticosteroid therapy +/- biological DMARD meeting ACR/EULAR 2019 classification criteria'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT04426513',\n",
       "  'inclusion': ['II ° and III ° of advancement of radiological changes',\n",
       "   'II ° and III ° of advancement of functional changes',\n",
       "   'Remission, low or moderate RA activity: DAS28',\n",
       "   'Medical order',\n",
       "   'Magnetotherapy and kinesiotherapy',\n",
       "   'Kinesiotherapy',\n",
       "   'Consent to participate in the study',\n",
       "   'Completion of the research program'],\n",
       "  'exclusion': ['Additional physiotherapy treatments for the hands',\n",
       "   'Change in type or dose of pharmacotherapy used',\n",
       "   'Taking steroid anti-inflammatory drugs',\n",
       "   'Malaise and side effects in the subject']},\n",
       " {'nct_id': 'NCT04426747',\n",
       "  'inclusion': ['aged above 18 and able to walk',\n",
       "   'Definite IA confirmed by the rheumatologist and based on usual criteria: axSpA (referring to the Assessment of Spondyloarthritis international Society classification criteria (51)), RA (referring to the international classification criteria of RA (52)) or PsA (referring to the ClASsification of Psoriatic Arthritis (CASPAR) criteria (53)), with no restriction for co-morbidities,',\n",
       "   'have a mobile phone compatible with apps that can track steps,',\n",
       "   'agree to participate and give informed consent,',\n",
       "   'ability to read and write in the language of participating country.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT04768413',\n",
       "  'inclusion': ['Quantitative and qualitative approach. Patients over 18 years of age with confirmed diagnosis of rheumatoid arthritis International Classification of Diseases: M069, M059, M060, treated at a reference center for these pathologies in the city of Bogotá.',\n",
       "   'Quantitative approach Patients with access to information and communication technologies',\n",
       "   'Qualitative approach: Patients seen in the teleconsultation modality on at least two occasions.',\n",
       "   'Qualitative approach: Patients attended in the face-to-face consultation modality on at least two occasions.',\n",
       "   'Qualitative approach: Health professionals who have carried out at least 25 teleconsultations directed at patients with rheumatoid arthritis in a reference center for these pathologies in the city of Bogotá.'],\n",
       "  'exclusion': ['Patients who due to their cognitive conditions do not have the ability to provide reliable information necessary for the development of the study.']},\n",
       " {'nct_id': 'NCT04692493',\n",
       "  'inclusion': ['Patients with active, disabling RA (CDAI ≥10 and HAQ ≥0.5) despite the use/experience for ≥ 3 months of a TNFi-biologic OR discontinued the medication(s) due to intolerability or toxicity irrespective of treatment duration prior to the first dose of study drug ;',\n",
       "   'If receiving glucocorticoids (≤10 mg/day of prednisone of equivalent) or NSAIDs, on stable doses for ≥2 weeks prior to randomization; and',\n",
       "   'Insurance plan or patient assistance program allows access to at least 1 drug in each of the two treatment strategies, TNFi-biologic',\n",
       "   'tsDMARD. Participants will be allowed to continue their conventional synthetic DMARD (csDMARD) therapy if they had been using it for ≥ 3 months and on a stable dose for ≥ 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide (TNFi-biologic and tsDMARD) through insurance plan or a patient assistance program/plan.'],\n",
       "  'exclusion': ['Prior treatment with more than three biologics, defined as TNFi-biologic or non-TNFi biologic',\n",
       "   'Prior treatment with targeted synthetic DMARD',\n",
       "   'Concomitant use of leflunomide, sulfasalazine, cyclosporine, or azathioprine within 2-months before randomization;',\n",
       "   'History of sensitivity to all 4 non-TNF-biologic or a targeted synthetic DMARD;',\n",
       "   'Glucocorticoid injection (intravenous, intramuscular, or intraarticular) within 1 month of study entry;',\n",
       "   'Live vaccine within 90 days of study entry;',\n",
       "   'Acute or chronic infections with parenteral antibiotics or hospitalization (including tuberculosis, bacterial sepsis; invasive fungal infections (such as histoplasmosis)) within 1 month or oral antibiotics within 2 weeks of study entry;',\n",
       "   'History of HIV or any opportunistic infection;',\n",
       "   'New York Heart Association Class III or IV heart failure;',\n",
       "   'Latent TB for which anti-tubercular treatment has not been started;',\n",
       "   'Untreated Hepatitis B or C infection;',\n",
       "   'History of deep venous thrombosis or pulmonary embolism; or',\n",
       "   'Pregnant or nursing women; or',\n",
       "   'History of herpes zoster or shingles.']},\n",
       " {'nct_id': 'NCT04691505',\n",
       "  'inclusion': ['1. No prior use of methotrexate or hydroxychloroquine anytime prior to cohort entry date',\n",
       "   '2. Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date'],\n",
       "  'exclusion': ['1. Prior history of dementia measured anytime prior to cohort entry date',\n",
       "   '2. No prior history of rheumatoid arthritis recorded in the 365 days prior to cohort entry date',\n",
       "   '3. Prior history of nursing home admission in the 365 days prior to the cohort entry date',\n",
       "   '4. Prior history of DMARD use measured anytime prior to cohort entry date']},\n",
       " {'nct_id': 'NCT04696718',\n",
       "  'inclusion': ['30-75 years',\n",
       "   'Non-menopausal or menopausal for more than 2 years because the tissue osteoarticular is under the influence of steroid hormones. Peri-menopause is accompanied by strong hormonal variations.',\n",
       "   'With rheumatoid arthritis (DAS28 threshold specified below)',\n",
       "   'Clinical arthritis score ≥ 2.6 (DAS28). Pathology needs to be characterized even if the score remains low',\n",
       "   'Person with good venous condition'],\n",
       "  'exclusion': ['Alcohol abuse with regard to WHO standards',\n",
       "   'Smoking (>5 cigarettes/day) -> 5 hours of intense sport per week',\n",
       "   'Food allergy and others',\n",
       "   'Antibiotic treatment in the month preceding inclusion',\n",
       "   'Persons under guardianship, curators, deprived of liberties, safeguard of justice',\n",
       "   'Refusal to sign the information and consent form']},\n",
       " {'nct_id': 'NCT04515589',\n",
       "  'inclusion': ['Adult (age≥18y) of any sex and ethnicity.',\n",
       "   'Satisfy EULAR criteria for',\n",
       "   '- Active RA, as defined as DAS28 ≥3.2 at baseline visit'],\n",
       "  'exclusion': ['Unable to give informed consent.',\n",
       "   'Insufficient understanding of spoken or written English to comply with the requirements of the study protocol',\n",
       "   'Unable or unlikely to complete the proposed 12-week study follow up (eg. moving house, terminal diagnosis, current or planned pregnancy).',\n",
       "   'Active comorbidity (e.g. uncontrolled diabetes mellitus, cancer, infection) requiring changes in medical treatment at baseline',\n",
       "   'Major active psychiatric condition (e.g. major depression)',\n",
       "   'Inability to meet the requirements of clinical assessments']},\n",
       " {'nct_id': 'NCT04512001',\n",
       "  'inclusion': ['Are ≥18 years of age.',\n",
       "   'Diagnosis of rheumatoid arthritis according to the revised 1987 ACR/European League Against Rheumatism (EULAR) Classification 2010 criteria with disease duration of ≥6 months.',\n",
       "   'Have moderately to severely active rheumatoid arthritis.',\n",
       "   'Must have been treated with methotrexate for at least 12 consecutive weeks immediately prior to randomization and are on a stable dose between 10 and 25 mg/week methotrexate for the last 8 weeks prior to screening.',\n",
       "   'Have had previous inadequate clinical response to at least one modifying anti-rheumatic drug.',\n",
       "   'Women of childbearing potential (i.e., considered fertile following menarche and until becoming postmenopausal unless permanently sterile) can participate only if they have a negative serum pregnancy test at screening and a negative urine pregnancy test at Day -1 before randomization. Women of childbearing potential must have used and agree to use a highly effective contraception (i.e., methods with a failure rate of less than 1% per year), for 4 weeks before randomization and must agree to continue to practice adequate contraception for 3 months after the last study drug administration.',\n",
       "   \"Must voluntarily give written informed consent before any study-related activities are performed. Participants must read and fully understand the Informed Consent Form and the requirements of the study. Participants must be willing to comply with all study visits and assessments. Participants must be willing to complete each study procedure. Note: A separate Informed Consent Form (containing important information about COVID 19, clinical research study participation and participant consent) will be provided to and signed by each participant to provide information on the general risks of study participation related to COVID-19 and to document that it is understood by the participant. Another separate Informed Consent Form will be required to be understood and signed by partners of male participating patients who become pregnant during the study or within 10 weeks after the participating patient's last dose of study drug.\"],\n",
       "  'exclusion': ['American College of Rheumatology functional class IV as defined by the ACR classification of functional status or wheelchair/bedbound.',\n",
       "   'Previously received tocilizumab, an investigational or licensed biosimilar of tocilizumab or any interleukin-6 acting drugs.',\n",
       "   'Prior use of targeted synthetic disease-modifying anti-rheumatic drugs like janus kinase inhibitors.',\n",
       "   'Prior use of more than 2 biologic treatments for rheumatoid arthritis.',\n",
       "   'Received a live or attenuated vaccine within 4 weeks prior to randomization.',\n",
       "   \"Participant is considered by the Investigator, for any reason, to be an unsuitable candidate for the study. Investigator should specifically evaluate the participant's eligibility taking into consideration COVID-19 risk factors and situation.\",\n",
       "   'Has a serious and/or unstable and/or poorly controlled medical condition such as but not limited to poorly controlled diabetes, unstable ischemic heart disease, uncontrolled hypertension or other cardiovascular, cerebrovascular, cardiovascular, gastrointestinal disease, hepatic, renal, hematological, endocrine, nervous system or pulmonary disease or other relevant medical condition or a history of clinically significant disease or any other condition that, in the opinion of the Investigator, would put the participant at risk by participation in the study.',\n",
       "   'Confirmed or, based on the signs and symptoms observed at the time of assessment, suspected active COVID-19 infection at the time of screening and/or randomization.',\n",
       "   'Has had any infection as follows:',\n",
       "   'Herpes zoster or any opportunistic invasive infection within 6 months of screening.',\n",
       "   'Frequent, chronic or recurrent infections.',\n",
       "   'A positive test for human immunodeficiency virus subtype 1 (HIV-1) or 2 (HIV-2), hepatitis C antibody, hepatitis B surface antigen and/or core antibody for immunoglobulin G and/or immunoglobulin M or total immunoglobulin at screening.',\n",
       "   'A serious infection within 8 weeks prior to randomization.',\n",
       "   'Required treatment with oral antibiotics and/or anti-fungal drugs within 14 days prior to randomization.',\n",
       "   'Medical evidence of active or latent tuberculosis as indicated by a positive QuantiFERON®-TB Gold Plus test, chest X-ray and/or clinical examination or has had active or latent tuberculosis disease at any time in the past.',\n",
       "   'Received a COVID 19 vaccine within 4 weeks prior to randomization, are receiving ongoing COVID-19 vaccination at the time of screening or plan to receive COVID-19 vaccination before the completion of the Week 30 visit of the study. COVID-19 vaccination is considered ongoing if a multidose regimen has been started but has not been completed.']},\n",
       " {'nct_id': 'NCT04497597',\n",
       "  'inclusion': ['Confirmed diagnosis of moderate to severe active Rheumatoid Arthritis (RA).',\n",
       "   'Physician decision on patient treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.',\n",
       "   'Upadacitinib prescribed in accordance to the applicable approved label and local regulatory and reimbursement policies.',\n",
       "   'French Participants Only: Taking oral glucocorticoids ≥5 mg/day of prednisone or equivalent for at least 3 months prior to study start.'],\n",
       "  'exclusion': ['Prior treatment with Upadacitinib.']},\n",
       " {'nct_id': 'NCT04493762',\n",
       "  'inclusion': ['Age between 18 to 85 years',\n",
       "   'Have regular follow up in Dermatology/ Rheumatology clinics of Queen Mary Hospital',\n",
       "   'Diagnosed with PsO/PsA or RA',\n",
       "   'Chinese ethnicity'],\n",
       "  'exclusion': ['Age below 18 years or above 85 years',\n",
       "   'Known decompensated cirrhosis',\n",
       "   'Pregnancy or breastfeeding',\n",
       "   'Unstable medical illness or active infection',\n",
       "   'Unable to provide written consent',\n",
       "   'Unable to adhere to the protocol',\n",
       "   'Unable to read and/or write Chinese language',\n",
       "   'On anticoagulant/ antiplatelet treatment',\n",
       "   'Abnormal platelet count <150',\n",
       "   'Known disease/condition with prolonged INR/bleeding tendency']},\n",
       " {'nct_id': 'NCT04018001',\n",
       "  'inclusion': ['At least one claim for tofacitinib between 01 January 2014 and 31 January 2017 (the identification period).',\n",
       "   'Presence of The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9 CM) code for RA (in any position) during the one-year pre-index period or on the index date. ICD-9 = 714.0x-714.4x & 714.81 or ICD10 = M05.* & M06.0*-M06.3* or M06.8*-M06.9*.',\n",
       "   'At least 18 years old as of the index date.'],\n",
       "  'exclusion': [\"Patients with claims for other conditions for which biologics are used during the one-year pre-index period or on the index date: ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, or ulcerative colitis will be excluded from the study.\",\n",
       "   \"Patients with evidence of the index medication during the one-year pre-index period will be removed from the analysis. Patients will be allowed to have been treated with other biologics approved for RA (Tumor-Necrosis Factor-alpha inhibitors (TNFi) [adalimumab (Humira), etanercept (Enbrel), certolizumab pegol (Cimzia), golimumab (Simponi), infliximab (Remicade)] and non-TNFi's with alternative mechanisms of action [abatacept (Orencia), and rituximab (Rituxan), anakinra (Kineret), tocilizumab (Actemra)]) during the one-year pre-index period.\"]},\n",
       " {'nct_id': 'NCT04563455',\n",
       "  'inclusion': ['RA patients were classified according to the ACR 2010 criteria.',\n",
       "   'taking regular medication.'],\n",
       "  'exclusion': ['having a history of trauma or surgery in the upper limb.',\n",
       "   'having neurological, cognitive, or psychiatric diseases.']},\n",
       " {'nct_id': 'NCT04569890',\n",
       "  'inclusion': ['A diagnosis of RA, as defined by 2010 ACR/EULAR criteria',\n",
       "   'DAS 28∙ESR<2.6 under the treatment of DMARDs',\n",
       "   'Subjects consider pregnancy, but not pregnant yet',\n",
       "   'Participant expects to continue CZP therapy throughout pregnancy and for at least 24 weeks postpartum',\n",
       "   \"Participant has a negative interferon gamma release assay (IGRA) or tuberculin skin test (TST) within the prior 6 months, and there has been no change in the study participant's clinical status, or social, family, or travel history. Participants with documented Bacillus Calmette-Guérin (BCG) vaccine and at low risk for tuberculosis (TB) may enroll without having a TB test performed Exclusion Criteria:\",\n",
       "   \"Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the study participant's ability to participate in this study\",\n",
       "   'Participant is not permitted to enroll into the study if she meets any of the following TB'],\n",
       "  'exclusion': ['Study participant is taking a prohibited medication or has taken a prohibited medication',\n",
       "   'Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during the study',\n",
       "   'Study participant has any clinically significant pregnancy-related clinical or test abnormality, as judged by the investigator',\n",
       "   'Study participant had a positive or indeterminate interferon gamma release assay (IGRA) or tuberculin skin test (TST) at Screening. In case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the study participant']},\n",
       " {'nct_id': 'NCT04847011',\n",
       "  'inclusion': [\"One of the following diagnoses: rheumatoid arthritis (first diagnosis >6 weeks ago and <8 years), parkinson's disease OR healthy volunteer\",\n",
       "   'Control (\"healthy\") individuals must be without any evidence of active, known or treated RA, without any evidence of active, known or treated central nervous system disease, and without a known family history of idiopathic PD',\n",
       "   'Arthritis in at least one joint',\n",
       "   'Control individuals should match the RA or PD individuals as closely as possible, especially their age, sex, and education',\n",
       "   'Present written declaration of consent',\n",
       "   'Consent to specimen collection and specimen use',\n",
       "   'Ability to understand the patient information and willingness to sign the consent form'],\n",
       "  'exclusion': ['gout or proven bacterial arthritis',\n",
       "   'Psychiatric illness that limits understanding of the examination protocol (unable to consent)',\n",
       "   'BMI < 18.5',\n",
       "   'Pre-existing/current eating disorders (bulimia nervosa, anorexia nervosa) within the past 5 years.',\n",
       "   'Severe internal diseases (e.g. renal insufficiency with creatinine > 2mg/dl)',\n",
       "   'Participation in another study',\n",
       "   'Existing vegan diet or fasting within the past 6 months',\n",
       "   'Pregnancy or breastfeeding',\n",
       "   'Chronic inflammatory bowel disease',\n",
       "   'Use of antibiotics within the past 12 months',\n",
       "   'Presence of anemia']},\n",
       " {'nct_id': 'NCT04351399',\n",
       "  'inclusion': ['Rheumatoid arthritis Quarantine'],\n",
       "  'exclusion': ['Non adult patient RA patient without quarantine']},\n",
       " {'nct_id': 'NCT04350216',\n",
       "  'inclusion': ['Age ≥18 years with active RA: DAS28>3.2 and PCR levels ≥1 mg/dL',\n",
       "   'Naïve to biological DMARDs or refractory to a single biological other than anti-IL-6 drugs.',\n",
       "   'Only patients with plaques detected by carotid ultrasound (at least 1.5 mm) should have a PET/CT scan.',\n",
       "   'Patients who are candidates for Sarilumab according to the summary of product characteristics',\n",
       "   'Patients who sign the informed consent form.'],\n",
       "  'exclusion': ['Previous history of CV events.',\n",
       "   'History of diabetes or chronic renal failure.',\n",
       "   'Absolute neutrophil count <2 x109/L.',\n",
       "   'Platelet count <150 x 103/μL.',\n",
       "   'Elevated transaminases (ALT or AST > 1.5 x LSN).',\n",
       "   'Active infection, including localized infection.',\n",
       "   'That have contraindicated the administration of Sarilumab.',\n",
       "   'Patients who are participating in another clinical trial or research project.',\n",
       "   'Refusal to participate in the study and to sign the consent form.',\n",
       "   'Pregnant or nursing women, or women of childbearing age who are not using an effective method of contraception.']},\n",
       " {'nct_id': 'NCT04356066',\n",
       "  'inclusion': ['Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis.',\n",
       "   'Adult rheumatoid arthritis patients with interstitial lung disease.'],\n",
       "  'exclusion': ['Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease).',\n",
       "   'Individuals with hepatitis, Rhinovirus infection, cerebral malaria.',\n",
       "   'Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.']},\n",
       " {'nct_id': 'NCT04356183',\n",
       "  'inclusion': ['Body mass index (BMI) 28-40 kg/m2.',\n",
       "   'Must have internet access.',\n",
       "   'Seropositive (positive rheumatoid factor or anti-citrullinated protein antibody) or erosions typical of RA on radiographs.'],\n",
       "  'exclusion': ['Subject unwilling/unable to utilize online platforms (e.g. ZOOM, REDCap, Pattern Health) for study activities.',\n",
       "   'Current use of biologic agents other than those targeting tumor necrosis factor alpha.',\n",
       "   'Current (within the last month) pharmacologic therapy with corticosteroids at doses greater than prednisone 5mg per day (or equivalent glucocorticoid doses).',\n",
       "   'Participating in regular exercise within the past 3 months (According to 2018 US guidelines: Not more than 150 minutes per week of moderate intensity exercise or 75 minutes per week of vigorous intensity exercise).',\n",
       "   'New medications within the last three months and stable doses for ≥ 1 month.',\n",
       "   'Diagnosis of coronary artery disease.',\n",
       "   'Diagnosis of type 2 diabetes mellitus.',\n",
       "   \"Other inflammatory arthropathy or myopathy, Paget's disease, pigmented villonodular synovitis, joint infection, ochronosis, neuropathic arthropathy, osteochondromatosis, acromegaly, hemochromatosis, or Wilson's disease.\",\n",
       "   'Absolute contra-indications to exercise: Recent (<6 months) acute cardiac event, unstable angina, uncontrolled dysrhythmias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspected or known dissecting aneurism or acute systemic infection.',\n",
       "   'Relative contra-indications to exercise: Left main coronary stenosis, moderate stenotic valvular heart disease, outflow tract obstruction, high degree AV block, ventricular aneurysm, uncontrolled metabolic disease (e.g. diabetes, thyrotoxicosis, myxedema), uncontrolled pulmonary disease (e.g. severe COPD or pulmonary fibrosis), mental or physical impairment leading to inability to exercise adequately.',\n",
       "   'Significant weight change (gain or loss of > 10 pounds in 1 month) within the past 6 months.',\n",
       "   'Unwillingness or inability to adhere to the diet structure of the study.']},\n",
       " {'nct_id': 'NCT04985812',\n",
       "  'inclusion': ['Demonstrated an inadequate response to, or loss of response or intolerance to: at least 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) and/or up to 2 biologic DMARD (bDMARD)/targeted synthetic DMARD (tsDMARD)',\n",
       "   'Have C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening',\n",
       "   'Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening',\n",
       "   'Have a diagnosis of rheumatoid arthritis (RA) (American College of Rheumatology [ACR]/ European League Against Rheumatism [EULAR] criteria 2010)',\n",
       "   'Body weight within the range of 50.0 kilograms (kg) to 120.0 kg, inclusive, and have a body mass index (BMI) of 19.0 kilograms per meter square (kg/m^2) to 32.0 kg/m^2, inclusive',\n",
       "   'All women must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) at screening'],\n",
       "  'exclusion': ['Known allergies, hypersensitivity, or intolerance to any biologic medication or excipients of JNJ-67484703',\n",
       "   'Has a diagnosed or reported history or current signs or symptoms indicating severe, progressive, or uncontrolled hepatic, renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances',\n",
       "   'Have other known inflammatory diseases that might confound the evaluations of benefit from JNJ-67484703 therapy',\n",
       "   'Have a history of any clinically significant adverse reaction to murine or chimeric proteins, including, but not limited to, allergic reactions',\n",
       "   \"Have a history of or currently have felty's syndrome\"]},\n",
       " {'nct_id': 'NCT04985435',\n",
       "  'inclusion': ['Adult male or female patients, at least 18 years of age.',\n",
       "   'Able and willing to give written informed consent.',\n",
       "   'Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol. Inclusion criteria:',\n",
       "   'Diagnosis of adult-onset RA as defined by the 2010 ACR/ EULAR Rheumatoid arthritis classification criteria;',\n",
       "   'Diagnosis of RA for ≥ three months;',\n",
       "   'Are being treated ≥ three months with ≥ 1 csDMARD therapy;',\n",
       "   'Have had an inadequate response or intolerance to at least 1 csDMARD;',\n",
       "   'Have moderately to severely active RA to the discretion of the rheumatologist or defined as a DAS28 ≥ 3.2 at screening and baseline visits;',\n",
       "   'Subjects must have been on a stable dose of csDMARD therapy (restricted to methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the baseline visit.'],\n",
       "  'exclusion': ['Previous treatment with any biological DMARD or targeted synthetic DMARD/JAKi;',\n",
       "   \"Inflammatory rheumatic disease other than RA, except for secondary Sjögren's syndrome.\",\n",
       "   'Having a contraindication for either TNFi or filgotinib;',\n",
       "   'Latent or active tuberculosis;',\n",
       "   'Active or recurrent infections;',\n",
       "   'History of any malignancy within 5 years except for successfully treated NMSC or localized carcinoma in situ of the cervix;',\n",
       "   '≥ 3x upper limit of normal ALT, AST;',\n",
       "   'eGFR ≤ 30 ml/min;',\n",
       "   'planned or actual pregnancy or planning to father a child.']},\n",
       " {'nct_id': 'NCT04594564',\n",
       "  'inclusion': ['Older than 18 years old',\n",
       "   'Non-inflammatory degenerative joint disease such as osteoarthritis or avascular necrosis',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Post-traumatic arthritis',\n",
       "   'Fractures of femoral neck'],\n",
       "  'exclusion': ['Local or systemic infection',\n",
       "   'Septicaemia',\n",
       "   'Persistent acute or chronic osteomyelitis',\n",
       "   'Confirmed nerve or muscle lesion compromising hip joint function',\n",
       "   'Unstable medical illness',\n",
       "   'Rapidly progressive neurological disease']},\n",
       " {'nct_id': 'NCT04378621',\n",
       "  'inclusion': ['confirmed RA diagnosis, in the early stage of the disease (1-3 years after the diagnosis, n=20); in the established stage of the disease (5-8 years after the diagnosis, n=30) and in the late stage of the disease (>12 years after the diagnosis, n=30)'],\n",
       "  'exclusion': ['any conditions precluding MRI imaging; e.g claustrophobia; pacemaker etc, medical history of ischemic stroke or cerebral hemorrhage; medical history of neurological disease; inability to read and communicate in Swedish, hence being able to give informed consent and fill out study questionnaires']},\n",
       " {'nct_id': 'NCT04999683',\n",
       "  'inclusion': ['patients diagnosed of rheumatoid arthritis',\n",
       "   'without changes in treatment in the last 3 months'],\n",
       "  'exclusion': ['food allergies', 'pregnancy']},\n",
       " {'nct_id': 'NCT04734496',\n",
       "  'inclusion': ['A formal confirmed diagnosis of their underlying chronic inflammatory condition:',\n",
       "   'Inflammatory bowel disease cohort patients will have endoscopic or radiological evidence. Some of the Chronic liver disease cohort will have had a liver biopsy, serological and radiological confirmation will be sufficient.',\n",
       "   'RA cohort, clinical, serological and radiological confirmation will be sufficient.',\n",
       "   'Biologic therapy naïve on recruitment or commencing a new biologic if in the IBD or IA cohort.',\n",
       "   'Adults aged ≥ 18 years',\n",
       "   'Able to confirm written consent to the study',\n",
       "   'Biologic therapy naïve on recruitment or commencing a new biologic if in the IBD or RA cohort Pre-existing or current use of immunosuppressant agents or Disease Modifying Antirheumatic Drugs (DMARDs) are acceptable in all cohorts.',\n",
       "   'Meeting ACR (American College of Rheumatology) /EULAR (European League Against Rheumatism) 2010 or ACR 1987 Criteria for rheumatoid arthritis and starting DMARD therapy.',\n",
       "   'Meeting criteria of an inflammatory arthritis as per the American College of Rheumatology',\n",
       "   'Meeting criteria of liver cirrhosis including all Child Pugh scores from A-C as per British Association for the Study of the Liver guidance.',\n",
       "   'Meeting criteria for Inflammatory bowel disease as per the British Society of Gastroenterology guidance.',\n",
       "   'For muscle biopsy sampling (does not preclude patients from participating if they do not meet the below criteria) INR ≤ 1.6 Platelet count > 30'],\n",
       "  'exclusion': ['Refusal or lack capacity to give informed consent.',\n",
       "   'Currently enrolled in an interventional trial with active treatment for their chronic disease condition.',\n",
       "   'Previously undergone LT or biliary intervention in the Chronic liver disease cohort.',\n",
       "   'Underlying or active cancer.',\n",
       "   'Biliary intervention if Chronic liver disease',\n",
       "   'For Muscle biopsies only (able to continue in study):',\n",
       "   'Obvious injury to both thighs.',\n",
       "   'Active bleeding of site, pre-procedure,',\n",
       "   'Abnormal observation parameters.',\n",
       "   'Acute illness.',\n",
       "   'INR > 1.6.',\n",
       "   'Platelet count <',\n",
       "   '7. Anticoagulation which cannot be paused due to increased risk to pre-existing co-morbidity.',\n",
       "   'For undergoing an Magnetic resonance imaging (MRI)',\n",
       "   'Pacemaker.',\n",
       "   'Metal work inserted that is not MRI compatible or further information cannot be obtained.']},\n",
       " {'nct_id': 'NCT04279691',\n",
       "  'inclusion': ['for first group patients with active rheumatoid arthritis with periodontitis.',\n",
       "   'second group , patients with periodontitis and otherwise systemically healthy',\n",
       "   'third group, systemically and periodontallly healthy subjects'],\n",
       "  'exclusion': ['smokers,',\n",
       "   'pregnant or lactating females',\n",
       "   'patients taking medications the affects levels of prolactin hormone.',\n",
       "   'no periodontal treatment in the past six months']},\n",
       " {'nct_id': 'NCT04275206',\n",
       "  'inclusion': ['signed consent statement',\n",
       "   'over 18 years of age',\n",
       "   'lack of underlying renal disease (GFR >60 mL/min/1.73m2)',\n",
       "   'lack of severe inflammation (WBC <20.000 G/l; CRP <50 mg/l; WE <40 mm/h)',\n",
       "   'psoriasis vulgaris with skin lesions',\n",
       "   'mild and inactive RA'],\n",
       "  'exclusion': ['having received any kind of balneotherapy within 1 year before admission',\n",
       "   'discontinuance of rehabilitation',\n",
       "   'withdrawal of consent',\n",
       "   \"clinically significant difference in severity of the patient's condition on 1st or 2nd admission\",\n",
       "   'severe RA',\n",
       "   'patients suffering from cancer',\n",
       "   'patients suffering from inflammatory bowel disease',\n",
       "   'patients underwent stroke within 1 year',\n",
       "   'severe hypercholesterolemia',\n",
       "   'severe diabetes',\n",
       "   'patients with renal insufficiency',\n",
       "   'patients receiving any kind biological therapy',\n",
       "   'patients whose medication has changed during the study period or one month prior to the second treatment session']},\n",
       " {'nct_id': 'NCT04278170',\n",
       "  'inclusion': ['patients with RA who met the 2010 American College of Rheumatology (ACR) RA classification criteria were included'],\n",
       "  'exclusion': ['Patients who had difficulties understanding and responding to questions were excluded from the study.']},\n",
       " {'nct_id': 'NCT04365842',\n",
       "  'inclusion': ['Those diagnosed with rheumatoid arthritis according to ARA criteria',\n",
       "   'RA patients with stage 2 or 3 according to ACR criteria',\n",
       "   'The first symptoms started at least a year ago and those who are undergoing medical treatment',\n",
       "   'Those between the ages of 18-65'],\n",
       "  'exclusion': ['Those who are in the inflammatory period',\n",
       "   'Those who have had surgery for neurological, orthopedic or other reasons recently',\n",
       "   'Those with specified depression or other psychological diagnosis',\n",
       "   'Those who have received physiotherapy and ergotherapy in the past year']},\n",
       " {'nct_id': 'NCT04709354',\n",
       "  'inclusion': ['Psoriasis confirmed by dermatologist.',\n",
       "   'Rheumatoid arthritis, ankylosing spondylitis confirmed by rheumatologist (newly diagnosed).'],\n",
       "  'exclusion': ['Unable to consent and understand',\n",
       "   'Patients with confirmed onychomycosis',\n",
       "   'Patients receiving biological therapy']},\n",
       " {'nct_id': 'NCT04704492',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.',\n",
       "   'Moderate to severe active RA with swollen joint count (SJC) ≥ 6 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.',\n",
       "   'At screening, either C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or Morning stiffness of joint for ≥ 45 minutes.',\n",
       "   'Receiving methotrexate (MTX) 7.5',\n",
       "   '25mg/week (oral) for at least 12 weeks, at a stable dose over the past 4 weeks.'],\n",
       "  'exclusion': ['Females who are pregnant, breastfeeding, or planning a pregnancy during the Treatment Period of and 12 months after the last infusion of study drug.',\n",
       "   'Rheumatic autoimmune disease other than',\n",
       "   '- Use of any biological DMARDs for RA within past 6 months.',\n",
       "   'Active infection, or history of serious or chronic infection.',\n",
       "   'Any significant cardiac disease, moderate to severe chronic obstructive pulmonary disease.',\n",
       "   'Allergy or sensitivity to components of the drug vial or any of the materials used for infusion']},\n",
       " {'nct_id': 'NCT04004429',\n",
       "  'inclusion': ['Written informed consent has been obtained prior to initiating any study specific procedures',\n",
       "   'Male and female subjects, 18 to 85 years of age',\n",
       "   'Confirmed diagnosis of (RA) Rheumatoid Arthritis according to the 2010 ACR/EULAR RA classification criteria',\n",
       "   'Polyarthritis with joint swelling and tenderness of a minimum of three joints out of 68 joints tested',\n",
       "   'Candidate for Methotrexate treatment',\n",
       "   'Is about to begin treatment with MTX (Methotrexate)',\n",
       "   'Tested positive for anti-CCP Anti-cyclic citrullinated peptide) or RF (Rheumatoid Factor)',\n",
       "   'Severe active RA (CDAI > 22) at screening and baseline',\n",
       "   'Negative QFG-IT (QuantiFERON-in-Tube test)',\n",
       "   'Subjects should be able to complete the PRO (Patient Reported Outcome) questionnaires',\n",
       "   'Females of child-bearing potential may only participate if using reliable means of contraception or are post-menopausal. Surgically sterilized women at least 6 months prior to screening',\n",
       "   'Females of childbearing potential must have a negative pregnancy test at screening and baseline Exclusion Criteria:',\n",
       "   'Participation in any other study involving investigational drug(s) within 4 weeks prior to study entry',\n",
       "   'Major surgery within 8 weeks prior to screening or planned surgery within 1 month following randomization',\n",
       "   'Rheumatic autoimmune disease other than RA, including SLE (systemic Lupus Erythematosus), MCTD (Mixed Connective Tissue Disease), scleroderma, polymyositis, or significant systemic involvement secondary to',\n",
       "   'Sjögren syndrome with RA is allowable',\n",
       "   'Functional class IV as defined by the ACR Criteria for Classification of Functional Status in RA or wheelchair/bedbound',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Subjects with fibromyalgia',\n",
       "   'Initiation or change in dose for NSAIDs within 2 weeks prior to dosing with the IMP (Investigational Medicinal Product)',\n",
       "   'Corticosteroids are prohibited within 2 weeks prior to screening (and during the entire treatment period and until the final visit',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal disease',\n",
       "   'Have prior renal transplant, current renal dialysis or severe renal insufficiency (determined by a derived glomerular filtration rate (GFR) using Cockcroft Gault Formula of ≤30 mL/min/1,73 m2 calculated by the local lab)',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids',\n",
       "   'Evidence of active malignant disease',\n",
       "   'Pregnant women or nursing mothers',\n",
       "   'History of alcohol, drug, or chemical abuse within the 6 months prior to screening',\n",
       "   'Neuropathies or other painful conditions that might interfere with pain evaluation',\n",
       "   'Body weight of >150 kg'],\n",
       "  'exclusion': ['Evidence of moderate and/or severe organ dysfunction',\n",
       "   'Abnormal chest x-ray (as per the discretion of the investigator',\n",
       "   'Evidence of positive hepatitis serology',\n",
       "   'Evidence of peptic ulcer disease']},\n",
       " {'nct_id': 'NCT04002765',\n",
       "  'inclusion': ['Adults aged 18 to 90 years-old',\n",
       "   'Diagnosis of rheumatoid arthritis (RA) based on ACR-EULAR 2010 criteria',\n",
       "   'Onset of disease duration at least 1 year and at most 10 years prior to inclusion'],\n",
       "  'exclusion': ['Pregnancy',\n",
       "   'Inability to provide informed consent',\n",
       "   'Inability to perform lung function tests or to comply with the protocol',\n",
       "   'Active pulmonary infection']},\n",
       " {'nct_id': 'NCT04333771',\n",
       "  'inclusion': ['Provide signed informed consent.',\n",
       "   'RA diagnosis consistent with the 2010 ACR/EULAR criteria;',\n",
       "   'Moderate to severe RA defined by 6 or more tender joints, 6 or more swollen joints (68- or 66-joint count), and an ESR of 28 mm/h or greater or a CRP level greater than 5mg/L.',\n",
       "   'Subjects were required to have an inadequate response to treatment with csDMARDs before baseline.',\n",
       "   'If subjects are taking permitted csDMARDs or low-dose corticosteroid orally at baseline , the stable doses should have lasted for more than 4 weeks already.',\n",
       "   'BMI ≥18 kg/m2'],\n",
       "  'exclusion': ['Pregnant women or refuse to receive contraception during the study.',\n",
       "   'Lab abnormality within 4 weeks of randomization as follows: WBC count <3.0×10^9/L；neutrophil count<1.5×10^9/L;hemoglobin level<90.0 g/L ; platelet count <100×10^9/L; AST or ALT levels greater than the upper limit of normal; HBsAg or HCV or HIV antibody positivity.',\n",
       "   'History of another autoimmune rheumatic disease ; history of cancer or infection including tuberculosis and hepatitis; history of important cardiovascular events or thrombotic diseases.',\n",
       "   'Previous treatment with JAK inhibitor or cytotoxic drugs; bDMARDs within 6 months of randomization; other strong immunosuppressants within 3 months of randomization.']},\n",
       " {'nct_id': 'NCT04927546',\n",
       "  'inclusion': ['Adult women diagnosed with rheumatoid arthritis under pharmacological treatment, for at least 6 months, with a monoclonal antibody against the interleukin-6 receptor or TNF-alpha inhibitors;',\n",
       "   'Stable dose of monoclonal antibody against the interleukin-6 receptor or TNF-alpha inhibitors in the previous 3 months;'],\n",
       "  'exclusion': ['Any physical limitation or disability that preclude exercise participation;',\n",
       "   'Participation in a structured exercise program in the previous 12 months;']},\n",
       " {'nct_id': 'NCT04927104',\n",
       "  'inclusion': ['Male and female subjects aged 55 years of age or older and less than 74 years of age, younger subjects should have urgent need for surgery.',\n",
       "   'Subjects skeletal maturity.',\n",
       "   'Subjects appropriate for total knee replacement, such as noninflammatory degenerative joint diseases (such as osteoarthritis, traumatic arthritis, or ischemic necrosis); Inflammatory degenerative joint diseases (including rheumatoid arthritis); Correction of functional deformity.',\n",
       "   'The diseased side knee appropriate for primary total knee arthroplasty .',\n",
       "   'Subjects or guardian is willing and able to sign the informed consent form .'],\n",
       "  'exclusion': ['Subjects with knee instability or abnormal gait caused by neuromuscular insufficiency.',\n",
       "   'Subjects with bilateral knee joint disease who are expected to require replacement of both knees during the course of the study (i.e., within the next 12 months) .',\n",
       "   'Alcoholics, drug addicts and drug abusers.',\n",
       "   'Subjects with severe diabetes (fasting blood glucose > 10mmol/L)',\n",
       "   'Body Mass Index, BMI>35.',\n",
       "   'Female subjects who are pregnant or lactating.',\n",
       "   'Subjects have disease limited their participation in the investigation or have an existing condition that would compromise their participation and follow-up in this clinical investigation.',\n",
       "   'In the month before inclusion, subjects who participated in clinical studies of other drugs, biological agents or medical devices and failed to meet the main research endpoints.',\n",
       "   'Other conditions, in the opinion of the Investigator, are inappropriate for participation in this clinical investigation.']},\n",
       " {'nct_id': 'NCT04924270',\n",
       "  'inclusion': [\"Newly diagnosis of rheumatoid arthritis (RA), reactive arthritis (ReA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (Ps), gouty arthritis (GA), hidradenitis suppurativa (HS), pulmonary sarcoidosis (PSar), Crohn's disease (CD), or ulcerative colitis (UC).\",\n",
       "   'Treatment-naïve which is defined as no current or previous disease-modifying anti-rheumatic drugs or systemic immunosuppressive drugs including glucocorticoids.',\n",
       "   'Presence of treatment indication (no contra-indications) and patient accept to start first-line treatment in accordance with the Danish national guideline for the specific diagnosis following the baseline visit.'],\n",
       "  'exclusion': ['Coeliac disease, food allergy or severe food intolerance.',\n",
       "   'Current cancer.',\n",
       "   'Hepatitis B and C, HIV, HTLV1/2, and active TB or other serious chronic infections.',\n",
       "   'Pregnant or breastfeeding women.',\n",
       "   'Not wishing to participate or not suited for FMT intervention or project evaluation.']},\n",
       " {'nct_id': 'NCT01846975',\n",
       "  'inclusion': ['Male or female subjects aged 18 years or older at the time of consent',\n",
       "   'Able to give informed consent',\n",
       "   'Patients classified as RA according to the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria (Aletaha D et al, 2010)',\n",
       "   'Patient treated with weekly SC-Abatacept for at least 3 months prior to study screening',\n",
       "   'Effective control of disease activity as defined by DAS-28 (ESR) < 3.2 (LDAS)',\n",
       "   'Available for the whole duration of the study',\n",
       "   'Female subjects of childbearing potential must use maximally effective birth control during the period of therapy, must be willing to use contraception for the duration of the study (up to 168 days post the IV infusion of Abatacept). They also must have a negative pregnancy test upon entry into the study. Otherwise, female subjects must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile.',\n",
       "   'Male subjects must be surgically sterile or willing to use a double barrier contraception method upon enrolment, for the duration of the study (up to 168 days post the IV infusion of Abatacept)'],\n",
       "  'exclusion': ['Subjects who have previously received >2 biologic DMARDs',\n",
       "   'Pregnant or breastfeeding women or such with a child-bearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period (up to Day 168/Safety follow-up visit)',\n",
       "   'Subjects with active vasculitis of a major organ system, with the exception of rheumatoid nodules',\n",
       "   'Subjects with current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease, whether or not related to RA and which, in the opinion of the investigator, might place a subject at unacceptable risk for participation in the study',\n",
       "   'Subjects with a history of cancer in the last 5 years, or with a current screening suspicious for cancer, other than non-melanoma skin cell cancers cured by local resection or carcinoma in situ',\n",
       "   'Subjects with evidence of active or latent bacterial (e.g. tuberculosis) or viral infections (e.g. Human Immunodeficiency Virus (HIV) at the time of potential enrolment',\n",
       "   'Subjects with herpes zoster or cytomegalovirus (CMV) that resolved less than 2 months before the informed consent document was signed',\n",
       "   'Subjects who have received any live vaccines within 3 months of the anticipated first dose of study medication',\n",
       "   'Having participated in another drug or an interventional study within 30 days preceding the present study screening']},\n",
       " {'nct_id': 'NCT01499732',\n",
       "  'inclusion': ['Subjects currently experiencing active early RA (duration of symptoms ≤ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.',\n",
       "   'Subjects with early RA must be drug naïve (no prior treatment with traditional disease-modifying antirheumatic drugs (DMARDs), or biologic response modifying agents). Group 2',\n",
       "   'Subjects currently experiencing active established RA (duration of symptoms ≥ 2 years) according to the 2010 ACR/EULAR criteria for the diagnosis of RA at screening.',\n",
       "   'Subjects with active established RA currently receiving methotrexate (MTX), must have received it for at least 12 weeks, and at a stable dose (≥15mg/week) for at least 6 weeks prior to screening. They must be biologic drug naïve. These subjects must receive at least 5 mg oral folic acid weekly.',\n",
       "   'Subjects diagnosed with RA must be seropositive with documented rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti CCP) positivity. If a documented history of RF or anti CCP positivity is not available, RF and anti CCP titers will be obtained at screening Group 3',\n",
       "   'Healthy subjects without',\n",
       "   '7. All subjects must have sitting diastolic BP ≤90 mm Hg and/or sitting systolic BP ≤ 140 at screening',\n",
       "   'Subjects must have fasting plasma glucose (FPG) of ≤ 100 mg/dL.',\n",
       "   'If subjects with established RA are receiving an oral corticosteroid, the dose must be ≤7 mg/day prednisone (or equivalent) and stable for at least 28 days prior to screening.',\n",
       "   'Subjects able and willing to give written informed consent and comply with the requirements of the study protocol. Informed consent must be obtained prior to any study-related procedures. A copy of the signed informed consent form must be given to the subject',\n",
       "   'Patients must have a BMI of less than 42'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening.',\n",
       "   \"Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome). Prior history of or current inflammatory joint disease other than RA (gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis and psoriatic arthritis)\",\n",
       "   'Functional class IV as defined by ACR Classification of Functional Status in RA',\n",
       "   'Current treatment with any traditional DMARDs other than MTX within 4 weeks before the screening visit (For subjects with established RA). Current or prior use of Leflunomide will be exclusionary.',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before screening',\n",
       "   'Exposure to any Biologic Response Modifying Agent for RA',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to screening (For subjects with established RA)',\n",
       "   'Exclusionary laboratory: Serum creatinine >2 mg/dL, ALT or AST > 2.0 x ULN, total bilirubin > 2.0 x ULN, platelet count <100 x 10⁹ /L, hemoglobin < 8.5 g/dL, WBC count < 1,000/mm³ , absolute neutrophil count < 1,000/ mm³, absolute lymphocyte count < 500/mm³, triglycerides >400 mg/dL, Serum potassium <3.5 or >5.5 mEq /L without medication, serum albumin <2.5 g/dL, Gamma GT 3.0 x UNL',\n",
       "   'Smokers (use of tobacco products in the recent past < 6 months). Urine cotinine levels will be measured during screening for all subjects. Smokers will be defined as any subject who reports cigarette use or has a urine cotinine greater than 200 ng/mL.',\n",
       "   'Pregnant women or nursing mothers',\n",
       "   'Females of child bearing potential who are not using reliable means of contraception',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular (including known CAD, HTN, or hyperlipidemia), nervous system, pulmonary, renal, hepatic, endocrine or GI disease.',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel syndrome, where flares are commonly treated with corticosteroids.',\n",
       "   'History or presence of severe bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).',\n",
       "   'History of cardiovascular abnormalities including myocardial infarction, angina pectoris, hypertensive encephalopathy, stroke, transient ischemic attack, valvular heart disease, ventricular arrhythmia A-V block, atrial fibrillation or cardiac revascularization/angioplasty. Symptoms or clinical evidence of congestive heart failure or known left ventricular ejection fraction < 40%.',\n",
       "   'Medical history of clinically significant ECG abnormalities, including history of a prolonged QT-interval syndrome.',\n",
       "   'History of autonomic dysfunction',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections such as atypical mycobacterial disease, hepatitis B and C, HIV, herpes zoster, or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.',\n",
       "   'Any malignancy except for skin cancer (basal cell or squamous cell) diagnosed within the previous 5 years']},\n",
       " {'nct_id': 'NCT01491815',\n",
       "  'inclusion': ['Subject is ≥18 years of age.',\n",
       "   'Subject has a diagnosis of RA as defined by the newly established ACR/EULAR criteria, 2010. (Patients should also be classified according to the 1987-revised ACR-classification criteria, without this being an inclusion criteria).',\n",
       "   '<24 months from arthritis symptom debut (symptom duration will be registered).',\n",
       "   'Subject must have DAS28 (CRP) > 3.2.',\n",
       "   '≥ 2 swollen joints AND ≥ 2 tender joints.',\n",
       "   'Subject must fulfill one of the following three criteria: RF positive OR ACPA positive OR CRP >10 mg/L.',\n",
       "   'Female subject is either not of childbearing potential (postmenopausal, surgically sterile etc.), or is of childbearing potential and practicing one of the following methods of birth control throughout the study and for 150 days after study completion:',\n",
       "   'Intrauterine device (IUD)',\n",
       "   'Contraceptives (oral, parenteral, patch) for three months prior to study drug administration)',\n",
       "   'A vasectomized partner',\n",
       "   'Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening visit.',\n",
       "   'Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, physical examination, chest X-ray (CXR), and 12-lead electrocardiogram (ECG) performed at Screening.',\n",
       "   'Subjects must be able and willing to provide written informed consent and comply with the requirements of this study protocol.',\n",
       "   'Subjects must be able and willing to self-administer s.c. injections or have a qualified person available to administer s.c. injections.'],\n",
       "  'exclusion': ['Subject has been previously treated with disease modifying antirheumatic drugs (DMARDs) for rheumatic diseases.',\n",
       "   'Current active inflammatory joint disease other than',\n",
       "   '3. Subjects has had a dose of prednisone (or equivalent) >7.5 mg/day or has had a dose change within the preceding 4 weeks.',\n",
       "   'Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks. Inhaled corticosteroids for stable medical conditions are allowed.',\n",
       "   'Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study).',\n",
       "   'Subject has chronic arthritis diagnosed before age 17 years.',\n",
       "   'Subject has a history of an allergic reaction or significant sensitivity to constituents of study drugs.',\n",
       "   'Subject has been treated with any investigational drug within one month prior to screening visit.',\n",
       "   'Active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization within 4 weeks of screening.',\n",
       "   'Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, congestive heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the study.',\n",
       "   'Subject has a history of clinically significant hematologic (e.g., severe anemia, leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis, hepatitis).',\n",
       "   'Subject has history of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease and/or diagnosis of central demyelinating disease.',\n",
       "   'Subject has history of cancer or lymphoproliferative disease. Allowable exceptions:',\n",
       "   'Successfully treated cutaneous squamous cell or basal cell carcinoma',\n",
       "   'Localized carcinoma in situ of the cervix',\n",
       "   'Curatively treated malignancy (treatment terminated) > 5 years prior to screening',\n",
       "   'Subject has a history of listeriosis, histoplasmosis, untreated TB, persistent chronic infections, or recent active infections requiring hospitalization or treatment with intravenous (iv) anti-infectives within 30 days or oral anti-infectives within 14 days prior to the BL visit.',\n",
       "   'Subjects will be evaluated for latent TB infection with a PPD or QuantiFERON test and X-ray. Subjects with evidence for latent TB will not be enrolled but first assessed according to local guidelines.',\n",
       "   'Subject is known to have immune deficiency, history of Human Immunodeficiency Virus (HIV) or is otherwise severely immunocompromised.',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study or within 150 days after the last dose of study medication.',\n",
       "   'Men who are planning to father a child during the time they are included in the study',\n",
       "   'Subject has a history of clinically significant drug or alcohol usage in the last year.',\n",
       "   'Subject has a chronic widespread pain syndrome.',\n",
       "   'Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.',\n",
       "   'Subject is unwilling to comply with the study protocol.',\n",
       "   'Screening clinical laboratory analyses show any of the following abnormal laboratory results:',\n",
       "   'Aspartate transaminase (AST) or alanine transaminase (ALT) > 1.75 times upper limit of normal (ULN).',\n",
       "   'Positive serum human chorionic gonadotropin (hCG).',\n",
       "   'Positive tests for hepatitis B surface antigen (HBsAg) or hepatitis C serology indicative of current infection.',\n",
       "   'Creatinine levels > 2x the ULN. If creatinine 1-2 times ULN, check GFR.',\n",
       "   'Hemoglobin < 90 g/L.',\n",
       "   'Absolute neutrophil count (ANC) < 1.5 x 10^3/microL.',\n",
       "   'Serum total bilirubin > 1.5 mg/dL (>26 micromol/L).']},\n",
       " {'nct_id': 'NCT01172639',\n",
       "  'inclusion': ['Diagnosis of RA as defined by the 1987 or 2010 revised American College of Rheumatology (ACR) criteria',\n",
       "   'Early RA (less than 1 year)',\n",
       "   'Use a reliable method of contraception for women of childbearing potential',\n",
       "   'Able and willing to give written informed consent and participate in the study'],\n",
       "  'exclusion': ['Previous treatment with DMARDs',\n",
       "   'Previous treatment with oral corticosteroids at a dosage of more than 10 milligrams (mg) prednisone within 4 weeks before baseline',\n",
       "   'Previous treatment with oral corticosteroids at a dosage equal to or less than 10 mg prednisone within 2 weeks before baseline',\n",
       "   'Previous treatment with oral corticosteroids for more than 4 weeks',\n",
       "   'Previous treatment with Intra Articular corticosteroids within 4 weeks before baseline',\n",
       "   'Previous treatment with an investigational drug for the treatment or prevention of RA',\n",
       "   'Contraindications for corticosteroids',\n",
       "   'Contraindications for DMARDs',\n",
       "   'Psoriatic Arthritis',\n",
       "   'Underlying cardiac, pulmonary, metabolic, renal or gastrointestinal conditions, chronic or latent infectious diseases or immune deficiency which in the opinion of the investigator places the patient at an unacceptable risk for participation in the study',\n",
       "   'Pregnancy, breastfeeding or no use of a reliable method of contraception',\n",
       "   'Alcohol or drug abuse']},\n",
       " {'nct_id': 'NCT01176682',\n",
       "  'inclusion': ['Diagnosis of arthritic disorder (osteoarthritis, rheumatoid arthritis or ankylosing spondylitis)',\n",
       "   'Already receiving NSAID treatment at enrolment visit'],\n",
       "  'exclusion': ['Inability to complete the study related questionnaires',\n",
       "   'Current participation in any interventional study']},\n",
       " {'nct_id': 'NCT01915537',\n",
       "  'inclusion': ['Able and willing to provide written informed consent and to comply with the study protocol',\n",
       "   'Age is from 18 to 70 years old',\n",
       "   'To accord with the diagnostic criteria of ACR/EULAR 2010 and the course of disease is less than 2 years;',\n",
       "   'Active RA, DAS28 score is above 5.1',\n",
       "   'At least has one poor prognostic factor including:(1)functional limitations,(2)extra-articular manifestation,(3)positive RF or Anti-Cyclic Citrullinated Peptide(CCP) antibody ,(4)X- ray confirmed bone erosion.'],\n",
       "  'exclusion': ['Received Infliximab or other biologics treatment previously;',\n",
       "   'Abnormal liver function, the level of alanine aminotransferase(ALT) and aspartate amino transferase(AST) is higher than 3 times of upper limit of normal (ULN);',\n",
       "   'Renal dysfunction, the level of serum creatinine is higher than 1.5 times of ULN;',\n",
       "   'Receive live virus or bacterial vaccination currently or 4 weeks before recruitment into the study;',\n",
       "   'Previously affected by tuberculosis or with positive tuberculin test result;',\n",
       "   'Has history of lymphoproliferative disease such as lymphoma or suspected lymphoproliferative disease through signs and symptoms such as lymphadenectasis in posterior cervical triangle, interclavicular or supratrochlear, or splenomegaly (more than 2 cm below the ribs);',\n",
       "   'History of multiple sclerosis or other demyelinating diseases of central nervous system;',\n",
       "   'Be allergic to experimental drug or with serious allergic constitution;',\n",
       "   'Malignancies excluding cured skin basal cell carcinoma or carcinoma in situ of cervix;',\n",
       "   'Systemic active infection, HIV infection or active Hepatitis B or Hepatitis B virus carriers;',\n",
       "   'With serious medical diseases such as cardiac insufficiency (), myocardial ischemia, serious arrhythmia, renal insufficiency, serious liver dysfunction, significant hematological system diseases, hypercortisolism, uncontrollable hypertension and diabetes mellitus;']},\n",
       " {'nct_id': 'NCT01918267',\n",
       "  'inclusion': ['Patients must have participated in the U-Act-Early trial (ML22497); these are adult patients (> 20 years of age) with rheumatoid arthritis.',\n",
       "   'Patients must be willing to give written informed consent'],\n",
       "  'exclusion': ['Patients who did not participate in the U-Act-Early trial',\n",
       "   'Patients who are drop-outs in the U-Act-Early trial due to withdrawal of consent, are lost to follow-up or are serious protocol violators']},\n",
       " {'nct_id': 'NCT01911234',\n",
       "  'inclusion': ['Has had a diagnosis of RA according to the revised ACR criteria (Aletaha et',\n",
       "   '2010) for at least 6 months.',\n",
       "   'Has been treated with and tolerated MTX for at least 3 months prior to the first administration of study product,',\n",
       "   'Has at least four swollen joints/66 and/or four tender joints/68,',\n",
       "   'Has CRP ≥ 10 mg/L at screening.',\n",
       "   'Is positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptides (CCP) antibodies at screening.'],\n",
       "  'exclusion': ['Has inflammatory rheumatic disease other than RA',\n",
       "   'Has been treated with non-biological DMARDs/systemic immunosuppressives',\n",
       "   'Has been treated with leflunomide within 12 weeks prior to first administration of study product.',\n",
       "   'Has received intra-articular, intramuscular (IM), or intravenous (IV) corticosteroids',\n",
       "   'Has received infliximab, etanercept, adalimumab, certolizumab, golimumab; another TNFα antagonist; or rituximab prior to the study.',\n",
       "   'Has been treated with any other biological DMARDs']},\n",
       " {'nct_id': 'NCT01913080',\n",
       "  'inclusion': [\"billing diagnosis of rheumatoid arthritis (714.0) or seronegative inflammatory arthritis and a member of the BRASS study at Brigham and Women's Hospital\"],\n",
       "  'exclusion': ['less than 18 years of age']},\n",
       " {'nct_id': 'NCT01752309',\n",
       "  'inclusion': ['Newly diagnosed rheumatoid arthritis patients, diagnosed according to the American College of Rheumatology (ACR) 1987-criteria',\n",
       "   'Naïve for Disease Modifying Anti Rheumatic Drugs (DMARDs), biologicals and glucocorticoids.',\n",
       "   'Starting with treatment with a potent anti-rheumaticum. E.g. methotrexate (MTX), biologicals or glucocorticoids.'],\n",
       "  'exclusion': ['Contra-indications for MTX, biologicals or glucocorticoids.',\n",
       "   'Insufficient ability to read and write in Dutch',\n",
       "   'Personality disorders that limit the participation in the study']},\n",
       " {'nct_id': 'NCT01759030',\n",
       "  'inclusion': ['Having signed a written informed consent form.',\n",
       "   'Patients must be from 18 to 80 years of age (both ages inclusive)',\n",
       "   'Rheumatoid arthritis confirmed according to ACR 1987 criteria.',\n",
       "   'Seropositive rheumatoid arthritis.',\n",
       "   'Active rheumatoid arthritis during the last 3 months.',\n",
       "   'Disease score according to DAS28 of 3.2 or more, TJC≥8 (68), SJC≥8 (66), hsCRP≥6 mg/l, ESR≥28 mm/hr (by Westergren) at the moment of screening.',\n",
       "   \"Patient's functional status\",\n",
       "   'class I-III according to ACR classification',\n",
       "   'Inadequate response to DMARDs that include one or more TNF inhibitors, intolerance or contraindications to TNF inhibitors.',\n",
       "   'Necessity of methotrexate treatment during the last 4 weeks prior to screening period with stable/consistent dosage of 7.5',\n",
       "   '20 mg per week.',\n",
       "   \"Patient's ability (in Investigator's opinion) to follow the protocol procedures;\",\n",
       "   'Willingness to use contraception during all study period.'],\n",
       "  'exclusion': [\"Patients with Felty's syndrome (irrespectively to clinical form).\",\n",
       "   \"Patient's functional status\",\n",
       "   'class IV according to ACR classification .',\n",
       "   'Rheumatoid arthritis low activity (less than 3.2 according to DAS28).',\n",
       "   'Concomitant therapy:',\n",
       "   'Previous treatment with any biological drug products causing CD20+ lymphocyte depletion, including biological investigational drugs.',\n",
       "   \"Treatment with azathioprine within 28 days before the study initiation and with leflunomide within 8 weeks before the study's principal phase (treatment with rituximab).\",\n",
       "   \"Intra-articular glucocorticosteroids within 4 weeks before the study's principal phase (treatment with rituximab).\",\n",
       "   'Necessity for prednisone or its equivalent administration at dose more than 10 mg per day.',\n",
       "   \"Necessity for prednisone or its equivalent administration at dose ≤10 mg per day in cases when this dose wasn't stable/consistent during last 4 weeks.\",\n",
       "   'Necessity for administration of non-steroidal anti-inflammatory drugs for arthritis treatment in cases when its doses were not stable/consistent during last 4 weeks.',\n",
       "   'Pregnancy and breast-feeding.',\n",
       "   'Changes of laboratory values:',\n",
       "   'Hemoglobin level is less than 100 g/l;',\n",
       "   'Leucocyte level is less than 3,0×10e9/l;',\n",
       "   'Absolute neutrophil count is less than 1,5×10e9/l;',\n",
       "   'Thrombocyte level is less than 100×10e9/l.',\n",
       "   'Confirmed chicken pox within 30 days before inclusion to the screening.',\n",
       "   'Confirmed herpes zoster infection.',\n",
       "   'Acute forms of any infectious diseases, history of chronic infections with severe clinical manifestations.',\n",
       "   'Active tuberculosis, history of latent tuberculosis.',\n",
       "   \"Inflammatory disease of the joints (present or in anamnesis) not related to rheumatoid arthritis (including gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease and others) or other systemic autoimmune disease (including systemic lupus erythematosus, Crohn's disease, ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed forms of connective tissue inflammatory diseases, cross-syndrome and others).\",\n",
       "   'Juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis developed before the age of',\n",
       "   '- Any determined immunodeficiency.',\n",
       "   'Pernicious anemia.',\n",
       "   'Confirmed cobalamine deficiency.',\n",
       "   'Other somatic diseases (apart from rheumatoid arthritis) that can increase the probability of adverse events during the study or can influence the estimation of symptom manifestation of RA ; mask, enhance or alter the symptoms of RA or cause clinical or laboratory symptoms similar to that of RA;',\n",
       "   'Positive results of serological test of Hepatitis B surface antigen (HbsAg) or presence of Hbc IgM together with positive results of HBV PCR test, presence of antibodies to Hepatitis C virus, syphilis or HIV.',\n",
       "   'Major surgery within 28 days prior to the trial principal phase (treatment with rituximab).',\n",
       "   \"Any mental disorder, including major depression and/or suicidal thoughts in anamnesis that can, in Investigator's opinion, create a risk for the patient or influence the patient's ability to follow the study protocol.\",\n",
       "   'Unstable angina pectoris.',\n",
       "   'Myocardial infarction within less than 1 year prior to participation in the study.',\n",
       "   'Severe central or peripheral nervous system diseases.',\n",
       "   'Drug addiction, alcoholism.',\n",
       "   'Known hypersensitivity to murine proteins or any other components of the medications used in the treatment, methotrexate, folic acid and any drugs used in premedication.',\n",
       "   'Presence of malignant neoplasm, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ and any malignancy with complete remission of more than 5 years;',\n",
       "   'Simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation; previous participation in this study.']},\n",
       " {'nct_id': 'NCT01756235',\n",
       "  'inclusion': ['Had rheumatoid arthritis (RA) and is eligible to start and/or continue adalimumab therapy according to the local product label and prescription guidelines',\n",
       "   'Had been started on adalimumab therapy no more than one (1) month prior to the study enrolment',\n",
       "   'Had negative result of tuberculosis (TB) screening test or was receiving TB prophylaxis as per local guidelines',\n",
       "   'Had provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations'],\n",
       "  'exclusion': ['Was unable to walk either due to RA or a comorbid condition',\n",
       "   'Was unable to perform basic self-care activities',\n",
       "   'Had contraindications for treatment with adalimumab']},\n",
       " {'nct_id': 'NCT01752855',\n",
       "  'inclusion': ['Subject has completed the preceding Study M13-390 for rheumatoid arthritis and has not developed any discontinuation criteria from that study.',\n",
       "   'If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing an approved method of birth control throughout the study and for 150 days after last dose of study drug. Examples of approved methods of birth control include the following (see local informed consent for more detail):',\n",
       "   'Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD);',\n",
       "   'Hormonal contraceptives for 90 days prior to study drug administration;',\n",
       "   'A vasectomized partner.',\n",
       "   'Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.',\n",
       "   'Subject is judged to be in good general health as determined by the Principal Investigator based upon the results of medical history, physical examination, laboratory profile performed at Baseline.',\n",
       "   'Subjects must be able and willing to provide written informed consent and to comply with the requirements of this study protocol.'],\n",
       "  'exclusion': ['Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated.',\n",
       "   'Subject currently uses or plans to use anti-retroviral therapy at any time during the study.',\n",
       "   'Subject plans to use any live vaccine during the study.',\n",
       "   'Positive pregnancy test at Baseline (Week 0).',\n",
       "   'Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.']},\n",
       " {'nct_id': 'NCT01754935',\n",
       "  'inclusion': ['Male and female subjects 18 to 65 years of age (inclusive)',\n",
       "   'Diagnosis of RA',\n",
       "   'Swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints',\n",
       "   'Seropositivity based on either a positive rheumatoid factor or anti cyclic citrullinated peptide antibody at screening -OR- known erosive disease based on previous X-ray report or erosions detected on screening hand and foot X-ray',\n",
       "   'Baseline CRP level or Westergren erythrocyte sedimentation rate ≥1.2 × upper limit of normal',\n",
       "   'Receiving stable therapy with 1 of the following DMARDs: methotrexate, sulfasalazine, leflunomide, anti-malarial drug, or penicillamine',\n",
       "   'Palpable 2+ synovitis of the wrist or ≥2 MCPs in the MRI-designated hand'],\n",
       "  'exclusion': ['History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.',\n",
       "   'Inflammatory, rheumatological disorders other than RA, where arthritis may be a prominent feature',\n",
       "   'Planned surgery during the study',\n",
       "   'History of alcohol or drug abuse, or excessive alcohol consumption',\n",
       "   'History of tuberculosis (TB) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.',\n",
       "   'Pregnant or nursing an infant or with a life partner who is pregnant, nursing, or planning to become pregnant']},\n",
       " {'nct_id': 'NCT01752335',\n",
       "  'inclusion': ['Age ≥ 18 and <70 years.',\n",
       "   'Diagnosis of active Rheumatoid Arthritis, moderate to severe (≥ 3.2 DAS28) of ≥ 6 months duration.',\n",
       "   'Patients with an inadequate clinical response to a stable dose of non-biological DMARDs or anti-TNF treatment for a period ≥ 8 weeks before treatment.',\n",
       "   'If patients are receiving oral corticosteroids, the dose should have been ≤ 10 mg predinosona and stable for at least one month before the start of treatment (day 1).',\n",
       "   'Patients who are able and wish to sign the informed consent and comply with the requirements of the study protocol.'],\n",
       "  'exclusion': ['Major surgery (including joints surgery) within eight weeks prior to the screening visit or major surgery scheduled for six months after first infusion.',\n",
       "   \"Other Rheumatic autoimmune diseases, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis or systemic involvement secondary to AR (such as vasculitis, pulmonary fibrosis or Felty's syndrome). It's allowed the inclusion of patients with interstitial pulmonary fibrosis and be still able to tolerate treatment with MTX. Sjögren's syndrome with RA is not considered exclusion criterion.\",\n",
       "   'Rheumatoid arthritis with Functional Class IV as defined in the RA Classification of the ACR (complete or significant disability of patients, confined to bed or to the wheelchair and without possibilities to take care themselves).',\n",
       "   'Prior or actual inflammatory joint disease different of RA (eg, gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease). Specific drug criteria',\n",
       "   'Treatment with any investigational agent in the four weeks before the screening visit (or time equivalent to five half-lives of the investigational drug, whichever is longer).',\n",
       "   'Immunization with a live vaccine / attenuated in the four weeks prior to the baseline visit.',\n",
       "   'Pretreatment with TCZ Laboratory Tests (at the screening visit)',\n",
       "   'Serum creatinine> 142 mmol / l (1.6 mg / dL) in women and> 168 mmol / l (1.9 mg / dl) in men and absence of active renal disease.',\n",
       "   'ALT (SGPT) and AST (SGOT)> 1.5 ULN (if the initial sample of ALT [SGPT] or AST [SGOT] gives a value> 1.5 times ULN, you can take and analyze a second sample during the selection period).',\n",
       "   'Platelet count <100 x 109 / l (100.000/mm3).',\n",
       "   'Hemoglobin <85 g / dl (<8.5 g / l, 5.3 mmol / l).',\n",
       "   'Leukocytes <1.0 x 109 / l (1000/mm3), ANC <0.5 x 109 / L (500/mm3).',\n",
       "   'RAL <0.5 x 109 / L (500/mm3).',\n",
       "   'Positivity for surface antigen of hepatitis B (HBsAg) and antibodies to hepatitis',\n",
       "   '15. Total bilirubin> ULN (if the initial sample of bilirubin> ULN, you can take and analyze a second sample during the selection period).',\n",
       "   'Triglycerides> 10 mmol / l (> 900 mg / dl) at the screening visit (non fasting).',\n",
       "   'Pregnant or lactating women.',\n",
       "   'not use of reliable means of contraception, such as a physical barrier (patient and partner), pill or contraceptive patch, spermicide and barrier or IUD.',\n",
       "   'Background of serious allergic or anaphylactic reactions to human monoclonal antibodies, humanized or murine.',\n",
       "   'RXT evidence of clinically significant abnormality.',\n",
       "   'Evidence of uncontrolled concomitant serious illness, cardiovascular, nervous system, lung (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal.',\n",
       "   'history of diverticulitis, diverticulosis in antibiotic treatment, the physician should consider the benefit-risk ratio.',\n",
       "   \"Background of lower GI ulcer disease as the Crohn's disease, ulcerative colitis or other symptomatic conditions predisposed to perforations lower GI\",\n",
       "   'Uncontrolled diseases such as asthma, psoriasis or inflammatory bowel disease,... treated normally with corticosteroids orally or parenterally.',\n",
       "   'Ongoing liver disease as determined by the principal investigator. (Patients with a history of elevated ALT (SGPT) will not be excluded)',\n",
       "   'Active infections or recurrent infections in the past by mycobacteria, fungus, virus or bacteria (for example: tuberculosis, atypical mycobacterial disease, clinically significant abnormalities in RXT, hepatitis B and C, herpes zoster), or any major episode infection that required hospitalization or IV antibiotic treatment in the 4 weeks preceding the screening visit or oral antibiotic in the 2 weeks prior to the screening visit.',\n",
       "   'Primary or secondary immunodeficiency.',\n",
       "   'Evidence of active malignancy diagnosed within 5 years before the inclusion(including solid tumors and hematological), or breast cancer diagnosed in the previous 5 years.',\n",
       "   'Active tuberculosis (TB) requiring treatment within 3 years above. Patients with a positive skin test tuberculin purified protein derivative (PPD) at the screening visit. Patients treated for tuberculosis no recurrence in the last three years will not be excluded.',\n",
       "   'HIV positive patients.',\n",
       "   'History of alcoholism, drug addiction or drug abuse in the six months before the screening visit.',\n",
       "   'Painful neuropathies or other conditions that may interfere with the pain assessment.']},\n",
       " {'nct_id': 'NCT01754805',\n",
       "  'inclusion': ['If female, subject must be at least 2 years post menopausal or is surgically sterile per documentation provided by a medical professional and the subject is not pregnant as documented by a negative serum pregnancy test at Screening and negative urine pregnancy test at check-in',\n",
       "   'If male, subject must agree to sexual abstinence and/or to use a highly effective method of birth control during the study period and for 60 days after the last dose of study drug',\n",
       "   'Subject must have a clinical diagnosis of Rheumatoid Arthritis (RA) at least 6 months prior to Screening',\n",
       "   'Subject must be on a stable 15',\n",
       "   '25 mg dose of methotrexate > 28 days prior to Screening',\n",
       "   'If subject is on a non-biologic disease modifying anti-rheumatic drug (DMARDs) therapy, the dose must be stable > 28 days prior to Screening',\n",
       "   'Subject must be willing and able to comply with the study requirements'],\n",
       "  'exclusion': ['Subject has a previous history of any clinically significant neurological, gastrointestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that would preclude participation in the study',\n",
       "   'Subject has a known history of positive test for hepatitis B surface antigen (HbsAg) or hepatitis C antibody or history of a positive test for human immunodeficiency virus (HIV) infection',\n",
       "   'Subject has received live virus vaccination within the last 30 days prior to study drug administration',\n",
       "   'Subject has a Body Mass Index (BMI) > 35 (kg/m2)',\n",
       "   'Subject is on biologic disease modifying anti-rheumatic drug (DMARDs) therapy',\n",
       "   'Subject has a current history of anemia as defined by hemoglobin of less than 12 g/dL',\n",
       "   'Subject has a recent history (within the last 6 months) of drug or alcohol abuse or a positive urine screen for alcohol or drugs of abuse/illegal drugs at Screening or check-in',\n",
       "   'Subject has received any investigational agent within 30 days of screening']},\n",
       " {'nct_id': 'NCT01083563',\n",
       "  'inclusion': ['Signed, IRB-approved, written informed consent',\n",
       "   'Subjects can be of either gender but must be more than 18 years old.',\n",
       "   'Subjects must fulfill the disease activity criteria for RA and a DAS28 will be assessed at baseline and at 2 months after rituximab therapy.',\n",
       "   'Aim A',\n",
       "   'Eligible subjects must meet criteria for RA and have an inadequate response to MTX defined as DAS28 >5.1. They must have been on a steady dose of MTX (between 15 and 20 mg /week for a minimum of 8 weeks). Subjects must have evidence of knee synovitis on exam to enter the study.',\n",
       "   'Aim B',\n",
       "   'Subjects must have demonstrated a response to a TNF antagonist as evidenced by a DAS score <2.8 or <4 tender and swollen joints. Flare will be defined as a DAS 28 >5.1 of more than 8 swollen and tender joints. Subjects must have evidence of knee synovitis to enter the study. Subjects will be off etanercept, infliximab or adalimumab for 4 weeks before starting BCDT. All subjects must also be on a stable dose of DMARD (MTX, leflunomide, azulfidine, hydroxychloroquine) for 8 weeks before entry into the study.'],\n",
       "  'exclusion': ['Patients will be excluded for medical or other reasons at the discretion of the investigators. The reasons for the exclusion must be recorded, e.g. risk of non-compliance, vulnerability, medically unstable, etc.',\n",
       "   'Active systemic disorders or inflammatory conditions (i.e., chronic infection with hepatitis B, hepatitis C or HIV) other than the conditions being studied.',\n",
       "   'Patients with a plasma creatinine > 1.5 mg/dl',\n",
       "   'Aim B',\n",
       "   'Subjects with an allergy to corticosteroids will be excluded from the study.',\n",
       "   'Anyone answering yes to the following questions will be excluded: Do you have a history of:',\n",
       "   'Cardiac (Heart) pacemaker or defibrillator?',\n",
       "   'Cardiac (Heart) valve replacement or prosthesis?',\n",
       "   'Aneurysm clips from brain surgery?',\n",
       "   'Ear prosthesis (cochlear or stapedial implant)? (hearing aids?)',\n",
       "   'Neurostimulator?',\n",
       "   'Biostimulator?',\n",
       "   'Any type of pumps in or on your body?',\n",
       "   'Shrapnel, gunshot wound, BB pellet?',\n",
       "   'Metallic penile prosthesis?',\n",
       "   'Metallic blood vessel filter or stent?',\n",
       "   'Orthopedic prosthesis?',\n",
       "   'Have you ever had an injury involving metal fragments in your eye?',\n",
       "   'Have you ever had neurosurgery (brain or skull surgery)? Note: Subjects treated with rituximab will not be excluded from study based on their immunosuppressive drugs but use of these agents will be recorded and discussed in the analysis.']},\n",
       " {'nct_id': 'NCT01086033',\n",
       "  'inclusion': ['Patients with moderate or severe active rheumatoid arthritis, who have been prescribed and are receiving Humira (adalimumab) under normal clinical practice for at least one month prior to inclusion and according to the approved Summary of Product Characteristics (SPC) in the European Union.',\n",
       "   'Patients must be willing to consent to data being collected and provided to Abbott Laboratories.'],\n",
       "  'exclusion': ['Contraindications according to the SPC.',\n",
       "   'Patients should not participate in another observational Abbott study.']},\n",
       " {'nct_id': 'NCT01083121',\n",
       "  'inclusion': ['Adult patients (19 years and above) with one of the following indications:',\n",
       "   'Moderately to severely active rheumatoid arthritis or',\n",
       "   'active and progressive psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate or',\n",
       "   'severe active ankylosing spondylitis who have had an inadequate response to conventional therapy or',\n",
       "   \"severely active Crohn's disease who have had no response, intolerance or contraindication to corticosteroid therapy or immunosuppressants or\",\n",
       "   'moderately to severely active psoriasis patients who have had no response, have intolerance or have contraindication to systemic therapies including cyclosporine, methotrexate or photochemotherapy (PUVA).',\n",
       "   'Patients who give verbal or written authorization to use their personal and health data.'],\n",
       "  'exclusion': ['Patients with known hypersensitivity to adalimumab or any of its excipients.']},\n",
       " {'nct_id': 'NCT01088321',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis',\n",
       "   'Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM',\n",
       "   'Age 18 years or older at the time of drug initiation',\n",
       "   'Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation'],\n",
       "  'exclusion': ['Below 18 years of age at the time of BDM or DMARD initiation',\n",
       "   'Lacking six months of continuous enrollment prior to the initiation of one of the study drugs']},\n",
       " {'nct_id': 'NCT01083693',\n",
       "  'inclusion': ['Patients age greater than or equal to 18',\n",
       "   'Patients must fulfill international and national guidelines for use of a BDMARD in RA, PsA and AS (Chest X-ray and purified protein derivative (PPD) skin test negative for tuberculosis). In addition one of the following criteria must be fulfilled:',\n",
       "   'unsatisfactory DMARD response defined as failure to treatment with at least two DMARDs including Methotrexate in patients with RA or PsA',\n",
       "   'unsatisfactory NSAID response in patients with AS or',\n",
       "   'unsatisfactory response to prior BDMARDs (in this case patients must have received BDMARDs at least 12 weeks before visit 1) in patients with RA or PsA or',\n",
       "   ''],\n",
       "  'exclusion': ['Patients who meet contraindications as outlined in the latest version of the Humira syringe® Summary of Product Characteristics (SmPC) and Humira Pen® SmPC',\n",
       "   'Patients participating in another study or clinical trial.']},\n",
       " {'nct_id': 'NCT01083160',\n",
       "  'inclusion': ['Patients ≥18 and <75 years of age that meet the American College of Rheumatology (ACR) criteria for',\n",
       "   '- Patients with active RA defined as:',\n",
       "   '≥3 tender joints and ≥3 swollen joints, or',\n",
       "   'DAS 28 score >3.1',\n",
       "   'Patients who are discontinuing treatment with either infliximab or etanercept due to:',\n",
       "   'Lack of efficacy, or',\n",
       "   'Incomplete response.',\n",
       "   'Patients that, in the opinion of the physician could result beneficiated with the locally approved treatment scheme of adalimumab',\n",
       "   'Those patients who switch from infliximab or etanercept to adalimumab has been done in the last 60 days could be included in the study.'],\n",
       "  'exclusion': ['Patients who have active infections.',\n",
       "   'Patients with latent',\n",
       "   'For this protocol, evidence of latent TB infection is defined as an induration (not erythema) of 5 mm or greater, 48-72 hrs after placement. Any suggested data on the clinical history or chest x-ray.',\n",
       "   'Patients participating into another study or clinical trial',\n",
       "   'Any condition that according to the criteria of the participating physician represents an obstacle for study conduct and/or represents a potential unacceptable risk for patients.']},\n",
       " {'nct_id': 'NCT01089023',\n",
       "  'inclusion': ['adult patients, >/=18 years of age',\n",
       "   'moderate to severe rheumatoid arthritis (DAS28 >3.2) of 6 months duration',\n",
       "   'inadequate clinical response to non-biologic DMARDs or anti-TNF',\n",
       "   'bodyweight </=150 kg'],\n",
       "  'exclusion': ['rheumatic autoimmune disease or inflammatory joint disease other than RA',\n",
       "   'major surgery within 8 weeks prior to screening or planned major surgery within 6 months following screening']},\n",
       " {'nct_id': 'NCT01088360',\n",
       "  'inclusion': ['Signed informed consent',\n",
       "   'Diagnosis of rheumatoid arthritis',\n",
       "   '> 18 years at index treatment initiation or switch',\n",
       "   'Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug.',\n",
       "   'Read/write English'],\n",
       "  'exclusion': ['None']},\n",
       " {'nct_id': 'NCT01712178',\n",
       "  'inclusion': ['Male or female subject, 18 years or older who has a diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987-revised American College of Rheumatology (ACR)-classification criteria or the new American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010-classification criteria and has a disease duration for a minimum of 3 months.',\n",
       "   'Subjects must be naïve to biologic therapy.',\n",
       "   'Subject must meet the following criteria for the joint assessment: • At least 6 swollen joints out of 66 assessed. • At least 6 tender joints out of 68 assessed.',\n",
       "   'Prior Disease Modifying Antirheumatic Drug (DMARD) therapy: a) Subjects not on methotrexate at baseline must remain without methotrexate throughout the study. Subjects on prior Methotrexate (MTX) must have discontinued at least 28 days prior to Week 0 (Day 1). b) Subjects on Disease Modifying Antirheumatic Drug (DMARD) therapy other than Methotrexate (MTX) (except prednisone/prednisolone less than or equal to 10 mg) must discontinue it for at least 28 days before the first dose of investigational product at Week 0 (Day 1).',\n",
       "   'Female subjects are either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least 1 of the following methods of birth control throughout the study and for at least 150 days after the last dose of study drug: • Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD). • Hormonal contraceptives for 90 days prior to study drug administration. • Vasectomized partner(s).',\n",
       "   'Subjects must be able and willing to self-administer subcutaneous (SC) injections or have a qualified person available to administer subcutaneous (SC) injections.',\n",
       "   'Subject is judged to be in good general health as determined by the Principal Investigator based upon the results of medical history, physical examination, laboratory profile, chest x-ray (CXR), and 12 lead electrocardiogram (ECG) performed during Screening.',\n",
       "   'Subject has a negative Tuberculosis (TB) screening assessment (including a (Purified Protein Derivative (PPD) test or QuantiFERON-Tuberculosis (TB) Gold test or equivalent) and negative chest x-ray (Posterior-Anterior (PA) and lateral view) at Screening. If a subject has evidence of a latent Tuberculosis (TB) infection, the subject must initiate and complete a minimum of 2 weeks of anti-Tuberculosis (TB) therapy or have documented completion of a course of anti-Tuberculosis (TB) therapy prior to Baseline.',\n",
       "   'Subjects must be willing to provide written consent and to comply with the requirements of this study protocol.'],\n",
       "  'exclusion': ['Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks from Baseline visit. Inhaled corticosteroids for stable medical conditions are allowed. Oral of less than or equal to 10 mg/d prednisone equivalent are allowed.',\n",
       "   'Subject has been treated with any investigational drug of a chemical or biological nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Baseline Visit.',\n",
       "   \"Subject has a history of acute inflammatory joint disease of different origin other than Rheumatoid Arthritis (RA) (e.g., seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, gouty arthritis, or any arthritis with onset prior to age 17 years).\",\n",
       "   'Known hypersensitivity to adalimumab or its excipients.',\n",
       "   'Subject currently uses or plans to use anti-retroviral therapy at any time during the study.',\n",
       "   'History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.',\n",
       "   'History of invasive infection (e.g., listeriosis and histoplasmosis), human immunodeficiency syndrome (HIV).',\n",
       "   'Chronic recurring infections or active Tuberculosis (TB).',\n",
       "   'History of moderate to severe congestive heart failure (New York Heart Association (NYHA) class III or IV), recent cerebrovascular accident and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.',\n",
       "   'Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma or localized carcinoma in situ of the cervix.',\n",
       "   'Subject received any live vaccine within 3 months prior to study drug administration.',\n",
       "   'Subject has a history of clinically significant hematologic (e.g., severe anemia, leukopenia, thrombocytopenia), renal or liver disease (e.g., fibrosis, cirrhosis, hepatitis).',\n",
       "   'Positive pregnancy test at Screening or Baseline.',\n",
       "   'Subject is considered by the investigator, for any reason, to be unsuitable candidate for the study']},\n",
       " {'nct_id': 'NCT01715896',\n",
       "  'inclusion': ['Age 18 through 80 years',\n",
       "   'Written consent',\n",
       "   'Diagnosis of adult onset Rheumatoid Arthritis (RA) as defined by the 2010 American College of Rheumatology European League Against Rheumatism (ACR/EULAR) classification criteria',\n",
       "   'Moderately active disease as defined by disease activity score in 28 joints C-reactive protein (DAS28[CRP]) greater than or equal to (>=) 3.2 at screening and DAS28 erythrocyte sedimentation rate(ESR) ≥ 3.2 at Day 1',\n",
       "   'Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'At least 4 swollen joints',\n",
       "   'Inadequate response to one or two anti-TNF agents other than the study comparator, as defined by the protocol',\n",
       "   'Receiving oral or injectable methotrexate, as defined by the protocol.'],\n",
       "  'exclusion': ['A rheumatic autoimmune disease or other inflammatory joint disease other than RA',\n",
       "   'Previous treatment with biologic therapies other than anti-TNF for RA',\n",
       "   'Treatment with other DMARDs or non-steroidal anti-inflammatory drugs (NSAIDs), as defined by the protocol.',\n",
       "   'Medical history as defined by the protocol.']},\n",
       " {'nct_id': 'NCT01710358',\n",
       "  'inclusion': ['Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA',\n",
       "   'Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints',\n",
       "   'Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥6 milligram per Liter (mg/L)',\n",
       "   'Have had regular use of methotrexate (MTX) for at least the 12 weeks prior to study entry at a dose that is considered acceptable to adequately assess clinical response.',\n",
       "   'Have at least 1 joint erosion in hand, wrist, or foot joints based on radiographic interpretation by the central reader and be rheumatoid factor or anticyclic citrullinated peptide (anti-CCP) antibody positive; or have at least 3 joint erosions in hand, wrist, or foot joints based on radiographic interpretation by the central reader regardless of rheumatoid factor or anti-CCP antibody status'],\n",
       "  'exclusion': ['Are currently receiving corticosteroids at doses >10 mg of prednisone per day (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine or combination of any 3 conventional disease-modifying antirheumatic drugs (cDMARDs)',\n",
       "   'Are currently receiving or have received cDMARDs (eg, gold salts, cyclosporine, azathioprine, or any other immunosuppressives) other than MTX, hydroxychloroquine (up to 400 mg/day), or sulfasalazine (up to 3000 mg/day) within 4 weeks prior to study entry',\n",
       "   'Have received leflunomide in the 12 weeks prior to study entry',\n",
       "   'Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry',\n",
       "   'Have ever received any biologic disease-modifying antirheumatic drugs (DMARD)',\n",
       "   'Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study',\n",
       "   'Have received any parenteral corticosteroid administered by intramuscular or intravenous injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study',\n",
       "   'Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization',\n",
       "   'Have any condition or contraindication for adalimumab that would preclude the participant from participating in this protocol',\n",
       "   'Have active fibromyalgia that would make it difficult to appropriately assess RA activity for the purposes of this study',\n",
       "   \"Have a diagnosis of any systemic inflammatory condition other than RA such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout(participants with secondary Sjögren's syndrome are not excluded)\",\n",
       "   \"Have a diagnosis of Felty's syndrome\",\n",
       "   'Have had any major surgery within 8 weeks prior to study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant',\n",
       "   'Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure',\n",
       "   'Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data',\n",
       "   'Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden or confined to a wheelchair',\n",
       "   'have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years',\n",
       "   'Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)',\n",
       "   'Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection',\n",
       "   'Have had symptomatic herpes zoster infection within 12 weeks prior to study entry',\n",
       "   'Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, or postherpetic neuralgia)',\n",
       "   'Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study',\n",
       "   'Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)',\n",
       "   \"Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study\",\n",
       "   \"Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study\",\n",
       "   'Have symptomatic herpes simplex at the time of study enrollment',\n",
       "   'Have evidence of active or latent tuberculosis (TB)']},\n",
       " {'nct_id': 'NCT01717846',\n",
       "  'inclusion': ['Over age 18',\n",
       "   'Meeting ACR Criteria 1987 for RA diagnosis',\n",
       "   'Naïve to treatment with abatacept',\n",
       "   'Must be able to understand information in the Informed Consent'],\n",
       "  'exclusion': ['Pregnancy or breast feeding',\n",
       "   'Previous exposure to abatacept.',\n",
       "   'History of a concomitant autoimmune disease (eg. SLE, PsA etc.)',\n",
       "   'Patients with history of cancer']},\n",
       " {'nct_id': 'NCT01711359',\n",
       "  'inclusion': ['Have a diagnosis of adult-onset rheumatoid arthritis (RA) as defined by American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA',\n",
       "   'Have documented history of positive rheumatoid factor and/or cyclic citrullinated peptide (CCP) antibody test',\n",
       "   'Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints',\n",
       "   'Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥1.2 times the upper limit of normal (ULN)',\n",
       "   'Have had limited or no treatment with methotrexate (MTX)'],\n",
       "  'exclusion': ['Have received conventional disease-modifying antirheumatic drugs (DMARDs) other than MTX (eg, gold salts, cyclosporine, leflunomide, azathioprine, hydroxychloroquine, sulfasalazine or any other immunosuppressives)',\n",
       "   'Are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry',\n",
       "   'Have ever received any biologic DMARD',\n",
       "   'Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study',\n",
       "   'Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require a parenteral injection of corticosteroids during the study',\n",
       "   'Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization',\n",
       "   \"Have active fibromyalgia that, in the investigator's opinion, would make it difficult to appropriately assess RA activity for the purposes of this study\",\n",
       "   \"Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis, or gout (Participants with secondary Sjogren's syndrome are not excluded.)\",\n",
       "   \"Have a diagnosis of Felty's syndrome\",\n",
       "   'Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant',\n",
       "   'Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage IV heart failure',\n",
       "   'Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data',\n",
       "   'Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair',\n",
       "   'Have an estimated Glomerular Filtration Rate (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)',\n",
       "   'Have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN',\n",
       "   'Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years',\n",
       "   'Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)',\n",
       "   'Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection',\n",
       "   'Have had symptomatic herpes zoster infection within 12 weeks prior to study entry',\n",
       "   'Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)',\n",
       "   'Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study',\n",
       "   'Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)',\n",
       "   \"Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study\",\n",
       "   \"Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study\",\n",
       "   'Have symptomatic herpes simplex at the time of study enrollment',\n",
       "   'Have evidence of active or latent tuberculosis (TB)']},\n",
       " {'nct_id': 'NCT01717859',\n",
       "  'inclusion': ['Patient must meet 1987 American College of Rheumatology (ACR) criteria,',\n",
       "   'Age > 18 years of age,',\n",
       "   'Baseline DAS28/ESR>4.4,',\n",
       "   'Stable concomitant DMARDs for more than 1 month (methotrexate, leflunomide, plaquenil, sulfasalazine, or no DMARDs). However, if the patient is not on DMARD, history of DMARD use required.',\n",
       "   'If not on DMARD (and the patient satisfies the above statement), the patient can opt for monotherapy with tocilizumab or combination therapy OR',\n",
       "   'If on biologic monotherapy, can opt for monotherapy with tocilizumab or DMARD combination therapy (ie. patients cannot be on biologic with TCZ) 6) Power Doppler score of >10 at screening. General Medical Concerns:',\n",
       "   'Normal organ function, except if abnormal due to the disease under investigation',\n",
       "   'Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.',\n",
       "   'Subject has provided written informed consent. Exclusion Criteria A patient will be excluded if the answer to any of the following statements is \"yes\". General:',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to baseline or planned major surgery within 6 months after baseline. Excluded Previous or Concomitant Therapy:',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of baseline.',\n",
       "   'Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3.',\n",
       "   'Previous treatment with anti-CD19 and anti-CD20 within 6 months of start of the study.',\n",
       "   'Treatment with intravenous gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline.',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.',\n",
       "   'Previous treatment with TCZ.',\n",
       "   'Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.',\n",
       "   'Use of prednisone > 10mg at baseline. Exclusions for General Safety:',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies.',\n",
       "   \"Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (include uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn's disease.)\",\n",
       "   'Current liver disease as determined by principal investigator unless related to primary disease under investigation',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of baseline or oral antibiotics within 2 weeks prior to baseline.',\n",
       "   'Active Tuberculosis (TB) requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating TCZ. Patients treated for tuberculosis with no recurrence in 3 years are permitted.',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 5 years.',\n",
       "   'Pregnant women or nursing (breast feeding) mothers.',\n",
       "   'Patients with reproductive potential not willing to use an effective method of contraception.',\n",
       "   'History of alcohol, drug or chemical abuse within 1 year prior to screening.',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation.',\n",
       "   'Patients with lack of peripheral venous access.',\n",
       "   'Body weight of > 150',\n",
       "   'Laboratory'],\n",
       "  'exclusion': ['Serum creatinine > 1.6 mg/dL (141 µmol/L) in female patients and > 1.9 mg/dL (168 µmol/L) in male patients. Patients with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are >30.',\n",
       "   'Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)',\n",
       "   'Total Bilirubin > ULN',\n",
       "   'Platelet count < 100 x 109/L (100,000/mm3)',\n",
       "   'Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)',\n",
       "   'White Blood Cells < 3.0 x 109/L (3000/mm3)',\n",
       "   'Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)',\n",
       "   'Absolute Lymphocyte Count < 0.5 x 109/L (500/mm3)',\n",
       "   'Positive Hepatitis BsAg, or Hepatitis C antibody',\n",
       "   'HIV positive']},\n",
       " {'nct_id': 'NCT01894516',\n",
       "  'inclusion': ['male or female subjects who are ≥18 years of age on the day of signing informed consent,',\n",
       "   'have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,',\n",
       "   'have ≥6 swollen joints (from a 66-joint count) and ≥8 tender joints (from a 68-joint count) at Screening and at Baseline,',\n",
       "   'Screening serum c-reactive protein ≥ 0.7 x upper limit of laboratory normal range (ULN),',\n",
       "   'have shown an inadequate response in terms of either lack of efficacy or toxicity to MTX,',\n",
       "   'have agreed to be washed out from MTX for a period of at least 4 weeks before or during the Screening period.'],\n",
       "  'exclusion': ['current therapy with any non-biological disease modifying anti-rheumatic drug (DMARD), with the exception of antimalarials, which must be at a stable dose for at least 12 weeks prior to Screening,',\n",
       "   'current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs: administered in a single clinical study setting, and; more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), and; where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,',\n",
       "   'previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.']},\n",
       " {'nct_id': 'NCT01895309',\n",
       "  'inclusion': ['Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6 months but not exceeding 15 years prior to Screening',\n",
       "   'Have moderate to severe active disease despite MTX therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive protein ≥ 1.0 mg/dL',\n",
       "   'Must have been treated with MTX for at least 6 months prior to Randomisation and on a stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening',\n",
       "   'Female subjects who are not pregnant or nursing at Screening and who are not planning to become pregnant from Screening until 2 months after the last dose of investigational product'],\n",
       "  'exclusion': ['Have been treated previously with any biological agents including any tumour necrosis factor inhibitor',\n",
       "   'Have a known hypersensitivity to human immunoglobulin proteins or other components of Enbrel or SB4',\n",
       "   'Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus',\n",
       "   'Have a current diagnosis of active tuberculosis',\n",
       "   'Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.',\n",
       "   'Have any of the following conditions',\n",
       "   'Other inflammatory or rheumatic diseases.',\n",
       "   'History of any malignancy within the previous 5 years prior to Screening',\n",
       "   'History of lymphoproliferative disease including lymphoma.',\n",
       "   'History of congestive heart failure',\n",
       "   'Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).',\n",
       "   'History of demyelinating disorders.']},\n",
       " {'nct_id': 'NCT01890473',\n",
       "  'inclusion': ['Subjects ≥18 years of age',\n",
       "   \"Diagnosis of Rheumatoid Arthritis confirmed by participant's physician\",\n",
       "   'Disease activity under control Key'],\n",
       "  'exclusion': ['Change in disease-modifying antirheumatic drug (DMARD) therapy within 3 months of enrollment',\n",
       "   'Exposure to investigational drug within 4 weeks or 5 half lives whichever is longer',\n",
       "   'Current or prior use of Rituximab ≤6 months',\n",
       "   'Current or prior use of the following within 4 weeks or 5 half lives whichever is longer: biologic DMARDS, Tofacitinib, Cyclophosphamide, Mycophenolate Mofetil & d-Penicillamine']},\n",
       " {'nct_id': 'NCT01893255',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment in accordance with the local label; this can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit',\n",
       "   'Patients who for any reason do not take methotrexate and the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy',\n",
       "   'Patients who were previously on a TNF inhibitor as monotherapy, and the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy',\n",
       "   'Concomitant treatment with corticosteroids (orally and intra-articularly) and/or NSAIDs is allowed'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Patients receiving concomitant DMARD treatment for rheumatoid arthritis (e.g. hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine)',\n",
       "   'Patients who have received treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'Patients with a history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01893151',\n",
       "  'inclusion': ['Subjects with a diagnosis of RA according to the diagnostic criteria of the American College of Rheumatology (ACR) (revised in 1987)',\n",
       "   'Rheumatoid Arthritis for 3 months to 2 years from the time of the initial diagnosis',\n",
       "   'Functional Class II-III',\n",
       "   'Subjects have active RA at the time of screening',\n",
       "   'Must have a negative Pregnancy test and use adequate method of contraception throughout the trial',\n",
       "   'Must have at least 4 tender joints and 4 swollen joints(involved in DAS28) and among these,at least one swollen Metacarpophalangeal joint is essential',\n",
       "   'Has a C-reactive protein ≥ 10 mg/L OR Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/hr',\n",
       "   'Written informed consent'],\n",
       "  'exclusion': ['Preceding treatment with DMARDs, immunosuppressants (cyclophosphamide, cyclosporine, azathioprine, etc.), biological agents or tripterygium within 12 weeks prior to study entry',\n",
       "   'Chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc',\n",
       "   'ALT >1.5×ULN, AST >1.5×ULN, Cr >135umol/L or Cr >1.5mg',\n",
       "   'WBC<4×109/L，HGB<85g/L，PLT<100×109/L',\n",
       "   'Subjects with serious cardiovascular, renal, hematologic,endocrine diseases or malignant',\n",
       "   'Subjects with immunodeficiency, uncontrolled infection and active gastrointestinal disease',\n",
       "   'Pregnant, intend to become pregnant, or are breastfeeding',\n",
       "   'Subjects with other rheumatological diseases such as SLE, mixed connective tissue disease, scleroderma, polymyositis, etc',\n",
       "   'Subjects with inflammatory arthritis, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease',\n",
       "   'Subjects with intra-articular corticosteroid injections within 6 weeks prior to study entry',\n",
       "   'Allergic to any of the study drugs',\n",
       "   'History of alcoholism',\n",
       "   'Subjects with mental illness',\n",
       "   'Subjects receiving live vaccines recently',\n",
       "   'Subjects participating in other clinical study within 3 months prior to study entry']},\n",
       " {'nct_id': 'NCT01893996',\n",
       "  'inclusion': ['Subject must be able and willing to give written informed consent and comply with the requirements of the study protocol.',\n",
       "   'Diagnosis of Rheumatoid Arthritis by ACR 1987 or ACR/EULAR 2010 criteria.',\n",
       "   'Low RA disease activity as defined by DAS28 < 3.2',\n",
       "   'No anti-TNF medication or other biologic agent (abatacept, rituximab, or tocilizumab) within the 12 months prior to enrollment.',\n",
       "   'If taking methotrexate, then on a stable dose between 7.5 mg and 25 mg (PO or SQ) weekly for at least 3 months prior to randomization. If on a DMARD other than methotrexate, then that DMARD must be at a stable therapeutic dose for at least 3 months prior to randomization.',\n",
       "   'If taking prednisone, then a stable dose of less than or equal to 10 mg/daily for at least 1 month prior to randomization',\n",
       "   'If NSAID taken on a regular, daily schedule, then patient must be on a stable dose for one week prior to FMD studies. PRN use is excluded within 1 week of FMD studies.',\n",
       "   'Age > 18',\n",
       "   'Subject must be able and willing to self-administer SQ injections or have available qualified person(s) or caregiver to administer SQ injections',\n",
       "   'Negative serum pregnancy test (for women of child bearing age)',\n",
       "   'Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment',\n",
       "   'Adequate renal function as indicated by serum creatinine < 2.0.',\n",
       "   'No use of phosphodiesterase type 5 inhibitors (PDE5) (i.e. sildenafil, tadalafil, and vardenafil) 1 week prior to the study and during the course of the study.'],\n",
       "  'exclusion': ['Use of an anti-TNF or other biologic medication (Including but not limited to abatacept, rituximab, or tocilizumab) within the previous 12 months.',\n",
       "   'Prior history of MI, CVA, CABG, PTCA, or peripheral vascular disease',\n",
       "   'SBP > 140/90 at two months prior to study enrollment',\n",
       "   'Diabetes mellitus requiring insulin therapy',\n",
       "   'The following laboratory parameters at the Screening visit',\n",
       "   'Neutropenia (absolute neutrophil count < 1,500/microliter [ L]);',\n",
       "   'Thrombocytopenia (platelets < 100,000/ L);',\n",
       "   'Anemia (hemoglobin < 8 g/dL);',\n",
       "   'Greater than or equal to 3 times the upper limit of normal (ULN) for either of the following liver function tests (LFTs): aspartate transaminase (AST) or alanine transaminase (ALT);',\n",
       "   'Renal insufficiency (serum creatinine> 2.0 mg/dL)',\n",
       "   'Purified protein derivative (PPD) test of > 5 mm induration regardless of prior BacilleCalmette Guerin vaccine administration or positive QuantiFERON®-TB Gold In-Tube Test (QFT-G_IT) without documentation of completed treatment or evidence of ongoing treatment of latent tuberculosis (TB) for 30 days. Subjects with active TB infection are excluded.',\n",
       "   'History of positive PPD, positive QuantiFERON®-TB Gold In-Tube Test (QFT-G_IT), or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure',\n",
       "   'Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 1 month of randomization',\n",
       "   'Presence of open leg ulcers',\n",
       "   'Chronic or persistent infection including but not limited to human immunodeficiency virus [HIV],hepatitis B, hepatitis C, listeriosis, TB, or other opportunistic infection)',\n",
       "   'Active infection or severe infections requiring hospitalization or treatment with intravenous(IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to randomization, or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to randomization',\n",
       "   'Receipt of a live vaccine within 4 weeks prior to randomization',\n",
       "   'History of malignancy within the past 5 years other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma',\n",
       "   'Any medical condition, such as uncontrolled diabetes with documented history of recurrent infections, unstable ischemic heart disease, known coronary artery disease or known significant cardiac arrhythmias or severe congestive heart failure (New York Heart Association classes III or IV), recent cerebrovascular accidents, severe, progressive or uncontrolled neurological disease, and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol',\n",
       "   'Women of childbearing potential who are sexually active and who do not agree to practiceone of the following methods of contraception during the duration of the study',\n",
       "   'condoms, sponge, foams, jellies, diaphragm or intrauterine device;',\n",
       "   'oral or parenteral contraceptives for 2 months prior to study product administration;',\n",
       "   'a vasectomized partner;',\n",
       "   'abstinence',\n",
       "   'Pregnant (all women of childbearing potential must have a negative serum pregnancy test) or breastfeeding',\n",
       "   'Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization',\n",
       "   'History of drug or alcohol abuse within 6 months prior to randomization',\n",
       "   'Known allergy or hypersensitivity to any study products',\n",
       "   'Any psychiatric disorder that prevents the subject from providing informed consent',\n",
       "   'Inability or unwillingness to follow the protocol',\n",
       "   'Any condition or treatment, which in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the trial',\n",
       "   'Any individual who plans to start or stop or change the dose of lipid lowering medication,antihypertensive medication, NSAIDS, Cox-2 inhibitors, aspirin within 1 month of the study or during the study.']},\n",
       " {'nct_id': 'NCT01698515',\n",
       "  'inclusion': ['Adult patients age 18-75, able to provide written informed consent',\n",
       "   'Diagnosis of RA by 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Criteria',\n",
       "   'Patients will not be required to be taking MTX unless they are being prescribed infliximab or golimumab as per approved indications. If taking background MTX, dose must be stable in 4 weeks and be expected to continue at the same dose for 3 months. Patients taking other nonbiological DMARDS will be excluded (leflunomide, hydroxychloroquine, sulfasalazine)',\n",
       "   'Prednisone greater than or equal to 10 mg/day',\n",
       "   'No prior treatment with a TNF inhibitor or other biological DMARD',\n",
       "   'Starting anti-TNF agents with documented insurance authorization for coverage. The decision to start TNF agent and choice of particular agent will be based on the opinion of the treating rheumatologist.',\n",
       "   'Standard starting dosing of agents will be:',\n",
       "   'Infliximab (Remicade) 3 mg/kg IV; baseline, 2 wk, 6 wk, then q 8 wk',\n",
       "   'Golimumab (Simponi) 50 mg subcutaneous (SC) q month',\n",
       "   'Etanercept (Enbrel) 50 mg SC q week',\n",
       "   'Adalimumab (Humira) 40 mg SC q every other week',\n",
       "   'Certolizumab (Cimzia) 400 mg SC baseline, 2 wk, 4 week, then 200 mg q every other week or 400 mg q month.',\n",
       "   'If it has been decided to use any other dosing regimen than those above, the patient will be excluded from participation.',\n",
       "   'At least 14 teeth in the functional dentition',\n",
       "   'Willing to practice contraception for the duration of the study period (as would be recommended to most patients starting these medications including MTX).',\n",
       "   'Are considered eligible for a TNF inhibitor according to the following tuberculosis (TB) screening criteria:',\n",
       "   'Have no history of latent or active TB prior to screening.',\n",
       "   'Have no signs or symptoms suggestive of active TB upon medical history and/or physical examination.',\n",
       "   'Have had no recent close contact with a person with active',\n",
       "   '- Have a negative (greater than 5mm induration) purified protein derivative (PPD) test within 6 weeks. Patients with a positive PPD will not be allowed to enroll regardless of exposure history or receipt of Bacille Calmette-Guérin (BCG).'],\n",
       "  'exclusion': ['Taking other nonbiological DMARD unless discontinued for at least 1 month: (sulfasalazine, hydroxychloroquine, leflunomide).',\n",
       "   'Used systemic or oral topical antibiotics (inc. tetracyclines) within 30 d of enrollment.',\n",
       "   'Taken phenytoin, cyclosporine, or coumadin within 3 months',\n",
       "   'Known bleeding diathesis or coagulopathy',\n",
       "   'Subjects with valvular heart disease, joint prosthesis, or other condition requiring routine antibiotic prophylaxis for dental procedures will not necessarily be excluded unless they are not willing to receive standard appropriate antibiotic prophylaxis before dental evaluations.',\n",
       "   'No planned elective surgery within 4 months',\n",
       "   'Comorbid condition that in the opinion of the investigator would preclude administration of a TNF inhibitor or the performance of oral examinations',\n",
       "   'History of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidiomycosis prior to screening.',\n",
       "   'History of positive PPD or other TB exclusions noted above.',\n",
       "   'History of persistently indeterminate on repeat exams, Quantiferon TB Gold or other gamma-interferon releasing TB assays.']},\n",
       " {'nct_id': 'NCT01694264',\n",
       "  'inclusion': ['Chronic hepatitis B, inactive HBsAg carriers or anti-HBc antibody positive patients with AST, ALT level equal or lower than 2x ULN',\n",
       "   'Patient who has systemic rheumatic disease for which anti-TNFα treatment indication has been approved by the KFDA; rheumatoid arthritis (RA, 1987 ACR criteria), ankylosing spondylitis (AS, modified New York criteria), psoriatic arthritis (PsA, modified ESSG criteria), and juvenile rheumatoid arthritis (JRA, 1977 ACR criteria).',\n",
       "   'Patient who is eligible to start anti-TNFα treatment (etanercept, infliximab, adalimumab, golimumab, and certolizumab pegol) due to treatment failure of other DMARDs against underlying RA, AS, PsA, or JRA. Patient who also fully understands that anti-TNFα agent expenses are not covered in this study.',\n",
       "   'Patient who is willing and able to comply with the study drug regimen and all other study requirements',\n",
       "   'Patient who is willing and able to provide a written informed consent to participate in the study'],\n",
       "  'exclusion': ['Patient who has liver cirrhosis or a history of hepatocellular carcinoma (HCC) or findings suggestive of HCC, such as suspicious foci or elevated serum alpha fetoprotein (AFP)',\n",
       "   'Patient who received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study',\n",
       "   'Patient who has concomitant other chronic viral infection (HCV or HIV)',\n",
       "   'Patient who is pregnant or breastfeeding or willing to be pregnant',\n",
       "   'A history of chronic infection, recent serious or life-threatening infection. Especially,',\n",
       "   'Patient with current clinical or laboratory evidence of active tuberculosis (TB) or latent TB unless there is documentation of prior anti-TB treatment was appropriate in duration according to the Korea Food and Drug Administration (KFDA) guidelines for management of latent TB in patients being treated with biologic agents',\n",
       "   'Patient with a history of herpes zoster within 2 months before screening for this study',\n",
       "   'Active malignancy or a history of treated malignancy less than 5 years prior to screening',\n",
       "   'Patients who are not cooperative or unable to comply with the study procedures',\n",
       "   \"Patients with any other condition which the investigator's judgment would make the patient unsuitable for inclusion in the study such as alcohol and drug abuse\"]},\n",
       " {'nct_id': 'NCT01691014',\n",
       "  'inclusion': ['Subject fulfils criteria for Rheumatoid Arthritis (RA) according to ACR or EULAR criteria.',\n",
       "   'Subjects who are planned to start treatment with ADA, ETA, CER or IFX',\n",
       "   'Subjects taking a minimum weekly dose of 7.5 mg of methotrexate'],\n",
       "  'exclusion': ['Patients with compliance problems',\n",
       "   'Patients who have difficulties in reading and understanding local language',\n",
       "   'Patients with Juvenile Idiopathic Arthritis (JIA)',\n",
       "   'Azathioprine or cyclophosphamide treatment within 6 months before entering into the study']},\n",
       " {'nct_id': 'NCT01692899',\n",
       "  'inclusion': ['RA defined by the 1987 ACR criteria [18]',\n",
       "   'first TNFα inhibitor prescribed in the previously mentioned period',\n",
       "   'TNFα inhibitor prescribed as first-line biotherapy',\n",
       "   'undergone at least one evaluation in the center after treatment initiation'],\n",
       "  'exclusion': ['previously received another biotherapy',\n",
       "   'TNFα inhibitor was prescribed in an RCT',\n",
       "   'refused to participate']},\n",
       " {'nct_id': 'NCT01694693',\n",
       "  'inclusion': ['Adult outpatients, male or female aged ≥ 18 years old',\n",
       "   'Diagnosed with a rheumatoid arthritis according to ACR criteria',\n",
       "   'Treated with Orencia according to usual practice conditions from June 1st 2007',\n",
       "   'Agreeing to participate'],\n",
       "  'exclusion': ['Patients treated by Orencia in the context of clinical trials']},\n",
       " {'nct_id': 'NCT01697202',\n",
       "  'inclusion': ['Diagnose of RA, age 20-65 years,'],\n",
       "  'exclusion': ['other serious physical or mental illness']},\n",
       " {'nct_id': 'NCT01692457',\n",
       "  'inclusion': ['Have rheumatoid arthritis and exhibit at least four of the following criteria: morning stiffness for at least one hour and present for at least six weeks, swelling of three or more joints for at least six weeks, swelling of wrist, metacarpophalangeal or proximal interphalangeal joints for six or more weeks, symmetrical joint swelling, X-ray changes of hand that include erosions or unequivocal bony decalcification, rheumatoid nodules, serum rheumatoid factor by a method positive in less than 5 percent of normal',\n",
       "   'Have ankylosing spondylitis and must have either of the following: Grade 3-4 sacroiliitis with at least one clinical criterion, Grade 3-4 unilateral sacroiliitis, Grade 2 bilateral sacroiliitis with clinical criterion 1 (limitation of motion of the lumbar spine in all 3 planes: anterior flexion, lateral flexion, extension) or criterion 2 (history of pain in the lumbar spine or at the dorso-lumbar junction) and criterion 3 (limited chest expansion to 2.5 cm or less, measured at the fourth intercostals line)',\n",
       "   'Have psoriatic arthritis and includes 3 of the following conditions: an inflammatory arthritis (peripheral arthritis and/or sacroiliitis or spondylitis), the presence of psoriasis, the (usual) absence of serological tests for rheumatoid factor'],\n",
       "  'exclusion': ['Known hypersensitivity to golimumab or to any of the components of the agent preparation',\n",
       "   'Pregnant or breastfeeding females',\n",
       "   'Not agreeing to protocol-defined use of effective contraception',\n",
       "   'Patients receiving live vaccines while on treatment',\n",
       "   'Patients with documented clinically important, active infection (eg, active tuberculosis infection)',\n",
       "   'Patients with documented past and current history of malignancy and significant cytopenias (reduction in the number of blood cells)']},\n",
       " {'nct_id': 'NCT01745055',\n",
       "  'inclusion': ['Adults diagnosed with moderate to severe RA (Rheumatoid Arthritis)',\n",
       "   'Diagnosis of RA based on the American College of Rheumatology 1987 revised criteria.',\n",
       "   'Treatment with an oral stable weekly dose of Methotrexate (MTX) (15-25 mg/week, administered as a single dose [SD]) for a minimum of 4 doses (4 weeks)'],\n",
       "  'exclusion': ['Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.2 x 109/L; Platelet count <100 x 109/L',\n",
       "   'Evidence or history of clinically significant infections within the past 6 months (eg, those requiring hospitalization, requiring parenteral antimicrobial therapy, or those with recurrent oral or genital herpes, recurrent herpes zoster, or any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the trial.',\n",
       "   'Total bilirubin, AST (aspartate aminotransferase) or ALT (alanine aminotransferase) more than 1.2 times the upper limit of normal at the Screening visit, or a history of clinically significant elevated liver function tests (LFTs) while on current MTX dose or chronic liver disease, recent or active hepatitis.']},\n",
       " {'nct_id': 'NCT01741688',\n",
       "  'inclusion': ['Adults, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria',\n",
       "   'Participants in whom the treating physician has made the decision to commence tocilizumab treatment (in accordance with the local label); this can include participants who have received tocilizumab treatment within 8 weeks prior to the enrollment visit'],\n",
       "  'exclusion': ['Participants who have received tocilizumab more than 8 weeks prior to the enrollment visit',\n",
       "   'Participants who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with tocilizumab',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01741493',\n",
       "  'inclusion': ['Male and female subjects 18 to 55 years of age, inclusive.',\n",
       "   'Subject is judged to be in good general health. Rheumatoid Arthritis Patients:',\n",
       "   'Male and female patients 18 to 75 years of age, inclusive.',\n",
       "   'Subject has a diagnosis of rheumatoid arthritis for at least six months.',\n",
       "   'Subject has been on methotrexate therapy for at least three months and on a stable dose for at least four weeks.'],\n",
       "  'exclusion': ['History or evidence of active or latent tuberculosis.',\n",
       "   'History or significant allergic reaction to any drug.',\n",
       "   'Use of known strong CYP3A and CYP2D6 inhibitors and CYP3A inducers within 21 days or within 5 half-lives of the respective medication, whichever is longer.',\n",
       "   'Current or expected need for oral intake of at least 10 mg prednisone per day or equivalent corticosteroid therapy.',\n",
       "   'History of acute inflammatory joint disease of different origin other than rheumatoid arthritis (rheumatoid arthritis patients).']},\n",
       " {'nct_id': 'NCT01746966',\n",
       "  'inclusion': ['Healthy controls age of 20-60 according to conclusion of preventive medicine department',\n",
       "   'Patients with RA according to ARA 1987 revised criteria and disease activity DAS 3-5'],\n",
       "  'exclusion': ['Past shoulder trauma',\n",
       "   'Shoulder osteoarthritis',\n",
       "   'Rotator cuff disorders',\n",
       "   'Shoulder injections',\n",
       "   'Cervical spondylosis with nerve root compression, Cervical symptomatic disc syndromes']},\n",
       " {'nct_id': 'NCT01742468',\n",
       "  'inclusion': ['Patient has a diagnosis of RA (according to the ACR classification criteria, revised 2010) for at least 6 months prior to randomization.',\n",
       "   'Patient has a moderate disease activity as defined by disease activity score DAS28 ≥ 2.4',\n",
       "   'Patient has the ability to comprehend the full nature and purpose of the study, including possible risks and side effects, to cooperate with the investigator, to understand verbal and written instructions, and to comply with the requirements of the entire study.',\n",
       "   'stable dosis of disease-modifying antirheumatic drugs within 4 weeks prior to randomization and presumably over the study periods (30 weeks).'],\n",
       "  'exclusion': ['Intra-articular corticosteroids within 4 weeks prior to randomization or blood sample taking',\n",
       "   'Patients are permitted to receive either oral or parenteral glucocorticoids equivalent to ≤10 mg daily prednisone and nonsteroidal anti-inflammatory drug, if they have received a stable dose for at least 4 weeks prior to randomization and presumably over the study periods (30 weeks).']},\n",
       " {'nct_id': 'NCT01746680',\n",
       "  'inclusion': ['Male or female aged ≥20years',\n",
       "   'Signed and dated informed consent document indicating that the patient',\n",
       "   'Women of childbearing potential must have a negative serum or urine pregnancy test at the screening visit. Except in the case of surgically sterile or amenorrhea for one year.',\n",
       "   'Female patients must agree to use adequate contraception measures during the period of therapy which should be continued for 4 weeks.',\n",
       "   'have RA and meet all of the following criteria; RA occurring ≥ 3months and less than 15 years and diagnosed based on 1987 ACR classification criteria for rheumatoid arthritis; Active RA patients with MTX and among them who has insufficiency response to DMARDs as defined DAS28>3.2 in active RA patient. Insufficiency response is defined despite MTX therapy for > 12 weeks, RA activity≥ more than moderate and confirmable during 12 weeks, sequence of taking MTX >7.5mg/week for more than 6 weeks; ESR≥28mm/h or CRP≥1.0mg/dl; Tender Joint Counts must be more than 6 and Swollen Joint Counts must be more than 3'],\n",
       "  'exclusion': ['Inflammatory joint diseases, Systematic inflammatory disease',\n",
       "   'Prosthesis and had an event of infected in',\n",
       "   '- Medical history of chronic infection, moderate infection or possibly to life threatening or signs and symptoms of serious infection.',\n",
       "   'Patients have received treatment with a live vaccine from baseline within 8 weeks.',\n",
       "   'HBsAg positive and hepatitis C virus positive patient.',\n",
       "   'Patients have a history of malignancy. (But, carcinoma in situ of the uterine cervix or basal cell carcinoma have been treated is allowed within 5years)',\n",
       "   'Patients have cardiovascular disease or associated disease which is not controlled.',\n",
       "   'uncontrollable blood sugar(HbA1C ≥8%) or required insulin.',\n",
       "   'Patients with a history of operation on index knee joint which could have influence on the result and need to have surgery as determined by investigator.',\n",
       "   'At screening, patients have laboratory result as defined by ; white blood cell(WBC) < 3,500/mm3, Absolute Neutrophil Count(ANC) < 1,500/mm3, Hemoglobin < 8.5g/dl, Platelet count(PLT) < 100,000/mm3, Serum creatinine >1.5*upper limit of normal or 2mg/dl, Total bilirubin > 2*upper limit of normal, aspartate aminotransferase(AST) > 2*upper limit of normal, alanine aminotransferase(ALT) > 2*upper limit of normal, alkaline phosphatase(ALP) > 2*upper limit of normal',\n",
       "   'Patients on any other clinical trial or experimental treatment in the past 8weeks',\n",
       "   \"An impossible one who participates in clinical trial by investigator's decision\"]},\n",
       " {'nct_id': 'NCT01951170',\n",
       "  'inclusion': ['Adult patients at least 18 years of age',\n",
       "   'Patients with a diagnosis of active moderate to severe rheumatoid arthritis (RA)',\n",
       "   'Oral corticosteroids and nonsteroidal anti-inflammatory are permitted if on a stable dose regimen for >/= 4 weeks prior baseline',\n",
       "   'Permitted non-biologic disease-modifying anti-rheumatic drugs (DMARDs) used alone or in combination are allowed if at a stable dose for at least 4 weeks prior to baseline',\n",
       "   'Receiving treatment on an outpatient basis, not including tocilizumab',\n",
       "   'Females of childbearing potential and males with female partners of childbearing potential may participate in this study only if using a reliable means of contraception for at least 5 months following the last dose tocilizumab',\n",
       "   'Previous or current treatment with methotrexate with an inadequate response to methotrexate, intolerance to methotrexate or treatment with methotrexate was considered as inappropriate',\n",
       "   'Evidence of one or more erosions in hands or feet assessed by X-ray attributable to RA or magnetic resonance imaging (MRI) of wrist of metacarpophalangeal (MCP) joints of dominant hand'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16',\n",
       "   'Prior history of current inflammatory joint disease other than RA',\n",
       "   'Exposure to tocilizumab at any time prior to baseline',\n",
       "   'Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of screening',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'Treatment with intravenous (IV) gamma globulin, plasmapheresis within 6 months of baseline',\n",
       "   'Intraarticular (IA) or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation',\n",
       "   'Treatment with 2 or more anti-tumor necrosis factor (TNF) agents or any other biologic agent at any time prior to screening',\n",
       "   'Evidence of serious uncontrolled concomitant disease (e.g., cardiovascular, nervous system, pulmonary)',\n",
       "   \"History of diverticulitis, diverticulosis requiring antibiotic treatment, or chromic ulcerative lower gastrointestinal (GI) disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower genitourinary (GU) conditions that might predispose to perforation\",\n",
       "   'Known active current or history of recurrent infections']},\n",
       " {'nct_id': 'NCT01952509',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment (in accordance with the local label); this can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Patients who have received treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'Patients with a history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01955603',\n",
       "  'inclusion': ['Male or female, age between 18 and 75 years (both years inclusive), for Russia only: Age between 18-65 years (both years inclusive)',\n",
       "   'Moderate to severe RA, confirmed by a Disease Activity Score based on 28 joints and C-reactive protein (DAS28 (CRP)) equal to or above 4.5 and a minimum of five tender and five swollen joints based on a 28 joint count (a joint can score as both tender and swollen)',\n",
       "   'MTX (10-25 mg/week both inclusive) for at least 16 weeks, with an unchanged dose for at least 6 weeks prior to screening and until randomisation',\n",
       "   'Females who are not of child-bearing potential must have been post-menopausal for at least 1 year confirmed by follicle-stimulating hormone (FSH) equal to or above 26.7 U/L or be surgically sterile'],\n",
       "  'exclusion': ['Past or current inflammatory joint disease other than RA (e.g. gout [crystal proven], psoriatic arthritis, juvenile idiopathic arthritis, reactive arthritis or Lyme disease',\n",
       "   'Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) within 4 weeks prior to randomisation',\n",
       "   'Clinically significant cardiac or cardiovascular disease',\n",
       "   'Past or current malignancy',\n",
       "   'Evaluation of tuberculosis screening indicative of latent or active tuberculosis (TB)']},\n",
       " {'nct_id': 'NCT01954381',\n",
       "  'inclusion': ['Patients over the age of 18 years',\n",
       "   'Patients with RA according to ACR 1987 criteria',\n",
       "   'Indication for adalimumab therapy, according to guidelines:',\n",
       "   'moderately to severely active RA, when the response to disease-modifying anti-rheumatic drugs, including methotrexate, is inadequate,and,severe, active and active RA in adults not previously treated with methotrexate.'],\n",
       "  'exclusion': ['Minors, pregnant women, not adequate contraception if female with childbearing potential, majors under guardianship, residents of social welfare or health care establishments, patients presenting an emergency situation, patients not covered by French social security, subjects deprived of their freedom and patients refusing to participate in the clinical research.',\n",
       "   'Absence of informed consent',\n",
       "   'Patients who have previously received anti-TNF therapy',\n",
       "   'Renal failure',\n",
       "   'History of demyelinising disease',\n",
       "   'Any unstable medical condition',\n",
       "   'Patients with recurrent serious infections',\n",
       "   'History of cardiovascular or cerebrovascular disease',\n",
       "   'History of cancer',\n",
       "   'Patients not having TB prophylaxis as per guidelines for latent TB, or patients non-treated active tuberculosis',\n",
       "   'Contraindication to adalimumab therapy:',\n",
       "   'Hypersensitivity to adalimumab or one of the excipients.',\n",
       "   'Active tuberculosis or other severe infections such as sepsis and opportunistic infections',\n",
       "   'Moderate to severe heart failure .']},\n",
       " {'nct_id': 'NCT01927263',\n",
       "  'inclusion': ['Patients with a diagnosis of RA as defined by the American College Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria (ACR/EULAR 2010)',\n",
       "   'Patients who received MTX treatment (6- 16mg/week) for 2 weeks for at least 12 weeks prior to the screening visit'],\n",
       "  'exclusion': ['Patients with a following past History or concomitant diseases',\n",
       "   'Other Connective tissue disorders which may interfere the efficacy assessment',\n",
       "   'Chronic or recurrent infectious disease',\n",
       "   'Demyelinating disease',\n",
       "   'Congestive heart failure',\n",
       "   'lymphoproliferative disorder or myelodysplastic syndrome',\n",
       "   'Malignancy',\n",
       "   'Interstitial lung disease',\n",
       "   'Patients with active or latent tuberculosis or history of tuberculosis']},\n",
       " {'nct_id': 'NCT01921309',\n",
       "  'inclusion': ['preoperative Harris Hip Score of ≤',\n",
       "   '2. preoperative Harris Hip Total Pain score of at least moderate.',\n",
       "   'diagnosed with non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis, rheumatoid arthritis, correction of functional deformity, developmental hip dysplasia (DDH) and congenital hip dysplasia (CDH).',\n",
       "   'pain rating of none or slight and are at least 12 months post-operative in the contralateral hip, if applicable.',\n",
       "   'have sufficient femoral and acetabular bone stock as determined by a clinician, and are suitable to receive implants as confirmed by x-rays.'],\n",
       "  'exclusion': ['have a nutritional problem (protein, calorie, or vitamin/mineral deficiency) that may impair wound healing mechanisms as determined by the clinician /investigator.',\n",
       "   'have a neurological disorders which may interfere or adversely affect gait, balance, or weight bearing (e.g. muscular dystrophy, multiple sclerosis).',\n",
       "   'diagnosed with metabolic disorders (e.g. osteomalacia), which may impair bone metabolism.',\n",
       "   \"diagnosed systemic disease that would affect their welfare or the overall outcome of study (i.e. Paget's disease, renal osteodystrophy)\",\n",
       "   'immunologically suppressed.',\n",
       "   'receiving systemic steroid therapy, excluding inhalers, within 3 months prior to surgery.',\n",
       "   \"diagnosed Charcot's disease, metastatic or neoplastic disease.\",\n",
       "   'evidence of active infections that may spread to other areas of the body (e.g. osteomyelitis, pyogenic infection of the hip joint, overt infection, untreated urinary tract infection, etc.).',\n",
       "   'presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.',\n",
       "   'previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.',\n",
       "   'diagnosed with systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatoid arthritis or other diagnoses with autoimmune etiology.',\n",
       "   'diagnosed with osteoporosis or as evidenced on a DEXA scan for males over 75 or females over 65 years of age (within the last 12 months).',\n",
       "   'require structural bone grafts in order to support the prosthetic component(s) or to shape the bone to receive the implant(s).',\n",
       "   'have acute femoral neck fracture or hip fractures.',\n",
       "   'have an above the knee amputation of the contralateral and/or ipsilateral leg.',\n",
       "   'have an existing total hip arthroplasty in the contralateral hip with a pain rating of 3 or more on a scale of 0 to 10, where 0 is \"no pain\" and 10 is \"severe pain\".',\n",
       "   'have had a total hip arthroplasty in the contralateral hip within the past 12 months.',\n",
       "   'have previously received a metal-on-metal hip arthroplasty.',\n",
       "   'have a highly communicable disease or diseases that may limit follow-up (e.g. immunocompromised conditions, hepatitis, active tuberculosis, etc.).',\n",
       "   'have any known sensitivity to device material.',\n",
       "   'Females who are pregnant.',\n",
       "   'Patients who are prisoners.']},\n",
       " {'nct_id': 'NCT01921478',\n",
       "  'inclusion': ['Adult patients, >=18 years of age',\n",
       "   'Diagnosed with rheumatoid arthritis and moderate to severe disease activity defined as a DAS28 >=5.1',\n",
       "   'Inadequate responder to at least 2 non-biological DMARDs',\n",
       "   'Absence of documented erosions at start of RoActemra/Actemra treatment',\n",
       "   'Received RoActemra/Actemra treatment for at least 6 months',\n",
       "   'Availability of data from at least the RoActemra/Actemra treatment initiation visit and the 6 months visit'],\n",
       "  'exclusion': ['Contraindications for treatment with RoActemra/Actemra']},\n",
       " {'nct_id': 'NCT01927757',\n",
       "  'inclusion': ['Able to provide informed consent',\n",
       "   'Diagnosed with moderate to severe rheumatoid arthritis for at least 6 months',\n",
       "   'Active RA with at least 3 swollen and tender joints',\n",
       "   'Failure to respond to a combination treatment of adalimumab and methotrexate (must have taken combination at least 3 months) or loss of a satisfactory response to the combination of adalimumab and methotrexate, which was taken for at least 6 months (if currently taking adalimumab must complete 2 weeks without it prior to starting study drug)',\n",
       "   'Negative for hepatitis B and C',\n",
       "   'Negative serum and urine pregnancy tests before starting study',\n",
       "   'currently taking (stable dose) 15 mg methotrexate weekly for at least 8 weeks/has been taking methotrexate for at least 12 weeks total',\n",
       "   'lower dose of 10 mg per week is permitted with documented intolerability',\n",
       "   'Normal chest X-ray within 3 months',\n",
       "   'Negative testing for tuberculosis (TB) Exclusion Criteria:',\n",
       "   'Class IV RA (wheel-chair or bed-bound)',\n",
       "   'Significant concurrent medical conditions, including: (uncontrolled type 1 diabetes, poorly controlled type 2 diabetes, symptomatic heart failure, myocardial infarction in past year, history of unstable angina within past year, uncontrolled hypertension, severe chronic pulmonary disease, major chronic inflammatory or connective tissue disease other than RA, Multiple sclerosis, active malignancy, or history of cancer, alcoholic hepatitis or history of alcoholic liver disease)',\n",
       "   'Other inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01925157',\n",
       "  'inclusion': ['Males or non-pregnant females age 18 to 65 years',\n",
       "   'Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m^2) Inclusion Criteria for Participants for RA:',\n",
       "   'Diagnosis of at least mildly active adult-onset RA',\n",
       "   'Positive anti-citrullinated protein (ACPA) antibodies or rheumatoid factor',\n",
       "   'Regular use of MTX for at least 12 weeks and at a stable dose (10 to 25 mg/week) for at least 4 weeks prior to baseline',\n",
       "   'American College of Rheumatology (ACR) Functional Class I, II or III Exclusion Criteria for Healthy Participants:',\n",
       "   'Have received biologic agents within 3 months or 5 half-lives',\n",
       "   'Have surgery within 12 weeks prior to screening',\n",
       "   'Known history of human immunodeficiency virus (HIV infection and/or positive human HIV antibodies)',\n",
       "   'Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus',\n",
       "   'Have evidence of active infection or fever',\n",
       "   'Have donated greater than 500 mL blood within 30 days prior to screening',\n",
       "   'Smoke greater than 10 cigarettes/day or equivalent',\n",
       "   'Have received live vaccine within 1 month of screening',\n",
       "   'Have a history of allergy to monoclonal antibodies or severe drug allergies'],\n",
       "  'exclusion': ['Have received prior or current treatment with biologic RA therapies',\n",
       "   'Have received a live vaccine 28 days prior to screening or intend to receive a live vaccine during the course of the study',\n",
       "   'Hemoglobin < 10 grams per deciliter (g/dL), platelet count < 100,000 cells/microliter (uL), total white blood cell count < 3000 cells/uL, neutrophil count < 2000 cells/uL, or lymphocyte count < 500 cells/uL',\n",
       "   'Aspartate transaminase (AST) > 1.5 x upper limit or the normal range (ULN), alanine transamine (ALT) > 1.5 x ULN, creatinine > 1.5 mg/dL (114 micromoles/liter [uMol/L])',\n",
       "   'Treatment with > 10 mg/day or unstable dose of oral prednisone or equivalent within 28 days of baseline',\n",
       "   'Have required an increase in dose or a new prescription of narcotic within 28 days prior to randomization',\n",
       "   'Have received any parenteral corticosteroids within 28 days before screening',\n",
       "   'Treatment with any oral disease-modifying anti-rheumatic drugs (DMARDs) other than MTX within 4 weeks prior to baseline',\n",
       "   'Any neurological, psychiatric, vascular, or system disorder that could also affect the evaluation of disease activity assessments. Anemia of chronic disease is allowed if hemoglobin > 10 g/dL',\n",
       "   'Have rheumatic or systemic autoimmune disease other than RA or significant active systemic involvement secondary to',\n",
       "   \"Participants with secondary Sjogren's syndrome are eligible.\",\n",
       "   'Uncontrolled arterial hypertension characterized by a confirmed systolic blood pressure of > 150 mm Hg or diastolic blood pressure > 90 mm Hg at screening or on day of study drug dosing',\n",
       "   'Poorly controlled diabetes as defined by glycosylated hemoglobin (HbA1c) > 8.0% at screening',\n",
       "   'Known history of human immunodeficiency virus (HIV infection and/or positive human HIV antibodies)',\n",
       "   'Have evidence of, or test positive for, hepatitis C virus or hepatitis B virus']},\n",
       " {'nct_id': 'NCT01442545',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis Functional Class I-III according to the American College of Rheumatology criteria for at least 3 months prior to Screening',\n",
       "   'Have been treated with and tolerated oral methotrexate (taken by mouth) for a minimum of 3 months prior to screening, and must have been on a stable once-weekly methotrexate dose (taken as a single dose) between 7.5 and 25 mg/week for a minimum of 1 month prior to Day 1',\n",
       "   'Participants may continue on stable nonsteroidal anti-inflammatory drug (NSAID) and/or corticosteroid background therapy for rheumatoid arthritis (RA) or stable therapies for other conditions as prescribed by physician, providing that the doses of such therapy are stable for at least 1 month prior to screening and will remain unchanged for the entire study duration',\n",
       "   'Medically stable on the basis of physical examination, medical history, vital signs, and electrocardiogram (ECG) performed at screening',\n",
       "   'Laboratory values within certain limits at screening and Day-1. Abnormalities consistent with those observed in patients with RA are permissible.'],\n",
       "  'exclusion': ['History of or current clinically significant medical illness as specified on the protocol, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results',\n",
       "   'Have been treated with a monoclonal antibody for RA in the 3 months prior to enrollment or have had a serious infection within 2 weeks of the study treatment period',\n",
       "   'Except for methotrexate, treated with approved or investigational non-biologic disease-modifying antirheumatic drugs (DMARDs) during the 4 weeks or 5 half-lives prior to the first dose of JNJ-39758979, whichever is longer. These agents include, but are not limited to D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold salts, sulfasalazine, leflunomide, azathioprine, cyclosporine, tacrolimus and mycophenolate mofetil.']},\n",
       " {'nct_id': 'NCT01443364',\n",
       "  'inclusion': ['diagnosis of adult-onset Rheumatoid Arthritis (RA) for a duration of at least 6 months but not longer than 5 years',\n",
       "   'positive Rheumatoid Factor (RF) and/or positive anti Cyclic Citrullinated Peptide (anti-CCP)',\n",
       "   'active RA disease',\n",
       "   'subjects must have failed at least one traditional Disease Modifying Anti-Rheumatic Drug (DMARD).',\n",
       "   'subject is naïve to RA related biologics'],\n",
       "  'exclusion': ['a diagnosis of any other inflammatory arthritis',\n",
       "   'history of infected joint prosthesis, or other significant infection',\n",
       "   'known Tuberculosis (TB) disease or high risk of acquiring TB infection']},\n",
       " {'nct_id': 'NCT01405326',\n",
       "  'inclusion': ['Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) criteria',\n",
       "   'Time from diagnosis of RA < 2 years',\n",
       "   'Age 25-55 years',\n",
       "   'Active RA with at least 3 active joints (tender and/or swollen joints)',\n",
       "   'Stable DMARD combination treatment for more than 3 months',\n",
       "   'At least one of the following',\n",
       "   'Rheumatoid factor positive',\n",
       "   'One or more erosions in x-rays of the hands and feet',\n",
       "   'Anti-citrulline antibodies positive',\n",
       "   'At least other of the following',\n",
       "   'HAQ-index 0.5 or more',\n",
       "   'Patient or physician evaluation of RA activity >25 mm (VAS 0-10 cm)',\n",
       "   'Patient has been steadily in work-life for at least one year and is currently working or on sick- leave but not applying for pension',\n",
       "   'Patient feels that he/she will likely have to be off-work during the following 6 months due to his/her RA',\n",
       "   'Patient must be willing and able to provide written informed consent for the trial',\n",
       "   'Each female subject must agree to use a medically accepted method of contraception while receiving study medication'],\n",
       "  'exclusion': ['A subject must not have a history of biological drug use for RA',\n",
       "   'A subject must not have evidence of active or latent tuberculosis,',\n",
       "   'A subject must not have any history of lymphoproliferative disease or malignancy within the previous 5 years',\n",
       "   \"A subject must not have any other condition, that according to the investigator's judgment makes him or her non-eligible for anti-TNF use\",\n",
       "   'A subject must not have any inflammatory rheumatic disease other than RA',\n",
       "   'A subject must not have received any other investigational agents within 30 days prior to baseline visit, and must not receive them during the current trial',\n",
       "   'A female subject must not be pregnant or breast-feeding or planning pregnancy during the study',\n",
       "   'A subject must not have had a major surgery within one month prior to study entry and must not have a scheduled operation during the 6-month follow up',\n",
       "   'A subject must not have any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the optimal participation in the trial.',\n",
       "   'A subject must not fulfill the criteria for reimbursement for biologics for RA and he/she would not normally be prescribed a biological drug according to physicians discretion and national treatment guidelines',\n",
       "   'A patient must not be currently on reimbursed rehabilitation period, or such period must not be scheduled for the next six months']},\n",
       " {'nct_id': 'NCT01408602',\n",
       "  'inclusion': ['Is 18 years of age',\n",
       "   'Is diagnosed with moderate to severe adult onset RA > = 6 months duration, as defined by the 1987 ACR classification criteria',\n",
       "   'Has moderate to severe RA as defined by:',\n",
       "   '≥4 tender joints/painful (28 joint count) at screening',\n",
       "   '≥4 swollen joints (28 joint count) at screening',\n",
       "   'Has a Health Assessment Questionnaire (HAQ) of >0',\n",
       "   'Has a physician global assessment (Likert scale) of >0',\n",
       "   'Has a patient global assessment of pain (Likert scale) of >0',\n",
       "   'Has a patient assessment of pain (Likert scale) of >0',\n",
       "   'Has stable doses of the following allowable medications during the study, if applicable:',\n",
       "   'Stable dose of NSAIDs or other analgesics for at least 2 weeks prior to administration of study drug at regulatory approved doses',\n",
       "   'Stable dose of methotrexate 7.5 mg to 25 mg/day once weekly for at least 6 weeks prior to administration of study drug (no changes in dosing regimen for 4 weeks prior to screening)',\n",
       "   'Stable dose of hydroxychloroquine either monotherapy or in combination with methotrexate 8 weeks prior to administration of study drug',\n",
       "   'Is a non-pregnant, non-lactating female who is postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months natural spontaneous amenorrhea',\n",
       "   'If female of childbearing potential, must agree to use one of the following acceptable birth control methods:',\n",
       "   'Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to screening, hysterectomy, or bilateral oophorectomy);',\n",
       "   'Intrauterine device (IUD) in place for at least 3 months prior to first dose of study drug;',\n",
       "   'Abstinence (not having sexual intercourse);',\n",
       "   'Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion;',\n",
       "   'Stable hormonal contraceptive for at least 3 months prior to study and through study completion',\n",
       "   'If female of childbearing potential, has a negative serum hCG pregnancy test at screening',\n",
       "   'Is able to swallow whole tablets of orally administered medication',\n",
       "   'Is able to understand and provide signed informed consent.'],\n",
       "  'exclusion': ['Has been diagnosed with any other inflammatory arthritis (eg, psoriatic arthritis)',\n",
       "   'Has a secondary type of arthritis (eg, osteoarthritis) that would interfere with study evaluations',\n",
       "   'Has taken the following drugs within the timeframe specified below:',\n",
       "   'Infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab)',\n",
       "   'Within 12 weeks prior to the administration of study drug;',\n",
       "   'Rituximab',\n",
       "   'Within 12 months prior to the administration of study drug;',\n",
       "   'Disease-modifying antirheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above including but not limited to: sulfasalazine, gold, leflunomide, penicillamine, dapsone, azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil',\n",
       "   'Within 12 weeks prior to the administration of study drug;',\n",
       "   'Any steroids (glucocorticoids); glucocorticoids must be discontinued for at least 4 weeks prior to administration of study drug. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to administration of study drug.',\n",
       "   'Note: Use of probiotics is allowed and is NOT an exclusion criterion.',\n",
       "   'Has a uncontrolled symptoms of fibromyalgia with sufficient symptoms requiring treatment (NOTE: patients on a stable dose of treatment for symptoms of fibromyalgia ≥ 4 weeks will be allowed in the study.)',\n",
       "   'Has a history of allergic reaction to tetracycline or other related drugs',\n",
       "   'Had major surgery or trauma within 28 days prior to screening',\n",
       "   'Is concurrently using minocycline or doxycycline (washout of 4 weeks required before the administration of study drug)',\n",
       "   'Patients who are on chronic antibiotics or who are on antibiotics for GI infections (such as Clostridium difficile)',\n",
       "   'Has clinically significant ECG abnormalities',\n",
       "   'Has any clinically significant abnormal laboratory test results found during medical screening including: AST or ALT > 2 x upper limit of normal or serum creatinine > 2.0 mg/dL',\n",
       "   'Has clinically significant history or presence of any gastrointestinal pathology (eg, chronic diarrhea, inflammatory bowel disease, acute diverticulitis), irritable bowel syndrome, unresolved gastrointestinal symptoms (eg. diarrhea, vomiting, symptoms of acute diverticulitis), liver or kidney disease, gastric bypass, gastric stapling, use of Lap-Band®, or other conditions known to or which might interfere with the absorption, distribution, metabolism, or excretion of the drug',\n",
       "   'Has any historical or active neurological, endocrine, cardiovascular, pulmonary, hematological, psychiatric, or metabolic disease that is considered clinically significant by the Investigator',\n",
       "   'Has known history of HIV, hepatitis B or C (patients that have positive hepatitis B serology due to prior vaccination will be allowed in the study)',\n",
       "   'Has an active malignancy of any type or history of malignancy. Patients who have a history of a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma (ie. non melanoma skin cancer)and/or localized carcinoma in situ of the cervix are eligible. Patients with a history of other malignancies that have been treated and who have no evidence of recurrence for at least 5 years before study enrollment are also eligible.',\n",
       "   'Has difficulty swallowing tablets',\n",
       "   'Is ACR Functional Class IV (limited ability to perform usual self-care, vocational, and avocational activities)',\n",
       "   'Has known or suspected pregnancy, planned pregnancy, or lactation (for female patients)',\n",
       "   'Has clinically significant mental illness (to be determined by the Investigator)',\n",
       "   'Has a history in the last 2 years or current evidence of abuse of illicit drugs, prescription medications, or alcohol that, in the opinion of the Investigator, would interfere with adherence to study requirements. Has exposure to any investigational agent within 30 days prior to study entry.',\n",
       "   'Was previously enrolled in this study',\n",
       "   'Has recent history of bacterial intestinal tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)',\n",
       "   'Has a condition the Investigator believes would interfere with the ability to provide informed consent or comply with study instructions, or that might confound the interpretation of the study results or put the patient at undue risk']},\n",
       " {'nct_id': 'NCT01402661',\n",
       "  'inclusion': ['Be at least 18 years of age or older.',\n",
       "   'Be able and willing to provide written consent for participation in the registry as well as Personally Identifiable Information (PII) that includes Full Name and Date of Birth at a minimum.',\n",
       "   'Have been diagnosed with rheumatoid arthritis by a rheumatologist.',\n",
       "   'Meet at least one of the following criteria: (A) Currently receiving an Eligible Medication** that was started within 365 days of the Enrollment Visit.',\n",
       "   'A temporary interruption of an Eligible Medication is allowed if the interruption in treatment lasted <180 days. (B) Prescribed or receiving the first dose of an Eligible Medication** on the day of the Enrollment Visit. (C) Diagnosed with RA within 365 days of the Enrollment Visit regardless of treatment regimen (\"Early RA\").'],\n",
       "  'exclusion': ['Have a diagnosis of Juvenile idiopathic arthritis (JIA), Psoriatic arthritis (PsA), Spondyloarthritis (SpA), Ankylosing spondylitis (AS), Systemic lupus erythematosus (SLE), or any other form of autoimmune inflammatory arthritis.',\n",
       "   'Be starting only a non-eligible medication, unless the patient was diagnosed with RA within 365 days of the Enrollment Visit. Non-eligible medications include conventional DMARDs',\n",
       "   'for example methotrexate, sulfasalazine, leflunomide, etc.',\n",
       "   'and including prednisone.',\n",
       "   'Be participating in or planning to participate in a double-blind randomized clinical trial of an RA drug. Of note, concurrent participation in another observational registry or open-label Phase 3b/4 trial is not excluded. Early Follow-Up Visit Criteria To be eligible for an early Corrona Follow-Up Visit that is conducted <150 days since the last registry visit, the following conditions must be met:',\n",
       "   'A follow-up set of questionnaires should always be completed whenever a registry subject is being prescribed or receiving the first dose of a new (different) Eligible Medication** at a routine office visit. If this occurs less than 150 days from the previous visit at which Corrona questionnaires had been completed, it is considered an \"Early Follow-Up Visit.\" The next anticipated visit that follow-up questionnaires would be completed would be calculated off the Early Follow-up Visit date (=>150 days). Prior use of an Eligible Medication** does not exclude a patient from an Early Follow-Up visit.',\n",
       "   'Eligible Medications are biologics, biosimilars, and JAK-inhibitors FDA-approved for the treatment of',\n",
       "   'Prior use of an Eligible Medication does not exclude a patient from enrollment']},\n",
       " {'nct_id': 'NCT01400516',\n",
       "  'inclusion': ['RA will be defined according to the 2010 American College of Rheumatology/European League Against Rheumatism diagnostic and classification criteria.',\n",
       "   'Osteopenic bone mineral density will be defined as a t-score between -1.0 and -2.5 on either a DXA of the posteroanterior (PA) or lateral lumbar spine or the femoral neck or total hip. Potential subjects with prior minimal trauma fractures will be excluded. 2.Subjects must be able to give written informed consent.'],\n",
       "  'exclusion': ['A switch in DMARD in the last 3 months;',\n",
       "   'Current use of chronic oral glucocorticoids > 5 milligrams per day;',\n",
       "   'A prior history of intolerance to teriparatide;',\n",
       "   'T-score < -2.5 or a prior minimal trauma fracture;',\n",
       "   'Use of a bone active agent for over 2 weeks in the last 12 months (these agents include oral and intravenous bisphosphonates, hormone replacement therapy, calcitonin, raloxifene, teriparatide, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU/day or anticonvulsants);',\n",
       "   'History of significant cardiac, hepatic, current alcohol abuse, or major psychiatric disorders;',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematologic malignancies and solid tumors, except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years;',\n",
       "   \"No current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, or Paget's disease. All participants will be required to have normal serum levels of 25-OH vitamin D (> 20 ng/ml), intact PTH, and thyroid stimulating hormone (TSH). If PTH and/or 25-hydroxy vitamin D (25-OH D) levels are abnormal, subjects may be given calcium and/or multivitamin supplements and be re-tested in 2-12 weeks;\",\n",
       "   'Serum calcium (Ca) > 10.6 mg/dl,and 24-hour urine calcium > 400',\n",
       "   'If minor abnormalities are detected in any of these parameters, the test may be repeated;',\n",
       "   'Patients who have had external beam radiation; and',\n",
       "   'Patients currently on digoxin.',\n",
       "   'Women that are currently pregnant or breast-feeding or plan on becoming pregnant over the course of participation in the study']},\n",
       " {'nct_id': 'NCT01404585',\n",
       "  'inclusion': ['Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening',\n",
       "   'Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects must have clinical evidence of synovitis in one hand/wrist at screening',\n",
       "   'Serum C-reactive protein (hsCRP) above upper limits of normal at screening',\n",
       "   \"Subjects must have been treated with and tolerated Methotrexate (MTX) therapy at a weekly oral or parenteral dose ≥ 10 mg for ≥ 4 months prior to screening. Dose must be stable, with no change in route of administration, for ≥ 6 weeks prior to randomization. A MTX weekly dose as low as 7.5 mg is permitted if intolerance to doses ≥10 mg has been documented in the subject's medical history\",\n",
       "   'Subjects must be receiving folic acid, folinic acid, or leucovorin supplementation at a stable dose for at least 4 weeks prior to randomization',\n",
       "   'Subjects who were previously treated with up to two tumor necrosis factor α (TNF-α) inhibitors',\n",
       "   'If taking antimalarials (e.g. hydroxychloroquine or chloroquine), subject must have been on a stable dose for ≥ 4 months prior to randomization',\n",
       "   'If taking non-steroidal anti-inflammatory drugs (NSAIDs), subjects must have been on stable doses for ≥ 2 weeks prior to randomization',\n",
       "   'If taking oral corticosteroids, daily doses must be ≤ 10 mg/day of prednisone or equivalent and stable for ≥ 4 weeks before randomization',\n",
       "   'Subject is willing to participate to the study and has signed the informed consent prior to undergoing any screening procedures',\n",
       "   'Women of childbearing potential (WOCBP) and men must agree to use at least two acceptable methods to avoid pregnancy for the entire study period and until 60 days (for women) and 90 days (for men) after the last dose of BMS-817399. WOCBP must have a negative urine pregnancy test at screening, randomization and at scheduled visits throughout the study'],\n",
       "  'exclusion': ['Arthritis onset prior to 16 years of age or subjects with documented juvenile RA',\n",
       "   'Subjects who are bed- or wheelchair-bound',\n",
       "   'Subjects with other autoimmune diseases or arthritis syndromes',\n",
       "   'Women who are pregnant, breastfeeding or with a positive pregnancy test at screening or prior to randomization',\n",
       "   'Subjects who have any condition that could impact upon the absorption of study drug (i.e., gastric stapling, duodenal surgery, malabsorption syndrome)',\n",
       "   'Subjects with a history of, or a concurrent severe, progressive, or uncontrolled disease (other than RA) that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study',\n",
       "   'Subjects who have present or previous (last 5 years) malignancies, except history of cured squamous or basal skin cell carcinoma or cured breast or cervical cancer',\n",
       "   'Subjects at risk for tuberculosis (TB) or with evidence of TB clinical history, chest X rays or tuberculin skin test',\n",
       "   'Subjects with evidence of active or latent bacterial or viral infections (including human immunodeficiency virus); Positive blood screen for hepatitis B surface antigen or hepatitis C antibody',\n",
       "   'Subjects with any serious bacterial infection within the last 2 months, unless treated and resolved with antibiotics',\n",
       "   'Subjects who have clinically significant drug or alcohol abuse or known cirrhosis including alcoholic cirrhosis',\n",
       "   'If a subject has received any of the following treatments, the indicated washout period prior to randomization must be followed:',\n",
       "   'Oral or injectable azathioprine, gold, D-Penicillamine, cyclosporine, anakinra, etanercept, parenteral or intra-articular corticosteroids: 30 days',\n",
       "   'Leflunomide: 6 months unless an active washout with Cholestyramine has been performed',\n",
       "   'Mycophenolate mofetil, cyclophosphamide, tacrolimus or other immunosuppressant: 3 months',\n",
       "   'Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Abatacept or Tocilizumab: 60 days',\n",
       "   'Rituximab or any B-cell depleting agent: 1 year',\n",
       "   'Use CYP3A4 inhibitors or inducers during the study',\n",
       "   'Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x upper limit of normal (ULN), total bilirubin ≥ 1.4x ULN, estimated glomerular filtration rate (GFR) < 50 mL/min/1.73m2, hemoglobin < 10.0 g/dL, white blood cell count < 3,500/mm3, absolute neutrophil count < 1,700/mm3 or platelets < 125,000/mm3']},\n",
       " {'nct_id': 'NCT01407419',\n",
       "  'inclusion': ['Patients eligible for the study will be both male and female adult (at least 18 years of age) patients who have a documented diagnosis of RA, are enrolled or willing to be enrolled in the CORRONA registry for the duration of the trial, have signed appropriate informed consent documents, are willing to participate in the trial, are medically appropriate for participation in the opinion of the investigator, and have moderate to severe RA disease activity as defined by CDAI >10.'],\n",
       "  'exclusion': ['Patients under the age of 18',\n",
       "   'Women who are pregnant, breastfeeding or planning to become pregnant during the study period.',\n",
       "   'Patients with chronic or acute pain condition(s) other than active RA which, in the opinion of the investigator, is likely to confound or interfere with assessments of RA disease activity.',\n",
       "   'Functional class IV as defined by the ACR classification of functional status',\n",
       "   'Patients receiving a daily dose of prednisone of >10 mg within the 4 weeks prior to enrollment.',\n",
       "   'History of positive tuberculin skin test or equivalents that have not received documented treatment for latent tuberculosis (TB).',\n",
       "   'Patients with a significant, uncontrolled concomitant illness such as, but not limited to cardiovascular, renal, neurological, endocrinological, gastrointestinal, hepatic, metabolic, pulmonary or lymphatic disease.']},\n",
       " {'nct_id': 'NCT01404429',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis fulfilling the ACR 1987 criteria',\n",
       "   'Between 18 years to 65 year of age',\n",
       "   'Having active disease Disease activity score (28 joints) DAS28-3 more than 5.1',\n",
       "   'Not on methotrexate in the last 2 months',\n",
       "   'Permitted to be on corticosteroids if the dosages stable for at least 1 weeks before randomization and if corticosteroid dosage less than 10 mg/day',\n",
       "   'Permitted to be on other disease modifying anti-rheumatic drug (DMARD) like sulfasalazine, leflunomide and hydroxychloroquine, if dosages stable for at least 2 weeks before randomization'],\n",
       "  'exclusion': ['Pregnant/Breastfeeding',\n",
       "   'Ongoing/Recent treatment with methotrexate (2 months)',\n",
       "   'Chronic liver disease',\n",
       "   'Renal failure',\n",
       "   'Any leucopenia or thrombocytopenia',\n",
       "   'Breast-feeding',\n",
       "   'Desirous of pregnancy in the next 6 months',\n",
       "   'Known Hepatitis B or C positive',\n",
       "   'Known clinically relevant chronic lung disease: ILD',\n",
       "   'Tuberculosis or other active infections',\n",
       "   'Known HIV positive']},\n",
       " {'nct_id': 'NCT01820611',\n",
       "  'inclusion': ['Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Correction of functional deformity',\n",
       "   'Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques.',\n",
       "   'Revision of previously failed total hip arthroplasty. The Arcos™ Modular Femoral Revision System hip components are single-use implants, intended for uncemented use only. Only subjects who have received or have already been scheduled to receive hip surgery with the Arcos Revision Stem System will be included in this outcomes study. Additional Inclusion Criteria:',\n",
       "   'No age limit, however, the patient must have reached full skeletal maturity.',\n",
       "   'Willing to return for follow up evaluation.'],\n",
       "  'exclusion': ['Uncooperative patient or patient with neurologic disorders who are incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, or neuromuscular disease.']},\n",
       " {'nct_id': 'NCT01558089',\n",
       "  'inclusion': ['signed and dated informed consent document',\n",
       "   '18 years of age and older at the time of consent',\n",
       "   'Patients with moderate-to-severe active rheumatoid arthritis, who satisfy the 2010 Rheumatoid Arthritis Classification Criteria',\n",
       "   'Patients who have been prescribed for first time to receive treatment with MTX + Etanercept prior to enrollment to this study, following routine clinical practice and according to the approved SmPC,',\n",
       "   'Patients with DAS28 ≥ 3.2',\n",
       "   'Duration of disease symptoms ≥ 6 weeks and ≤2 years',\n",
       "   'Failure to respond to prior DMARDs including MTX monotherapy according to routine clinical practice.'],\n",
       "  'exclusion': ['Contraindications according to the SmPC',\n",
       "   'History of or present anti-TNFa or other biologic therapy for the treatment of RA',\n",
       "   \"Known significant concurrent medical disease according to investigator's opinion and the current SmPC\"]},\n",
       " {'nct_id': 'NCT01557322',\n",
       "  'inclusion': ['Patients aged 18 years and over at the time of diagnosis;',\n",
       "   'Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);',\n",
       "   'Patients who have given informed consent for long term follow-up and access to all medical records;',\n",
       "   'Patients initiating (i.e. at leats one treatment) treatment with etanercept (Enbrel) for',\n",
       "   'The Control Group:',\n",
       "   'Patients aged 18 years and over a the time of diagnosis;',\n",
       "   'Patients from the BSRBR with moderate RA as defined by a DAS28 (>3.2 and ≤5.1);',\n",
       "   'Patients who have given informed consent for long term follow-up and access to all medical records; Patients are receiving at least one traditional DMARD and have never been prescribed a biologic agent;'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01557348',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Patients with rheumatoid arthritis (RA) who have not responded or have been intolerant to a single TNF-inhibitor therapy',\n",
       "   'Initiated on treatment with MabThera/Rituxan or an alternative TNF-inhibitor therapy, in accordance with the relevant Summary of Product Characteristics'],\n",
       "  'exclusion': ['Patients whose second biologic therapy is given as part of a clinical trial studying RA treatment']},\n",
       " {'nct_id': 'NCT01554917',\n",
       "  'inclusion': ['Subjects with a diagnosis of RA',\n",
       "   'Subjects who have active RA at the time of screening',\n",
       "   \"Subjects who haven't used any antirheumatic drugs or have used antirheumatic drugs for more than 3 months at the time of screening\",\n",
       "   'Written informed consent'],\n",
       "  'exclusion': ['Subjects with serious cardiovascular, renal, hematologic or endocrine diseases',\n",
       "   'Pregnant or lactating women',\n",
       "   'ALT>1.5×ULN, AST>1.5×ULN, Cr>135umol/L',\n",
       "   'WBC<4×109/L，HGB<85g/L，PLT<100×109/L',\n",
       "   'Subjects with uncontrolled infection',\n",
       "   'Patients with active gastrointestinal diseases (such as gastric ulcer, etc.)',\n",
       "   'Allergic to any of the study drugs',\n",
       "   'History of alcoholism',\n",
       "   'Subjects receiving live vaccines within 3 months prior to study entry',\n",
       "   'Subjects participating in other clinical study within 3 months prior to study entry']},\n",
       " {'nct_id': 'NCT01552941',\n",
       "  'inclusion': ['Adult-onset rheumatoid arthritis of at least six months duration as defined by the 2010 ACR/EULAR classification criteria (Aletaha, 2010)',\n",
       "   'Male or female patients, 18-75 years of age, inclusive',\n",
       "   'Functional status I, II, or III as classified according to the ACR 1991 revised criteria (Hochberg, 1992)',\n",
       "   'Patients must have active disease as defined by at least 4 active tender or swollen joints and CRP above 0.7 mg/dL, despite at least 3 months of treatment with methotrexate at a dose of up to 25 mg orally per week.',\n",
       "   'Patients may have been previously treated with TNF antagonists, but must have failed by reason of inadequate safety, intolerance to side effects, or development of antibodies (i.e., secondary failures), and specifically cannot have failed on the basis of primary lack of efficacy',\n",
       "   'Study amended to add a second cohort of up to 10 patients who have failed both a TNF antagonist and at least one other biological therapy having a non-TNF antagonist mechanism of action'],\n",
       "  'exclusion': ['History of unilateral or bilateral vagotomy',\n",
       "   'History of recurrent vaso-vagal syncope episodes',\n",
       "   'Known obstructive sleep apnea',\n",
       "   'Known history of cardiac rhythm disturbances, atrio-ventricular block of greater than first degree, or cardiac conduction pathway abnormalities other than isolated right bundle branch block or isolated left anterior fascicle block',\n",
       "   'Significant pharyngeal dysfunction or swallowing difficulties',\n",
       "   'Pre-existing clinically significant vocal cord damage or hoarseness',\n",
       "   'Previously implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)',\n",
       "   'Asthma or chronic obstructive pulmonary disease not controlled by medications, or any other disease causing clinically significant dyspnea at time of screening',\n",
       "   'Active peptic ulcer disease']},\n",
       " {'nct_id': 'NCT01557374',\n",
       "  'inclusion': ['Patients of at least 18 years old.',\n",
       "   'Patients with RA, defined by ACR-EULAR 2010 criteria',\n",
       "   'Treated for at least 1 year with Abatacept or Tocilizumab with market authorized doses*, and possibly with a DMARD and ≤ 5 mg per day of corticoids.',\n",
       "   'In remission since at least 6 months according to ACR/ EULAR 2010 remission criteria or a DAS 28 ≤ 2.6**',\n",
       "   'Without destructive structural progression during the previous year on the hand and feet x-rays (judged by the reference rheumatologist)',\n",
       "   'Informed on the study and have given their acknowledged written consent to participate in the study.',\n",
       "   'Having had a prior medical visit.',\n",
       "   'Prescribed dose stability (a spacing related to an infection or a surgery is not a prescribed dose spacing).',\n",
       "   'An increase in inflammatory parameters and pain due to an intercurrent event must be distinguished from the RA activity increasing.'],\n",
       "  'exclusion': ['Already included in another treatment evaluation trial for the same pathology.',\n",
       "   'Surgical intervention programmed for in the next 24 months to come.',\n",
       "   \"Pregnancy or it's anticipation in the next 24 months to come.\",\n",
       "   'Non comprehension of French language.',\n",
       "   'Non affiliation to social security.',\n",
       "   'Patients under legal guardianship.']},\n",
       " {'nct_id': 'NCT01559103',\n",
       "  'inclusion': ['Active Rheumatoid Arthritis (RA) for 6 months or more.',\n",
       "   'Males or nonpregnant, nonlactating femails aged 20 to 75 years, inclusive.',\n",
       "   'Body Mass Index (BMI) between 19 and 36 kg/m2 and weight between 50 and 145 kg, inclusive.',\n",
       "   'Males, unless surgically sterile, must use 2 effective methods of birth control from Day 1 through follow-up.'],\n",
       "  'exclusion': ['History or presence of any clinically significant disease or disorder which has not been stable over the previous 3 months.',\n",
       "   \"History of liver disease, bilirubin elevations, or Gilbert's Syndrome.\",\n",
       "   'Any systematic inflammatory condition in addition to RA (polymyalgia rheumatica, giant cell arthritis, systemic lupus, gout, pyrophosphate arthropathy).',\n",
       "   'Current, chronic pain disorders including fibromyalgia and chronic regional pain syndromes or chronic fatigue syndromes.',\n",
       "   'Intramuscular steroid injection or intraarticular steroid injection within 1 month of enrollment.']},\n",
       " {'nct_id': 'NCT01815411',\n",
       "  'inclusion': ['Age>18 years',\n",
       "   'Able and willing to give written informed consent, and to comply with the requirements of the study protocol.',\n",
       "   'Fulfilling the ACR 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis.',\n",
       "   'Moderate disease activity based on the clinical evaluation including DAS28-ESR (DAS28 3.2-5.1) [11, 12].',\n",
       "   'Stable medication by disease modifying drugs (DMARDs) and systemic glucocorticosteroids for 3 months prior to the inclusion.'],\n",
       "  'exclusion': ['Lack of cooperativity.',\n",
       "   'Clinically significant chronic infection, including positive serology for hepatitis B or C, history of positive HIV status.',\n",
       "   'Acute significant infection during the last 3 weeks before the inclusion. Surgery during the last 4 weeks before the inclusion, and during the study period.',\n",
       "   'Clinically significant malignancy .',\n",
       "   'Drug addiction',\n",
       "   'Any inflammatory disease of permanence not related to',\n",
       "   '- Use of prednisolone >7,5 mg daily for 1 month prior to the inclusion.',\n",
       "   'Use of biologic treatment including antibodies to cytokines and their receptors for 6 weeks prior to the inclusion.',\n",
       "   'Use of intramuscular, intra-articular or intravenous injections of corticosteroids during or within 4 weeks prior to inclusion in the trial.',\n",
       "   'Vaccination during the trial.',\n",
       "   'Pregnancy or breast-feeding.']},\n",
       " {'nct_id': 'NCT01813409',\n",
       "  'inclusion': ['Clinical diagnosis of Rheumatoid Arthritis'],\n",
       "  'exclusion': ['None']},\n",
       " {'nct_id': 'NCT01362153',\n",
       "  'inclusion': ['Have a diagnosis of RA for at least 3 months prior to screening',\n",
       "   'Have no history of latent or active tuberculosis (TB) and test negative for TB'],\n",
       "  'exclusion': ['Have inflammatory diseases other than RA',\n",
       "   'Have been treated with disease-modifying anti-rheumatic drugs (DMARDs)/systemic immunosuppressives other than methotrexate (MTX), sulfasalazine, or hydroxychloroquine during the 4 weeks prior to the first administration of study agent',\n",
       "   'Have received intramuscular (IM), IV, or intra-articular corticosteroids within 4 weeks of study agent administration',\n",
       "   'Have a known hypersensitivity to human Ig proteins',\n",
       "   'Have received infliximab, golimumab, adalimumab or abatacept within 3 months, or etanercept or anakinra within 1 month prior to the first administration of study agent',\n",
       "   'Have received alefacept, efalizumab, natalizumab, rituximab, or any B-cell-depleting agent',\n",
       "   'Have been treated with any other biologics or investigational drugs, within 5 half-lives of that drug prior to the first administration of study agent',\n",
       "   'Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, prior to screening',\n",
       "   'Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening',\n",
       "   'Have had a serious infection (eg, hepatitis, pneumonia, pyelonephritis, or sepsis)']},\n",
       " {'nct_id': 'NCT01369745',\n",
       "  'inclusion': ['Meet the ACR / EULAR criteria for classification of RA',\n",
       "   'Have moderate to severe RA, defined as involving a minimum (≥6 total swollen and ≥6 total tender) of the 28 joints assessed',\n",
       "   'Have screening CRP levels of at least 0.6 mg/dl and a DAS28-CRP score ≥4.5',\n",
       "   'Have been on a stable dose of conventional DMARD therapy for at least 90 days without dosage adjustment or modification and should be able to maintain the same dose of conventional DMARD therapy during study participation (with or without glucocorticoid therapy'],\n",
       "  'exclusion': ['Treatment-refractory patients are excluded',\n",
       "   'Has active cardiovascular disease, unless well controlled by appropriate treatment for a minimum of 3 months prior to screening',\n",
       "   'Is taking aspirin for reasons other than for cardiovascular prophylaxis or their total daily dose is greater than 325 mg',\n",
       "   'Is currently taking steroids at a daily prednisone dose, or the equivalent, of >10 mg',\n",
       "   'Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study',\n",
       "   \"The need to continue the use of one or multiple NSAID's at the same time, or the use of acetaminophen on a chronic basis\",\n",
       "   'All opiate use is prohibited',\n",
       "   'Use of any other medications or herbs used for the treatment of pain is prohibited',\n",
       "   'Patients with a history of or currently active tuberculosis as per specific country guidelines are excluded',\n",
       "   'Has uncontrolled diabetes mellitus as defined by a serum glucose >126 mg/dl',\n",
       "   'Knowingly has HIV infection or hepatitis',\n",
       "   'Has undergone administration of any investigational drug within 30 days of study initiation',\n",
       "   'All biologic agents are excluded for 90 days prior to Screening and throughout the study.',\n",
       "   'Has undergone administration of rituximab or any B-cell depleting investigational drugs within 6 months of study initiation',\n",
       "   'Has had a history of alcohol or drug abuse within the past 2 years',\n",
       "   'Has a history of hypersensitivity to glucocorticoids and/or dipyridamole']},\n",
       " {'nct_id': 'NCT01362062',\n",
       "  'inclusion': ['Moderate to severe active RA with an inadequate response to existing therapies (DMARDs and/or anti-TNFs)',\n",
       "   'Considered eligible for tocilizumab therapy by the treating physician as per routine clinical practice'],\n",
       "  'exclusion': ['Pregnant or breastfeeding females',\n",
       "   'Immunization with live/attenuated vaccine within 4 weeks prior to baseline',\n",
       "   'Participants with clinically significant raised liver enzyme, abnormal lipid profile, platelet count, hemoglobin, white blood cell and neutrophil count',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies',\n",
       "   'Participants with active tuberculosis (TB). Participants with latent TB should be treated with standard anti-mycobacterial therapy before initiating tocilizumab and have a negative chest x ray for active TB at enrolment',\n",
       "   \"History of diverticulitis, chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis or other symptomatic lower GI conditions that might predispose to perforations then the benefit risk ratio should be considered by treating physician\",\n",
       "   'Know active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency or known human immunodeficiency virus (HIV) positive status',\n",
       "   \"Any other condition which puts the participant to undue risk for tocilizumab therapy as per local prescribing information or Investigator's judgement\"]},\n",
       " {'nct_id': 'NCT01198002',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years',\n",
       "   'Regular use of methotrexate (MTX) in the past 12 weeks, with the dose being stable during the past 8 weeks',\n",
       "   'At least 8 tender and swollen joints',\n",
       "   'At least one erosion of a hand or foot joint observed on an X-ray',\n",
       "   'An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)',\n",
       "   'Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody',\n",
       "   'Woman must not be pregnant, breastfeeding, or become pregnant during the study'],\n",
       "  'exclusion': ['Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6 weeks',\n",
       "   'Steroid injection or intravenous (iv) infusion in the last 6 weeks',\n",
       "   'Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks',\n",
       "   'History of an inadequate response to a biologic disease-modifying anti-rheumatic drug (DMARD)',\n",
       "   'History of a serious reaction to other biological DMARDs',\n",
       "   'History of the use of rituximab or other B cell therapy',\n",
       "   'Use of DMARDS other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks',\n",
       "   'Use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed up the elimination of leflunomide)',\n",
       "   'Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study',\n",
       "   \"Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA\",\n",
       "   'Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years',\n",
       "   'Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)',\n",
       "   'Hepatitis or human immunodeficiency virus (HIV)',\n",
       "   'A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months',\n",
       "   'Symptoms of herpes zoster or herpes simplex within the last month',\n",
       "   'Active or latent tuberculosis (TB)',\n",
       "   'Current symptoms of a serious disorder or illness',\n",
       "   'Use of an investigational drug within the last month',\n",
       "   'History of the use of rituximab, any other B cell targeted biotherapy, or denosumab']},\n",
       " {'nct_id': 'NCT01197534',\n",
       "  'inclusion': ['Active rheumatoid arthritis (RA) diagnosed after the age of 16',\n",
       "   'Treatment with one the following disease modifying anti-rheumatic drug: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine',\n",
       "   '4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count)and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more',\n",
       "   'At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)'],\n",
       "  'exclusion': ['Females who are pregnant or breast feeding',\n",
       "   'Poorly controlled hypertension',\n",
       "   'Liver disease or significant liver function test abnormalities',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders',\n",
       "   'Recent or significant cardiovascular disease',\n",
       "   'Significant active or recent infection including tuberculosis',\n",
       "   'Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent',\n",
       "   'Severe renal impairment',\n",
       "   'Neutropenia']},\n",
       " {'nct_id': 'NCT01197521',\n",
       "  'inclusion': ['Active rheumatoid arthritis (RA) diagnosed after the age of 16',\n",
       "   'Currently taking methotrexate',\n",
       "   '6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more',\n",
       "   'At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)'],\n",
       "  'exclusion': ['Females who are pregnant or breast feeding',\n",
       "   'Poorly controlled hypertension',\n",
       "   'Liver disease or significant liver function test abnormalities',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders',\n",
       "   'Recent or significant cardiovascular disease',\n",
       "   'Significant active or recent infection including tuberculosis',\n",
       "   'Previous failure to respond to a TNF alpha antagonist, anakinra or previous treatment with other biological agent',\n",
       "   'Severe renal impairment',\n",
       "   'Neutropenia']},\n",
       " {'nct_id': 'NCT01195272',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis of >/= 6 months duration',\n",
       "   'DAS28 >/= 3.2 at screening and baseline',\n",
       "   'Inadequate response to biologic or non-biologic DMARDs',\n",
       "   'Biologic DMARDs must be withdrawn (approximately 5 half-lives for the agent) before first dose of study drug',\n",
       "   'If continuing on a non-biologic DMARD, dose should be stable for at least 8 weeks',\n",
       "   'Oral corticosteroids must have been at stable dose for at least 25 out of 28 days prior to baseline'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or not recovered from prior surgery',\n",
       "   'Rheumatic autoimmune disease other then RA',\n",
       "   'Functional class IV as defined by the American College of Rheumatology (ACR) classification',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Active infection or history of recurrent infection',\n",
       "   'Positive for HIV or hepatitis B or C',\n",
       "   'History of or current primary or secondary immunodeficiency']},\n",
       " {'nct_id': 'NCT01197755',\n",
       "  'inclusion': ['Active rheumatoid arthritis (RA) diagnosed after the age of 16',\n",
       "   'Currently taking methotrexate',\n",
       "   '6 or more swollen joints and 6 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more',\n",
       "   'At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of rheumatoid factor (blood test), radiographic erosion within 12months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)'],\n",
       "  'exclusion': ['Females who are pregnant or breast feeding',\n",
       "   'Poorly controlled hypertension',\n",
       "   'Liver disease or significant liver function test abnormalities',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders',\n",
       "   'Recent or significant cardiovascular disease',\n",
       "   'Significant active or recent infection including tuberculosis',\n",
       "   'Previous failure to respond to anakinra or previous treatment with biological agent (other than TNF alpha antagonists including rituximab, abatacept and tocilizumab)',\n",
       "   'Severe renal impairment',\n",
       "   'Neutropenia']},\n",
       " {'nct_id': 'NCT01196780',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active Rheumatoid Arthritis',\n",
       "   'Inadequate response to anti-TNF',\n",
       "   \"Eligible for MabThera/Rituxan therapy according to physician's decision\"],\n",
       "  'exclusion': ['According to Summary of Product Characteristics']},\n",
       " {'nct_id': 'NCT01198509',\n",
       "  'inclusion': ['Rheumatoid Arthritis (RA) patients must meet American College of Rheumatology (ACR) criteria for RA',\n",
       "   'RA patients: duration of disease will be greater than 6 weeks and less than 2 years.',\n",
       "   'RA patients should have a Disease Activity Score 28 (DAS28) greater than or equal to',\n",
       "   '- PsA patients will be required to have disease duration and DAS28 similar to the RA patients, and to meet Moll and Wright criteria for PsA.',\n",
       "   'Allowable medications for both groups at study entry will include: prednisone (or equivalent) 5 mg or less per day (stable dose for at least 2 months); methotrexate 15 mg or less per week (stable dose for at least 2 months); and nonsteroidal anti-inflammatory drugs (NSAIDs) at FDA-approved doses.',\n",
       "   'Healthy controls will be age- and sex-matched individuals with no personal or family history of inflammatory arthritis.'],\n",
       "  'exclusion': ['Patients who are unable to provide informed consent.',\n",
       "   'Pregnant or lactating women.',\n",
       "   'Recent (<3 months prior) use of any antibiotic therapy',\n",
       "   'Current consumption of probiotics',\n",
       "   'Current extreme diet (parenteral nutrition, macrobiotic diet, etc.)',\n",
       "   'Prednisone >5 mg/day or equivalent',\n",
       "   'Use of other disease-modifying antirheumatic drugs (DMARDs) with known antibiotic properties (Gold salts, hydroxychloroquine, sulfasalazine or minocycline).',\n",
       "   'Use of biologic DMARDs',\n",
       "   'Known inflammatory bowel disease',\n",
       "   'Known gastrointestinal (GI) tract neoplasm.',\n",
       "   'Recent GI tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)',\n",
       "   'Chronic unexplained diarrhea.',\n",
       "   'Any GI tract surgery leaving permanent residua (e.g., gastrectomy; bariatric surgery; colectomy)',\n",
       "   'Significant liver, renal or peptic ulcer disease, defined as:',\n",
       "   'Liver: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2 x upper limit of normal (ULN)',\n",
       "   'Renal: Creatinine >1.5 or endstage renal disease',\n",
       "   'Peptic ulcer disease: recent ulcer or GI bleed (within past 12 months)',\n",
       "   'Inability or unwillingness to abstain from alcohol consumption.']},\n",
       " {'nct_id': 'NCT01194414',\n",
       "  'inclusion': ['Adult participants, ≥ 18 years of age',\n",
       "   'Rheumatoid arthritis of ≥ 6 months duration, according to American College of Rheumatology (ACR) criteria',\n",
       "   'Swollen joint count (SJC) ≥ 4 (66 joint count), tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline',\n",
       "   'Inadequate response to current DMARD therapy',\n",
       "   'Permitted DMARDs must be at stable dose for ≥ 8 weeks prior to baseline',\n",
       "   'Oral corticosteroids (≤ 10 mg/day prednisone or equivalent) and NSAIDs (up to maximum recommended dose) must be at stable dose for ≥ 4 weeks prior to baseline'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV (ACR classification)',\n",
       "   'Diagnosis of juvenile idiopathic arthritis (JIA) or juvenile rheumatoid arthritis (JRA) and/or RA before the age of 16',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Active current or history of recurrent infection']},\n",
       " {'nct_id': 'NCT01194401',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active moderate to severe rheumatoid arthritis',\n",
       "   'Inadequate response or intolerant to previous therapy with one or more disease-modifying antirheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists',\n",
       "   'Prescription of RoActemra/Actemra according to label'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01788098',\n",
       "  'inclusion': ['rheumatoid arthritis or healthy'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01789151',\n",
       "  'inclusion': ['In order to provide written consent all patients will be older than 18 years old. Patients with RA need to satisfy the ACR criteria. Similarly for AS patients need to satisfy current criteria for the diagnosis. Exclusion Criteria:',\n",
       "   ''],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01782469',\n",
       "  'inclusion': ['Male or Female patients ≥ 18 years of age with diagnosis of RA',\n",
       "   'Patient is eligible to start adalimumab therapy according to the local product label and prescription guidelines',\n",
       "   'Patient is naïve to all biologics e.g. anti-cluster of differentiation 4 (anti-CD4) and anti-TNF treatments at the start of the study',\n",
       "   'Patient has no history of inflammatory arthritis other than rheumatoid arthritis',\n",
       "   'Patient has no history of lymphoma or leukemia or other malignancies',\n",
       "   'Has negative result of tuberculosis (TB) screening test or is receiving TB prophylaxis as per local guidelines, Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations'],\n",
       "  'exclusion': ['Patients that are not diagnosed with rheumatoid arthritis as judged by the American College of Rheumatology criteria',\n",
       "   'Patient is currently diagnosed with any condition other than rheumatoid arthritis that may affect radiography progression',\n",
       "   'Susceptibility to infections including TB, as judged by the investigator',\n",
       "   'Patient is carrier of Hepatitis B virus',\n",
       "   'Patient is a pregnant or lactating female at the time of screening']},\n",
       " {'nct_id': 'NCT01783015',\n",
       "  'inclusion': ['Met the 1987 ACR Revised Criteria for RA',\n",
       "   'A history of inadequate response to infliximab or adalimumab in combination with methotrexate.',\n",
       "   'A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.'],\n",
       "  'exclusion': ['ACR functional class IV',\n",
       "   'Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab.',\n",
       "   'Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.']},\n",
       " {'nct_id': 'NCT01781702',\n",
       "  'inclusion': ['Adult males/Females aged 18~80 years',\n",
       "   'Patient who are taking NSAIDs for the treatment of rheumatoid arthritis',\n",
       "   'Patients who belong to ACR functional class 1, 2, 3'],\n",
       "  'exclusion': ['Patients who belong to ACR functional class 4',\n",
       "   'Patients who are hypersensitive to clinical trial medicines or excipient',\n",
       "   'Patients who have experience of Cerebrovascular bleeding, bleeding disorder']},\n",
       " {'nct_id': 'NCT01202773',\n",
       "  'inclusion': ['Diagnosis of RA of more than 6 months and less than 15 years',\n",
       "   'At least 8 tender and swollen joints',\n",
       "   'An abnormally high C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR)',\n",
       "   'Positive for rheumatoid factor (RF) or anti-cyclic citrullinated peptide (CCP) antibody',\n",
       "   'Previously treated with biologic TNF-α inhibitor therapy (infliximab, certolizumab, golimumab, etanercept, adalimumab) and stopped treatment due to insufficient efficacy or intolerance',\n",
       "   'Regular use of at least 1 conventional disease-modifying anti-rheumatic drug (DMARD), with a stable dose for at least 8 weeks prior to study start',\n",
       "   'Woman must not be pregnant, breastfeeding, or become pregnant during the study'],\n",
       "  'exclusion': ['Use of unstable doses of non-steroidal anti-inflammatory drugs (NSAIDS) in the past 6 weeks',\n",
       "   'Steroid injection or intravenous (IV) infusion in the last 6 weeks',\n",
       "   'Use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks',\n",
       "   'History of a serious reaction to other biological DMARDs',\n",
       "   'Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the last 8 weeks',\n",
       "   'Surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study',\n",
       "   \"Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA\",\n",
       "   'Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years',\n",
       "   'Received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)',\n",
       "   'Hepatitis or human immunodeficiency virus (HIV)',\n",
       "   'A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months',\n",
       "   'Symptoms of herpes zoster or herpes simplex within the last month',\n",
       "   'Active or latent tuberculosis (TB)',\n",
       "   'Current symptoms of a serious disorder or illness',\n",
       "   'Use of an investigational drug within the last month']},\n",
       " {'nct_id': 'NCT01208506',\n",
       "  'inclusion': ['For all subjects the following applies:',\n",
       "   'Male subjects, if not sterilized, must be using two acceptable methods of contraception (e.g., spermicidal gel plus condom) for the entire duration of the trial corresponding to up to three months following trial drug administration. Male subjects must also agree to refrain from sperm donation from screening (trial start) until 120 days beyond trial drug administration',\n",
       "   'For healthy subjects (HS) the following additional criteria applies:',\n",
       "   'Male subjects, aged between 18 and 60 years (both inclusive) and in good health, as determined by past medical history, physical examination, vital signs, (electrocardiogram) ECG, and laboratory tests at screening (trial start)',\n",
       "   'For subjects with rheumatoid arthritis (RA) the following additional criteria applies:',\n",
       "   'Diagnosed with RA at least 3 months prior to trial drug administration',\n",
       "   'Active RA, characterised by a Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) greater than 3.2',\n",
       "   'Effective methods of contraception',\n",
       "   'Male and female subjects aged greater and equal to 18 and greater and equal to 75 years',\n",
       "   'Females must be post-menopausal or surgically sterile (post-menopausal for at least 1 year). If female of child-bearing potential must be willing to use highly effective method of birth control during the trial until their final visit',\n",
       "   'Methotrexate treatment (MTX) treatment for at least 12 weeks at a stable dose (dose at least 7.5 mg/week and maximum 25 mg/week inclusive) for at least 4 weeks prior to trial product administration',\n",
       "   'Concomitant medication according to specific list'],\n",
       "  'exclusion': ['For all subjects the following applies:',\n",
       "   'Body mass index (BMI) between 20.0-38.0 kg/m2 (both inclusive)',\n",
       "   'Females with a positive pregnancy test',\n",
       "   'History of regular alcohol consumption exceeding 14 drinks per week for females or 21 drinks per week for men',\n",
       "   'Donation or loss of at least 400 mL of blood within 8 weeks prior to trial product administration',\n",
       "   'For healthy subjects (HS) the following additional criteria applies:',\n",
       "   'Body weight greater than 110.0 kg',\n",
       "   'For subjects with rheumatoid arthritis (RA) the following additional criteria applies:',\n",
       "   \"Chronic inflammatory autoimmune disease other than RA (except secondary Sjögren's syndrome or stable hypothyroidism)\",\n",
       "   'History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease']},\n",
       " {'nct_id': 'NCT01205854',\n",
       "  'inclusion': ['Male or non-pregnant, non-nursing female',\n",
       "   '> 18 years of age and < 75 years of age',\n",
       "   'Patients classified as having RA (according to new ACR/EULAR criteria)',\n",
       "   'Disease duration less than 2 years (defined as time from 1st joint swelling)',\n",
       "   'The treating rheumatologist decides the patient requires treatment with a Disease Modifying Anti-Rheumatic Drug (DMARD)',\n",
       "   'The patient has taken no prior DMARD',\n",
       "   'Patients able and willing to give written informed consent and comply with the requirements of the study protocol'],\n",
       "  'exclusion': ['Abnormal renal function (serum creatinine > 142 µmol/L in female and > 168 µmol/L in male)',\n",
       "   'Abnormal liver function, active or recent hepatitis, cirrhosis',\n",
       "   'Major co-morbidities like severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease and/or severe respiratory diseases.',\n",
       "   'Leukopenia and/or thrombocytopenia',\n",
       "   'Inadequate birth control conception, pregnancy, and/or breastfeeding',\n",
       "   'Indications of active tuberculosis',\n",
       "   'Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible']},\n",
       " {'nct_id': 'NCT01202760',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA) of more than 6 months and less than 15 years',\n",
       "   'Global Assessment of Disease Activity visual analog scale (VAS) greater than or equal to 20/100 millimeters (mm)',\n",
       "   'If on one or more conventional disease-modifying anti-rheumatic Drugs (DMARDs) at randomization, must have been on a stable dose for at least 8 weeks prior to study start.',\n",
       "   'Women must not be pregnant, breastfeeding, or become pregnant during the study'],\n",
       "  'exclusion': ['Use of unstable doses of non-steroidal inflammatory drugs (NSAIDS) in the past 6 weeks',\n",
       "   'Steroid injection or intravenous (IV) infusion in the last 6 weeks',\n",
       "   'Use of more than 10 milligrams per day (mg/day) of oral steroids in the last 6 weeks',\n",
       "   'Use of biologic DMARD concurrently or recently',\n",
       "   'History of a serious reaction to other biological DMARDs',\n",
       "   'Use of an oral calcineurin inhibitor (for example, cyclosporin or tacrolimus) in the last 8 weeks',\n",
       "   'Surgery on a joint or other major surgery less than 2 months prior to study start, or plans to have joint surgery or major surgery during the study',\n",
       "   \"Active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except RA\",\n",
       "   'Cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years',\n",
       "   'Received a live vaccine within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines)',\n",
       "   'Hepatitis or human immunodeficiency virus (HIV)',\n",
       "   'A serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months',\n",
       "   'Symptoms of herpes zoster or herpes simplex within the last month',\n",
       "   'Active or latent tuberculosis (TB)',\n",
       "   'Current symptoms of a serious disorder or illness',\n",
       "   'Use of an investigational drug within the last month']},\n",
       " {'nct_id': 'NCT01426347',\n",
       "  'inclusion': ['Rheumatoid Arthritis diagnosed according to American College of Rheumatology (ACR) criteria',\n",
       "   'ages 18-75 years'],\n",
       "  'exclusion': [\"Diagnosis of any other autoimmune disease: such as Lupus, Scleroderma, Myositis, Sjogren's Syndrome, Vasculitis'\",\n",
       "   'Having any of the following conditions with in the last 6 months Hypercalcemia, Hyperparathyroidism, Active tuberculosis (TB), Lymphoma or any other type of cancer, Sarcoidosis, Seizure, Stroke',\n",
       "   'Severe heart problems',\n",
       "   'Kidney failure requiring dialysis treatment',\n",
       "   'Liver failure or cirrhosis of the liver',\n",
       "   'Poorly controlled hypertension',\n",
       "   'current uncontrolled Depression, Bipolar Disorder, or other Psychiatric illness',\n",
       "   'Pregnancy']},\n",
       " {'nct_id': 'NCT01426789',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis',\n",
       "   'Patients must be either DMARD naive or have failed at least one DMARD agent (e.g. MTX, leflunamide or sulfasalazine)',\n",
       "   'Patients are allowed up to 3 DMARDs at study entry (e.g. MTX, sulfasalazine or hydroxychloroquine) as long as their dose was stable for 4 weeks prior to initiating study treatment',\n",
       "   'Disease activity at screening defined by ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints and hsCRP >10mg/L Exclusion Criteria:',\n",
       "   'Patients with severe rheumatoid arthritis (functional status class IV according to the ACR 1991 revised criteria)',\n",
       "   'Previous exposure to secukinumab or any other biologic, including TNF inhibitors.',\n",
       "   'Use of high potency opioid analgesics',\n",
       "   'Pregnant or nursing (lactating) women',\n",
       "   'Use of any investigational drug other than RA therapy and/or devices at the time of randomization or within 30 days or 5 half-lives of randomization, whichever is longer. Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01422564',\n",
       "  'inclusion': ['Male and non-pregnant female subjects 65 years of age or older',\n",
       "   'Subjects undergoing cementless hip arthroplasty. If a press fit metal articulation acetabulum is not possible; the modular cup system will be utilized with screw fixation and a metal head of the greatest diameter deemed appropriate and safe for the patient will be utilized.(At the discretion of the surgeon). The cup in this situation may have a metal or poly articulation. The patient will be followed as an intent to treat (the patient will be evaluated and included in the group as randomized)',\n",
       "   'Subjects with, but not limited to, original diagnoses of osteoarthritis, avascular necrosis, rheumatoid arthritis, congenital dysplasia of the hip, ankylosing spondylitis, posttraumatic arthritis, and traumatic injury to the hip joint.',\n",
       "   \"Subjects who are able and willing to understand the conditions of informed consent, to participate in the study according to the protocol for the length of the expected term of follow-up, and to follow their physician's directions.\"],\n",
       "  'exclusion': ['Subjects undergoing hip arthroplasty using a cemented femoral component and/or a bipolar prosthesis.',\n",
       "   'Subjects with gross obesity, >45% over ideal body weight for age and height. Refer to Appendix A, Obesity Table.',\n",
       "   'Subjects with active infections.',\n",
       "   'Subjects with malignancy in the area of the involved hip joint.',\n",
       "   \"Subjects with a neuromuscular deficit that interferes with the subject's ability to limit weight bearing or places an extreme load on the implant during the healing period.\",\n",
       "   'Subjects with a diagnosis of Fibromyalgia',\n",
       "   'Female subjects who are pregnant or may be pregnant.',\n",
       "   'Subjects whom, as judged by the surgeon, are not capable of understanding the informed consent or the requirements of the protocol, or are reasonably unlikely to be compliant with the prescribed postoperative routine and the follow-up evaluation schedule.',\n",
       "   'Subjects who have a known sensitivity to device materials.']},\n",
       " {'nct_id': 'NCT01463566',\n",
       "  'inclusion': ['Patient 18-75 years of age, inclusive;',\n",
       "   'Patient qualifies for a total knee arthroplasty based on physical exam and medical history including at least one of the following: osteoarthritis, inflammatory arthritis, post-traumatic arthritis, rheumatoid arthritis, or valgus, varus, or flexion deformities;',\n",
       "   'Patient has undergone a study related informed consent process;',\n",
       "   'Patient is willing and able to provide written consent;',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy;',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations.'],\n",
       "  'exclusion': ['Patient has previous history of infection in the affected joint and/or a local or systemic infection that could affect the prosthetic joint;',\n",
       "   'Insufficient bone stock on femoral or tibial surfaces;',\n",
       "   'Skeletal immaturity',\n",
       "   'Neuropathic arthropathy',\n",
       "   'Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;',\n",
       "   'Stable, painless arthrodesis in a satisfactory functional position;',\n",
       "   'Severe instability secondary to the absence of collateral ligament integrity;',\n",
       "   'Patient has rheumatoid arthritis and an ulcer of the skin or a history of recurrent breakdown of the skin because of their risk of postoperative infection is greater;',\n",
       "   'Patient has known sensitivity or allergy to one or more of the implanted materials;',\n",
       "   'Patients pregnant or considered a member of a protected population (e.g., prisoner, mental incompetence, unable to understand what clinical trial participation entails, etc.)']},\n",
       " {'nct_id': 'NCT01468077',\n",
       "  'inclusion': ['Adult patients, at least 18 years of age, inclusive',\n",
       "   'Diagnosis of rheumatoid arthritis of at least 6 months duration',\n",
       "   'Moderate to severe active rheumatoid arthritis (DAS28 >/=3.2)',\n",
       "   'Patients received at least 1 disease-modifying anti-rheumatic drug (DMARD) and/or 1 or more TNFalfa-inhibitors over a period of at least 8 weeks'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following randomization',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Functional class IV (ACR criteria)',\n",
       "   'History of severe allergic reaction to human, humanized or murine monoclonal antibodies',\n",
       "   'Known active current or history of recurrent infection (including tuberculosis)',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Body weight >150 kg',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'Previous treatment with tocilizumab']},\n",
       " {'nct_id': 'NCT01462162',\n",
       "  'inclusion': ['Participants with moderate to severe RA who have been considered and proposed by the rheumatologist to start treatment with Tocilizumab according to his/her clinical judgment and the conditions approved in the Summary of Product Characteristics (SPC).'],\n",
       "  'exclusion': ['Participants previously or currently treated with RoActemra/Actemra in clinical trials',\n",
       "   'Absolute neutrophil count less than or equal to (</=) 2x10^9 per liter (/L)']},\n",
       " {'nct_id': 'NCT01463059',\n",
       "  'inclusion': [\"Have a diagnosis of adult-onset RA of at least 6 months' (24 weeks) duration as defined by the 1987 ACR classification criteria or a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for RA\",\n",
       "   'Must have moderately to severely active RA disease as defined by ≥6 tender joints (68-joint count) at Screening and Baseline, ≥6 swollen joints (66-joint count) at Screening and Baseline, CRP ≥1.2 times the upper limit of normal (ULN) or ESR >28mm/hour',\n",
       "   'Must be on an MTX dose of 6 to 16mg/week in Japan or 7.5 to 20mg/week in Korea and Taiwan, which has been stable for at least 6 weeks prior to Screening with a stable route of administration',\n",
       "   'Must have had intolerance or inadequate response to treatment with 1 or more TNF-blocker therapies within 2 years of Screening',\n",
       "   'Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing 2 acceptable methods of contraception'],\n",
       "  'exclusion': ['Have a diagnosis of any other inflammatory arthritis',\n",
       "   'Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the study or within 24 weeks',\n",
       "   'Disease modifying antirheumatic drug (DMARDs) other than methotrexate (MTX)',\n",
       "   'Subjects with known concurrent acute or chronic viral hepatitis B or C infection',\n",
       "   'Subject has known tuberculosis (TB) disease, high risk of acquiring TB infection, or latent TB infection',\n",
       "   'Subjects with known history of or current clinically active infection',\n",
       "   'Subjects at high risk of infection',\n",
       "   'Subjects with known human immunodeficiency virus (HIV) or human T cell lymphotropic virus type 1 (HTLV 1) infection',\n",
       "   'Have received vaccinations within 8 weeks prior to Screening or plan to receive vaccines during the study (with the exception of injectable influenza and pneumococcal vaccinations which are permitted)',\n",
       "   'Concurrent malignancy or a history of malignancy (with the exception of successfully treated carcinoma of the cervix more than 5 years prior to Screening or no more than 2 successfully treated basal cell carcinomas within 2 years prior to Screening']},\n",
       " {'nct_id': 'NCT01462240',\n",
       "  'inclusion': ['Patient 18-75 years of age, inclusive;',\n",
       "   'Patient qualifies for a total knee arthroplasty based on physical exam and medical history including at least one of the following: rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis, collagen disorders, avascular necrosis of the femoral condyle;',\n",
       "   'Post-Traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;',\n",
       "   'Moderate valgus, varus, or flexion deformities;',\n",
       "   'Patient has undergone a study related informed consent process;',\n",
       "   'Patient is willing and able to provide written consent;',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy;',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations.'],\n",
       "  'exclusion': ['Patient has previous history of infection in the affected joint and/or a local or systemic infection that could affect the prosthetic joint;',\n",
       "   'Insufficient bone stock on femoral or tibial surfaces;',\n",
       "   'Skeletal immaturity;',\n",
       "   'Neuropathic arthropathy;',\n",
       "   'Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;',\n",
       "   'Stable, painless arthrodesis in a satisfactory functional position;',\n",
       "   'Severe instability secondary to the absence of collateral ligament integrity;',\n",
       "   'Patient has rheumatoid arthritis and an ulcer of the skin or a history of recurrent breakdown of the skin because of their risk of postoperative infection is greater;',\n",
       "   'Patient has a known sensitivity or allergy to one or more of the implanted materials;',\n",
       "   'Patient is pregnant or considered a member of a protected population (e.g., prisoner, mental incompetence, unable to understand what clinical trial participation entails, etc.)']},\n",
       " {'nct_id': 'NCT01463189',\n",
       "  'inclusion': ['Be at least 18 years of age;',\n",
       "   'Be able to provide informed consent',\n",
       "   'Be able to read and speak English',\n",
       "   'Have reliable Internet access and e-mail',\n",
       "   'Have a self-reported doctor diagnosis of arthritis, limited to the following conditions',\n",
       "   'osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), or other arthritis conditions (e.g., psoriatic arthritis)',\n",
       "   'Have a self-reported pain level of 4 or more in the past week on the 0 to 10 Numeric Rating Scale (McCaffery & Beebe, 1993) because 4 indicates moderate or higher level of pain.'],\n",
       "  'exclusion': ['Participation in another Inflexxion pain management study.',\n",
       "   'Participation in an online research study related to arthritis in the past year',\n",
       "   'Currently in pain from a recent injury',\n",
       "   'Has been hospitalized for non-medical reasons related to emotional or mental health in the past year']},\n",
       " {'nct_id': 'NCT01973569',\n",
       "  'inclusion': ['Diagnosed with rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria for rheumatoid arthritis classification (1987 revision) or the 2010 ACR-EULAR (The European League Against Rheumatism) classification criteria for rheumatoid arthritis'],\n",
       "  'exclusion': ['Functional class IV according by the ACR revised classification (1991)']},\n",
       " {'nct_id': 'NCT01975610',\n",
       "  'inclusion': ['Female between 18 and 80 years of age (inclusive) at the time of signing the informed consent.',\n",
       "   'Must meet the 2010 ACR/EULAR Classification Criteria for RA (Appendix A), have RA for at least 6 months and must continue to have active RA at the time of randomization despite at least 3 months of treatment with stable doses of MTX (7.5 to 25 mg/week oral or parenteral) for at least 4 weeks prior to randomization.',\n",
       "   'Must have been treated with MTX for at least 3 months prior to randomization, and must be on a stable dose between 7.5 and 25 mg/week (PO or parenteral, not both) for at least 4 weeks prior to randomization. Subjects will be required to maintain their stable dose through Day 28/Week 4 of the study. Oral folate supplementation is required with a minimum dose of 5 mg/week (ie, folic acid) while the subject is taking MTX. Leucovorin may be used instead of folic acid and may be dosed up to 10 mg/week orally.',\n",
       "   'Sulfasalazine is allowed as a concomitant medication, however, subject must be on a stable dose for at least 4 weeks prior to randomization and through Day 28/Week 4 of the study.',\n",
       "   'Hydroxychloroquine or chloroquine is allowed as concomitant medications, however, subject must be on a stable dose for at least 4 weeks prior to randomization and through Day 28/Week 4 of the study.',\n",
       "   'Modification of Diet in Renal Disease formula (MDRD) estimated glomerular filtration rate (MDRD eGFR) ≥ 60 mL/min/1.73m2+'],\n",
       "  'exclusion': ['Male subjects',\n",
       "   'Any condition that could affect CC-292 absorption, including gastric restrictions, bariatric surgery, such as gastric bypass, and clinical conditions that are associated with decreased intragastric acid production such as acid pernicious anemia.',\n",
       "   'Currently using treatment with DMARDs (other than sulfasalazine, hydroxychloroquine or chloroquine and MTX), including biologics. Previous use is only allowed after adequate washout (4 weeks or 5 half-lives, whichever is longer) prior to randomization.',\n",
       "   'Previous treatment with any cell depleting therapies, including investigational agents (eg, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19 and anti-CD20) within 6 months of screening.',\n",
       "   'Treatment with intravenous gamma globulin, plasmapheresis or Prosorba® column within 2 weeks prior to randomization.',\n",
       "   'Intra-articular or parenteral corticosteroids are not allowed within 2 weeks prior to randomization.']},\n",
       " {'nct_id': 'NCT01328522',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis (RA) > or = 3 months duration.',\n",
       "   'Treated for a minimum of 12 weeks with Methotrexate (MTX) prior to randomization. Treatment must be continued on a stable dose for the duration of the study.'],\n",
       "  'exclusion': ['Autoimmune disease other than',\n",
       "   '- History of acute inflammatory joint disease other than',\n",
       "   '- Surgery within 4 weeks prior to the screening visit or with planned elective surgery within the next 3 months.',\n",
       "   'Latent or active tuberculosis.',\n",
       "   'Fever (≥38 C) or persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening visit, or history of frequent recurrent infections.',\n",
       "   'Received administration of any live (attenuated) vaccine within 3 months prior to the randomization visit (eg, varicella-zoster vaccine, oral polio, rabies).',\n",
       "   'Received tuberculosis vaccination within 12 months prior to screening',\n",
       "   'Prior therapy with a Tumor Necrosis Factor (TNF) antagonist or any other biologic agents within 3 months prior to inclusion.',\n",
       "   \"Known latex sensitivity. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01329991',\n",
       "  'inclusion': ['Male or female patients ≥ 18 years old with a diagnosis of rheumatoid arthritis by ACR criteria for ≥ 3 months.',\n",
       "   'Prior to Day 1, patients must be on oral or subcutaneous methotrexate (≥10 mg/week and ≤ 25 mg/week) for at least 12 weeks (with a stable dose for at least 4 weeks) and folate (≥ 5 mg/week) for at least 6 weeks, and willing to continue on this regimen for the duration of the study.',\n",
       "   'Adequate hematologic, hepatic, and renal function (absolute neutrophil count ≥ 1.5 X 109/L, Hgb > 9 g/dL, platelet count ≥ 100 X 109/L, AST/ALT WNL, albumin ≥ 3 g/dL, calculated CrCl>60 mL/min using Cockcroft-Gault formula).',\n",
       "   'Women of child-bearing potential must have a negative pregnancy test within 7 days prior to initiation of dosing with study drug and must agree to use a double barrier method of birth control from the time of the negative pregnancy test up to 30 days after the last dose of study drug. Women of nonchildbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥ 1 year.',\n",
       "   'Fertile men must agree to use an acceptable method of birth control while on study drug. Acceptable methods of contraception must include either abstinence from the first dose of study drug through 4 weeks after the last dose of study drug, or use of a condom with instructions to the female partner of child-bearing potential to also be protected as above.',\n",
       "   'Willing and able to provide written informed consent prior to any study-related procedures and to comply with all study requirements.'],\n",
       "  'exclusion': ['Use of biologic response modifiers within the following periods prior to Day 1: 4 weeks for Kineret (anakinra) and Enbrel (etanercept); 12 weeks for Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept), Actemra (tocilizumab), or Cimzia (certolizumab); 12 months for Rituxan (rituximab).',\n",
       "   'Use of Arava (leflunomide) within 12 weeks prior to Day 1 or any immunosuppressive agents, including hydroxychloroquine or sulfasalazine, within 4 weeks of Day',\n",
       "   '- Investigational drug use within 4 weeks of Day',\n",
       "   '- Positive urine drug screen for drugs of abuse (except for opiates if being used for RA).',\n",
       "   'Concomitant use of DMARDs (other than methotrexate), biological response modifiers, or known strong inducers or inhibitors of CYP3A4 (see Appendix 2).',\n",
       "   'Uncontrolled intercurrent illness.',\n",
       "   'Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption.',\n",
       "   'QTc ≥ 450 msec at Screening.',\n",
       "   'The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study.']},\n",
       " {'nct_id': 'NCT01326962',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active moderate to severe rheumatoid arthritis of >/= 6 months duration',\n",
       "   '>/=1 non-biologic DMARD and/or anti-TNF therapy at stable dose for >/=8 weeks at any time prior to study treatment',\n",
       "   'Inadequate clinical response to non-biologic DMARD or anti-TNF therapy',\n",
       "   'Oral corticosteroids must be at stable dose for at least 25 out of 28 days prior to first dose of study drug'],\n",
       "  'exclusion': ['Pregnant or lactating women',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or major surgery planned within 6 months of enrolment',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV (ACR classification)',\n",
       "   'Prior history of or current joint disease other than RA',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Previous treatment with RoActemra/Actemra',\n",
       "   'Known active current or history of recurrent infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'Positive for HIV']},\n",
       " {'nct_id': 'NCT01768572',\n",
       "  'inclusion': ['Anti-TNF therapy failures, was defined as participants with an inadequate clinical response was defined by the investigator, after being treated for at least 3 consecutive months, and/or intolerance to at least 1 TNF-antagonist, resulting in or requiring their discontinuation. TNF-antagonists were include, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab pegol Continuous treatment with one or a combination of non-biologic disease modifying antirheumatic drugs (DMARDs) for at least 12 consecutive weeks prior to screening and on a stable dose(s) for at least 6 consecutive weeks prior to screening:',\n",
       "   'Methotrexate',\n",
       "   '10 to 25 milligram/week orally or parenteral (or per local labelling requirements if the dose range differs)',\n",
       "   'Leflunomide',\n",
       "   '10 to 20 mg orally daily',\n",
       "   'Sulfasalazine (SSZ)',\n",
       "   '1000 to 3000 mg orally daily',\n",
       "   'Hydroxychloroquine (HCQ)',\n",
       "   '200 to 400 mg orally daily'],\n",
       "  'exclusion': [\"Severe systemic RA, including but not limited to vasculitis, pulmonary fibrosis, and/or Felty's syndrome Participation in any clinical research study that evaluated an investigational drug or therapy within 5 half-lives or 60 days of the Screening Visit, whichever was longer Participants with active tuberculosis or latent tuberculosis infection. Prior or current history of interstitial lung disease. Prior treatment with anti-interleukin (IL) -6 or anti-IL-6R therapies, including but not limited to tocilizumab or sarilumab Treatment with anti-TNF agents, as follows:\",\n",
       "   'Etanercept: within 28 days prior to randomization',\n",
       "   'Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to randomization Treatment with RA-directed biologic agents with non- TNF-α antagonist mechanisms without adequate washout as follows:',\n",
       "   'Anakinra: within 28 days prior to randomization',\n",
       "   'Abatacept: within 42 days prior to randomization',\n",
       "   \"Rituximab or other cell depleting agent: Within 6 months prior to randomization or until total lymphocyte count and CD 19+ lymphocyte count were normalized, or whichever was longer Prior treatment with a janus kinase (JAK) inhibitor (eg, tofacitinib). Participants with a history of invasive opportunistic infection. Prior or current history of malignancy, including lymphoproliferative diseases, other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit Prior or current history of other significant concomitant illness(es) that, according to Investigator's judgement, was adversely affect the participant's participation in the study. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01764997',\n",
       "  'inclusion': ['Diagnosis of RA >/= 3 months duration.',\n",
       "   'Continuous treatment of MTX 10',\n",
       "   '25 mg/week (or per local labeling requirements if the dose range differs) for at least 12 weeks before screening visit and on a stable dose for 8 weeks before screening visit.',\n",
       "   'Active disease defined as: at least 6/66 swollen and 8/68 tender joints and high sensitivity C-reactive protein > 10 mg/L.'],\n",
       "  'exclusion': ['Age < 18 years.',\n",
       "   'Use of parenteral corticosteroids or intra-articular corticosteroids within 4 weeks of the screening visit.',\n",
       "   'Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks of the screening visit.',\n",
       "   'Prior treatment with a tumor necrosis factor (TNF)-alpha inhibitor, or other biological disease modifying anti-rheumatoid drug (DMARD) or Janus Kinase inhibitor.',\n",
       "   'New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors within 4 weeks of the screening visit.',\n",
       "   \"Treatment with traditional oral DMARD /immunosuppressive agents other than MTX within 4 weeks or 12 weeks before the screening visit, depending on DMARD. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01768923',\n",
       "  'inclusion': ['fulfilled the 2010 ACR/EULAR classification criteria for RA',\n",
       "   'have symptoms onset of less than 2 years',\n",
       "   'have active disease (DAS28> 3.2)',\n",
       "   'are positive for rheumatoid factor or anti-cyclic citrullinated protein antibodies'],\n",
       "  'exclusion': ['have a history of overt cardiovascular diseases',\n",
       "   'are on aspirin, or HMG-CoA reductase inhibitors (statins) or angiotensin-converting-enzyme inhibitor (ACEI)',\n",
       "   'have severe renal impairment defined as a glomerular filtration rate of less than 30 ml/min/1.73m2',\n",
       "   'have been previously treated with tumor necrosis factor alpha (TNFa) inhibitors or other biological DMARDs',\n",
       "   'on glucocorticoids at a dose >10mg/day']},\n",
       " {'nct_id': 'NCT01767844',\n",
       "  'inclusion': ['fulfil the American Rheumatism Association 1987 revised criteria for the diagnosis of RA',\n",
       "   'be functional class I or II',\n",
       "   'be age 18 years or over'],\n",
       "  'exclusion': ['be cognitively impaired; (b) have any other cachectic diseases and any condition preventing safe participation in the study',\n",
       "   'have a glomerular filtration rate above 60mL/min/1.73m2, assessed from medical records, and no other evidence of kidney damage',\n",
       "   'be taking drugs or other nutritional supplements known to increase muscle mass',\n",
       "   'be participating in regular and intense physical training program be pregnant']},\n",
       " {'nct_id': 'NCT01768858',\n",
       "  'inclusion': ['Participants ≥18 years of age with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn´s disease (CD), or ulcerative colitis (UC)',\n",
       "   'Participants must fulfill international and national guidelines for the use of a biologic disease-modifying antirheumatic drug (bDMARD) in RA, PsA, AS, PS, CD, or UC (chest X-ray and interferon gamma release assay (IGRA) or purified protein derivative (PPD) skin test negative for tuberculosis)',\n",
       "   'In addition one of the following criteria must be fulfilled:',\n",
       "   'unsatisfactory DMARD response defined as treatment failure with at least two DMARDs including methotrexate in participants with RA or PsA',\n",
       "   'unsatisfactory nonsteroidal anti-inflammatory drug (NSAID) response in participants with AS',\n",
       "   'unsatisfactory response to prior bDMARDs in participants with RA, PsA, or AS',\n",
       "   'unsatisfactory response to, contraindication to, or intolerance to other systemic therapy including cyclosporine, methotrexate, or psoralen with ultraviolet A light (PUVA) in participants with PS',\n",
       "   'unsatisfactory response despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or intolerance or medical contraindications for such therapies in CD',\n",
       "   'unsatisfactory response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or intolerance to or medical contraindications for such therapies in UC'],\n",
       "  'exclusion': ['Participants who are not covered in the latest version of the adalimumab Summary of Product Characteristics (SPC) for the syringe and pen',\n",
       "   'Participants currently enrolled in another study program or clinical trial',\n",
       "   'Participants who have been treated with adalimumab before']},\n",
       " {'nct_id': 'NCT01762176',\n",
       "  'inclusion': ['patients with at least 1 tender and swollen joint',\n",
       "   'duration of symptoms less than 2 years',\n",
       "   'no previous use of DMARDs For intensive care group:',\n",
       "   'patients with at least 1 tender and swollen joint',\n",
       "   'duration of symptoms less than 2 years',\n",
       "   'no previous use of DMARDs',\n",
       "   'patients who fulfill the 2010 ACR/EULAR classification criteria for RA'],\n",
       "  'exclusion': ['patients with renal impairment (on dialysis or estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73m^2)']},\n",
       " {'nct_id': 'NCT01764321',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA)',\n",
       "   'Moderate to severe disease activity of RA',\n",
       "   'The patient receives Tumor Necrosis Factor (TNF) inhibitor in combination with at least 1 synthetic Disease Modifying Antirheumatic Drug (DMARD)',\n",
       "   'The decision to prescribe a TNF inhibitor in combination with DMARD is made by the treating physician, prior to and independently from the decision to include the patient in this Non-Interventional Study (NIS)',\n",
       "   'Male or female patients ≥ 18 years of age, considered by the treating physician to be reliable and capable of adhering to the observational plan (eg, able to understand and complete questionnaires)',\n",
       "   'The patient personally signed and dated Patient Data Consent Form (PDCF) prior to Visit 2',\n",
       "   'Treatment is according to the Summary of Product Characteristics (SmPC)'],\n",
       "  'exclusion': ['Known contraindications to Tumor Necrosis Factor (TNF) inhibitors',\n",
       "   'Prior use of any TNF inhibitors (including Adalimumab, Etanercept, Infliximab, Certolizumab, or Golimumab), or other biologic DMARDs (including Abatacept, Rituximab, Tocilizumab, or Anakinra)',\n",
       "   'Participation in an investigational study']},\n",
       " {'nct_id': 'NCT01721044',\n",
       "  'inclusion': ['Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA',\n",
       "   'Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints',\n",
       "   'Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ (greater than or equal to) 1 times the upper limit of normal (ULN)',\n",
       "   'Have been treated at approved doses with at least 1 biologic tumor necrosis factor (TNF)- alpha inhibitor for at least 3 months and either:',\n",
       "   'experienced insufficient efficacy or loss of efficacy',\n",
       "   'experienced intolerance of such treatment',\n",
       "   'Have had regular use of at least 1 conventional disease-modifying antirheumatic drugs (cDMARD) for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry'],\n",
       "  'exclusion': ['Have received a biologic treatment for RA within 28 days of planned randomization; have received rituximab within 6 months of planned randomization',\n",
       "   'Are currently receiving corticosteroids at doses > (greater than) 10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Are currently receiving concomitant treatment with methotrexate (MTX), hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs',\n",
       "   'Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study',\n",
       "   'Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization',\n",
       "   \"Have active fibromyalgia that, in the investigator's opinion, would make it difficult to appropriately assess RA activity for the purposes of this study\",\n",
       "   \"Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout (participants with secondary Sjogren's syndrome are not excluded.)\",\n",
       "   \"Have a diagnosis of Felty's syndrome\",\n",
       "   'Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant',\n",
       "   'Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure',\n",
       "   'Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data',\n",
       "   'Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair',\n",
       "   'Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of < (less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)',\n",
       "   'Have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ≥1.5 times the ULN',\n",
       "   'Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years',\n",
       "   'Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)',\n",
       "   'Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection',\n",
       "   'Have had symptomatic herpes zoster infection within 12 weeks prior to study entry',\n",
       "   'Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)',\n",
       "   'Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study',\n",
       "   'Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)',\n",
       "   \"Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study\",\n",
       "   \"Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study (e.g. Fridericia's corrected QT interval >500 millisecond [msec])\",\n",
       "   'Have symptomatic herpes simplex at the time of study enrollment',\n",
       "   'Have evidence of active or latent tuberculosis (TB)']},\n",
       " {'nct_id': 'NCT01721200',\n",
       "  'inclusion': ['Subjects must be at least 18 years of age',\n",
       "   'Able to speak and read English',\n",
       "   'Meet the revised American College of Rheumatology criteria for the diagnosis of RA',\n",
       "   'Have active disease warranting initiation of a new biologic (or small molecule if and when FDA-approved) therapy as determined by their rheumatologist'],\n",
       "  'exclusion': ['Fail to meet the inclusion criteria',\n",
       "   'Have a current infection',\n",
       "   'Have cancer of any type diagnosed within the past five years (except non-melanoma skin cancer)',\n",
       "   'Have a history of lymphoma, leukemia, or melanoma',\n",
       "   'Have a chronic inflammatory disease (in addition to rheumatoid arthritis) requiring treatment with immunosuppressive medications',\n",
       "   'Have chronic liver disease due to hepatitis C or B',\n",
       "   'Are HIV positive',\n",
       "   'Have a positive screening test for tuberculosis (tuberculin skin test or interferon-gamma release assay) or radiographic lesions suggestive of inactive tuberculosis and have not completed an adequate course of chemoprophylactic therapy',\n",
       "   'Are hearing or visually impaired',\n",
       "   'Are scheduled for surgery']},\n",
       " {'nct_id': 'NCT01724268',\n",
       "  'inclusion': ['Males or females aged 18 years or older.',\n",
       "   'Satisfies the 2010 American College of Rheumatology/European League Against Rheumatism Criteria for Rheumatoid Arthritis.',\n",
       "   'Rheumatoid arthritis of < 2 years duration',\n",
       "   'Has active disease at the time of enrollment. (Modified Disease Activity Score ≥ 3.2)',\n",
       "   'Demonstrates functional status of class I, II, or III as defined by American College of Rheumatology revised criteria.',\n",
       "   'Is on methotrexate 25 mg weekly or the maximum tolerated dose, therapy should be for at least 3 months duration and on the highest tolerated dose for the last 4 weeks.',\n",
       "   'Is able and willing to self-inject study drug if assigned to the injectable drug group or have a designee who can do',\n",
       "   '8. Is PPD negative (skin test for TB exposure) or completed ≥1 month of latent TB treatment if PPD ≥ 5 or quantiferon (blood test for TB exposure) positive.',\n",
       "   'Is having normal Chest X-Ray.',\n",
       "   'Is Hepatitis B Negative.',\n",
       "   'Not on NSAID (e.g. Ibuprofen) or receiving the same dose of the same NSAID throughout the study period unless side effects occur',\n",
       "   'All patients in childbearing age should use effective birth control methods',\n",
       "   'Is capable of understanding and signing an informed consent form.'],\n",
       "  'exclusion': ['Received any previous treatment with Tumor Necrosis Factor inhibitor or other biologic treatments for Rheumatoid Arthritis (such as abatacept, rituximab, tocilizumab, or Anakinra).',\n",
       "   'Received any previous treatment with oral corticosteroids (e.g. prednisolone)',\n",
       "   'Has a known or expected allergy, contraindication, or hypersensitivity to the medications tested.',\n",
       "   \"Any major illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in, and completion of, the study, or could preclude the evaluation of the subject's response.\",\n",
       "   'Received any of the following within 4 weeks before baseline visit: leflunomide, hydroxychloroquine, chloroquine, cyclosporine, sulphasalazine, auranofin, intramuscular gold, azathioprine, minocycline, or D-penicillamine',\n",
       "   'Received cyclophosphamide within 6mths before screening visit.',\n",
       "   'Received any live (attenuated) vaccines within 4 weeks before screening visit.',\n",
       "   'Received intra-articular or subcutaneous corticosteroid injection within 4 weeks before screening visit.',\n",
       "   'Received bolus intramuscular/ intravenous treatment with corticosteroids (> 20mg prednisone or equivalent) within 4 weeks before screening visit.']},\n",
       " {'nct_id': 'NCT01724931',\n",
       "  'inclusion': ['> 18 years of age.',\n",
       "   'A diagnosis of RA established by the ACR/EULAR 2010 criteria applied to patients who: 1) have >1 joint with definite clinical synovitis (swelling); 2) with the synovitis not better explained by another disease. Add scores of categories A-D; a score >6/10 is required for study entry.',\n",
       "   'Joint involvement: 1 large joint=0; 2-10 large joints=1; 1-3 small joints (with or without involvement of large joints=2; 4-10 small joints (with or without involvement of large joints)=3; >10 joints (at least 1 small joint)=5.',\n",
       "   'Serology (at least 1 test result is needed for classification): Negative RF and negative ACPA=0; Low-positive RF or low-positive ACPA=2; High-positive RF or high-positive ACPA=3.',\n",
       "   'Acute-phase reactants (at least 1 test result is needed for classification): Normal CRP and normal ESR=0; Abnormal CRP or abnormal ESR=1.',\n",
       "   'Duration of symptoms: less than 6 weeks=0; 6 weeks or greater=1.',\n",
       "   'Class I, II or III functional according to the ACR 1992 revised criteria for the classification of global functional status in',\n",
       "   '4. RA is active, defined as ≥ 6 swollen joints and ≥ 6 tender joints.',\n",
       "   'Ability to understand and sign written informed consent.',\n",
       "   'For sexually active men and for women of childbearing potential, an adequate form of contraception.',\n",
       "   'For pre-menopausal women, a negative pregnancy test, obtained within 1 week prior to first study drug dose.',\n",
       "   'Negative serology for hepatitis B and hepatitis',\n",
       "   '9. The following screening laboratory blood tests must have the following values, or not clinically significant as determined by the PI and Medical Monitor: WBC WNL; absolute neutrophil count > lower limit of normal; platelet count WNL; hemoglobin >10.0 g/dL; AST WNL.',\n",
       "   'Adequate renal function: GFR estimated by Cockcroft-Gault formula >60 ml/min'],\n",
       "  'exclusion': ['Known history of hepatitis, HIV infection, interstitial lung disease.',\n",
       "   'Alcohol consumption on a regular basis and unwilling, or unable, to discontinue this consumption during the study period.',\n",
       "   'Prior methotrexate or aminopterin therapy.',\n",
       "   'Prior biologic drug therapy (e.g., etanercept, adalimumab, infliximab).',\n",
       "   'Within 2 weeks prior to Study Day 0, or on Study Day 0, or at any time during the study, use of any of the following medications that may result in drug/drug interactions with AMT: trimethoprim with or without sulfamethoxazole; sulfonamides; sulfonylureas; pyrimethamine; triamethamine; dipyridamole; colchicine; probenecid; aminoglycosides; theophylline; phenytoin; and folinic acid (i.e., leucovorin).',\n",
       "   'At Study Day 0 use of DMARDs and biologics (except antimalarials) including oral or injectable gold, azathioprine, penicillamine, sulfasalazine or cyclosporine. Subjects previously treated with any of these medications are eligible provided a 28 day wash-out is completed prior to Study Day',\n",
       "   'Antimalarial can be continued at the same dose if they have been administered at the same dose for 8 weeks before Study Day 0, and they will be administered at the same dose throughout the study. NSAIDs or corticosteroid (≤ 10 mg prednisone or equivalent/day) may be continued at the same dose if they have been used at a stable dose for two weeks prior to Study Day 0, and will be continued at the same doses throughout the study.',\n",
       "   'Use of corticosteroids in excess of 10 mg prednisone or equivalent/day.',\n",
       "   'Known concurrent malignancy except basal or squamous cell skin carcinoma, or cervical carcinoma in situ.',\n",
       "   'Concurrent participation in another clinical trial involving experimental treatment within 30 days of Study Day',\n",
       "   '10. Current and uncontrolled infection, cardiovascular, renal, pulmonary, hepatic or GI conditions that will interfere with the conduct of the trial or pose a morbid risk.',\n",
       "   \"Investigator's opinion that a concurrent disease or condition impairs the subject's ability to complete the trial: includes psychological, familial, sociological, geographical or medical conditions.\"]},\n",
       " {'nct_id': 'NCT01721057',\n",
       "  'inclusion': ['Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA',\n",
       "   'Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints',\n",
       "   'Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥ (greater than or equal to) 1.2 times the upper limit of normal (ULN)',\n",
       "   'Have had an insufficient response or are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs) and either:',\n",
       "   'Have had regular use of a cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry',\n",
       "   \"For participants not receiving a cDMARD at the time of entry, the investigator will document in the participant's history that the participant had failed, was unable to tolerate, or had a contraindication to treatment with a cDMARD\"],\n",
       "  'exclusion': ['Are currently receiving corticosteroids at doses > (greater than)10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization',\n",
       "   'Are currently receiving concomitant treatment with methotrexate (MTX), hydroxychloroquine, and sulfasalazine or combination of any 3 cDMARDs',\n",
       "   'Have ever received any biologic DMARD',\n",
       "   'Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study',\n",
       "   'Have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study',\n",
       "   'Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization',\n",
       "   \"Have active fibromyalgia that, in the investigator's opinion, would make it difficult to appropriately assess RA activity for the purposes of this study\",\n",
       "   \"Have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis,spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout(participants with secondary Sjogren's syndrome are not excluded.)\",\n",
       "   \"Have a diagnosis of Felty's syndrome\",\n",
       "   'Have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant',\n",
       "   'Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure',\n",
       "   'Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data',\n",
       "   'Are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair',\n",
       "   'Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of < (less than) 40 milliliter per minute per 1.73 m^2 (mL/min/1.73 m^2)',\n",
       "   'Have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin >/=1.5 times the ULN',\n",
       "   'Have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years',\n",
       "   'Have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)',\n",
       "   'Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection',\n",
       "   'Have had symptomatic herpes zoster infection within 12 weeks prior to study entry',\n",
       "   'Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, postherpetic neuralgia)',\n",
       "   'Are immunocompromised and, in the opinion of the investigator, are at an unacceptable risk for participating in the study',\n",
       "   'Have a history of active hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)',\n",
       "   \"Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study\",\n",
       "   \"Have screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study (eg, Fridericia's corrected QT interval >500 millisecond [msec] for men and >520 msec for women)\",\n",
       "   'Have symptomatic herpes simplex at the time of study enrollment',\n",
       "   'Have evidence of active or latent tuberculosis (TB)']},\n",
       " {'nct_id': 'NCT01985464',\n",
       "  'inclusion': ['Signed inform consent by the subject.',\n",
       "   'Age older than 18 years and ability to understand the planned treatment.',\n",
       "   'Patients of either gender with RA with a duration of 6 months to 20 years defined as the presence of at least three of the following criteria: 3 or more painful, 2 or more swollen joints, morning stiffness for at least 45 minutes (on average during the week prior to entry), and an erythrocyte sedimentation rate (ESR) of at least 28',\n",
       "   '- Non-responsive to at least one course of one DMARD selected from the group comprising of: gold salts, leflunomide, methotrexate, and hydroxychloroquine.',\n",
       "   'Second-line agents are discontinued at least 4 weeks prior to entry.',\n",
       "   'Able to tolerate ALL study procedures',\n",
       "   'Able to give informed Consent',\n",
       "   'Negative for HcG with a serum pregnancy test',\n",
       "   'Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000,',\n",
       "   'Life expectancy of 6 months or more in the opinion of the investigator',\n",
       "   'Serum bilirubin, ALT, AST up to 2.5 time the upper level of normal.',\n",
       "   'Controlled blood pressure (systolic blood pressure ≤140 and a diastolic blood pressure of ≤90 mmHG) and established anti-hypertensive therapy as necessary prior to entry into the study',\n",
       "   'Patient has received stable, standard medical therapy for at least one month with no new medications to treat the disease introduced in the last month.',\n",
       "   'Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia) are adequately controlled in the opinion of the investigator',\n",
       "   'Fertile patients (male and female) must agree to use an appropriate form of contraception while participating in the study.'],\n",
       "  'exclusion': ['Female who is pregnant or nursing, or of child-bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.',\n",
       "   'History of prior radiation exposure for oncological treatment.',\n",
       "   'History of Bone Marrow Disorder (especially NHL, MDS)',\n",
       "   'History of abnormal bleeding or clotting.',\n",
       "   'History of Liver Cirrhosis.',\n",
       "   'End stage renal disease (Creatinine ≤ 3.0 mg / dl) and/or dialysis',\n",
       "   'Active clinical infection being treated by antibiotics before one week enrollment',\n",
       "   'Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.',\n",
       "   'History of life-threatening arrhythmias, except if an automated implantable cardioverter defibrillator (AICD) is implanted',\n",
       "   'Life expectancy <6 months due to concomitant illnesses',\n",
       "   'Known cancer and undergoing treatment; chemotherapy and/or radiotherapy',\n",
       "   'Patients receiving treatment with hematopoietic growth factors (e.g., EPO, G-CSF)',\n",
       "   'Patients who can not stop anticoagulation therapy (warfarin) 72hrs prior to infusion',\n",
       "   'Patients who can not stop anti-platelet therapy (clopidogrel) 7 days prior infusion',\n",
       "   'Prior admission for substance abuse',\n",
       "   'Body Mass Index (BMI) of 40 kg/m2 or greater',\n",
       "   'Patient receiving experimental medication or participating in another clinical study within 30 days of signing the informed consent',\n",
       "   'In the opinion of the investigator or the sponsor, the patient is unsuitable for cellular therapy']},\n",
       " {'nct_id': 'NCT01981473',\n",
       "  'inclusion': ['Age 18 years or older.',\n",
       "   'Diagnosis of RA based on the 1987 American College of Rheumatology revised criteria',\n",
       "   'Current continuous treatment with either etanercept, adalimumab, or infliximab for a minimum of 6 months and maximum of 24 months.'],\n",
       "  'exclusion': ['Treatment with biosimilar or investigational etanercept, adalimumab, or infliximab within past 6 months.',\n",
       "   'Treatment with any other investigational drugs within past 3 months or five half lives of the drug, whichever is longer.',\n",
       "   'Any medical condition that would interfere with rheumatoid arthritis evaluation or other study assessments (eg, fibromyalgia, lupus).']},\n",
       " {'nct_id': 'NCT01987479',\n",
       "  'inclusion': ['Participants with a diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria.',\n",
       "   'Oral corticosteroids (≤10 mg/day prednisone or equivalent), nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic DMARDs are permitted if on a stable dose regimen for greater than or equal to (≥]) 4 weeks prior to Baseline.',\n",
       "   'Use of effective contraception throughout the study as defined by protocol; female participants of childbearing potential cannot be pregnant.'],\n",
       "  'exclusion': ['Presence of clinically significant medical conditions.',\n",
       "   'History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal disease that might predispose to perforation.',\n",
       "   'Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections.',\n",
       "   'Any infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening.',\n",
       "   'Clinically significant findings on laboratory tests.',\n",
       "   'Positive hepatitis B surface antigen or hepatitis C antibody.',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years.',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years, or breast cancer diagnosed within the previous 20 years.',\n",
       "   'History of alcohol, drug, or chemical abuse within 1 year prior to Screening.',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation.',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline.',\n",
       "   \"Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome with RA is permitted.\",\n",
       "   'Functional Class IV as defined by the ACR Classification of Functional Status in',\n",
       "   '- Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of 16 years.',\n",
       "   'Prior history of or current inflammatory joint disease other than',\n",
       "   '- Exposure to tocilizumab (either intravenous or SC) at any time prior to Baseline.',\n",
       "   'Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening.',\n",
       "   'Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, with alkylating agents such as chlorambucil, or with total lymphoid irradiation.',\n",
       "   'Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.']},\n",
       " {'nct_id': 'NCT01988012',\n",
       "  'inclusion': ['Adults >/= 18 years of age',\n",
       "   'Diagnosis of active rheumatoid arthritis (RA) according to the revised (1987) American College of Rheumatology (ACR) criteria or European League Against Rheumatism (EULAR)/ACR (2010) criteria',\n",
       "   'Previously treated with the following: three non-biologic DMARDs, and not treated with any biologic agent OR one biologic agent (alone or in combination with non-biologic DMARDs), and discontinued that agent for a reason',\n",
       "   'Oral corticosteroids (</= 10 mg/day prednisone or equivalent), non-steroidal anti-inflammatory drug (NSAIDs) and non-biologic DMARDs are permitted if on a stable dose regimen for >/= 4 weeks prior to Baseline',\n",
       "   'Use of effective contraception throughout the study as defined by protocol; female patients of childbearing potential must not be pregnant'],\n",
       "  'exclusion': ['Presence of serious, uncontrolled, clinically significant medical conditions',\n",
       "   'History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower gastrointestinal (GI) disease that might predispose to perforation',\n",
       "   'Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections',\n",
       "   'Any infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening',\n",
       "   'Clinically significant findings on lab tests and/or hepatitis B or C, or human immunodeficiency virus (HIV) screenings',\n",
       "   'Active tuberculosis (TB) requiring treatments within the previous 3 years',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years, or breast cancer diagnosed within the previous 20 years',\n",
       "   'History of alcohol, drug, or chemical abuse within 1 year prior to Screening',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline',\n",
       "   \"Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome with RA is permitted\",\n",
       "   'Functional Class IV as defined by the ACR Classification of Functional Status in-Rheumatoid Arthritis',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of 16',\n",
       "   'Prior history of current inflammatory joint disease other than RA',\n",
       "   'Exposure to tocilizumab (either IV or subcutaneous administration) at any time prior to Baseline',\n",
       "   'Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening',\n",
       "   'Previous treatment with any cell-depleting therapies, including investigational agents approved therapies, with alkylating agents such as chlorambucil, or with total lymphoid irradiation',\n",
       "   'Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline']},\n",
       " {'nct_id': 'NCT01984268',\n",
       "  'inclusion': ['Male or female at least 18 years of age at the time of screening',\n",
       "   'Subject is diagnosed with RA no less than 6 months prior to the screening',\n",
       "   'Subject meets the 2010 ACR/EULAR Classification Criteria for RA (Arthritis Rheum 2010:62;2569-2581) with a score of ≥6',\n",
       "   'Subject is seropositive for RF and/or anti-CCP antibodies as part of the diagnostic criteria for RA',\n",
       "   'Subject has moderately to severely active RA during screening, as defined by a DAS28-ESR > 3.2',\n",
       "   'Subject has moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints',\n",
       "   'Subject has had an inadequate response to the continuous use of methotrexate for at least 12 weeks prior to study entry with a nonchanging dose for at least 8 weeks prior to study entry'],\n",
       "  'exclusion': ['Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening',\n",
       "   'Treatment with any biological agents within 4 weeks (or 5 half-lives of the agent, whichever is longer) of screening',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to baseline',\n",
       "   \"Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including Cushing's disease or uncontrolled diabetes mellitus) or gastrointestinal disease (including complicated diverticulitis, ulcerative colitis, or Crohn's disease.)\",\n",
       "   'Current liver disease as determined by principal investigator unless related to primary disease under investigation',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds)',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening',\n",
       "   'Active TB requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating treatment. Patients treated for tuberculosis with no recurrence in 3 years are permitted.',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years unless related to primary disease under investigation',\n",
       "   'Pregnant women or nursing (breast feeding) mothers',\n",
       "   'Patients with reproductive potential not willing to use an effective method of contraception.',\n",
       "   'History of alcohol, drug or chemical abuse within 1 year prior to screening.',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation.',\n",
       "   'Body weight of > 150 kg',\n",
       "   'Serum creatinine > 1.6 mg/dL (141 µmol/L) in female subjects and > 1.9 mg/dL (168 µmol/L) in male subjects. Subjects with serum creatinine values exceeding limits may be eligible for the study if their estimated glomerular filtration rates (GFR) are >30',\n",
       "   'Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 times upper limit of normal (ULN)',\n",
       "   'Total Bilirubin > ULN',\n",
       "   'Platelet count < 100 x 109/L (100,000/mm3)',\n",
       "   'Hemoglobin < 85 g/L (8.5 g/dL; 5.3 mmol/L)',\n",
       "   'White Blood Cells < 3.0 x 109/L (3000/mm3)',\n",
       "   'Absolute Neutrophil Count < 2.0 x 109/L (2000/mm3)',\n",
       "   'Absolute Lymphocyte Count < 0.5 x 109/L (500/mm3)',\n",
       "   'Positive Hepatitis BsAg or Hepatitis C antibody',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization',\n",
       "   'A diagnosis of any of the followings: scleroderma, osteoporosis, infection throughout the body, ocular herpes simplex, history of or a current stomach ulcer, uncontrolled hypertension (systolic blood pressure greater than 160), or allergy to pig-derived proteins',\n",
       "   'Subject does not tolerate methotrexate and/or NSAID due to side effects or toxicities']},\n",
       " {'nct_id': 'NCT01980836',\n",
       "  'inclusion': ['Rheumatoid Arthritis patients treated with Tocilizumab for at least 3 months',\n",
       "   'Above the age of 18'],\n",
       "  'exclusion': ['Allergy to eggs']},\n",
       " {'nct_id': 'NCT01315652',\n",
       "  'inclusion': ['Rheumatoid Arthritis',\n",
       "   'Stable (no change in therapy)',\n",
       "   'Adult',\n",
       "   'Able to collaborate'],\n",
       "  'exclusion': ['Pregnant woman',\n",
       "   'Change of the therapy for 3 months before the inclusion',\n",
       "   'Alcoholism, toxicomania, psychological problem, sever co morbidity which could invalid the consent or limit the protocol compliance',\n",
       "   'No social coverage affiliate']},\n",
       " {'nct_id': 'NCT01317797',\n",
       "  'inclusion': ['Out-patients with active rheumatoid arthritis (RA), according to the ACR 1987 revised criteria, with low to moderate disease activity (DAS28-ESR ≥ 2.6 and ≤ 5.1)',\n",
       "   'Patients must be on stable doses of methotrexate (MTX) ≥ 7.5 and ≤ 25 mg/week for at least 12 weeks before the first injection, with appropriate folic acid supplementation',\n",
       "   'Age ≥ 18 years at Screening',\n",
       "   'Body weight at least 50 kg at Screening; BMI: ≥ 18.0 and ≤ 30.0 kg/m2 at Screening',\n",
       "   'Negative tuberculosis test at Screening',\n",
       "   'Heterosexually active male and female patients of childbearing potential are obliged to follow whatever contraceptive and / or breastfeeding restrictions may be required for their concomitant medication(s), including methotrexate. In addition, heterosexually active male and female patients of childbearing potential are required to use effective double-method contraception (one hormonal contraceptive or intrauterine device and one other additional contraceptive method) for 1 month before the first administration of the IMP, during the course of the trial, and for 6 month after the last injection of MT203. No special requirements are made for female patients proven to be post-menopausal (at least 2 years after last menstrual period and FSH ≥ 40IU/L), surgically sterilized or hysterectomized. Likewise no special requirements for heterosexually active male who are surgical sterilized. Pregnant or lactating female patients have to be excluded.'],\n",
       "  'exclusion': ['Participation in another clinical trial or previous dosing in this trial',\n",
       "   'Use of specified medications within certain timeframes or use of certain comedications',\n",
       "   'History or presence of specified diseases',\n",
       "   'Drug abuse',\n",
       "   'Certain laboratory parameters outside a specified range',\n",
       "   'Donation of blood',\n",
       "   'Relevant decrease in lung function',\n",
       "   'Infections, frequent or chronic infections, herpes zoster',\n",
       "   'Females: positive pregnancy test',\n",
       "   'Presence of history of tuberculosis',\n",
       "   'History of malignancy']},\n",
       " {'nct_id': 'NCT01313208',\n",
       "  'inclusion': ['Male or female ≥18 and ≤80 years of age at time of screening',\n",
       "   'Diagnosed with rheumatoid arthritis as determined by meeting 1987 American College of Rheumatology (ACR) classification criteria and has had rheumatoid arthritis for at least 6 months',\n",
       "   'Moderate rheumatoid arthritis during screening, as defined by a disease activity score (28 joint) calculated using the C-reactive protein formula (DAS28-CRP) > 3.2 and ≤ 5.1',\n",
       "   'Active rheumatoid arthritis defined as ≥ 3 swollen joints (out of 28 joints examined) and ≥ 3 tender/painful joints (out of 28 joints examined) at screening and baseline. (A full 66/68 count joint count will be performed at baseline, but only joints in the 28-count joint count will be considered for eligibility. The 28-joint count consists of the finger joints excluding the distal interphalangeal joints, the wrists, elbows, shoulders, and knees)',\n",
       "   'Must be currently taking a DMARD such as methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine'],\n",
       "  'exclusion': ['Prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening',\n",
       "   'Class IV rheumatoid arthritis according to ACR revised response criteria',\n",
       "   'Any active infection (including chronic or localized infections) for which anti-infectives were indicated within 28 days prior to first investigational product dose',\n",
       "   'Previously used more than one experimental biologic DMARD. Patient with prior use of no more than one experimental biologic is permitted if the subject received no more than 8 weeks of treatment. The use of the experimental biologic must not have occurred within 2 months of the first dose of investigational product',\n",
       "   'Previously used more than one commercially available biologic DMARD. Subject with prior use of no more than one commercially available biologic is permitted if the patient received no more than 8 weeks of treatment and did not discontinue because of lack of effect. The use of the biologic must not have occurred within 2 months of the first dose of investigational product. Acceptable prior use of biologics include the following examples:',\n",
       "   'No more than 4 injections of adalimumab',\n",
       "   'No more than 8 (50 mg) injections of etanercept',\n",
       "   'No more than 2 infusions of infliximab',\n",
       "   'No more than 2 infusions of abatacept',\n",
       "   'Additional inclusion (exclusion) criteria may apply']},\n",
       " {'nct_id': 'NCT01670045',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patient in whom the treating physician has made the decision to commence RoActemra/Actemra treatment in accordance with the local label (DMARD-IR, TNF-IR or need of RoActemra/Actemra monotherapy); this can include patients who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Patients who have received treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'Patients with a history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01677416',\n",
       "  'inclusion': ['RA with at least one year since diagnosis',\n",
       "   'Asymptomatic feet',\n",
       "   'Age between 18 and 65 years Control group',\n",
       "   'absence of known osteoarticular disease'],\n",
       "  'exclusion': ['Peripheral venous insufficiency with retrograde venous flow and/or ochre dermatitis',\n",
       "   'Previous surgical intervention and/or fracture in feet/ankles',\n",
       "   'Intra-articular corticosteroid injection in previous three months in any of the joints evaluated',\n",
       "   'Foot neuropathy',\n",
       "   'Pain and swelling in feet or ankles']},\n",
       " {'nct_id': 'NCT01672970',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment (in accordance with the local label); this can include patients who have received RoActemra/Actemra treatment within 8 week prior to the enrolment visit'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01671059',\n",
       "  'inclusion': ['Adult participants, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) American College of Rheumatology (ACR) criteria',\n",
       "   'Participants in whom the treating physician made the decision to commence tocilizumab treatment (in accordance with the local label); this could include participants who had received tocilizumab treatment within 8 weeks prior to the enrollment visit'],\n",
       "  'exclusion': ['Participants who had received tocilizumab more than 8 weeks prior to the enrollment visit',\n",
       "   'Participants who had previously received tocilizumab in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever was longer) before starting treatment with tocilizumab',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01676701',\n",
       "  'inclusion': ['Ambulatory males or females ≥18 years of age',\n",
       "   'Diagnosis of adult-onset RA',\n",
       "   'Active RA (at least 8/68 tender and at least 8/66 swollen joints)',\n",
       "   'Screening C-reactive protein (CRP) >1.2 times the upper limit of normal (ULN) or a screening erythrocyte sedimentation rate (ESR) >28 millimeters per hour (mm/hr)',\n",
       "   'Documented history of, or current, positive rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP Ab) test',\n",
       "   'Regular use of methotrexate (MTX) for at least 12 weeks and stable dose (10 to 25 mg/week) for at least 8 weeks prior to baseline',\n",
       "   'American College of Rheumatology (ACR) functional class I, II, or III',\n",
       "   'Able and willing to inject tabalumab by themselves (or have an assistant who will inject tabalumab) and able and willing to complete all study procedures',\n",
       "   'Able and willing to have blood drawn for pharmacokinetic (PK) sampling'],\n",
       "  'exclusion': ['Use of oral corticosteroids at average daily doses of >10 milligrams per day (mg/day) of prednisone or its equivalent within 6 weeks prior to baseline',\n",
       "   'Injection of any parenteral (including intraarticular) corticosteroid within 6 weeks of baseline',\n",
       "   'Have previously discontinued treatment with a biologic disease-modifying antirheumatic drug (DMARD) or a novel drug that interrupts cytokine signaling [for example, Janus kinase (JAK) inhibitors] due to insufficient efficacy',\n",
       "   'Participants who had discontinued biologic DMARDS for reasons other than efficacy will not be excluded but must have done so prior to baseline',\n",
       "   'Participants who discontinued a JAK inhibitor for lack of efficacy',\n",
       "   'Participants who discontinued a JAK inhibitor for reasons other than efficacy will not be excluded, but must have done so prior to baseline for 21 days',\n",
       "   'Previous severe reaction to any biologic therapy that, in the opinion of the Investigator, would pose an unacceptable risk to the participant if participating in the study',\n",
       "   'Have had an inadequate response to treatment with 3 or more of the following DMARDs prescribed alone or in combination at approved doses for a minimum of 90 days: leflunomide, azathioprine, cyclosporine, and/or sulfasalazine',\n",
       "   'Use of other DMARDs (for example, gold salts, cyclosporin, azathioprine, or any other immunosuppressives) other than MTX, hydroxychloroquine, chloroquine, or sulfasalazine, or the use of a JAK inhibitor in the 8 weeks prior to baseline']},\n",
       " {'nct_id': 'NCT01679951',\n",
       "  'inclusion': ['Has had rheumatoid arthritis for at least 6 months prior to the date of signing the informed consent at screening',\n",
       "   'Must be positive for either anti-cyclic citrullinated peptide antibody or rheumatoid factor in serum at screening',\n",
       "   'Must have active rheumatoid arthritis (at least 6 swollen and 6 tender joints using a 66/68 joint count at the time of screening and at baseline and Serum C reactive protein greater than or equal to 0.80 mg/dL at the time of screening',\n",
       "   'Has been treated with and tolerated methotrexate treatment at dosages from 10 to 25 mg/week inclusive, for a minimum of 6 months with stable dose for at least 8 weeks prior to the date of signing the informed consent at screening'],\n",
       "  'exclusion': [\"Has inflammatory diseases other than rheumatoid arthritis, including but not limited to adult onset Still's disease, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, and Lyme disease that might confound the evaluation of the benefit of study agent therapy\",\n",
       "   'Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive or uncontrolled',\n",
       "   'Has ever received any approved or investigational biologic agent for a rheumatoid indication',\n",
       "   'Has been treated with any nonbiologic disease modifying antirheumatic drugs within 4 weeks prior to the first administration of study agent']},\n",
       " {'nct_id': 'NCT01941940',\n",
       "  'inclusion': ['Diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria',\n",
       "   'Moderate to severe RA (CDAI at least [>/=] 10 and DAS28 >/=3.2) at screening',\n",
       "   'Tumor necrosis factor inhibitors-inadequate responder (TNF-IR), methotrexate-inadequate responder (MTX-IR), and/or DMARDs-inadequate responder (DMARDs-IR)',\n",
       "   'Oral corticosteroids (less than or equal to [</=] 10 mg per day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for >/=4 weeks prior to baseline',\n",
       "   'Permitted non-biologic DMARDs are allowed if at a stable dose for >/=4 weeks prior to baseline',\n",
       "   'Receiving treatment on an outpatient basis, not including tocilizumab',\n",
       "   'Females of childbearing potential and males with female partners of childbearing potential must agree to use a reliable means of contraception for at least 3 months following the last dose of tocilizumab'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 12 months following baseline',\n",
       "   \"Rheumatic autoimmune disease other than RA; secondary Sjögren's syndrome with RA is permitted\",\n",
       "   'Functional Class IV as defined by the ACR Classification of Functional Status in RA',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal disease',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening',\n",
       "   'Active tuberculosis (TB) requiring treatment within the previous 3 years',\n",
       "   'Positive for hepatitis B surface antigen or hepatitis C antibody',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (except for basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years',\n",
       "   'Pregnant or breast feeding women',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation']},\n",
       " {'nct_id': 'NCT01948388',\n",
       "  'inclusion': ['Patient must be at least 18 years old at the screening visit.',\n",
       "   'Patient must be able to understand the information provided to them and to give written Informed Consent.',\n",
       "   'Female patients must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral/parenteral/implantable hormonal contraceptives, Intrauterine Device (IUD), or barrier and spermicide). Abstinence only is not an acceptable method. Patients must agree to use adequate contraception during the study and for 4 weeks after their last dose of corticotrophin (ACTH). Male patients must agree to ensure they or their female partner(s) are using adequate contraception during the study and for 4 weeks after the patient receives their last dose of corticotrophin (ACTH).',\n",
       "   'Patients must have a new diagnosis of adult-onset rheumatoid arthritis (RA) as defined by the 2010 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria and who have had symptoms for <1 year.',\n",
       "   'Patients must be experiencing mild to moderate rheumatoid arthritis ( RA), have at least 6 tender and 6 swollen joints at screening and a clinical disease activity index (CDAI) score of > 6.0',\n",
       "   'A Baseline Magnetic Resonance Imaging ( MRI) must show the presence of osteitis or erosions in the hand or wrist.',\n",
       "   'Patients must be able and willing to comply with the requirements of the study protocol.',\n",
       "   'Patients must have a C-reactive Protein (CRP) or erythrocyte sedimentation rate (ESR) > upper limits of normal'],\n",
       "  'exclusion': ['Patients who have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis).',\n",
       "   'Patients with exposure to any disease modifying antirheumatic drug (DMARD), Biologic, Non-biologic or experimental medication for the treatment of rheumatoid arthritis (RA).',\n",
       "   \"Patients with a non-inflammatory type of arthritis (e.g. osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the patient's primary diagnosis of rheumatoid arthritis (RA).\",\n",
       "   'Patients with history of an infected joint prosthesis at any time with that prosthesis still in situ.',\n",
       "   'Patients have received prohibited medication:',\n",
       "   'non-steroidal anti-inflammatory drug (NSAIDs /COX-2 inhibitors) (any change in dose regimen in the 7 days prior to baseline)',\n",
       "   'Oral corticosteroids within 4 weeks of baseline',\n",
       "   'Intra-muscular, intra-venous, intra-articular (IM/IV/IA) corticosteroids/ Intra-articular (IA) Hyaluronic acid (any dose 28 days prior to baseline)',\n",
       "   'Female patients who are breast-feeding, pregnant, or plan to become pregnant during the trial or within twelve weeks following last dose of study drug.',\n",
       "   'Patients with a history of chronic infection due to fungal, parasitic or mycotic pathogens during the preceding year, recent serious or life-threatening infection within 6 months (including herpes zoster), or any current sign or symptom that may indicate an infection.',\n",
       "   'Patients with active Tuberculosis (TB) (or history of active TB), positive chest X-ray for TB, or positive (defined as induration of ≥ 5mm) purified protein derivative (PPD) skin test, positive QuantiFERON, or patients having close contact with an individual with active',\n",
       "   'Patients having a PPD skin test ≥ 5 mm or a positive QuantiFERON test can enter the study, provided that active TB is excluded and provided that they are adequately treated for latent TB (e.g., isonicotinic acid hydrazide [INH therapy] for 9 months [with vitamin B6]) and provided that appropriate treatment is initiated simultaneously with the first administration of ACTH.',\n",
       "   'Patients at a high risk of infection (e.g. leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections and patients who are permanently bedridden or wheelchair bound).',\n",
       "   'Patients with a known allergy or intolerance to steroids 11 Concurrent malignancy or a history of malignancy (other than carcinoma of the cervix or basal cell carcinoma successfully treated more than 5 years prior to screening).',\n",
       "   'Patients with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease.',\n",
       "   'Patients with class III or IV congestive heart failure according to the New York Heart Association (NYHA) 1964 classification criteria.',\n",
       "   'Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis).',\n",
       "   \"Patients with any other condition (e.g. clinically significant laboratory values) which in the Investigator's judgment would make the patient unsuitable for inclusion in the study.\",\n",
       "   'Patients who have a metal device affected by MRI (e.g., any type of electronic, mechanical, or magnetic implant; cardiac pacemaker; aneurysm clip(s); implanted cardioverter defibrillator; or a cochlear implant)',\n",
       "   'Patients who have a potential ferromagnetic foreign body (metal slivers, metal shavings, other metal objects) for which they have sought medical attention.',\n",
       "   'Concurrent steroid use for any concomitant disease.',\n",
       "   'Subjects who are known to be Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C positive']},\n",
       " {'nct_id': 'NCT01941095',\n",
       "  'inclusion': ['Diagnosis of active rheumatoid arthritis according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria',\n",
       "   'Oral corticosteroids (less than or equal to [</=] 10 milligrams per day [mg/day] prednisolone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for greater than or equal to [>/=] 4 weeks prior to baseline',\n",
       "   'Permitted non biologic DMARDs are allowed if a stable dose for at least 4 weeks prior to baseline',\n",
       "   'Receiving treatment on an outpatient basis, not including tocilizumab',\n",
       "   'Females of childbearing potential and males with female partners of childbearing potential must agree to use a reliable means of contraception during the study; females of childbearing potential must use a reliable means of contraception for at least 3 month following the last dose of tocilizumab'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline',\n",
       "   \"Rheumatic autoimmune disease other than rheumatoid arthritis; secondary Sjögren's syndrome with rheumatoid arthritis is permitted\",\n",
       "   'Functional Class 4 as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Participants with lack of peripheral venous access',\n",
       "   'Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline',\n",
       "   'Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of screening',\n",
       "   'Previous treatment with any cell-depending therapies',\n",
       "   'Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline',\n",
       "   'Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to baseline',\n",
       "   'Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal disease',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections',\n",
       "   'Any major episode of infection requiring hospitalization of treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening',\n",
       "   'Active tuberculosis (TB) requiring treatment within the previous 3 years',\n",
       "   'Positive for hepatitis B surface antigen or hepatitis C antibody',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (except for basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years',\n",
       "   'Pregnant or breast feeding women',\n",
       "   'History of alcohol, drug or chemical abuse within 1 year prior to screening',\n",
       "   'Neuropathies or other conditions that interfere with pain evaluation']},\n",
       " {'nct_id': 'NCT01941433',\n",
       "  'inclusion': ['Be 18 years of age or older',\n",
       "   'Have a diagnosis of rheumatoid arthritis',\n",
       "   'Be under the ongoing care of a rheumatologist',\n",
       "   'Be comfortable using a computer and online applications',\n",
       "   'Have access to an Internet connection',\n",
       "   'Be able to read and write English without needing a translator'],\n",
       "  'exclusion': ['Younger than 18 years of age;',\n",
       "   'Diagnoses of arthritis other than rheumatoid arthritis',\n",
       "   'not under the ongoing care of a rheumatologist',\n",
       "   'not comfortable using a computer',\n",
       "   'lack of Internet access',\n",
       "   'inability to read and write in English without a translator']},\n",
       " {'nct_id': 'NCT01942174',\n",
       "  'inclusion': ['Adult (>18 yeas old) suffers from rheumatoid arthritis considering ACR/EULAR 2010 criteria',\n",
       "   'Rheumatoid arthritis considering 3,2<DAS<5,1',\n",
       "   'Patient did not treat by long term treatment or has stopped a treatment by sulfasalazine, hydroxychloroquine or methotrexate for at least 3 months',\n",
       "   'Patient has never treated by biotherapy',\n",
       "   'Patient has never vaccinated against pneumococcal',\n",
       "   'Patient has signed study consent form'],\n",
       "  'exclusion': ['Patient has ever treated by leflunomide or has treated previously by leflunomide (last 3 months)',\n",
       "   'Patient is currently treated by methotrexate or has treated previously by methotrexate (last 3 months)',\n",
       "   'Contraindication to methotrexate: renal insuffisance, alcoolic, chronic hepatisis, infectious condition, AIDS, hematological failure (cytopeny), pregnancy, obesity, diabet, respiratory disease, gastric ulcer',\n",
       "   'Contraindication to corticotherapy',\n",
       "   'Pregnancy or pregancy wish',\n",
       "   'Nursing',\n",
       "   'Absence of oral contraception for women of childbearing age',\n",
       "   'Patient of age protected by law et deprived of liberty',\n",
       "   'Subject who refuses to be vaccinated against pneumococcis agent',\n",
       "   'Previous history of vaccination allergy (anaphylactic shok, Quincke oedema...)',\n",
       "   'Gluten hypersensivity or intolerance',\n",
       "   'Other vaccination during the last month before inclusion',\n",
       "   'Ig perfusion during the last 3 months period before the study inclusion or during the study duration',\n",
       "   'Patient currently treated by anticoagulant or has not been stopped for at least 48h before the study inclusion or hemostasis failure which is contraindicated with muscular injection',\n",
       "   'Participation with an other clinical trial']},\n",
       " {'nct_id': 'NCT01940926',\n",
       "  'inclusion': ['Patients fulfilled the 1987 revised criteria of the American College of Rheumatology (ACR) for RA;',\n",
       "   'Males and females, ≥18 years old'],\n",
       "  'exclusion': ['Concurrent medical conditions of other autoimmune diseases',\n",
       "   'Latent or active joint infection or joint injury',\n",
       "   'Renal dysfunction (serum level of creatinine more than 1.2 mg/dL)',\n",
       "   'Females planning to bear a child recently or with childbearing potential',\n",
       "   'Known severe allergy or hypersensitivity to intravenous radiographic contrast',\n",
       "   'Inability to lie still for the entire imaging time because of cough, pain, etc',\n",
       "   'Inability to complete the needed examinations due to severe claustrophobia, radiation phobia, etc',\n",
       "   'Concurrent severe and/or uncontrolled and/or unstable other medical disease that, in the opinion of the investigator, may significantly interfere with study compliance']},\n",
       " {'nct_id': 'NCT01096823',\n",
       "  'inclusion': ['People with rheumatoid arthritis between the ages of 16-35',\n",
       "   'Diagnosis of RA, according to the revised 1987 ACR criteria, or juvenile idiopathic arthritis (JIA) for at least 6 months',\n",
       "   'Concomitant use of disease modifying antirheumatic medications (hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, etc) biologic agents (infliximab, etanercept, adalimumab, abatacept, rituximab, anakinra) is permitted provided that the dose(s) have been stable for 4 weeks prior to screening, and may reasonably be expected to remain on stable doses throughout the duration of the trial',\n",
       "   'Concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) and low dose corticosteroids (e.g prednisone at doses of 10 /day prednisone or equivalent is permitted provided that the dose(s) have been stable for 4 weeks prior to screening, and may reasonably be expected to remain on stable doses throughout the duration of the trial',\n",
       "   'Disease activity, as defined using a 28 joint count by > 5 tender joints, > 5 swollen joints, and one of the following: ESR > 28 mm/hour, CRP > 1.5 mg/dL, duration of a.m. stiffness > 45 minutes',\n",
       "   'Ability to provide written informed consent',\n",
       "   'Ability to speak and understand English'],\n",
       "  'exclusion': ['Intra-articular steroid injections within 4 weeks of screening',\n",
       "   'Treatment with any investigational agent within 8 weeks of screening or 5 half-lives of the investigational drug (whichever is longer)',\n",
       "   'History of drug, alcohol, or chemical abuse within 6 months prior to screening',\n",
       "   'Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion that might affect the interpretation of the results or render the patient at high risk from treatment complications',\n",
       "   'Inability to comply with study and follow-up procedures',\n",
       "   'Currently pregnant',\n",
       "   'Inability to speak or understand English',\n",
       "   'Any recent injury.']},\n",
       " {'nct_id': 'NCT01090570',\n",
       "  'inclusion': ['Male or female patients ≥ 18 years old with a diagnosis of rheumatoid arthritis by ACR criteria for ≥ 3 months.',\n",
       "   'Prior to Baseline, patients must be on oral or subcutaneous methotrexate (≥ 10 mg/week and ≤ 25 mg/week) for at least 12 weeks (with a stable dose for at least 4 weeks) and folate (≥ 5 mg/week) for at least 6 weeks, and willing to continue on this regimen for the duration of the study.',\n",
       "   'Adequate hematologic, hepatic, and renal function (absolute neutrophil count ≥ 1.5 X 109/L, Hgb > 9 g/dL, platelet count ≥ 100 X 109/L, AST/ALT WNL, albumin ≥ 3 g/dL, calculated CrCl>60 mL/min using Cockcroft-Gault formula).',\n",
       "   'Women of child-bearing potential must have a negative pregnancy test within 7 days prior to initiation of dosing and must agree to use a double barrier method of birth control from the time of the negative pregnancy test up to 30 days after the last dose of study drug. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year.',\n",
       "   'Fertile men must agree to use an acceptable method of birth control while on study drug. Acceptable methods of contraception must include either abstinence from the first dose of study drug through 4 weeks after the last dose of study drug, or use of a condom with instructions to the female partner of child-bearing potential to also be protected as above.',\n",
       "   'Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements.'],\n",
       "  'exclusion': ['Use of biologic response modifiers within the following periods prior to Day 1 Baseline: 4 weeks for Kineret (anakinra) and Enbrel (etanercept); 12 weeks for Remicade (infliximab), Humira (adalimumab), Simponi (golimumab), Orencia (abatacept), Actemra (tocilizumab), or Cimzia (certolizumab); 12 months for Rituxan.',\n",
       "   'Use of Arava (leflunomide) within 12 weeks prior to Day 1 Baseline or any immunosuppressive agents other then hydroxychloroquine or sulfasalazine within 4 weeks of Day 1 Baseline.',\n",
       "   'Investigational drug use within 4 weeks of Day 1 Baseline.',\n",
       "   'Concomitant use of DMARDs (other than methotrexate), biological response modifiers, or known strong inducers or inhibitors of CYP3A4.',\n",
       "   'Positive HepBsAg or HCV, or presence of clinically significant hepatic or biliary disease.',\n",
       "   'Uncontrolled intercurrent illness.',\n",
       "   'Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant bowel resection that would preclude adequate absorption.',\n",
       "   'QTc ≥ 450 msec at Screening.',\n",
       "   'The presence of a medical or psychiatric condition that, in the opinion of the Principal Investigator, makes the patient inappropriate for inclusion in this study.']},\n",
       " {'nct_id': 'NCT01096069',\n",
       "  'inclusion': ['Patients of both gender, aged greater than or equal to 18 years; and lower than 70 years.',\n",
       "   'Patients diagnosed with RA for at least 6 months according to the criteria of the American College of Rheumatology (ACR) in 1987 for classification of',\n",
       "   '3. Patients with a medical indication for therapy with rituximab, with prescription of this therapy for the first time and have not yet received the first dose.',\n",
       "   'DAS28 score greater than or equal to 3.2.',\n",
       "   'Use of adequate contraception, as judged from the attending physician.',\n",
       "   'Desire to participate voluntarily, the ability to understand the protocol, documented by signing the consent form (attached).'],\n",
       "  'exclusion': ['overlapping rheumatic disease, autoimmune lymphoproliferative and neoplastic.',\n",
       "   'active infection, patients with the use of cytotoxic drugs, presence of positive serology for HCV, HBV and HIV, active or latent tuberculosis.',\n",
       "   'allergy or hypersensitivity to rituximab.',\n",
       "   'pregnant woman or performing breastfeeding.',\n",
       "   'participating in another clinical study with intervention.',\n",
       "   'with functional class IV defined based on the criteria of Steinbrocker functional classification for',\n",
       "   '7. prior therapy with Rituximab.']},\n",
       " {'nct_id': 'NCT01589770',\n",
       "  'inclusion': ['Written informed consent',\n",
       "   'Age >= 18',\n",
       "   'RA only: meet American College of Rheumatology(ACR)criteria for Diagnosis of RA',\n",
       "   'Controls only: no evidence of RA or other inflammatory disease'],\n",
       "  'exclusion': ['Previous or current heart failure or ischemic cardiovascular disease (eg stroke, myocardial infarction, angina, CABG, stent).',\n",
       "   'Atrial fibrillation.',\n",
       "   'Known structural or functional cardiac abnormality, including pulmonary htn.',\n",
       "   'Glomerular filtration rate < 60 ml/min.',\n",
       "   'Pregnancy or breastfeeding.',\n",
       "   'Unable to perform MRI (claustrophobia, unable to fit in magnet,pacemaker,defibrillator or non-MR safe implant).',\n",
       "   'Hypersensitivity to gadolinium.']},\n",
       " {'nct_id': 'NCT01583244',\n",
       "  'inclusion': ['Patients must be diagnosed with: Adult Rheumatoid arthritis (RA): adult patients with moderate-to-severe active RA Or',\n",
       "   'Juvenile idiopathic RA: juvenile patients aged 6 years and older with moderate-to-severe active RA'],\n",
       "  'exclusion': ['Children aged <6 years',\n",
       "   'Pregnant or lactating women',\n",
       "   'Patients who are participating in another study',\n",
       "   'Patients known to be hypersensitive to the active component of the surveillance drug or any other component of the surveillance drug',\n",
       "   'Patients who had a positive tuberculosis screening test but were not treated with standard therapy before participating in the study',\n",
       "   'Patients who have a positive hepatitis virus test',\n",
       "   'Patients who were given a live vaccine concurrently with the surveillance drug or are expected to be given a live vaccine again within 3 months after discontinuation of the surveillance drug']},\n",
       " {'nct_id': 'NCT01587989',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Rheumatoid arthritis of >/= 1 year duration',\n",
       "   'Mild to moderate disease activity at screening (DAS 28 </= 4.5 and >2.6)',\n",
       "   'On methotrexate treatment for at least 12 weeks, at stable oral dose of (10)15 mg to 25 mg/week for at least 6 weeks prior to Day 1',\n",
       "   'Body weight </= 150 kg',\n",
       "   'Oral corticosteroids must have been at stable dose (maximum 10 mg/day) for at least 25 out of 28 days prior to baseline'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Functional class IV American College of Rheumatology (ACR) Classification',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Treatment with a biologic agent at any time prior to baseline',\n",
       "   'Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Pregnant or lactating women',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections',\n",
       "   'History of or currently active primary or secondary immunodeficiency',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 5 years',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'Positive for HIV infection']},\n",
       " {'nct_id': 'NCT01582880',\n",
       "  'inclusion': ['Ability to provide written informed consent and comply with study assessments for the full duration of the study.',\n",
       "   'Age > 18 years.',\n",
       "   'A negative urine pregnancy test.',\n",
       "   'Candidate for a Boston Keratoprosthesis/Corneal transplant.',\n",
       "   'Generally good stable overall health.',\n",
       "   'Patients with an eye at risk for a cornea sterile ulcer which includes:',\n",
       "   'Chemical injuries.',\n",
       "   'Autoimmune diseases (ocular cicatricial pemphigoid, Stevens Johnson Syndrome, systemic lupus erythematosus, rheumatoid arthritis, or other autoimmune diseases).',\n",
       "   'History of previous sterile corneal ulceration requiring a cornea transplant.'],\n",
       "  'exclusion': ['Age < 18 years.',\n",
       "   'Inability to provide written informed consent and comply with study assessments for the full duration of the study.',\n",
       "   'Pregnant or lactating women.',\n",
       "   'No or minimal tear production.',\n",
       "   'Ocular or periocular malignancy.',\n",
       "   'Inability to wear a contact lens due to lid abnormalities or shortened fornix.',\n",
       "   'Signs of current infection, including fever and current treatment with antibiotics.',\n",
       "   'Participation in another simultaneous medical investigation or trial']},\n",
       " {'nct_id': 'NCT01585064',\n",
       "  'inclusion': ['Patient has a diagnosis of rheumatoid arthritis',\n",
       "   'Patient is > 18 years of age',\n",
       "   'Patient is naïve to HUMIRA® (adalimumab) therapy.',\n",
       "   'Patient has access to reimbursement for their standard of care.',\n",
       "   'If female, patient is either: 1) not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or 2) of childbearing potential and practicing one of the following methods of birth control:',\n",
       "   'condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)',\n",
       "   'contraceptives (oral or parenteral) for three months prior to enrollment in the study',\n",
       "   'a vasectomized partner',\n",
       "   'total abstinence from sexual intercourse',\n",
       "   'If female and of childbearing potential, patient must have a negative serum pregnancy test performed at Screening.',\n",
       "   'Patient is able to give written informed consent and to complete the survey requirements.'],\n",
       "  'exclusion': ['Patients had a history of cancer within the past 5 years other than a successfully treated basal cell carcinoma and/or localized carcinoma in situ of the cervix',\n",
       "   'Patients with a history either of lymphoma or leukemia.',\n",
       "   'Patients with a history of untreated active tuberculosis, or listeriosis, or other currently active infections suggestive of significant or profound immunosuppression, such as Pneumocystis carinii, aspergillosis or other systemic protozoal or fungal infections.',\n",
       "   'Patients with a known positive HIV test.',\n",
       "   'Patients with a known positive HepBsAg test.',\n",
       "   'Patients with a persistent or severe infection(s) requiring hospitalization or treatment with iv antibiotics within 30 days, or oral antibiotics within 14 days, prior to enrollment.',\n",
       "   'Female patients who are breast-feeding.',\n",
       "   \"Patients with clinically significant concurrent illness that in the investigator's judgment may influence the study outcomes (such as MS, moderate to severe CHF, etc,).\",\n",
       "   'Patients with any condition that would prevent participation or completion in this study including language limitation or possibility that the patient will not be available for the complete study period (18 months).']},\n",
       " {'nct_id': 'NCT01106560',\n",
       "  'inclusion': ['Males and females aged 18-75 years at time of surgery.',\n",
       "   'Those presenting with primary or secondary osteoarthritis and/or rheumatoid arthritis of the hip.',\n",
       "   'Those deemed capable of giving informed consent, understanding the aims of the study and expressing willingness to comply with the post-operative review programme.',\n",
       "   'Patients who signed the study consent form prior to surgery.'],\n",
       "  'exclusion': ['Pregnant women or women who plan to conceive in the future.',\n",
       "   'Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems.',\n",
       "   'Those already treated by with a Total Hip Replacement (THR) (i.e. requiring a revision hip replacement).',\n",
       "   'Those with co-existent ipsilateral knee disease or back problems',\n",
       "   'Muscle contracture around the hip joint',\n",
       "   'Individuals who have undergone organ transplant.',\n",
       "   'Those with a known co-existent medical condition where death is anticipated within five years due to the pre-existing medical condition.',\n",
       "   'Individuals who have had a THR on the contra-lateral side within the 6 months.',\n",
       "   'Individuals who have undergone a THR on the contralateral side and whose outcome is considered unsatisfactory or not good. An unsatisfactory or poor result is defined as achieving a total UCLA score (including activity) < 16 points.',\n",
       "   'Individuals requiring bilateral hip replacement.',\n",
       "   'Individuals whose body mass index (BMI; kg/m2) >35.',\n",
       "   'Individuals with active or suspected infection or sepsis.',\n",
       "   'Individuals with renal failure and/or renal insufficiency.',\n",
       "   'Patients with severe forms of developmental dysplasia of the hip (DDH): Crowe types II, III,',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01105715',\n",
       "  'inclusion': ['Fulfill the American College of Rheumatology (ACR) 1987 Classification Criteria for RA',\n",
       "   'Have currently active disease as assessed by Clinical Disease Activity Index (CDAI)score (a validated composite RA activity index) of > 10',\n",
       "   'Have ≥ 3 swollen joints For Controls:',\n",
       "   'Control subjects will be age, sex, and 5-year age categories matched to cases',\n",
       "   'No historical diagnosis of RA and other primary autoimmune or inflammatory disorders'],\n",
       "  'exclusion': ['Known clinical history of CVD',\n",
       "   'Current cancer (other than skin)',\n",
       "   'Current or recent (within past 2 weeks) infection',\n",
       "   'Individuals taking lipid-lowering medications',\n",
       "   'Any other condition the PI staff feels will jeopardize the health and welfare of the participants',\n",
       "   'Rheumatoid vasculitis (for cases only)']},\n",
       " {'nct_id': 'NCT01506661',\n",
       "  'inclusion': ['Age ≥ 50 years',\n",
       "   'Willing and able to provide written informed consent',\n",
       "   'History of primary varicella vaccination or positive VZV IgG antibodies',\n",
       "   'Diagnosis of RA according to ACR criteria for > 1 year, or healthy control subject',\n",
       "   'Stable, mild disease activity as defined by a DAS28 score of 4.0',\n",
       "   'Current medical treatment for RA has been stable for 4 weeks prior to screening',\n",
       "   'Acceptable immunosuppressive medications are limited to Prednisone ≤ 10 mg daily Methotrexate ≤ 20 mg weekly Hydroxychloroquine ≤ 6.5 mg/kg daily Any TNF inhibitor',\n",
       "   'Female subjects of childbearing potential and non-sterile males must agree to use acceptable form of contraception for the duration of the study'],\n",
       "  'exclusion': ['History of receiving any VZV-containing vaccine',\n",
       "   'History of herpes zoster reactivation (shingles) within 5 years of enrollment',\n",
       "   'Received any vaccine within 6 weeks',\n",
       "   'Known Hepatitis B, C or HIV virus infection',\n",
       "   'History of drug or alcohol abuse within 1 year',\n",
       "   'Rituximab therapy within 2 years of screening',\n",
       "   'Cyclophosphamide within 6 months of screening',\n",
       "   'Biologic therapy: TNF inhibitors with longer half-lives (infliximab, golimumab, etc), or other non-TNF biologic therapies (IL-1 or IL-6 inhibition, or CTLA-4Ig)',\n",
       "   'Use of mycophenolate mofetil within 3 months of screening',\n",
       "   'History of receiving immunoglobulin or other blood product within 3 months of screening',\n",
       "   'Allergic reaction, intolerance or other contraindication to use of famciclovir.',\n",
       "   'Has received an experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 3 months of screening; or expects to receive another experimental/investigational agent within 6 months post immunization.',\n",
       "   'Pregnant or lactating women',\n",
       "   'Unwilling to use acceptable method of contraception for the duration of the study',\n",
       "   'WBC <3.0; ANC <1500; CD4+ <200',\n",
       "   'Proteinuria >1.5 mg/day',\n",
       "   'Impaired renal function defined by serum Cr >1.5',\n",
       "   'Transaminases > 2x upper limit of normal',\n",
       "   'DAS28 > 4',\n",
       "   'Anticipation of need to increase level of immunosuppression or add biologic therapy for 6 months following dosing.',\n",
       "   'History of neoplastic disease within 5 years of screening, except for completely excised non-melanoma cancer of the skin or in-situ carcinoma of the uterine cervix.',\n",
       "   'History of any hematological malignancy, current bleeding disorder or taking anticoagulant medication (heparin or warfarin).',\n",
       "   'Any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.']},\n",
       " {'nct_id': 'NCT01502423',\n",
       "  'inclusion': ['Male or female subject age 18 years or older, who requires Humira 40 mg SC every other week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance with the local Humira label.',\n",
       "   'Subject must be a current, on-label user of Humira who rates his/her average Humira injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve subject who requires initiation of on-label treatment with Humira.',\n",
       "   'Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR classification criteria or the ACR/EULAR 2010 criteria,',\n",
       "   'Female subjects are either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least one method of birth control throughout the study and for at least 70 days after the last dose of study drug.',\n",
       "   'All female subjects of childbearing potential must have a negative test for pregnancy on a serum sample at Screening and prior to study drug dosing on a urine sample obtained at Visit',\n",
       "   ''],\n",
       "  'exclusion': ['Subject has been treated with any investigational drug of a chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Visit',\n",
       "   '- Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit',\n",
       "   '- Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).',\n",
       "   'Known hypersensitivity to adalimumab or its excipients.',\n",
       "   'History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.']},\n",
       " {'nct_id': 'NCT01500278',\n",
       "  'inclusion': ['Subject must have a diagnosis of Rheumatoid Arthritis (RA) at Screening, as defined by the 2010 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria (Aletaha D et al, 2010)',\n",
       "   'Subject must have a positive Rheumatoid Factor (RF) and/or a positive anti-Cyclic Citrullinated Peptide antibody (anti-CCP) as determined by the central laboratory at Screening',\n",
       "   'Subject must have moderate to severe RA disease at Screening and Baseline defined as:',\n",
       "   'Screening (all criteria required)',\n",
       "   '≥ 4 swollen joints (of 28 prespecified joints)',\n",
       "   'Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28[ESR]) > 3.2',\n",
       "   'C-Reactive Protein (CRP) concentration ≥ 10 mg/L (or 1.0 mg/dL) or Erythrocyte Sedimentation Rate (ESR) (Westergren) ≥ 28 mm/hr',\n",
       "   'Baseline (both criteria required)',\n",
       "   '≥ 4 swollen joints (of 28 prespecified joints)',\n",
       "   'Disease Activity Score [Erythrocyte Sedimentation Rate] (DAS28[ESR]) > 3.2',\n",
       "   'Subject must have inadequately responded previously to Methotrexate (MTX)',\n",
       "   'Subject is using MTX 15 to 25 mg/week orally or subcutaneously at Screening and has used the same MTX regimen for a minimum of 28 days prior to Baseline'],\n",
       "  'exclusion': ['Subject has previously received any biological Disease Modifying Antirheumatic Drug (DMARD) or has received treatment with cyclophosphamide, chlorambucil, Janus Kinase, phosphodiesterase 4 inhibitors or investigational agents such as spleen tyrosine kinase',\n",
       "   'Diagnosis of any other inflammatory arthritis',\n",
       "   'Infected with Tuberculosis (TB) or high risk of acquiring TB infection',\n",
       "   'Subjects with concurrent acute or chronic viral hepatitis B or C infection',\n",
       "   'Subjects with a history of chronic or recurrent infections or subjects at high risk of infection',\n",
       "   'Use of prohibited medications like nonbiological DMARDs (excluding MTX), biological DMARDs excluding study medications, experimental therapy, IA hyaluronic acid']},\n",
       " {'nct_id': 'NCT01009242',\n",
       "  'inclusion': ['RA > 6 months duration on stable Methotrexate',\n",
       "   '≤9 swollen and ≤9 tender joints (28 joint count)',\n",
       "   'Minimum Screening CRP of 0.5mg/L'],\n",
       "  'exclusion': ['Participation in previous studies with defined agents and durations',\n",
       "   'Previous treatment with defined agents and durations',\n",
       "   'Presence of, or history of defined medical conditions including those particularly associated with deficiency in immune response',\n",
       "   'Pregnancy',\n",
       "   'Positive tests/signs of possible latent/active tuberculosis',\n",
       "   'Positive HIV',\n",
       "   'Drug addiction or alcohol abuse']},\n",
       " {'nct_id': 'NCT01007175',\n",
       "  'inclusion': ['Meets the ACR 1987 revised criteria for classification of Rheumatoid Arthritis (RA).',\n",
       "   'ACR functional class I through III.',\n",
       "   'Active RA at the time of screening and at baseline consisting of = 6 swollen and = 6 tender joints at least.',\n",
       "   'hs-CRP level = 8 mg/L.',\n",
       "   'Must be receiving MTX for at least 12 wks, with a stable dose and route of MTX for at least 6 wks prior to the baseline and continuing on that dose for the duration of the study.',\n",
       "   \"The report of a chest x-ray performed within 12 wks before the screening documenting the absence of any evidence of malignancy, infection, or abnormalities suggestive of TB must be obtained and available in the subject's study file prior to baseline.\",\n",
       "   'All WOCBP must have a negative pregnancy test result at screening and baseline.',\n",
       "   'All WOCBP who have sexual intercourse with a nonsurgically sterilized male partner must agree and commit to the use of the following highly effective forms of contraception for the duration of the study and for 8 wks after the last dose of investigational product.',\n",
       "   'All male subjects who are biologically capable of fathering children must agree and commit to the use of a reliable method of birth control for the duration of the study and for 8 wks after the last dose of investigational product. Exclusion Criteria:',\n",
       "   'Pregnant or breastfeeding women.',\n",
       "   'Presence of active infections or open cutaneous ulcers or any underlying disease that could predispose subjects to infections or history of serious infection within 4 wks before the baseline.',\n",
       "   'A history or current evidence of latent or active TB, evidence of prior or currently active TB by chest X-ray, recent close contact with an individual with active TB, or a positive Mantoux tuberculin skin test.',\n",
       "   'Other significant concurrent medical conditions at the time of the screening or baseline.',\n",
       "   'Laboratory abnormalities at screening. Positive for HBsAg, HBcAb, and/or HepCAb. ALTand/or AST= 2 times the ULN or higher. Hemoglobin = 8.5 g/dL or lower. Platelet = 125,000 /mm³ or lower, or = 1,000,000 /mm³ or higher. WBC = 3500 /mm³ or lower. Serum creatinine= 2 mg/dL or higher.',\n",
       "   'Any prior use of B cell-depleting therapy.',\n",
       "   'Receipt within 24 wks before the baseline visit: Any cytotoxic drugs. Leflunomide. Any investigational biological drug(s).',\n",
       "   'Receipt within 12 wks before the baseline visit: Any biological drugs not listed under the exclusion criteria. Any surgical joint interventions (open or arthroscopic). Any investigational drugs (other than investigational biological drugs), procedures, or devices.',\n",
       "   'Receipt within 8 wks before the baseline: Abatacept. Any type of TNF inhibitors not listed under the exclusion criteria.',\n",
       "   'Receipt within 4 wks before the baseline: Any DMARDs, other than stable background MTX, or immunosuppressive drugs not listed under the'],\n",
       "  'exclusion': ['Etanercept. IA hyaluronic acid injections. Any live (attenuated) vaccine.',\n",
       "   'Receipt within 2 wks before the baseline: > 10 mg/day of oral prednisone or equivalent, or change in the dose of oral prednisone or its equivalent.',\n",
       "   'IA, bolus IM, or IV treatment with corticosteroids. > 1 NSAID, change of dose of the NSAID, or NSAID use greater than the maximum recommended dose.',\n",
       "   'Initiation of statins or dosage adjustment to a current statin. Change in the dose of folic acid.',\n",
       "   'Known or suspected allergy to ATN-103, any type of TNF inhibitors, human immunoglobulin proteins, or other compounds related to these classes of medication.',\n",
       "   'Current or history of psychiatric disease or alcohol or drug abuse that, in the opinion of the investigator, would interfere with the ability to comply with the study protocol or give informed consent.']},\n",
       " {'nct_id': 'NCT01002716',\n",
       "  'inclusion': ['Rheumatoid arthritis'],\n",
       "  'exclusion': ['Allergy to egg']},\n",
       " {'nct_id': 'NCT01007435',\n",
       "  'inclusion': ['Adult patients ≥ 18 years of age.',\n",
       "   'Rheumatoid arthritis of ≤ 2 years duration.',\n",
       "   'Disease Activity Score 28 (DAS28) > 3.2.',\n",
       "   'Swollen joint count (SJC) ≥ 4 of 66 joints, tender joint count (TJC) ≥ 6 of 68 joints.',\n",
       "   'Rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) positive (if RF and anti-CCP negative > 1 erosion required at screening).',\n",
       "   'Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h or C-reactive protein (CRP) ≥ 10 mg/L at screening.'],\n",
       "  'exclusion': ['Previous treatment with tocilizumab.',\n",
       "   'Previous treatment with methotrexate or biologic agent.',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis (RA).',\n",
       "   'History of or current inflammatory joint disease other than',\n",
       "   '- Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01008852',\n",
       "  'inclusion': ['Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening',\n",
       "   'Active RA as defined by >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h',\n",
       "   'Must be seropositive as defined by a documented history of rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) positivity',\n",
       "   'Must be receiving a stable route and dose of methotrexate (up to 25 mg weekly)'],\n",
       "  'exclusion': ['Any significant health problem other than rheumatoid arthritis',\n",
       "   'Any clinically significant laboratory abnormalities',\n",
       "   'Any prior use of B cell-depleting therapy']},\n",
       " {'nct_id': 'NCT01009879',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA) patients will be eligible for the study if they meet ACR criteria for a diagnosis of RA (Arnett et',\n",
       "   '1988. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 31:315.) and have active disease (≥ 6 tender and/or swollen joints).',\n",
       "   'Subjects must be ≥ 18 years of age.',\n",
       "   'Subjects must be rheumatoid factor (RF) positive (any RF titer greater than the upper limits of normal) and/or anti-CCP antibody positive (any anti-CCP titer greater than the upper limits of normal). Subjects must have a negative TB skin test at entry into the study or a negative screening chest x-ray if the PPD test is inconclusive (borderline, reactive but non-diagnostic) or in prior BCG inoculated subjects. Female subjects of child bearing potential (excludes those that are surgically sterile or at least 5 years postmenopausal) must have a negative pregnancy test (serum β-HCG). Sexually active subjects of childbearing potential must agree to use medically acceptable forms of contraception during screening and throughout the study.',\n",
       "   'Subjects or a designee must have the ability to self-inject ENBREL or a care-giver at home who can administer subcutaneous injections. Subjects must be willing to remain on ENBREL (50 mg SQ qweek) for at least 12 weeks and have not taken anti-rheumatic agents (DMARDS and/or corticosteroids) besides NSAIDs for the previous 4 weeks.',\n",
       "   'The subject must be able and willing to give written informed consent and comply with the requirements of the study protocol and must authorize release and use of protected health information. Before any study-specific procedure, the appropriate written informed consent must be obtained.'],\n",
       "  'exclusion': [\"RA patients will be excluded if they have a history of congestive heart failure, recurrent or active infection, a positive PPD, history of neurologic disease, Felty's syndrome, hematologic malignancy or liver disease.\",\n",
       "   'RA patients will be excluded if they have a WBC count < 4.0, Hct < 30 or liver profile abnormalities (> 2x normal values of AST, ALT, TBili and/or APhos).',\n",
       "   'RA patients will be excluded if they have been previously treated with anti-TNFα therapy (ENBREL, infliximab or adalimumab), IL-1ra, abatacept or B and T cell depleting therapies including rituximab or alemtuzumab. Subjects who have previously received other DMARD therapies including methotrexate, leflunomide, sulfasalazine, hydroxychloroquine, gold, penicillamine, cyclosporine A, and cyclophosphamide must not have taken one of these medications within the past 30 days prior to instituting ENBREL.',\n",
       "   'General: Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit. Subjects who have known hypersensitivity to Enbrel or any of its components or who is known to have antibodies to etanercept. Prior or concurrent cyclophosphamide therapy. Concurrent sulfasalazine therapy. Known HIV-positive, mycobacterial disease, active severe infections, untreated Lyme disease, severe comorbidities, history of TB or TB exposure, chronic hepatitis B or hepatitis C, SLE, history of multiple sclerosis, transverse myelitis, optic neuritis or epilepsy, history of recent alcohol or substance abuse (< 1 year), pregnant or lactating females and/or use of a live vaccine 90 days prior to, or during this study.']},\n",
       " {'nct_id': 'NCT01001832',\n",
       "  'inclusion': ['Meeting criteria of the American Rheumatism Association for the diagnosis of rheumatoid arthritis (RA) and the American College of Rheumatology functional Classes I, II, or III.',\n",
       "   'Inadequate response (as deemed by investigator) to methotrexate taken for at least 3 months (12 weeks) at a stable dose (6 to 8 mg/week) for 28 days prior to randomization (Day 1).',\n",
       "   'Stabilization requirements for concomitant therapy: Oral corticosteroid treatment reduced to the equivalent of ≤10 mg prednisolone daily for 28 days and stabilized for at least 25 of 28 days prior to treatment (Day 1). No intra-articular, intravenous, or intramuscular injections of corticosteroids were permitted within 28 days prior to randomization (Day 1.)',\n",
       "   'Washout requirements: Participants receiving combination RA therapy had to discontinue the following therapies at least 28 days prior to treatment (Day 1): disease-modifying antirheumatic drugs (DMARDs), such as gold (auranofin and aurothiomalate sodium), actarit, bucillamine, azathioprine, salazosulfapyridine, lobenzarit disodium, D-penicillamine, cyclophosphamide, mycophenolate mofetil, mizoribine; cyclosporin, tacrolimus, and other calcineurin inhibitors; and immunoadsorption columns.',\n",
       "   'Disease Activity Requirements: At randomization (Day 1), participants had to meet the following disease activity criteria: Swollen joint count: 10 or more swollen joints (66 joint count); tender joint count: 12 or more tender joints (68 joint count); C reactive protein (CRP): ≥0.8 mg/dL (result from screening visit).',\n",
       "   'For participants receiving methotrexate plus other DMARDs(washout of a combination therapy required): At screening visit, participants had to meet the following disease activity criteria: Swollen joint count: 6 or more swollen joints (66 joint count); tender joint count: 8 or more tender joints (68 joint count); CRP: no restriction on CRP (not applicable).',\n",
       "   'After washout, at randomization (Day 1), participants must meet the following disease activity criteria: Swollen joint count-10 or more swollen joints (66 joint count) and tender joint count-12 or more tender joints (68 joint count) and CRP: ≥0.8 mg/dL (result from screening visit). For those whose screening period were longer than 4 weeks, CRP test needed to be performed on Day',\n",
       "   '28 to Day -3 (prior to treatment Day 1) to verify eligibility. Key'],\n",
       "  'exclusion': ['Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease. Concomitant medical conditions that, in the opinion of the investigator, might place the participant at unacceptable risk for participation in this study.',\n",
       "   'Female participants who had undergone breast cancer screening that was suspicious for malignancy, and in whom the possibility of malignancy could not be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.',\n",
       "   'History of cancer within the last 5 years (other than nonmelanoma skin cell cancers cured by local resection)',\n",
       "   'Existing nonmelanoma skin cell cancers had been removed prior to the first administration. Participants with carcinoma in situ, treated with definitive surgical intervention prior to study entry were allowed to participate.',\n",
       "   'Clinically significant drug or alcohol abuse',\n",
       "   'Any serious acute bacterial infection (such as pneumonia or pyelonephritis unless treated and completely resolved with antibiotics)',\n",
       "   'Serious, chronic, or recurrent bacterial infections (such as recurrent pneumonia, chronic bronchiectasis)',\n",
       "   'Those at risk for tuberculosis (TB). Specifically, those with current clinical, radiographic, or laboratory evidence suggestive of active TB; history of active TB within the last 3 years, even if treated; history of active TB more than 3 years ago unless there was documentation that the prior anti-TB treatment was appropriate in type and duration; latent TB that was not successfully treated. Participants with a positive result on TB screening test indicative of latent TB were not eligible for the study unless active TB infection had been ruled out and treatment for latent TB with isoniazid had been initiated for at least 4 weeks prior to administration of the study drug and the participant had a negative finding for TB on a chest X-ray film at enrollment.',\n",
       "   'Herpes zoster resolving less than 2 months prior to enrollment',\n",
       "   'Current evidence (as assessed by the investigator) suggestive of active or latent bacterial or viral infections, including human immunodeficiency virus infection.',\n",
       "   'Physical examination and laboratory test findings: Hepatitis B surface antigen-positive status; hepatitis C antibody-positive status. Any of the following laboratory values: Hemoglobin concentration: <.5 g/dL; white blood cell count: <3,000/μL (3*10^9/L); platelet count: <100,000/mm^3(100*10^9/L); serum creatinine: >2 times upper limit of normal (ULN); serum alanine aminotransferase: >2 ULN; serum aspartate aminotransferase: >2 ULN.',\n",
       "   'Prohibited treatments and/or therapies: Prior exposure to abatacept (CTLA4-Ig); prior RA treatment with any biologics, such as anti-tumor necrosis factor therapy; prior exposure to any investigational biologic not currently approved in Japan; exposure to any study medication in any other previous study within 4 weeks or 5 half-lives, whichever was longer; receipt of any live vaccines within 3 months of administration of study medication or scheduled to receive live vaccines.']},\n",
       " {'nct_id': 'NCT01001182',\n",
       "  'inclusion': ['Subjects aged 18 years or older',\n",
       "   'Confirmed diagnosis of theumatoid arthritis by investigating physician.',\n",
       "   'Evidence of a personally signed and dated informed consent document (or legally acceptable representative).'],\n",
       "  'exclusion': ['Simultaneous participation in an interventional clinical trial.']},\n",
       " {'nct_id': 'NCT01000610',\n",
       "  'inclusion': ['adult patients >/= 18 years of age',\n",
       "   'rheumatoid arthritis DAS28 >/= 3.2',\n",
       "   'receiving treatment on an outpatient basis',\n",
       "   'experienced an inadequate response to previous or current treatment with methotrexate'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA',\n",
       "   'history of or current inflammatory joint disease other than RA',\n",
       "   'previous treatment with any cell-depleting therapies']},\n",
       " {'nct_id': 'NCT01143337',\n",
       "  'inclusion': ['Subjects with a diagnosis of RA according to the diagnostic criteria of the American College of Rheumatology (ACR) (revised in 1987) for at least 6 months.',\n",
       "   'Subjects who inadequately response for stable dose of MTX.'],\n",
       "  'exclusion': [\"Patients with Class IV functional activity by the Steinbrocker's scale.\",\n",
       "   'Patients who have received a biological agent in the past.',\n",
       "   'Patients who have other rheumatic diseases, or who have other diseases with joint symptoms.',\n",
       "   'Patients with severe or uncontrolled endocrine, psychiatric, cardiac, hematological, pulmonary, hepatic, kidney, gastrointestinal, or thyroid disease.']},\n",
       " {'nct_id': 'NCT01147341',\n",
       "  'inclusion': ['Have a diagnosis of RA at least 6 months',\n",
       "   'Have received treatment with a TNF-alpha inhibitor',\n",
       "   'Be receiving Methotrexate (with folic acid)at a dose of at least 10mg/week or another non-biologic DMARD if Methotrexate intolerant *Have at least 6 tender joint and 6 swollen joints*',\n",
       "   'Have an CRP greater than or equal to ULN',\n",
       "   'Availability of a chest x-ray that shows no evidence of active TB or infection'],\n",
       "  'exclusion': ['Prior exposure to Cimzia',\n",
       "   'Prior treatment with B-cell depleting therapy',\n",
       "   'No significant response to previous TNF inhibitor',\n",
       "   'Congestive heart failure',\n",
       "   'Clinically abnormal laboratory tests',\n",
       "   'History of cancer',\n",
       "   'Active TB']},\n",
       " {'nct_id': 'NCT01149057',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Active moderate to severe rheumatoid arthritis',\n",
       "   'Inadequate response to >/=3 DMARDs (non-biologic and/or biologic)',\n",
       "   'Current treatment at stable dose for >/=8 weeks',\n",
       "   'Etanercept discontinued >/=2 weeks, Anakinra >/=1 week, Infliximab, Adalimumab, Abatacept, Golimumab, Certolizumab >/=4 weeks, prior to baseline visit. Patients have discontinued MabThera/Rituxan or Ocrelizumab >/=16 weeks, and must have proven B-cell repletion'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV (American College of Rheumatology Classification)',\n",
       "   'Prior history or current inflammatory joint disease other than RA',\n",
       "   'Oral corticosteroids at a dose of >10 mg/day prednisone equivalent',\n",
       "   'Positive hepatitis B surface antigen (HBsAg) and / or total hepatitis B core antibodies (HBcAb) or hepatitis C virus (HCV) antibody',\n",
       "   'Current or history of recurrent bacterial, viral, fungal or mycobaterial infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency']},\n",
       " {'nct_id': 'NCT01141413',\n",
       "  'inclusion': ['Commercial health plan enrollees with medical and pharmacy coverage',\n",
       "   'At least 3 claims on separate days for infliximab (HCPCS J1745) or abatacept (HCPCS C9230, J0129, J3590) administration during the subject identification period',\n",
       "   'The 3 initial claims for abatacept occurred within a 6-week period inclusive of the index date and the three initial claims for infliximab occur within a 9-week period inclusive of the index date',\n",
       "   'Presence of a diagnosis of RA (ICD-9-CM 714.xx)',\n",
       "   'Continuous enrollment during the baseline and follow-up periods',\n",
       "   'At least 18 years of age or older on the index date'],\n",
       "  'exclusion': ['Prior exposure to the index medication during the baseline period',\n",
       "   \"Diagnosis of psoriasis (ICD-9-CM 696.1), psoriatic arthritis (696.0), ankylosing spondylitis (720.0), Crohn's disease (555.x), or ulcerative colitis (556.x) in any position at any time during the study period\",\n",
       "   'Exposure to alefacept (HCPCS J0215, C9211, C9212) or efalizumab (HCPCS S0162) at any time during the study period']},\n",
       " {'nct_id': 'NCT01144598',\n",
       "  'inclusion': ['Diagnosed with rheumatoid arthritis by a specialist or by the treating rheumatologist',\n",
       "   'Treated with at least one disease-modifying anti-rheumatic drug or biologics',\n",
       "   'Patients over 18 years',\n",
       "   'Patients already employed at a paid work',\n",
       "   'Patients able to provide data for disease history',\n",
       "   'Able to provide written consent to release information for this study'],\n",
       "  'exclusion': ['Patients who cannot provide necessary outcome measurements for any reason will be excluded from the study']},\n",
       " {'nct_id': 'NCT01793259',\n",
       "  'inclusion': ['Written informed consent',\n",
       "   'Age between 18 and 75 years',\n",
       "   'Rheumatoid arthritis according to the American College of Rheumatology (ACR) criteria 1987 or ACR/European Liga Against Rheumatology (EULAR)2010',\n",
       "   'Disease activity score (DAS) 28 > 2.6 Main'],\n",
       "  'exclusion': ['Prior or other current subcutaneous treatment with self-injection',\n",
       "   'Prior or concomitant treatment with biologics',\n",
       "   'Contraindications to MTX treatment',\n",
       "   'History or diagnosis of a dermatological disease at the injection site',\n",
       "   'Women with child-bearing potential who do not use a highly effective method of contraception or men who have a partner with child-bearing potential and do not use a contraception during the study and at least 6 months thereafter.']},\n",
       " {'nct_id': 'NCT01791205',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis according to American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR) criteria',\n",
       "   'Patients who received at least one cycle of biologic therapy, either in monotherapy or in combination, in the 12 months preceding the opening of the first site Part 2:',\n",
       "   'Patients on monotherapy with RoActemra/Actemra already enrolled in Part 1 of the study'],\n",
       "  'exclusion': ['Patients simultaneously participating in other studies with RoActemra/Actemra at the time of signing informed consent']},\n",
       " {'nct_id': 'NCT01793103',\n",
       "  'inclusion': ['Are 18 years of age or older;',\n",
       "   'Are a patient registered at the R.B.Brigham Arthritis Center.',\n",
       "   'Have, at the time of enrollment a diagnosis of RA made by a board certified rheumatologist.',\n",
       "   'Are able and willing to provide informed consent.'],\n",
       "  'exclusion': ['less than 18 years of age',\n",
       "   'do not have a diagnosis of RA',\n",
       "   'have a history of SLE or Psoriasis']},\n",
       " {'nct_id': 'NCT01999192',\n",
       "  'inclusion': ['Subject demonstrates active RA according to the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) classification criteria for RA with functional class I-III for ≥6 months.',\n",
       "   'Subject receives oral or parenteral MTX treatment for ≥12 weeks (overall), with an unchanged mode of application and stable MTX dose of ≥15 mg per week (or ≥12.5 mg per week in case of MTX intolerance), but no more than the highest locally approved dose for RA, for ≥8 weeks prior to baseline. The dose of MTX is expected to remain stable throughout the study and may be adjusted only for safety reasons. If applicable, the dose of folic acid must be unchanged for ≥8 weeks prior to baseline.',\n",
       "   'Subject meets the following two criteria at both screening and baseline:',\n",
       "   'At least 6 swollen joints at 28-joint assessment.',\n",
       "   'At least 6 tender joints at 28-joint assessment.',\n",
       "   'Subject has an erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) above the upper limit of normal (ULN) at screening. These tests may be repeated once during the screening period at the discretion of the investigator.',\n",
       "   'Subject is ≥18 and ≤75 years of age.',\n",
       "   'Subject has a body mass index ≥18 and ≤35 kg/m².',\n",
       "   'Subject receives treatment with corticosteroids ≤10 mg prednisone equivalent, stable for at least 4 weeks prior to baseline and during the study, if applicable.',\n",
       "   'Subject receives treatment with non-steroidal anti-inflammatory drugs (NSAIDs), stable for at least 2 weeks prior to baseline and during the study, if applicable.',\n",
       "   'Female subjects of childbearing potential: has both a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.',\n",
       "   'Subject is judged to be in good general health as determined by the investigator based upon the results of medical history, laboratory profile, physical examination, chest X-ray (within 3 months before screening date is acceptable), and 12-lead electrocardiogram (ECG).',\n",
       "   'Subject has a cluster of differentiation 4 (CD4) cell count of > 400/µl at screening.'],\n",
       "  'exclusion': ['Subject has previous exposure to any systemic biologic therapy (e.g., etanercept, adalimumab, rituximab, abatacept, tocilizumab), to Janus kinase (JAK) or spleen tyrosine kinase (SYK) inhibitors, or to Tregalizumab. Previous treatment with an anti-TNF agent is allowed only, if all of the following criteria apply:',\n",
       "   'treatment was stopped for reasons other than lack of efficacy or adverse events (AEs)',\n",
       "   'treatment was stopped at least 12 weeks or five half-lives of the compound prior to baseline (whichever is longer), and',\n",
       "   'the treatment period did not exceed 6 weeks.',\n",
       "   'Subject received treatment with conventional disease-modifying anti-rheumatic drugs (DMARDs) apart from MTX in the 12 weeks prior to baseline, and for DMARD leflunomide in the 24 weeks prior to baseline (except where specific leflunomide wash-out procedures were completed, following applicable guidelines).',\n",
       "   'Subject has been treated with intra-articular or parenteral administration of corticosteroids in the 4 weeks prior to baseline. Inhaled corticosteroids for stable medical conditions are allowed.',\n",
       "   'Subject has undergone joint surgery in the 12 weeks prior to baseline (at joints to be assessed within the study) or has undergone major surgery (e.g., abdominal surgery) in the 8 weeks prior to baseline.',\n",
       "   \"Subject has a history of acute inflammatory joint disease of an origin other than RA or subject has any other rheumatic disease other than RA (e.g., mixed connective tissue disease, seronegative spondylarthropathy, psoriatic arthritis, Reiter's syndrome, fibromyalgia, systemic lupus erythematosus or any arthritis with onset prior to age 17 years). However, subjects may have secondary Sjögren's syndrome.\"]},\n",
       " {'nct_id': 'NCT01995201',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active rheumatoid arthritis (DAS28-ESR > 3.2), according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria of > 6 months duration',\n",
       "   'Patients with intolerance or inadequate response to methotrexate or other non-biologic DMRADs or inadequate response to a first ant-TNF agent',\n",
       "   'Oral corticosteroids (</= 10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for >/= 4 weeks prior to baseline',\n",
       "   'Permitted non-biologic DMRAD is allowed if at stable dose for at least 4 weeks prior to baseline',\n",
       "   'Females of childbearing potential and males with female partners of childbearing potential must be using a reliable means of contraception as defined by protocol during the study and for at least 3 months following the last dose of RoActemra/Actemra',\n",
       "   'Patients with intolerance or inadequate response to methotrexate or other non-biologic DMARDs or inadequate response to first anti-TNF agent'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline',\n",
       "   \"Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA; secondary Sjögren's syndrome with RA is permitted\",\n",
       "   'Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16',\n",
       "   'Prior history of current inflammatory joint disease other than RA',\n",
       "   'Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline',\n",
       "   'Treatment with any investigational agent with four weeks (or five-half lives of the investigational drug, whichever is longer) of screening',\n",
       "   'Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Previous treatment with Abatacept',\n",
       "   'History of severe allergic of anaphylactic reactions to human, humanized, or murine monoclonal antibodies',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, or gastrointestinal (GI) disease',\n",
       "   \"History of diverticulitis, diverticulitis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforation\",\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections or nail beds)',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening',\n",
       "   'Active TB requiring treatment within the previous 3 years',\n",
       "   'Positive hepatitis B or hepatitis C',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed with the previous 10 years (including hematological malignancies and solid tumors, except basal of squamous cell carcinoma of the skin diagnosed within the previous 20 years',\n",
       "   'Pregnant and lactating women',\n",
       "   'History of alcohol, drug, or chemical abuse within 1 year prior to screening',\n",
       "   'Neuropathies or other conditions that might interfere with pain evaluation',\n",
       "   'Inadequate hematological, real of liver function']},\n",
       " {'nct_id': 'NCT01990157',\n",
       "  'inclusion': ['Patients must sign and date informed consent prior to any study procedures.',\n",
       "   'Male and female patients aged 18-65 years.',\n",
       "   'Rheumatoid arthritis (RA) diagnosed from 6 months to 10 years ago in accordance with American College of Rheumatology (ACR) diagnostic criteria of rheumatoid arthritis, 1987, or ACR / European League against Rheumatism (EULAR), 2010.',\n",
       "   'Patients for whom standard treatment does not result in sufficient control of symptoms of RA, per investigator opinion.',\n",
       "   'Treatment with Methotrexate for at least 3 months before Screening visit, and a stable dose of ≥ 10 mg weekly for at least 28 days before the first infusion of the study drug. Patients should be also treated with folic acid.',\n",
       "   'Active disease of RA despite standard treatment:',\n",
       "   'At least 6 out of 66 joints are swollen and at least 6 out of 68 joints are painful.',\n",
       "   'Level of C-reactive protein >= 15 mg/L or erythrocyte sedimentation rate >= 28 mm/hour or morning stiffness > 45 minutes.',\n",
       "   'Rheumatoid factor > 20 IU/mL.',\n",
       "   'Adequate hematological, renal and hepatic laboratory values.',\n",
       "   'For men and women of childbearing potential: consent to use double barrier methods of contraception during the entire study period.'],\n",
       "  'exclusion': ['Use of other disease-modifying antirheumatic drugs (DMARDs) except for Methotrexate within 4 weeks before the treatment initiation. Use of Leflunomide within 8 weeks before the first study drug infusion. Use of biological immunosuppressive drugs (Adalimumab, Etanercept, Infliximab, Anakinra, Abatacept and others) 2 months before the first study drug administration. Use of Rituximab within 12 months before the first study drug administration.',\n",
       "   'Change of Methotrexate dose within 4 weeks before study treatment initiation.',\n",
       "   'Any autoimmune disease except for rheumatoid arthritis and dry keratoconjunctivitis.',\n",
       "   'Functional grade IV based on American College of Rheumatology scale.',\n",
       "   'Active rheumatoid vasculitis.',\n",
       "   'Any systemic diseases related to joint inflammation.',\n",
       "   'Pregnant and breastfeeding women.',\n",
       "   'Women with childbearing potential refusing to use effective contraceptive methods during the entire study period.',\n",
       "   'Any active infectious disease or tuberculosis at the moment or within 2 weeks before inclusion into the study.',\n",
       "   'Syphilis, hepatitis В, С, HIV-infection or tuberculosis based on the results of laboratory tests at Screening visit.',\n",
       "   'Vaccination with live or attenuated vaccines within 6 weeks before the first study drug administration; planned vaccination during the study period.',\n",
       "   'Medical history of recurrent clinically significant infections.',\n",
       "   'Primary or secondary immunodeficiency.',\n",
       "   'Medical history of malignant oncologic diseases except for excised basal cell skin cancer.',\n",
       "   'Treatment with glucocorticosteroids (GKS) in a dose corresponding to over 12.5 mg/day of prednisolone equivalent, or change of GKS dose as well as treatment with intraarticular, i/m or i/v injections of GKS within 4 weeks before the first infusion of the study drug except for topical low active GKS, GKS in eardrops or eyedrops/ointment, inhalant GKS in a stable dose for the entire study period.',\n",
       "   'Dose change of non-steroid anti-inflammatory agents within 4 weeks before first infusion of the study drug.',\n",
       "   'Any factors that per investigator opinion might prevent patient from adhering to the visit schedule or performing study requirements.',\n",
       "   'Participation in any other clinical study of an experimental drug within 3 months or within 5 elimination half-lives (depending on whichever is longer) before the first infusion of the study drug.',\n",
       "   'Medical history of the following diseases: myocardial infarction, angina pectoris, bronchial asthma, chronic obstructive pulmonary disease or other cardiovascular or respiratory pathology which is considered serious by investigator.',\n",
       "   'Current uncontrolled pathology of renal, endocrine, hematology or central nervous system.',\n",
       "   'Alcohol and/or drug abuse within 1 year before first study drug administration.']},\n",
       " {'nct_id': 'NCT01217086',\n",
       "  'inclusion': ['diagnosed with active rheumatoid arthritis',\n",
       "   'at least 3 months of treatment with methotrexate'],\n",
       "  'exclusion': ['have allergies to infliximab', 'serious infection']},\n",
       " {'nct_id': 'NCT01211834',\n",
       "  'inclusion': ['adult patients, >= 18 years of age',\n",
       "   'Active RA of > 6monts duration',\n",
       "   'Received permitted DMARDs each at a stable dose for at least 8 weeks'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'Significant systemic involvement secondary to RA',\n",
       "   'ALT or AST > ULNⅹ1.5',\n",
       "   'Platelet count < 100,000/mm3',\n",
       "   'Hemoglobin < 8.5 g/dL',\n",
       "   'White blood cells < 3,000/mm3',\n",
       "   'Absolute neutrophil count < 2,000/mm3',\n",
       "   'Absolute lymphocyte count < 500/mm3']},\n",
       " {'nct_id': 'NCT01213017',\n",
       "  'inclusion': ['moderate to severe RA (DAS > 4.4)',\n",
       "   'at least two swollen and tender joints in one of the hand/ wrist',\n",
       "   'patients must have failed at least one non-biologic or biologic DMARDs',\n",
       "   'currently receiving MTX therapy'],\n",
       "  'exclusion': ['concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment']},\n",
       " {'nct_id': 'NCT01211249',\n",
       "  'inclusion': ['Must have active RA (≥5 tender or painful joints on motion and ≥5 joints swollen AND a C-reactive protein (CRP) concentration ≥1.5 mg/dL).',\n",
       "   'Must have been on methotrexate for ≥6 months at a stable dose of 7.5-25 mg/week for ≥12 weeks, to be continued throughout study;',\n",
       "   'If on oral steroids, these should be at a dose ≤10 mg/day of prednisone eq and stable for ≥4 weeks prior to screening;',\n",
       "   'If on NSAIDs, these must be at a stable dose for ≥2 weeks prior to screening;',\n",
       "   'Women must have negative pregnancy test unless surgically sterile or post-menopausal for ≥1 year;',\n",
       "   'Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for ≥12 weeks after the last dose of study drug.',\n",
       "   'Informed consent'],\n",
       "  'exclusion': ['Must not have received treatment with DMARDs, other than background methotrexate;',\n",
       "   'Must not be receiving or have received RA treatment with a biological agent, except if administered in a clinical study ≥six months prior to screening (12 months for rituximab or other B cell depleting agents);',\n",
       "   'Must not have received any treatment with a cytotoxic agent, other than methotrexate, before screening (e.g. chlorambucil, cyclophosphamide, nitrogen mustard, or other alkylating agents);',\n",
       "   'Must not have received intra-articular or parenteral corticosteroid injection within four weeks prior to screening;',\n",
       "   'Must not regularly be using aspirin or any other anti-coagulant medication;',\n",
       "   'Must not have a known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;',\n",
       "   'Must not have positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of HIV or hepatitis from any cause with the exception of hepatitis A;',\n",
       "   'Must not have a history of any inflammatory rheumatological disorders other than RA;',\n",
       "   'Must not have undergone (or planned) surgical treatments for RA;',\n",
       "   'Must not have symptoms of clinically significant illness other than RA (including but not limited to cardiopulmonary, renal, metabolic, hematologic, or psychiatric disorders) within three months prior to screening;',\n",
       "   'Must not have a history of active infections requiring intravenous antibiotics within the past four weeks;',\n",
       "   'Must not have a history of malignancy within the past five years (except for basal cell carcinoma of the skin or carcinoma in situ of the cervix that has been treated with no evidence of recurrence);',\n",
       "   'Must not have a history of tuberculosis (TB) infection as determined by a positive diagnostic TB test result (defined as a positive QuantiFERON TB Gold test), AND a recent chest radiograph (both posterior-anterior and lateral views), read by a qualified radiologist, with evidence of current active TB or old inactive',\n",
       "   '- Must not have been administered a live vaccine within four weeks prior to screening;',\n",
       "   'Must not have participated in any investigational drug/device clinical study within four weeks prior to screening, in biological agents clinical studies within six months prior to screening, and B cell-depleting agent clinical studies within 12 months prior to screening;',\n",
       "   'Must not have a history within the previous two years or current evidence of drug or alcohol abuse;',\n",
       "   \"Must not have any condition or circumstances which in the opinion of the Investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements, or may pose a risk to the patient's safety.\"]},\n",
       " {'nct_id': 'NCT01214733',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis of more than 6 months duration upon entering the study',\n",
       "   'Patients successfully completed studies WA17823 and WA18696 in South Africa',\n",
       "   'Body weight <150 kg'],\n",
       "  'exclusion': ['Patients who have withdrawn from studies WA17823 and WA18696 are not eligible to participate in this study Treatment with any investigational agent since last administration of study drug in studies WA17823 and WA18696',\n",
       "   'Previous treatment with any cell depleting therapies',\n",
       "   'Treatment with intravenous gamma globulin, plasmapheresis or Prosorba(TM) column since the last administration of study drug in studies WA17823 and WA18696']},\n",
       " {'nct_id': 'NCT01217814',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis ≥6 months duration and American College of Rheumatology (ACR) Class I-III functional status at screening and baseline visits;',\n",
       "   'Active disease defined as:',\n",
       "   'At least 6 of 68 tender joints and 6 of 66 swollen joints at screening and baseline visits, and',\n",
       "   'hs-C-Reactive Protein (hs-CRP) >10 g/L or Erythrocyte Sedimentation Rate (ESR) >28 mm/hr at screening visit;',\n",
       "   'Continuous treatment with Methotrexate for at least 12 weeks and on stable dose (minimum 10 mg/week) for at least 6 weeks prior to the screening visit;',\n",
       "   'Participant considered as Primary TNF-α blocker nonresponder. i.e.:',\n",
       "   'Appropriate for previous TNF-α blocker therapy',\n",
       "   'Lack of adequate clinical response after at least 3 months TNF-α blocker therapy with MTX or other synthetic disease modifying anti-rheumatic drug (DMARD) co-therapy.'],\n",
       "  'exclusion': ['Age <18 years or >75 years;',\n",
       "   'Pregnant or breastfeeding woman or woman of childbearing potential, unwilling to utilize adequate contraception or not to become pregnant during the entire study;',\n",
       "   'Fever (>38°C), or chronic, persistent, or recurring infection(s);',\n",
       "   'History of demyelinating disease;',\n",
       "   \"Current underlying hepatobiliary disease. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01219933',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis defined as Disease Activity Score using 28-joint count (DAS28) >/=5.1',\n",
       "   'Patients with inadequate clinical response to a current treatment with 2 or more non-biologic disease-modifying anti-rheumatic drugs (DMARDs), one of them being methotrexate (MTX) optimally administered during a period of more than 3 months or inadequate response to a current anti-TNF therapy',\n",
       "   'Current use of oral glucocorticoids started at least 4 weeks prior to enrolment Interventional phase',\n",
       "   'Patients enrolled in the non-interventional phase',\n",
       "   'Patients with low disease activity defined as DAS28 </=3.2 at Visit 2',\n",
       "   'Use of oral glucocorticoids with methylprednisolone equivalent dose of >/=1mg and </=20mg/day at Visit 2'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis',\n",
       "   'Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in rheumatoid arthritis',\n",
       "   'Prior history or current inflammatory joint disease other than rheumatoid arthritis (e.g. gout)']},\n",
       " {'nct_id': 'NCT01295151',\n",
       "  'inclusion': ['Male and female subjects aged ≥18 years at the time of signing the Informed Consent Form.',\n",
       "   'Patients with a diagnosis of rheumatoid arthritis as per the ACR/EULAR 2010 classification criteria (Appendix 7) confirmed at least 24 weeks prior to the screening visit.',\n",
       "   'Patients who have failed conventional DMARD therapy as per NICE/BSR Guidelines (49) i.e. failure of at least 2 DMARDS including MTX.',\n",
       "   'Patients with persistent RA disease activity despite having been treated with a current initial TNFi agent for at least 12 weeks. Active RA defined as*:',\n",
       "   \"Primary non-response: failing to improve DAS28 by > 1.2 (Appendix 6) or failing to achieve DAS28 ≤ 3.2 within the first 12 to 24 weeks of starting the initial TNFi. • This may include patients that have shown a reduction in DAS28 of > 1.2 but still demonstrate unacceptably high disease activity in the physician's judgement with evidence of an overall DAS28 of ≥ 3.2 OR\",\n",
       "   'Secondary non-response: defined as inefficacy to first TNFi (having demonstrated prior satisfactory response) as per clinician judgement; with intolerance not the reason for cessation of first TNFi.',\n",
       "   'MTX dose stable for 4 weeks prior to the screening visit and to be continued for the duration of the study.',\n",
       "   'Patients on NSAIDs and / or corticosteroids (oral prednisolone not exceeding 10mg daily) who have been on an unchanged regimen for at least 4 weeks prior to the screening visit and are expected to remain on a stable dose until the baseline assessments have been completed.',\n",
       "   'Provided written informed consent prior to any trial-specific procedures.'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to the screening visit or planned major surgery within 52 weeks following randomization.',\n",
       "   \"Patients with inflammatory joint disease of different origin, mixed connective tissue disease, Reiter's syndrome, psoriatic arthritis, systemic lupus erythematosus, or any arthritis with onset prior to 16 years of age.\",\n",
       "   'Patients receiving doses of prednisolone > 10mg/day within the 4 weeks prior to the screening visit.',\n",
       "   'Patients receiving intra-articular or intra-muscular steroid injections within 4 weeks prior to the screening visit.',\n",
       "   'Patients who have previously received more than 1 TNFi drug OR any other biological therapy for the treatment of',\n",
       "   '6. Patients unable or unwilling to stop treatment with a prohibited DMARD (i.e synthetic DMARD aside from MTX e.g. oral or injectable gold, chloroquine, hydroxychloroquine, cyclosporine, azathioprine, leflunomide, sulphasalazine) prior to the start of protocol treatment.',\n",
       "   'Treatment with any investigational drug in the last 12 weeks prior the start of protocol treatment.',\n",
       "   'Patients with other co-morbidity including acute, severe infections, uncontrolled diabetes, uncontrolled hypertension, unstable ischaemic heart disease, moderate/severe heart failure (Class III/IV of the New York Heart Association (NYHA) functional classification system (79)), active bowel disease, active peptic ulcer disease, recent stroke (within 12 weeks before the screening visit), or any other condition which, in the opinion of the investigator, would put the patient at risk to participate in the study or would make implementation of the protocol difficult.',\n",
       "   'Patients with any major episode of infection requiring hospitalisation or treatment with IV antibiotics within 12 weeks of start of treatment protocol or oral antibiotics within 4 weeks of start of protocol treatment.',\n",
       "   'Patients at significant risk of infection, which in the opinion of the investigator would put the patient at risk to participate in the study (e.g. leg ulceration, indwelling urinary catheter, septic joint within 52 weeks (or ever if prosthetic joint still in situ)).',\n",
       "   'Patients with known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections including herpes zoster (for tuberculosis and Hepatitis B and C see below), but excluding fungal infections of nail beds as per clinical judgment.',\n",
       "   'Patients with untreated active current or latent tuberculosis (TB). Patients should have been screened for latent TB (as per BSR guidelines) within 24 weeks prior to the screening visit and, if positive, treated following local practice guidelines prior to the start of protocol treatment.',\n",
       "   'Patients with active current hepatitis B and/or C infection. Patients should have been screened for hepatitis B and C within 24 weeks prior to the screening visit and if positive, excluded from the study.',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation.',\n",
       "   'Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use an effective birth control measure (Appendix 2) whilst receiving treatment and after the last dose of protocol treatment as indicated in the relevant SmPC/IB.',\n",
       "   'Men whose partners are of child-bearing potential but who are unwilling to use an effective birth control measure (Appendix 2) whilst receiving treatment and after the last dose of protocol treatment as indicated in the relevant SmPC/IB.',\n",
       "   'Patients with known significantly impaired bone marrow function as for example significant anaemia, leukopaenia, neutropaenia or thrombocytopaenia as shown by the following laboratory values at the time of the screening visit:',\n",
       "   'Haemoglobin < 8.5 g/dl',\n",
       "   'Platelet count < 100 x 109 / L',\n",
       "   'White blood cell count < 2.0 x 109 / L',\n",
       "   'Neutrophil count < 1 x 109 / L',\n",
       "   'Patients with known severe hypoproteinaemia at the time of the screening visit, e.g. in nephrotic syndrome or impaired renal function, as shown by:',\n",
       "   'Serum Creatinine > 150 umol / L']},\n",
       " {'nct_id': 'NCT01299545',\n",
       "  'inclusion': ['Patient with a confirmed Rheumatoid Arthritis according the American College of Rheumatology (ACR) classification criteria. Disease Activity',\n",
       "   'Patient with a DAS28 greater than 3.2. Treatment',\n",
       "   'Patient eligible for a first line TNFα blocking agent treatment with infliximab according to the \"Summary of Product Characteristics\",',\n",
       "   'Patient refractory to treatment with at least one classical DMARDs (one of which has to be MTX) prescribed according to the international recommendations, i.e. for at least 12 weeks at the maximal tolerated dose prior to infliximab treatment and with doses which must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy (patients may be included if they have undergone a wash-out period using cholestyramine or equivalent subsequent to leflunomide treatment),',\n",
       "   'Use of oral steroids (≤ 10mg/day of prednisone or equivalent dose of another molecule) and/or NSAIDs will be permitted; doses must have been kept stable during the 4 weeks preceding the initiation of the infliximab therapy, Other criteria',\n",
       "   'Patient (male or female) at 18 years of age or older at inclusion,',\n",
       "   \"Negative β-HCG pregnancy test, when appropriate according to the patient's age and contraceptive method,\",\n",
       "   'Informed consent signed.'],\n",
       "  'exclusion': ['Patient having received previous courses of other biologic therapy (TNF blocking agents, anti-CD20, anti-CTLA4, IL1 blockers, IL6 blockers and other molecules in development),',\n",
       "   'Patient non eligible to infliximab therapy according to the \"Summary of Product Characteristics\",',\n",
       "   'Patient with clinically significant, severe and uncontrolled infectious diseases,',\n",
       "   'Patient with symptoms of a significant somatic or psychiatric/mental illness,',\n",
       "   'Patient with other auto-immune diseases (i.e. Inflammatory Bowel Diseases, Systemic Lupus Erythematosus, vasculitis, uncontrolled asthma, etc...),',\n",
       "   'Patient with evidence of cardiac, pulmonary, metabolic, renal, hepatic, gastro-intestinal conditions, which, in the opinion of the investigator, may interfere with the study,',\n",
       "   'Pregnancy,',\n",
       "   'Patient that is participating in a clinical trial or that participated in a previous one within 10 weeks prior to study entry.']},\n",
       " {'nct_id': 'NCT01299961',\n",
       "  'inclusion': ['Over 18 years old',\n",
       "   'Has a diagnosis of rheumatoid arthritis',\n",
       "   'Stable DMARDs for at least 1 month (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine)',\n",
       "   'Disease activity score DAS28/ESR > 3.2 or all must be met: TJC (tender joint count)>=4, SJC (swollen joint count)>=4',\n",
       "   'Must be able to understand information in the Informed Consent and comply with study requirements',\n",
       "   'Total ultrasound synovitis (inflammation of joint-lining membrane) power Doppler score >=1 for at least 2 joints and total synovitis score >=1 for at least 1 joint'],\n",
       "  'exclusion': ['Current or prior use of biologic drugs (TNF inhibitors, IL-6 inhibitors, CD20 inhibitors, IL-1 inhibitors, etc.)',\n",
       "   'Pregnancy or breast feeding',\n",
       "   'Daily prednisone > 10mg (stable dose for at least 1 month)',\n",
       "   'Intra-articular steroid injection of the wrist or joints within last 2 months',\n",
       "   'History of a concomitant autoimmune disease such as lupus, psoriatic arthritis',\n",
       "   'History of cancer',\n",
       "   'Previous exposure to abatacept']},\n",
       " {'nct_id': 'NCT01294722',\n",
       "  'inclusion': ['Diagnosed with RA',\n",
       "   'Visiting a medical internist in a study site during the study period on out patient basis',\n",
       "   'Able to give written informed consent voluntarily'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01292616',\n",
       "  'inclusion': ['RA fulfilling the criteria of the american college of rheumatology (ACR) (revised 1987)',\n",
       "   '18 years and older',\n",
       "   'Cervical pain',\n",
       "   'Recent MRI with detectable atlanto-axial pannus'],\n",
       "  'exclusion': ['Use of TNF-inhibitors 3 months prior to inclusion',\n",
       "   'Previous treatment with any biologics other than TNF-Blockers',\n",
       "   'History of inflammatory joint disease other than RA',\n",
       "   'History of active tuberculosis, histoplasmosis or listeriosis',\n",
       "   'History of lymphoma or other malignancies within 5 years',\n",
       "   'Contraindication for the use of TNF inhibitors',\n",
       "   'Comorbidities: severe myocardial dysfunction, recent stroke (within 3 months), uncontrolled diabetes and other disease which in the opinion of the investigator, would put the subject at risk by participation in the trial',\n",
       "   'History of demyelinating disorders',\n",
       "   'Persistent or recurrent infections',\n",
       "   'Pregnancy or breast feeding']},\n",
       " {'nct_id': 'NCT01292265',\n",
       "  'inclusion': ['Diagnosed with adult-onset Rheumatoid Arthritis (RA) >6 months and <3 years',\n",
       "   'Active RA',\n",
       "   'Must have failed at least one disease modifying Anti Rheumatic Drug (DMARD) treatment',\n",
       "   'Subject can have attempted no more than one previous Anti Tumor Necrosis factor (anti-TNF) and discontinued due to drug intolerance'],\n",
       "  'exclusion': ['Subject cannot have a second non-inflammatory musculoskeletal condition',\n",
       "   'Subject cannot have a diagnosis of any other inflammatory arthritis',\n",
       "   'Subject cannot have any previously infected prosthesis',\n",
       "   'Subject cannot have arthroplasties in any of the joints assessed in the study',\n",
       "   'Subject cannot have a history of chronic infections',\n",
       "   'Subject cannot have known Tuberculosis (TB) disease, high risk of acquiring TB, or latent TB infection',\n",
       "   'Subject cannot have a history of or current Lymphoproliferative disorder',\n",
       "   'Subject cannot have known Human Immunodeficiency Virus (HIV) infection',\n",
       "   'Subject cannot have received a live or attenuated vaccine within 8 weeks',\n",
       "   'Subject cannot have current or history of malignancy',\n",
       "   'Subject cannot have a history of blood disorders',\n",
       "   'Subject cannot have a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease',\n",
       "   'Subjects must not have a history of adverse reaction to Polyethylene glycol (PEG), a protein medicinal product, or ultrasound gel applied to the skin']},\n",
       " {'nct_id': 'NCT01906177',\n",
       "  'inclusion': ['Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis, where one or more compartments are involved.',\n",
       "   'Correction of varus, valgus, or posttraumatic deformity.',\n",
       "   'Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure',\n",
       "   'Need to obtain pain relief and improve function',\n",
       "   'Ability and willingness of the patient to follow instructions, including control of weight and activity level',\n",
       "   'A good nutritional state of the patient, and',\n",
       "   'The patient must have reached full skeletal maturity (at least 18 years old).'],\n",
       "  'exclusion': ['infection',\n",
       "   'sepsis',\n",
       "   'osteomyelitis',\n",
       "   'Uncooperative patient or patient with neurologic disorders who are incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, neuromuscular disease',\n",
       "   'Incomplete or deficient soft tissue surrounding the knee']},\n",
       " {'nct_id': 'NCT01901185',\n",
       "  'inclusion': ['Subject has diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on history.',\n",
       "   'Subject is willing to self-inject per investigator judgement at screening.',\n",
       "   'Subject has no known history of tuberculosis.'],\n",
       "  'exclusion': ['Latex allergy.',\n",
       "   'Subject has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to first study dose of etanercept.',\n",
       "   'Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.',\n",
       "   'Other criteria may apply.']},\n",
       " {'nct_id': 'NCT01909427',\n",
       "  'inclusion': ['Have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987 criteria of the American Rheumatism Association) and have had RA for at least 6 months prior to the date of signing the informed consent at screening',\n",
       "   'Have active RA defined study as persistent disease activity with both of the following criteria: at least 6 swollen and 6 tender joints using a 66/68 joint count at the time of screening and at baseline; and serum C-reactive protein (CRP) ≥ 0.8 mg/dL at screening or erythrocyte sedimentation rate (ESR) ≥ 28 mm in the first hour at screening or baseline',\n",
       "   'Have been treated with and tolerated methotrexate (MTX) treatment at dosages from 7.5 to 25 mg/week, inclusive, for a minimum of 6 months prior to screening and must have a stable MTX dose for a minimum of 6 weeks prior to the first dosing with study agent'],\n",
       "  'exclusion': ['Has inflammatory diseases other than RA, that might confound the evaluation of the benefit of study agent therapy',\n",
       "   'Has a diagnosis of fibromyalgia',\n",
       "   'Has a recent history (within 12 months prior to screening) of uncontrolled, chronic disease including, but not limited to, pulmonary, psychiatric, and metabolic disturbances, cardiovascular, endocrine, neurological, hepatic, gastrointestinal, renal, hematological, or urological diseases that the investigator believes are clinically significant',\n",
       "   'At screening, the results of laboratory tests must meet protocol-specified criteria',\n",
       "   'Has ever received any approved or investigational biologic agent for a rheumatic indication']},\n",
       " {'nct_id': 'NCT01561313',\n",
       "  'inclusion': ['Male or female subject age 18 years or older, who requires Humira 40 mg SC every other week (eow) or every week (ew) for the treatment of rheumatoid arthritis, in accordance with the local Humira label.',\n",
       "   'Subject must be a current, on-label user of Humira who rates his/her average Humira injection site related pain as at least 3 cm on a pain Visual Analogue Scale and has had at least 6 consecutive doses of Humira prior to Screening, or a biologic naïve subject who requires initiation of on-label treatment with Humira.',\n",
       "   'Subject has diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised ACR classification criteria or the ACR/EULAR 2010 criteria,',\n",
       "   'Female subjects are either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy and/or hysterectomy), or are practicing at least one method of birth control throughout the study and for at least 70 days after the last dose of study drug.',\n",
       "   'All female subjects of childbearing potential must have a negative test for pregnancy on a serum sample at Screening and prior to study drug dosing on a urine sample obtained at Visit',\n",
       "   ''],\n",
       "  'exclusion': ['Subject has been treated with any investigational drug of a chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to Visit',\n",
       "   '- Any infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Visit 1 or oral anti-infectives within 14 days prior to Visit',\n",
       "   '- Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).',\n",
       "   'Known hypersensitivity to adalimumab or its excipients.',\n",
       "   'History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of demyelinating disease.']},\n",
       " {'nct_id': 'NCT01565122',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   'Patients for whom the treating physician has made the decision to commence RoActemra/Actemra treatment. In Group A RoActemra/Actemra has been prescribed within 8 weeks prior to the enrolment visit. In Group B RoActemra/Actemra has been started more than 8 weeks before inclusion in the study, but not before January 2011'],\n",
       "  'exclusion': ['RoActemra/Actemra treatment more than 8 weeks prior to inclusion visit for Group A, before January 2011 for Group B',\n",
       "   'Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01565408',\n",
       "  'inclusion': ['A diagnosis of RA, meeting the 2010 ACR-EULAR (American College of Rheumatology-European League Against Rheumatism) or the 1987 ACR classification criteria, made at least 4 months prior to trial drug administration',\n",
       "   'Active RA, characterised by a DAS28-CRP equal to or above 4.5 and at least 5 tender and 5 swollen joints',\n",
       "   'Methotrexate (MTX) treatment for at least 16 weeks (dose equal to or above 7.5 mg/week and equal to or below 25 mg/week) at a stable dose for at least 6 weeks prior to dosing',\n",
       "   'Female subjects not pregnant and not nursing'],\n",
       "  'exclusion': ['Subjects with chronic inflammatory autoimmune disease other than RA',\n",
       "   'Any active or ongoing chronic infectious disease requiring systemic anti-infectious treatment within 4 weeks prior to randomisation',\n",
       "   'Body mass index (BMI) below 18.0 or above 35.0 kg/m^2']},\n",
       " {'nct_id': 'NCT01566851',\n",
       "  'inclusion': ['Patients over 18 years, affiliated to RSI, with rheumatoid arthritis treated with at least one DMARDS and/or biologic therapy'],\n",
       "  'exclusion': ['patients under 18 years',\n",
       "   'Patients declared as rheumatoid arthritis without DMARDS or biologic therapy or treated with steroids alone']},\n",
       " {'nct_id': 'NCT01569074',\n",
       "  'inclusion': ['Male or female aged 18 and over',\n",
       "   'Active rheumatoid arthritis (RA) diagnosed after the age of 16',\n",
       "   '6 or more swollen joints and 6 or more tender/painful joints from certain joints in the hands, wrists, arms and knees',\n",
       "   'At least one of: positive result for rheumatoid factor test, either in the past or currently (blood test); x-ray showing bone erosion within the last 12 months; presence of certain antibodies in the blood (blood test)',\n",
       "   'Currently taking methotrexate for at least 4 months (and on a stable dose for at least 6 weeks)'],\n",
       "  'exclusion': ['Females who are pregnant or breast feeding',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders.',\n",
       "   'Previously taken, but not responded to, certain biological treatments for rheumatoid arthritis',\n",
       "   'High blood pressure that is not controlled by medication',\n",
       "   'Low levels of neutrophils in the blood (blood test).']},\n",
       " {'nct_id': 'NCT01564901',\n",
       "  'inclusion': ['Adults patients, over 18 years of age',\n",
       "   'Patients with moderate to severe rheumatoid arthritis (RA)',\n",
       "   'Patients on a stable dose of prednisone or equivalent (>/=7.5 mg/day) for at least 4 weeks before study inclusion'],\n",
       "  'exclusion': ['Patients previously treated with RoActemra/Actemra',\n",
       "   'Any contraindication to RoActemra/Actemra']},\n",
       " {'nct_id': 'NCT01566201',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis and coexistent coronary artery disease or without CAD who had an inadequate response to disease modifying antirheumatic drugs (DMARDs) and corticosteroids and were going to initiate treatment with interleukin-1 inhibitor.'],\n",
       "  'exclusion': ['Familiar hyperlipidemia',\n",
       "   'Diabetes mellitus',\n",
       "   'Chronic obstructive pulmonary disease or asthma, moderate or severe valvular heart disease, primary cardiomyopathies,malignant tumors']},\n",
       " {'nct_id': 'NCT01562327',\n",
       "  'inclusion': ['Adult participants, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   \"Participants initiating treatment with RoActemra/Actemra on their physician's decision (in accordance with the local label), including participants who started treatment with RoActemra/Actemra in the 8 weeks prior to the enrolment visit\"],\n",
       "  'exclusion': ['RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit',\n",
       "   'Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01569152',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis for at least 6 months prior to screening',\n",
       "   'Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66 count) and >= 6 tender joints (of 68 joint count)',\n",
       "   'C-reactive protein blood level >0.9 mg/dL',\n",
       "   'Anti-citrullinated protein antibody positive and/or rheumatoid factor positive at screening',\n",
       "   'American College of Rheumatology Functional Class I, II, or III',\n",
       "   'Received methotrexate for a minimum of 3 months prior to screening with a regionally appropriate stable weekly dose for at least 4 weeks prior to screening',\n",
       "   'If using oral corticosteroids, the participant must be on a stable dose of 10 mg prednisone',\n",
       "   'No history of either untreated, latent, or active tuberculosis prior to baseline',\n",
       "   'Participants of reproductive potential must agree to remain abstinent or use 2 acceptable methods of birth control'],\n",
       "  'exclusion': ['Presence of inflammatory disease other than rheumatoid arthritis, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease',\n",
       "   'Positive hepatitis B surface antigen or hepatitis C test result or the presence of Human immunodeficiency virus (HIV) infection',\n",
       "   'HIV positive',\n",
       "   'User of recreational or illicit drugs or has had a history (within the previous 2 years) of drug or alcohol abuse or dependence',\n",
       "   'Females of childbearing potential who are pregnant, intend to become pregnant, or are lactating;',\n",
       "   'Severe opportunistic infection within 6 months prior to study start.']},\n",
       " {'nct_id': 'NCT01563978',\n",
       "  'inclusion': ['Male and female patients aged 18 or over diagnosed with rheumatoid arthritis after the age of 16',\n",
       "   'Active rheumatoid arthritis defined as: ≥4 swollen joints and ≥4 tender/painful joints (from 28 joint count) and either erythrocyte sedimentation rate ≥28 mm/h, or C-reactive protein ≥10 mg/L.',\n",
       "   'Currently taking one of the following disease-modifying anti-rheumatic drugs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.',\n",
       "   'Patients without essential hypertension or with essential hypertension if their blood pressure is controlled (<140/90 mmHg) with anti-hypertensive medications being stable at least 4 weeks prior to randomisation.'],\n",
       "  'exclusion': ['Females who are pregnant or breastfeeding.',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders',\n",
       "   'History of liver problems that have required previous investigations',\n",
       "   'Evidence of tuberculosis infection',\n",
       "   'Conditions that preclude or render difficult the 24-hour ambulatory blood pressure monitoring technique.']},\n",
       " {'nct_id': 'NCT01567358',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with ACR Functional Classification class I-III and disease duration of no less than 3 months',\n",
       "   'Patients must receive a minimum of 3 months treatment with methotrexate (MTX) (≥ 6 mg/week) prior to the Screening Visit. Patients must be on a stable dose of MTX (6 mg~16 mg mg/week) for a minimum of 4 weeks prior to the Screening Visit'],\n",
       "  'exclusion': ['History of following diseases',\n",
       "   'Other Connective tissue disorders with joint symptom which may interfere the efficacy assessment',\n",
       "   'Chlonic or recurrent infectious disease（bronchial ectasia, sinus inflammation etc.）',\n",
       "   'Severe infectious disease（hepatitis, pneumonia、sepsis）',\n",
       "   'History of demyelinating disease or multiple sclerosis',\n",
       "   'Congestive heart failure',\n",
       "   'lymphoproliferative disorder or myelodysplastic syndrome',\n",
       "   'History of malignancy',\n",
       "   'Interstitial lung disease',\n",
       "   'Patients with active or latent tuberculosis or history of tuberculosis']},\n",
       " {'nct_id': 'NCT01564147',\n",
       "  'inclusion': ['Patient presenting at clinics for Rheumatology or the Rheumatology Day Hospital at the University Hospital or hospitalized in the department of Rheumatology',\n",
       "   'Men or women',\n",
       "   'Having signed the consent',\n",
       "   'major',\n",
       "   'Affiliated to social security or covered by the CMU',\n",
       "   'Patient with rheumatoid arthritis meeting the ACR criteria',\n",
       "   'Patient with rheumatoid arthritis stable for at least 6 months (change in DAS 28 <1.2)'],\n",
       "  'exclusion': ['Patient can not understand the information',\n",
       "   'Patient confined to bed or chair, unable to care for himself or not doing with difficulty',\n",
       "   'pregnant patient',\n",
       "   'minors',\n",
       "   'Adults under guardianship']},\n",
       " {'nct_id': 'NCT01044498',\n",
       "  'inclusion': ['Adult patients with child bearing potential, 18-44 years of age.',\n",
       "   'Rheumatoid arthritis (RA) for over 6 months duration.',\n",
       "   'On oral contraceptive without interruption for at least 3 months with normal cycle control.',\n",
       "   'Treatment with disease-modifying anth-rheumatic drugs (DMARD) for at least 12 weeks prior to study start.',\n",
       "   'Body weight < 150',\n",
       "   ''],\n",
       "  'exclusion': ['Functional class IV rheumatoid arthritis (American College of Rheumatology [ACR] classification).',\n",
       "   'History of amenorrhea (unrelated to pregnancy).',\n",
       "   'History or current inflammatory joint disease other than',\n",
       "   '- Rheumatic autoimmune disease other than',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01040715',\n",
       "  'inclusion': ['Diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology (ACR) (Arnett 1988) since at least six months prior to first study product administration.',\n",
       "   'Male or female between 18 and 70 years of age at the time of the first immunization',\n",
       "   'Active RA disease as evidenced by a Disease Activity Score 28 (DAS 28) ≥ 3.2.',\n",
       "   'Current or past treatment with an anti-TNF antagonist (infliximab, adalimumab,etanercept, certolizumab, golimumab).',\n",
       "   'A wash-out period before the first administration of the study product of at least ten weeks since the last administration of certolizumab or golimumab; at least eigth weeks since the last administration of infliximab; at least four weeks since the last administration of adalimumab or etanercept',\n",
       "   'History of positive response defined as an ACR20 or DAS 28 decrease ≥ 1.2 or by the investigator opinion with previous TNFα antagonist treatment.',\n",
       "   'Secondary treatment failure to maximum one previous TNFα antagonist treatment as defined by:',\n",
       "   'Investigator opinion. OR',\n",
       "   'DAS28 increase ≥ 0.6 during the last six months. OR',\n",
       "   'Decrease in European League Against Rheumatoid (EULAR) score.',\n",
       "   'Written informed consent .'],\n",
       "  'exclusion': ['Treatment with non-biological DMARDs within four weeks prior to first study product administration. MTX is allowed provided it is administered at as table dosage < ou = 20 mg/week since at least 4 weeks.',\n",
       "   'Treatment with any rheumatoid arthritis biological therapy other than TNFα antagonists at any time prior to first study product administration.',\n",
       "   'Administration of high doses of intra-articular corticosteroids for the treatment of an acute mono-arthritis (eg knee) within 3 months prior to first study product administration. High dose of corticosteroids is defined as > 50 mg triamcinolone or equivalent.',\n",
       "   'History of documented severe bacterial infection within 28 days prior to first immunization',\n",
       "   'History of primary resistance or intolerance to any TNFα antagonist.',\n",
       "   'History of or current congestive heart failure, controlled or not.',\n",
       "   'Corticosteroids (prednisone or equivalent, < ou = 10 mg per day) are allowed if they are administered at stable dosage since at lesat 4 weeks prior to the first immunization. Inhaled and topical steroids are allowed.',\n",
       "   'Known history of tuberculosis (TB).',\n",
       "   'Suspicion of TB at chest X-rays at screening or within three months prior to first administration of study product.',\n",
       "   'Suspicion of latent or active tuberculosis as defined by :',\n",
       "   'Positive Mantoux/Purified Protein Derivative (PPD)test (> ou = 5mm induration measured 48 to 72 hours after intradermal injection of tuberculin) at screening or within 30 days prior to first administration of study product.',\n",
       "   'and/or positive interferon-γ (IFN γ) TB diagnostic test (as measured by the ELISpot method) at screening or within three months prior to first administration of study product.',\n",
       "   'Positive for HIV, HCV or HBV including HBsAg and anti-HBc antibodies.',\n",
       "   'Use of any investigational or non-registered product (drug or vaccine).',\n",
       "   'Administration of any live vaccine within three months prior to study entry',\n",
       "   'Any confirmed or suspected immunosuppressive or immunodeficient condition.']},\n",
       " {'nct_id': 'NCT01438892',\n",
       "  'inclusion': ['Adults with moderate to severe RA who are currently using a DMARD'],\n",
       "  'exclusion': ['Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use']},\n",
       " {'nct_id': 'NCT01430507',\n",
       "  'inclusion': ['Male or female ≥18 to ≤ 65 years of age',\n",
       "   'Documented history of RA; diagnosed according to the revised American College of Rheumatology criteria (ACR)',\n",
       "   'Active RA defined as patients with:',\n",
       "   '6 swollen joint counts',\n",
       "   '6 tender/painful joint counts, and',\n",
       "   'At least two of the three following criteria:',\n",
       "   'Rheumatoid Factor positive or Anti CCP positive',\n",
       "   'CRP ≥1.2 times upper limit of normal reference range or ESR >28 mm/hr',\n",
       "   'Morning stiffness lasting >45 min for at least last4 weeks',\n",
       "   'DAS-28 CRP values ≥ 4.5 at screening (visit 1)',\n",
       "   'Patients must have been on stable (15 mg to 25 mg) or maximum tolerated dose of MTX for at least 12 weeks prior to screening',\n",
       "   \"The patient's written informed consent to participate in the study\",\n",
       "   'Female participants must have a negative serum pregnancy test at screening visit.',\n",
       "   'Males must agree to use barrier while on study medication and for 90 days after taking the last dose of study medication',\n",
       "   'Must meet the following laboratory criteria:',\n",
       "   'Hemoglobin ≥ 9 g/dL',\n",
       "   'White blood cell (WBC) count; ≥3.0 X 109/L',\n",
       "   'Platelet count ≥ 100,000 /L (100 X 109/L)',\n",
       "   'Serum creatinine <1.5 mg/dL (or 133mol/L)',\n",
       "   'Total bilirubin <2.0 mg/dL',\n",
       "   'AST & ALT<1.5 times upper limit of normal'],\n",
       "  'exclusion': ['Diagnosis of RA prior to 16 years of age (Juvenile RA)',\n",
       "   'Non-degenerative joint diseases or other joint diseases that could interfere with the evaluation of RA',\n",
       "   \"Patients with any other autoimmune rheumatic disorders with the exception of Sjogren's syndrome.\",\n",
       "   'Patients with first degree relative with immune deficiency',\n",
       "   'History of infection with human immunodeficiency virus and/or active hepatitis B or C',\n",
       "   'Severe disabling arthritis leaving the patient eligible for surgical intervention, or incapacitated and prostrated patients',\n",
       "   'Patients with a history of drug or alcohol abuse or chronic smoking',\n",
       "   'Uncontrolled diabetes mellitus',\n",
       "   'Concurrent diseases that might interfere with the conduct of the study,',\n",
       "   'ECG abnormalities judged by the investigator to be clinically significant',\n",
       "   'History of using any other test drug, one month before the beginning of this trial',\n",
       "   'Women who are pregnant or breast-feeding or on hormonal therapy',\n",
       "   \"Patients who in the Investigator's opinion might not be suitable for the study.\",\n",
       "   'Patients with a life expectancy of less than 1 year']},\n",
       " {'nct_id': 'NCT01482507',\n",
       "  'inclusion': ['Subject has Rheumatoid Arthritis as defined by the ACR/Eular criteria',\n",
       "   'Subject is able to understand and comply with study protocol',\n",
       "   'Active disease as defined by DAS28> 3.0',\n",
       "   'Disease duration less than 12 months',\n",
       "   'If female, subject is either not of childbearing potential, or is of childbearing potential and is practicing an approved method of birth control throughout the study',\n",
       "   'subject is judged to be in good health as determined by the PI based upon results of medical history, laboratory profile and physical examination.',\n",
       "   'Prednisone dose 10mg or less, dose stable for 28 days prior to baseline'],\n",
       "  'exclusion': ['Inflammatory arthropathy other than Rheumatoid Arthritis',\n",
       "   'Inactive disease as evidenced by DAS 28 CRP and / or ESR < 2.5',\n",
       "   'Prednisone dose greater than 10mg within 28 days prior to baseline',\n",
       "   'Intra-articular steroid within 28 days prior to baseline visit',\n",
       "   'IV Methyl-prednisone within 28 days prior to baseline visit',\n",
       "   'Any contra-indication to Magnetic Resonance Imaging',\n",
       "   'Permanent Pacemaker',\n",
       "   'Intracerebral aneurysm clip',\n",
       "   'Claustrophobia to the extent that patient cannot manage MRI investigations',\n",
       "   'Implanted metallic device',\n",
       "   'Cochlear implant']},\n",
       " {'nct_id': 'NCT01480388',\n",
       "  'inclusion': ['Has a diagnosis of rheumatoid arthritis (RA) for at least 6 months before screening.',\n",
       "   'Positive test for either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum at screening.',\n",
       "   'Has active RA defined as persistent disease activity with the following criteria: at least 6 swollen and 6 tender joints, and serum CRP ≥ 0.70 mg/dL at screening.',\n",
       "   'Has been treated with and tolerated methotrexate (MTX) treatment at dosages of 10 to 25 mg/week for a minimum of 6 months prior to screening and must be on a stable dose for a minimum of 8 weeks prior to screening',\n",
       "   'Must be post-menopausal or if pre-menopausal, must use an acceptable form of birth control',\n",
       "   'Has completed at least 5 days of daily pain diary in the 10 days prior to randomization.'],\n",
       "  'exclusion': ['Has inflammatory diseases other than RA, such as Lupus.',\n",
       "   'Is currently receiving treatment for RA other than methotrexate, NSAIDS, or oral corticosteroids such as prednisone, or pain medicines.',\n",
       "   'Has ever received any biologic agent for a rheumatic indication.',\n",
       "   'Has current signs or symptoms of liver insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled.',\n",
       "   'Has moderate or severe renal insufficiency',\n",
       "   'Has a recent (within 2 months) serious infection',\n",
       "   'Has had an opportunistic infection.',\n",
       "   'Has had cancer within the past 5 years (except certain skin or cervical conditions)',\n",
       "   'Has abused substances or alcohol within the past 2 years',\n",
       "   'Has active Hepatitis B or C infection',\n",
       "   'Has had active tuberculosis',\n",
       "   'Has had exposure to tuberculosis without preventative treatment']},\n",
       " {'nct_id': 'NCT01483326',\n",
       "  'inclusion': ['Adult patients, >18 years of age',\n",
       "   'Participants in the ACT-SURE trial, or patients with moderate to severe rheumatoid arthritis starting or receiving RoActemra/Actemra'],\n",
       "  'exclusion': ['Contra-indications for RoActemra/Actemra']},\n",
       " {'nct_id': 'NCT01483157',\n",
       "  'inclusion': ['female with rheumatoid arthritis',\n",
       "   'Disease activity scores > 2.6',\n",
       "   'use of anti-TNF-alpha drugs for at least 8 weeks'],\n",
       "  'exclusion': ['BMD < 20 kg/m2', 'fibromyalgia', 'cardiovascular disease']},\n",
       " {'nct_id': 'NCT01481493',\n",
       "  'inclusion': ['Patients with active Rheumatoid Arthritis (RA) according to 1987 revised ACR criteria with functional class II-III',\n",
       "   'Disease activity at screening and baseline (more than 6 swollen joint count; more than 6 tender joint count; elevat. of CRP or ESR)',\n",
       "   'Duration of RA more than 12 month',\n",
       "   'History of at least one disease-modifying anti-rheumatic drug (DMARD) with an inadequate response despite more than 3 month of treatment',\n",
       "   'MTX treatment at least 6 month with a stable dose at least 15mg MTX',\n",
       "   'Patients could continue at more than daily 7,5mg of prednisone or equivalent stable dose at least 6 weeks prior baseline',\n",
       "   'Written Informed Consent'],\n",
       "  'exclusion': ['Treatment with traditional DMARDs apart from MTX 12 weeks prior to baseline and DMARD leflunomide 24 weeks',\n",
       "   'Treatment with any biologics other than TNF-α inhibitors (e.g. abatacept, rituximab, tocilizumab, anakinra)',\n",
       "   'treatment with any TNF-α inhibitor within 5 elimination half-lives prior baseline and during the study',\n",
       "   'Clinical non-response to more than one of TNF-α inhibitor exceeding adequate treatment duration']},\n",
       " {'nct_id': 'NCT01480453',\n",
       "  'inclusion': ['Patient is >18 years of age;',\n",
       "   'Patient is skeletally mature;',\n",
       "   'Patient qualifies for primary unilateral or bilateral total or hemi shoulder arthroplasty based on physical exam and medical history including the following: Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis, Ununited humeral head fracture, Irreducible 3- and 4-part proximal humeral fractures, Avascular necrosis',\n",
       "   'Patient is willing and able to provide written informed consent;',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy;',\n",
       "   'Patient is will and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent;',\n",
       "   'Patient has participated in the Informed Consent process and has signed the IRB/ERB approved informed consent;'],\n",
       "  'exclusion': ['The patient is a prisoner;',\n",
       "   'The patient is mentally incompetent or unable to understand what participation in the study entails;',\n",
       "   'The patient is a known alcohol or drug abuser;',\n",
       "   'The patient is anticipated to be non-compliant;',\n",
       "   'The patient has one of the following compromising the affected limb; a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable;',\n",
       "   'The patient has a local/systemic infection;',\n",
       "   'The patient is known to be pregnant;',\n",
       "   'The patient has marked bone loss;',\n",
       "   'The patient has a known sensitivity or allergic reaction to one or more of the implanted materials;',\n",
       "   'The patient is unwilling or unable to give consent or to comply with the follow-up program.']},\n",
       " {'nct_id': 'NCT01489384',\n",
       "  'inclusion': ['Patient must be ≥ 18 years of age.',\n",
       "   'Patient must be able to understand the information provided to them and to give written Informed Consent.',\n",
       "   'Patient must fulfill the old or new criteria for RA (see Appendix 1) or have a clinical diagnosis of',\n",
       "   '4. Patient must be receiving (for 3 months before baseline) one of the following: methotrexate (≥ 12.5 mg) or another DMARD (leflunomide 10 to 20 mg/day, sulfasalazine >1000 mg/day, IM myochrysine for at least 20 weeks at 25 mg per month or more, azathioprine> 75mg/day), or combination DMARDs such as methotrexate with any other DMARD, or other combinations.',\n",
       "   'If patient is on prednisone they must be on a stable dose (≤ 10 mg/day) for 1 month prior to baseline.',\n",
       "   'Patient with active RA (≥ 3 SJC, on 28 joint count) who needs anti-TNF therapy as determined by the investigator and ability to obtain coverage for anti-TNF (Cimzia).',\n",
       "   'Patient must not have previously been exposed to Cimzia, however, previous anti-TNF exposure is allowed.',\n",
       "   'Patient with past anti-TNF exposure will be included if 1st anti-TNF was stopped due to secondary loss of efficacy, side effect or discontinuation for other reasons.',\n",
       "   'Patient must use Cimzia as per the dosing guidelines in the approved product monograph.'],\n",
       "  'exclusion': ['Female patient who is breast-feeding or pregnant or does plan to become pregnant over the next year',\n",
       "   'Failure to use acceptable form of contraception in a pre-menopausal woman',\n",
       "   'Patient with concurrent serious liver disease',\n",
       "   'Patient with concurrent serious renal disease',\n",
       "   'Patient with significant hematological impairments',\n",
       "   'Patient with a history of cancer within the last 2 years, other than a successfully treated skin basal cell or squamous cell carcinoma and/or localized carcinoma in situ of the cervix',\n",
       "   'Patient with a history of malignant lymphoma of leukemia',\n",
       "   'Patient with a history of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease (e.g. Multiple Sclerosis)',\n",
       "   'Patient with a history of untreated active tuberculosis',\n",
       "   'Patient with positive PPD (>5 mm) who have not had prophylaxis',\n",
       "   'Patient with a known positive HIV test',\n",
       "   'Patient with a persistent or severe infection(s) requiring hospitalization or treatment with iv antibiotics within 30 days or oral antibiotics within 7 days prior to baseline.',\n",
       "   'Patient with significant congestive heart failure',\n",
       "   \"Patient with clinically significant concurrent medical of psychiatric disorders that in the physician's judgment may influence the study outcomes.\",\n",
       "   'Patient with any condition that would prevent participation or completion in this study including language limitation or possibility that the patient will not be available for the complete study period',\n",
       "   'Patient with severe noncompliance',\n",
       "   'Patient receiving an experimental product within the last 6 weeks prior to first dose of Cimzia.',\n",
       "   'Other joint disease or joint pain condition where the patient or physician cannot distinguish RA assessments from the other joint disease',\n",
       "   'Concomitant SLE',\n",
       "   'Chest x-ray shows evidence of',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01480440',\n",
       "  'inclusion': ['Patient is > 18 years of age;',\n",
       "   'Patient is skeletally mature;',\n",
       "   'Patient qualifies for primary or revision unilateral or bilateral reverse total shoulder arthroplasty based on physical exam and medical history including the following: osteoarthritis, rheumatoid arthritis, post-traumatic arthritis, ununited humeral head fracture, irreducible 3-and 4-part proximal humeral fractures, avascular necrosis, gross rotator cuff deficiency or failed total shoulder arthroplasty (both glenoid and humeral components require revision);',\n",
       "   'Patient is willing and able to provide written informed consent;',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy;',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations/questionnaires as described in the Informed Consent;',\n",
       "   'Patient has participated in the Informed Consent process and has signed the Institutional Review Board (IRB)/Ethical Review Board (ERB) approved informed consent.'],\n",
       "  'exclusion': ['The patient is a prisoner;',\n",
       "   'The patient is mentally incompetent or unable to understand what participation in the study entails;',\n",
       "   'The patient is a known alcohol or drug abuser;',\n",
       "   'The patient is anticipated to be non-compliant;',\n",
       "   'The patient has one of the following compromising the affected limb: a significant injury to the upper brachial plexus, paralysis of the axillary nerve or a neuromuscular disease compromising the affected limb which would render the procedure unjustifiable;',\n",
       "   'The patient has a local/systemic infection;',\n",
       "   'The patient is known to be pregnant;',\n",
       "   'The patient has marked bone loss;',\n",
       "   'The patient has a known sensitivity or allergic reaction to one or more of the implanted materials;',\n",
       "   'The patient is unwilling or unable to give consent or to comply with the follow-up program.']},\n",
       " {'nct_id': 'NCT01270035',\n",
       "  'inclusion': ['patients with rheumatoid arthritis receiving MTX ≧ 6 mg/week for at least 3 months disease activity : DAS28 > 5.1'],\n",
       "  'exclusion': ['allergy to ADA present active infection including TB history of demyelinating disease, HBV infection and malignancy']},\n",
       " {'nct_id': 'NCT01273519',\n",
       "  'inclusion': ['Patients aged ≥ 18 years for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis',\n",
       "   'Patients must fulfill international and national guidelines for the use of a biological disease modifying antirheumatic drug in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (chest x-ray and interferon gamma release assay or purified protein derivative-skin test negative for tuberculosis). In addition one of the following criteria must be fulfilled:',\n",
       "   'unsatisfactory disease modifying antirheumatic drug response defined as failure to treatment with at least two disease modifying antirheumatic drugs including Methotrexate in patients with rheumatoid arthritis or psoriatic arthritis',\n",
       "   'unsatisfactory non steroidal antiinflammatory drug response in patients with ankylosing spondylitis or unsatisfactory response to prior biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis or ankylosing spondylitis'],\n",
       "  'exclusion': ['Patients who meet contraindications as outlined in the latest version of the Humira syringe® summary of product characteristics and Humira Pen® summary of product characteristics',\n",
       "   'Patients participating in another study program or clinical trial',\n",
       "   'Patients who have been treated with Humira before']},\n",
       " {'nct_id': 'NCT01277328',\n",
       "  'inclusion': ['Adult patients >/=18 years of age',\n",
       "   'Patients with rheumatoid arthritis eligible for RoActemra'],\n",
       "  'exclusion': ['Hypersensitivity to RoActemra', 'Active, severe infections']},\n",
       " {'nct_id': 'NCT01270087',\n",
       "  'inclusion': ['Clinical diagnosis of rheumatoid arthritis',\n",
       "   'Fulfillment of the American College of Rheumatology 1987 criteria for rheumatoid arthritis',\n",
       "   'Active disease despite treatment with at least one disease modifying anti-rheumatic drug',\n",
       "   \"Treatment with adalimumab indicated according to the the patient's rheumatologist\",\n",
       "   'At least six swollen joints in 28-joint index',\n",
       "   'CRP > 8 mg / L within the last three months'],\n",
       "  'exclusion': ['Treatment with anti-TNF drugs in the last three months',\n",
       "   'Treatment with intravenous corticosteroids within fourteen days',\n",
       "   'Ongoing treatment with oral high-dose corticosteroids (equivalent to ≥ 20 mg of prednisolon daily) or completed such treatment less than fifteen days before inclusion',\n",
       "   'Severe bleeding disorder',\n",
       "   'Extensive or refractory leg ulcers',\n",
       "   'Severe peripheral vascular disease']},\n",
       " {'nct_id': 'NCT01274182',\n",
       "  'inclusion': ['Rheumatoid arthritis as defined by the 1987 ACR classification',\n",
       "   'Severe active seropositive disease',\n",
       "   'Inadequate response or intolerance to other DMARDs and anti-TNFs',\n",
       "   'Treatment with Methotrexate Exclusion Criteria:',\n",
       "   'Patients with systemic manifestations of rheumatoid arthritis',\n",
       "   'Female patients nursing',\n",
       "   'Women of childbearing potential unless using birth control',\n",
       "   'Active infection',\n",
       "   'Known immunodeficiency syndrome',\n",
       "   'Positive Hepatitis B surface antigen or antibodies to Hepatitis C',\n",
       "   'History of cancer Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01270997',\n",
       "  'inclusion': ['Males and females who are 20 or over',\n",
       "   'Patients who satisfy the classification criteria of Rheumatoid Arthritis according to American Colleague of Rheumatology (ACR 1987)',\n",
       "   'Patients who are applicable to functional status I',\n",
       "   'III of American Colleague of Rheumatology'],\n",
       "  'exclusion': ['Patients who have autoimmune diseases other than rheumatoid arthritis or have significant secondary systematic disease caused by rheumatoid arthritis',\n",
       "   'Patients who are currently participating in other clinical studies or receiving treatment for drugs not sold in the market or for experiment',\n",
       "   'Patients who have significant other diseases that may affect the clinical trial when judged by the clinical trial Investigator',\n",
       "   \"In the opinion of the investigator, may put the patient at risk because of participation on the study or may influence the patients' ability to participate in the study\"]},\n",
       " {'nct_id': 'NCT01272908',\n",
       "  'inclusion': ['Adult patients, 18-80 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis',\n",
       "   'Inadequate response to a single previous or current treatment with an anti-TNF agent',\n",
       "   'Methotrexate for at least 12 weeks, at a stable dose over the past 4 weeks'],\n",
       "  'exclusion': ['Previous treatment with MabThera',\n",
       "   'Use of an anti-TNF agent within past 8 weeks (4 in the case of etanercept)',\n",
       "   'Concurrent treatment with any Disease Modifying Anti-Rheumatic Drug (DMARD) other than methotrexate',\n",
       "   'Active infection, or history of serious or chronic infection']},\n",
       " {'nct_id': 'NCT01181050',\n",
       "  'inclusion': ['A diagnosis of RA meeting the American College of Rheumatology 1987 (ACR1987) criteria, obtained at least three months prior to dosing with the trial product',\n",
       "   'Subjects with active RA having a Disease Activity Score (DAS28-CRP) of 4.5 or more, at least five tender and five swollen joints (can be the same), including one swollen wrist or at least two swollen ipsilateral metacarpophalangeal (MCP) joints (second to fifth)',\n",
       "   'Concomitant treatment with methotrexate (MTX) (7.5-25 mg/week) for at least 12 weeks, with stable dose for at least 4 weeks prior to dosing',\n",
       "   'Ability to be examined by Magnetic Resonance Imaging (MRI)',\n",
       "   'Having failed no biologic therapies for RA and no more than two non-biologic disease modifying antirheumatic drugs'],\n",
       "  'exclusion': ['Chronic inflammatory autoimmune disease other than RA (rheumatoid arthritis)',\n",
       "   'Any ongoing chronic or active infectious disease or microbial infection requiring systemic oral or intravenous treatment against infection within 1 month prior to trial start',\n",
       "   'Body mass index (BMI) below or equal to 18 or above or equal to 40 kg/m^2']},\n",
       " {'nct_id': 'NCT01185301',\n",
       "  'inclusion': ['Male and female subjects at least 18 years of age',\n",
       "   'Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987-revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider',\n",
       "   'Subject must meet the following criteria:',\n",
       "   'Disease Activity Score of C-reactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline visit only)',\n",
       "   'At least 6 swollen joints out of 66 assessed (at the Screening and Baseline visits)',\n",
       "   'At least 8 tender joints out of 68 assessed (at the Screening and Baseline visits)',\n",
       "   'C-reactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline visits)',\n",
       "   'Fulfill at least one of the following three criteria: Rheumatoid Factor (RF) positive, have at least 1 bony erosion, anti-cyclic citrullinated peptide (anti-CCP) antibody positive',\n",
       "   'Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray (CXR), and a 12-lead electrocardiogram (ECG) performed during Screening'],\n",
       "  'exclusion': ['Subject has previous exposure to any systemic biologic therapy including adalimumab',\n",
       "   'Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX)',\n",
       "   'Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study)',\n",
       "   'Subject has chronic arthritis diagnosed before age 17 years',\n",
       "   'History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active Hepatitis C infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB)',\n",
       "   'Hepatitis B virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR) qualitative test',\n",
       "   'Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Baseline Visit or oral anti-infectives within 14 days prior to the Baseline visit',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT01185522',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   'Inadequate response to disease-modifying antirheumatic drugs (DMARDS) or anti-TNF (tumor necrosis factor) drugs'],\n",
       "  'exclusion': ['Hypersensitivity to RoActemra/Actemra or any component',\n",
       "   'Active infection',\n",
       "   'Participation in a clinical trial in rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01185288',\n",
       "  'inclusion': ['Adult subjects with moderately to severely active rheumatoid arthritis',\n",
       "   'Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify)',\n",
       "   'Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline',\n",
       "   'Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening',\n",
       "   'Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab)'],\n",
       "  'exclusion': ['Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva)',\n",
       "   'Subject has been treated with intra-articular or parenteral administration of corticosteroids within 4 weeks of screening',\n",
       "   'Subject has diagnosis or history of gout or pseudogout',\n",
       "   'Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound)',\n",
       "   'Subject has history of chronic arthritis diagnosed before age 16 years']},\n",
       " {'nct_id': 'NCT01187563',\n",
       "  'inclusion': ['≥ 18 years of age',\n",
       "   'Moderately to severely active rheumatoid arthritis',\n",
       "   'Inadequate response to previous treatment with an anti-TNF agent',\n",
       "   'Receiving methotrexate for at least 12 wks before study'],\n",
       "  'exclusion': ['Previous treatment with tocilizumab',\n",
       "   'Previous treatment with other IL-6 receptor inhibitors',\n",
       "   'Treatment with corticosteroids (oral prednisone >10 mg/day or equivalent) within 4 wks',\n",
       "   'Conditions noted in the tocilizumab prescribing information']},\n",
       " {'nct_id': 'NCT01285752',\n",
       "  'inclusion': ['Diagnosis of RA (class I to III)',\n",
       "   'Stable dose of methotrexate (at least 12 weeks)'],\n",
       "  'exclusion': ['Pregnant or breastfeeding',\n",
       "   'Abnormal screening laboratory test values considered to be clinically significant']},\n",
       " {'nct_id': 'NCT01285310',\n",
       "  'inclusion': ['Must have a documented diagnosis of Rheumatoid Arthritis (1987 American College of Rheumatology Criteria) with onset of signs/symptoms of disease ≥ 4 months of duration from randomization.',\n",
       "   'Must be receiving treatment on an outpatient basis.',\n",
       "   'Must have active disease despite current methotrexate treatment as defined below:',\n",
       "   '≥ 6 swollen joints (66 swollen joint count) AND',\n",
       "   '≥ 6 tender joints (68 tender joint count) -. Must meet at least one of the four lab requirements below:',\n",
       "   'High Sensitivity C-Reactive Protein (hsCRP) ≥ 10 mg/L',\n",
       "   'Erythrocyte Sedimentation Rate (ESR) > 28 mm after the first 1 hour',\n",
       "   'Positive for Rheumatoid Factor (RF)',\n",
       "   'Positive for Anti-cyclic Citrullinated Peptide (anti-CCP) antibodies',\n",
       "   'For participants participating in the Magnetic Resonance Imaging (MRI) assessment: • Must have Rheumatoid Arthritis joint involvement, as assessed by swollen joint counts in: 1) at least two Metacarpophalangeal (MCP) swollen joints on the same hand, or 2) at least one swollen Metacarpophalangeal (MCP) joint and swollen wrist on the same hand.',\n",
       "   'Must have been treated with methotrexate for at least 4 months prior to randomization, and must be on stable dose. Participants will be required to maintain their stable dose through Week 52 of the study. Oral folate (folic acid) supplementation is required with a minimum dose of 5 mg/week, or instead leucovorin may be used up to 10 mg/week orally. • Non-steroidal anti-inflammatory drugs (NSAIDs) and pain medications are allowed, however, must be on stable regimen for at least 7 days prior to randomization and through Week 52 of the study.',\n",
       "   'Oral corticosteroids (if taken) are allowed, however, must be on stable dose of prednisone ≤ 10 mg/day or equivalent for at least 28 days prior to randomization and through Week 52 of the study.',\n",
       "   'Must meet the following laboratory criteria at screening:',\n",
       "   'White blood cell count ≥ 3000/mm^3 (≥ 3.0 x 10^9/L) and < 14,000/mm^3 (< 14 x 10^9/L)',\n",
       "   'Platelet count (≥ 100,000/μL ((≥ 100 x 10^9/L)',\n",
       "   'Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)',\n",
       "   'Aspartate aminotransferase or serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase or serum glutamic-pyruvic transaminase (ALT/ SGPT) ≤ 2 x upper limit of normal (ULN). If initial test shows Aspartate aminotransferase (AST) or alanine aminotransferase (SLT) or 2 times the upper limit of normal (ULN), one repeat test is allowed during the screening period.',\n",
       "   'Total bilirubin ≤ 2 mg/dL (≤ 34 μmol/L). If initial test result is > 2 mg/dL, one repeat test is allowed during the screening period.',\n",
       "   'Hemoglobin ≥ 9 g/dL (≥ 5.6 mmol/L)',\n",
       "   'Hemoglobin A1c ≤ 9.0%',\n",
       "   'Negative for hepatitis B surface antigen',\n",
       "   'Negative for hepatitis C antibody',\n",
       "   'Males who engage in activity in which conception is possible must use protocol described barrier contraception while on Investigational Product and for at least 28 days after the last dose of Investigational Product.',\n",
       "   'Females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use protocol described contraception while on Investigational Product and for at least 28 days after taking the last dose or Investigational Product.'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.',\n",
       "   'Rheumatic autoimmune disease other than Rheumatoid Arthritis, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis or significant systemic involvement secondary to Rheumatoid Arthritis (eg, vasculitis, pulmonary fibrosis or Felty syndrome). Sjögren syndrome secondary to Rheumatoid Arthritis is allowable.',\n",
       "   'Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.',\n",
       "   'Prior history of, or current, inflammatory joint disease other than Rheumatoid Arthritis (eg, gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis, Lyme disease).',\n",
       "   'Receiving treatment with Disease-modifying antirheumatic drugs (DMARDs) (other than methotrexate), including biologic Disease-modifying antirheumatic drugs (DMARDs)Previous use is only allowed after adequate washout prior to randomization.',\n",
       "   'Inadequate response to treatment with an anti-tumor necrosis factor (anti-TNF) agent. Patients who terminated previous anti-tumor necrosis factor (anti-TNF) treatment due to cost or safety reason, such as discomfort with the subcutaneous injections, may participate in this study after adequate washout.',\n",
       "   'Treatment with any investigational agent within four weeks (or five half-lives of the investigational drug, whichever is longer) of screening.',\n",
       "   'Previous treatment with any cell depleting therapies, including investigational agents.',\n",
       "   'Treatment with intravenous gamma globulin, plasmapheresis or Prosorba® column within 6 months of baseline.',\n",
       "   'Intra-articular or parenteral corticosteroids are not allowed within 6 weeks prior to randomization.',\n",
       "   'Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.',\n",
       "   'Pregnant women or nursing (breast feeding) mothers.',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including severe or very severe chronic obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus as defined by Hemoglobin A1c > 9.0%) or gastrointestinal (GI) disease.',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids.',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and herpes zoster, but excluding onychomycosis) or any major episode of infection requiring hospitalization or treatment with IV or oral antibiotics within 4 weeks of screening.',\n",
       "   'History of positive Human Immunodeficiency Virus (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).',\n",
       "   'History of malignancy, including solid tumors and hematologic malignancies (except basal cell carcinoma of the skin that has been excised and cured).',\n",
       "   'History of alcohol, drug or chemical abuse within the 6 months prior to screening.',\n",
       "   'Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.',\n",
       "   'Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.',\n",
       "   \"Any condition that in the investigator's opinion would interfere significantly with the efficacy evaluations, including the pain and joint assessments (eg, fibromyalgia). For Magnetic Resonance Imaging (MRI) Only:\",\n",
       "   \"Receiving medication(s) or will require medication(s) during the study that impact on vascular flow (eg, nitrates, calcium channel blockers, ergot containing drugs) on the day of the Magnetic Resonance Imaging (MRI test and in the investigator's judgement the subject cannot hold back from taking these medications on the day of the Magnetic Resonance Imaging (MRI) prior to the Magnetic Resonance Imaging (MRI) test. The subject can continue taking the medication(s) at any time after the Magnetic Resonance Imaging (MRI) test is completed, as clinically indicated and scheduled. Exclusions of antihypertensive and migraine medications can be determined after discussion with the Sponsor.\",\n",
       "   'Unable to undergo an Magnetic Resonance Imaging (MRI) examination, including but not limited to the presence of a pacemaker, defibrillator, or other implanted device such as anterior interbody cages, aneurysm clip, pedicle screws, or any other metal contained in the body (eg, such as tattoos that contain metallic pigment, or metal in the eyes from metal grinding [eg, a metal worker, etc]), or severe claustrophobia, or any other contraindication to an Magnetic Resonance Imaging (MRI) as per local imaging center guidelines.',\n",
       "   'Allergic or adverse reactions to gadolinium',\n",
       "   'Estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2 (based on the Modification of Diet in Renal Disease [MDRD] formula).']},\n",
       " {'nct_id': 'NCT01284569',\n",
       "  'inclusion': ['Body mass index (BMI) <35.0 kg/m2',\n",
       "   'Diagnosed with rheumatoid arthritis (RA) according to the 2010 European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) criteria for at least 6 months prior to randomisation',\n",
       "   'Treatment with methotrexate (MTX) for at least 12 weeks prior to screening, with at least 4 weeks before screening at a stable dose, that will remain stable throughout the study period. Inadequate response or or intolerance to disease modifying antirheumatic drugs (DMARDs) (including MTX, where a patient may remain on treatment with %TX at a lower dose for improved tolerance, but with reduced effectiveness)',\n",
       "   'For patients (men and women) of reproductive potential, use of an acceptable method of contraception for the duration of the study. Female patients must be willing to use appropriate birth control measures that would prevent pregnancy starting from the time of signing the informed consent until 90 days after the last dose of study drug is administered',\n",
       "   'For single dose part: Disease Activity Score using 28 joint counts (DAS28) score >= 2.4',\n",
       "   'For multiple dose part: DAS28 score >= 3.2',\n",
       "   'For multiple dose part: swollen joint count >= 3'],\n",
       "  'exclusion': [\"A documented history of an autoimmune disease other than RA (other than secondary Sjögren's syndrome)\",\n",
       "   'Functional class IV by ACR classification',\n",
       "   'Any new/additional biologic DMARD therapy, cytotoxic drugs and immunosuppressants within four weeks prior to screening, and between screening and Day 1 with the exception of ALX-0061',\n",
       "   'Suspicion of active tuberculosis verified by quantiferon test and abnormal chest X-ray',\n",
       "   'Female patients who are pregnant during the study, or are breastfeeding',\n",
       "   'History of anaphylactic reactions to protein therapeutics',\n",
       "   'Participation in an investigational drug study within 60 days prior to drug administration except for the patients who participated in the single dose part of this study and who are eligible to participate in the multiple dose part',\n",
       "   'Donation of more than 300 mL of blood within 60 days prior to drug administration',\n",
       "   'Malignancy, or prior malignancy, with a disease free interval of <5 years after diagnosis and intervention except curative treatment for non-melanoma skin cancer or resected carcinoma in situ',\n",
       "   'Any current or recent (within 4 weeks prior to first dose) signs or symptoms of infection that requires parenteral antibiotic administration, any known active viral infection (hepatitis B virus [HBV], hepatitis C virus [HCV], human immunodeficiency virus [HIV]) that would impair the participation in the study',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening and hospitalisation for a clinically relevant event within the 4 weeks prior to screening',\n",
       "   'Any other disease, metabolic dysfunction, physical examination finding, or clinically significant laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk for treatment complications',\n",
       "   'Administration of a live, attenuated vaccine within 1 month before dosing with ALX-0061, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose',\n",
       "   'For multiple dose part: contraindication to MRIs or the use of contrast agents for MRI scanning']},\n",
       " {'nct_id': 'NCT01287533',\n",
       "  'inclusion': ['Rheumatoid arthritis fulfilling the 1987 ACR criteria',\n",
       "   'Women equal and above 18 years, less than 75 years old',\n",
       "   'L1-4 T score less than -1.0 and equal or above -3.0 SD measured by DXA (Dual Energy X-ray Absorptiometry)',\n",
       "   'Patient must have taken prednisolone 5mg or its equivalent for more than 3 consecutive months within 1 year',\n",
       "   'Patient who would be taking glucocorticoids for more than 3 months after enrollment'],\n",
       "  'exclusion': ['Patient with vertebral fractures or nonvertebral fractures associated with osteoporosis',\n",
       "   'Patient diagnosed with malignancy within 5 years',\n",
       "   'Patient with endocrine dysfunction',\n",
       "   'RA functional class 4',\n",
       "   'Patient who took bisphosphonates within 6 months',\n",
       "   'Patient on medication affecting bone mineral metabolism']},\n",
       " {'nct_id': 'NCT01284985',\n",
       "  'inclusion': ['Age ≥ 18 years;',\n",
       "   'Have willingness to give his/her data transfer authorisation;',\n",
       "   'has an indication of: Hallux Rigidus, Hallux Limitus with degenerative joint disease, Painful Hallux Valgus, Osteoarthritis, Rheumatoid arthritis, Post-traumatic arthritis, for which surgeon has recommended that a METIS® prosthesis be implanted'],\n",
       "  'exclusion': ['active infection or inflammation;',\n",
       "   'excessive bone loss, bone deficiency or rapid joint destruction;',\n",
       "   'suspected or documented metal allergy or intolerance;',\n",
       "   'metatarsal head or phalangeal avascular necrosis;',\n",
       "   'joint instability involving soft and fibrous tissue deficiency;',\n",
       "   'severe metatarso-phalangeal axis deviation (Hallux Valgus angle > 20°);',\n",
       "   'prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol;',\n",
       "   'a previous joint replacement.']},\n",
       " {'nct_id': 'NCT01283399',\n",
       "  'inclusion': ['Active rheumatoid arthritis',\n",
       "   'Inadequate response to a single TNF inhibitor',\n",
       "   'Participants receiving rituximab therapy in accordance with the prescribing information',\n",
       "   'Signed data release form within 6 weeks (42 days) of initiating rituximab therapy',\n",
       "   'Women of childbearing potential must use effective form of contraception'],\n",
       "  'exclusion': ['Contra-indication to receive rituximab according to the local labelling',\n",
       "   'Previous treatment with rituximab',\n",
       "   'Treatment with any investigational drug within 30 days prior to enrolment']},\n",
       " {'nct_id': 'NCT01283971',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Rheumatoid arthritis of >/= 6 months duration (according to American College of Rheumatology (ACR) criteria)(according to ACR criteria)',\n",
       "   'Inadequate response due to inefficacy of treatment (for at least 3 months) with only one approved Tumor Necrosis Factor (TNF)-agent other than adalimumab Depending on the TNF-inhibitor, last dose of TNF-inhibitor should have been 1 to 8 weeks before randomization to the study',\n",
       "   'On methotrexate treatment for >/=12 weeks immediately prior to baseline, with stable dose (10-25 mg/week) for the last 8 weeks',\n",
       "   'Disease Activity Score (DAS28) >3.2 at baseline',\n",
       "   'Oral corticosteroids (</=10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs) are permitted if the dose has been stable for >/=6 weeks prior to baseline.'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following randomization',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Functional class IV (ACR criteria)',\n",
       "   'History of severe allergic reaction to human, humanized or murine monoclonal antibodies',\n",
       "   'Known active current or history of recurrent infection (including tuberculosis)',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Body weight >150 kg',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Intra-articular or parenteral corticosteroids within 6 weeks prior to baseline.']},\n",
       " {'nct_id': 'NCT01282528',\n",
       "  'inclusion': ['age 18-65 years, male or female and who are capable of providing informed consent, which must be obtained prior to any study-related procedures.',\n",
       "   'Those who have a definitive diagnosis of RA based on the criteria of American College of Rheumatology in 1987 and have moderate to severe disease (DAS28 more than 3.2).',\n",
       "   'Patients using oral corticosteroids, must have been on a stable dose of prednisone 10mg/day or its equivalent for at least 4 weeks prior to screening. If currently not using corticosteroids the patient must have not received corticosteroids for at least 4 weeks prior to screening.',\n",
       "   'Patients using DMARDs, must have been on a stable dose for at least 12 weeks prior to screening. If currently not using DMARDs the patient must have not received DMARDs for at least 12 weeks prior to screening.',\n",
       "   'If using NSAIDs or other analgesics for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent.'],\n",
       "  'exclusion': ['Patient who has a known hypersensitivity to human immunoglobulin proteins or other components of infliximab.',\n",
       "   'Patient who suffers from systemic inflammatory disease whose signs and symptoms are expected to affect the evaluation of the study drug.',\n",
       "   'Patient who has a history of receiving infliximab or any other biologics.',\n",
       "   'Patient who has stage IV',\n",
       "   '5. Patient who has had or is on live viral or bacterial vaccinations within 4 weeks to study entry.',\n",
       "   'Patient who ever suffered from chronic or recurrent infection, including but not limited to: chronic kidney infection, chronic thoracic cavity infection (eg. bronchiectasis), nasosinusitis, recurrent urinary tract infection, open, drain or dermal infected wound.']},\n",
       " {'nct_id': 'NCT01284283',\n",
       "  'inclusion': ['Moderate or severe pain, loss of mobility and function of the ankle (Buechel-Pappas Scale)',\n",
       "   'Primary arthrosis, post traumatic arthrosis or rheumatoid arthrosis',\n",
       "   'At least six months of conservative treatment for severe ankle conditions, confirmed by the patient medical history, radiograph studies and medication record',\n",
       "   'Willing and able to give informed consent'],\n",
       "  'exclusion': ['Patients who have not reached skeletal maturity',\n",
       "   'Active or prior deep infection inthe ankle joint or adjacent bones',\n",
       "   'Prior arthrodesis at the involved site',\n",
       "   'History of prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol',\n",
       "   'Obesity (weight greater than 250 lbs)',\n",
       "   'History of current prior drug abuse or alcoholism',\n",
       "   'Any physical condition precluding major surgery',\n",
       "   'Hindfoot malpositioned by more than 35 degrees or forefoot malalignment which would preclude a plantigrade foot',\n",
       "   'Lower extremity vascular insufficiency demonstrated by Doppler arterial pressure',\n",
       "   'Avascular necrosis of the talus',\n",
       "   'Inadequate skin coverage above the ankle joint',\n",
       "   'Patients under the age of 35 who are unwilling or unable to accept the physical limitations imposed by ankle arthroplasty, including limitations on certain vigorous physical activities (e.g. basketball, football) and on manual labor',\n",
       "   'Juvenile onset Type I diabetes',\n",
       "   'Adult onset Type II diabetes when accompanied by neuropathic changes or a history of foot infection in either foot',\n",
       "   'Pregnancy',\n",
       "   'Avascular necrosis of the tibia',\n",
       "   'Significant bone tumor of the foot or ankle',\n",
       "   'Severe deformity that would not normally be eligible for ankle surgery',\n",
       "   'Prior surgery and/or injury that has adversely affected the ankle bone stock',\n",
       "   'Severe osteoporotic or osteopenic condition or other conditions that may lead to inadequate implant fixation in the bone',\n",
       "   'Insufficient ligament support',\n",
       "   'Motor dysfunction due to neuromuscular impairment']},\n",
       " {'nct_id': 'NCT01282255',\n",
       "  'inclusion': ['Czech Republic: Age between 18',\n",
       "   '65 years (both inclusive)',\n",
       "   'A diagnosis of RA made at least 3 months prior to trial start',\n",
       "   'Active RA',\n",
       "   'Methotrexate treatment (between 7.5 mg and 25 mg/week, both inclusive) for at least 12 weeks with a stable dose for at least 4 weeks prior to trial start',\n",
       "   'Female subjects must be willing to avoid pregnancy and breast feeding throughout this trial at least until 15 weeks following the last dose of trial medication',\n",
       "   'Male subjects with partners of childbearing potential must be willing to use a highly effective contraception throughout trial incl. a 15 week follow up periode'],\n",
       "  'exclusion': ['Known or suspected allergy to trial product or related products',\n",
       "   'Body Mass Index (BMI) lower than 18.5 or higher than 35.0 kg/m^2',\n",
       "   \"Subjects with chronic inflammatory autoimmune disease other than RA (except secondary Sjögren's syndrome or stable hypothyroidism)\"]},\n",
       " {'nct_id': 'NCT01806974',\n",
       "  'inclusion': ['patient over 18 years presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is prescribed.',\n",
       "   'At least 18 permanent teeth in the mouth at least 3 teeth with a healthy periodontal status',\n",
       "   'Having expressed their written free and informed consent'],\n",
       "  'exclusion': ['Hypersensitivity to any of the following components : tocilizumab, saccharose, polysorbate 80, phosphate disodique dodécahydrate, phosphate monosodique dehydrate',\n",
       "   'Severe or active infections',\n",
       "   \"Systemic Pathology affecting the immune system including Sjögren's syndrome\",\n",
       "   'Surgery in the previous month',\n",
       "   'HIV positive',\n",
       "   'Alcoholic',\n",
       "   'Toxicoman',\n",
       "   'Antibiotic treatment in the last 2 months',\n",
       "   'Legally protected patients']},\n",
       " {'nct_id': 'NCT01253226',\n",
       "  'inclusion': ['Have given written informed consent',\n",
       "   'Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation',\n",
       "   'Diagnosis of RA',\n",
       "   'Active RA',\n",
       "   'Current, regular use of Methotrexate, at a stable dose',\n",
       "   'Body weight between 40 and 105 kilograms (kg), inclusive'],\n",
       "  'exclusion': ['Use of excluded medications (reviewed by study doctor)',\n",
       "   'Have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study',\n",
       "   'Have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation',\n",
       "   'Evidence of tuberculosis',\n",
       "   'Have systemic inflammatory condition other than RA']},\n",
       " {'nct_id': 'NCT01258712',\n",
       "  'inclusion': ['Patients diagnosed with history of moderate-to- severe rheumatoid arthritis for more than 6 months according to the American College of Rheumatology (ACR) 1987 revised criteria for the classification of',\n",
       "   '- Patients who failed to achieve clinical response to treatment of at least 2 DMARDs(disease modifying anti-rheumatic drug) (including MTX) for at least 12 weeks within 12 months prior to screening, of which MTX must have been at a stable dose of 10-20 mg/wk for at least 12 weeks prior to screening. All other DMARDs should be given at standard therapeutic dose.',\n",
       "   'Patients who satisfy swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.',\n",
       "   'C-reactive protein (CRP) level ≥ 1 mg/dl or an erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour at screening and at baseline.'],\n",
       "  'exclusion': ['Patients who have received a major surgery including joint surgery 8 weeks prior to the screening or are scheduled to be operated within 6 months after the enrolment.',\n",
       "   'Patients with rheumatoid autoimmune disease other than RA, including but not limited to SLE(system lupus erythematosus), or significant systemic involvement secondary to',\n",
       "   '- Patients who belong to the Class IV of the ACR classification criteria for functional status of',\n",
       "   '(ACR Amended Criteria for the Classification of Functional Capacity in Rheumatoid Arthritis; Class IV: Largely or wholly incapacitated with patient bedridden or confined to wheel chair, permitting little or no self-care).',\n",
       "   'Patients with a history of hypersensitivity to human, humanized or murine monoclonal antibodies or patients with contraindication for them.',\n",
       "   'Patients who currently have or have a history of recurrence of bacterial, viral,fungal, or mycobacterial infections or other infectious diseases; tuberculosis(TB),atypical mycobacterial disease, clinically significant granulomatous disease on chest radiograph, hepatitis B, hepatitis C, or herpes zoster and etc. However, a patient with hand & foot fungal infections can participate.']},\n",
       " {'nct_id': 'NCT01255761',\n",
       "  'inclusion': ['Subjects 18 years of age or older',\n",
       "   'Subjects with a diagnosis of Adult-onset Rheumatoid Arthritis of at least 3 months as defined by the 1987 American College of Rheumatology (ACR) classification criteria',\n",
       "   'Subjects with active Rheumatoid Arthritis as defined by:',\n",
       "   '4 tender joints (28 joint count) at Screening and Baseline Visits; and',\n",
       "   '4 swollen joints (28 joint count) at Screening and Baseline Visits',\n",
       "   'Subjects who have had an unsatisfactory response or intolerance to at least 1 traditional Disease-modifying Antirheumatic Drugs (DMARD)'],\n",
       "  'exclusion': ['Subjects must not have a diagnosis of any other inflammatory Arthritis',\n",
       "   'Subjects must not have greater than 3 Arthroplasties due to Rheumatoid Arthritis and/or Steinbrocker IV Functional Capacity',\n",
       "   'Subjects must not have a secondary non-inflammatory type of Arthritis that would interfere with study evaluation',\n",
       "   'Subjects must not be diagnosed with Fibromyalgia with sufficient symptoms requiring treatment',\n",
       "   'Subjects must not have a history of Infected Joint Prosthesis',\n",
       "   'Subjects must not have discontinued biological therapy for their Rheumatoid Arthritis due to Severe Hypersensitivity Reaction or Anaphylactic Reaction',\n",
       "   'Subjects must not have received more than 2 anti- Tumor Necrosis Factor (TNF) agents prior to enrollment',\n",
       "   'Subjects must not have received treatment with Abatacept and/or Rituximab or have received any experimental or approved B cell therapeutic agent',\n",
       "   'Subjects must not have a history of chronic alcohol or drug abuse',\n",
       "   'Subjects must not have known hypersensitivity to any components of the investigational medicinal product',\n",
       "   'Subjects must not have a history of chronic infections, recent serious or life-threatening infection within 6 months or any current sign or symptom that may indicate an infection',\n",
       "   'Subjects must not have a history of a Blood Dyscrasias',\n",
       "   'Subjects with known Tuberculosis (TB) Disease, high risk of acquiring TB or latent TB infection',\n",
       "   'Subjects must not be at high risk of infection',\n",
       "   'Subjects must not have a history of Lymphoproliferative Disorder including Lymphoma signs and symptoms suggestive of Lymphoproliferative Disease',\n",
       "   'Subjects must not have concurrent acute or chronic Viral Hepatitis B or C',\n",
       "   'Subjects must not have known Human Immunodeficiency Virus (HIV) infection',\n",
       "   'Subject must not have concurrent Malignancy or history of Malignancy',\n",
       "   'Subjects must not have a current or recent history of severe, progressive, and/or uncontrolled Renal, Hepatic, Hematological, Gastrointestinal, Endocrine, Pulmonary, Cardiac, Neurological or Cerebral Disease',\n",
       "   'Subjects must not have Class III or IV Congestive Heart Failure',\n",
       "   'Subjects must not have history of, or suspected Demyelinating Disease of the Central Nervous System',\n",
       "   'Subjects must not have a history of adverse reaction to Polyethylene Glycol (PEG)',\n",
       "   'Subjects must not have significant laboratory abnormalities which in the investigators judgment would make the subject unsuitable for inclusion',\n",
       "   'Subjects must not have a known history or clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, Nontuberculous Mycobacteria, Blastomyces or Aspergillus',\n",
       "   'Subject must not have a known history of or be currently diagnosed with Systemic Lupus Erythematosus']},\n",
       " {'nct_id': 'NCT01253265',\n",
       "  'inclusion': ['Ambulatory male or female patients between the ages of 20 and 75 years',\n",
       "   'Male patients: Agree to use a reliable method of birth control during the study including barrier contraceptives or a monogamous relationship with a partner who is not child bearing. Female patients: Are women who test negative for pregnancy at the time of entry based on a pregnancy test and are not breast feeding. Women of child bearing potential must agree to use a reliable method of birth control during the study.',\n",
       "   'Patients who are between the body weight of 40 and 105 kilogram (kg)',\n",
       "   'Patients who have an established diagnosis of Rheumatoid Arthritis (RA)',\n",
       "   'Patients who have C reactive protein (CRP) measurement greater than the upper limit of normal or erythrocyte sedimentation rate of at least 28 millimeters per hour (mm/hr)',\n",
       "   'Patients who have been treated with regular use of Methotrexate (MTX) for at least 12 weeks, and stable treatment (at least 7.5 milligrams per week (mg/week)) for at least 8 weeks',\n",
       "   'Patients who have given written informed consent approved by the Sponsor and the Institutional Review Board (IRB) governing the investigational site',\n",
       "   'Patients who have reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures'],\n",
       "  'exclusion': ['Patients who use oral corticosteroids at average daily doses of >10 mg/day of prednisone or its equivalent or use of variable doses of oral corticosteroids within the last 4 weeks',\n",
       "   'Patients who have had a live vaccination within the last 12 weeks, or intend to have a live vaccination during the course of the study, or have participated in a vaccine clinical study within the last 12 weeks',\n",
       "   'Patients who have a diagnosis of any systemic inflammatory condition other than RA',\n",
       "   'Patients who have evidence of active vasculitis or uveitis',\n",
       "   \"Patients who have a diagnosis of Felty's syndrome\",\n",
       "   'Patients who have had surgical treatment of a joint within the last 8 weeks, or will require it during the study',\n",
       "   'Patients who have had lymphoma, leukemia, or any malignancy within the last 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease',\n",
       "   'Patients who have suffered a serious bacterial infection within the last 12 weeks, or a recent or ongoing infection',\n",
       "   'Patients who have an evidence or suspicion of active tuberculosis (TB) by medical history, physical examination, and/or chest radiograph or documentation of TB by a positive purified protein derivative (PPD) test',\n",
       "   'Patients who have uncontrolled arterial hypertension characterized by a systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg',\n",
       "   'Patients who have an evidence of positive hepatitis B (HBV) surface antigen, positive hepatitis B surface antibody, positive hepatitis B core antibody, or hepatitis B DNA (HBV DNA); an evidence of human immunodeficiency virus (HIV), evidence of hepatitis B; or an evidence of hepatitis C',\n",
       "   'Patients who have clinical laboratory test results at entry that are outside the normal reference range, or results with unacceptable deviations that are considered clinically significant by the investigator',\n",
       "   'Patients who have a serum creatinine >2.0 milligrams per deciliter (mg/dL)',\n",
       "   'Patients who have known hypogammaglobulinemia or a serum immunoglobulin (Ig) G (IgG), IgM, or IgA concentration less than the lower limit of normal',\n",
       "   'Patients who have an abnormality in the 12 lead electrocardiogram (ECG).',\n",
       "   'Patients who have donated of blood more than 200 mL within the past 30 days, or more than 400 milliliters (mL) within the past 90 days',\n",
       "   'Patients who are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an off label use of an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. For unapproved Disease-Modifying Anti-Rheumatic Drug (DMARDs), have received 30 days or 5 fold of the half life prior to inclusion whichever is longer',\n",
       "   'Patients who previously completed or withdrawn from this study or any other study investigating LY2439821',\n",
       "   'Patients who have been treated with any biologic DMARD currently or previously for 5 half lives',\n",
       "   'Patients who have had serious reaction to other biologic Disease-Modifying Anti-Rheumatic Drug (DMARDs)',\n",
       "   'Patients who have received non biologics DMARDs (other than MTX, sulfasalazine, bucillamine or hydroxychloroquine)']},\n",
       " {'nct_id': 'NCT01250548',\n",
       "  'inclusion': ['Must be able to adhere to the study visit schedule and other protocol requirements',\n",
       "   'documented rheumatoid arthritis (RA) diagnosis by the 1987 American College of Rheumatology (ACR) criteria for at least 6 months',\n",
       "   'disease duration 6 or more months (from symptom onset)',\n",
       "   'failed 1 or more DMARD',\n",
       "   'active RA despite current DMARD therapy; active disease defined as 4 or more tender and 4 or more swollen joints (out of 28 joints examined) and any one of the following:',\n",
       "   'ESR 28 or higher mm/hr;',\n",
       "   'CRP 1.0 or more mg/dl;',\n",
       "   'Morning stiffness 45 or more minutes.',\n",
       "   'Patients receiving DMARD or biologic therapy must undergo a drug washout.',\n",
       "   'Patients receiving a nonsteroidal anti-inflammatory drug (NSAID) and/or prednisone (10 or less mg day) must be on stable doses of these agents for more than 2 weeks.',\n",
       "   'Must meet laboratory criteria as specified in the protocol',\n",
       "   'Females of childbearing potential (FCBP) must have a negative urine pregnancy test at screening and must adhere to adequate forms of contraception as defined in the protocol. Must agree to pregnancy tests every 28 days while on study medication.',\n",
       "   'Males (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in sexual activity with FCBP while on study medication and for 28 days after taking the last dose of study medication'],\n",
       "  'exclusion': ['Inability to provide voluntary consent',\n",
       "   'History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, neurologic, gastrointestinal, immunologic, or other major diseases',\n",
       "   'Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study',\n",
       "   'Pregnant or breastfeeding female',\n",
       "   'Systemic fungal infection',\n",
       "   'Active tuberculosis (TB) or a history of incompletely treated tuberculosis.',\n",
       "   'History of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years)',\n",
       "   'Clinically significant abnormality on the chest x-ray (CXR) at screening. Chest x-rays performed within 3 months prior to start of study drug are acceptable.',\n",
       "   'Use of any investigational medication within 28 days prior to randomization or 5 half-lives if known (whichever is longer)',\n",
       "   'Any clinically significant abnormality on 12-lead ECG at screening',\n",
       "   'History of congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency [CVID])',\n",
       "   'History of Human Immunodeficiency Virus (HIV) infection',\n",
       "   'Presence of hepatitis B surface antigens (HBsAg) or Hepatitis core antibody positive at screening.',\n",
       "   'Antibodies to Hepatitis C virus at screening',\n",
       "   'History of malignancy within 5 years prior to the screening visit (except for treated [i.e. cured] basal cell skin carcinomas and treated [i.e. cured] carcinoma in situ of the cervix)',\n",
       "   'currently on DMARD therapy',\n",
       "   'currently taking biologics',\n",
       "   'treated with rituximab in the last 6 months',\n",
       "   'Recent hospitalization (last 3 months)',\n",
       "   'Planned pregnancy or major surgery']},\n",
       " {'nct_id': 'NCT01254331',\n",
       "  'inclusion': ['Adult patients >/=18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis defined as DAS 28>3.2',\n",
       "   'Body weight </=150 kg',\n",
       "   'Patient on at least 1 non-biologic DMARD on a stable dose for at least 8 weeks at any time prior to study start',\n",
       "   'Inadequate clinical response to a stable dose of a non-biologic DMARD'],\n",
       "  'exclusion': ['Major surgery within 8 weeks prior to screening or planned major surgery within 6 months following enrollment',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis (RA)',\n",
       "   'Functional class IV as defined by the ACR classification',\n",
       "   'History or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with any cell depleting therapy',\n",
       "   'Previous treatment with methotrexate',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Previous treatment with any biologic drug that is used in the treatment of RA']},\n",
       " {'nct_id': 'NCT01251120',\n",
       "  'inclusion': ['Adult patients, over the age of 18 years',\n",
       "   'Diagnosis of moderate-to-severe active early rheumatoid arthritis (RA) of less than 2 years duration',\n",
       "   'DAS28 >3.2',\n",
       "   'Swollen joint count (SJC) >/=6 (66 joint count), and tender joint count (TJC) >/=6 (68 joint count)',\n",
       "   'Patients who have received DMARDs (including methotrexate) for 3-7 months'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis (secondary Sjögrens syndrome or nodulosis with RA is permitted)',\n",
       "   'Functional class III or IV as defined by ACR Classification of Functional Status in Rheumatoid Arthritis',\n",
       "   'Prior history of or current inflammatory joint disease other than RA']},\n",
       " {'nct_id': 'NCT01617421',\n",
       "  'inclusion': ['Adult patients enrolled in the NIAMS Natural History of Rheumatic Disease in Minority Communities',\n",
       "   'Diagnosis of osteoarthritis (OA) or rheumatoid arthritis (RA)',\n",
       "   'Willingness and ability to provide informed consent',\n",
       "   'Age greater than or equal to 18 years'],\n",
       "  'exclusion': ['Recent (less than 6 months) or planned joint surgery',\n",
       "   'Use of assistive ambulatory devices',\n",
       "   'Other significant medical or psychiatric conditions, including other inflammatory conditions',\n",
       "   'Hyper-mobility or unstable disease that could compromise participation in the study.']},\n",
       " {'nct_id': 'NCT01610791',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis (DAS28 > 3.2 at screening)',\n",
       "   'Inadequate response to DMARDs',\n",
       "   'Body weight < 150 kg'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of enrollment',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'American College of Rheumatology (ACR) functional class IV',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with any biologic drug that is used in the treatment of RA',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Pregnant or lactating women',\n",
       "   'Active current or history of recurrent infection, active TB within the previous 3 years, HIV infection']},\n",
       " {'nct_id': 'NCT01615419',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis , according to the revised ACR criteria',\n",
       "   'Patients initiated on RoActemra/Actemra treatment (in accordance with the local label) on their treating physicians decision'],\n",
       "  'exclusion': ['RoActemra/Actemra treatment more than 8 weeks prior to enrolment visit',\n",
       "   'Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or of any joint inflammatory disease other than RA']},\n",
       " {'nct_id': 'NCT01617590',\n",
       "  'inclusion': ['Male and female patients aged 18',\n",
       "   '75 years (inclusive).',\n",
       "   'Body weight between 50 and 100 kg (inclusive).',\n",
       "   'Post menopausal or surgically sterile female patients are allowed. Female patients of child-bearing potential may participate if they are already on a stable dose of methotrexate. Additional birth control details to be provided at screening. Male patients must use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study.',\n",
       "   'Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria.',\n",
       "   'Active disease evaluation (DAS 28 > 3.2).',\n",
       "   'Patients who using steroids before enrollment, the dose should not be more than 30mg/d, and remain unchanged for more than 30days.',\n",
       "   'Without use of other disease activity controlling drugs.',\n",
       "   'Get the informed consent.'],\n",
       "  'exclusion': ['Advanced patients with severe joints disability.',\n",
       "   'Pregnant or breast- feeding female patients.',\n",
       "   'Patients with severe primary disease or impairment of heart, brain, lung, liver (ALT or AST > 1.5 normal value), kidney (sCr > normal value), endocrine, and hematology system.',\n",
       "   'Concomitant with other rheumatic disease.',\n",
       "   'Alcohol taken or drug abusing patients.',\n",
       "   'Patients with congestive heart failure, QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded.',\n",
       "   'Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4 weeks prior to randomization.']},\n",
       " {'nct_id': 'NCT01616641',\n",
       "  'inclusion': ['rheumatoid arthritis (American College of Rheumatology) Control group:',\n",
       "   'healthy'],\n",
       "  'exclusion': ['edentate be total, have been subjected to surgical procedure in the last six months in the region of the hands or oral maxillo facial']},\n",
       " {'nct_id': 'NCT01618968',\n",
       "  'inclusion': ['Male or female patients ≥18 years of age, diagnosed with Rheumatoid Arthritis'],\n",
       "  'exclusion': ['Pregnant females',\n",
       "   'Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk']},\n",
       " {'nct_id': 'NCT01611688',\n",
       "  'inclusion': ['Active RA, characterised by a DAS28 (CRP)(Disease Activity Score based on 28 joints and CRP) above 3.2 and a minimum of two swollen joints based on a 68/66 joint count at screening',\n",
       "   'Concomitant treatment with MTX (7.5',\n",
       "   '25 mg/week both inclusive) for at least 16 weeks, with a stable dose for at least 6 weeks prior to dosing'],\n",
       "  'exclusion': ['Subjects with chronic inflammatory autoimmune disease other than RA',\n",
       "   'History of or current inflammatory joint disease other than RA such as gout (crystal proven), psoriatic arthritis, juvenile idiopathic arthritis, current reactive arthritis or Lyme disease',\n",
       "   'Any active or ongoing chronic infectious disease (e.g. chronic osteomyelitis, chronic pyelonephritis) requiring systemic anti-infectious treatment within 4 weeks prior to randomisation',\n",
       "   'Clinically significant cardiac or cardiovascular disease',\n",
       "   'Past or current malignancy',\n",
       "   'Latent or active tuberculosis (TB) as documented by: A positive QuantiFeron® test (test can be performed up to 2 months prior to dosing). One retest is allowed in case of inconclusive results.- A history of active TB within the last 3 years even, if treated effectively.',\n",
       "   'A history of active TB more than 3 years ago, if there is no documentation that the prior anti-TB treatment was appropriate in duration and type']},\n",
       " {'nct_id': 'NCT01613027',\n",
       "  'inclusion': ['Age >18 years with rheumatoid arthritis (RA)',\n",
       "   'Seropositive participants with RA (positive for rheumatoid factor (RF) and/or anti-Citrullinated Cyclic Peptide [CCP])',\n",
       "   'Active disease despite receiving one or more TNF inhibitors',\n",
       "   'Absence of serious or active infection'],\n",
       "  'exclusion': ['Participants with serious history of heart failure (class New York Heart Association [NYHA] IV) or severe uncontrolled heart disease',\n",
       "   'Participants pregnant or lactating',\n",
       "   'Prior treatment with Mabthera®',\n",
       "   'Participants receiving any other investigational product in the context of other clinical study',\n",
       "   'Participants with known hypersensitivity to rituximab or to any of the excipients']},\n",
       " {'nct_id': 'NCT01617005',\n",
       "  'inclusion': ['Moderate to severe active RA (European League Against Rheumatism [EULAR] criteria)',\n",
       "   'Inadequate response to DMARDs or tumor necrosis factor (TNF) antagonists',\n",
       "   'Initiating treatment with tocilizumab according to SPC'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'Prior history or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with any biological drug used in the treatment of RA',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Any contraindication to treatment with tocilizumab',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment',\n",
       "   'Pregnant women or nursing (breastfeeding) mothers']},\n",
       " {'nct_id': 'NCT01618955',\n",
       "  'inclusion': ['Male or female patients >18 years of age, diagnosed with Rheumatoid Arthritis'],\n",
       "  'exclusion': ['Pregnant females',\n",
       "   'Any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk']},\n",
       " {'nct_id': 'NCT01613378',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to revised (1987) American college of rheumatology (ACR) criteria',\n",
       "   'Initiated on tocilizumab treatment by the treating physician in accordance with the Canadian product monograph',\n",
       "   'Informed consent to data being subject to computerized data processing',\n",
       "   'Participant must fulfill the reimbursement criteria for treatment with tocilizumab under provincial or private health insurance coverage'],\n",
       "  'exclusion': ['Received tocilizumab prior to enrolment visit',\n",
       "   'Previously received tocilizumab in a clinical trial or for compassionate use',\n",
       "   'Enrolled in an ongoing clinical trial and/or received treatment with any investigational agent within 4 weeks, or 5 half-lives of the investigational agent, whichever is longer, before starting treatment with tocilizumab',\n",
       "   'Participation in another clinical trial or industry sponsored observational study',\n",
       "   \"History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis, with the exception of concomitant secondary Sjörgen's syndrome\"]},\n",
       " {'nct_id': 'NCT01619176',\n",
       "  'inclusion': ['The patient should be diagnosed as the first or second stage of rheumatoid Arthritis (RA) and checked with X ray for additional diagnose.',\n",
       "   'diagnosed for RA according to ACR(1987)',\n",
       "   'the patient should be in the active stage of the disease, defined as：',\n",
       "   'swollen joints >3',\n",
       "   'tender joints > 5',\n",
       "   'any one of the following： (c1.) morning stiffness lasting more than 45 minutes (c2.) Erythrocyte Sedimentation Rate (ESR) >= 28mm/h (c3.) C-reactive protein (CRP)>= 12mg/L',\n",
       "   'Should not be resistant to MTX nor leflunomide',\n",
       "   'Blood test should satisfy:',\n",
       "   'Hemoglobin (Hb)>=85g/L',\n",
       "   'White cell >=3.5 10+9/L',\n",
       "   'Platelets >= 100 10+9/L',\n",
       "   'Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit of normal (ULN)',\n",
       "   'Kidney function: Serum creatinine (Cr) level should be less than ULN.',\n",
       "   'Pregnancy test should be negative',\n",
       "   'should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP).',\n",
       "   'should agree to sign the informed consent'],\n",
       "  'exclusion': ['Serious diseases affecting liver, kidney, heart and lung, or diseases related to hematologic，endocrine and nervous systems. .',\n",
       "   'Be treated by MTX or Leflunomide in the last 3 months.',\n",
       "   'Be treated with cortical hormone （could be intramuscular injection, intravenous injection or injection to articular cavity） in the last 4 weeks.',\n",
       "   'Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 mono antibody in the last 3 months.',\n",
       "   'Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine, chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last 3 months.',\n",
       "   'Pregnant and breast-feeding woman',\n",
       "   'Having history of serious drug allergy',\n",
       "   'In the acute or chronic phase of infection (such as lung diseases)',\n",
       "   'Easy bleeding patients or patients with local skin infection (only for acupuncture)',\n",
       "   'The patients cannot accept acupuncture (only for acupuncture)',\n",
       "   'Be treated with acupuncture in the past 3 months（only for acupuncture）.',\n",
       "   'No pregnant and breast-feeding woman.',\n",
       "   'No history of serious drug allergy.']},\n",
       " {'nct_id': 'NCT01618019',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis diagnosed based on American College of Rheumatology guideline and receiving NSAID, glucocorticoids, or DMARD were eligible if the dosage had been stable for at least 3 months prior to entering the study.'],\n",
       "  'exclusion': ['Patients were excluded if they were pregnant, lactating, under the age of 18 or over age 80, taking supplements containing n-3 PUFA, white blood cell (WBC) ≤ 3.5 × 109/L, hemoglobin (Hb) ≤ 8.5 g/dL, platelet ≤ 100 × 109/L, creatinine ≥ 2.0 mg/dL, and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2.5 times upper limit of normal.']},\n",
       " {'nct_id': 'NCT01023256',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA) per revised 1987 ACR criteria',\n",
       "   'Active RA: ≥3 swollen and 3 tender joints with at least 1 swollen joint in the hand, excluding the PIP joint',\n",
       "   'CRP > 5.0 mg/L (RF and anti-CCP seronegative); CRP >2 mg/l (RF and/or anti-CCP seropositive)',\n",
       "   'DAS28 ≤ 5.1',\n",
       "   'Stable regimen of concomitant RA therapy (NSAIDs, steroids, non- biological DMARDs).',\n",
       "   'Negative PPD tuberculin skin test'],\n",
       "  'exclusion': ['Previous therapy with B or T cell depleting agents other than Rituximab (e.g. Campath). Prior treatment with Rituximab, TNF-inhibitors, other biologics (e.g. anti-IL-1 therapy) and systemic immunosuppressive agents is allowed with a washout period.',\n",
       "   'Any history of ongoing, significant or recurring infections',\n",
       "   'Any active inflammatory diseases other than RA',\n",
       "   'Treatment with a systemic investigational drug within 6 months prior to screening',\n",
       "   'Women of childbearing potential, unless receiving stable doses of methotrexate or leflunomide',\n",
       "   'Significant cardiac or pulmonary disease (including methotrexate- associated lung toxicity)',\n",
       "   'Hepatic or renal insufficiency']},\n",
       " {'nct_id': 'NCT01026519',\n",
       "  'inclusion': ['Male or female ≥18 years of age',\n",
       "   'Subjects must weigh >50 and <100 kg',\n",
       "   'Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with disease duration of no less than 6 months and ACR class I-III'],\n",
       "  'exclusion': ['A history of Listeriosis or active tuberculosis (TB)',\n",
       "   'Persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit',\n",
       "   'History of prior articular or prosthetic joint infection',\n",
       "   'History of a hypersensitivity reaction, other than localized injection site reaction (ISR), to any biological molecule',\n",
       "   \"Significant concomitant illness such as, but not limited to cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease that would adversely affect the subject's participation in this study\"]},\n",
       " {'nct_id': 'NCT01027728',\n",
       "  'inclusion': ['Male or female subjects, aged 18-75 years inclusive, with stable RA based on American College of Rheumatology (ACR) criteria (see section 11.3) for at least 3 months (subjects do not need to have active RA for Stage A of the study);',\n",
       "   'Subjects must have been on a stable dose of methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly, but not intravenously, for ≥ 8 weeks prior to randomization;',\n",
       "   'If a subject is also taking sulfasalazine or hydroxychloroquine, the subject must have been on a stable dose of these medications for at least 8 weeks prior to randomization;',\n",
       "   'If a subject is on corticosteroid therapy, the dose must not exceed 10 mg prednisone or equivalent and the subject must have been on a stable dose for at least 4 weeks prior to randomization;',\n",
       "   'Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;',\n",
       "   'Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen;',\n",
       "   'Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments;',\n",
       "   'Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after, any administration of study medication. Adequate contraception is defined as usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Screening, of a stable regimen of any form of hormonal contraception or an intra-uterine device. Use of abstinence alone is not considered adequate. Use of a barrier method alone is considered adequate only if the male partner was vasectomized at least six months prior to Screening. Use of a double-barrier method of contraception is acceptable.'],\n",
       "  'exclusion': ['Diagnosed with RA prior to 16 years of age;',\n",
       "   'Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at Screening;',\n",
       "   'History within one year prior to randomization of illicit drug use;',\n",
       "   'History of alcohol abuse at any time in the past;',\n",
       "   'Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomization;',\n",
       "   'Use of leflunomide within 6 months of randomization;',\n",
       "   'Use of etanercept or anakinra within 4 weeks of randomization;',\n",
       "   'Use of rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomization;',\n",
       "   'Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir,indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin,clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant,or verapamil;',\n",
       "   'History or presence of any form of cancer within the 10 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;',\n",
       "   'Evidence of tuberculosis based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.TB test performed during screening;',\n",
       "   \"Presence of Felty's syndrome, psoriatic arthritis, or other auto-immune diseases;\",\n",
       "   'Major surgery (including joint surgery) within 12 weeks prior to randomization;',\n",
       "   \"Subject's hemoglobin is less than 11 g/dL (6.83 mmol/L) at Screening;\",\n",
       "   'Subject has any evidence of hepatic disease; AST, ALT, alkaline phosphatase, or bilirubin > 1.5 x the upper limit of normal;',\n",
       "   'Subject has any evidence of renal impairment; serum creatinine > 1.5 x upper limit of normal;',\n",
       "   'The subject had an infection requiring antibiotic treatment within 4 weeks of randomization;',\n",
       "   'History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study; and',\n",
       "   'Participated in any clinical study of an investigational product within 30 days prior to randomization.']},\n",
       " {'nct_id': 'NCT01029613',\n",
       "  'inclusion': ['Age > 18 years old and < 85 years old',\n",
       "   'RA in accordance with American College of Rheumatology 1987 criteria',\n",
       "   'Moderate or highly active RA defined as DAS28 > 3,2 (CRP based)',\n",
       "   'Clinical indication for TNF-α inhibitor treatment by the treating physician',\n",
       "   'No contraindications for TNF-α inhibitor treatment',\n",
       "   'No contraindications for MRI',\n",
       "   'Serum creatinine in normal range',\n",
       "   'Sufficient contraception for fertile women',\n",
       "   'Capable of giving informed consent',\n",
       "   'Capable of complying with the examination program of the protocol'],\n",
       "  'exclusion': ['Other DMARDs than MTX from less than 4 weeks before inclusion and throughout the study period',\n",
       "   'Cyclophosphamide, Chlorambucil or other alkylating agents from less than 4 weeks before inclusion and throughout the study period',\n",
       "   'Intramuscular or intravenous injection of glucocorticoid from less than 4 weeks before inclusion and throughout the study period',\n",
       "   'Pregnancy wish, pregnancy or breast-feeding',\n",
       "   'Contraindications for TNF-α inhibitor treatment',\n",
       "   'Contraindications for MRI',\n",
       "   'Known recent drug or alcohol abuse',\n",
       "   'Failure to provide written consent',\n",
       "   'Incapable of complying with the examination program for physical or mental reasons']},\n",
       " {'nct_id': 'NCT01021735',\n",
       "  'inclusion': ['Rheumatoid arthritis',\n",
       "   'Eligible for biologic therapy according to BSR/NICE guidelines'],\n",
       "  'exclusion': ['Prior biologic therapy',\n",
       "   'Contra-indication to anti-TNF therapy or rituximab']},\n",
       " {'nct_id': 'NCT01034397',\n",
       "  'inclusion': ['adult patients, >/=18 years of age',\n",
       "   'moderate to severe rheumatoid arthritis of >/=6 months duration',\n",
       "   'synovitis (swollen and tender joint) in the wrist of the dominant hand',\n",
       "   'non-biologic DMARDs at stable dose for >/=12 weeks prior to baseline',\n",
       "   'oral corticosteroids at stable dose for at least 25 out of 28 days prior to baseline'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA',\n",
       "   'history of or current inflammatory joint disease other than RA',\n",
       "   'functional class IV (ACR classification)',\n",
       "   'intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'previous treatment with a biologic agent for RA']},\n",
       " {'nct_id': 'NCT01038349',\n",
       "  'inclusion': ['Able to read, understand, and sign the informed consent form',\n",
       "   'Able to read, write, and speak English',\n",
       "   '≥18 years of age',\n",
       "   'Diagnosed with RA within past 24 months (waiver)',\n",
       "   'Taking oral methotrexate therapy for a minimum of 3 months',\n",
       "   'Considered to have an insufficient response to methotrexate and therefore a candidate for change to therapy, including changing MTX dose or changing route of delivery, or adding or switching DMARDs (including but not limited to biologic DMARDs)'],\n",
       "  'exclusion': ['Prior exposure of the study center, study physician or study patient to the Avise PG laboratory test',\n",
       "   'Patients with known abnormal hepatic and or hematological parameters',\n",
       "   'Use of prednisone >10mg/day (or its equivalent)',\n",
       "   'Rheumatologic diagnosis other than primary RA']},\n",
       " {'nct_id': 'NCT01034306',\n",
       "  'inclusion': ['Males and females ages 18-75 years',\n",
       "   'Meet the criteria of the American College of Rheumatology for RA (Arnett FC et',\n",
       "   'Arthritis Rheum 1988;31:315-324, Appendix 1)',\n",
       "   'Not bed- or wheelchair-bound',\n",
       "   'Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory',\n",
       "   'Elevated PBMC A3AR expression level, defined as >= 1.5-fold over a predetermined normal population standard, following the appropriate DMARD/biologic washout period (see Exclusion Criteria) but within 2 weeks of beginning dosing',\n",
       "   'If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to the A3AR Qualification Visit, and will remain unchanged during protocol participation',\n",
       "   'If taking an oral corticosteroid, dose is <=10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the A3AR Qualification Visit, and will remain unchanged during protocol participation',\n",
       "   \"In the Investigator's opinion, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol\",\n",
       "   'Negative screening serum pregnancy test for female patients of childbearing potential',\n",
       "   'Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)',\n",
       "   'All aspects of the protocol explained and written informed consent obtained'],\n",
       "  'exclusion': ['Receipt of any of the following for at least a 1 month washout period prior to the A3AR Qualification Visit: methotrexate, sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra',\n",
       "   'Receipt of etanercept for at least a 6 week washout period prior to the A3AR Qualification Visit',\n",
       "   'Receipt of chloroquine, hydroxychloroquine, cyclosporine, infliximab, golimumab or adalimumab for at least a 2 month washout period prior to the A3AR Qualification Visit',\n",
       "   'Receipt of leflunomide for at least a 2 month washout period prior to the A3AR Qualification Visit, unless patient has undergone cholestyramine washout at least 1 month prior to testing',\n",
       "   'Receipt of cyclophosphamide for at least a 6 month period prior to the A3AR Qualification Visit',\n",
       "   'Receipt of rituximab at any previous time',\n",
       "   'Previous failure to respond to methotrexate or any anti-rheumatic biological agent',\n",
       "   'Participation in a previous trial CF101 trial',\n",
       "   'Use of oral corticosteroids >10 mg of prednisone, or equivalent, per day',\n",
       "   'Change in NSAID dose level for 1 month prior to the A3AR Qualification Visit',\n",
       "   'Change in oral corticosteroid dose level during the 1 month prior to the A3AR Qualification Visit',\n",
       "   'Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to the A3AR Qualification Visit']},\n",
       " {'nct_id': 'NCT01038674',\n",
       "  'inclusion': ['Informed consent obtained before any trial-related activities',\n",
       "   'A diagnosis of rheumatoid arthritis made at least 3 months prior to screening',\n",
       "   'Active rheumatoid arthritis, characterised by a DAS28 equal or above 3.2',\n",
       "   'Methotrexate treatment (stable dose, equal or below 25 mg/week) for at least 4 weeks prior to study start (subjects receiving stable doses of oral corticosteroids, and/or non-steroidal anti-inflammatory drugs and/or acetaminophen and/or opioids according to prescribed recommended doses can be included)',\n",
       "   'Male subjects and female subjects of non-child bearing potential'],\n",
       "  'exclusion': ['Body mass index (BMI) less than 18.5 or above 35.0 kg/m2',\n",
       "   'Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis',\n",
       "   'History of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Chronic or ongoing infectious disease requiring systemic anti-infectious treatment within 2 weeks prior to study start',\n",
       "   'Past or current malignancy (as judged by the investigator)',\n",
       "   'Clinically significant cardiac or cardiovascular disease',\n",
       "   'Positive for human immunodeficiency virus (HIV), hepatitis or tuberculosis',\n",
       "   'Blood donation or blood loss of more than 0.45L within 2 months prior to study start, or longer if required by local regulations',\n",
       "   'Breast-feeding women']},\n",
       " {'nct_id': 'NCT01034137',\n",
       "  'inclusion': ['adult patients, >/=18 years of age',\n",
       "   'early rheumatoid arthritis (disease symptoms <1 year) according to ACR criteria',\n",
       "   'disease activity DAS28 >2.6',\n",
       "   'body weight </=110kg, BMI </=36'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA',\n",
       "   'current inflammatory joint disease other than RA',\n",
       "   'previous treatment with any DMARD or biologic drug used in the treatment of RA',\n",
       "   'intra-articular, parenteral or oral glucocorticoids used for the arthritis']},\n",
       " {'nct_id': 'NCT01137838',\n",
       "  'inclusion': ['ICD 9 diagnosis RA 714.0',\n",
       "   'Documented first biologic prescription (\"index\" prescription) for abatacept, infliximab, etanercept, or adalimumab',\n",
       "   'Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index',\n",
       "   'Prescription claims data available for 6 months before and 12 months after index biologic prescription',\n",
       "   'Continuous eligibility for 6 months before and 12 months after index biologic prescription'],\n",
       "  'exclusion': ['Prescription claims for another biologic during the observation period (including rituximab and anakinra)',\n",
       "   'Prescriptions not continuous for at least 6 months']},\n",
       " {'nct_id': 'NCT01132118',\n",
       "  'inclusion': ['Age 18 or older',\n",
       "   'Able to provide informed consent and comply with study visits',\n",
       "   'Hemoglobin ≥ 10 g/dL (within last two months)',\n",
       "   'WBC ≥ 4 K/uL (within last two months)',\n",
       "   'Platelet count ≥ 150 ≤ 450 K/uL (within last two months)',\n",
       "   '(GFR) Creatinine clearance ≥ 70 ml/min (MDRD) (within last two months)',\n",
       "   'SGOT, SGPT ≤ 1.5 times upper limits of normal (within last two months)',\n",
       "   \"Normal eye exam within 12 months of study entry (copy of letter from subject's ophthalmologist or optometrist stating that the subject has no evidence of macular pathology)\",\n",
       "   'Diagnosis of rheumatoid arthritis'],\n",
       "  'exclusion': ['History of any neuromuscular disease including muscular dystrophy, metabolic myopathies, peripheral neuropathy, multiple sclerosis, and other myopathies or myositides',\n",
       "   'History of diabetes or fasting plasma glucose of 126 mg/dl or greater',\n",
       "   'History of any untoward reaction to antimalarials',\n",
       "   'Uncontrolled hypertension (>140/90)',\n",
       "   'History of any ophthalmologic disease except for glaucoma or cataracts',\n",
       "   'Planned elective surgery during the study period',\n",
       "   'Digoxin therapy',\n",
       "   'Treatment with corticosteroids (> 5 mg) for any disorder',\n",
       "   'History of psoriasis',\n",
       "   'Any chronic disease that in the opinion of the investigator warrants exclusion (e.g. inflammatory bowel disease, malignancy other than basal cell carcinoma, chronic liver disease)',\n",
       "   \"History of chronic intestinal disorders (Crohn's disease, ulcerative colitis, celiac sprue, collagenous colitis, eosinophilic enteritis)\",\n",
       "   'Creatinine clearance ≤ 60 ml/min (MDRD) (within last two months)',\n",
       "   'Hemoglobin ≤ 10 g/dL (within last two months)',\n",
       "   'WBC ≤ 4 K/uL (within last two months)',\n",
       "   'Platelet count ≤ 150 ≥ 450 K/uL (within last two months)',\n",
       "   'SGOT, SGPT ≥ 1.5 times upper limits of normal (within last two months)',\n",
       "   'Women who are pregnant or breastfeeding']},\n",
       " {'nct_id': 'NCT01136707',\n",
       "  'inclusion': ['Patients will be identified based on the presence of first infusion claim during study period for Orencia',\n",
       "   'At least 1 medical or facility claim for rheumatoid arthritis at the time of or 6 months prior to index date',\n",
       "   'Patients are required to be continuously enrolled for a minimum pre-index and follow-up period as detailed below',\n",
       "   'Patients with a minimum of 3 infusion claims for Orencia',\n",
       "   'Only those patients will be included whose first 3 infusion claims occur within 84 days'],\n",
       "  'exclusion': ['Patients less than 18 years of age at index date.',\n",
       "   \"One or more diagnoses of regional enteritis (including Crohn's disease), ulcerative colitis, anal or intestinal fistula, ankylosing spondylitis or other inflammatory spondylopathy, psoriatic arthropathy, or psoriasis any time during the 6-month pre-index period\",\n",
       "   'Patients who switch between biologics within their first three infusion claims',\n",
       "   'Restarts, defined as those patients who go back on Orencia after a gap of 42 days',\n",
       "   'Patients who are on other biologics at the same time as Orencia']},\n",
       " {'nct_id': 'NCT01131910',\n",
       "  'inclusion': ['Rheumatoid arthritis treated with methotrexate and/or TNF-alfa blocking drugs',\n",
       "   'Interest to be vaccinated',\n",
       "   'Written consent',\n",
       "   'Age 18 years or more'],\n",
       "  'exclusion': ['Previous TBE-infection',\n",
       "   'Previous Vaccination with TBE',\n",
       "   'Pregnancy',\n",
       "   'Breast feeding',\n",
       "   'Treatment with rituximab the last 9 months',\n",
       "   'Inability to follow study protocol']},\n",
       " {'nct_id': 'NCT01136694',\n",
       "  'inclusion': ['Evidence of a bDMARD or DMARD during the identification period (01 February 2009',\n",
       "   '31 July 2009)',\n",
       "   '18 years of age or older at the index year',\n",
       "   'At least 12 months of continuous enrollment in a large commercial US health plan affiliated with i3 Innovus, including the at least 6 months and up to 12 months prior the index date (i.e., the pre-index period) and at least 6 months following the index date (i.e., the post-index (follow-up) period)',\n",
       "   'Diagnosis of RA (reported on baseline survey)'],\n",
       "  'exclusion': [\"Diagnosis of psoriasis, plaque psoriasis, or psoriatic arthritis (ICD-9 code 696.0x, or 696.1x), ankylosing spondylitis (720.0x), Crohn's disease (555.x), non-Hodgkins lymphoma (200.xx, 202.0x-202.2x, 202.7x-202.8x), or ulcerative colitis (556.x) in any position at any time during the 18-month identification period\"]},\n",
       " {'nct_id': 'NCT01137851',\n",
       "  'inclusion': ['18 to 64 years of age at index date',\n",
       "   'Diagnosis of RA during the study period (ICD-9CM 714.xx)',\n",
       "   'Evidence of at least one biologic DMARD of interest during the study timeframe',\n",
       "   'Continuous enrollment during the study timeframe',\n",
       "   'Both medical and pharmacy benefits',\n",
       "   'No evidence of a claim for a bDMARD in the 6-month pre-period'],\n",
       "  'exclusion': [\"Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have Medicare or Medicaid during the study timeframe\"]},\n",
       " {'nct_id': 'NCT01685918',\n",
       "  'inclusion': ['Retrospective study',\n",
       "   'Patients who satisfy the 1987 ACR classification criteria for RA',\n",
       "   'Patients with RA who have received or are receiving biologic agents including infliximab, etanercept, adalimumab, rituximab.',\n",
       "   'Prospective study',\n",
       "   'Patients who satisfy the 1987 ACR classification criteria for RA',\n",
       "   'Patients with RA who have received or are receiving biologic agents including infliximab, etanercept, adalimumab, rituximab, abatacept.'],\n",
       "  'exclusion': ['Patients younger than eighteen',\n",
       "   'Patients enrolled in clinical trials',\n",
       "   'For the prospective study: Sex and Reproductive Status',\n",
       "   'WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 10 weeks after the last dose of study drug.',\n",
       "   'Women who are pregnant or breastfeeding.',\n",
       "   'Women with a positive pregnancy test on enrollment']},\n",
       " {'nct_id': 'NCT01683604',\n",
       "  'inclusion': ['Severe',\n",
       "   '- Inadequate response (or intolerant) to non-biological DMARDs or one biologic agent',\n",
       "   \"Participants initiating treatment with tocilizumab on their physician's decision (in accordance with the local label), including participants who started treatment with tocilizumab within the 8 weeks prior to the enrolment visit.\"],\n",
       "  'exclusion': ['Tocilizumab treatment more than 8 weeks prior to the enrolment visit.',\n",
       "   'Previous tocilizumab treatment in a clinical trial or for compassionate use.',\n",
       "   'Enrolled in an ongoing clinical trial and/or treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with tocilizumab.',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01450982',\n",
       "  'inclusion': ['Have a body mass index (BMI) between 18 and 38 kg/m2 inclusive, and a body weight between 50-110 kg, inclusive',\n",
       "   'Have a diagnosis of Rheumatoid Arthritis functional class I-III for at least 3 months prior to Screening',\n",
       "   'Have been treated with and tolerated oral MTX treatment for a minimum of 3 months prior to screening and must have been on a once-weekly stable MTX dose (taken as a single dose) (between 7.5-25 mg/week) for a minimum of 1 month',\n",
       "   'Participants may continue on stable non-steroid anti-inflammatory drugs and corticosteroid background therapy for RA or stable therapies for other conditions as prescribed by physician, provided that the doses of such therapy are stable for at least 1 month prior to screening and will remain unchanged for the entire study duration.'],\n",
       "  'exclusion': [\"Have current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive or uncontrolled in the study doctor's opinion\",\n",
       "   'Have been treated with a monoclonal antibody for RA or have had a serious infection with 2 weeks of the study treatment period.']},\n",
       " {'nct_id': 'NCT01451203',\n",
       "  'inclusion': ['Subjects with RA as defined by the ACR/EULAR criteria (2010) who meet all of the following criteria:',\n",
       "   'Subjects who developed RA within one year after onset of',\n",
       "   '2. Subjects who have never received MTX before (MTX naive)',\n",
       "   'Subjects whose disease activity is moderate or higher (DAS28(ESR) ≥ 3.2）',\n",
       "   'Subjects must satisfy at least two of the three criteria (Anti-CCP antibody positive, Rheumatoid factor positive, Presence of X-ray erosion） for poor prognostic factors. The anti-CCP antibody positive is essential for every patient.'],\n",
       "  'exclusion': ['Patients who have a diagnosis of any other type of inflammatory arthritis.',\n",
       "   'Patients who have a secondary, non-inflammatory type of arthritis.',\n",
       "   'Patients who have used with MTX, reflunomide, or any other biologics prior to the start of study drug administration.',\n",
       "   'Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure',\n",
       "   'Patients who currently have, or who have a history of, tuberculosis.',\n",
       "   'Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)',\n",
       "   'Patients who currently have, or have a history of, malignant tumor',\n",
       "   'Female patients who are breastfeeding or pregnant, who are of childbearing potential']},\n",
       " {'nct_id': 'NCT01834807',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis',\n",
       "   'Currently receiving a biologic agent in monotherapy (corticosteroids and/or non-steroidal anti-inflammatory drugs are permitted)'],\n",
       "  'exclusion': ['Concomitant treatment with disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis',\n",
       "   'Patients that have started their current monotherapy before 01/01/2009']},\n",
       " {'nct_id': 'NCT01835613',\n",
       "  'inclusion': ['Signed informed consent form;',\n",
       "   'Patients aged 18',\n",
       "   '75 years;',\n",
       "   'RA classified in compliance with the 2010 ACR/EULAR criteria;',\n",
       "   'Patients that have to suspend a previous treatment with DMARDs for total ineffectiveness or intolerance to drugs and/or patients that have not responded adequately to first-line combination DMARDs / biological treatment;',\n",
       "   'Patients for which is indicated to start a treatment with an inhibitor of IL-6R for high values indicative of systemic inflammation (ESR>=28 mm/hour, PCR>5 mg/l , Fibrinogen >400 mg/dl and or Albumin <3.5 g/dl) and high disease activity (DAS>2.4), or contraindications to DMARDs use which make it necessary to take biological drug in monotherapy.',\n",
       "   'Corticosteroids therapy stable (< = 7.5 mg)for at least four weeks;',\n",
       "   'Joint symptoms for at least three but no more than 24 months from the screening visit;',\n",
       "   'DAS44 >2.4 and/or SDAI >11',\n",
       "   'Willing and able to comply with study procedures and timing.'],\n",
       "  'exclusion': ['On going pregnancy or lactation;',\n",
       "   'Severe active infections;',\n",
       "   'Patients with other clinically significant concomitant diseases whose treatment or outcome could interfere with the expected evaluations of the study protocol.',\n",
       "   'Blood AST or ALT levels >5 times the upper normal limit;',\n",
       "   'ANC count <0.5 x 109/L',\n",
       "   'Platelet count <50 x103 /μL',\n",
       "   'Patients with other autoimmune rheumatic diseases, in addition to AR (for example systemic lupus erythematosus [SLE], scleroderma, polymyositis, ecc…)',\n",
       "   'Medical history or concomitant joint diseases in additions to AR (for example tophaceous gout, reactive arthritis, psoriatic arthritis).']},\n",
       " {'nct_id': 'NCT01399697',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active moderate to severe rheumatoid arthritis (DAS28 >/= 3.2) at baseline',\n",
       "   'Currently receiving methotrexate for at least 12 weeks, at a stable oral dose of at least 15 mg/week for at least 6 weeks prior to treatment (Day 1)',\n",
       "   'Body weight < 150 kg',\n",
       "   'Oral corticoids must have been at stable dose for at least 25 out of 28 days prior to baseline; maximum dose 10 mg/day'],\n",
       "  'exclusion': ['Pregnant or nursing women',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Treatment with a biologic agent at any time prior to baseline',\n",
       "   'Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Previous treatment with RoActemra/Actemra',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies',\n",
       "   'Known active current or history of recurrent infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'Positive for HIV infection']},\n",
       " {'nct_id': 'NCT01390441',\n",
       "  'inclusion': ['Female participants of reproductive potential must demonstrate a serum β-human chorionic gonadotropin (hCG) level consistent with the nongravid state at the pre-study (screening) visit, and a negative urine pregnancy test within 24 hours prior to all doses and agree to use (and/or have their partner use) two acceptable methods of birth control beginning at least 2 weeks prior to administration of the first dose of study drug, throughout the study (including washout intervals between treatment periods/panels) and until at least 12 months after administration of the last dose of study drug in the last treatment period',\n",
       "   'The participant has a Body Mass Index (BMI) ≤35 kg/m^2 at the prestudy (screening) visit',\n",
       "   'For Part A Only: The participant has a body surface are (BSA) ≤2.0 m^2 at the prestudy (screening) visit.',\n",
       "   'Has satisfied at least 4 of 7 American Rheumatology Association (ARA) 1987 revised criteria for the diagnosis of RA',\n",
       "   'Is American College of Rheumatology (ACR) Functional Class I, II, or III',\n",
       "   'Had a diagnosis of RA made at least 6 months prior to the prestudy (screening) visit, was ≥ 16 years of age when diagnosed, and has active disease',\n",
       "   'Is on a stable oral, IM, or SC dose of methotrexate and is continuing to take methotrexate',\n",
       "   'Has an inadequate response or intolerance to at least one disease-modifying antirheumatic drug (DMARD)',\n",
       "   'For Part A: Participant is either naïve to biological therapy for RA or has had an inadequate response to previous or current treatment with an anti-tumor necrosis factor (TNF) treatment (patient could have failed up to three anti-TNF agents treatments) or participant has had intolerance up to three anti-TNF treatments.',\n",
       "   'For Part B: Participant has had an inadequate response to previous or current treatment with an anti-TNF treatment (patient could have failed up to three anti-TNF agents treatments) or participant has had intolerance up to three anti-TNF treatments',\n",
       "   'Participant has no clinically significant abnormality on electrocardiogram performed at the prestudy (screening) visit and/or prior to administration of the initial dose of study drug',\n",
       "   'For Part B Only: Participant is positive for rheumatoid factor (RF) or, if negative for RF, is positive for anti-CCP at screening visit',\n",
       "   'For Part C Only: Participant must have completed the first 52 weeks of treatment in the base study',\n",
       "   'For Part C Only: Participant achieved a minimum 20% response from baseline on the American College of Rheumatology (ACR) Responder Index (ACR20) at Visit 19 (last visit for the base study)'],\n",
       "  'exclusion': ['Mentally or legally incapacitated, has significant emotional problems at the time of the prestudy (screening) visit or during the conduct of the study or has a history of a clinically significant psychiatric disorder over the last 5 years',\n",
       "   'Creatinine clearance of ≤ 80 mL/min',\n",
       "   'History of stroke, chronic seizures or major neurological disorder',\n",
       "   'History of neoplastic disease, except treated basal cell carcinoma or carcinoma in situ of the cervix or other malignancies which have been successfully treated ≥ 5 years',\n",
       "   'History of leukemia, lymphoma, malignant melanoma, or myeloproliferative disease regardless of the time since treatment',\n",
       "   'History of coronary artery disease, congestive heart failure (New York Heart Association Class I-IV), or a history of clinically significant arrhythmia (including any history of atrial fibrillation, atrial flutter, or any sustained ventricular arrhythmia)',\n",
       "   'Hypersensitivity or allergy to rituximab or any of the excipients of MK-8808 or rituximab (MabThera® or Rituxan® )',\n",
       "   'History of a rheumatic autoimmune disease other than RA (e.g. systemic lupus erythematosus (SLE), polymyositis, etc.)',\n",
       "   'Severe active infection of any type or history of a medically serious infection as defined by a history of treatment requiring hospitalization, long term IV outpatient treatment for systemic bacterial, viral or fungal infection, use of IV antibiotics within 30-days of screening, or use of antibiotic therapy three or more times in the last six months prior to screening',\n",
       "   'History of opportunistic infection',\n",
       "   'Active-virus vaccination within 4 weeks',\n",
       "   'Active tuberculosis with or without adequate treatment, history of latent tuberculosis without written confirmation from health care provider of adequate prophylaxis or any evidence of tuberculosis on a chest X-ray performed within 3 months of dosing',\n",
       "   'Chronic hepatitis B or hepatitis C infection or has human immunodeficiency virus (HIV) infection',\n",
       "   'Previously treated with rituximab (MabThera® or Rituxan®) or any investigational anti-CD20 antibody',\n",
       "   'Active use or planned use of a prohibited DMARD during the course of study participation, and/or insufficient washout from a prohibited DMARD at the time of the planned first dose of MK-8808/rituximab (MabThera® or Rituxan®)',\n",
       "   'Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks',\n",
       "   'Participated in another investigational study with length of time within at least 5 half-lives of the previous investigational study drug',\n",
       "   'Pregnant or breastfeeding or expecting to conceive',\n",
       "   'Allergy to murine proteins',\n",
       "   'Allergy or sensitivity to components of the drug vial or any of the materials used for infusion']},\n",
       " {'nct_id': 'NCT01392001',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Patients with rheumatoid arthritis for whom the rheumatologist decided to introduce RoActemra',\n",
       "   'Patients taking more than 5 mg/day of oral prednisone (or equivalent) for at least 3 months'],\n",
       "  'exclusion': ['Participation in a clinical trial in rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01390545',\n",
       "  'inclusion': ['Active disease defined as:',\n",
       "   'Diagnosis of RA using the ACR criteria for the classification of RA for at least 6 months prior to trial entry (Screening, Visit 1)',\n",
       "   'Swollen joint count (SJC) ≥ 6 and tender joint count (TJC) ≥ 6 referred to as the 66/68',\n",
       "   'joint count system',\n",
       "   'High sensitivity C-reactive protein (hs-CRP) ≥ 15 mg/L and/or an erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour',\n",
       "   'Positive rheumatoid factor (RF) ≥ 14 IU/mL and/or anti-cyclic citrullinated protein (CCP) ≥ 20 U',\n",
       "   'An inadequate response (insufficient initial or loss of response and/or intolerance to at least one administration of these agents) to previous or current treatment with either MTX alone or MTX plus anti-tumour necrosis factor alpha (anti-TNFα) biological treatment. Subjects should not have received more than two different anti-TNFα therapies.',\n",
       "   'Receiving MTX 15-25 mg/week (oral or parenteral) for at least 20 weeks, including the last 6 weeks prior to Baseline (Visit 3, Day 1) at a stable dose via the same route of administration and formulation. A stable dose of 12.5 mg of MTX is acceptable if the MTX dose has been reduced for reasons of toxicity, e.g. pulmonary, hepatic or haematological toxicity. MTX co-medication will be continued until the end of the trial (Week 48) Main'],\n",
       "  'exclusion': ['Primary or secondary immunodeficiency including HIV infection',\n",
       "   'Evidence of acute or chronic infection with hepatitis B and C virus (HBV and HCV)',\n",
       "   'Evidence (e.g. chest X-ray [posterior-anterior view], tuberculin/ PPD skin test, etc., according local guidelines) and/or history of active tuberculosis (TB), prior to successfully completing an anti-TB treatment. X-rays performed prior to inclusion (Screening, Visit 1) into the trial are accepted provided they were done within 3 months prior to Screening (Visit 1). Subjects with latent TB infection (LTBI) can be included',\n",
       "   'Significant cardiac disease or history of severe COPD',\n",
       "   'Diabetes mellitus type 1 or unstable type 2',\n",
       "   'History of cancer within the last 5 years treated with anti-cancer chemotherapy']},\n",
       " {'nct_id': 'NCT01394913',\n",
       "  'inclusion': ['Patients must be able to understand the study procedures agree to participate and give written consent.',\n",
       "   'Patients with clinical diagnosis of moderate to severe rheumatoid arthritis according to American College of Rheumatology (ACR) criteria;',\n",
       "   'Patients with at least 6 swollen joints',\n",
       "   'Patients with partial response in treatment with methotrexate for 2 months'],\n",
       "  'exclusion': ['Pregnancy and Lactation',\n",
       "   'Patients with uncontrolled hypertension',\n",
       "   'Patients with other rheumatic disease such as Sjogren syndrome, systemic lupus erythematosus or spondyloarthritis',\n",
       "   'Non-steroidal anti-inflammatory drug in the last 4 weeks',\n",
       "   'Any pathology or past medical condition that can interfere with this protocol',\n",
       "   'Patients with immunodeficiency and/or immunosuppressive disease;',\n",
       "   'Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.']},\n",
       " {'nct_id': 'NCT01394276',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria',\n",
       "   'Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center'],\n",
       "  'exclusion': ['Current serious infection',\n",
       "   'Hypersensitivity to the active component or any of the excipients',\n",
       "   'Pregnant women']},\n",
       " {'nct_id': 'NCT01413061',\n",
       "  'inclusion': ['Must be diagnosed with degenerative osteoarthritis, post-traumatic arthritis, inflammatory arthritis (ie: rheumatoid arthritis) or other conditions of the hindfoot requiring subtalar arthrodesis.',\n",
       "   'Patients must be able to attend follow-up examinations for the duration of the trial.',\n",
       "   'The patient is at least 18 years of age and skeletally mature, or less than 80 years of age at the time of surgery.',\n",
       "   'Is willing and able to comply with the clinical trial plan and able to understand and sign the Patient Informed Consent Form.'],\n",
       "  'exclusion': ['Younger than 18 years old or older than 80 years old.',\n",
       "   'Has a condition that prevents ambulation or completion of any of the trial measurements.',\n",
       "   'Requires fusion of additional hindfoot or ankle joints simultaneously (i.e. a pantalar, tibiotalocalcaneal or triple arthrodesis). Concomitant midfoot or forefoot procedures, such as osteotomies, tendon or metatarsal procedures are not exclusionary.',\n",
       "   'Has treatment planned for the arthrodesis which does not require the use of screws.',\n",
       "   'Has any active infection of the hindfoot, a systemic infection or bacteremia.',\n",
       "   'Has received any treatment within the past 12 months which may interfere with bone metabolism [bisphosphonates (Fosamax, Actonel, Boniva, Reclast) and calcitonin (Miacalcin)].',\n",
       "   'Is scheduled to have any surgical procedure on the contralateral foot within 6 weeks before or after the study procedure.']},\n",
       " {'nct_id': 'NCT01411215',\n",
       "  'inclusion': ['Subject has a confirmed diagnosis of rheumatoid arthritis or ankylosing spondylitis.',\n",
       "   \"Subject has accepted physician's prescription of etanercept in rheumatology department.\",\n",
       "   'Subject agreed to be enrolled in the observational study and sign the ICD.',\n",
       "   'Subject is≥18 years of age at the time of consent.',\n",
       "   'Subject is willing and able to understand and complete questionnaires'],\n",
       "  'exclusion': ['Presence of active or suspected latent infection including HIV, or any underlying disease, including open cutaneous ulcers that could predispose the subject to infections.',\n",
       "   'Immunodeficiency syndromes including Felty syndrome or large granular lymphocyte syndrome.',\n",
       "   \"Active tuberculosis (TB) or a history of TB, or findings consistent with previous exposure to TB on a chest x-ray (CXR). Investigators must follow China's guidelines for appropriate screening and treatment of\",\n",
       "   '- History of hypersensitivity to any of the ingredients in either preparation.']},\n",
       " {'nct_id': 'NCT01410695',\n",
       "  'inclusion': ['Patient with rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria for at least 6 months',\n",
       "   'Patient with ACR functional class I-III',\n",
       "   'Patient who have active RA',\n",
       "   'Patient who failed (defined as active RA with stable dose during 3 months) methotrexate or any DMARD including biologics drugs if patients previously failed methotrexate or methotrexate in combination with any DMARD including biologics drugs',\n",
       "   'Patient with a disease onset at > 16 years of age'],\n",
       "  'exclusion': ['Patient for whom the use of methotrexate is contraindicated as per its SPC',\n",
       "   'Patient with documented fibromyalgia',\n",
       "   'Patient with lactose intolerance',\n",
       "   'Patient presenting with cardiac disorders']},\n",
       " {'nct_id': 'NCT01416493',\n",
       "  'inclusion': ['Male or non-pregnant, non-lactating female patients of any race with an age >18 years. Woman of child-bearing potential must be on regular contraceptives throughout the trial (Pregnancy tests). 1A: RA according to the 1987 revised ARA criteria (Arnett 1987) with an active disease with DAS28>3.2 despite the prior or concurrent use of DMARDs.',\n",
       "   'Patients may be on no active therapy or may be on continuous DMARD therapy including Methotrexate, Sulphasalazine, Leflunomide, Hydroxychloroquine, Myocrisin alone or in combination, or on NSAID treatment, or on steroid (prednisolone not more than 10mg/day).',\n",
       "   'Patients must have a measurable acute phase response: CRP (> 10mg/dl), ESR >',\n",
       "   '(to be measured on routine lab range CRP/ ESR/AP/ standard biochemistry)',\n",
       "   'Patients eligible for treatment with biological TNFα blockers and who are awaiting the administration of such treatment may enroll in the laboratory and safety protocols Data for Clinical Phase observations will be collected but will be handled as last observation carried forward for the final records prior to the administration of TNF blocking agent, should that occur within the 3-month Clinical Phase. The administration of TNFα blockers will not be delayed for the protocol.',\n",
       "   'Patients who have given written informed consent prior to participation in the trial and who undertake to comply with the protocol.'],\n",
       "  'exclusion': ['Patients who are unwilling or unable to be fully evaluated for follow-up.',\n",
       "   'Patients who have an active infection or who are suspected of having systemic infection and or patients that are treated with antibiotics.',\n",
       "   'Patients whose screening blood do not reflect a sufficient cytokine or acute phase response.',\n",
       "   'Patients who have evidence of significant hepatic disease, including history of clinical signs or laboratory values of total bilirubin > 34.2 umol/L (> 2.0 mg/dL), ALT (>120) or AST (>135) corresponding to > 3X upper limit of normal.',\n",
       "   'Alkaline phosphatase levels must be less 145 IU/L (routine clinical method)',\n",
       "   'Patients who received investigational drugs in the 30 days prior to study drug administration, or are currently participating in a study during which the administration of investigational drugs within one month is anticipated.',\n",
       "   'Patients who have renal insufficiency (history of creatinine >177umol/L or >2.0 mg/dL) or chronic renal failure requiring dialysis.',\n",
       "   'Patients with severe neurological deficits (see Appendix I).',\n",
       "   'Patients who have a recent history of drug substance or alcohol abuse.',\n",
       "   'Patients with a diagnosis of idiopathic thrombocytopenia.',\n",
       "   'Patients with a history of cancer who have received chemotherapy or radiation therapy within the past 3 months. Patients receiving only adjuvant hormonal therapy are not excluded. If the cancer has not resolved completely, the patient should not be enrolled without permission of Alloksys.',\n",
       "   'Patients receiving oral glucocorticoids >10mg /day or any IV, IM or Intra articular dosing within 30 days of commencing the protocol.',\n",
       "   'Patients who are vegetarians or veganists or those patients that may be expected not to be tolerant to bovine proteins, or not to wish exposure to bovine proteins for personal reasons.',\n",
       "   'Patients who are, in the opinion of the Investigator or the Sponsor, unsuitable for the study.']},\n",
       " {'nct_id': 'NCT01414101',\n",
       "  'inclusion': ['Male or female; age 18 to 75 years',\n",
       "   'Active RA for at least 6 months',\n",
       "   'Active disease defined by having equal to or greater than 6 swollen joints and 6 tender joints, based on a 28 joint count',\n",
       "   'On stable doses and regimen of allowed RA medications',\n",
       "   'Currently receiving at least 10 mg of methotrexate a week. Patients unable to tolerate doses greater than 10 mg may also be eligible for enrollment.'],\n",
       "  'exclusion': [\"Diagnosis of Felty's syndrome, psoriatic arthritis, gout, or auto-immune rheumatic disease\",\n",
       "   'Any surgical procedure within 30 days of Screening or likely to need joint or tendon surgery or other surgical procedure during the study',\n",
       "   'Intra-articular or intra-muscular corticosteroids within 60 days prior to dosing',\n",
       "   'Previous treatment with any biologic response modifying agent for RA within 90 days or 5 half-lives, whichever is greater, prior to screening',\n",
       "   'Previous treatment with rituximab at any time',\n",
       "   'Use of corticosteroid therapy equivalent to an average daily dose of >10 mg of prednisone',\n",
       "   'Any Screening laboratory values that are out of allowed reference ranges',\n",
       "   'Inability to comply with protocol or study procedures',\n",
       "   'Any other significant illness or condition that may adversely affect the subjects participation in the study']},\n",
       " {'nct_id': 'NCT01411046',\n",
       "  'inclusion': ['Adult patients > 18 years)',\n",
       "   'Caucasian classified with rheumatoid arthritis.',\n",
       "   '1987 ACR-classification criteria.',\n",
       "   'Prednisolone min 5mg/day for at least 6 months.',\n",
       "   'Presence of either BclI (high GC sensitivity) or 9β (low GC sensitivity)polymorphisms, or wildtype for for all 4 SNPs studied. Patients with or without these polymorphisms were invited to a Synacthen® test, but patients with a mixed hetero- and homozygote genotype were not'],\n",
       "  'exclusion': ['Other major organ disease',\n",
       "   'Females pregnant',\n",
       "   'Females not willing to pause estrogen-containing medications 6 weeks prior to Synacthen® test',\n",
       "   'unable to give a written informed content']},\n",
       " {'nct_id': 'NCT01417455',\n",
       "  'inclusion': ['Patients with RA diagnosis (according to the revised American Rheumatism Association criteria, 1988) and AS diagnosis (according to the European Spondyloarthropathy Study Group criteria, 1991) followed up in the Rheumatology and Bone and Metabolic Diseases Department of Hospital de Santa Maria (HSM) will be recruited for this study. Patients have to have active RA (Disease Activity Score 28 (DAS28)>3.2) or active AS (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)>4).'],\n",
       "  'exclusion': ['Inactive disease']},\n",
       " {'nct_id': 'NCT01417052',\n",
       "  'inclusion': ['Adult subjects, aged 18 to 75 years',\n",
       "   'Active rheumatoid arthritis (RA), class I to III (defined by the American College of Rheumatology), diagnosed at least 3 months prior to Screening',\n",
       "   'Minimum of 4 swollen joints (at Screening and Day 1), minimum of 4 tender joints (at Screening and Day 1), and serum C-reactive protein (CRP) level >1.2x the upper limit of normal and/or elevated erythrocyte sedimentation rate (ESR)',\n",
       "   'If receiving methotrexate (7.5 mg to 25 mg/week), subject must have been treated for at least 6 weeks prior to Screening and currently receiving a stable dose of methotrexate (MTX) with a stable route of administration, and have no plans to change MTX dose during the study',\n",
       "   'Ability to give written informed consent'],\n",
       "  'exclusion': ['Women who are pregnant or nursing',\n",
       "   'RA diagnosis prior to 16 years of age (juvenile RA)',\n",
       "   'Intra-articular and/or parenteral corticosteroids within 4 weeks of study Day 1',\n",
       "   'Receipt of live vaccine within 4 weeks prior to Day 1',\n",
       "   'Major surgical procedure within 8 weeks prior to Day 1',\n",
       "   'Blood donation within 4 weeks prior to Day 1',\n",
       "   'Any systemic inflammatory condition',\n",
       "   'History of bleeding diathesis',\n",
       "   'History of medically significant opportunistic infection',\n",
       "   'History of drug or alcohol abuse within 3 years prior to Day 1',\n",
       "   'History of cancer within 5 years prior to Day 1',\n",
       "   'Presence of hepatic or biliary disease',\n",
       "   'History of tuberculosis',\n",
       "   'History of human immunodeficiency virus (HIV)',\n",
       "   'Any clinically significant laboratory test results, in the opinion of the investigator',\n",
       "   'Use of any investigational agent or participation in an investigative trial within 30 days of Day 1',\n",
       "   'Concurrent use of any biologic agent for the treatment of RA or concomitant disease modifying antirheumatoid drugs (other than MTX, hydroxychloroquine, leflunomide, and sulfasalazine',\n",
       "   'at stables doses for 8 weeks)']},\n",
       " {'nct_id': 'NCT01770834',\n",
       "  'inclusion': ['Adult patients, >/= 21 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis (DAS28 >/= 3.2)',\n",
       "   'Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'Initiated on RoActemra/Actemra treatment in accordance with the prescribing information'],\n",
       "  'exclusion': ['Pregnant or lactating women',\n",
       "   'Contra-indication to RoActemra/Actemra treatment according to the local labelling',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'Women of childbearing potential not using effective methods of contraception as defined by protocol']},\n",
       " {'nct_id': 'NCT01770106',\n",
       "  'inclusion': ['with a diagnosis of RA according to the 2010 new 2010 American College of Rheumatology/ European League Against Rheumatism classification criteria',\n",
       "   'at an age over 18 years old',\n",
       "   'have a lumbar spine, or total hip or distal radius T-score lower than -1.5 by DXA',\n",
       "   'without severe deformity in metacarpophalangeal (MCP) joints which would influence the longitudinal assessment of HR-pQCT',\n",
       "   'consent to receive alendronate if randomized to standard treatment group.'],\n",
       "  'exclusion': ['they have previous use of denosumab, teriparatide, alendronate or other anti-resorptive agents;',\n",
       "   'they have a history of recent major gastrointestinal (GI) tract disease (e.g. oesophagitis or GI ulceration) or have experienced any previous adverse reaction to bisphosphonate therapy;',\n",
       "   'they are receiving other bone-active drugs, such as hormonal replacement therapy, thyroxine, thiazide and diuretics;',\n",
       "   'they have conditions affecting bone metabolism; contraindications to alendronate and denosumab (uncorrected hypocalcemia);',\n",
       "   'they have unexplained hypocalcemia;',\n",
       "   'they have severe renal impairment or serum creatinine level of >200umol/L;',\n",
       "   'they are pregnant or breastfeeding;',\n",
       "   'they do not understand Chinese or are incompetent in giving consent.']},\n",
       " {'nct_id': 'NCT01774877',\n",
       "  'inclusion': ['Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria.',\n",
       "   'According with the Zheng diagnosis of Traditional Chinese Medicine.',\n",
       "   'age from 18 to 65 years.',\n",
       "   'For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs): Treatment at a stable dose during last 4 weeks prior to screening，or Patients do not take NSAIDs at least 1 weeks prior to screening.',\n",
       "   'Patients not taking DMARDs at least 4 weeks prior to screening.',\n",
       "   'Patients taking corticosteroids (≤15mg prednisone or Equivalent) ≥4 weeks before entering the trial.',\n",
       "   'Patients agree to participate in this study and sign the informed consent form.'],\n",
       "  'exclusion': ['Patients have received intra-articular or systemic corticosteroid injection within 4 weeks of screening.',\n",
       "   'Patients have high disease activity (DAS28-3 scores> 5.1).',\n",
       "   'Patients have diagnosed any other chronic inflammatory disease or connective tissue disease like sicca syndrome（SS）, systemic lupus erythematosus (SLE)etc;',\n",
       "   'Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and hematopoietic system ;',\n",
       "   'Patients who are pregnant or nursing mothers or Psychiatric patients.',\n",
       "   'Patients with active gastroduodenal ulcer or gastritis which caused by long-term use of NSAIDs;',\n",
       "   'The patient who has known hypersensitivity to trial medicine .',\n",
       "   'Patients have participated in other clinical trials within 4 weeks of screening.']},\n",
       " {'nct_id': 'NCT01773681',\n",
       "  'inclusion': ['RA by 2010 ACR classification criteria',\n",
       "   'Age ≥ 18 years at enrollment',\n",
       "   'Ability to give consent and follow the study protocol',\n",
       "   'Prednisone permitted in doses ≤10 mg daily',\n",
       "   'Women of reproductive potential must agree to use an acceptable method of birth control during treatment Additional inclusion criteria for group I:',\n",
       "   'DAS28 ≤ 3.2 during the last 2-months prior to the baseline visit',\n",
       "   'On MTX at a stable dose for > 8 weeks prior to the baseline visit',\n",
       "   'No biologic therapy during the past 6-months prior to the baseline visit',\n",
       "   'No anticipated biologic therapy Additional inclusion criteria for group II:',\n",
       "   'DAS28 > 3.2',\n",
       "   'No biologic therapy during the past 6-months prior to the baseline visit',\n",
       "   'Scheduled to initiate anti-TNF therapy using CIMZIA Exclusion Criteria for all patients to be enrolled are:',\n",
       "   'Any psychiatric disorder that prevents the subject from providing informed consent',\n",
       "   'Inability or unwillingness to follow the protocol',\n",
       "   'Estimated glomerular filtration rate (eGFR, calculated based on serum creatinine) < 60 ml/min/1.72m2',\n",
       "   'Known allergy or hypersensitivity to any study products (including gadolinium)',\n",
       "   'History of injury or surgery of the wrist and hand to be scanned',\n",
       "   'Inability to place non-dominant hand appropriately for imaging',\n",
       "   'History of claustrophobia; inability to tolerate MRI and other contraindication of MRI',\n",
       "   'Pregnancy or breast-feeding',\n",
       "   'Diabetes mellitus requiring insulin therapy',\n",
       "   'Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 1 month of baseline visit',\n",
       "   'Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization',\n",
       "   'Any biologic therapy within 6-month prior to the baseline visit',\n",
       "   'Any condition or treatment, which in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the study Additional'],\n",
       "  'exclusion': ['Chronic or persistent infection including but not limited to human immunodeficiency virus [HIV], hepatitis B, hepatitis C, listeriosis, TB, or other opportunistic infection)',\n",
       "   'Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to baseline visit, or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to baseline visit',\n",
       "   'Receipt of a live vaccine within 4 weeks prior to baseline visit',\n",
       "   'History of malignancy within the past 5 years other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma']},\n",
       " {'nct_id': 'NCT01063062',\n",
       "  'inclusion': ['Adult patients ≥ 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis (RA) for at least 6 months (defined as a Disease Activity Score (DAS28) > 3.2 at screening)',\n",
       "   'Patients with active RA after more than 12 weeks of treatment with DMARDs',\n",
       "   'Patients with inadequate response to a stable dose of non-biologic DMARD'],\n",
       "  'exclusion': ['Autoimmune disease other than',\n",
       "   \"Patients with interstitial pulmonary fibrosis and able to tolerate methotrexate (MTX) and patients with Sjögren's Syndrome and RA are permitted\",\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment',\n",
       "   'Prior history of or current inflammatory joint disease other than RA']},\n",
       " {'nct_id': 'NCT01061736',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis ≥3 months duration',\n",
       "   'Active disease defined as:',\n",
       "   'at least 8/68 tender joints and 6/66 swollen joints,',\n",
       "   'high sensitivity C-reactive protein (hs-CRP) >6 mg/l,',\n",
       "   'continuous treatment with MTX for at least 12 weeks prior to baseline visit and on stable dose for at least 6 weeks prior to screening visit. Part B only:',\n",
       "   'Bone erosion based on documented X-ray prior to first study drug intake, or',\n",
       "   'Cyclic Citrullinated Peptide (CCP) positive, or',\n",
       "   'Rheumatoid Factor (RF) positive.'],\n",
       "  'exclusion': ['Age <18 years or >75 years.',\n",
       "   'Treatment with disease-modifying antirheumatic drugs (DMARDs) other than MTX within 4 weeks or 12 weeks prior to screening (depending on DMARDs).',\n",
       "   'Past history of non-response to prior Tumor Necrosis Factor (TNF) or biologic treatment.',\n",
       "   'Any past or current biologic agents for the treatment of rheumatoid arthritis within 3 months.',\n",
       "   'Use of parenteral glucocorticoids or intraarticular glucocorticoids within 4 weeks prior to screening visit.',\n",
       "   \"Use of oral glucocorticoid greater than 10mg/day or equivalent/day, or a change in dosage within 4 weeks prior to baseline visit. The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01060098',\n",
       "  'inclusion': ['Only anti-TNF naïve patients will be included in this study',\n",
       "   'Patients between 18 to 80 years of age',\n",
       "   'Patients due to start treatment with anti-TNF blocking agents',\n",
       "   'etanercept or adalimumab Patients with rheumatoid arthritis',\n",
       "   'Only patients meeting the 1987 American College of Rheumatology (ACR) revised classification criteria for rheumatoid arthritis will be included',\n",
       "   'Patients should have active rheumatoid arthritis, defined by an initial DAS28 score >5.1',\n",
       "   'Patients should have at least 1 joint suitable for synovial biopsy',\n",
       "   'Patients can be on concurrent DMARDs but they should have been on a stable dose of DMARD for at least 1 month prior to study entry',\n",
       "   'Patients can be on a concurrent dose of glucocorticoids (up to 10mg daily) and they should have been on a stable dose for at least 4 weeks prior to study entry Patients with psoriatic arthritis',\n",
       "   'Patients should have a secure diagnosis of psoriatic arthritis determined by a rheumatologist',\n",
       "   'Patients with psoriatic arthritis included in this study should have evidence of concurrent psoriatic skin lesions at the time of study entry',\n",
       "   'Patients should have at least one joint suitable for synovial biopsy',\n",
       "   'Patients can be on concurrent DMARDs',\n",
       "   'they should be on a stable dose of DMARD for at least 1 month prior to study entry Patients with Ankylosing spondylitis',\n",
       "   'Patient should fulfil the Modified New York Criteria for diagnosis of ankylosing spondylitis',\n",
       "   'Patients can be on concurrent NSAIDs',\n",
       "   'Patients can be on concurrent DMARDs',\n",
       "   'they should be on a stable dose of DMARD for at least 1 month prior to study entry'],\n",
       "  'exclusion': ['Patients who have been previously treated with anti-TNF therapy for whatever reason',\n",
       "   'Patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who do not fulfil the diagnostic criteria for these conditions as above',\n",
       "   'Patient who have received an intra-articular injection of steroids or have received an intra-muscular injection of depot steroid to treat disease flare in the preceding 4 weeks prior to commencing anti-TNF therapy.',\n",
       "   'Patients with intercurrent, active infection of any type, excluding the common cold']},\n",
       " {'nct_id': 'NCT01067430',\n",
       "  'inclusion': ['Male and female subjects aged 18 years and over.',\n",
       "   'Subjects who are NSAID tolerant.',\n",
       "   'Subjects with a clinical diagnosis of rheumatoid arthritis.',\n",
       "   'Subjects who are willing to complete QOL questionnaires.',\n",
       "   'Written informed consent'],\n",
       "  'exclusion': ['Co-occurrence of other disabling conditions in addition to rheumatoid arthritis likely to warrant the persistent use of escape analgesia.',\n",
       "   'Subjects who have received an intra-articular or muscular steroid injection within 3 months of study entry or in whom such treatment is planned within the study period.',\n",
       "   'Subjects scheduled for elective surgery of the disease site or any other elective major surgery which would fall within the study period.',\n",
       "   'Severe respiratory impairment.',\n",
       "   'Clinically significant hepatic or renal dysfunction, subjects whose LFTs and serum creatinine is outside normal recognized limits.',\n",
       "   'Subjects with convulsive disorders, head injury, shock, reduced level of consciousness of uncertain origin, intracranial lesions or increased intracranial pressure.',\n",
       "   'Subjects with a known allergy or hypersensitivity to NSAIDs.',\n",
       "   'Subjects with unstable gastro-intestinal complications or disease.',\n",
       "   \"Subjects who currently abuse alcohol or drugs, or have a recent history of alcohol or drug abuse, or who in the Investigator's opinion, have previously demonstrated drug-seeking behaviour.\",\n",
       "   'Subjects who are currently participating in another clinical research study involving a new chemical entity or who have participated in a clinical study within the previous 30 days.']},\n",
       " {'nct_id': 'NCT01064063',\n",
       "  'inclusion': ['Pre-op knee score of <70',\n",
       "   'Scheduled to undergo primary total knee replacement with any of the following indication:',\n",
       "   'pain and disabled knee joint resulting from Osteoarthritis, Rheumatoid Arthritis, or Traumatic arthritis.',\n",
       "   'One or more compartments involved.',\n",
       "   'Need to obtain pain relief and improve function',\n",
       "   'Ability and willingness to follow instructions, including control of weight and activity level, and to return for follow-up evaluations',\n",
       "   'A good nutritional state of the patient',\n",
       "   'Full skeletal maturity of the patient, patients who are at least 18 years of age.',\n",
       "   'Patients of either sex',\n",
       "   'Consent form read, understood, and signed by patient'],\n",
       "  'exclusion': ['Pre-op knee score greater than or equal to 70',\n",
       "   'Infection',\n",
       "   'Osteomyelitis',\n",
       "   'Previous partial or total prosthetic knee replacement on the operative side',\n",
       "   'Skeletal immaturity of the patient, patients who are less than 18 years of age.',\n",
       "   'Sepsis',\n",
       "   'Uncooperative patient or patient with neurological disorders who are incapable of following directions',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections',\n",
       "   'Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, or neuromuscular disease in affected limb',\n",
       "   'Incomplete or deficient soft tissue surrounding the knee']},\n",
       " {'nct_id': 'NCT01966835',\n",
       "  'inclusion': ['age 18-70 years',\n",
       "   'a clinical diagnosis of rheumatoid arthritis',\n",
       "   'Experience poor sleep quality (PSQI >5)',\n",
       "   'Low disease activity (DAS28<3.2)',\n",
       "   'Understand Danish'],\n",
       "  'exclusion': ['Documented sleep apnea (AHI >15/hour)',\n",
       "   'ECG that does not allow exercise',\n",
       "   'Night work during the period in which the intervention takes place',\n",
       "   'Pregnant or are breast-feeding',\n",
       "   'Treatment with steroid, hypnotics, antidepressants, antipsychotics',\n",
       "   'Cardiac symptoms',\n",
       "   'NYHA >2',\n",
       "   'Regular physically active (aerobic exercise >3 x per week)']},\n",
       " {'nct_id': 'NCT01961271',\n",
       "  'inclusion': ['Males and females aged 18-80 years (both inclusive) at the time of recruitment.',\n",
       "   'Clinical diagnosis of osteoarthritis, rheumatoid arthritis, lower back pain or joint / muscle pain.',\n",
       "   'Having non-malignant pain of moderate or severe intensity requiring an opioid for adequate analgesia (according to local label of Norspan® or Sovenor®). This is to be determined using BS-11 scores, where the cut-off point is ≥4.',\n",
       "   'Patients with chronic uncontrolled pain and is assessed to require opioid treatment but have not been treated with opioids (including tramadol, morphine etc.) within 4 weeks or more before study entry.'],\n",
       "  'exclusion': ['Pregnant and lactating females.',\n",
       "   'Patients with chronic condition(s), in addition to osteoarthritis, that require(s) frequent analgesic treatment (e.g. frequent headaches, frequent migraine, and gout).',\n",
       "   'Patients who are awaiting a scheduled operation or other surgical procedure during study period or 3 months or less post-operative.',\n",
       "   'Prior history of being on opioids in the preceding 1 month prior to the study for the management of chronic non-malignant pain.',\n",
       "   'Prior history of buprenorphine transdermal system use.',\n",
       "   'Patients with history of allergic reactions against paracetamol/ acetaminophen, NSAIDs and/or opioids.',\n",
       "   'Patients with allergies or other contraindications to transdermal systems or patch adhesives.',\n",
       "   'Patients with dermatological disorders who may have problems applying patch or rotating patch placement area.',\n",
       "   'Patients with cancer (except for basal cell carcinoma) or history of cancer who have been diagnosed within five years prior to the first study visit (except for treated basal cell carcinoma).',\n",
       "   'Patients with conditions such as brain tumour, brain injury or raised intracranial pressure.',\n",
       "   'Patients with history of psychiatric disorder, uncontrollable epilepsy, untreated depression or other psychiatric disorders of a type that would make participation in the study an unacceptable risk to the patient.',\n",
       "   'Patients with any conditions causing poor cognitive function as assessed by the participating physician.',\n",
       "   'Patients with history of alcohol and drug abuse or patients who have demonstrated behaviour that suggests a dependency or drug abuse.',\n",
       "   'Patients currently taking hypnotics or other central nervous system depressants that may pose a risk of additional central nervous system depression with study medication.',\n",
       "   'Patients who are currently being administered monoamine oxidase inhibitors (MAOIs) or have taken MAOIs within 2 weeks before screening.',\n",
       "   'Patients requiring dose titration of adjuvant analgesics i.e. antidepressants (e.g. amitriptyline, amoxapine, clomipramine, selective serotonin re-uptake inhibitors (SSRIs)) and anticonvulsants (e.g. gabapentin, pregabalin). Patients will be allowed to enter the study as long as they are on the stable doses of adjuvant analgesics at screening and do not have dose adjustments during the study.',\n",
       "   'Patients who have received steroid treatment (intra-articular, intramuscular, oral, intravenous, epidural or other corticosteroid injections) within 6 weeks prior to clinical study or planned steroid treatment during the clinical study period.',\n",
       "   'Patients who have to use heating facility (examples: heating lamp, electric blanket, sauna, warm compresses, heated saline baths, etc.).',\n",
       "   'Patients who cannot or do not wish to remove hair growing at body surface where the patch can be placed.',\n",
       "   'Patients who are currently on disability claims or in the process of applying for disability claims.',\n",
       "   'Patients at child-bearing age who are planning to conceive a child during the study period and are not practicing adequate contraception.',\n",
       "   'Patients with known severe hepatic impairment as determined by liver function test within the past one year.',\n",
       "   'Patients who are currently in or have participated in other clinical trials within the last 30 days prior to study recruitment.']},\n",
       " {'nct_id': 'NCT01965132',\n",
       "  'inclusion': ['Patients diagnosed with RA, AS or PsA',\n",
       "   'RA deemed by their rheumatologist to require treatment with a biologic or targeted synthetic DMARDs or a conventional DMARD(s)',\n",
       "   'AS or PsA patients who are to initiate, restart or switch to a biologic agent or a targeted synthetic DMARD',\n",
       "   'Patients who provide a written consent of participating in this registry (data collection and review).'],\n",
       "  'exclusion': ['RA, AS, PsA patients who are already on biologics or targeted synthetic DMARDs upon screening']},\n",
       " {'nct_id': 'NCT01969604',\n",
       "  'inclusion': ['Diagnosed with RA (defined by the American College Rheumatology (ACR) criteria)',\n",
       "   'Over the age of 18 years',\n",
       "   'Self-reported sitting time for five hours or more per day (measured by Physical Activity Scale, PAS 2.1)',\n",
       "   'Physical function score <2.5 (measured by Health Assessment Questionnaire, HAQ)',\n",
       "   'Informed consent',\n",
       "   'Understand and speak Danish',\n",
       "   'Access to mobile phone.'],\n",
       "  'exclusion': ['Severe physical disabilities (HAQ-score > 2.5) which would prevent them from reducing daily sitting time (e.g. use of wheelchair);',\n",
       "   'Pregnancy',\n",
       "   'Vigorous physical activity for more than eight hours a week (measured by PAS 2,1).']},\n",
       " {'nct_id': 'NCT01966718',\n",
       "  'inclusion': ['Rheumatoid arthritis of at least 2 years duration',\n",
       "   'On at least third biologic with a different mechanism of action for at least 12 weeks',\n",
       "   'Active disease as defined by at least 6 tender and 6 swollen joints',\n",
       "   'Erythrocyte sedimentation rate (ESR) at least 28 mm/hr or C-reactive protein (CRP) at least 1.2 times the upper limit of normal',\n",
       "   'Stable dose of disease modifying anti-rheumatic drug (DMARD) and prednisone for at least 4 weeks'],\n",
       "  'exclusion': ['Prior treatment with Acthar Gel',\n",
       "   'History of intolerance or allergy to glucocorticoids',\n",
       "   'Unstable diabetes',\n",
       "   'Active infection']},\n",
       " {'nct_id': 'NCT01960855',\n",
       "  'inclusion': ['Diagnosed with rheumatoid arthritis (RA) based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 American College of Rheumatology/European League against Rheumatism (ACR/EULAR) criteria for ≥ 3 months.',\n",
       "   'Subjects must have been receiving oral or parenteral methotrexate (MTX) therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to initiating the study drug. Subjects should also be on a stable dose of folic acid (or equivalent) for at least 4 weeks prior to initiating the study drug. Subjects should continue with their stable doses of MTX and folic acid throughout the study',\n",
       "   'Subjects have been treated with 1 or more anti-tumor necrosis factor (TNF) biologics (no maximum cap) for ≥ 3 months but continue to exhibit active RA, or had to discontinue due to intolerability or toxicity. In addition, subjects with prior exposure to non-anti-TNF biologic(s) (no maximum cap) (e.g., abatacept, rituximab, anakinra, or tocilizumab) are allowed.',\n",
       "   'Have active RA as defined by the following minimum disease activity criteria: ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline, ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline, high sensitivity C reactive protein (hs-CRP) > Upper Limit of Normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) antibody.'],\n",
       "  'exclusion': ['Prior exposure to Janus Activated Kinase (JAK) inhibitor (e.g. tofacitinib, baricitinib)',\n",
       "   'Pregnant or breastfeeding female',\n",
       "   'Ongoing or active infection.']},\n",
       " {'nct_id': 'NCT01962337',\n",
       "  'inclusion': ['Healthy adult male and female subjects between the ages of 21-55 years inclusive.',\n",
       "   'Subject must be willing to remain in the Clinical Research Unit (CRU) for a minimum of 72 hours after each dose. Part 3:',\n",
       "   'RA male and female subjects between the ages of 21-70 years inclusive',\n",
       "   'Evidence of active RA disease',\n",
       "   'Inadequate response to biologic or non-biologic DMARDs',\n",
       "   'Subjects will be required to be on background therapy with methotrexate.'],\n",
       "  'exclusion': ['BMI <18 or >32 kg/m2',\n",
       "   'Clinically significant findings in physical exams and laboratory tests at screening and/or baseline',\n",
       "   'Unwilling to abstain from alcohol for 48 hours prior to study start, during CRU confinement, as applicable, and for 48 hours prior to study visits.',\n",
       "   'Unwilling to abstain from exercise more strenuous than walking during CRU confinement, as applicable, and for 48 hours prior to study visits. Parts 1 and 2:',\n",
       "   'Use of any prescription, non-prescription, or herbal medications as well as supplements or vitamins within 4 weeks prior to dosing, unless approved by the Investigator.',\n",
       "   'Smoking more than 10 cigarettes, or the equivalent, per day. Part 3:',\n",
       "   'Current or previous history of inflammatory joint disease other than RA',\n",
       "   'Evidence of extra-articular RA disease or systemic involvement',\n",
       "   'Currently taking any medications other than those allowed per protocol guidelines',\n",
       "   'Any surgical procedure including bone or joint surgery within 12 weeks prior to dosing',\n",
       "   'Use of intra-articular (IA), intramuscular (IM), or IV corticosteroids for RA',\n",
       "   'Neuropathies and neurovasculopathies',\n",
       "   'Concomitant use of statins while on study.']},\n",
       " {'nct_id': 'NCT01961505',\n",
       "  'inclusion': ['Documented diagnosis of rheumatoid arthritis, as defined by the American Rheumatism Association 1987 Revised Criteria or European League Against Rheumatism criteria (2009).',\n",
       "   'Patients must have moderately to severely active RA,and the DAS-28 score should be from 3.2 to 5.1.',\n",
       "   'If taking disease modifying antirheumatic drug (DMARDs)(e.g.Methotrexate), subject must have been on a stable dose for ≥ 3 months prior to randomization.',\n",
       "   'If taking non-steroidal anti-inflammatory drugs (NSAIDs), subject must have been on a stable dose for ≥ 4 weeks prior to randomization.',\n",
       "   '16 to 65 years old, having signed the informed consent.'],\n",
       "  'exclusion': ['Patients who have skin burst or allergies.',\n",
       "   'Patients with sever diseases in Cardiovascular, brain, lung, liver, kidney and hematopoietic system.',\n",
       "   'Patients who have been treated by tripterygium, hormones or biological agents.',\n",
       "   'Patients who have not been treated by DMARDs before.',\n",
       "   'Patients who are unwilling to comply with all study procedures.']},\n",
       " {'nct_id': 'NCT01163747',\n",
       "  'inclusion': ['Adult patients, ≥ 18 to < 65 years of age',\n",
       "   'Rheumatoid Arthritis (RA) of > 6 months duration at baseline (American College of Rheumatology criteria)',\n",
       "   'Willing to receive immunization with pneumococcal polysaccharide and tetanus toxoid adsorbed vaccines',\n",
       "   'Previous immunization with pneumococcal polysaccharide must have occurred ≥ 3 years of baseline, with tetanus containing vaccine ≥ 5 years',\n",
       "   'Methotrexate therapy for at least 8 weeks prior to baseline at stable dose of 7.5-25 mg/week (oral or parenteral)',\n",
       "   'Other disease-modifying antirheumatic drugs (DMARDs) must be withdrawn before baseline',\n",
       "   'Oral corticosteroids must be at stable dose of < 10 mg/day prednisone or equivalent',\n",
       "   'Body weight ≤ 150 kg at screening'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 8 weeks after baseline',\n",
       "   'History of or current inflammatory joint disease or rheumatic autoimmune disease other than RA',\n",
       "   'Pre-existing central nervous system demyelinating or seizure disorders',\n",
       "   'Active current or history of recurrent bacterial, viral fungal, mycobacterial and other infections',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to baseline or oral antibiotics within 2 weeks prior to baseline',\n",
       "   'Active tuberculosis requiring treatment within 3 years prior to baseline',\n",
       "   'Primary or secondary immunodeficiency (history or currently active)',\n",
       "   'Intra-articular or parenteral corticosteroids within 4 weeks prior to baseline',\n",
       "   'Previous treatment with RoActemra/Actemra']},\n",
       " {'nct_id': 'NCT01166620',\n",
       "  'inclusion': ['18 years of age and older;',\n",
       "   'Have a diagnosis of of rheumatoid arthritis (ICD-9:714x.xx);',\n",
       "   'Have been enrolled for at least 6 months for the 6 months assessment and 12 months for the 12 months assessment;',\n",
       "   'are enrolled in a health plan between February 2006 and June 2009',\n",
       "   'have claims indicating at least one use of either abatacept, etanercept, adalimumab or infliximab for at least 6 months for teh 6 months assessment and 12 months for the 12 months assessment'],\n",
       "  'exclusion': ['Patients not continuously eligible for health plan benefits for the same evaluation periods will be excluded',\n",
       "   'Patients who are on other biologics in the 6 and 12 month post-index period will be excluded (ex. those in the abatacept cohort will be excluded if they also have claims for etanercept in the 6 and 12 month post-index period).',\n",
       "   'Patients on biologics 6 months prior to the biologic index date will also be excluded',\n",
       "   \"Patients with diagnosis for other non-RA conditions commonly treated with biologics (ex. Crohn's disease) during the 6 month pre-index period.\"]},\n",
       " {'nct_id': 'NCT01162421',\n",
       "  'inclusion': ['Subject has a diagnosis of Rheumatoid Arthritis as defined by the 1987-revised American College of Rheumatology-classification criteria and has disease duration of less than 2 years from diagnosis.',\n",
       "   'Subject must have been on a dose of methotrexate therapy either subcutaneously or orally administered (15-25 mg/week) for at least 3 months prior to baseline visit and has had an inadequate response to treatment defined as having a Disease Activity Score DAS28 > 3.2 (at Screening visit).',\n",
       "   'Subject must also meet the following three criteria (at screening visit): at least 4 swollen joints out of 66 assessed; at least 4 tender joints out of 68 assessed; subject must have an elevated erythrocyte sedimentation rate >/= 20 mm/1h or C-reactive protein > upper limit of normal.',\n",
       "   'Subject must fulfill at least one of the following three criteria: history of rheumatoid factor positive; history of at least one erosion on X-ray or magnetic resonance imaging; history of anti-cyclic-citrullinated protein antibody positive.'],\n",
       "  'exclusion': ['Subject has previous exposure to any biologic therapy including adalimumab.',\n",
       "   'Prior disease-modifying antirheumatic drugs triple therapy with methotrexate.',\n",
       "   'Subject has been treated with intra-articular or parenteral administration of corticosteroids in the preceding 4 weeks prior to baseline visit. Inhaled corticosteroids for stable medical conditions are allowed.',\n",
       "   'Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study) of Baseline.',\n",
       "   'Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, congestive heart failure, recent cerebrovascular accidents and any other condition which, in the opinion of the Investigator, would put the subject at risk by participating in the study.']},\n",
       " {'nct_id': 'NCT01163617',\n",
       "  'inclusion': ['Subject was judged to be in good health as determined by the investigator based upon the results of medical history, laboratory profile, physical examination, chest x-ray, and a 12-lead electrocardiogram performed during Screening.',\n",
       "   'Subject had a negative purified protein derivative (PPD) test (or equivalent) and chest x-ray (posterior-anterior and lateral view) at Screening.',\n",
       "   'Subject has a diagnosis of moderate to severe rheumatoid arthritis and is treated with adalimumab in accordance with the FDA-approved Humira prescribing information.',\n",
       "   'Subject must have self-administered adalimumab subcutaneous (SC) 40 mg injections every other week (eow) without interruption for at least 3 months prior to Screening.',\n",
       "   'For the Phase A portion of the study, the subject must be able and willing to self administer SC injections in the thigh or abdomen (administration by another person was not permissible).'],\n",
       "  'exclusion': ['Subject has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half-lives (whichever is longer) of the drug prior to the Visit 1, with the exception of adalimumab.',\n",
       "   'Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to the Visit 1 or oral anti-infectives within 14 days prior to Visit',\n",
       "   '- Prior exposure to natalizumab (Tysabri®) or efalizumab (Raptiva®).',\n",
       "   'Known hypersensitivity to adalimumab or its excipients.',\n",
       "   'Regular use of any SC medications, with the exception of adalimumab.']},\n",
       " {'nct_id': 'NCT01164579',\n",
       "  'inclusion': ['Adult patients with moderate to severe early rheumatoid arthritis (< 2 years) who are methotrexate and biologic disease modifying antirheumatic drug naive.'],\n",
       "  'exclusion': ['Pregnant or lactating patients;',\n",
       "   'Patients with renal or hepatic impairment or other severe or progressing disease;',\n",
       "   'Patients with contraindication to magnetic resonance imaging with gadolinium contrast.']},\n",
       " {'nct_id': 'NCT01850966',\n",
       "  'inclusion': ['Participants with rheumatoid arthritis',\n",
       "   'Participants who take iguratimod'],\n",
       "  'exclusion': ['Participants registered for this survey previously',\n",
       "   'Pregnant women or women suspected of being pregnant',\n",
       "   'Participants with a serious liver disorder',\n",
       "   'Participants with peptic ulcer',\n",
       "   'Participants with known hypersensitivity to iguratimod or any of its excipients']},\n",
       " {'nct_id': 'NCT01852851',\n",
       "  'inclusion': ['Between ages 18 and 59 years',\n",
       "   'Able to read and write English',\n",
       "   'Have inflammatory arthritis confirmed by a rheumatologist (Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis, Other Connective Tissue Diseases and Spondylarthropathy)',\n",
       "   'Have access to a computer, a web-cam, a headset and a printer, or willingness to purchase these items',\n",
       "   'Are willing to travel to Vancouver, Kelowna, Victoria, Prince Rupert, Prince George, Cranbrook or Kamloops, Calgary, Toronto, Newmarket or Brampton for one visit with an occupational therapist'],\n",
       "  'exclusion': ['Individuals who are not working',\n",
       "   'Individuals on sick leave, short term or long term work disability',\n",
       "   'Students',\n",
       "   'People performing unpaid work such as volunteer work or taking care of family',\n",
       "   'People planning to retire in the next six years',\n",
       "   'Individuals unable to provide informed consent',\n",
       "   'Individuals living outside of British Columbia, Alberta, Ontario']},\n",
       " {'nct_id': 'NCT01851278',\n",
       "  'inclusion': ['patients with established RA',\n",
       "   'age between 18 and 65 years',\n",
       "   'disease modifying anti-rheumatic drugs (DMARDs) stable for at least 3 months',\n",
       "   'synovitis in wrist with pain visual analogic scale (VAS) between 4 and 8cm'],\n",
       "  'exclusion': ['patients with overlap syndromes',\n",
       "   'polyarticular synovitis',\n",
       "   'diabetes mellitus or uncontrolled hypertension and those with suspected local or systemic infection']},\n",
       " {'nct_id': 'NCT01851707',\n",
       "  'inclusion': ['Documented diagnosis of Rheumatoid Arthritis for at least 6 months',\n",
       "   'Active disease, based on Screening clinical and laboratory criteria, despite taking methotrexate for at least 3 months'],\n",
       "  'exclusion': ['Pregnant or lactating females',\n",
       "   'Previous failure or inadequate response to >2 biologic disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'Concurrent DMARD treatment other than methotrexate, sulfasalazine, chloroquine, or hydroxychloroquine',\n",
       "   'Treatment with > 10 mg daily prednisone (or equivalent) or more than one non-steroidal anti-inflammatory drug']},\n",
       " {'nct_id': 'NCT01850680',\n",
       "  'inclusion': ['Male or female Japanese who are 20 to 65 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis (RA) ≥ 3 months duration',\n",
       "   'Treated for a minimum of 8 weeks with Methotrexate (MTX) and with a stable dose of MTX (6-16 mg/week) for a minimum of 4 weeks prior to the screening visit'],\n",
       "  'exclusion': ['Autoimmune or inflammatory systemic or localized joint disease other than RA',\n",
       "   'Women of a positive pregnancy test',\n",
       "   'Latent or active tuberculosis',\n",
       "   'Prior treatment with anti-interleukin-6 (anti-IL-6) or anti-interleukin-6 receptor (IL-6R) antagonist',\n",
       "   'Treatment with anti-TNF agents, as follows:',\n",
       "   'Etanercept: within 28 days prior to randomization',\n",
       "   'Infliximab, adalimumab, golimumab, certolizumab pegol: within 42 days prior to randomization',\n",
       "   'Received any live, attenuated vaccine within 3 months prior to the randomization visit (eg, varicella-zoster, oral polio, rubella vaccines)',\n",
       "   \"Significant concomitant illness such as, but not limited to, cardiovascular, renal, neurological, endocrinological, gastrointestinal, hepato-biliary, metabolic, pulmonary or lymphatic disease that would adversely affect the patient's participation in the study.\",\n",
       "   'Received surgery within 4 weeks prior to the screening visit or planned surgery during the study',\n",
       "   \"History of a systemic hypersensitivity reaction The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.\"]},\n",
       " {'nct_id': 'NCT01851070',\n",
       "  'inclusion': ['Males and Females ages 18-80 years old',\n",
       "   'Active rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of',\n",
       "   '- Must be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation',\n",
       "   'Patient with active RA defined as:',\n",
       "   '≥ 4 tender joint count (TJC) 28 joint count at screening and',\n",
       "   '≥ 4 swollen joint count (SJC) count 28 joint count at screening',\n",
       "   'ESR ≥ 28 mm/hr or hsCRP >2.0 mg/L',\n",
       "   'Patient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening',\n",
       "   'Patient has had an inadequate response to at least one TNFα inhibitor with last dose at least 6 weeks prior to screening',\n",
       "   'Use of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening'],\n",
       "  'exclusion': ['Pregnant women or women who are breastfeeding.',\n",
       "   'Other investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13).',\n",
       "   'Known or suspected alcohol or drug abuse within three years preceding Screening.',\n",
       "   'Autoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)',\n",
       "   'History of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded.',\n",
       "   'Bedridden or confined to a wheelchair or patients with > 3 arthroplasties due to',\n",
       "   '- History of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years',\n",
       "   'Surgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure).',\n",
       "   'Use of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening.',\n",
       "   'Prior use of biologic agent for treatment of RA within 6 weeks prior to screening']},\n",
       " {'nct_id': 'NCT01859130',\n",
       "  'inclusion': ['Patient 18-75 years of age, inclusive;',\n",
       "   'Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:',\n",
       "   'rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis;',\n",
       "   'collagen disorders and/or avascular necrosis of the femoral condyle;',\n",
       "   'post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;',\n",
       "   'moderate valgus, varus, or flexion deformities;',\n",
       "   'the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee;',\n",
       "   'Patient has participated in a study-related Informed Consent process;',\n",
       "   'Patient is willing and able to complete scheduled study procedures and follow-up evaluations;',\n",
       "   'Independent of study participation, patient is a candidate for commercially available Persona fixed bearing knee components implanted in accordance with product labeling.'],\n",
       "  'exclusion': ['Patient is currently participating in any other surgical intervention studies or pain management studies;',\n",
       "   'Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint;',\n",
       "   'Insufficient bone stock on femoral or tibial surfaces;',\n",
       "   'Skeletal immaturity;',\n",
       "   'Neuropathic arthropathy;',\n",
       "   'Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb;',\n",
       "   'Stable, painless arthrodesis in a satisfactory functional position;',\n",
       "   'Severe instability secondary to the absence of collateral ligament integrity;',\n",
       "   'Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin;',\n",
       "   'Patient has a known or suspected sensitivity or allergy to one or more of the implant materials;',\n",
       "   'Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.);',\n",
       "   'Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.']},\n",
       " {'nct_id': 'NCT01853033',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA) > 3 months.',\n",
       "   'On methotrexate (MTX) therapy => 3 months and on a stable dose for at least 4 weeks.',\n",
       "   'Except for MTX, must have discontinued all disease-modifying antirheumatic drugs (DMARDs) for at least 3 months or 5 half-lives, whichever is longer.',\n",
       "   'Body Mass Index (BMI) is 19 to 38, inclusive.',\n",
       "   'Other than RA, subjects should be in good general health.'],\n",
       "  'exclusion': ['Evidence of anti-ABT-122 antibody on a serum sample taken at Screening.',\n",
       "   'History of significant allergic reaction; or history of anaphylactic reaction to any agent; or history of major reaction to any IgG containing product.',\n",
       "   'History of persistent chronic or active infection(s) requiring hospitalization or treatment with intravenous or oral anti-microbials/antibiotics within the past 30 days.',\n",
       "   'History or evidence of active tuberculosis (TB) or the subject has evidence of risk factor for latent',\n",
       "   '- Subject has any medical condition or illness other than RA that is not well controlled with treatment.']},\n",
       " {'nct_id': 'NCT01855789',\n",
       "  'inclusion': ['Body weight </=150 kg',\n",
       "   'Active moderate to severe rheumatoid arthritis (DAS28 >/=4.4) according to the revised 1987 ACR criteria at screening and baseline (prior to treatment on Day 1)',\n",
       "   'Currently receiving oral MTX for at least 24 weeks and on a stable oral dose of at least 15 mg/week for at least 6 weeks prior to treatment (Day 1), with the following exception: a stable dose of at least 10 mg/week is allowed for participants with a body weight <50 kg or calculated glomerular filtration rate (or creatinine clearance) <60 milliliters per minute (mL/min)',\n",
       "   'History of parenteral (SC or intramuscular [IM]) MTX is allowed, but not within 6 weeks prior to treatment (Day 1). Participants must not have a documented, clinically significant intolerance to oral MTX and must be receiving oral MTX at a dose of 15 mg/week for at least 6 weeks prior to treatment (Day 1)',\n",
       "   'Participants who have received one prior anti-tumor necrosis factor (TNF) must have discontinued etanercept, infliximab, certolizumab, adalimumab, or golimumab for at least 6 months prior to screening',\n",
       "   'Oral corticosteroids must have been </=10 mg/day prednisone (or equivalent) and stable for at least 25 out of 28 days prior to treatment (Day 1)',\n",
       "   'Participants receiving treatment on an outpatient basis'],\n",
       "  'exclusion': ['Documented medical history of significant intolerance to oral MTX >/=15 mg/week',\n",
       "   'Participants receiving other (non-MTX) disease modifying anti-rheumatic drugs (DMARDs) within 8 weeks of screening',\n",
       "   'Previous treatment with abatacept, rituximab, tofacitinib, or anakinra',\n",
       "   'Treatment with parenteral corticosteroids within 4 weeks prior to treatment',\n",
       "   'Previous treatment with cell-depleting therapies or alkylating agents',\n",
       "   'Previous treatment with TCZ',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery during the study',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Non-rheumatic active autoimmune diseases (for example, inflammatory bowel diseases, psoriasis, multiple sclerosis)',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Functional Class IV according to the revised (1987) ACR criteria for rheumatoid arthritis',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies',\n",
       "   'Evidence of significant uncontrolled concomitant diseases; uncontrolled disease states where flares are commonly treated with oral or parenteral corticosteroids',\n",
       "   'Active current or history of recurrent infection, or any major episode of infection requiring hospitalization or treatment with intravenous antibiotics within 4 weeks prior to screening or oral antibiotics within 2 weeks prior to screening',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'History of or currently active primary or secondary immunodeficiency',\n",
       "   'Pregnant or breast-feeding women',\n",
       "   'Positive for hepatitis B or hepatitis C infection',\n",
       "   'For potential MRI substudy participants: the presence of any metal-containing device or object in the body']},\n",
       " {'nct_id': 'NCT01936181',\n",
       "  'inclusion': ['Diagnosed as having RA according to the revised 1987 ACR criteria for at least 6 months',\n",
       "   'Have moderate to severe active disease despite MTX therapy defined as having more than or equal to six swollen joints and more than or equal to six tender joints and either erythrocyte sedimentation rate (ESR, Westergren) ≥ 28 mm/h or serum C-reactive protein ≥ 1.0 mg/dL',\n",
       "   'Must have been treated with MTX for at least 6 months prior to Randomisation and on a stable dose of MTX 10-25 mg/week given at least 4 weeks prior to Screening',\n",
       "   'Female subjects who are not pregnant or nursing at Screening and who are not planning to become pregnant from Screening until 6 months after the last dose of investigational product Inclusion Criteria for Transition-Extension Period:',\n",
       "   'Have been enrolled and completed the scheduled Week 54 visit of the randomised, double-blind period of the SB2-G31-RA study',\n",
       "   'In the opinion of the Investigator, subjects who may benefit from continuing IP treatment (either SB2 or Remicade), understand the implications of taking part in the study and willing to participate in the transition-extension period Exclusion Criteria:',\n",
       "   'Have been treated previously with any biological agents including any tumour necrosis factor inhibitor',\n",
       "   'Have a known hypersensitivity to human immunoglobulin proteins or other components of Remicade or SB2',\n",
       "   'Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus',\n",
       "   'Have a current diagnosis of active tuberculosis',\n",
       "   'Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.',\n",
       "   'Have any of the following conditions',\n",
       "   'Other inflammatory or rheumatic diseases.',\n",
       "   'History of any malignancy within the previous 5 years prior to Screening',\n",
       "   'History of lymphoproliferative disease including lymphoma.',\n",
       "   'History of congestive heart failure',\n",
       "   'Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).',\n",
       "   'History of demyelinating disorders.'],\n",
       "  'exclusion': ['Have been withdrawn from the SB2-G31-RA study for any reason',\n",
       "   'Have had any significant medical conditions, such as an occurrence of a serious AE (SAE) or intolerance of SB2 or Remicade during the randomised, double-blind period of the SB2-G31-RA study which may render the subject unsuitable to participate in the transition-extension period, at the discretion of the Investigator']},\n",
       " {'nct_id': 'NCT01877239',\n",
       "  'inclusion': ['The patient is eligible to receive Etanercept treatment according to the Austrian SmPC.',\n",
       "   'The decision to treat the patient with Etanercept has been made independently by the physician and is clearly separated from the decision to include the patient in the study. The treatment decision was made in advance and is not dependent on the protocol.',\n",
       "   'The patient was informed about the study and gave his/her consent and signed an Independent Ethics Committee (IEC) submitted written Informed Consent form on use of the data.',\n",
       "   'The patient has moderately active RA, defined as a disease activity of CDAI >10 and ≤22 and/or DAS28 (CRP)>3.2 and ≤ 5.1'],\n",
       "  'exclusion': ['Any contraindication according to the Austrian SmPC, which includes: A hypersensitivity to any component of Etanercept, active tuberculosis or any other serious infection.',\n",
       "   'Patient has previously participated in this study.']},\n",
       " {'nct_id': 'NCT01878318',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis according to ACR/EULAR classification (2010) of >/= 6 months duration',\n",
       "   'Active moderate to severe rheumatoid arthritis (DAS >/= 3.2)',\n",
       "   'Swollen joint count (SJC) >/= 6, tender joint count >/= 8',\n",
       "   'Synovitis in the dominant hand',\n",
       "   'Inadequate response to stable dose of a non-biological DMARD for at least 3 months',\n",
       "   'Oral corticosteroids must have been on stable dose for at least 25 out of 28 days before first dose of study drug',\n",
       "   'Patient on outpatient treatment'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) in the 8 weeks prior to screening, or planned major surgery within 6 months of randomization',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'American College of Rheumatology (ACR) functional class IV',\n",
       "   'History of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Previous inadequate response to a biologic DMARD; prior biologic therapy for no longer than 1 month is allowed if discontinued for reasons of tolerability at least 6 months prior to study recruitment',\n",
       "   'Intra-articular or parenteral corticosteroids within 6 weeks prior to study start',\n",
       "   'Inadequate hematologic, renal or liver function',\n",
       "   'Positive for hepatitis B, hepatitis C or HIV infection',\n",
       "   'Pregnant or lactating women',\n",
       "   'History of severe allergic reactions or anaphylaxis to human, humanized or mural monoclonal antibodies',\n",
       "   'Current infections or history of recurrent infections',\n",
       "   'History of or currently active primary or acquired immunodeficiency',\n",
       "   'Active tuberculosis requiring treatment in the previous 3 years',\n",
       "   'Body weight > 150 kg']},\n",
       " {'nct_id': 'NCT01875991',\n",
       "  'inclusion': ['Naive to etanercept.',\n",
       "   'Naive to other autoinjector pens or prefilled syringes for Tumor Necrosis Factor (TNF)-inhibitor therapy or other subcutaneous biologics for',\n",
       "   '- Willing to self-inject per investigator judgement at screening and capable of self-injection using the autoinjector A or B as documented at baseline by the investigator.',\n",
       "   'Able to read and write in English.',\n",
       "   ''],\n",
       "  'exclusion': ['Subject has an active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to first dose of etanercept.',\n",
       "   'Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.',\n",
       "   'Other criteria may apply.']},\n",
       " {'nct_id': 'NCT01870128',\n",
       "  'inclusion': ['Rheumatoid Arthritis diagnosed on the basis of revised American college of rheumatology criteria,1987',\n",
       "   'Age >18 years',\n",
       "   'Early Rheumatoid Arthritis i.e. less than 2 years duration',\n",
       "   'Patient giving consent to participate in study',\n",
       "   'Disease Modifying Anti-Rheumatic Drugs naive',\n",
       "   ''],\n",
       "  'exclusion': ['Pregnant and lactating patient or planning to conceive in next year',\n",
       "   'Patient who had joint surgery in last 6 months',\n",
       "   'Co morbidities such as liver disease, kidney disease, hematological malignancies',\n",
       "   'Uncontrolled hypertension, diabetes mellitus',\n",
       "   'Coronary artery disease',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01874977',\n",
       "  'inclusion': [\"Physicians' diagnosis of RA\",\n",
       "   'English verbal fluency',\n",
       "   'Residence in the greater San Francisco Bay Area',\n",
       "   'Score ≥20 on 10-item PROMIS fatigue scale, or at least one item rated \"often\"',\n",
       "   'BMI ≥ 20 kg/m2'],\n",
       "  'exclusion': ['Currently engaging in regular exercise',\n",
       "   'Non-ambulatory or presence of a condition or comorbid disease that would limit the ability to engage in walking (e.g., foot deformities, lower extremity joint surgery upcoming or in past 6 months, myocardial infarction in past 6 months, stroke, congestive heart failure, severe chronic obstructive pulmonary disease).']},\n",
       " {'nct_id': 'NCT01878123',\n",
       "  'inclusion': ['Must be able to provide written informed consent',\n",
       "   'Body mass index 18.5 to 35.0 kg/m2',\n",
       "   'Diagnosis of Rheumatoid Arthritis according to 1987 revised American College of Rheumatology (ACR) criteria',\n",
       "   'Global Functional Class I, II, or III according to ACR 1991 revised criteria',\n",
       "   'Stable use of >/= 1 Disease Modifying Anti-rheumatic Drugs (DMARD) for >/= 4 weeks prior to Day 0, including:',\n",
       "   'Methotrexate (MTX) 7.5',\n",
       "   '25 mg/week',\n",
       "   'Hydroxychloroquine (HCQ) </= 400 mg/day',\n",
       "   'Sulfasalazine (SSZ) 1,000',\n",
       "   '3,000 mg/day',\n",
       "   'Leflunomide 5',\n",
       "   '20 mg/day',\n",
       "   'Azathioprine 150 mg/day or 2 mg/kg/day',\n",
       "   'Combinations of MTX, HCQ, and/or SSZ allowed'],\n",
       "  'exclusion': ['Prior to Day 0, use of',\n",
       "   'Abatacept',\n",
       "   'Rituximab within 6 months',\n",
       "   'Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or Mycophenolate mofetil within 2 months',\n",
       "   'Etanercept or Anakinra within 28 days',\n",
       "   'Immunoglobulin or blood products within 28 days',\n",
       "   'Evidence of any active or recent infection including ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis',\n",
       "   'History of systemic autoimmune disease other than Rheumatoid Arthritis',\n",
       "   'History of allergic reactions to other protein therapeutics such as monoclonal antibodies or fusion proteins',\n",
       "   'History of anaphylaxis or allergic diathesis',\n",
       "   'Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram',\n",
       "   'Evidence of active or latent tuberculosis',\n",
       "   'Vaccination wtih live attenuated viruses within the 2 weeks prior to Day 0',\n",
       "   'Evidence of infection with hepatitis B virus, hepatitis C virus, human immunodeficiency virus 1 or 2, or active infection with hepatitis A',\n",
       "   'Pregnant or breastfeeding women']},\n",
       " {'nct_id': 'NCT01871961',\n",
       "  'inclusion': ['Is a suitable candidate for treatment with Methotrexate for Rheumatoid Arthritis',\n",
       "   'Male or female patient who is 16 years of age or older'],\n",
       "  'exclusion': ['Is a female patient who is pregnant, trying to become pregnant, or breast feeding, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control during the study and at least 6 months thereafter',\n",
       "   'Has any history of hypersensitivity to the investigational medicinal product',\n",
       "   'Has a history of or current inflammatory arthritis or rheumatic autoimmune disease other than Rheumatoid Arthritis (RA)',\n",
       "   'Is unable to comprehend written labeling and training materials']},\n",
       " {'nct_id': 'NCT01525654',\n",
       "  'inclusion': [\"billing diagnosis of rheumatoid arthritis (714.0) or seronegative inflammatory arthritis or a member of the BRASS and PACO studies at Brigham and Women's Hospital\"],\n",
       "  'exclusion': ['less than 18 years of age']},\n",
       " {'nct_id': 'NCT01526057',\n",
       "  'inclusion': ['Confirmed diagnosis of rheumatoid arthritis',\n",
       "   'Meets Class I, II or III of the ACR 1991 Revised Criteria',\n",
       "   'RA seropositivity',\n",
       "   'Stable dose of methotrexate',\n",
       "   'Inadequate response to TNF inhibitors'],\n",
       "  'exclusion': ['Any prior treatment with lymphocyte depleting therapies',\n",
       "   'History of active TB infection',\n",
       "   'Known or screen test positive for specific viruses or indicators of viral infection']},\n",
       " {'nct_id': 'NCT01526434',\n",
       "  'inclusion': ['Patient is male or female, aged 18 years or older',\n",
       "   'Patient has active Rheumatoid Arthritis according to American College of Rheumatology (ACR) criteria with duration ≥ 3 months',\n",
       "   'Patient has DAS28 (ESR) > 4.5 and CRP > 1.0 mg/dl at Baseline',\n",
       "   'Patient has failed previous Disease Modifying Anti-Rheumatic Drugs (DMARDs) including Methotrexate treatment',\n",
       "   'Patient has initiated treatment with subcutaneous anti-Tumour Necrosis Factor alpha (anti-TNFα) CZP, administered every 2 weeks',\n",
       "   'Patient has no other prior anti-TNFα treatment (Naïve Patient) or CZP is administered after failure to the first anti-TNFα treatment (First Switch Patient)',\n",
       "   'Patient is considered reliable and capable of adhering to the protocol, visit schedule or medication intake according to the judgment of the physician',\n",
       "   'Patient has signed and dated a written informed consent form',\n",
       "   \"The patient's treatment must be within the terms of Summary of Product Characteristics (SmPC)\"],\n",
       "  'exclusion': ['Patient has a known hypersensitivity to the active substance or to any of the excipients',\n",
       "   'Patient has active Tuberculosis or other severe infections such as Sepsis or Opportunistic Infections',\n",
       "   'Patient has moderate to severe Heart Failure (New York Heart Association (NHYA) classes III/IV)',\n",
       "   \"Patient has any medical or psychiatric condition that, in the opinion of the physician, could jeopardize or would compromise the patient's ability to participate in this study or to complete the scheduled questionnaires\",\n",
       "   'Pregnant women or women of childbearing potential who are not using adequate contraception to prevent pregnancy']},\n",
       " {'nct_id': 'NCT01521884',\n",
       "  'inclusion': ['Are active RA patients (as judged by treating MD)',\n",
       "   'Are 18 years of age or older at time of consent',\n",
       "   'Are scheduled by their rheumatologist to initiate SC anti-TNF-α therapy + MTX'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01534871',\n",
       "  'inclusion': ['Only those patients that 1) have RA fulfilling the American College of Rheumatology criteria, 2) have two or more swollen joints, 3) are receiving stable pharmacotherapy (defined as greater than 3 months of unchanged antirheumatic drugs and greater than 1 month of unchanged nonsteroidal anti-inflammatory drugs), 4) have moderate risk of CVD as identified by the Framingham risk score, 5) are able to walk on treadmill or cycle on a stationary bike for 15 minutes and 6) are able to attend the Community Cardiovascular Hearts in Motion program (held in the Halifax Regional Municipality).'],\n",
       "  'exclusion': ['Patients that are 1) diabetic, 2) have known coronary, cerebral or peripheral artery disease, 3) taking statins, or 4) have one or more arthroplasties of weight bearing joints will not be eligible to participate in the study.']},\n",
       " {'nct_id': 'NCT01534884',\n",
       "  'inclusion': ['Patient has a diagnosis of RA according to the revised 1987 ACR classification criteria (Arnett et al 1987) for at least 6 months prior to randomization.',\n",
       "   'Patient has active disease as defined by the presence of 6 or more swollen joints (of 66 assessed) and 6 or more tender joints (of 68 assessed), and serum CRP ≥1.5 mg/dL or an ESR ≥28 mm/hour.'],\n",
       "  'exclusion': ['Patient is unresponsive or intolerable to more than 2 biologic agents.',\n",
       "   'Patient has allergies or hypersensitivity to murine, chimeric, human, or humanized proteins.',\n",
       "   'Patient has current or past history of chronic infection with hepatitis B, hepatitis C, or infection with human immunodeficiency virus (HIV)-1 or -2 or who has a positive result to the screening test for these infections.']},\n",
       " {'nct_id': 'NCT01636843',\n",
       "  'inclusion': ['Informed consent must be obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial',\n",
       "   'A documented diagnosis of RA at least 6 months prior to screening visit, according to the American College of Rheumatology (EULAR/ACR 2010 criteria) or by standard criteria (ACR 1987) if diagnosis was made earlier than 2010',\n",
       "   'Active RA, characterised by:',\n",
       "   'more than 5 tender and more than 5 swollen joints based on a 28 joint count',\n",
       "   'C-reactive protein (CRP) above or equal to 1.0 mg/dL (10 mg/L)',\n",
       "   'Patients can be on methotrexate with or without hydroxychloroquine/chloroquine:',\n",
       "   'Methotrexate treatment (above or equal to 15.0 mg/week) for at least 16 weeks, (above or equal to 15.0 mg/week to below or equal to 25 mg/week) for at least 8 weeks prior to screening. Patient can be on MTX as low as 10 mg/week only if due to MTX intolerance',\n",
       "   'Hydroxychloroquine (200-400 mg/day per os, oral dosing (p.o.)) or chloroquine (250-500 mg/day p.o.) treatment for at least 8 weeks prior to screening visit'],\n",
       "  'exclusion': ['Patients with arthritis due to other autoimmune diseases than RA',\n",
       "   'Any active or ongoing bacterial infections within 4 weeks prior to screening visit, unless treated and resolved with appropriate therapy or any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)',\n",
       "   'History of severe, systemic viral or fungal infections within the past 6 months prior to screening visit, unless treated and/or resolved with appropriate therapy',\n",
       "   'Patients with active malignancy within the previous 5 years with the exception of adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to screening visit',\n",
       "   'Females of childbearing potential who are pregnant or breast feeding or intend to become pregnant',\n",
       "   'Any other disease or clinically significant abnormality in laboratory parameters which, according to the Investigator, might compromise the safety of the patient, interfere with participation in the trial or compromise the trial objective']},\n",
       " {'nct_id': 'NCT01636817',\n",
       "  'inclusion': ['Informed consent must be obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.',\n",
       "   'A documented diagnosis of RA at least 6 months prior to screening visit, according to the American College of Rheumatology (EULAR/ACR 2010 criteria) or by standard criteria (ACR 1987) if diagnosis was made earlier than 2010',\n",
       "   'Active RA, characterised by:',\n",
       "   'above 5 tender and above 5 swollen joints based on a 28 joint count',\n",
       "   'CRP (C-reactive protein) above or equal to 1.0 mg/dL (10 mg/L)',\n",
       "   'Patients must be anti-TNF (anti-Tumour Necrosis Factor) inadequate responders to at least one but not more than two anti-TNF biologics with active disease documented in medical records at the time of discontinuation'],\n",
       "  'exclusion': ['Patients with arthritis due to other autoimmune diseases than RA',\n",
       "   'Any active or ongoing bacterial infections within 4 weeks prior to screening visit, unless treated and resolved with appropriate therapy or any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)',\n",
       "   'History of severe, systemic viral or fungal infections within the past 6 months prior to screening visit, unless treated and/or resolved with appropriate therapy',\n",
       "   'Patients with active malignancy within the previous 5 years with the exception of adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to screening visit',\n",
       "   'Females of childbearing potential who are pregnant or breast feeding or intend to become pregnant',\n",
       "   'Any other disease or clinically significant abnormality in laboratory parameters which, according to the Investigator, might compromise the safety of the patient, interfere with participation in the trial or compromise the trial objective']},\n",
       " {'nct_id': 'NCT01633346',\n",
       "  'inclusion': ['Diagnosis of moderate to severe active RA of ≥6 months duration.',\n",
       "   'Patients who have commenced treatment with Ro-Actemra® (tocilizumab) in accordance with the approved Summary of Product Characteristics.',\n",
       "   'Age > 18 years.',\n",
       "   'Body weight ≤150',\n",
       "   '- Non-pregnant, non-nursing female, and females of child-bearing potential must use a reliable means of contraception, eg, physical barrier (patient and partner), contraceptive pill or patch, spermicide and barrier, or intrauterine device (IUD)',\n",
       "   'If female and of childbearing potential, the patient must have a negative urine at screening and baseline.',\n",
       "   'If patients are receiving an oral corticosteroid, the prednisone dose or its equivalent must be ≤10 mg/day and stable for ≥28 days prior to screening.',\n",
       "   'If patients are currently taking a permitted non-biologic DMARD, the dose must be stable for ≥7 weeks prior to baseline. Willing to receive oral folate or leucovorin if taking methotrexate.',\n",
       "   'Patients who have been given written information about the study and have consented to data collection and review.'],\n",
       "  'exclusion': ['History of autoimmune disease or inflammatory joint disease other than',\n",
       "   '- Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting treatment with Ro-Actemra®',\n",
       "   'Pregnant women or nursing (breastfeeding) mothers',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.',\n",
       "   'Functional class IV as defined by the ACR Classification of Functional Status in RA (ie, largely or wholly incapacitated with patient bedridden or confined to wheel chair, permitting little or no self-care)',\n",
       "   'Treatment with rituximab within 6 months before screening.',\n",
       "   'Treatment with IV gamma globulin, plasmapheresis or Prosorba® column within months, or any investigational cell-depleting therapies before baseline.',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to baseline.',\n",
       "   'Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.',\n",
       "   'Treatment with: Intraarticular (IA) corticosteroids within 8 weeks prior to screening. Intramuscular (IM) or IV corticosteroids within 12 weeks prior to screening.',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine(including uncontrolled diabetes mellitus) or GI disease (including complicated',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 5 years (including hematological malignancies and solid tumors, except non melanoma skin cancer that has been excised and cured), or breast cancer diagnosed within the previous 5 years.',\n",
       "   'Active TB requiring treatment within the previous 3 years. Patients previously treated for TB with no recurrence in the past 3 years are permitted. Patients who have a positive purified protein derivative (PPD) tuberculin skin test and have not been adequately treated for TB must be treated for latent TB with isoniazid (INH) for 1 month prior to enrollment whether or not they have been vaccinated in the past. Patients with a positive PPD that is ≥5mm at screening are not eligible for the study unless they begin treatment for latent TB with INH a minimum of 1 month prior to enrollment in the trial. The required total INH treatment duration is 9 months. Patients must have a negative CXR at enrollment.',\n",
       "   'HIV-positive.',\n",
       "   'History of alcohol, drug or chemical abuse within the 6 months prior to screening.']},\n",
       " {'nct_id': 'NCT01638715',\n",
       "  'inclusion': ['Men and women, ≥18 and ≤75 years of age, capable of understanding and signing an informed consent.',\n",
       "   'Classifiable RA according to the 2010 ACR/EULAR criteria (American College of Rheumatology/European League Against Rheumatism classification criteria) or 1987 ARA criteria (Criteria of American Rheumatology Association) (present or past) (2;3)',\n",
       "   'Duration of RA ≤3 years',\n",
       "   'Ongoing conventional DMARD therapy (Disease Modifying Antirheumatic Drugs) with methotrexate (at least 20mg/week, or lower if not tolerated in higher doses) or leflunomide (≥100mg/week), for ≥6 months or ≥3 months with documented worsening of disease activity.',\n",
       "   'Clinical Disease Activity Index (CDAI)≥15 corresponding to moderate to severe disease activity.'],\n",
       "  'exclusion': ['Be incapacitated, largely or wholly bedridden, or confined to a wheelchair, or have little or no ability for self care.',\n",
       "   'Weigh more than 100 kg',\n",
       "   'Use glucocorticoids >10 mg/day prednisone or equivalent',\n",
       "   'Have previously received other treatments for their rheumatic disease:',\n",
       "   'intra-muscular or intra-articular injection of steroids in the previous month.',\n",
       "   'monoclonal antibodies or antibody fragments, licenced or investigational',\n",
       "   'any investigational drug within 3 months prior to screening or within 5 half-lives of the investigational agent, whichever is longer.',\n",
       "   'Azathioprine or other cytostatic drugs.',\n",
       "   'Have a history of receiving human/murine recombinant products or a known allergy to murine products.',\n",
       "   'Have documentation of seropositivity for human immunodeficiency virus (HIV), or a positive test for hepatitis B surface antigen or hepatitis C ¬antibodies.',\n",
       "   'Have hypergammaglobulinemia',\n",
       "   'Have a history of alcohol or substance abuse within the preceding 6 months.',\n",
       "   'Have or have had a known history of',\n",
       "   'serious infections (such as, but not limited to hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.',\n",
       "   'opportunistic infections (eg, herpes zoster, cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 12 months prior to screening.',\n",
       "   'a chronic or recurrent infectious disease (eg, chronic renal infection, chronic chest infection, COPD, sinusitis, recurrent urinary tract infection, open, draining or infected skin wound or ulcer etc.).',\n",
       "   'Have undergone any joint replacement surgery.',\n",
       "   'Be men and women of childbearing potential without use of adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization), and willingness to continue this precaution for the duration of the study until 6 months after receiving the last medication.',\n",
       "   'Be considered ineligible according to the tuberculosis (TB) eligibility assessment and screening, or show a positive test for latent Tbc using Quantiferon assay, unless treatment with INH has been installed for at least 2 weeks prior to starting trial drug.',\n",
       "   'Show evidence of malignancy, or lymphoproliferative disease, or any history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.',\n",
       "   'Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.',\n",
       "   'Be unable or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.',\n",
       "   'Have presence of a transplanted solid organ (with the exception of a corneal transplant > 3 months prior to screening).',\n",
       "   'Have a concomitant diagnosis or history of congestive heart failure (New York Heart Association',\n",
       "   'NYHA',\n",
       "   'class III or IV) or diverticulitis.',\n",
       "   'Have a known history of a demyelinating disease, such as multiple sclerosis.',\n",
       "   'Be women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion']},\n",
       " {'nct_id': 'NCT01639287',\n",
       "  'inclusion': ['longstanding rheumatoid arthritis',\n",
       "   'chronically painless synovitis in the hands or painful'],\n",
       "  'exclusion': ['uncompensated systemic disease, e.g. diabetes mellitus, hypothyroidism',\n",
       "   'change of basic drug in the last 3 months']},\n",
       " {'nct_id': 'NCT01635582',\n",
       "  'inclusion': ['Men and women',\n",
       "   'Aged between 30-70 years',\n",
       "   'Clinical diagnosis of Rheumatoid arthritis or Osteoarthritis of hands according to American college of rheumatology criteria',\n",
       "   'Must own a home computer and have basic working knowledge of computers.',\n",
       "   'Present with scores ranging from 0-75 on self-reported hand function ability with the Disabilities of Arm, Shoulder and Hand (DASH) questionnaire'],\n",
       "  'exclusion': ['Severely deformed finger joints',\n",
       "   'Neurological conditions of dominant side upper limb',\n",
       "   'Trauma in wrist or hand',\n",
       "   'Upper limb surgeries in previous six months',\n",
       "   'Co-existing hand conditions in the dominant hand',\n",
       "   'Problems with vision or hearing',\n",
       "   'Recent changes in drug regimen (Disease modifying anti-rheumatic drugs (DMARDs) or corticosteroids <3 months)',\n",
       "   'Major diseases of heart or lungs or liver',\n",
       "   'DASH scores 0-75.']},\n",
       " {'nct_id': 'NCT01388608',\n",
       "  'inclusion': ['Patients with active rheumatoid arthritis (Disease activity score -DAS28 > 3.2) who are eligible to a treatment with etanercept.',\n",
       "   'Age 18 and older',\n",
       "   'Male or female'],\n",
       "  'exclusion': ['Contraindications against a therapy with etanercept',\n",
       "   'Patients not able to comply with the requirements of the protocol']},\n",
       " {'nct_id': 'NCT01384461',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   'RoActemra/Actemra treatment initiated by rheumatologist in an Arthritis Center for (up to 2 months prior to study entry)'],\n",
       "  'exclusion': ['History of severe allergic or anaphylactic reactions or known hypersensitivity to any component of the drug',\n",
       "   'Active, severe infection or history of recurrent clinically significant infection',\n",
       "   'Pregnancy',\n",
       "   'Treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before baseline visit',\n",
       "   'Methotrexate intolerance']},\n",
       " {'nct_id': 'NCT01389388',\n",
       "  'inclusion': ['Women and men with RA, AS and other inflammatory forms of arthritis, aged 35-80 years.',\n",
       "   'Cholesterol plaques demonstrated in carotid artery by ultrasound.',\n",
       "   'Informed consent.'],\n",
       "  'exclusion': ['Concomitant statin treatment',\n",
       "   'Arterial fibrillation or others with chronic irregular heart rhythm (because of CT).',\n",
       "   'Contraindication to statin treatment.',\n",
       "   'Hypersensitivity to statins',\n",
       "   'Liver disease with ASAT/ALAT ≥ twice the upper normal limit',\n",
       "   'Previous statin-induced myopathy or severe hypersensitivity reactions to other statins',\n",
       "   'Raised creatinine (because of contrast medium)',\n",
       "   'Pregnancy or breast feeding',\n",
       "   'Fertile women who do not use contraceptives',\n",
       "   'Cyclosporine treatment',\n",
       "   'Treatment with medicinal products that have a known interaction with Rosuvastatin',\n",
       "   'Uncontrolled hypothyroidism defined as TSH > 1.5 times ULN at the first visit (because of the connection between myopathy and hypothyroidism with statin treatment)',\n",
       "   'Creatinine clearance < 30 ml/min and <60 ml/min with a Rosuvastatin dose of 40 mg per day',\n",
       "   'Secondary hyperlipidemia',\n",
       "   'Primary hyperthyroidism',\n",
       "   'Nephrotic syndrome, creatinine > 2 mg/dl',\n",
       "   'Uncontrolled diabetes mellitus (HbA1C > 10 %)',\n",
       "   'Plasma Triglycerides > 6.8 mmol/l',\n",
       "   'Other diseases or treatment that reduces the safety, or treatment with Rosuvastatin which would interfere with the end points of the study',\n",
       "   'Heart failure: NYHA class III B/IV',\n",
       "   'Haemodynamically significant valve defects',\n",
       "   'Established statin treatment',\n",
       "   'Gastrointestinal disease/treatment that can give malabsorption of Rosuvastatin',\n",
       "   'Cancer',\n",
       "   'Severe psychiatric disease',\n",
       "   'Life-threatening ventricular arrhythmias',\n",
       "   'Other medication that increases the risk of rhabdomyolysis',\n",
       "   'Known abuse of alcohol',\n",
       "   'Participation in other studies']},\n",
       " {'nct_id': 'NCT01382160',\n",
       "  'inclusion': ['RA according to the American College of Rheumatology (ACR) 1987 criteria',\n",
       "   'Treatment with Adalimumab has been chosen by the physician / patient',\n",
       "   'Treatment given in accordance to the SPC',\n",
       "   'Stable Disease modifying anti rheumatic drugs (DMARDs) and glucocorticoids 4 weeks before enrollment and during the study period.',\n",
       "   'Signed consent'],\n",
       "  'exclusion': ['more than one previous treatment with anti TNF-alpha',\n",
       "   'Past history of malignancy, AIDS',\n",
       "   'Pregnancy',\n",
       "   'Change in DMARDS or glucocorticoid dose 4 weeks before entering the study',\n",
       "   'Active or latent tuberculosis, other active infections',\n",
       "   'Surgery scheduled during the study period']},\n",
       " {'nct_id': 'NCT01382940',\n",
       "  'inclusion': ['Adult patients, ≥ 18 years of age',\n",
       "   'Rheumatoid arthritis of ≥ 6 months duration, diagnosed according to the revised 1987 American College of Rheumatology criteria',\n",
       "   'Inadequate response to at least one approved anti-TNF agent (adalimumab, etanercept, infliximab, golimumab, or certolizumab)',\n",
       "   'Patients who have received 1 to 2 prior courses of rituximab (RTX) may be enrolled, provided their most recent course of RTX occurred over 6 months but no more than 9 months prior to baseline. The RTX dosage must have been two 1000 mg infusions per course administered at the standard approved rate',\n",
       "   'Methotrexate treatment between 10 and 25 mg/week (oral or parenteral) for at least 8 weeks immediately prior to baseline Key'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned surgery within 6 months following baseline',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Functional class IV as defined by American College of Rheumatology (ACR) criteria',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies',\n",
       "   'Previous serious infusion reaction to any prior biologic therapy',\n",
       "   'Known active current or history of recurrent infection',\n",
       "   'Evidence of chronic hepatitis B or C infection',\n",
       "   'Pregnant or lactating women',\n",
       "   'Body weight of > 150 kg']},\n",
       " {'nct_id': 'NCT01384422',\n",
       "  'inclusion': ['Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;',\n",
       "   'Have received methotrexate for six months or longer and at a stable dose of 7.5 to 25 mg/week (extremes included) for at least four weeks prior to screening and willing to continue on this regimen for the duration of the study;',\n",
       "   'If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least four weeks prior to screening;',\n",
       "   'If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least two weeks prior to screening;',\n",
       "   'Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year (12 consecutive months without menses);',\n",
       "   'Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least four weeks after the last dose of study drug. Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and',\n",
       "   'Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.'],\n",
       "  'exclusion': ['Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;',\n",
       "   'Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);',\n",
       "   'Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;',\n",
       "   'Receipt of an intra-articular or parenteral corticosteroid injection within four weeks prior to screening;',\n",
       "   'Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator, such as anaphylaxis, requiring hospitalization;',\n",
       "   'Positive serology for human immunodeficiency virus (HIV)1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A;',\n",
       "   'History of any inflammatory rheumatological disorders other than RA;',\n",
       "   'History of tuberculosis (TB) infection;',\n",
       "   'Pregnant or lactating women.']},\n",
       " {'nct_id': 'NCT01383421',\n",
       "  'inclusion': ['Male or female aged at least 18 years that has been newly prescribed adalimumab therapy according to the local product label, with the first dose corresponding to the Enrollment/Baseline visit.',\n",
       "   'Patient with a diagnosis of moderate to severe RA, who has had insufficient response to one or more disease-modifying antirheumatic drugs (DMARDs), and has a prescription of adalimumab according to the local regulations.',\n",
       "   'Patients should be evaluated for tuberculosis (TB) exposure/risk factors for active and latent TB (per local requirements and according to the local product label).',\n",
       "   'Patients must be able and willing to provide written authorization to disclose and use personal health information (and informed consent where applicable) and comply with the requirements of this study protocol as well as agree to data being collected and provided to AbbVie.'],\n",
       "  'exclusion': ['Patients should not be enrolled if they cannot be treated in accordance with the local adalimumab product label.',\n",
       "   'Patients treated with > 1 prior biologic DMARD for',\n",
       "   'Any prior treatment with adalimumab is prohibited.']},\n",
       " {'nct_id': 'NCT01388309',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis',\n",
       "   'Inadequate response or intolerance to previous therapy with one or more traditional DMARDs'],\n",
       "  'exclusion': ['Pregnant or lactating women',\n",
       "   'Active infection',\n",
       "   'Positive for hepatitis B, hepatitis C or HIV infection',\n",
       "   'Concomitant anti-TNF drugs',\n",
       "   'Contraindications to treatment with RoActemra/Actemra']},\n",
       " {'nct_id': 'NCT01387789',\n",
       "  'inclusion': ['Patients 18 years of age and older with a diagnosis of Rheumatoid Arthritis for at least 3 months according to the American College of Rheumatology (ACR) criteria',\n",
       "   \"Patients who have not been instituted on any anti -Tumour Necrosis Factor (anti-TNF) agents prior to inclusion into this study (anti-TNF naïve patients). Only anti-TNF Naive Rheumatoid Arthritis patients who are scheduled to begin HUMIRA treatment, according to the relevant Summary of Product Characteristics, on the basis of their own physician's judgment (and on the current clinical practice), will be selected for inclusion in this study\",\n",
       "   'Patients not included in other clinical/observational trials',\n",
       "   'Patients providing a written informed consent before the enrollment in the study'],\n",
       "  'exclusion': ['Refusal to participate in the study or to sign the informed consent',\n",
       "   'Contraindications to adalimumab according to the terms of the local marketing authorization (label)']},\n",
       " {'nct_id': 'NCT01651936',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis for at least 6 months prior to screening',\n",
       "   'Active rheumatoid arthritis as defined by the presence of >= 6 swollen joints (of 66 count) and >= 6 tender joints (of 68 joint count)',\n",
       "   'C-reactive protein blood level >0.9 mg/dL or an elevated erythrocyte sedimentation rate (ESR) >28 mm/hr and evidence of synovitis on imaging',\n",
       "   'American College of Rheumatology Functional Class I, II, or III',\n",
       "   'Received methotrexate for a minimum of 3 months prior to screening with a regionally appropriate stable weekly dose for at least 4 weeks prior to screening. The dose of methotrexate must remain stable through Week 24 of the study.',\n",
       "   'Failed treatment with 1 or 2 anti-tumor necrosis factor alpha (anti-TNF-α) therapies or was intolerant to anti-TNF-α therapy prior to screening',\n",
       "   'If using non-steroidal anti-inflammatory drugs or other analgesics, participant must be on a stable dose',\n",
       "   'No history of either untreated latent or active tuberculosis (TB) prior to baseline',\n",
       "   'Participants of reproductive potential must agree to remain abstinent or use 2 acceptable methods of birth control'],\n",
       "  'exclusion': ['Presence of inflammatory disease other than rheumatoid arthritis, including but not limited to psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease',\n",
       "   'Hospitalization due to an acute cardiovascular event, cardiovascular illness, or cardiovascular surgery within 6 months of screening',\n",
       "   'Participant has a transplanted organ, excluding corneal transplant, performed > 3 months prior to the first dose of trial medication',\n",
       "   'History of, or current ongoing ,chronic or recurrent infectious disease',\n",
       "   'Positive hepatitis B surface antigen or hepatitis C test result',\n",
       "   'Human immunodeficiency virus (HIV) positive',\n",
       "   'User of recreational or illicit drugs or has had a history (within the previous 2 years) of drug or alcohol abuse or dependence',\n",
       "   'Prior exposure to fostamatinib or other spleen tyrosine kinase inhibitors',\n",
       "   'Prior exposure to 3 or more anti-TNF therapeutic agents',\n",
       "   'Has been treated for RA with a marketed biologic agent (other than anti-TNF therapeutic agents) and failed the agent due to lack of efficacy',\n",
       "   'Currently participating in another interventional clinical trial or has participated in an interventional clinical trial within 4 weeks prior to screening',\n",
       "   'Severe opportunistic infection within the 6 months prior to screening']},\n",
       " {'nct_id': 'NCT01652937',\n",
       "  'inclusion': ['Adult onset RA satisfying 2010 Revised ACR Criteria for the Classification of RA with a disease history of at least 6 months',\n",
       "   'Active RA as defined by: at least 4 swollen joints (based on 28-joint count), at least 4 tender joints (based on 28-joint count), and high-sensitivity CRP (hsCRP) 10mg/L or greater',\n",
       "   'No prior treatment with biologics',\n",
       "   'Receiving a DMARD therapy for at least 3 months, using a regimen that has been stable for at least 28 days prior to screening'],\n",
       "  'exclusion': ['History of inflammatory joint disease other than RA',\n",
       "   'Abnormal chest X-ray consistent with tuberculosis, malignancy, or infection',\n",
       "   'History of malignancy, carcinoma in situ, or high-grade dysplasia',\n",
       "   'History of opportunistic infection, infection requiring treatment, serious local infection, recent fever, active herpes zoster or Epstein-Barr virus, or diagnosis or family history of Creutzfeldt-Jakob disease.',\n",
       "   'Clinically significant cardiac disease',\n",
       "   'Treatment with prednisone >10 mg orally daily',\n",
       "   'Intra-articular steroid injection within 28 days before screening',\n",
       "   'Clinically significant abnormality in hematology or blood chemistry values at screening']},\n",
       " {'nct_id': 'NCT01659242',\n",
       "  'inclusion': ['Male and female patients aged between 21 and 65 years.',\n",
       "   'Patients with no childbearing potential (For example postmenopausal or sterilised) or have decided not to have offspring(s).',\n",
       "   'All female patients must consent not to get pregnant/breastfeed, male patients must consent not to father a child and all must consent to practice effective birth control.',\n",
       "   'Fulfills either the 1987 ACR criteria and/or the 2010 ACR / EULAR RA Classification Criteria.',\n",
       "   'Seropositivity: Rheumatoid factor (RF) and/or anti -cyclic citrullinated protein antibodies (anti-CCP) must be positive.',\n",
       "   'MCPJ(s) and/or Wrist(s) joint(s) involvement.',\n",
       "   'Rheumatoid arthritis patients (less than 5 years duration) who remain at least moderately active based on DAS28 score of > 3.2, following 3 months of therapy with an optimal dose of methotrexate(e.g. at least 15 mg/week).',\n",
       "   'If patient is on oral corticosteroids, this should not exceeding 10mg prednisolone daily (or oral steroid equivalent) for at least 4 weeks and should be at an unchanged dose for at least 2 weeks before entering study.',\n",
       "   'If patient is on NSAIDs, this should be at an unchanged dose for at least 2 weeks before entering study.',\n",
       "   'Glomerular filtration rate > 60 mls/min/1.73m2.'],\n",
       "  'exclusion': ['Patient known to have the following medical condition(s) will be excluded:',\n",
       "   'Other autoimmune disease /inflammatory joint disease/connective tissue disease ( e.g. lupus, seronegative spondylarthropathy (e.g. ankylosing spondylitis/psoriatic arthropathy ), reactive arthritis, overlap syndrome, primary sjogren syndrome and mixed connective tissue disease.)',\n",
       "   'Inflammatory arthritis with onset before 18 years old.',\n",
       "   'Current or previous history of cancer or lymphoproliferative disease.',\n",
       "   'HIV positive status, Hepatitis B/C positive status.',\n",
       "   'Persistent and/or severe infection in the previous 12 weeks.',\n",
       "   'Major traumatic injury, terminal illness, or other medical condition(s)that could place the patient at risk to participate in the study.',\n",
       "   'Clinically relevant cardiovascular (e.g unstable ischemic heart disease), neurological (e.g recent stroke), gastroenterology (e.g active peptic ulcer disease), renal (e.g chronic renal failure), hepatic (e.g alcoholic liver disease, fatty liver) and any other major systemic disease that could i) place the patient at risk to participate in the study; or ii) make protocol implementation difficult; or iii) make study results interpretation difficult.',\n",
       "   'Presence of any known condition(s)/circumstance(s) which would negatively impact compliance or study completion.',\n",
       "   'Impaired laboratory parameters:',\n",
       "   'Hemoglobin less than 10.5 g/dl, white blood count less than 4 x 10 (9)/L , platelet count less than 150 x 10(9)/L.',\n",
       "   'Deranged Liver function test: e.g. elevated AST/ALT.',\n",
       "   'Wants to consume alcohol while taking the study medications.',\n",
       "   'Body weight that is less than 45',\n",
       "   '5. Pregnancy/Breastfeeding/Male patient wishing to father children.',\n",
       "   'Patients with the following medication history will be excluded:',\n",
       "   'History of Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency.',\n",
       "   'Known allergy to: i) study medications; or ii) contrast; or iii) drugs whose chemical structures are similar (e.g. sulphonamides, salicylates, etc).',\n",
       "   'On anticoagulation for any reasons.',\n",
       "   'Previous treatment (within the last 4 weeks) with: i) oral corticosteroid greater than prednisolone equivalent of 10mg/day; or ii) parenteral/intra-articular corticosteroid injection.',\n",
       "   'Previous treatment (within the last 12 weeks) with: i) other DMARDs such as sulfasalazine,hydroxychloroquine,chloroquine,gold salts, etc; or ii) investigational drug(s); or iii) other immunosuppressive agents such as cyclophosphamide,cyclosporin,azathioprine and any biologic agents, e.g. anti-TNF.',\n",
       "   'Previous treatment(any duration) with i) Leflunomide; or ii) Sulfasalazine used together with methotrexate',\n",
       "   'Contraindication to MRI (e.g. pacemakers, metallic implants/stents, claustrophobia).']},\n",
       " {'nct_id': 'NCT01111357',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis according to ACR criteria',\n",
       "   'Come from French West Indies (At least 3 grandparents are African-Caribbean)',\n",
       "   'Sign written informed consent Exclusion Criteria:',\n",
       "   'Minor',\n",
       "   'Patient with no Rheumatoid Arthritis according to ACR criteria',\n",
       "   'Patient does not agree for a genetic study For the control Inclusion Criteria:',\n",
       "   'Blood donor',\n",
       "   'Sign written informed consent',\n",
       "   'Patient with no Rheumatoid Arthritis according to ACR criteria',\n",
       "   'Come from French West Indies (At least 3 grandparents are African-Caribbean)'],\n",
       "  'exclusion': ['Minor', 'Patient does not agree for a genetic study']},\n",
       " {'nct_id': 'NCT01119859',\n",
       "  'inclusion': ['Adult patients, ≥ 18 years of age.',\n",
       "   'Rheumatoid arthritis of > 6 months duration.',\n",
       "   'Intolerant of methotrexate or continued treatment with methotrexate is considered inappropriate.',\n",
       "   'All disease-modifying anti-rheumatic drugs (DMARD) are to be withdrawn prior to receiving study drug.',\n",
       "   'Weight ≤ 150',\n",
       "   ''],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 12 weeks prior to baseline or planned major surgery within 6 months after baseline.',\n",
       "   'History of or current inflammatory joint disease other than rheumatoid arthritis (RA).',\n",
       "   'Treatment with a biologic agent at any time prior to baseline.',\n",
       "   'Intra-articular or parenteral corticosteroids ≤ 4 weeks prior to baseline.',\n",
       "   'Active current infection or history of recurrent bacterial, viral, fungal or mycobacterial infection.']},\n",
       " {'nct_id': 'NCT01117480',\n",
       "  'inclusion': ['Participant is eligible to take part in the registry as per the product monograph.',\n",
       "   'Participants that are naïve to adalimumab therapy / or participants that have been receiving adalimumab therapy for less than 4 months.',\n",
       "   'Participant has moderately to severely active',\n",
       "   '- Participant who has had an inadequate response to one or more Disease Modifying Anti-Rheumatic Drugs (DMARDs).',\n",
       "   'Participant received provincial or private (insurance companies) approval for adalimumab.',\n",
       "   'Participant is able to give written informed consent and to understand the survey requirements.'],\n",
       "  'exclusion': ['Participant to whom a traditional DMARD had never been tried.',\n",
       "   'Participant with a known hypersensitivity to adalimumab, or any of its components.',\n",
       "   'Participant is receiving free adalimumab as part of a compassionate program or an early access drug distribution program.',\n",
       "   'Participant with clinically significant concurrent medical or psychiatric disorders that may influence survey outcomes.',\n",
       "   'Participant with any condition that would prevent participation in the survey and completion of the survey procedures including language limitation or possibility that the participant will not be available for a period of time (> 12 months) while being enrolled in the survey.']},\n",
       " {'nct_id': 'NCT01117129',\n",
       "  'inclusion': ['adult patients, 18-75 years of age',\n",
       "   'active rheumatoid arthritis (DAS28-CRP>3.2)',\n",
       "   'refractory to one or more anti-TNF',\n",
       "   'on stable treatment for RA for >/=4 weeks',\n",
       "   'evidence of erosive disease and/or synovitis in wrist and/or knuckles'],\n",
       "  'exclusion': ['active systemic or local infection',\n",
       "   'previous or current history of any demyelinization process in central nervous system, pancytopenia or aplasic anaemia',\n",
       "   'signs of immunodeficiency, HIV infection or tuberculosis',\n",
       "   'contraindications to MRI, such as metal devices, claustrophobia, moderate or severe renal insufficiency, or allergy to contrast agent']},\n",
       " {'nct_id': 'NCT01116141',\n",
       "  'inclusion': ['Patients must be between the ages of 18 and 80;',\n",
       "   'Have diagnosed active rheumatoid arthritis according to ACR criteria functional class I-III;',\n",
       "   'Have at least 6 swollen joints (max = 66) and 6 tender joints (max = 68) at screening and baseline visits;',\n",
       "   'Patients must have at least one of the following:',\n",
       "   'C-reactive protein > 1.0 mg/dl at screening;',\n",
       "   'erythrocyte sedimentation rate > 28 mm/Hr;',\n",
       "   'Patients must have been taking methotrexate between 15 and 25 mg/week for at least 3 months and at a stable dose for at least 6 weeks;',\n",
       "   'Patients must be either Rheumatoid Factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) positive;',\n",
       "   'Patients must have voluntarily signed the informed consent.'],\n",
       "  'exclusion': ['Patients who received previous therapy with any biologic agent;',\n",
       "   'Patients currently taking any disease modifying anti-rheumatic drug (DMARD) other than MTX;',\n",
       "   'Previous non-biologic DMARD therapy is permitted as long as their last dose was at least 30 days prior to baseline;',\n",
       "   'Female patients of child bearing potential who are pregnant or who are not using two methods of contraception (at least one barrier: i.e. condom) with their partner;',\n",
       "   'Male patients who are sexually active and not using two methods of contraception (at least one barrier: i.e. condom) with their partner;',\n",
       "   'Patients with any current active infection or infections requiring IV drug therapy within 30 days of baseline or oral therapy within 15 days of Baseline;',\n",
       "   'Patients that have had any surgical procedures within 30 days of baseline;',\n",
       "   'Patients with a history of HIV;',\n",
       "   'Patients with Hepatitis B surface antigen positive and/or Hepatitis C antibody positive;',\n",
       "   'Patients who consume more than 4 units of alcohol per week (1 unit = 5 ounces/150 ml of wine = 1.5 ounces/45 ml spirits = 12 ounces/360 ml of beer);',\n",
       "   'Patients currently receiving any investigational drug or have received an investigational drug within 30 days of baseline or 5 half-lives of the investigational drug (whichever is longer);',\n",
       "   'Patients with a history of cancer within the past 5 years other than a successfully treated, non-metastatic cutaneous squamous cell or basal cell carcinoma or cervical cancer in situ;',\n",
       "   'Patients with a history of, or any, disease associated with an inflammatory arthritis other than RA;',\n",
       "   'Patients with pulmonary fibrosis (Chest x-ray must be taken within 28 days of screening);',\n",
       "   'Patients receiving probenecid;',\n",
       "   'Patients who have received any steroid injections within 30 days of baseline;',\n",
       "   'Patients with concomitant diseases that are unstable (i.e. cardiac, pulmonary) or that may affect drug activity (i.e. absorption, reactions, change in kinetics);',\n",
       "   \"Patients, in the investigator's opinion, that have any significant renal or hepatic impairment;\",\n",
       "   'Patients with a serum creatinine level > 1.5 mg/dl at screening;',\n",
       "   'Patients with an ALT >1.5 ULN at screening;',\n",
       "   'Patients considered by the investigator to be an unsuitable candidate to receive CH-4051;',\n",
       "   'Wheelchair or bed-bound patients.']},\n",
       " {'nct_id': 'NCT01262118',\n",
       "  'inclusion': ['Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older'],\n",
       "  'exclusion': ['Pregnant or lactating women',\n",
       "   'Clinically significant systemic disease (other than RA for RA arm)',\n",
       "   'Use of lipid-regulating agents']},\n",
       " {'nct_id': 'NCT01264770',\n",
       "  'inclusion': ['Male or female aged 18 and over',\n",
       "   'Active rheumatoid arthritis (RA) diagnosed after the age of 16 and diagnosis within 5 years prior to study visit 1 and inadequate response to treatment with a maximum 2 Disease-Modifying anti-rheumatic drug (DMARD) therapies, or diagnosis within 5 years prior to study visit 1 and intolerance to DMARD therapy, or diagnosis within 2 years prior to study visit 1 and no previous use of DMARDs',\n",
       "   '4 or more swollen joints and 4 or more tender/painful joints (from 28 joint count) and either Erythrocyte Sedimentation Rate (ESR) blood result of 28mm/h or more, or C-Reactive Protein (CRP) blood result of 10mg/L or more',\n",
       "   'At least 2 of the following: documented history or current presence of positive rheumatoid factor (blood test), radiographic erosion within 12 months prior to study enrolment, presence of serum anti-cyclic citrullinated peptide antibodies (blood test)'],\n",
       "  'exclusion': ['Females who are pregnant or breast feeding',\n",
       "   'Poorly controlled hypertension',\n",
       "   'Liver disease or significant liver function test abnormalities',\n",
       "   'Certain inflammatory conditions (other than rheumatoid arthritis), connective tissue diseases or chronic pain disorders',\n",
       "   'Recent or significant cardiovascular disease',\n",
       "   'Significant active or recent infection including tuberculosis',\n",
       "   'Previously received treatment with a TNF alpha antagonist (including etanercept, certolizumab, adalimumab, infliximab, golimumab) or anakinra or previous treatment with other biological agent including rituximab, abatacept and tocilizumab',\n",
       "   'Use of any DMARDs within 6 weeks before first study visit',\n",
       "   'Severe renal impairment',\n",
       "   'Neutropenia']},\n",
       " {'nct_id': 'NCT01264211',\n",
       "  'inclusion': ['Male or female aged between 18 and 65 years;',\n",
       "   'Active RA of ≥ 3 months duration but < 2 years, diagnosed according to the American College of Rheumatology (ACR) 1987 revised criteria for RA;',\n",
       "   'RA global functional status class I-III;',\n",
       "   'Treatment on an outpatient basis;',\n",
       "   'Treatment with MTX for a minimum of 12 weeks, with stable weekly dose (10-20 mg) for at least 4 weeks before randomisation;',\n",
       "   'Insufficient response to treatment with MTX, with disease activity score DAS28 > 4.0 at the time of screening and randomisation; the DAS28 must not change significantly from screening to baseline visit (change < 0.6);',\n",
       "   'Tender joint count (TJC) ≥ 6 (68 joint count) and swollen joint count (SJC) ≥ 6 (66 joint count) at screening and randomisation;',\n",
       "   'Screening ESR ≥ 28 mm/h;',\n",
       "   'Evidence of adequate contraceptive methods in women of childbearing potential. Female patients of childbearing potential are those who are not surgically sterile or post-menopausal. Adequate contraceptive methods are hormonal contraceptive, intra-uterine device, diaphragm with spermicide or condom with spermicide for the entire duration of the study;',\n",
       "   'Agreement not to drink alcohol for the duration of the study;',\n",
       "   'Ability and agreement to comply with the requirements of the study protocol;',\n",
       "   'Having given written informed consent to participate in the study.'],\n",
       "  'exclusion': ['History of active inflammatory arthritis other than RA;',\n",
       "   'Any uncontrolled medical condition such as diabetes mellitus, asthma, cardiopulmonary disease, congestive heart failure, neurological disease, etc.;',\n",
       "   'Alcohol abuse, defined as the consumption of more than one glass of beer or wine in a day;',\n",
       "   'Moderate or severe liver disease (cirrhosis, hepatitis, liver insufficiency);',\n",
       "   'Blood anomalies (significant cytopenia);',\n",
       "   'History of, or currently active primary or secondary immunodeficiency;',\n",
       "   'Chronic hepatitis B (HBsAg positive or HBcAb positive with HBV DNA load ≥ 400 copies/ml) or hepatitis C (anti-HCV positive);',\n",
       "   'Current known active, or history of, recurrent bacterial, viral, fungal, mycobacterial or other infections, or any infection requiring hospitalisation or treatment with i.v. antibiotics within 4 weeks prior to randomisation or oral antibiotics within 2 weeks prior to randomisation;',\n",
       "   'Treatment with biologic DMARDs such as TNF antagonists, IL 1 receptor antagonists, IL 6 receptor antagonists, CTLA4Ig within 12 weeks prior to randomisation, and rituximab within 24 weeks prior to randomisation;',\n",
       "   'Treatment with non-biologic DMARDs such as chloroquine, hydroxychloroquine, penicillamine, sulfasalazine within 4 weeks prior to randomisation, leflunomide, parenteral gold, oral gold within 8 weeks prior to randomisation, azathioprine and ciclosporin within 12 weeks prior to randomisation;',\n",
       "   'Treatment with intra-articular injection of a depocorticosteroid within 8 weeks prior to randomisation;',\n",
       "   'Treatment with NSAID or oral corticosteroids, unless the patient has been on a stable dose for at least 4 weeks before randomisation (maximal allowed daily dose of oral corticosteroid equivalent to prednisone 10 mg);',\n",
       "   'Physical therapy and alternative therapies, unless the patient has received them regularly for at least 4 weeks before randomisation;',\n",
       "   'Initiation of chronic treatment with antihistaminics, antidepressants or tranquilisers, within less than 12 weeks before randomisation.']},\n",
       " {'nct_id': 'NCT01888874',\n",
       "  'inclusion': ['have a diagnosis of RA since at least 6 months and meeting the 2010 ACR/EULAR criteria of RA and ACR functional class I-III,',\n",
       "   'have ≥6 swollen joints (from a 66 joint count) and ≥8 tender joints (from a 68 joint count) at Screening and at Baseline,',\n",
       "   'Screening serum c-reactive protein ≥0.7 x upper limit of laboratory normal range (ULN),',\n",
       "   'have received MTX for ≥6 months and have been on a stable dose (15 to 25 mg/week) of MTX for at least 4 weeks prior to Screening and willing to continue on their current regimen for the duration of the study. Stable doses of MTX as low as 10 mg/week are allowed when there is documented evidence of intolerance or safety issues at higher doses.'],\n",
       "  'exclusion': ['current therapy with any disease-modifying anti-rheumatic drugs (DMARD) other than MTX,',\n",
       "   'current or previous RA treatment with a biologic DMARD, with the exception of biologic DMARDs administered in a single clinical study setting more than 6 months prior to Screening (12 months for rituximab or other B cell depleting agents), where the biologic DMARD was effective, and if discontinued, this should not be due to lack of efficacy,',\n",
       "   'previous treatment at any time with a cytotoxic agent, other than MTX, before Screening.']},\n",
       " {'nct_id': 'NCT01881308',\n",
       "  'inclusion': ['Rheumatoid arthritis according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria',\n",
       "   'Male or non-pregnant, non-nursing female',\n",
       "   '>18 years of age and <80 years of age',\n",
       "   'Patient in the TNF-inhibitor group: Any disease duration. Patient in the synthetic DMARD group: RA diagnosis after 01.01.2010.',\n",
       "   'Sustained remission for ≥12 months according to DAS or Disease Activity Score based on 28 joints (DAS28), with documented remission status at a minimum of 2 consecutive visits during the last 18 months OR participation in the first ARCTIC trial',\n",
       "   'DAS <1.6 and no swollen joints at inclusion OR participation in the first ARCTIC trial',\n",
       "   'Unchanged treatment with TNF inhibitors and/or synthetic DMARDs during the previous 12 months, with a stable or reduced dose of glucocorticosteroids OR participation in the first ARCTIC trial',\n",
       "   'Subject capable of understanding and signing an informed consent form',\n",
       "   'Provision of written informed consent'],\n",
       "  'exclusion': ['Abnormal renal function, defined as serum creatinine >142 μmol/L in female and >168 μmol/L in male, or a glomerular filtration rate (GFR) <40 mL/min/1.73 m2',\n",
       "   'Abnormal liver function (defined as aspartate transaminase (ASAT)/alanine aminotransferase (ALAT) >3x upper normal limit), active or recent hepatitis, cirrhosis',\n",
       "   'Major co-morbidities, such as severe malignancies, severe diabetic mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease (NYHA class 3 or 4) and/or severe respiratory diseases',\n",
       "   'Leukopenia and/or thrombocytopenia',\n",
       "   'Inadequate birth control, pregnancy, and/or breastfeeding',\n",
       "   'Indications of active tuberculosis',\n",
       "   'Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol impossible.']},\n",
       " {'nct_id': 'NCT01885819',\n",
       "  'inclusion': ['Nonresponsive to at least one course of one DMARD selected from the group comprising of: gold salts, leflunomide, methotrexate, and hydroxychloroquine. Second-line agents are discontinued at least 4 weeks prior to entry. Able to tolerate ALL study procedures Able to give informed Consent Negative for HcG with a serum pregnancy test Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Life expectancy of 6 months or more in the opinion of the investigator Serum bilirubin, ALT, AST up to 2.5 time the upper level of normal. Controlled blood pressure (systolic blood pressure ≤140 and a diastolic blood pressure of ≤90 mmHG) and established anti-hypertensive therapy as necessary prior to entry into the study Patient has received stable, standard medical therapy for at least one month with no new medications to treat the disease introduced in the last month. Pre-existing condition (e.g. thromboembolic risk, diabetes, hypercholesterolemia) are adequately controlled in the opinion of the investigator Fertile patients (male and female) must agree to use an appropriate form of contraception while participating in the study.'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT01664117',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Patients with moderate to severe rheumatoid arthritis who have had an inadequate response or intolerance to disease modifying antirheumatic drugs (DMARDs) or other biological drugs',\n",
       "   'Patients treated with biologic DMARDs alone for at least 6 months'],\n",
       "  'exclusion': ['Patients not willing or unable to give written informed consent for participation in this study',\n",
       "   'Patients who are participating in any clinical trial at the time of this study']},\n",
       " {'nct_id': 'NCT01669902',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients who for any reason do not take methotrexate and for whom the treating physician has made a decision to prescribe RoActemra/Actemra as monotherapy; patients who commenced RoActemra/Actemra as monotherapy within 8 weeks prior to the enrolment visit may be included',\n",
       "   'Concomitant treatment with non-steroidal anti-inflammatory drug (NSAID) or corticosteroids (orally or intra-articularly) is allowed'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to enrolment visit',\n",
       "   'Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use',\n",
       "   'Concomitant DMARD treatment for rheumatoid arthritis (e.g. hyroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine)',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before starting RoActemra/Actemra treatment',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01663116',\n",
       "  'inclusion': ['Must understand and voluntarily sign an informed consent form prior to the conduct of any study related assessment/procedures.',\n",
       "   'Subjects with RA under treatment with at least one non-biologic-DMARD and failure to treatment with at least two biologics.',\n",
       "   'Of either gender, aged ≥ 18 years at time of consent.',\n",
       "   'Able to adhere to the study visit schedule and other protocol requirements.',\n",
       "   'Have a diagnosis of RA for ≥6 months.',\n",
       "   'EULAR DAS28-ESR activity criteria >3.2.',\n",
       "   'Four tender joints to palpation and four swollen joints, based on a 68/66-joint count.',\n",
       "   'Be receiving treatment on an outpatient basis.',\n",
       "   'If taking methotrexate, leflunomide, or sulfasalazine, must have been treated for at least 16 weeks and on a stable dose (oral methotrexate ≤ 25 mg/week; parenteral methotrexate ≤ 20 mg/week; leflunomide ≤ 20 mg/day; sulfasalazine ≤ 3 g/day) for at least 4 weeks prior to the start of treatment and throughout the study. (See also section 7.5). The rest of the DMARDs (gold salts, etc) should be maintained at stable doses during at least the 4 weeks prior to the start of treatment and throughout the study (see also section 7.5).',\n",
       "   'If taking oral corticosteroids, must be on a stable dose of prednisone ≤ 10 mg/day or equivalent for at least 1 month prior to screening. ( See also section 7.5).',\n",
       "   'If taking NSAIDs, must be on stable dose for at least 2 weeks prior to screening and until they have completed the Week 24 study visit. (See also section 7.5).',\n",
       "   'Male subjects (including those who have had a vasectomy) must agree to use barrier contraception (latex condoms) when engaging in activity in which conception is possible while on study medication and for at least 28 days after taking the last dose of study medication.',\n",
       "   'Females of Childbearing Potential* must have a negative urine pregnancy test at Screening and Baseline and must be willing to use one medically approved form of birth control when engaging in activity in which conception is possible while on study medication and for at least 28 days after taking the last dose of study medication.',\n",
       "   'A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral ovariectomy (the surgical removal of both ovaries) or 2) has not been postmenopausal for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).'],\n",
       "  'exclusion': ['Treatment with biologics within the following period prior to the start of treatment:',\n",
       "   'Infliximab: 8 weeks',\n",
       "   'Etanercept: 2 weeks',\n",
       "   'Adalimumab and certolizumab: 4 weeks',\n",
       "   'Abatacept, tocilizumab and golimumab: 8 weeks',\n",
       "   'Rituximab: 6 months',\n",
       "   'Anakinra: 3 days No treatment with biologics is allowed during the first 12 weeks after the start of the study treatment. Thus, the patients should have complied with the periods indicated above, and should not receive any biologics during the period specified.',\n",
       "   'Presence of a severe bleeding or thrombotic disorder.',\n",
       "   'History of known pulmonary embolism or known secondary anti-phospholipid syndrome.',\n",
       "   'Received any of the following treatments within 2 years prior to study entry: anti-cancer therapy (e.g. alkylating agents, anti-metabolites, purine analogues, monoclonal antibodies for malignancy).',\n",
       "   'Received within 4 weeks prior to the start of treatment: intra-articular, intramuscular or intravenous corticosteroids. (See also section 7.5).',\n",
       "   'Past or current malignant melanoma.',\n",
       "   'Past or current malignancy; except for in situ cervical cancer, non-invasive basal cell and squamous cell skin carcinoma, superficial bladder tumors (Ta and Tis) with a complete response duration of >10 years. In the case of lymphoma or breast cancer patients will be allowed to participate in the trial with a complete response duration of >20 years.',\n",
       "   'Other autoimmune diseases, previous or current inflammatory joint disease other than rheumatoid arthritis, currently active or previous recurrent bacterial, viral, fungal, or other infections including, but not limited to, tuberculosis and atypical mycobacterial disease, clinically significant abnormalities on chest radiograph, hepatitis B and C, and recurrent herpes zoster.',\n",
       "   'Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, Mycobacterium tuberculosis infection (TB) and active hepatitis B and',\n",
       "   'For the screening of latent TB, the results of the tests performed in the last year according to the usual practice of the center or local guidelines will be accepted, as long as the investigator rules out a situation of high contact risk in the months after the last screening in accordance with the medical history of the patient. If the patient has a recent chest X-ray (performed in the month prior to enrollment in the study) and there is no clinical evidence or history suggestive of recent contact, it will not be necessary to repeat the test.',\n",
       "   'Subjects with signs of latent TB can be included if they have started treatment according to local guidelines at least one month prior to starting investigational therapy.',\n",
       "   'Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from screening, congestive heart failure of worse than grade II of the New York criteria.',\n",
       "   'Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral psychiatric disease, or evidence of demyelinating disease.',\n",
       "   'History of significant cerebrovascular disease.',\n",
       "   'Subjects with congenital or acquired immunodeficiencies.',\n",
       "   'Known human immunodeficiency virus (HIV) positive.',\n",
       "   'Screening laboratory values (according to central laboratory):',\n",
       "   'Haemoglobin <5.6 mmol/L (9.0 g/dL).',\n",
       "   'Neutrophils <1.5 x 10(9)/L.',\n",
       "   'Leukocytes <3.0 x 10(9)/L.',\n",
       "   'Platelets <100 x 10(9)/L.',\n",
       "   'Serum IgG <lower limit of normal (LLN).',\n",
       "   'Alanine amino transferase (ALT) > 1.5 times the upper limit of normal (ULN).',\n",
       "   'Total bilirubin >2 mg/dl.',\n",
       "   'Aspartate amino transferase (AST) >1.5 times ULN.',\n",
       "   'Alkaline phosphatase (ALP) >2 times ULN.',\n",
       "   'Creatinine >133 mmol/L (1.5 mg/dL).',\n",
       "   'Serologic evidence of hepatitis C (HC) infection.',\n",
       "   'Serologic evidence of hepatitis B (HB) infection based on the results of testing for HBsAg, anti-HBc and anti-HBs antibodies as follows:',\n",
       "   'Subjects positive for HBsAg are excluded.',\n",
       "   'Subjects negative for HBsAg but positive for both anti-HBc and anti-HBs antibodies were eligible to participate.',\n",
       "   'Subjects negative for HBsAg and anti-HBc antibody but positive for anti-HBs antibody are eligible to participate.',\n",
       "   'Subjects negative for HBsAg and anti-HBs antibody but positive for anti-HBc antibody required clarification of their status by testing for HB DNA which if positive excludes the subject from participation.',\n",
       "   'Patients with documented vaccination against hepatitis B (primary and secondary immunization and booster) are considered negative.',\n",
       "   'Receipt of any vaccination (live, attenuated or killed) in 8 wks prior to baseline.',\n",
       "   'Subjects who had received treatment with any non-marketed drug substance or experimental therapy within 4 weeks prior to screening.',\n",
       "   'Current participation in any other interventional clinical study.',\n",
       "   'Subjects known or suspected of not being able to comply with a study protocol (e.g. due to alcoholism, drug dependency or psychological disorder).',\n",
       "   'MRI is unfeasible, (e.g. due to the presence of pacemakers, hip replacements or severe claustrophobia).',\n",
       "   'Subjects with impossibility of having a radiological exploration.',\n",
       "   \"Known allergies or hypersensitivity to antibiotics, HSA, DMEM, materials of bovine origin, gadolinium (MRI contrast) and Ringer's Lactate Solution.\",\n",
       "   'Pregnancy and breastfeeding.',\n",
       "   'Any other condition which the PI judges would make patient unsuitable for study participation.']},\n",
       " {'nct_id': 'NCT01663506',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment (in accordance with the local label); this can include patients who have received RoActemra/Actemra treatment within 8 week prior to the enrolment visit'],\n",
       "  'exclusion': ['Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01664104',\n",
       "  'inclusion': ['Diagnosis of moderate to severe RA according to revised American College of Rheumatology criteria',\n",
       "   'Participants have started tocilizumab treatment according to routine clinical practice within 3 months prior to site opening and still in treatment, as well as participants who began treatment at enrollment'],\n",
       "  'exclusion': ['Participants who have started tocilizumab treatment more than 3 months prior to site opening',\n",
       "   'Participants who have previously received tocilizumab in a clinical trial setting or for compassionate use',\n",
       "   'Participants who have been enrolled in an ongoing clinical trial and/or have received treatment with any investigational drug within 4 weeks prior to study start',\n",
       "   'Participants with a history of autoimmune disease or joint inflammatory disease other than RA']},\n",
       " {'nct_id': 'NCT01661140',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active severe rheumatoid arthritis (DAS28 > 5.1) according to European League of Rheumatism (EULAR)/American College of Rheumatology (ACR) criteria',\n",
       "   'Inadequate response to a trial of 2 DMARDs, including methotrexate, a trial being defined as 6 months with 2 months at standard dose; no previous treatment with a biologic agent such as a tumor necrosis factor (TNF) inhibitor',\n",
       "   'Oral corticosteroids must have been at a stable dose of </= 10 mg/day prednisolone or equivalent for at least 25 out of 28 days prior to start of treatment (Day 1)'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Functional class IV as defined by the ACR Classification of Functional Status in RA',\n",
       "   'Prior history of or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with tocilizumab',\n",
       "   'Previous treatment with any biologic drug (e.g. TNF inhibitor) that is used in the treatment of RA',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to enrollment',\n",
       "   'Inadequate liver, bone marrow or hepatic function',\n",
       "   'Positive for hepatitis B, hepatitis C or HIV infection',\n",
       "   'Pregnant or breastfeeding women',\n",
       "   'Females of child-bearing potential who are not using reliable means of contraception',\n",
       "   'History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies',\n",
       "   'Active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections',\n",
       "   'History of, or currently active, primary or secondary immunodeficiency']},\n",
       " {'nct_id': 'NCT01668641',\n",
       "  'inclusion': ['Have active RA as shown by five or more swollen joints (from the 66-joint count), five or more tender joints (from 68-joint count), and a serum CRP ≥1.0 mg/dL;',\n",
       "   'Have received methotrexate for 12 weeks or longer and at a stable dose of 7.5 to 25 mg/week for at least 4 weeks prior to screening and willing to continue on this regimen for the duration of the study;',\n",
       "   'If taking oral steroids, these should be at a dose ≤10 mg/day of prednisone or prednisone equivalent and stable for at least 4 weeks prior to screening;',\n",
       "   'If taking non-steroidal anti-inflammatory drugs (NSAIDs), these must be at a stable dose for at least 2 weeks prior to screening;',\n",
       "   'Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year;',\n",
       "   'Women of childbearing potential must use a medically acceptable means of birth control and agree to continue its use during the study and for at least 12 weeks after the last dose of study drug.',\n",
       "   'Sexually active men must agree to use a medically acceptable form of contraception during the study and continue its use for at least 3 months after the last dose of study drug; and',\n",
       "   'Able and willing to sign the informed consent prior to screening evaluations and agree to schedule of assessments.'],\n",
       "  'exclusion': ['Treatment with disease-modifying antirheumatic drugs (DMARDs), other than background methotrexate;',\n",
       "   'Current or previous RA treatment with a biological agent, with the exception of biologics administered in a clinical study setting more than six months prior to screening (12 months for rituximab or other B cell depleting agents);',\n",
       "   'Previous treatment at any time with a cytotoxic agent, other than methotrexate, before screening;',\n",
       "   'Previous use of the study drug GLPG0634;',\n",
       "   'Receipt of an intra-articular or parenteral corticosteroid injection within 4 weeks prior to screening;',\n",
       "   'Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug as determined by the Investigator;',\n",
       "   'Positive serology for HIV1 or 2 or hepatitis B or C, or any history of hepatitis from any cause with the exception of hepatitis A;',\n",
       "   'History of any inflammatory rheumatological disorders other than RA;',\n",
       "   'History of tuberculosis (TB) infection']},\n",
       " {'nct_id': 'NCT01667458',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis, defined as DAS28 >/= 3.7',\n",
       "   'Inadequate clinical response to current treatment with >/= 2 non-biologic DMARDs, 1 of them being methotrexate optimally administered for >/= 3 months, or inadequate clinical response to anti-TNF therapy',\n",
       "   'Eligible for RoActemra/Actemra treatment in daily clinical practice',\n",
       "   'Absence of evolutive tuberculosis (TB)'],\n",
       "  'exclusion': ['Hypersensitivity to tocilizumab or any of the excipients',\n",
       "   'Active, severe infections',\n",
       "   'Pregnant or lactating women',\n",
       "   'Participation in any other interventional study',\n",
       "   'Patients with major depression']},\n",
       " {'nct_id': 'NCT01736189',\n",
       "  'inclusion': ['Disease duration of RA ≤2 years',\n",
       "   'Methotrexate (MTX) administration ≥3 months prior to starting adalimumab',\n",
       "   'Dose of MTX ≥12mg/week',\n",
       "   'Disease Activity Score 28 (DAS28)-C-reactive protein (CRP) score >3.2'],\n",
       "  'exclusion': ['Participants who had been previously treated with biologics (including tumor necrosis factor [TNF] inhibitors and others)']},\n",
       " {'nct_id': 'NCT01737944',\n",
       "  'inclusion': ['Male or female >18 years of age with diagnosed Rheumatoid Arthritis(RA).'],\n",
       "  'exclusion': ['Chronic or acute renal disease',\n",
       "   'Any other clinically significant disease or disorder which, in the opinion of the investigator, might put the subject at risk']},\n",
       " {'nct_id': 'NCT01242488',\n",
       "  'inclusion': ['Have a diagnosis of rheumatoid arthritis (according to the 1987 ACR classification criteria OR a score of ≥6 as defined by the ACR/European League Against Rheumatism Classification and Diagnostic Criteria for rheumatoid arthritis ) for at least 6 months prior to screening',\n",
       "   'Must have been treated with MTX 12.5-25 mg/week, for at least 6 weeks prior to screening. Doses of 10 to < 12.5mg/week are allowed if there is documented intolerance',\n",
       "   'Have moderately to severely active rheumatoid arthritis disease with at least 6 tender and 6 swollen joints',\n",
       "   'CRP ≥1.2 times the upper limit of normal (central laboratory) or erythrocyte sedimentation rate of more than 28mm/hour',\n",
       "   'Intolerant or inadequate response to treatment (ie, TNF blocker failure)≥1 licensed TNF-blocker therapies within 2 years of screening'],\n",
       "  'exclusion': ['Have a diagnosis of any other inflammatory arthritis or secondary, noninflammatory type of arthritis, such as psoriatic arthritis, lupus, gout, or ankylosing spondylitis',\n",
       "   'Wheelchair bound or bedridden.',\n",
       "   'Disease modifying antirheumatic drugs (DMARDs) other than MTX.',\n",
       "   'Treatment with tocilizumab or any other anti-IL-6 investigational therapies at any time.',\n",
       "   'Treatment with other biologics within 4-24 weeks (depending on the biologic)',\n",
       "   'History of ongoing, chronic or recurrent infections or recent serious or life-threatening infection',\n",
       "   'Known concurrent acute or chronic viral hepatitis B or C infection or human immunodeficiency virus (HIV) infection.',\n",
       "   'Vaccinations (other than injectable influenza or pneumococcal) within 8 weeks prior to screening or plan to receive vaccines during the study',\n",
       "   'Concurrent or history of malignancy with the exception of nonmelanoma skin cancer successfully treated more than 2 years prior to screening or cervical cancer successfully treated more than 5 years prior to screening.',\n",
       "   'History of chronic alcohol abuse or drug addiction within the last 1 year or current drug addiction or use of illicit drugs.']},\n",
       " {'nct_id': 'NCT01248780',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis for at least 6 months',\n",
       "   'Be on a stable dose of methotrexate for 4 weeks',\n",
       "   'Have at least 4 swollen and 4 tender joints'],\n",
       "  'exclusion': ['Prior exposure to biologic anti-TNFalpha agents',\n",
       "   'Inflammatory diseases other than rheumatoid arthritis',\n",
       "   'Treatment with Disease Modifying Anti-rheumatic drug (DMARDs)/systemic immunosuppressives other than methotrexate during the 4 weeks prior to the first administration of study agent',\n",
       "   'History of, or ongoing, chronic or recurrent infectious disease']},\n",
       " {'nct_id': 'NCT01247766',\n",
       "  'inclusion': ['Rheumatoid arthritis',\n",
       "   'Receipt of abatacept, other biologic disease-modifying drug, or any non- biologic disease-modifying anti-rheumatic drug',\n",
       "   'Age 18 years or older'],\n",
       "  'exclusion': ['Below 18 years of age']},\n",
       " {'nct_id': 'NCT01245452',\n",
       "  'inclusion': ['Diagnosis of RA (according to American College of Rheumatology ACR criteria)',\n",
       "   'Disease duration < 2 years.',\n",
       "   'Age between 18 and 70 years old.',\n",
       "   'Active RA defined by a disease activity score 28 DAS28-CRP score > 3.2 with a swollen joint count ≥ 4',\n",
       "   'MTX naive',\n",
       "   'Stable therapy with corticosteroids or nonsteroidal anti-inflammatory drug NSAIDs',\n",
       "   'Presence of knee arthralgia or synovitis (addendum protocol with synovial biopsy).'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01242917',\n",
       "  'inclusion': ['Male or female subjects, aged 18-75 years inclusive, with functional class I to III rheumatoid arthritis (RA) based on American College of Rheumatology (ACR) criteria for at least 3 months prior to screening; wheel-chair bound subjects or those with irreversible disease will not be eligible;',\n",
       "   'Subjects must have active RA, defined by a minimum of 8 swollen joints and 8 tender/painful joints (based on 66/68 joint count), at screening',\n",
       "   'Serum C-reactive protein (CRP) above 5 mg/L at screening;',\n",
       "   'Must have been on methotrexate (7.5 to 25 mg/week) taken orally, subcutaneously, or intramuscularly for ≥ 16 weeks and on a stable dose for ≥ 8 weeks prior to randomization;',\n",
       "   'If on hydroxychloroquine, must have been on a stable dose for ≥ 16 weeks prior to randomization;',\n",
       "   'If taking non-steroidal anti-inflammatory drugs (NSAIDs), must have been on stable doses for ≥ 2 weeks before randomization;',\n",
       "   'If taking oral corticosteroids, subjects may not take more than 10 mg/day of prednisone or equivalent, and must have been on a stable dose for ≥ 4 weeks before randomization;',\n",
       "   'Willing and able to give written Informed Consent and to comply with the requirements of the study protocol;',\n",
       "   'Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, and the hepatitis C screen;',\n",
       "   'Judged to be otherwise healthy by the Investigator, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments;',\n",
       "   'Female subjects of childbearing potential, and male subjects with partners of childbearing potential, may participate if adequate contraception is used during, and for at least the four weeks after administration of study medication'],\n",
       "  'exclusion': ['Diagnosed with RA prior to 16 years of age;',\n",
       "   'Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at screening;',\n",
       "   'History within one year prior to randomization of illicit drug use;',\n",
       "   'History of alcohol abuse at any time in the past;',\n",
       "   'Have received sulfasalazine, azathioprine, 6-mercaptopurine, mycophenolate mofetil, tetracycline, cyclosporine, gold, tacrolimus, sirolimus, or other disease modifying anti-rheumatic drug (DMARD) within 8 weeks of randomization;',\n",
       "   'Use of infliximab, adalimumab, abatacept, certolizumab, golimumab, or tocilizumab within 8 weeks of randomization;',\n",
       "   'Use of leflunomide within 6 months of randomization;',\n",
       "   'Use of etanercept or anakinra within 4 weeks of randomization;',\n",
       "   'Use of a B-cell depleting agent such as rituximab or ocrelizumab, or cytotoxic agents, such as cyclophosphamide or chlorambucil, within one year of randomization;',\n",
       "   'Currently taking cytochrome P450 inhibitors including protease inhibitors such as ritonavir, indinavir, nelfinavir, or macrolide antibiotics such as erythromycin, telithromycin, clarithromycin, or azole antifungals such as fluconazole, ketoconazole, itraconazole, or cimetidine, nefazodone, bergamottin (constituent of grapefruit juice), quercetin, aprepitant, or verapamil;',\n",
       "   'Currently taking cytochrome P450 inducers including',\n",
       "   \"John's wort, rifampicin, rifabutin, rifapentin, dexamethasone, phenytoin, carbamazapine, phenobarbitol, or troglitazone;\",\n",
       "   'Intra-articular, intravenous, or intramuscular corticosteroid injection within 4 weeks of randomization;',\n",
       "   'History or presence of any form of cancer within the 10 years prior to randomization, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis;',\n",
       "   'Evidence of tuberculosis (TB) based on chest X rays, tuberculin skin test, QuantiFERON®-TB Gold test, or T-SPOT®.',\n",
       "   \"Presence of Felty's syndrome, psoriatic arthritis, gout, or other auto-immune diseases;\",\n",
       "   'Major surgery (including joint surgery) within 12 weeks prior to randomization;',\n",
       "   'The subject had an infection requiring antibiotic treatment within 4 weeks of randomization;',\n",
       "   'Subject has any evidence of hepatic disease; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), alkaline phosphatase, or bilirubin > 1.5 x the upper limit of normal;',\n",
       "   'Subject has any evidence of renal impairment; serum creatinine > 1.5 x upper limit of normal or estimated Glomerular Filtration Rate (GFR) based on the Cockcroft-Gault equation < 30 mL/min;',\n",
       "   'History or presence of any medical or psychiatric condition or disease, or laboratory abnormality that, in the opinion of the Investigator, may place the subject at unacceptable risk for study participation and may prevent the subject from completing the study',\n",
       "   'Participated in any clinical study of an investigational product including CCX354-C within 30 days or 5 times the half life of the agent, whichever is longer, prior to randomization']},\n",
       " {'nct_id': 'NCT01245439',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis (DAS28>/=3.2) of >/=6 months duration',\n",
       "   'Body weight </=150 kg',\n",
       "   'Patients are on one or more non-biologic DMARDs at a stable dose for a period >/=8 weeks prior to study treatment',\n",
       "   'Patients with inadequate clinical response to a stable dose of non-biologic DMARD'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis, including systemic lupus erythematosus, mixed connective tissue disease, scleroderma, polymyositis, or significant systemic involvement secondary to rheumatoid arthritis',\n",
       "   'History of or current inflammatory joint disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01244958',\n",
       "  'inclusion': ['Male and female patients with rheumatoid arthritis for at least 3 months diagnosed according to the revised 1987 ACR criteria for the classification of rheumatoid arthritis.',\n",
       "   'Willingness and capability to give written informed consent, and willingness to participate and to comply with the study protocol.',\n",
       "   'Not more than 2 non-biological DMARDs other than leflunomide in history, which are washed out at least 4 weeks prior to first rituximab infusion',\n",
       "   'Previous use of anti-TNF therapy is allowed. Patient will only be allowed to be pre-treated with a maximum of two anti-TNF therapies and only one stopped due to inadequate response. The second anti-TNF could be stopped for instance due to intolerance, e.g. injection site reactions. Anti-TNF treatment must be discontinued prior to baseline considering the different characteristics of the specific compound: Use of infliximab, adalimumab, certolizumab, golimumab within 8 weeks of baseline, use of etanercept within 4 weeks of baseline.'],\n",
       "  'exclusion': ['RA functional class IV: limited in ability to perform usual self-care, work, and other activities',\n",
       "   'Male and female patients with other chronic inflammatory articular disease or systemic autoimmune disease',\n",
       "   'Any active infection, a history of recurrent clinically significant infection, a history of recurrent bacterial infections with encapsulated organisms (Hepatitis B, C and HIV (human immune deficiency virus)',\n",
       "   'will be tested at screening)',\n",
       "   'Chronic, latent and acute infections of the lung',\n",
       "   'Positive result of a Tuberculosis specific Interferon gamma release assay (will be tested at screening)',\n",
       "   'Primary or secondary immunodeficiency',\n",
       "   'History of cancer with curative treatment not longer than 5 years ago except basal-cell carcinoma of the skin that had been excised',\n",
       "   \"Evidence of significant uncontrolled concomitant diseases or serious and / or uncontrolled diseases that are likely to interfere with the evaluation of the patient's safety and of the study outcome\",\n",
       "   \"Neuropathy that can interfere with filling out the patient's questionnaires\",\n",
       "   'History of a severe psychological illness or condition',\n",
       "   'Known hypersensitivity to any component of the product or to murine proteins',\n",
       "   'Severe heart failure (New York Heart Association Class III and IV) or severe,uncontrolled cardiac disease.',\n",
       "   'Women lactating, pregnant, nursing or of childbearing potential with a positive pregnancy test or planned pregnancy.',\n",
       "   'Women of childbearing potential without adequate contraception (medically acceptable methods (pearl Index < 1) are contraceptive implant, contraceptive injection, intrauterine device (IUD), or oral contraceptives taken for at least 3 months,which the patient agrees to continue using during the study, or a double-barrier method which must consist of a combination of any of the following: diaphragma,cervical cap, condom, or spermicide)',\n",
       "   'History of alcohol, drug or chemical abuse (defined as impaired / questionable reliability) as well as neurotic personality.',\n",
       "   'Participation in another investigational study within 4 weeks prior to the screening visit.',\n",
       "   'Previous treatment with any B-cell depleting agents including rituximab',\n",
       "   'Intolerance to ingredients of rituximab or murine proteins',\n",
       "   'Pre-treatment with abatacept, tocilizumab or other anti-TNF biologicals.',\n",
       "   'Inadequate response to more than one anti-TNF-therapy',\n",
       "   'Pre-treatment of more than two anti-TNF, only one is allowed to be stopped due to inadequate response. The second anti-TNF could be stopped due to intolerance, e.g. injection site reactions',\n",
       "   'Corticosteroids at doses exceeding 10 mg per day of prednisolone or equivalents within the last 2 weeks or corticosteroids at instable doses within the last 2 weeks',\n",
       "   'Intolerance or contraindication to drugs required for the treatment of the side effects of rituximab',\n",
       "   'Previous treatment with any investigational medicinal product within last 3 months prior to baseline',\n",
       "   'Receipt of a live vaccine within 4 weeks prior to treatment',\n",
       "   'Intra- articular or parenteral corticosteroids within 4 weeks prior to screening visit',\n",
       "   'Haemoglobin < 8.5 g / dl (equivalent to < 5,28 mmol/l Haemoglobin)',\n",
       "   'Neutrophil counts < 1.500 / μl (equivalent to 1,5 / nl)',\n",
       "   'Platelet count < 75.000 / μl (equivalent to 75 / nl)',\n",
       "   'Lower than 500 / μl (equivalent to 0,5 / nl) lymphocytes',\n",
       "   'Serum creatinine > 1.4 mg / dl for women or 1.6 mg / dl for men',\n",
       "   'Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 2.5 times upper limit of normal',\n",
       "   'IgG (immunoglobulin G) level < 5g/l']},\n",
       " {'nct_id': 'NCT01641952',\n",
       "  'inclusion': ['Adult participants, >/= 18 years of age',\n",
       "   'Participants with rheumatoid arthritis, eligible for treatment with MabThera/Rituxan in accordance with summary of product characteristics (SPC)',\n",
       "   'Inadequate response to a single TNF inhibitor defined as change in disease activity score-28 erythrocyte sedimentation rate (DAS28-ESR) <1.2 or DAS28-ESR >3.5 at 5 months after first course of anti-TNF therapy',\n",
       "   'Participants with a clinical and biological evaluation performed within 12 weeks prior to enrollment may be included'],\n",
       "  'exclusion': ['More than one previous anti-TNF therapies',\n",
       "   'Any other biological therapy apart from the one anti-TNF therapy',\n",
       "   'Hypersensitivity to rituximab or any of the excipients or to murine proteins',\n",
       "   'Active severe infections',\n",
       "   'Participants in a severely immunocompromised state',\n",
       "   'Severe heart failure [New York Heart Association (NYHA) Class IV] or severe, uncontrolled cardiac disease',\n",
       "   'Women of childbearing potential not willing to use contraception',\n",
       "   'Pregnant or breastfeeding women',\n",
       "   'Participation in another trial']},\n",
       " {'nct_id': 'NCT01646385',\n",
       "  'inclusion': ['adult',\n",
       "   'rheumatoid arthritis',\n",
       "   'group 1: initiating etanercept as first biologic therapy',\n",
       "   'group 2: DAS28<4.2, biologic naive and treated with non-biologic DMARDs'],\n",
       "  'exclusion': ['diagnosis of other inflammatory arthritis']},\n",
       " {'nct_id': 'NCT01642706',\n",
       "  'inclusion': ['Age over 18 year old',\n",
       "   'Blood sample taken as part of the usual management',\n",
       "   'Steroid less than or equal to 15 mg/day and stable for at least a week For RA patients:',\n",
       "   'Patient with RA meeting the ACR / EULAR 2010 For control patients:',\n",
       "   \"Patients with systemic autoimmune disease (lupus, Sjogren's syndrome, scleroderma) or other inflammatory arthritis (spondylitis, crystals) or a mechanical pathology (limb osteoarthritis or spinal pathology) .\"],\n",
       "  'exclusion': ['steroids over 15 mg/day',\n",
       "   'rituximab infusion in less than 12 months']},\n",
       " {'nct_id': 'NCT01643863',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Patients in whom the treating physician has made the decision to commence RoActemra/Actemra treatment in monotherapy, in case of methotrexate intolerance or when continuous methotrexate treatment is inadequate (in accordance with the local label), and who have received (or started) RoActemra/Actemra monotherapy treatment within 8 weeks prior to the enrolment visit.',\n",
       "   'Concomitant corticosteroids (oral or intra-articular) or non-steroidal anti-inflammatory drugs (NSAIDs) are allowed'],\n",
       "  'exclusion': ['Patients in whom RoActemra/Actemra is contraindicated according to the approved Summary of Product Characteristics',\n",
       "   'Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Patients who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Concomitant DMARD treatment for rheumatoid arthritis (e.g. hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine) when starting treatment with RoActemra/Actemra',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01641705',\n",
       "  'inclusion': ['Volunteers with Rheumatoid Arthritis for Patients Group;',\n",
       "   'Volunteers without any respiratory disease for the control group.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01643928',\n",
       "  'inclusion': ['Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.',\n",
       "   'Participated for a minimum of 16 weeks after the initiation of the last course of treatment in a previous rheumatoid arthritis study in the rituximab-Pfizer program within the past 2 months.'],\n",
       "  'exclusion': ['Investigational site staff members or relatives of those site staff members or subjects who are Pfizer employees directly involved in the conduct of the study.',\n",
       "   'Initiated treatment with investigational agents or other biologics (including Rituxan and MabThera) since participating in a previous rheumatoid arthritis study in the rituximab-Pfizer program.']},\n",
       " {'nct_id': 'NCT01649817',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised 1987 ACR criteria at baseline',\n",
       "   'RoActemra/Actemra treatment must have been initiated 6 months prior to ICF signing',\n",
       "   'Patient eligible according to the summary of product characteristics (SPC) and routine clinical practice/European recommendations for the use of biologic DMARDs for the treatment of rheumatoid arthritis'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'Participation in interventional clinical trials during the observational period']},\n",
       " {'nct_id': 'NCT01640548',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis by a Rheumatologist',\n",
       "   'Patient being prescribed with a biologic in monotherapy'],\n",
       "  'exclusion': ['N/A']},\n",
       " {'nct_id': 'NCT01647451',\n",
       "  'inclusion': ['A diagnosis of RA meeting the 2010 ACR (American College of Rheumatology) classification criteria, obtained at least 6 months prior to dosing with the trial product. (If the diagnosis was made prior to 2010, a diagnosis meeting the 1987 ACR classification criteria is acceptable)',\n",
       "   'Active RA characterised by DAS28-CRP (disease activity score based on 28 joints and c-reactive protein) equal to or above 4.5 and at least five tender and five swollen joints (can be the same joints) of the 28 joint count',\n",
       "   'Concomitant treatment with MTX above or equal to 15 mg/week for at least 4 months prior to screening, with stable dose of between or equal to 15 mg/week and 25 mg/week for at least 6 weeks prior to screening (MTX doses between 7.5 and 12.5 mg/week are allowed, if patient had intolerance to 15 mg/week)',\n",
       "   'Biologic naïve subjects or subjects having been treated with biologics for RA (biologic experienced) provided they meet one of the following criteria:',\n",
       "   'Reason for discontinuation of biologic therapy was intolerance (e.g., unable to receive recommended doses or achieve adequate treatment duration because of drug related side effects),',\n",
       "   'Discontinued biologic therapy for other reasons than lack of efficacy (primary or secondary failure) or intolerance (e.g., drug holiday)'],\n",
       "  'exclusion': ['Body mass index (BMI) below or equal to 18.0 or above or equal to 38.0 kg/m^2',\n",
       "   \"Subjects with rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome). Subjects with secondary Sjögren's syndrome or stable hypothyroidism are eligible\",\n",
       "   'Any active or ongoing bacterial infections within 4 weeks prior to randomisation, unless treated and resolved with appropriate therapy (e.g., simple urinary tract infection)',\n",
       "   'Any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis)',\n",
       "   'History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate therapy']},\n",
       " {'nct_id': 'NCT01577563',\n",
       "  'inclusion': ['Provision of subject informed consent.',\n",
       "   'Female and/or male, aged > 21 years.',\n",
       "   'Patients diagnosis with RA (ACR 1987 or ACR/EULAR 2010 criteria), OA (ACR 1986, 1990 and 1991 criteria) or AS (New York 1984 criteria or ESSG 2002 criteria) (documented in the medical record).',\n",
       "   'Patients receiving at least one dose of NSAIDs.'],\n",
       "  'exclusion': ['Participation in any interventional study involving investigational drugs.',\n",
       "   'Patient refuses to fill in the study questionnaires.',\n",
       "   'Pregnant or breastfeeding women.',\n",
       "   'Patients with active neoplastic disease in the last 5 years, except basal-cell carcinoma.']},\n",
       " {'nct_id': 'NCT01576549',\n",
       "  'inclusion': ['Diagnosis of adult onset RA disease according to revised 1987 American Rheumatism Association (ARA) criteria and currently have a documented history of positive for rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP Ab) and have moderately to severely active RA despite ongoing methotrexate (MTX) therapy',\n",
       "   'Have active RA defined as the presence of at least 8/68 tender and at least 8/66 swollen joints, as determined by the tender joint count and swollen joint count assessment forms',\n",
       "   'Have a screening C-reactive protein (CRP) measurement greater than 1.2 times upper limit of normal or erythrocyte sedimentation rate (ESR) greater than 28 millimeters/hour (mm/hr)',\n",
       "   'Have a clinically inflamed joint suitable for synovial biopsy procedure'],\n",
       "  'exclusion': ['Have used an unstable dose of non-steroidal anti-inflammatory drugs (NSAIDs) within 6 weeks prior to baseline',\n",
       "   'Have used oral corticosteroids at average daily doses of >10 milligrams/day (mg/day) of prednisone or its equivalent within 6 weeks prior to baseline',\n",
       "   'Have received any parenteral corticosteroid injection within 6 weeks of baseline',\n",
       "   'Have used other disease-modifying anti-rheumatic drugs (DMARDs) other than MTX, hydroxychloroquine, and/or sulfasalazine in the 8 weeks prior to baseline']},\n",
       " {'nct_id': 'NCT01578850',\n",
       "  'inclusion': ['Subject has a minimum 1 year history/diagnosis of rheumatoid arthritis based on the 1987 American College of Rheumatology (ACR) Revised criteria for',\n",
       "   '2. Subject must have active rheumatoid arthritis despite methotrexate (MTX) therapy of ≥10 mg/wk for at least 12 weeks. The MTX dose must be stable for at least 4 weeks immediately prior to screening.'],\n",
       "  'exclusion': ['Subjects who used any of the following systemic treatments during the washout periods given below:',\n",
       "   'Oral corticosteroid dose of prednisone >7.5 mg/day (or equivalent) or a change in dose within 28 days of baseline.',\n",
       "   'Treatment with more than 1 NSAID within 14 days at baseline.',\n",
       "   'Methotrexate dose greater than 25 mg/week, or change in the dose of methotrexate within 28 days of baseline.',\n",
       "   'Subjects will be allowed to continue the following non biologic DMARDs: sulfasalazine, hydroxychloroquine, and leflumomide. All other non-biologic DMARDs (including but not limited to gold, penicillamine, azathioprine, cyclophospamide), and biologic DMARDs must have been discontinued at least 2 months prior to Week',\n",
       "   '5. Any biologic B cell depleting agent (eg, rituximab) within 2 years of Week',\n",
       "   '2. Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.',\n",
       "   'Receipt of any live (attenuated) vaccine within 4 weeks prior to baseline.']},\n",
       " {'nct_id': 'NCT01579006',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   'Inadequate response (or intolerant) to non-biological DMARDs or one biologic agent',\n",
       "   \"Patients initiating treatment with RoActemra/Actemra on their physician's decision (in accordance with the local label), including patients who started treatment with RoActemra/Actemra in the 8 weeks prior to the enrolment visit\"],\n",
       "  'exclusion': ['RoActemra/Actemra treatment more than 8 weeks prior to the enrolment visit',\n",
       "   'Previous RoActemra/Actemra treatment in a clinical trial or for compassionate use',\n",
       "   'Enrolled in an ongoing clinical trial and/or treatment with any investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'History of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01700543',\n",
       "  'inclusion': ['Patient is 18 to 80 years of age, inclusive.',\n",
       "   'The patient is skeletally mature.',\n",
       "   'Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history.',\n",
       "   'Patient has failed conservative treatment.',\n",
       "   'Patient meets at least one of the following indications: Osteoarthritis, Posttraumatic arthrosis, Rheumatoid arthritis without humeral metaphyseal defects, Focal avascular necrosis of the humeral head, Previous surgeries of the shoulder that do no compromise the fixation.',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy.',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.',\n",
       "   'Patient has participated in the Informed Consent process and has signed the Ethics Committee approved \"Informed Consent\".'],\n",
       "  'exclusion': ['Patient is unwilling or unable to give consent or to comply with the follow-up program.',\n",
       "   'Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is an known drug abuser, a known alcoholic or anyone who cannot understand what is required of them.',\n",
       "   'Patient is known to be pregnant or breastfeeding.',\n",
       "   \"Patient meets at least one of the contraindications: Soft or inadequate humeral bone (including osteoporosis and extensive avascular necrosis or rheumatoid arthritis) leading to poor implant fixation, Metaphyseal bony defect (including large cysts), Posttraumatic tuberosity non-union, Signs of infection, Irreparable cuff tear, Revision from a failed stemmed prosthesis, Charcot's shoulder (neuroarthropathy)\"]},\n",
       " {'nct_id': 'NCT01700881',\n",
       "  'inclusion': ['the confirmed presence of synovitis in at least 1 joint',\n",
       "   'absence of an alternative diagnosis that better explains the synovitis',\n",
       "   'and achievement of a total score of 6 or greater (of a possible 10): 24 Joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through third metatarsophalangeal joint and wrist as small joints, and elbows, hip joints and knees as large joints:',\n",
       "   'Involvement of 1 large joint gives 0 points',\n",
       "   'Involvement of 2-10 large joints gives 1 point',\n",
       "   'Involvement of 1-3 small joints (with or without involvement of large joints) gives 2 points',\n",
       "   'Involvement of 4-10 small joints (with or without involvement of large joints) gives 3 points',\n",
       "   'Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points',\n",
       "   'Serological parameters',\n",
       "   'including the rheumatoid factor as well as anti-citrullinated protein antibody (ACPA):',\n",
       "   'Negative RF and negative ACPA gives 0 points',\n",
       "   'Low-positive RF or low-positive ACPA gives 2 points',\n",
       "   'High-positive RF or high-positive ACPA gives 3 points Acute phase reactants: 1 point for elevated erythrocyte sedimentation rate (ESR) or elevated C-reactive protein (CRP) value Duration of arthritis: 1 point for symptoms lasting six weeks or longer',\n",
       "   'Continuing or recurring pain (i.e., joint pain daily, unless on pain medication).',\n",
       "   'Age at least 18 years',\n",
       "   'Ability and willingness to participate in all components of the study',\n",
       "   'Willingness to be assigned to either the diet group or supplement group',\n",
       "   'Pain medications unchanged within last 6 weeks.'],\n",
       "  'exclusion': ['< 18 years of age',\n",
       "   'Rheumatoid arthritis for more than 6 years',\n",
       "   'Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use',\n",
       "   'Use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion)',\n",
       "   'Pregnancy',\n",
       "   'Unstable medical or psychiatric illness',\n",
       "   'Likely to be disruptive in group sessions (as determined by research staff)',\n",
       "   'Already following a low-fat, vegan diet',\n",
       "   'Lack of English fluency',\n",
       "   'Inability to maintain current medication regimen',\n",
       "   'Inability or unwillingness to participate in all components of the study']},\n",
       " {'nct_id': 'NCT01706029',\n",
       "  'inclusion': ['Adults with RA treated with DMARDs and/or biotherapy,',\n",
       "   'Capable of providing written consent'],\n",
       "  'exclusion': ['Patients affected by a painful disease other one than RA,',\n",
       "   'Fibromyalgia,',\n",
       "   'A malignancy disease,',\n",
       "   'An hemopathy,',\n",
       "   'Psychiatric disorders or dementia and',\n",
       "   'Acute infectious diseases and',\n",
       "   'Receive or had received anti-IL6 therapy']},\n",
       " {'nct_id': 'NCT01707186',\n",
       "  'inclusion': ['Participant is willing and able to give informed consent for participation in the study.',\n",
       "   'Male or Female, aged 18 years or above.',\n",
       "   'Written confirmed diagnosed of rheumatoid arthritis'],\n",
       "  'exclusion': ['A diagnosis of any of the following:',\n",
       "   'Multiple sclerosis',\n",
       "   'Motor neurone disease',\n",
       "   \"Parkinson's disease\",\n",
       "   \"Alzheimer's disease\",\n",
       "   'Depression or anxiety disorders as identified using the Patient depression screening questions from the patient health questionnaire 9 (PHQ9).']},\n",
       " {'nct_id': 'NCT01706926',\n",
       "  'inclusion': ['A diagnosis of adult onset Rheumatoid Arthritis (RA) in line with the protocol',\n",
       "   'Moderately active disease in line with the protocol',\n",
       "   'A pre-defined number of swollen joints in line with the protocol',\n",
       "   'Inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'No evidence of respiratory disease.'],\n",
       "  'exclusion': ['A rheumatic autoimmune disease other than RA, or significant systemic extra-articular involvement secondary to RA',\n",
       "   'A history of, or current, inflammatory joint disease other than RA',\n",
       "   'Previous treatment with the investigational drug',\n",
       "   'Discontinuation of a biologic DMARD due to lack of efficacy',\n",
       "   'Non-compliant concurrent medications',\n",
       "   'Non-compliance with medical history criteria.']},\n",
       " {'nct_id': 'NCT01706874',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis according to EULAR criteria / ACR 2010 under 10 years of evolution',\n",
       "   'Patients included in the ESPOIR cohort',\n",
       "   'Patients with DAS28 > 3.2',\n",
       "   'Anti-CCP positive and negative',\n",
       "   'Age: 18 years old to 80 years',\n",
       "   'Affiliated to social security'],\n",
       "  'exclusion': ['Refusal to participate in the study',\n",
       "   'DAS28 < 3.2',\n",
       "   'Patient under guardianship',\n",
       "   'Participation in another protocol without agreement of the dentist',\n",
       "   'Not affiliated to social security']},\n",
       " {'nct_id': 'NCT01709578',\n",
       "  'inclusion': ['TNF-blockers included, but were not limited to, etanercept, infliximab, adalimumab, golimumab and/or certolizumab Moderate-to-severely active RA Continuous treatment with one or a combination of DMARDs (except for simultaneous combination use of leflunomide and methotrexate) for at least 12 weeks prior to baseline and on a stable dose(s) for at least 6 weeks prior to screening:',\n",
       "   'Methotrexate',\n",
       "   '6 to 25 mg/week orally or parenterally',\n",
       "   'Leflunomide',\n",
       "   '10 to 20 mg orally daily',\n",
       "   'Sulfasalazine',\n",
       "   '1000 to 3000 mg orally daily',\n",
       "   'Hydroxychloroquine',\n",
       "   '200 to 400 mg orally daily'],\n",
       "  'exclusion': ['Within 28 days prior to the baseline visit',\n",
       "   'etanercept',\n",
       "   'Within 42 days prior to the baseline visit',\n",
       "   'infliximab, adalimumab, golimumab, certolizumab pegol Treatment with previous RA-directed biologic agents with other than TNF antagonist mechanisms: Within 28 days prior to the randomization (baseline) visit',\n",
       "   'anakinra Within 42 days prior to the randomization (baseline) visit',\n",
       "   'abatacept Within 6 months prior to the randomization (baseline) visit',\n",
       "   \"any cell depleting agents including but not limited to rituximab without a normal lymphocyte and cluster of differentiation (CD) 19+ lymphocyte count Treatment with any DMARD other than those allowed per protocol and limited to the maximum specified dosage within 12 weeks prior to baseline Treatment with prednisone >10 mg or equivalent per day, or change in dosage within 4 weeks prior to baseline visit Any parenteral or intra-articular glucocorticoid injection within 4 weeks prior to baseline Prior treatment with anti-interleukin (IL) -6 or IL-6 receptor antagonist therapies, including tocilizumab or sarilumab, participation in a prior study of sarilumab, irrespective of treatment arm Prior treatment with a Janus kinase inhibitor (such as tofacitinib) New treatment or dose-adjustment to ongoing medication for dyslipidemia within 6 weeks prior to randomization, ie, stable dose for at least 6 weeks prior to randomization Participation in any clinical research study evaluating another investigational drug or therapy within 5 half-lives or 60 days of first investigational medicinal product (IMP) administration, whichever was longer History of alcohol or drug abuse within 5 years prior to the screening visit Participants with a history of malignancy other than adequately-treated carcinoma in-situ of the cervix, nonmetastatic squamous cell or basal cell carcinoma of the skin, within 5 years prior to the randomization (baseline) visit. Nonmalignant lymphoproliferative disorders were also excluded Participants with active tuberculosis or latent tuberculosis infection The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial\"]},\n",
       " {'nct_id': 'NCT01709760',\n",
       "  'inclusion': ['Male or female patients aged ≥ 20 years old;',\n",
       "   'Patient meet ACR criteria for rheumatoid arthritis over 6 month duration;',\n",
       "   'Patient with active disease at the time of screening as defined by six or more swollen joints and six or more tender joints;',\n",
       "   'Presence of at least one of the following criteria:',\n",
       "   'Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/h,',\n",
       "   'C-Reactive Protein (CRP) ≥ 10 mg/L,',\n",
       "   'RA functional class I, II, or III;',\n",
       "   'Patients have been treated on methotrexate for at least 3 month, and maintained at stable dose of 15-25 mg/week for at least 8 weeks; MTX low dose as 10 mg per week is allowed for patients who had a documented history of constitutional symptoms at higher doses.',\n",
       "   'Patient is willing and able to comply with study procedures and sign informed consent.'],\n",
       "  'exclusion': ['Active autoimmune disease (other than RA) requiring immunosuppressive therapy;',\n",
       "   'In the opinion of the investigator, the patient shows persistent signs of immunosuppression;',\n",
       "   'Known hypersensitivity to etanercept or ENIA11 or any of its components;',\n",
       "   'Previous unsuccessful treatment with etanercept, anti-TNF monoclonal antibodies or a soluble TNF receptor (e.g., infliximab);',\n",
       "   'Suspected or diagnosed pulmonary tuberculosis, or other chronic or current infectious disease at discretion of investigator;',\n",
       "   'Patients who have a history or evidence of a medical condition that would expose them to an undue risk of a significant adverse event during the course of the trial, including but not limited to hepatic, renal, respiratory, cardiovascular, endocrine, immune, neurological, hematological, gastrointestinal or psychiatric disease as determined by the clinical judgment of the investigator;',\n",
       "   'Patients with any of the following laboratory abnormalities: ALT/AST > 3 times ULN, creatinine > 2 mg/dl, WBC < 3,000/mm3, Hgb < 8.5 g/dL, platelet count < 100,000/mm3;',\n",
       "   'Patients have received live attenuated vaccination program within 3 months or BCG vaccine within 12 months prior enrollment;',\n",
       "   'Female patient of childbearing potential who:',\n",
       "   'is lactating; or',\n",
       "   'has positive urine pregnancy test at Visit 1; or',\n",
       "   'refuse to adopt reliable method of contraception during the study;',\n",
       "   'Diagnosis of primary fibromyalgia or other joint inflammatory disease including but not limited to gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease;',\n",
       "   'Known or suspected positive serology for human immunodeficiency, hepatitis B or C virus;',\n",
       "   'Patient has received any investigational agent within 28 days or 5 half-lives, whichever is longer, prior to the first dose of investigational product;',\n",
       "   'Patient has history of substance abuse, drug addiction or alcoholism;',\n",
       "   'Patient who have had participated in prior phase I/II clinical trial.']},\n",
       " {'nct_id': 'NCT01705730',\n",
       "  'inclusion': ['Adult participants, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria',\n",
       "   'Participants in whom the treating physician has made the decision to commence RoActemra/Actemra treatment in monotherapy in accordance with the local label and the reimbursement criteria indicating that RoActemra/Actemra can be given in monotherapy in case of methotrexate intolerance or where continued treatment with methotrexate is inappropriate; this can include participants who have received RoActemra/Actemra treatment within 8 weeks prior to the enrolment visit',\n",
       "   'Concomitant treatment with NSAIDs and/or corticosteroids is allowed'],\n",
       "  'exclusion': ['Participants who have received RoActemra/Actemra more than 8 weeks prior to the enrolment visit',\n",
       "   'Participants who have previously received RoActemra/Actemra in a clinical trial or for compassionate use',\n",
       "   'Participants receiving concomitant DMARD treatment for rheumatoid arthritis at baseline (e.g. hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds, cyclosporine) will be excluded from the study',\n",
       "   'Participants who have received treatment with an investigational agent within 4 weeks (or 5 half-lives of the investigational agent, whichever is longer) before starting treatment with RoActemra/Actemra',\n",
       "   'Participants with a history of autoimmune disease or any joint inflammatory disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01126541',\n",
       "  'inclusion': ['Adult patients >18 years of age',\n",
       "   'RA for >=6 months',\n",
       "   'Receiving outpatient treatment',\n",
       "   'Ongoing treatment with methotrexate for >=3 months, stable for >=1 month',\n",
       "   'Inadequate response or intolerance to etanercept, infliximab or adalimumab'],\n",
       "  'exclusion': ['Previous treatment with MabThera',\n",
       "   'Concurrent treatment with any anti TNF-alfa therapy or biologic therapy',\n",
       "   'Previous treatment with any investigational cell-depleting therapies']},\n",
       " {'nct_id': 'NCT01120366',\n",
       "  'inclusion': ['Diagnosed with RA in accordance with the 1987 classification criteria of ACR',\n",
       "   'Aged 20 to 75 years inclusive at enrolment (within 2 weeks before starting treatment with the investigational drug)',\n",
       "   'Treated with MTX at ≥6 mg/week for at least 8 weeks immediately before enrolment',\n",
       "   'Rheumatoid arthritis of duration ≤10 years',\n",
       "   'DAS28-ESR ≥3.2 (within 2 weeks before starting treatment with the investigational drug)',\n",
       "   'Having received and thoroughly understood an adequate explanation about participation in the study, patients who have personally and voluntarily provided written informed consent Major'],\n",
       "  'exclusion': ['Patients who were Steinbrocker Class',\n",
       "   '- Patients who received leflunomide within 12 weeks, DMARDs other than MTX within 8 weeks , or tacrolimus within 4 weeks before the 1st TCZ infusion.',\n",
       "   'Patients who previously received biologic DMARDs including TCZ.']},\n",
       " {'nct_id': 'NCT01123655',\n",
       "  'inclusion': ['Male or female; age > 18 years.',\n",
       "   'American College of Rheumatology (ACR) 1988 revised criteria for rheumatoid arthritis.',\n",
       "   'Onset of disease age 16 or older.',\n",
       "   'Onset of disease at least 3 months prior to enrollment.',\n",
       "   'RA patients ages 18-85 with RA of 3 month duration which in the opinion of the examining rheumatologist is \"clinically stable\" and will likely not require adjustment of doses of Disease-modifying antirheumatic drugs (DMARDS), NSAIDS, prednisone, anti-tumor necrosis factor (anti-TNF) alpha therapies for the 16 weeks of the treatment phase of the study.',\n",
       "   'Patients must agree to discontinue all \"herbal remedies\" as described in this protocol.',\n",
       "   'Women of childbearing age will be advised to use effective means of contraception for the treatment phase of the trial and for 90 days thereafter. They must have a negative urine pregnancy test at the randomization visit. (Required by the FDA.)',\n",
       "   'Men will be advised to use effective means of contraception for the treatment phase of the trial and for 90 days thereafter. (Required by the FDA.)',\n",
       "   \"Crohn's Disease Activity Index (CDAI) less than or equal to 30 at the baseline visit.\",\n",
       "   'Patients with a past history of malignant neoplasm will be eligible if they are 1 or greater years with no recurrence of malignant neoplasm.'],\n",
       "  'exclusion': ['Inability to render an informed consent in accordance with institutional guidelines.',\n",
       "   'Participation in another clinical research study involving the evaluation of another investigational drug within 90 days of entry into this study.',\n",
       "   'RA patients on >7.5 mg prednisone a day.',\n",
       "   'RA patients with intra-articular corticosteroid injections during the previous 30 days.',\n",
       "   'Concurrent serious medical condition which in the opinion of the investigator makes the patient inappropriate for the study. Hepatitis B abd/or C patients with inactive disease (as determined by PI) will be enrolled.',\n",
       "   'Positive urine pregnancy test',\n",
       "   'Age 85 years or greater.',\n",
       "   'Use of \"fish oil\" within the previous 4 weeks of the baseline visit.',\n",
       "   'Therapy consisting of auranofin or cyclophosphamide (all other DMARDs are allowed).',\n",
       "   'Previous autologous or heterologous stem cell transplantation.',\n",
       "   'Active malignant neoplasm or past treatment for malignant neoplasm 1 year from screening visit.',\n",
       "   'Use of oral CII within the past 1 year. (Since oral tolerance is short-lived, we will permit patients in the study who have been off oral CII for > 1 year)',\n",
       "   'Diabetes requiring insulin or on oral medications must be well managed at baseline. Adjustment of insulin or on oral medications will be allowed during the study.',\n",
       "   'Serum creatinine 2.0 mcg/dL.',\n",
       "   'An 1(II) IFN value <100% of the PBS IFN value within 1 month or less prior to the baseline and less than 25% reduction in APL A12 + 1(II) IFN from 1(II) IFN concentration.',\n",
       "   'CDAI > 30 at the baseline visit.']},\n",
       " {'nct_id': 'NCT01123070',\n",
       "  'inclusion': ['Adult subjects',\n",
       "   'Rheumatoid arthritis as defined by the 1987 ACR Classification',\n",
       "   'Severe active seropositive disease',\n",
       "   'Inadequate response or intolerance to other DMARDs',\n",
       "   'Treatment with MTX'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'Active infection',\n",
       "   'Known immunodeficiency syndrome',\n",
       "   'Positive Hepatitis B surface antigen or antibodies to Hepatitis C',\n",
       "   'History of cancer']},\n",
       " {'nct_id': 'NCT01223911',\n",
       "  'inclusion': ['CZ: Age between 18 and 65 years (both inclusive)',\n",
       "   'A diagnosis of rheumatoid arthritis of at least three months before entry in trial',\n",
       "   'Active rheumatoid arthritis (RA)',\n",
       "   'Subjects are on stable doses of methotrexate (up to and including 25 mg/week) for at least 4 weeks before trial drug administration'],\n",
       "  'exclusion': ['Known or suspected allergy to trial product or related products',\n",
       "   'Body mass index (BMI) less than 18.0 or more than 38.0 kg/m2 (inclusive)']},\n",
       " {'nct_id': 'NCT01225393',\n",
       "  'inclusion': ['Diagnosis of RA according to the 1987 revised ACR Criteria for the Classification of RA for at least 6 months prior to screening',\n",
       "   'Positive for rheumatoid factor or anti-cyclic citrullinated peptide (CCP) antibody, or both',\n",
       "   'Active disease, defined as: CRP >= 1.0 mg/dL; swollen joint count >= 6 (66 joint count); tender joint count >= 6 (68 joint count)',\n",
       "   'Previous inadequate clinical response to at least one disease-modifying anti-rheumatic drug (DMARD) consisting of either methotrexate (MTX) or leflunomide (LFU)',\n",
       "   'For patients currently receiving corticosteroids: Treatment at a stable dose during last 4 weeks prior to screening',\n",
       "   'For patients currently receiving non-steroidal anti-inflammatory drugs (NSAIDs): Treatment at a stable dose during last 4 weeks prior to screening',\n",
       "   'For patients currently receiving sulfasalazine or anti-malarials: Treatment initiated and continued for at least the last 6 months prior to screening and on a stable dose',\n",
       "   'For patients of reproductive potential (males and females): Willing to use a highly effective birth control method for the duration of the study according to local guidelines'],\n",
       "  'exclusion': ['Pregnant, planning to become pregnant during the study, or breastfeeding',\n",
       "   'Clinically significant abnormal laboratory values or abnormal ECG or vital signs',\n",
       "   'History of anaphylactic reactions',\n",
       "   \"Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome), however patients with secondary Sjogren's syndrome are eligible for the study\",\n",
       "   'History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthritis, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or other overlap syndrome)',\n",
       "   'Current or recent (within 4 weeks prior to screening) infection, including signs, symptoms or serology of any infection, including HIV, hepatitis B or C, tuberculosis',\n",
       "   'Administration of a live, attenuated vaccine within 1 month before dosing or anticipation that such a live attenuated vaccine will be required during the study',\n",
       "   'Previous treatment with anti-TNF biologics or other biologic agents, including anti-CD20-directed therapy (e.g. rituximab), anti-IL6-directed therapy (e.g. tocilizumab), or T cell-directed therapy (e.g. abatacept)']},\n",
       " {'nct_id': 'NCT01224041',\n",
       "  'inclusion': ['Patients with more than 6 months history of rheumatoid arthritis according to ACR criteria',\n",
       "   'Patients who have been treated unsuccessfully to more than single DMARDs including methotrexate at the discretion of investigator',\n",
       "   'ESR ≥ 30 mm/h or CRP ≥ 1.0 mg/dL (ESR: Erythrocyte Sedimentation Rate, CRP: C-Reactive Protein)',\n",
       "   'Patients are required to have at least 3 of 66 joints assessed as swollen',\n",
       "   'Patients are required to have at least 6 of 68 joints assessed as painful with pressure'],\n",
       "  'exclusion': ['Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed during the study and within 6 month after completion of study',\n",
       "   'Previous experience of tacrolimus (ointment excluded)',\n",
       "   'Renal impairment or serum creatinine > 1.4 mg/dL',\n",
       "   'Liver function failure as follows: viral hepatitis, non-viral hepatitis, cirrhosis, SGOT/SGPT > 2x upper limit normal',\n",
       "   'Patients with history of pancreatitis, glucose intolerance or complication or who indicates any of the following criteria:Blood glucose level >110mg/dl before the meal and >200mg/dl after the meal HbA1c > 6.4%',\n",
       "   'Cardiac disease(ischemic heart disease, treatment-requiring arrhythmia, heart failure)or complications',\n",
       "   'Other investigational drug within last 30 days',\n",
       "   'Patients who have been treated with infliximab, adalimumab, or leflunomide within 8 weeks of start of the study']},\n",
       " {'nct_id': 'NCT01228812',\n",
       "  'inclusion': ['Rheumatoid arthritis',\n",
       "   'Functional classes I, II and III',\n",
       "   'Age 40 to 80 years',\n",
       "   'Stable disease activity',\n",
       "   'Stable DMARDS last 3 months'],\n",
       "  'exclusion': ['Functional classes IV', 'Inflammatory flare']},\n",
       " {'nct_id': 'NCT01224418',\n",
       "  'inclusion': ['Patients with more than 6 months history of rheumatoid arthritis according to ACR criteria',\n",
       "   'Patients who have been treated unsuccessfully to more than single DMARDs including methotrexate at the discretion of investigator',\n",
       "   'ESR ≥ 30 mm/h or CRP ≥ 1.0 mg/dL (ESR: Erythrocyte Sedimentation Rate, CRP: C-Reactive Protein)',\n",
       "   'Patients are required to have at least 3 of 66 joints assessed as swollen',\n",
       "   'Patients are required to have at least 6 of 68 joints assessed as painful with pressure'],\n",
       "  'exclusion': ['Pregnant or breast-feeding patients. Patients who plan to bear children or breast-feed during the study and within 6 month after completion of study',\n",
       "   'Previous experience of tacrolimus (ointment excluded)',\n",
       "   'Renal impairment or serum creatinine > 1.4 mg/dL',\n",
       "   'Liver function failure as follows: viral hepatitis, non-viral hepatitis, cirrhosis, SGOT/SGPT > 2x upper limit normal',\n",
       "   'Patients with history of pancreatitis, glucose intolerance or complication or who indicates any of the following criteria:Blood glucose level >110mg/dl before the meal and >200mg/dl after the meal HbA1c > 6.4%',\n",
       "   'Cardiac disease(ischemic heart disease, treatment-requiring arrhythmia, heart failure)or complications',\n",
       "   'Other investigational drug within last 30 days',\n",
       "   'Patients who have been treated with infliximab, adalimumab, or leflunomide within 8 weeks of start of the study']},\n",
       " {'nct_id': 'NCT01626573',\n",
       "  'inclusion': ['Subjects with active RA aged 18 to 75 years of age and meet tender and swollen joint assessment expectations defined in the study protocol.',\n",
       "   'c-Reactive protein (CRP) or erythrocyte sedimentation rate (ESR) laboratory values meet minimal study protocol expectations.'],\n",
       "  'exclusion': ['Females who are pregnant or breastfeeding.',\n",
       "   'Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively.',\n",
       "   'Subjects treated with a biologic agent within 12 weeks prior to first dose of study drug. (12 months in the case of rituximab.)',\n",
       "   'Subjects with a history or currently suspected inflammatory disease other than',\n",
       "   '- Subjects with a history of hematological disorders.']},\n",
       " {'nct_id': 'NCT01623752',\n",
       "  'inclusion': [\"Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before subjects are included in the study.\",\n",
       "   'Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study is a requirement for inclusion into this study. Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:',\n",
       "   'Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.',\n",
       "   'Definitive diagnosis of RA or PsA.',\n",
       "   'Eligible for Etanercept treatment according to Summary of Product Characteristics (SmPC).',\n",
       "   'Inclusion of subjects pretreated with other biologics other than Etanercept is possible',\n",
       "   'One plain radiograph of hands and feet (Anteroposterior) within 3 month prior to initiation of treatment with Etanercept and one planned consecutive radiograph of hand and feet taken over 12 to 18 months according to German recommendations for patients treated with biologics. Exclusion Criteria:',\n",
       "   'Receipt of any investigational drug within 3 months of study inclusion.',\n",
       "   ''],\n",
       "  'exclusion': ['Hypersensitivity to the active substance (etanercept) or to any of the excipients.',\n",
       "   'Sepsis or risk of sepsis.',\n",
       "   'Active infections, including chronic or localised infections.',\n",
       "   'Subjects who have received any previous treatment with etanercept',\n",
       "   'Subjects who are investigational site staff members or subjects who are Pfizer employees directly involved in the conduct of the trial.']},\n",
       " {'nct_id': 'NCT01625650',\n",
       "  'inclusion': ['The CORRONA CERTAIN Sub-study is particularly focused on understanding the effectiveness and safety of biologic medications. Male and female patients, who',\n",
       "   'are at least 18 years of age;',\n",
       "   'have a documented diagnosis of RA by their treating rheumatologist;',\n",
       "   'have at least moderate disease activity; and',\n",
       "   'are initiating a biologic agent that has not be used for their treatment in the past are eligible to participate. Moderate disease activity is defined by a CDAI score greater than',\n",
       "   ''],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01076205',\n",
       "  'inclusion': ['Moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs',\n",
       "   'Inclusive methotrexate',\n",
       "   'Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before; In case of incompatibility with methotrexate, Humira can be used as monotherapy.'],\n",
       "  'exclusion': ['Hypersensitivity against the drug or one of the other ingredients',\n",
       "   'Active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections)',\n",
       "   'Moderate to severe cardiac insufficiency']},\n",
       " {'nct_id': 'NCT01078402',\n",
       "  'inclusion': ['Adult patients with active RA, PsA or AS for whom Humira therapy is indicated according to the local product label and who meet the following criteria:',\n",
       "   'Are newly prescribed Humira therapy (no prior history of treatment with Humira), including patients with infliximab or etanercept treatment history OR',\n",
       "   'Completed Abbott sponsored interventional clinical trials and are continuing treatment with commercial Humira thereafter.'],\n",
       "  'exclusion': ['Patients who are being treated or will be treated with drugs at risk of interactions with Humira (see Humira Summary of Product Characteristics)',\n",
       "   'Patients currently participating in another clinical trial',\n",
       "   'Patients with diagnosis of active tuberculosis']},\n",
       " {'nct_id': 'NCT01078090',\n",
       "  'inclusion': ['Moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs, including methotrexate.',\n",
       "   'Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before.',\n",
       "   'In case of incompatibility with methotrexate, adalimumab can be used as monotherapy'],\n",
       "  'exclusion': ['Hypersensitivity against the drug or one of the other ingredients; active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections); moderate to severe cardiac insufficiency']},\n",
       " {'nct_id': 'NCT01071863',\n",
       "  'inclusion': ['Male and female subjects',\n",
       "   'Subjects with a clinical diagnosis of Rheumatoid Arthritis who have been referred for a biologic treatment',\n",
       "   'Subjects who are willing to complete the questionnaires and wear the Numact activity monitor',\n",
       "   'Written informed consent Inclusion criteria Control group:',\n",
       "   'Male and female subjects',\n",
       "   'Age and sex matched to RA population (any appropriate sibling will be invited possibly siblings)',\n",
       "   'Subjects who are willing to complete the questionnaires and wear the Numact activity monitor',\n",
       "   'Written informed consent Exclusion criteria RA Population:',\n",
       "   'Diagnosis or evidence of any other physically limiting condition',\n",
       "   'Subjects who have received an intramuscular steroid injection within 2 months of study entry or in whom such treatment is planned within the study period',\n",
       "   'Subjects scheduled for elective surgery of the disease site or any other elective major surgery which would fall within the study period',\n",
       "   \"Subjects who currently abuse alcohol or drugs, or have a recent history of alcohol or drug abuse, or who in the Investigator's opinion, have previously demonstrated drug-seeking behavior\",\n",
       "   'Subjects who are currently participating in another clinical research study involving a new chemical entity or who have participated in a clinical study within the previous 30 days',\n",
       "   'Subjects who the Investigator believes are unsuitable for the study'],\n",
       "  'exclusion': ['Diagnosis or evidence of any physically limiting condition',\n",
       "   \"Subjects who currently abuse alcohol or drugs, or have a recent history of alcohol or drug abuse, or who in the Investigator's opinion, have previously demonstrated drug-seeking behavior\",\n",
       "   'Subjects who the Investigator believes are unsuitable for the study']},\n",
       " {'nct_id': 'NCT01078116',\n",
       "  'inclusion': ['Patients with moderate or severe active rheumatoid arthritis, who have been prescribed and are receiving adalimumab under normal clinical practice for at least one month and according to the approved Summary of Product Characteristics (SmPC) in the European Union.',\n",
       "   'Patients must be willing to consent to data being collected and provided to Abbott Laboratories.'],\n",
       "  'exclusion': ['Contraindications according to the SmPC',\n",
       "   'Patients should not participate in other observational Abbott study']},\n",
       " {'nct_id': 'NCT01078155',\n",
       "  'inclusion': ['Patients with active early and long-standing RA according to American College of Rheumatology (ACR) 1987 revised criteria.',\n",
       "   'Patients with high disease activity DAS28 ≥ 5.1 according to the Czech Rheumatological Society criteria.',\n",
       "   'Patients must fulfill national guidelines for use of anti-TNF: inadequate clinical response to at least one disease-modifying antirheumatic drug (DMARD; methotrexate, sulphasalazine, leflunomide, hydroxychloroquine, or combinations) and oral glucocorticoids (equivalent to ≥ 5 mg prednisolone per day), (for Romania except glucocorticoids); chest X-ray, purified protein derivative (PPD)-skin test, Quantiferon/tuberculosis (TB) Gold test (if available) negative for',\n",
       "   ''],\n",
       "  'exclusion': ['Patients who have had a history of TNF blocking or rituximab therapy.',\n",
       "   'Patients who are being treated or will be treated with drug at risk of interaction with adalimumab (Humira).',\n",
       "   'Pregnant females and/or females without adequate method of contraception.',\n",
       "   \"Patients who didn't receive prior DMARD therapy.\",\n",
       "   'Patients participating in another study or clinical trial.',\n",
       "   'Patients with severe osteoporosis (T-score [number that indicates whether or not bone loss has occurred] of ≤ -2.5 and/or prior vertebral fracture/s).',\n",
       "   'Patients with a history of total hip replacement of both extremities.',\n",
       "   'Patients who currently receive and/or received bone metabolism modulating agents including Selective Estrogen Receptor Modulators (SERMs), bisphosphonates, parathyroid hormone or anti-receptor activator of nuclear factor-kappaB ligand (RANKL) therapy.',\n",
       "   'Subjects who are not eligible for TNF-blocking therapy according to the Czech National Registry (ATTRA).']},\n",
       " {'nct_id': 'NCT01077258',\n",
       "  'inclusion': ['Moderate to severe active rheumatoid arthritis in adults with insufficient response to disease-modifying antirheumatic drugs, including methotrexate',\n",
       "   'Moderate to severe active rheumatoid arthritis in adults who have not been treated with methotrexate before. In case of incompatibility with methotrexate, Humira can be used as monotherapy'],\n",
       "  'exclusion': ['Hypersensitivity against the drug or one of the other ingredients',\n",
       "   'Active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections)',\n",
       "   'Moderate to severe cardiac insufficiency']},\n",
       " {'nct_id': 'NCT01071798',\n",
       "  'inclusion': ['No pretreatment with rituximab',\n",
       "   'Age 18 years or older',\n",
       "   'Patients with active, severe rheumatoid arthritis with prescription of rituximab according to German Summary of Product Characteristics (SmPC',\n",
       "   '\"Fachinformation\")',\n",
       "   'Patients with signed informed consent',\n",
       "   'Female patients with secure contraception'],\n",
       "  'exclusion': ['Violation of Selection criteria:',\n",
       "   'Active severe infection',\n",
       "   'Severe heart failure (NYHA class IV) or severe, uncontrollable heart disease',\n",
       "   'Participation in an interventional study within the last 3 months before therapy start with rituximab',\n",
       "   'Pretreatment with rituximab',\n",
       "   'Age <18 years',\n",
       "   'Known intolerability of monoclonal antibodies or chimeric monoclonal antibodies',\n",
       "   'Known pregnancy or breastfeeding',\n",
       "   'Data of patients without approval of data by the physician',\n",
       "   'Patients without informed consent',\n",
       "   'Double documentation']},\n",
       " {'nct_id': 'NCT01075477',\n",
       "  'inclusion': ['adult patients, >/= 18 years of age',\n",
       "   'rheumatoid arthritis',\n",
       "   'treatment with rituximab'],\n",
       "  'exclusion': ['unable/unwilling to give informed consent to data collection']},\n",
       " {'nct_id': 'NCT01070121',\n",
       "  'inclusion': ['Age 19 years or older;',\n",
       "   'Diagnosis of RA based on the cumulative presence of at least 4 of 7 ACR Criteria;',\n",
       "   'Willing and able to provide informed consent; and One of the following:',\n",
       "   'Starting MTX OR',\n",
       "   'Previous or current use of Methotrexate and starting (or switching to) any of the following medications (with or without MTX)',\n",
       "   'Etanercept',\n",
       "   'Infliximab',\n",
       "   'Adalimumab',\n",
       "   'Rituximab',\n",
       "   'Abatacept',\n",
       "   'Golimumab',\n",
       "   'Certolizumab',\n",
       "   'Tocilizumab There is no minimum disease activity (number of swollen joints, DAS28, CRP or ESR, etc.) necessary for enrollment. Treatment decisions are entirely at the discretion of the treating rheumatologist. There are no combinations of drugs to be excluded, except those that do not include at least one of the seven drugs noted above. Use of corticosteroids (oral, parenteral, intra-articular) is allowed, but must be recorded.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01078597',\n",
       "  'inclusion': ['Patient is 18 years of age or older.',\n",
       "   'Patient was diagnosed with Rheumatoid Arthritis with evidence of disease activity within the past year.',\n",
       "   'Patient has known anti-CCP status (positive or negative).',\n",
       "   'Patient has agreed to participate in the study by signing an informed consent.',\n",
       "   'Patient will be available for a period of follow-up of 12 months, from the time of enrollment in the study',\n",
       "   'Patient is fluent in the English language'],\n",
       "  'exclusion': [\"Patient's anti-CCP status (positive or negative) has not been determined.\",\n",
       "   'Patient with any other rheumatological disorder such as mixed connective tissue disease, psoriatic arthritis, ankylosing spondylitis, scleroderma and crystal induced arthropathies. Osteoarthritis is not an exclusion criterion.',\n",
       "   'Patient with any condition that would prevent participation in the study and completion of the study procedures, including language limitation.',\n",
       "   'Patient is not willing to sign an informed consent']},\n",
       " {'nct_id': 'NCT01010503',\n",
       "  'inclusion': ['adult patients >/= 18 years of age',\n",
       "   'moderate to severe active rheumatoid arthritis',\n",
       "   'inadequate response, or intolerance to previous therapy with one or more traditional DMARDs',\n",
       "   'DAS >3.6',\n",
       "   'pneumology examination (including chest x-ray and quantiferon)'],\n",
       "  'exclusion': ['< 18 years of age',\n",
       "   'active infection',\n",
       "   'active tuberculosis',\n",
       "   'uncontrolled hyperlipoproteinaemia',\n",
       "   'demyelinating disorders',\n",
       "   'concomitant anti-TNF drugs',\n",
       "   'history of intestinal ulceration and diverticulitis']},\n",
       " {'nct_id': 'NCT01010269',\n",
       "  'inclusion': ['Painful and disabled knee joint resulting form osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.',\n",
       "   'Correction of varus, valgus, or posttraumatic deformity.',\n",
       "   'Correction or revision of unsuccessful osteotomy, or arthrodesis.',\n",
       "   'Need to obtain pain relief and improve function.',\n",
       "   'Ability and willingness of the patient to follow instructions, including control of weight and activity level.',\n",
       "   'Good nutritional state of the patient.',\n",
       "   'Patient must have reached full skeletal maturity.'],\n",
       "  'exclusion': ['Infection, sepsis, osteomyelitis, and failure of previous joint replacement.',\n",
       "   'Uncooperative patient or patients with neurologic disorders who are incapable of following directions.',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, neuromuscular disease',\n",
       "   'Incomplete or deficient soft tissue surrounding the knee']},\n",
       " {'nct_id': 'NCT01017367',\n",
       "  'inclusion': ['Must meet the ACR criteria for RA',\n",
       "   'Must have active RA, characterized by at least 6 out of 66 swollen joints and 6 out of 68 tender joints, and at least 2 of the following: a serum C-reactive protein level greater than the upper limit of normal, an erythrocyte sedimentation rate >= 28 mm per hour, or morning stiffness > 45 minutes',\n",
       "   'Seropositive for rheumatoid factor, as defined by a plasma rheumatoid factor level of at least 20 IU per milliliter and/or be seropositive for anti-cyclic citrullinated peptide antibody',\n",
       "   'Must be on MTX (10 to 25 mg weekly) for at least 6 months receiving a stable dose for 42 days before randomization and no anticipated change in MTX dose while on study',\n",
       "   'Low-dose corticosteroids and NSAIDs are permitted at study entry and must have been stable for at least 28 days before randomization',\n",
       "   'All other disease modifying non-biologic anti-rheumatic drugs (DMARDs) must have been discontinued at least 28 days prior to randomization except for leflunomide (discontinued at least 60 days before randomization). Etanercept (discontinued at least 28 days prior to randomization) and infliximab, adalimumab, and abatacept (discontinued at least 56 days prior to randomization)',\n",
       "   'Screening laboratory values',\n",
       "   'Hemoglobin ≥ 8.5 g/dL',\n",
       "   'White blood cell (WBC) ≥ 3000/mm³',\n",
       "   'Neutrophils ≥ 1.5x10(9)/L',\n",
       "   'Platelets ≥ 125x10(9)/L',\n",
       "   'Serum creatinine < 2 mg/dL',\n",
       "   'Aspartate aminotransferase (AST) ≤ 2xULN',\n",
       "   'Alanine aminotransferase (ALT) ≤ 2xULN',\n",
       "   'Women must be postmenopausal (> 12 months without menses) or surgically sterile or using effective contraception for at least 4 weeks prior to the anticipated Visit 2 date and agree to continue contraception for the duration of their participation in the study',\n",
       "   'Sexually active male subjects must use a barrier method of contraception during the course of the study.'],\n",
       "  'exclusion': ['Prior treatment with B cell depleting therapy',\n",
       "   'Any other monoclonal antibody or immunoglobulin-based fusion proteins ≤ 8 weeks prior to randomization',\n",
       "   'Any other experimental treatment ≤ 4 weeks prior to randomization',\n",
       "   'Primary or secondary immunodeficiency',\n",
       "   \"Any other autoimmune disease other than RA (except concurrent Sjogren's syndrome or hypothyroidism)\",\n",
       "   'Complications of RA including:',\n",
       "   'Active rheumatoid vasculitis',\n",
       "   'Bed bound or wheelchair bound',\n",
       "   'Clinically significant pulmonary fibrosis',\n",
       "   \"Felty's syndrome\",\n",
       "   'Any history of malignancy, excluding adequately treated and cured basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ',\n",
       "   'Active major psychiatric disease',\n",
       "   'Evidence of acute or chronic infection',\n",
       "   'Clinically significant cardiac disease requiring medication, unstable angina, myocardial infarction within 6 months of randomization, or congestive heart failure',\n",
       "   'Arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities;',\n",
       "   'History of cerebrovascular disease requiring medication/treatment;',\n",
       "   'Concomitant anticoagulation therapy or a known bleeding disorder',\n",
       "   'Seizure disorder requiring active therapy',\n",
       "   'Known drug or alcohol abuse',\n",
       "   'Pregnant or nursing']},\n",
       " {'nct_id': 'NCT01011959',\n",
       "  'inclusion': ['Patients with an established diagnosis of Rheumatoid Arthritis',\n",
       "   'Patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks'],\n",
       "  'exclusion': ['Persistent chronic or current active infections',\n",
       "   'Patients who have taken anakinra within 2 weeks',\n",
       "   'Patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks',\n",
       "   'Patients who have taken adalimumab within 6 weeks',\n",
       "   'Patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks',\n",
       "   'Patients who have taken leflunomide or rituximab within 6 months',\n",
       "   'Patients who have had prior treatment with tocilizumab or any other anti-IL-6 medication',\n",
       "   'Significant arthritis or other medical condition that could interfere with study evaluations',\n",
       "   'Participation in any clinical research study evaluating another investigational drug within 30 days']},\n",
       " {'nct_id': 'NCT01010581',\n",
       "  'inclusion': ['Patients with active RA of functional classes I, II or III according to the criteria of American Rheumatism Association for RA',\n",
       "   'DAS28(ESR) ≥ 4.5 (DAS28 formula with 4 variables using ESR)',\n",
       "   'Patients who have received weekly doses of MTX (10-25 mg/week) for a minimum of 3 months prior to Day 1 dosing, and who have received a stable MTX dose of 10-25 mg/week without any change in route or change in folic acid supplementation for at least 6 weeks prior to Day 1 dosing',\n",
       "   'Patients may receive up to 10 mg/day of oral prednisolone or steroid equivalent. Dose must have been stable for at least 30 days and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements Main'],\n",
       "  'exclusion': ['Patients with RA of functional classes IV according to the criteria of American Rheumatism Association for RA',\n",
       "   'Patients who have received any of the following treatments must abide by the indicated washout period:',\n",
       "   'Leflunomide requires a 6 month washout period prior to Day 1 dosing',\n",
       "   'Oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day washout period prior to Day 1 dosing',\n",
       "   'Cyclosporine, abatacept, etanercept, adalimumab, infliximab, and rituximab require a 60 day washout period prior to Day 1 dosing',\n",
       "   'Cyclophosphamide requires a 180 day washout period prior to Day 1 dosing',\n",
       "   'Parenteral or intra-articular corticosteroids require a 30 day washout period prior to Day 1 dosing',\n",
       "   'Receipt of the following drugs within 4 weeks prior to dosing:',\n",
       "   'Sulfasalazine',\n",
       "   'Hydroxychloroquine',\n",
       "   'Use of corticosteroids > 10 mg/day']},\n",
       " {'nct_id': 'NCT01866150',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis by a rheumatologist',\n",
       "   'Patients who have responded inadequately to methotrexate or disease-modifying anti-rheumatic drugs (DMARDs) and are being prescribed a biologic in monotherapy or in combination with methotrexate and other classical DMARDs as per NICE guidelines'],\n",
       "  'exclusion': ['Primary diagnosis of a condition other than rheumatoid arthritis',\n",
       "   'Current treatment with a biologic in combination without methotrexate',\n",
       "   'Prior treatment with an experimental agent for rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01864265',\n",
       "  'inclusion': ['Understands and voluntarily signs an informed consent form',\n",
       "   'Male or female, aged ≥ 18 years at time of consent',\n",
       "   'Must be able to adhere to the study visit schedule and other protocol requirements',\n",
       "   'Must satisfy the 2010 ACR/EULAR classification criteria for rheumatoid arthritis plus a disease duration of at least 6 months.',\n",
       "   'Must have active RA with a DAS28 ≥3.2',\n",
       "   'Must be RF and/or ACPA positive',\n",
       "   '≥ 3 swollen and/or tender joints of the hands',\n",
       "   'At screening- visit patients should have been treated without alterations of therapy for at least three months with DMARDS (i.e. Methotrexate) with or without concomitant use of steroids).',\n",
       "   'Glucocorticoids treatment up to 10mg prednisolone per day will be allowed at study entry. .'],\n",
       "  'exclusion': ['Individuals not able to understand and follow study protocol and not able to voluntarily sign informed consent',\n",
       "   'Individuals not willing to follow study protocol and sign informed consent',\n",
       "   'Individuals with claustrophobia, tattoos containing metal, magnetic endoprostheses, surgery on bone in between a time interval < 3 months.',\n",
       "   'Patients treated before with any biological or small molecule or medication under investigation for the treatment of',\n",
       "   '- Patients with serious or chronic infections within the previous 3 months',\n",
       "   'Opportunistic infections within the 6 months before screening',\n",
       "   'Cancer within the 5 years before screening (with the exception of treated and cured squamous or basal cell carcinoma of the skin)',\n",
       "   'History of severe congestive heart failure',\n",
       "   'Current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal (a.e.diverticulitis), endocrine, pulmonary, cardiac, neurologic or cerebral disease',\n",
       "   'Transplanted organ (with the exception of corneal transplantation done more than 3 months before screening)',\n",
       "   'Evidence of active tuberculosis']},\n",
       " {'nct_id': 'NCT01862224',\n",
       "  'inclusion': ['Have had rheumatoid arthritis (RA) for at least 6 months prior to the date of signing the informed consent at screening',\n",
       "   'Be positive for either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum at screening',\n",
       "   'Have active RA defined for the purpose of this study as persistent disease activity with both of the following criteria: At least 4 swollen and 4 tender joints using a 66/68 joint count. At the time of screening, one of the tender or swollen joints or both must include the non-prosthetic knee to be biopsied; and serum C-reactive protein (CRP_ ≥ 0.60 mg/dL at screening',\n",
       "   'Have been treated with and tolerated oral methotrexate (MTX) treatment at doses from 10 mg/week to 25 mg/week inclusive, for a minimum of 3 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0',\n",
       "   'If using nonsteroidal anti-inflammatory drugs (NSAIDs) or other analgesics (pain relievers) regularly for RA, the participant must have been on a stable dose for at least 2 weeks prior to the first administration of study agent. If not using NSAIDs or other analgesics for RA at Week 0, the participant must have not received NSAIDs or other analgesics for RA for at least 2 weeks prior to the first administration of study agent'],\n",
       "  'exclusion': ['Has inflammatory diseases other than RA',\n",
       "   'Has a history of juvenile idiopathic arthritis (JIA)',\n",
       "   'Has current signs or symptoms of liver or renal insufficiency or cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances that are severe, progressive, or uncontrolled']},\n",
       " {'nct_id': 'NCT01861782',\n",
       "  'inclusion': ['Male and female ≥ 18',\n",
       "   'Patients with diagnosed rheumatoid arthritis',\n",
       "   'Patients with moderate disease activity (DAS28 > 3.2)'],\n",
       "  'exclusion': ['Patients who suffer from Photosensitivity',\n",
       "   'Patients with Suspected Lupus Erythematoides',\n",
       "   'Patients with tendency to sudden loss of consciousness and/or dizziness',\n",
       "   'Patients under chemotherapeutic treatment',\n",
       "   'Patients with Active Malignancy',\n",
       "   'Patients with lowest level of physical functioning (class 4)',\n",
       "   'Patients with serious uncontrolled concomitant chronic disease',\n",
       "   'Drug Abuser',\n",
       "   'Patients with severe peripheral venous insufficiency',\n",
       "   'Pregnant women']},\n",
       " {'nct_id': 'NCT01476956',\n",
       "  'inclusion': ['18 years of age or older',\n",
       "   'RA according to the 2010 Rheumatoid Arthritis Classification Criteria',\n",
       "   'Joint symptoms for ≥ 3 months prior to screening',\n",
       "   'DAS44 > 2.4',\n",
       "   'About to start DMARD therapy (methotrexate, salazopyrin, hydroxychloroquine, chloroquine, leflunomide) or',\n",
       "   'increased dose of methotrexate by ≥10 mg weekly to a maximum dose of 25mg weekly (if already receiving >15mg will require add-on DMARD/anti-TNF or switch to alternative DMARD),',\n",
       "   'add-on of alternative DMARD,',\n",
       "   'switch to alternative DMARD,',\n",
       "   'start of first anti-TNFα agent (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab)',\n",
       "   'If already on DMARD therapy this has been stable for the 3 months prior to the baseline visit',\n",
       "   'If already on systemic steroid, dose must be stable (prednisone ≤ 7.5mg/day) for 1 month prior to the baseline visit',\n",
       "   'Patient will be available for follow up for a minimum of 24 months from the baseline visit'],\n",
       "  'exclusion': ['Intra-articular steroid injection within 4 weeks prior to the baseline visit',\n",
       "   'Prior treatment with anti-TNFα or other biological agent (rituximab, abatacept, tocilizumab)',\n",
       "   'Malignancy within past 5 years (other than basal cell carcinoma that has been adequately treated or excised, squamous cell cancer of the skin, and cervical carcinoma in situ)',\n",
       "   'History of:',\n",
       "   'Serious infection (defined as requiring parenteral antibiotics or hospitalization) within 3 months prior to the baseline visit;',\n",
       "   'Active tuberculosis or history of tuberculosis without documented curative treatment and/or positive tuberculin reaction to PPD (Purified Protein Derivative)',\n",
       "   'For patients starting anti-TNF therapy, a positive TB screening test and no record of effective prophylaxis according to local expert recommendations',\n",
       "   'Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or Hepatitis C']},\n",
       " {'nct_id': 'NCT01474291',\n",
       "  'inclusion': ['Adult participants, >/= 18 years of age',\n",
       "   'Patients with rheumatoid arthritis for whom the rheumatologist decides to start tocilizumab in combination with DMARD or as monotherapy'],\n",
       "  'exclusion': ['Current participation in a clinical trial in rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01307384',\n",
       "  'inclusion': ['Patient is 18 to 75 years of age, inclusive.',\n",
       "   'Patient is skeletally mature.',\n",
       "   'Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:',\n",
       "   'Avascular necrosis (AVN)',\n",
       "   'Osteoarthritis',\n",
       "   'Inflammatory arthritis (i.e., Rheumatoid arthritis)',\n",
       "   'Post-traumatic arthritis',\n",
       "   'Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).',\n",
       "   'Patient has moderate, marked or disabling pain.',\n",
       "   'Patient is willing and able to provide written informed consent.',\n",
       "   'Patient is willing and able to cooperate in the required post-operative therapy.',\n",
       "   'Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.',\n",
       "   'Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.'],\n",
       "  'exclusion': ['The patient is:',\n",
       "   'A prisoner',\n",
       "   'Mentally incompetent or unable to understand what participation in the study entails',\n",
       "   'A known alcohol or drug abuser',\n",
       "   'Anticipated to be non-compliant',\n",
       "   'The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.',\n",
       "   'The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.',\n",
       "   'The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.',\n",
       "   'The patient is known to be pregnant.',\n",
       "   'The patient is unwilling or unable to give consent or to comply with the follow-up program.',\n",
       "   'The patient has received an investigational drug or device within the previous 6 months.',\n",
       "   'The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.',\n",
       "   'The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.',\n",
       "   'The patient has osteoradionecrosis in the affected hip joint.',\n",
       "   'The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.',\n",
       "   'The patient has known local bone tumors and/or cysts in the operative hip.',\n",
       "   'The patient has a Body Mass Index (BMI) >',\n",
       "   '']},\n",
       " {'nct_id': 'NCT01305356',\n",
       "  'inclusion': ['at least 18 years old and considered skeletally mature',\n",
       "   'diagnosed with degenerative joint disease (DJD) affecting the hindfoot due to a congenital or acquired deformity, osteoarthritis, rheumatoid arthritis, post- traumatic arthritis or ankylosing spondylitis of the ankle, subtalar, calcaneocuboid, and/or talonavicular joints',\n",
       "   'requires one of the following hindfoot fusion proceduress with supplemental bone graft/substitute: ankle fusion (tibiotalar), subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, triple arthrodesis (subtalar, talonavicular and calcaneocuboid joints) OR double fusions (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints)',\n",
       "   'fusion site able to be rigidly stabilized with no more than 3 screws across the fusion site',\n",
       "   'supplemental pins or staples allowed',\n",
       "   'supplemental screws external to the fusion site(s) allowed',\n",
       "   'signed informed consent document, independent, ambulatory, and can comply with all post-operative evaluations and visits KEY'],\n",
       "  'exclusion': ['undergone previous fusion surgery at the proposed location, i.e., revision of a failed fusion',\n",
       "   'more than one previous procedure at the involved joints',\n",
       "   'retained hardware spanning the joint(s) intended for fusion',\n",
       "   'procedure anticipated to require plate fixation (including claw plates), IM nails or more than 3 screws to achieve rigid fixation based on pre-op planning',\n",
       "   'procedure expected to require more than 9cc of graft material based on pre-op planning',\n",
       "   'procedure expected to require structural bone graft, allograft, bone graft substitute, platelet rich plasma (PRP) or bone marrow aspirate',\n",
       "   'procedure expected to require a pantalar fusion, i.e., fusion of ankle plus all hindfoot joints (talonavicular, subtalar, and calcaneocuboid) or an ankle fusion in combination with any hindfoot fusion',\n",
       "   'radiographic evidence of bone cysts, segmental defects or growth plate fracture near the fusion site that could negatively impact the proposed fusion procedure',\n",
       "   'tested positive or been treated for a malignancy in the past or is suspected of having a malignancy or currently undergoing radio- or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed surgical site',\n",
       "   'pre-existing sensory impairment, e.g., diabetics with baseline sensory impairment, which limits ability to perform objective functional measurements and may be at risk for complications',\n",
       "   'diabetics not sensitive to the 5.07 monofilament (Semmes-Weinstein) are to be excluded',\n",
       "   'metabolic disorder known to adversely affect the skeleton other than primary osteoporosis or diabetes, e.g., renal osteodystrophy or hypercalcemia',\n",
       "   'use of chronic medications known to affect the skeleton, e.g., glucocorticoid usage > 10mg/day',\n",
       "   'pre-fracture neuromuscular or musculoskeletal deficiency which limits the ability to perform objective functional measurements',\n",
       "   \"physically or mentally compromised, e.g., current treatment for a psychiatric disorder, senile dementia, Alzheimer's disease, etc., to the extent that the Investigator judges the subject to be unable or unlikely to remain compliant\",\n",
       "   'allergic to yeast-derived products or bovine collagen or other bovine-sourced products',\n",
       "   'received an investigational therapy within 30 days of proposed surgery or during the follow-up phase of the study',\n",
       "   'is a prisoner, known or suspected transient or a history of drug/alcohol abuse within the 12 months prior to screening',\n",
       "   'pregnant or intending to become pregnant within 12 months of the study procedure',\n",
       "   'morbidly obese defined as BMI > 45 kg/m2',\n",
       "   'currently has an acute infection at the surgical site']},\n",
       " {'nct_id': 'NCT01308255',\n",
       "  'inclusion': ['Men & Women 18-80 years of age.',\n",
       "   'Fulfil 1987 ACR criteria for',\n",
       "   '- Symptoms of > 3 months and < 12 months duration.',\n",
       "   'Men and women must use adequate birth control measures for the duration of the study and should continue such precautions for 6 months after receiving the last infusion or dose of methotrexate.',\n",
       "   'The patient must be able to adhere to the study visit schedule and other protocol requirements.',\n",
       "   'The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures.',\n",
       "   'Must have a chest radiograph within 3 months prior to first treatment dose with no evidence of malignancy, infection or fibrosis.',\n",
       "   'Are considered eligible according to the tuberculosis (TB) eligibility assessment.',\n",
       "   'Active disease as defined by DAS > 2.4.',\n",
       "   'TNF therapy naïve.',\n",
       "   'DMARD therapy naïve.',\n",
       "   'Negative hepatitis B and C screening tests within 3 months prior to screening.'],\n",
       "  'exclusion': ['Women who are pregnant, nursing, or men or women planning pregnancy within 24 months after screening.',\n",
       "   'Use of any investigational (unlicensed) drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.',\n",
       "   'Previous or current treatment with any other therapeutic agent targeted at reducing TNF.',\n",
       "   'Prior treatment with any DMARD.',\n",
       "   'Serious infections (such as pneumonia or pyelonephritis) in the previous 3 months.',\n",
       "   'Documented HIV infection.',\n",
       "   'Hepatitis- B or Hepatitis-C serology positive (must be checked within 3 months prior to screening).',\n",
       "   'Are considered ineligible according to the TB eligibility assessment.',\n",
       "   'Have or have had an opportunistic infection within 6 months prior to screening.',\n",
       "   'Significant haematological or biochemical abnormality.',\n",
       "   'Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.',\n",
       "   'Concomitant congestive heart failure, including medically controlled asymptomatic patients.',\n",
       "   'Presence of a transplanted organ (with the exception of a corneal transplant > 3 months prior to screening).',\n",
       "   'Malignancy within the past 5 years.',\n",
       "   'History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease.',\n",
       "   'Known recent substance abuse (drug or alcohol).',\n",
       "   'Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.',\n",
       "   'Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of',\n",
       "   '- Have a positive Mantoux test or evidence of active TB infection, or recent close contact with an individual with active',\n",
       "   '- Previous oral, IM, IA or IV corticosteroids within 1 month prior to baseline.',\n",
       "   'Receiving treatment with anakinra.',\n",
       "   'Contra-indications to methotrexate, infliximab or steroids.']},\n",
       " {'nct_id': 'NCT01307787',\n",
       "  'inclusion': ['medical diagnosis of RA according to the American College of Rheumatology (ACR) criteria',\n",
       "   'between 18 and 66 years of age'],\n",
       "  'exclusion': ['severe disease activity (Disease Activity Score:DAS-28 > 5.1)',\n",
       "   'cardiac or pulmonary diseases resulting in restrictions in their ability to follow a physical exercise program',\n",
       "   'a Steinbrocker classification of functional capacity in RA ≥ 3',\n",
       "   'no stable medication for the RA',\n",
       "   'intra-articular injections during the time of the study']},\n",
       " {'nct_id': 'NCT01301703',\n",
       "  'inclusion': ['Patients suffering from RA', 'Aged 18 to 64 years old'],\n",
       "  'exclusion': ['Active disease requiring a change in drug regimen',\n",
       "   'Known allergy to vaccine']},\n",
       " {'nct_id': 'NCT01309282',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Rheumatoid arthritis positive for rheumatoid factor and/or anti-CCP',\n",
       "   'Non-responder or intolerant to single TNF-inhibitor therapy',\n",
       "   'Initiating treatment with MabThera/Rituxan'],\n",
       "  'exclusion': ['Contra-indications to MabThera/Rituxan therapy']},\n",
       " {'nct_id': 'NCT01338545',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis (RA) of at least 6 months duration',\n",
       "   'Non-responder or intolerant to at least one DMARD or TNF inhibitor treatment',\n",
       "   'Initiated on treatment with RoActemra according to Summary of Product Characteristics (SPC) indications'],\n",
       "  'exclusion': ['History of autoimmune disease or of any joint inflammatory disease other than RA',\n",
       "   'Pregnant or lactating women',\n",
       "   'Patients who have started RoActemra treatment in a clinical trial or for compassionate use',\n",
       "   'Treatment with any investigational drug in the previous 4 weeks (or at least 5 times the half-life of the drug)']},\n",
       " {'nct_id': 'NCT01331837',\n",
       "  'inclusion': ['Participants with moderate to severe RA of greater than or equal to (>=6) months duration',\n",
       "   'Inadequate response to at least one non-biologic DMARD',\n",
       "   'Positive for Rheumatoid Factor (RF) and/or anti-cyclic citrullinated peptide (CCP) antibodies at screening',\n",
       "   'Have C-reactive protein (CRP) greater than (>) 0.3 milligrams per deciliter (mg/dL) at screening or at the baseline visit',\n",
       "   'Swollen joint count (SJC) >=8 (66 joint count) and tender joint count (TJC) >= 8 (68 joint count) during screening or at the baseline visit',\n",
       "   'History of Coronary Heart Disease (CHD) or presence of one or more additional CHD risk factors, including current cigarette smoking, hypertension, low High Density Lipoprotein (HDL) cholesterol, family history of premature CHD, diabetes, presence of extra-articular disease associated with rheumatoid arthritis',\n",
       "   'At the time of randomization, will have discontinued infliximab, adalimumab, golimumab, or certolizumab for >= 4 weeks'],\n",
       "  'exclusion': ['Major surgery (including joint surgery or coronary revascularization) within 8 weeks prior to screening or planned major surgery within 1 year of study start',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'History of or current inflammatory joint disease other than RA',\n",
       "   'Current or recent (within past 3 months) evidence of serious uncontrolled concomitant cardiovascular or cerebrovascular disease (myocardial infarction, revascularization, stroke, transient ischemic attack, or acute coronary syndrome)',\n",
       "   'Current or previous (within the past 2 years) evidence of serious uncontrolled concomitant pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus) or gastrointestinal disease',\n",
       "   'Uncontrolled disease states, such as asthma or inflammatory bowel disease where flares are commonly treated with oral or parenteral corticosteroids',\n",
       "   'Pre-existing central nervous system demyelinating or seizure disorders',\n",
       "   'History of diverticulitis, diverticulosis requiring treatment or other lower gastrointestinal tract conditions that might predispose to perforations',\n",
       "   'Current liver disease as determined by the investigator; a history of asymptomatic elevations in liver function tests (LFTs) is not considered an exclusion',\n",
       "   'Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds',\n",
       "   'Any major episode of infection requiring hospitalization or treatment with IV antibiotics within four weeks of screening or oral antibiotics within two weeks prior to screening visit',\n",
       "   'Active tuberculosis (TB) requiring treatment within 3 years prior to baseline',\n",
       "   'Latent TB diagnosed during screening that has not been appropriately treated',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active)',\n",
       "   'Moderate to severe heart failure',\n",
       "   'Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematologic malignancies and solid tumors, except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years',\n",
       "   'Breast feeding mothers',\n",
       "   'History of alcohol, drug or chemical abuse within the 6 months prior to screening',\n",
       "   'Participants with lack of peripheral venous access',\n",
       "   'Participants with a history of allergic reactions to latex',\n",
       "   'Previous treatment with non-tumor necrosis factor (non-TNF)-inhibitor biologic therapy',\n",
       "   'Treatment with any investigational agent within 4 weeks of screening visit',\n",
       "   'Treatment with any cell depleting therapies within 1 year of baseline',\n",
       "   'Treatment with IV gamma globulin, plasmapheresis or Prosorba column within 6 months of baseline visit',\n",
       "   'Immunization with a live/attenuated vaccine within 4 weeks prior to baseline visit',\n",
       "   'Any previous treatment with alkylating agents, such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation']},\n",
       " {'nct_id': 'NCT01332994',\n",
       "  'inclusion': ['Adult patients >/=18 years of age',\n",
       "   'Body weight < /=130kg',\n",
       "   'Active rheumatoid arthritis of at least 6 months duration, diagnosed according to the American College of Rheumatology (ACR) criteria of 1987',\n",
       "   'Disease Activity Score (DAS28) of >3.2',\n",
       "   'Inadequate clinical response to a stable dose of traditional Disease-Modifying Anti-Rheumatic Drugs (DMARD)',\n",
       "   'Have received permitted DMARDs, one or more; current DMARD therapy must have been at stable dose for at least 4 weeks prior to baseline'],\n",
       "  'exclusion': ['Prior treatment with TNF-inhibitors or other biologic DMARD',\n",
       "   'Major surgery (including joint surgery) within eight weeks prior to baseline or planned major surgery within the study duration',\n",
       "   'Functional class IV (American College of Rheumatology classification)',\n",
       "   'Rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'History of or current inflammatory joint disease other than rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT01333878',\n",
       "  'inclusion': ['Subjects currently experiencing active moderate to severe RA according to the revised 1987 ACR criteria for the diagnosis of RA at screening. The ESR-based DAS 28 must be equal or greater than 3.2',\n",
       "   'MTX inadequate responders with moderate to severe',\n",
       "   'Subjects currently receiving MTX for at least 12 weeks and who have received MTX at a stable dose (≥15mg/week) for at least 6 weeks prior to treatment (Day 0). They must be biologic drug naive',\n",
       "   'All subjects must receive at least 5 mg oral folic acid weekly.',\n",
       "   'At screening active RA as defined by ≥ 6 swollen joints and ≥ 6 tender joints with erythrocyte sedimentation rate (ESR) ≥ 28 mm/h.',\n",
       "   'Subjects must be seropositive with documented rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti CCP) positivity. If a documented history of RF or anti CCP positivity is not available, RF and anti CCP titers will be obtained at screening',\n",
       "   'MRI evidence of at least one joint with osteitis or erosion attributable to RA as determined by an MRI musculoskeletal radiologist. Any joint of the dominant hand or wrist can be considered with the exception of distal interphalangeal joints of the hands.',\n",
       "   'If subjects are receiving an oral corticosteroid, the dose must be ≤10 mg/day prednisone (or equivalent) and stable for at least 28 days prior to treatment (Day 0).',\n",
       "   'Subjects able and willing to give written informed consent and comply with the requirements of the study protocol. Informed consent must be obtained prior to any study-related procedures. A copy of the signed informed consent form must be given to the subject',\n",
       "   'Subjects must be willing to self-inject or allow a caregiver to administer the subcutaneous injection'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization',\n",
       "   \"Rheumatic autoimmune disease other than RA, including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), scleroderma, polymyositis, or significant systemic involvement secondary to RA (vasculitis, pulmonary fibrosis or Felty's syndrome). Prior history of or current inflammatory joint disease other than RA (gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis and psoriatic arthritis)\",\n",
       "   'Functional class IV as defined by the ACR Classification of Functional Status in RA',\n",
       "   'Current treatment with any traditional DMARDs other than MTX within 4 weeks before the screening visit',\n",
       "   'Treatment with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is longer) before screening',\n",
       "   'Exposure to any Biologic Response Modifying Agent',\n",
       "   'Intra Articular or parenteral corticosteroids within 6 weeks prior to screening',\n",
       "   'Immunization with live vaccine within 3 months prior to enrollment and a need for a live vaccine during the study',\n",
       "   'Subjects who have a metal device where the use of MRI is contraindicated (e.g.,any type of electronic, mechanical, or magnetic implant; cardiac pacemaker, aneurysm clip; implanted cardioverter defibrillator; or a cochlear implant). Subjects who have a potential ferromagnetic foreign body (metal shavings, metal slivers, other metal objects) for which they have sought medical attention',\n",
       "   'Exclusionary laboratory: Serum creatinine >2 mg/dL, ALT or AST > 2.0 x ULN, total bilirubin > 2.0 x ULN, platelet count <100 x 109 /L, hemoglobin < 8.5 g/dL, WBC count < 1,000/mm3 , absolute neutrophil count < 1,000/ mm3, absolute lymphocyte count < 500/mm3, positive HBsAg or HCV antibody, or positive HIV test.',\n",
       "   'Pregnant women or nursing mothers',\n",
       "   'Females of child bearing potential who are not using reliable means of contraception',\n",
       "   'Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine or GI disease',\n",
       "   'Uncontrolled disease states, such as asthma, psoriasis, or inflammatory bowel syndrome, where flares are commonly treated with corticosteroids',\n",
       "   'Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections such as atypical mycobacterial disease, hepatitis B and C, HIV, herpes zoster, or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening.',\n",
       "   'A history of active TB within the last 3 years even if it was treated. A history of active TB greater than 3 years ago unless there is documentation that the prior anti-TB treatment was appropriate in duration and type. A positive PPD skin test (≥5 mm) or positive QuantiFERON-TB Gold serum test without appropriate prophylaxis (at least 1 month of the planned local guidelines treatment regimen)',\n",
       "   'Any malignancy except for skin cancer (basal cell or squamous cell) diagnosed within the previous 5 years',\n",
       "   'History of alcohol, drug, or chemical abuse',\n",
       "   'Neuropathies or other painful conditions that might interfere with pain evaluation']},\n",
       " {'nct_id': 'NCT01337388',\n",
       "  'inclusion': ['Adult patients, > 18 years of age',\n",
       "   'Rheumatoid arthritis, defined as fulfilling at least 4 of 7 American College of Rheumatology (ACR) criteria',\n",
       "   'Treatment with RoActemra/Actemra'],\n",
       "  'exclusion': ['Participation in interventional clinical studies']},\n",
       " {'nct_id': 'NCT01345071',\n",
       "  'inclusion': ['Rheumatoid Arthritis according to 2010 ACR/EULAR criteria',\n",
       "   'active pregnancy wish',\n",
       "   'either DAS28(3)CRP > 3.2 or the current use of anti-TNF Inclusion criteria for second objective (no limit on number of subjects needed, recruitment will end when 150 RA patients have been included)',\n",
       "   'rheumatic disease that requires the use of anti-TNF before or during pregnancy',\n",
       "   'active pregnancy wish'],\n",
       "  'exclusion': ['none']},\n",
       " {'nct_id': 'NCT01346488',\n",
       "  'inclusion': ['Paid worker (PW) RA patients who are engaged in paid work for more than 35 hours per week',\n",
       "   'Home worker (HW)',\n",
       "   'Category 1 unpaid workers; RA patients who are engaged in paid work for less than 35 hours per week',\n",
       "   'Category 2 unpaid workers; RA patients who perform basic activities of daily life (household duties, shopping, child caring, exercise, study, etc.) other than PW'],\n",
       "  'exclusion': ['RA patients showing lowered basic activities of daily life, such as hospitalization and being bedridden',\n",
       "   'RA patients with a history of previous treatment with adalimumab']},\n",
       " {'nct_id': 'NCT01156155',\n",
       "  'inclusion': ['Age 19 years or older',\n",
       "   'Diagnosis of rheumatoid arthritis, or osteoarthritis',\n",
       "   'Have 9 or more evaluable posterior teeth (out of a total of 28 teeth, excluding third molars)',\n",
       "   'Willing and able to provide informed consent'],\n",
       "  'exclusion': ['Received tetracyclines within the last 6 months.',\n",
       "   'Need for antibiotic premedication for dental probing.',\n",
       "   'Pregnant or breast feeding']},\n",
       " {'nct_id': 'NCT01055899',\n",
       "  'inclusion': ['Male or female ≥ 18 years of age',\n",
       "   'Subjects must weigh > 50 kg and < 100 kg',\n",
       "   'Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with disease duration of no less than 6 months and ACR class I-III',\n",
       "   'For women of childbearing potential, a negative serum pregnancy test at the Screening Visit (Visit 1) and a negative urine pregnancy test at Day -1',\n",
       "   'For men and women of childbearing potential, willingness to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant) during the full course of the study.'],\n",
       "  'exclusion': ['A history of Listeriosis or active tuberculosis (TB)',\n",
       "   'Persistent chronic or active recurring infection requiring treatment with antibiotics, antivirals, or antifungals within 4 weeks prior to the Screening Visit',\n",
       "   'History of prior articular or prosthetic joint infection',\n",
       "   'History of a hypersensitivity reaction, other than localized injection site reaction (ISR), to any biological molecule',\n",
       "   \"Significant concomitant illness such as, but not limited to cardiac, renal, neurological, endocrinological, metabolic or lymphatic disease that would adversely affect the subject's participation in this study\",\n",
       "   'Received administration of any live (attenuated) vaccine within 3 months prior to the Screening Visit']},\n",
       " {'nct_id': 'NCT01052194',\n",
       "  'inclusion': ['All subjects must have been diagnosed with RA as defined by the ACR revised criteria with disease duration of at least 6 months from confirmed diagnosis',\n",
       "   'Subjects must have a swollen joint count of ≥6 out of 28 joints and tender joint count of ≥6 out of 28 joints. Joints that have had prior surgery are to be excluded from the joint count.',\n",
       "   'Baseline CRP level must be 1.5 times greater than the upper limit of normal at Screening.',\n",
       "   'Subjects must have failed at least 1 nonbiologic DMARD for any reason.',\n",
       "   'Subjects may have previously failed no more than 1 biologic DMARD and discontinued treatment for reasons other than inadequate response. Subjects must not have been treated with Rituximab previously.',\n",
       "   'Subjects must be willing to comply with contraception requirements.'],\n",
       "  'exclusion': ['Subjects with inflammatory rheumatological disorders other than',\n",
       "   '- History or evidence of a clinically significant disorder other than RA (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric disorders), condition or disease that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.',\n",
       "   'Subjects with clinically important abnormalities in screening physical examination or in screening laboratory test results (including the presence of either hepatitis B surface antigen, hepatitis C virus antibody, or HIV types 1 -- Subjects with elevation in alanine aminotransferase or aspartate aminotransferase above the upper limit of normal.',\n",
       "   'History of hematologic disorders including neutropenia and thrombocytopenia.',\n",
       "   'Subjects with an acute or chronic active infection requiring systemic antimicrobial treatment, or subjects who are at high risk of developing an infection due to a compromised immune system. Antifungals for onychomycosis or low-dose antibiotics for rosacea, that are not inhibitors or inducers of CYP3A, will be allowed.',\n",
       "   'Subjects who require concomitant use of any inhibitors or inducers of cytochrome P450 (CYP)',\n",
       "   '- Subjects who have been treated with intra-articular injections of corticosteroids within 28 days prior to Day',\n",
       "   '- Subjects who have planned major surgery (e.g., joint replacement) or any procedures during the study.',\n",
       "   'Have received any live, attenuated vaccinations within 1 month prior to study drug administration.',\n",
       "   'History of drug or alcohol abuse or excessive alcohol as determined by the investigator, during the last 12 months before the screening visit.',\n",
       "   'History of TB infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.']},\n",
       " {'nct_id': 'NCT01059864',\n",
       "  'inclusion': ['must be diagnosed as having active rheumatoid arthritis',\n",
       "   'agree to participate in the study and sign and informed consent document'],\n",
       "  'exclusion': ['History of serious infection within the past 6 months',\n",
       "   'test positive for TB',\n",
       "   'have any uncontrolled clinically significant disease or laboratory tests',\n",
       "   'require administration of prohibited medications during the study']},\n",
       " {'nct_id': 'NCT01050998',\n",
       "  'inclusion': ['Age 18 through 80 years (20 to 75 years in Japan)',\n",
       "   'Written consent',\n",
       "   'Diagnosis of adult onset Rheumatoid Arthritis (RA) of at least 3 months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria (Arnett et al, 1988)',\n",
       "   'Treatment with methotrexate at a stable and tolerated doses',\n",
       "   'Positive anti-cyclic citrullinated peptide (CCP) immuno-globulin G antibodies (more than [>] 5 international unit per milliliter [IU/mL]) and/or rheumatoid factor (RF >14 IU/mL) at screening',\n",
       "   'Received more than or equal to (>=) 5 milligram (mg) per week folic acid as a single or divided dose during the study.'],\n",
       "  'exclusion': ['A rheumatic autoimmune disease other than RA',\n",
       "   'A history of, or current, inflammatory joint disease other than RA or other systemic autoimmune disorder',\n",
       "   'Subjects at a high risk of infection',\n",
       "   'Subjects (male and female) of reproductive potential who are not willing to use contraception from screening through the end date of the trial',\n",
       "   'History of methotrexate or any drug-induced lung fibrosis or pneumonitis.']},\n",
       " {'nct_id': 'NCT01050010',\n",
       "  'inclusion': ['Earlier rheumatoid arthritis (<1 year)',\n",
       "   'Clinical remission (DAS 28 <2,6 ou SDAI <5) since 6 months before the inclusion',\n",
       "   'Unchanged DMARds and /or biologic therapy since 6 months before the inclusion',\n",
       "   'Unchanged corticosteroid (5 mg/day) since 3 months before the inclusion in patients treated with this therapy',\n",
       "   'No contre-indication to the MRI'],\n",
       "  'exclusion': ['Contra-indication to MRI',\n",
       "   'Pregnant or breast-feeding women']},\n",
       " {'nct_id': 'NCT01374971',\n",
       "  'inclusion': ['Signed and dated informed consent document',\n",
       "   'Subjects must be at least 18 years of age or older',\n",
       "   'Subject must be willing and able to comply with scheduled visits, arthroscopy, laboratory tests, and other procedures',\n",
       "   'Diagnosis of RA based on American College of Rheumatology (ACR) 1987 Revised Criteria',\n",
       "   'Active disease at screening visit',\n",
       "   'Methotrexate taken continuously for at least 12 weeks at a stable dosage',\n",
       "   'Sexually active women of child-bearing potential and men whose partners are women of child-bearing potential are required to use adequate contraceptive methods during participation on this trial',\n",
       "   'Treatment with non-steroidal anti-inflammatory drugs (NSAIDS)and oral corticosteroids (less than or equal to 10 mg/day prednisone or equivalent)is accepted'],\n",
       "  'exclusion': ['Diagnosis of any other inflammatory arthritis',\n",
       "   'History of infected joint prosthesis that is still in situ',\n",
       "   'History of allergy to local anesthetic agents',\n",
       "   'Pregnant or lactating women',\n",
       "   'Current or recent history of uncontrolled clinically significant conditions(e.g..,kidney disease, liver disease, class III or IV congestive heart failure, according to the New York Heart Association)',\n",
       "   'History or suspected demyelinating disease of the central nervous system, e.g. multiple sclerosis or optic neuritis',\n",
       "   'Current participation in clinical trial']},\n",
       " {'nct_id': 'NCT01377012',\n",
       "  'inclusion': ['Male or non-pregnant, non-lactating female patients',\n",
       "   'Presence of RA classified by American College of Rheumatology (ACR) 2010 revised criteria for at least 3 months before screening',\n",
       "   'At Baseline: Disease activity criteria defined by ≥ 6 tender joints out of 68 and ≥6 swollen joints out of 66 with at least 1 of the following at screening:',\n",
       "   'Anti-Cyclic Citrullinated Peptide (CCP) antibodies positive OR Rheumatoid Factor positive and with at least 1 of the following at screening:',\n",
       "   'High sensitivity C-reactive protein (hsCRP) ≥ 10 mg/L OR Erythrocyte sedimentation rate (ESR) ≥ 28 mm/1st hr',\n",
       "   'Patients must have been taking at least one anti-TNF-α agent given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-TNF-α agent',\n",
       "   'Patients must be taking MTX for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7.5 to 25 mg/week For Japan only: 6 to 25 mg/week) Exclusion criteria:',\n",
       "   'Chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician RA patients functional status class IV according to the ACR 1991 revised criteria',\n",
       "   'Patients who have ever received biologic immunomodulating agents except for those targeting TNFα',\n",
       "   'Previous treatment with any cell-depleting therapies including but not limited to anti-CD20, investigational agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)',\n",
       "   'Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01375478',\n",
       "  'inclusion': ['Adult patients, over 18 years of age',\n",
       "   'Moderate to severe rheumatoid arthritis',\n",
       "   'RoActemra/Actemra treatment must have been initiated 6 months prior to signing the informed consent form'],\n",
       "  'exclusion': ['Patients with rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'Patients who are not willing to sign the informed consent form',\n",
       "   'Patients who participate in interventional trials during the period of this observational study']},\n",
       " {'nct_id': 'NCT01232569',\n",
       "  'inclusion': ['Adult patients, ≥ years of age.',\n",
       "   'Moderate to severe rheumatoid arthritis of ≥ 6 months duration.',\n",
       "   'Receiving treatment on an outpatient basis.',\n",
       "   'Swollen joint count (SJC) ≥ 6 (66 joint count) and tender joint count (TJC)≥ 8 (68 joint count) at screening and study start.',\n",
       "   'On a stable dose of disease-modifying anti-rheumatic drugs for at least 8 weeks prior to study start. Exclusion Criteria:',\n",
       "   'Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.',\n",
       "   \"Rheumatic autoimmune disease other than rheumatoid arthritis, Secondary Sjögren's Syndrome with rheumatoid arthritis is allowed.\",\n",
       "   'Functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis.',\n",
       "   'Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16 years.',\n",
       "   'Prior history of or current inflammatory joint disease other than rheumatoid arthritis.',\n",
       "   'History of malignancy, active or recurrent infections, positive to hepatitis B surface antigen or hepatitis C antibody, active tuberculosis, serious allergy to biologics, or a history of diverticular disease or other symptomatic GI conditions that might predispose to perforations. Other inclusion and'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01235507',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Active moderate to severe rheumatoid arthritis (RA)',\n",
       "   'On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks',\n",
       "   'Oral corticosteroids must have been at stable dose of </= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug',\n",
       "   'Body weight </= 150 kg'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry',\n",
       "   'Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV according to American College of Rheumatology (ACR) classification',\n",
       "   'Prior history of or current inflammatory joint disease other then RA',\n",
       "   'Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline',\n",
       "   'Treatment with any biologic drug that is used in the treatment or RA',\n",
       "   'Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Known active current or history of recurrent infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency',\n",
       "   'Positive for HIV']},\n",
       " {'nct_id': 'NCT01235598',\n",
       "  'inclusion': ['Subjects with a diagnosis of adult-onset Rheumatoid Arthritis (RA) of at least 3 months duration but no longer than 15 years',\n",
       "   'Subjects with an active adult Rheumatoid Arthritis disease',\n",
       "   'Subjects who have been on Disease-Modifying Anti-Rheumatic Drug (DMARD) therapy for at least 12 weeks'],\n",
       "  'exclusion': [\"Subject must not have a secondary, non-inflammatory type of musculoskeletal condition (eg, osteoarthritis or fibromyalgia) that in the investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of Rheumatoid Arthritis (RA)\",\n",
       "   'Subject must not have a diagnosis of any other inflammatory arthritis (eg, psoriatic arthritis or ankylosing spondylitis)',\n",
       "   'Subject must not have a history of an infected joint prosthesis at any time with prosthesis still in situ',\n",
       "   'Subject must not have received more than 1 biological agent',\n",
       "   'Subject must not have a history of lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease at any time',\n",
       "   'Subject with known Tuberculosis (TB) disease, high risk of acquiring TB infection or latent TB infection',\n",
       "   'Subject must not have a known hypersensitivity to any components of the investigational medicinal product',\n",
       "   'Subject must not have contraindications for Magnetic Resonance Image (MRI) and contrast agent',\n",
       "   \"Subject must not have any other condition which, in the investigator's judgement, would make them unsuitable for inclusion in the study\"]},\n",
       " {'nct_id': 'NCT01231321',\n",
       "  'inclusion': ['Males and females >= 18 years of age.',\n",
       "   'A negative pregnancy test (human chorionic gonadotropin in serum samples) for women of childbearing potential prior to start of study treatment.',\n",
       "   'Female subject is either not of childbearing potential, defined as postmenopausal (at least 1 year since last menses) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control throughout the study and for 150 days after study completion:',\n",
       "   'Condoms, sponge, foams, jellies, diaphragm or intrauterine device.',\n",
       "   'Contraceptives (oral, parenteral, patch) for three months prior to study drug administration.',\n",
       "   'A vasectomized partner.',\n",
       "   'American College of Rheumatology criteria for diagnosis of rheumatoid arthritis for at least 6 months.',\n",
       "   'Subjects must meet the following three criteria:',\n",
       "   'Disease Activity Score (28 joints) more or equal 3.2 (at Baseline only)',\n",
       "   'At least 6 swollen joints out of the 66 assessed',\n",
       "   'At least 8 tender joints out of the 68 assessed',\n",
       "   'Subjects must have a C-reactive protein >= 1.5mg/dL or erythrocyte sedimentation rate >= 28 mm/1h.',\n",
       "   'Unsatisfactory response or intolerance to prior disease modifying anti-rheumatic drugs (must have failed at least 1 disease modifying anti-rheumatic drug).',\n",
       "   'Able and willing to administer subcutaneous injections.',\n",
       "   'Able and willing to give written informed consent and to comply with the requirements of the study protocol.',\n",
       "   'Documented negative purified protein derivative test, defined as < 5 mm induration, or willingness and ability to start tuberculosis prophylaxis before first dose of study drug if the purified protein derivative result is positive and the chest X-ray is not suggestive of active tuberculosis and there is no history of active tuberculosis.'],\n",
       "  'exclusion': ['Prior treatment with alkylating agents such as cyclophosphamide or chlorambucil within at least 5 years before enrollment.',\n",
       "   'Prior treatment with intravenous immunoglobulin or any investigational agent \"chemical\" in nature within 30 days, or 5 half lives of the product, whichever is longer.',\n",
       "   'Prior treatment with cyclosporine within the last 6 months.',\n",
       "   'Prior treatment with investigational biologic therapy.',\n",
       "   'Subject has chronic arthritis diagnosis before the age 17 years.',\n",
       "   'Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study).',\n",
       "   'History of an allergic reaction or significant sensitivity to the constituents of study drug (adalimumab).',\n",
       "   'Treatment within the last 2 months with approved biologic therapy (e.g. infliximab) prior to Baseline.',\n",
       "   'Prior treatment with total lymphoid irradiation.',\n",
       "   'History of cancer or lymphoproliferative disease other than a successfully and completely treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.',\n",
       "   'History of or current acute inflammatory joint disease of origin other than rheumatoid arthritis, e.g. mixed connective tissue disease, systemic lupus erythematosus etc.',\n",
       "   'History of uncontrolled diabetes, unstable ischemic heart disease, congestive heart failure (New York Heart Association III-IV), active peptic ulcer disease, recent stroke (within 3 months) and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.',\n",
       "   'Subject is known to have immune deficiency, history of positive human immunodeficiency virus status or is immunocompromised.',\n",
       "   'Persistent chronic infection, or severe infections requiring hospitalization or treatment with intravenous antibiotics within 30 days, or oral antibiotics within 14 days prior to enrollment.',\n",
       "   'Female subjects who are pregnant or breast-feeding or is considering becoming pregnant during the study or for 150 days after the last dose of study medication.',\n",
       "   'History of clinically significant drug or alcohol abuse in the last year.',\n",
       "   'Previous diagnosis or signs of central nervous system demyelinating diseases.',\n",
       "   'History of untreated or active tuberculosis, histoplasmosis or listeriosis.',\n",
       "   'History of clinically significant hematologic (e.g. severe anemia, leucopenia, thrombocytopenia), renal or liver disease (e.g. fibrosis, cirrhosis, hepatitis).',\n",
       "   'Screening clinical laboratory analysis showing any of the following abnormal laboratory results:',\n",
       "   'Aspartate transaminase or alanine transaminase > 1.75 x the upper limit of normal.',\n",
       "   'Serum total bilirubin >= 1.5 mg/dL (>= 26 micromol/L).',\n",
       "   'Creatinine > 1.5 mg/dL (133 micromol/L) in subjects < 65 years old and > upper limit of normal range in subjects >= 65 years old.',\n",
       "   'Positive Hepatitis B or C serology indicative of previous or current infections.',\n",
       "   'Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.']},\n",
       " {'nct_id': 'NCT01519375',\n",
       "  'inclusion': ['Confirmed diagnosis (documented in the medical record) of OA, RA or AS',\n",
       "   'Prescription of oral NSAID treatment for OA, RA or AS, where low dose is not sufficient',\n",
       "   'Prescription of PPI for prevention of NSAID associated GI ulcers, with instruction to take PPI same day as when taking NSAID.'],\n",
       "  'exclusion': ['Participating in any clinical trial involving PPI or NSAID',\n",
       "   'Patients prescribed PPI as acute treatment of GI events or symptoms within 8 weeks',\n",
       "   'Inability to complete PROs']},\n",
       " {'nct_id': 'NCT01511926',\n",
       "  'inclusion': ['Diagnosis of arthritic disorder (osteoarthritis, rheumatoid arthritis or ankylosing spondylitis) Risk for developing gastrointestinal ulcer Already prescribed Vimovo'],\n",
       "  'exclusion': ['Participation in any interventional drug study at the time Vimovo™ was prescribed',\n",
       "   'Patients started on Vimovo during the first 3 months after country-specific launch date',\n",
       "   'Patients started on Vimovo after the study site is initiated (in order to avoid influence on prescribing decision and recruitment)']},\n",
       " {'nct_id': 'NCT01511003',\n",
       "  'inclusion': ['Subjects who have rheumatoid arthritis for 6 months or longer based on American College of Rheumatology (ACR) diagnostic criteria',\n",
       "   'Subjects who used more than 1 Disease Modifying Antirheumatic Drug (DMARD) including MTX (methotrexate) for 6 months or longer',\n",
       "   'Subjects with ESR (erythrocyte sedimentation rate) ≥ 28mm/h or CRP (C-reactive protein)≥ 1.0 mg/dL',\n",
       "   'Subjects with ≥ 3 swollen joints out of 66 joints assessed',\n",
       "   'Subjects with ≥ 6 tender joints out of 68 joints assessed'],\n",
       "  'exclusion': ['Pregnant or nursing women, or subjects who plan to become pregnant within 6 months or whose screening test results show pregnancy cannot be ruled out',\n",
       "   'Subjects with previous experience of tacrolimus (excluding external preparations)',\n",
       "   'Subjects with renal dysfunction or with serum creatinin > 1.4 mg/dL at screening',\n",
       "   'Following subjects with hepatic dysfunction: viral infection, non-viral infection, hepatic cirrhosis, and Serum Glutamic Oxaloacetic Transaminase / Serum Glutamic Pyruvic Transaminase (SGOT/SGPT) exceeding twice the upper limit of normal at screening',\n",
       "   'Subjects with pancreatitis, uncontrolled diabetes or complication(s) or with HbA1c > 6.4% at screening',\n",
       "   'Subjects complicated with hyperkalemia or with serum potassium level >5.5 mEq/L at screening',\n",
       "   'Subjects with history of heart disease (ischemic heart disease, arrhythmia requiring treatment, and heart failure), etc or complications',\n",
       "   'Subjects complicated with severe respiratory disease and infection',\n",
       "   'Subjects with history of malignant tumor or complication(s) (However, the subjects who are considered to have no risk of recurrence with malignant tumor untreated for 5 years or longer can enter the study. The subjects who succeeded in treatment for basal cell or squamous cell carcinoma of skin can also enter the study.)',\n",
       "   'Subjects who were treated with other investigational product(s) within 3 months before screening',\n",
       "   'Other subjects who are considered ineligible for the study by the investigator']},\n",
       " {'nct_id': 'NCT01519791',\n",
       "  'inclusion': ['Subjects must have a time since diagnosis of adult-onset Rheumatoid Arthritis (RA) less than 1 year as defined by the 2010 ACR/EULAR classification criteria from Screening Visit',\n",
       "   'Positive Rheumatoid Factor (RF) and/or positive anticyclic Citrullinated Peptide Antibody (anti-CCP)',\n",
       "   'Active RA disease',\n",
       "   'DMARD-naïve',\n",
       "   'Subject is naïve to RA related biologics'],\n",
       "  'exclusion': ['A diagnosis of any other inflammatory Arthritis',\n",
       "   'History of infected joint prosthesis, or other significant infection and other serious medical condition',\n",
       "   'Known Tuberculosis (TB) disease or high risk of acquiring TB infection']},\n",
       " {'nct_id': 'NCT01609205',\n",
       "  'inclusion': ['Adult patient (> 18 years of age), male or female',\n",
       "   'Rheumatoid arthritis according to the 1987 ACR or 2010 EULAR/ACR classification criteria',\n",
       "   'Moderate to high disease activity',\n",
       "   'Ongoing anti-rheumatic treatment with DMARD, with stable dosage during the last 3 months, and being a candidate for anti-TNF add-on therapy OR ongoing treatment with first anti-TNF therapy and being a candidate for switch to another anti-TNF therapy',\n",
       "   'Women with child-bearing potential: use of an adequate method of contraception to avoid pregnancy throughout the study',\n",
       "   'Signed Informed Consent *Signed Informed Consent must be obtained before any study specific procedures take place.'],\n",
       "  'exclusion': ['Biologic treatment with Adalimumab before inclusion',\n",
       "   'Two or more ongoing biologic treatments before inclusion',\n",
       "   'Treatment with other biologic treatment than anti-TNF therapy before inclusion',\n",
       "   'Any contraindication for treatment with Adalimumab',\n",
       "   'Intraarticular corticosteroid injection during the last 4 weeks before each follow-up visit',\n",
       "   'Positive for tuberculosis or hepatitis',\n",
       "   '- Ongoing pregnancy or lactation']},\n",
       " {'nct_id': 'NCT01602302',\n",
       "  'inclusion': ['Male or female patient ≥18 years and <90 years of age',\n",
       "   'Classification of RA according to the ACR/EULAR 2010 criteria',\n",
       "   'Persistent clinical remission as defined by the ACR/EULAR remission criteria for at least 6 months (documented at ≥2 visits)',\n",
       "   'Written informed consent',\n",
       "   'Current treatment with a single csDMARD or a combination of csDMARDs plus a stable dose and administration interval (for the last 6 months) of a TNF-alpha inhibitor',\n",
       "   'No current systemic corticosteroid treatment (stopped for at least 4 weeks), no corticosteroid injection within 4 weeks',\n",
       "   'Stable dose of NSAIDs for at least 1 week'],\n",
       "  'exclusion': ['• Current treatment with any investigational drug',\n",
       "   'Current administration interval of the anti-TNF-alpha agent of >11 weeks',\n",
       "   'Complete destruction of any joint to be investigated by sonography',\n",
       "   'Current RA-related vasculitis or other active systemic (i.e. extraarticular) RA- manifestation with the exception of rheumatoid nodules',\n",
       "   'Initial arthritis manifestations before the age of 17 years',\n",
       "   'Planned surgery within the study period or history of surgery of any of the joints to be investigated clinically or by sonography',\n",
       "   'Current severe medical illness requiring hospitalization',\n",
       "   'Active infection or active malignancy at screening or infection during the past 4 weeks requiring (even temporary) discontinuation of the anti-TNF-alpha agent',\n",
       "   'Pregnancy or lactation',\n",
       "   'Inability of the patient to follow the protocol',\n",
       "   'Current treatment with Rituximab (MabThera®)']},\n",
       " {'nct_id': 'NCT01600521',\n",
       "  'inclusion': ['age of 18 years or older',\n",
       "   'active RA, defined by at least 8 swollen joints and at least 10 tender joints (excluding distal interphalangeal joints)',\n",
       "   'an erythrocyte sedimentation rate (ESR) of at least 28 mm per hour',\n",
       "   'the 1987 revised American College of Rheumatology (ACR) criteria for diagnosis of RA for at least 6 months',\n",
       "   'not use of NSAIDs within two weeks',\n",
       "   'agreement to participate in this study.'],\n",
       "  'exclusion': ['poor compliance',\n",
       "   'severe medical conditions',\n",
       "   'abnormalities in liver, or kidney function, or in haematological parameters,',\n",
       "   'pregnancy or breast feeding']},\n",
       " {'nct_id': 'NCT01592292',\n",
       "  'inclusion': ['Adult participants, >/=20 years of age',\n",
       "   'Participants with rheumatoid arthritis, who have not responded or have been intolerant to a single anti-TNF alpha therapy and who have initiated MabThera or an alternative anti-TNF alpha therapy'],\n",
       "  'exclusion': ['Participants whose first anti-TNF alpha treatment was, or second biological therapy is given as part of a clinical trial studying rheumatoid arthritis',\n",
       "   'Participants who have not signed the informed consent form']},\n",
       " {'nct_id': 'NCT01590459',\n",
       "  'inclusion': ['Male and female subjects, between 18 and 80 years of age (inclusive)',\n",
       "   'All subjects must have been diagnosed with RA',\n",
       "   'Must have a swollen joint count of ≥6 out of 66 joints and tender joint count of ≥6 out of 68 joints',\n",
       "   'Baseline CRP level must be above the upper limit of normal',\n",
       "   'All subjects must have been receiving stable MTX coadministered with folic or folinic acid (at least 5 mg/week)',\n",
       "   'Subjects may remain on 1 nonsteroidal anti-inflammatory medication during the study (aspirin ≤ 325 mg/day is allowed).',\n",
       "   'Subjects must not have received prior treatment with a JAK inhibitor',\n",
       "   'Subjects who are on an additional nonbiologic DMARD (e.g., sulfasalazine) must be willing to discontinue that DMARD after signing consent, except for hydroxychloroquine',\n",
       "   'Subjects may have received previous therapy with a single TNF inhibitor (e.g., etanercept, adalimumab, infliximab, golimumab, certolizumab pegol)',\n",
       "   'Females must have a negative pregnancy test prior to study dosing',\n",
       "   'Sexually active subjects and their partners must agree to contraceptive requirements'],\n",
       "  'exclusion': ['History or presence of a clinically significant medical disorder other than RA that, in the opinion of the investigator and medical monitor, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.',\n",
       "   'Subjects with inflammatory, rheumatological disorders other than RA',\n",
       "   'Pregnant or nursing female subjects',\n",
       "   'Subjects who have a female partner who is pregnant, nursing, or planning to become pregnant',\n",
       "   'Subjects who have planned major surgery (e.g., joint replacement) or procedures during the study',\n",
       "   'History of drug abuse or positive drug screen',\n",
       "   'History of alcohol abuse or excessive alcohol consumption',\n",
       "   'History of tuberculosis (TB) infection of any kind (pulmonary or extrapulmonary, active or latent), regardless of history of anti-TB treatment.']},\n",
       " {'nct_id': 'NCT01593332',\n",
       "  'inclusion': ['1987 ACR criteria for classification of RA',\n",
       "   'Positive for rheumatoid factor(RF)',\n",
       "   'Active RA despite therapy with conventional for at least 3 months as evidenced by DAS 28 > 3/2',\n",
       "   \"Patients with active, resistant RA who didn't receive anti TNF agents.\"],\n",
       "  'exclusion': ['Patient with hypogammaglobulinemia',\n",
       "   'Patient with congestive heart failure (classIV)',\n",
       "   'Active current bacterial,viral,fungal,myocardial or other infections',\n",
       "   'Chronic hepatitis B or hepatitis C carriers',\n",
       "   'History of severe allergic reaction to human,humanized or murine monoclonal antibodies',\n",
       "   'History of malignancies',\n",
       "   'Pregnant women or lactating mothers 8) Patients with Chronic renal failure and hepatic disease.']},\n",
       " {'nct_id': 'NCT01590966',\n",
       "  'inclusion': ['Age between 18 and 70 years-old with documented diagnosis (clinical evaluation, x-ray hands and feet minimum 2 months before inclusion) of rheumatoid arthritis minimum 3 months and maximum 15 years according to ACR criteria 1987. At least 8 tender and 8 swollen joints with inadequate response to at least 2 disease-modifying antirheumatic drugs (DMARDs) of which one is Methotrexate (MTX). Methotrexate must have been administered at least 3 months before baseline and doses and route must be stable for at least 2 months before baseline. Minimum dosage of MTX is 10 mg weekly and maximum dosage is 25 mg weekly. HAQ (Health assessment Score) score at least 25 at baseline and DAS 28(Disease Activity Score) > 3.7 at baseline.',\n",
       "   'All patients are biological naïve patients.',\n",
       "   'Negative for Tuberculosis (TB) (also in history) and negative screening for TB (Mantoux test / x-ray thorax)',\n",
       "   'Female patients must be post-menopausal for at least 1 year or must underwent surgery so that they cannot become pregnant. Women of child bearing potential must use adequate contraception throughout the study and 12 weeks after the last dose of certolizumab pegol.',\n",
       "   'Patient need to understand the study and sign an informed consent form approved by the ethics committee before participation in this study. INCLUSION CRITERIA FOR PATIENTS WITH AXIAL SPONDYLARTHROPATY (15 PATIENTS)',\n",
       "   'Age between 18 and 70-years old with presence of a documented diagnosis of spondylarthropathy according to current ASAS criteria valid for all of the 3 sub-groups (early axial, early peripheral and established axial)',\n",
       "   '10 patients with axial SpA must fulfill current ASAS criteria for AxSpA and 5 of them need to fulfill the current modified New York criteria:',\n",
       "   'Chronic low back pain > 3 months and onset of age < 45 years',\n",
       "   'Active inflammatory injury on sacro-iliac joints on MRI. Active inflammatory injuries are defined as oedema of bone in or around the sacro-iliac joints, compatible with active injuries seen on axial SpA with STIR (short tau inversion recovery) MRI',\n",
       "   'Inadequate response on previously, optimal use of min 2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) in a anti-inflammatory dosage during 3 months or a medical contra-indication for use of NSAIDs',\n",
       "   'BASDAI score ≥ 4',\n",
       "   '5 patients with peripheral SpA must have presence of clinical peripheral arthritis or enthesitis or dactylitis with active disease activity, even under a stable dose of sulfasalazine during 3 months AND presence of one of the following:',\n",
       "   'Psoriasis of skin',\n",
       "   'Inflammatory bowel disease',\n",
       "   'Positive HLA B27',\n",
       "   'sacro-iliitis on image (X-ray or MRI of the sacro-iliac joints)',\n",
       "   'all patients are anti-TNF naive',\n",
       "   'No active tuberculosis (in medical history as current) and negative screening for latent TB (Mantoux test and X-ray thorax).',\n",
       "   'Female patients must be post-menopausal for at least 1 year or must underwent surgery so that they cannot become pregnant. Women of child bearing potential must use adequate contraception throughout the study and 12 weeks after the last dose of certolizumab pegol.',\n",
       "   'Patient need to understand the study and sign an informed consent form approved by the ethics committee before participation in this study.'],\n",
       "  'exclusion': ['Patients cannot have treatment with experimental biological and non-biological therapy in the last 3 months or 5-times the half-live prior to baseline visit',\n",
       "   'Patients who had previously treatment with anti-TNF',\n",
       "   'Patients who had previously treatment with rituximab and/or abatacept',\n",
       "   'Known hypersensitivity to certolizumab pegol (Cimzia®) or one of it compounds',\n",
       "   'Current or recent medical history of progressive uncontrolled renal, hepatic, hematological, gastro-intestinal, endocrine, pulmonary, cardial, neurological or cerebral diseases.',\n",
       "   'Severe or life threatening infections in the last 6 months; signs of current or recent infection',\n",
       "   'Active or latent tuberculosis: in case one or more of the 3 criteria are positive: medical history of TB, recent (< 6 months) X-ray chest or recent positive PPD skin',\n",
       "   'Known history or current viral hepatitis B of hepatitis C',\n",
       "   'Known HIV infection',\n",
       "   'Malignancy or history of a malignancy',\n",
       "   'History of lymph-proliferative disease or signs/symptoms suggestive fort his disease.',\n",
       "   'Moderate to severe hart failure (NYHA-class III/IV)']},\n",
       " {'nct_id': 'NCT01599260',\n",
       "  'inclusion': ['diagnosis of rheumatoid arthritis OR systemic vasculitis (defined as granulomatosis with polyangiitis, Churg-Strauss, microscopic polyangiitis, Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, or giant cell arteritis)'],\n",
       "  'exclusion': ['Non-English speaking',\n",
       "   'Pregnancy',\n",
       "   'Absolute cardiac or pulmonary contraindication to exercise',\n",
       "   'pacemaker']},\n",
       " {'nct_id': 'NCT01596348',\n",
       "  'inclusion': ['Rheumatoid arthritis', 'Age 30 to 80 years'],\n",
       "  'exclusion': ['Language difficulties and no help from family members or friends']},\n",
       " {'nct_id': 'NCT01357018',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis or ankylosing spondylitis'],\n",
       "  'exclusion': ['Patients with mental illness which interfered with questionaire answering']},\n",
       " {'nct_id': 'NCT01359150',\n",
       "  'inclusion': ['The subject must meet the American College of Rheumatology (ACR) classification criteria for the diagnosis of RA by satisfying at least four of the seven criteria.',\n",
       "   'The subject must have active disease at both screening and baseline'],\n",
       "  'exclusion': ['History of any documented influenza or pneumococcal infection within the last 3 months.',\n",
       "   'Receipt of any vaccine within 1 month prior to the initial study drug administration (CP-690,550 or placebo CP-690,550).',\n",
       "   'If a subject has received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of initial study drug administration.']},\n",
       " {'nct_id': 'NCT01351480',\n",
       "  'inclusion': ['Able and willing to give written informed consent',\n",
       "   'Patients must have a diagnosis of rheumatoid arthritis > 3 months',\n",
       "   'Patients must have been receiving methotrexate for 12 weeks prior to screening at a dose of 10mg',\n",
       "   '25 mg weekly.',\n",
       "   'Patient must have had an inadequate response after receiving or previously receiving one (1) but no more than two (2) anti-TNF biologic agents',\n",
       "   'Age >/= 18 yrs',\n",
       "   'Must have active RA as defined by a DAS28 (Erythrocyte sedimentation rate) score >4.4',\n",
       "   'Must have synovitis of at least two joints in one hand/wrist at screening and baseline',\n",
       "   'Must have a negative Pregnancy test and use adequate method of contraception throughout the trial',\n",
       "   'Stable use of Corticosteroids is permitted',\n",
       "   'Stable use of Non-steroidal anti-inflammatory drugs is permitted'],\n",
       "  'exclusion': ['Functional Class IV',\n",
       "   'Pregnancy or breastfeeding',\n",
       "   'History of any other inflammatory arthritis',\n",
       "   'Sexually active patients who are not using acceptable birth control',\n",
       "   'Subjects who have undergone metacarpophalangeal (MCP) arthroplasty or anticipate the need for such a procedure',\n",
       "   'Subjects with a history of cancer in the last five years other than non melanoma skin cancers',\n",
       "   'Subjects who are unable to comply with study and followup procedures',\n",
       "   'Subjects who have current or severe symptoms of renal, hepatic, hematologic, gastrointestinal, pulmonary cardiac, neurologic, or cerebral disease',\n",
       "   'Subjects who currently abuse drugs or alcohol',\n",
       "   'Subjects with evidence of active or latent bacterial or viral infections at the time of enrollment',\n",
       "   'Subjects who have received live vaccines within 4 months of first dose of study medication',\n",
       "   'Subjects with herpes zoster or cytomegalovirus that resolved less than two months prior to dosing',\n",
       "   'Subjects at risk for tuberculosis (TB). Specifically excluded will be subjects with a history of active TB within the last 3 years and subjects with latent TB must have a negative chest X-ray and be started on treatment for at least 28 days prior to dosing.',\n",
       "   'Prior treatment with Rituximab within 12 months',\n",
       "   'Prior treatment with more than 2 TNFs',\n",
       "   'Intramuscular(IM), Intravenous(IV) Intra-articular (IA) corticosteroids within 28 days prior to baseline',\n",
       "   'Subjects who have a metal device affected by MRI (e.g. any type of electronic, mechanical or magnetic implant, metal slivers, metal objects, cardioverter defibrillator)',\n",
       "   'Subjects who have received any disease modifying agent (DMARD) other than methotrexate within the past 28 days prior to baseline']},\n",
       " {'nct_id': 'NCT01357759',\n",
       "  'inclusion': ['Male or female subjects age greater than or equal to 18 years and less than or equal to 75 years.',\n",
       "   'Subjects with RA diagnosis per the 2010 Rheumatoid Arthritis Classification Criteria per American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR.)',\n",
       "   'BMI less than or equal to 35 kg/m2 at Screening.',\n",
       "   'Active RA characterized by DAS28 score of less than or equal to 5.1 at Screening.',\n",
       "   'Have been stabilized on their current dose (up to 25 mg/week) of methotrexate(MTX) for at least 4 weeks before randomization.'],\n",
       "  'exclusion': ['Subjects with severe active RA and are not on a stable therapeutic regimen at Screening.',\n",
       "   'Subjects without significant articular',\n",
       "   '- Relevant history of significant respiratory disease (e.g., chronic bronchitis, asthma in last 5 years, chronic obstructive pulmonary disease, tuberculosis, interstitial lung disease, such as pneumonitis and pulmonary alveolar proteinosis, as well as significant inhalation exposure to silicon and other substances) that required treatment and/or follow up under the direction of a physician.',\n",
       "   'Presence of GM-CSF autoantibodies above normal at Screening.',\n",
       "   'Abnormal chest x-ray or PFTs as judged by the investigator at Screening as clinically significant.',\n",
       "   'Positive Quantiferon test.',\n",
       "   'History of clinically relevant hypersensitivity reactions (e.g., to gold therapy)',\n",
       "   'History of medication use that might have carryover effects during the study.',\n",
       "   'Previous administration of a GM-CSF modulator within 6 months of randomization, or previous administration of a monoclonal antibody or immunoglobulin fusion protein that is not (or worded as \"other than\") a GM-CSF modulator within 3 months of randomization.',\n",
       "   'Use of any biological therapy other than the test article during the study (informed consent to termination visit)',\n",
       "   'Subjects who consume greater than 14 alcoholic drinks per week for males or 7 alcoholic drinks per week for females.',\n",
       "   'Weight greater than 120 kg at Screening.',\n",
       "   'Use of parenteral and/or intra-articular steroids, immunosuppressants, investigational drugs, and oral anticoagulant drugs within 4 weeks prior to randomization. Oral steroid treatment is permitted if the dosage is less than or equal to 10 mg of prednisone daily, is stable for a minimum of 4 weeks before the study and remains unchanged throughout the study.']},\n",
       " {'nct_id': 'NCT01350804',\n",
       "  'inclusion': ['Male or non-pregnant, non-lactating female patients',\n",
       "   'Presence of RA classified by ACR 2010 revised criteria for at least 3 months before screening',\n",
       "   'At Baseline: Disease activity criteria defined by >= 6 tender joints out of 68 and >= 6 swollen joints out of 66 WITH at least 1 of the following at screening:',\n",
       "   'Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibodies positive OR',\n",
       "   'Rheumatoid Factor positive AND WITH at least 1 of the following at screening:',\n",
       "   'High sensitivity C-Reactive Protein (hsCRP) >= 10 mg/L OR',\n",
       "   'Erythrocyte Sedimentation Rate (ESR) >= 28 millimeter (mm)/1st hour',\n",
       "   'Patients must have been taking at least one anti-TNF-α agent given at an approved dose for at least 3 months before randomization and have experienced an inadequate response to treatment or have been intolerant to at least one administration of an anti-TNF-α agent',\n",
       "   'Patients must be taking MTX or any other DMARD (but not more than 1 DMARD) for at least 3 months before randomization and have to be on a stable dose at least 4 weeks before randomization (7.5 to 25 mg/week for MTX or other DMARD at maximum tolerated dose) Exclusion Criteria:',\n",
       "   'Chest x-ray with evidence of ongoing infectious or malignant process, obtained within 3 months prior to screening and evaluated by a qualified physician',\n",
       "   'RA patients functional status class IV according to the ACR 1991 revised criteria',\n",
       "   'Patients who have ever received biologic immunomodulating agents except for those targeting TNFα',\n",
       "   'Previous treatment with any cell-depleting therapies Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01359943',\n",
       "  'inclusion': ['presence of RA classified by ACR 2010 revised criteria for at least 3 months before screening',\n",
       "   'must have been taking MTX for at least 3 months before randomization and must currently be on a stable dose of MTX for at least 4 weeks before randomization.',\n",
       "   'At Baseline: Disease activity criteria defined by >6 tender joints out of 68 and >6 swollen joints out of 66 and with at least 1 of the following at screening: Anti-CCP antibodies positive OR Rheumatoid Factor positive and with at least 1 of the following at screening: hsCRP ≥ 10 mg/L OR ESR ≥ 28 Exclusion criteria:',\n",
       "   'RA patients functional status class IV according to the ACR 1991 revised criteria',\n",
       "   'Previous exposure to secukinumab or any other biologic drug directly targeting IL-17 or IL-17 receptor',\n",
       "   'Previous exposure ever to an anti-TNF-a agent or any other immunomodulatory biologic agent (experimental or approved)',\n",
       "   'Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)',\n",
       "   'Any therapy by intra-articular injections (e.g. corticosteroid, hyaluronan) required for treatment of arthritis within 4 weeks before randomization',\n",
       "   'Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01353859',\n",
       "  'inclusion': ['Adult patients, >/= 18 years of age',\n",
       "   'Moderate to severe active rheumatoid arthritis (RA) of >/= 6 months duration',\n",
       "   'Prior treatment with DMARDs for >/= 12 weeks (at stable dose for >/= 8 weeks)',\n",
       "   'Inadequate clinical response to stable dose of non-biologic DMARD (either single or in combination)'],\n",
       "  'exclusion': ['Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment',\n",
       "   'Autoimmune disease other than RA',\n",
       "   'History of or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with any biologic drug that is used in the treatment of RA',\n",
       "   'Intra-articular or parenteral corticosteroids within 6 weeks prior to baseline',\n",
       "   'Impaired liver, renal or hematologic function',\n",
       "   'Active current or history of recurrent infection',\n",
       "   'History of or currently active primary or secondary immunodeficiency']},\n",
       " {'nct_id': 'NCT01547091',\n",
       "  'inclusion': ['All patients fulfilled the classification criteria (2010) for rheumatoid arthritis, man or woman aged from 18 to 70 years old.',\n",
       "   'Patients must be informed of the investigational nature of this study and give written informed consent in accordance with the institutional and hospital guidelines.',\n",
       "   'Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on this trial. Women of child-bearing potential must have a pregnancy test performed within 72 hours prior to initiation of treatment.'],\n",
       "  'exclusion': ['Any history of ongoing, significant or recurring infections.',\n",
       "   'Any active inflammatory diseases other than',\n",
       "   '- Significant cardiac or pulmonary disease.',\n",
       "   'End-stage renal failure.',\n",
       "   'Pregnant or nursing women may not participate due to the possibility of fetal harm or harm to nursing infants from this treatment regimen.']},\n",
       " {'nct_id': 'NCT01542580',\n",
       "  'inclusion': ['Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.',\n",
       "   'Correction of varus, valgus or post-traumatic deformity',\n",
       "   'Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure',\n",
       "   'Ability and willingness of the patient to attend follow-up visit.',\n",
       "   'Willing to give written informed consent',\n",
       "   'Patients are at least 18 years of age, no upper age limit, must have reached full skeletal maturity. Exclusion Criteria:',\n",
       "   'infection',\n",
       "   'sepsis',\n",
       "   'osteomyelitis Relative Contraindications:',\n",
       "   'An uncooperative patient or a patient with neurologic disorders who is incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair brain function',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, neuromuscular disease',\n",
       "   'Incomplete or deficient soft tissue surrounding the knee Additional research-related'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT01546610',\n",
       "  'inclusion': ['Patients with established diagnosis RA according to criteria of the American College of Rheumatology (ACR) functional classes I, II and III',\n",
       "   'Foot pain with VAS between 3',\n",
       "   '8 cm for walking',\n",
       "   'Age 18-65 years',\n",
       "   'Basic medication stable for at least three months',\n",
       "   'Not made infiltrations in feet and ankles in the last three months and not during the study',\n",
       "   'Agreed to participate and signed term of informed consent'],\n",
       "  'exclusion': ['Other musculoskeletal disorders in symptomatic lower limbs',\n",
       "   'Diseases of the central and peripheral nervous system',\n",
       "   'Decompensated diabetes mellitus',\n",
       "   'No walking',\n",
       "   'Rigid deformities in the feet',\n",
       "   'Use of insoles in the last three months',\n",
       "   'Surgery scheduled in the next 12 months',\n",
       "   'Allergy to the material',\n",
       "   'Mental deficiency']},\n",
       " {'nct_id': 'NCT01548001',\n",
       "  'inclusion': ['Subjects with a diagnosis of RA according to the diagnostic criteria of the American College of Rheumatology (ACR) (revised in 1987)',\n",
       "   'Rheumatoid Arthritis for 3 months to 2 years from the time of the initial diagnosis',\n",
       "   'Subjects have active RA at the time of screening',\n",
       "   'Subjects are naive to MTX or RA related biologics',\n",
       "   'Written informed consent'],\n",
       "  'exclusion': ['Preceding treatment with DMARDs, immunosuppressants (cyclophosphamide, cyclosporine, azathioprine, etc.), or Tripterygium within 4 weeks prior to study entry',\n",
       "   'Chest x-ray abnormalities, such as tuberculosis, interstitial pulmonary fibrosis, etc.',\n",
       "   'ALT >1.5×ULN, AST >1.5×ULN, Cr >135umol/L',\n",
       "   'WBC<4×109/L，HGB<85g/L，PLT<100×109/L',\n",
       "   'Subjects with serious cardiovascular, renal, hematologic or endocrine diseases',\n",
       "   'Pregnant or lactating women',\n",
       "   'Allergic to any of the study drugs',\n",
       "   'History of alcoholism',\n",
       "   'Subjects with mental illness',\n",
       "   'Subjects receiving live vaccines recently',\n",
       "   'Subjects participating in other clinical study within 3 months prior to study entry']},\n",
       " {'nct_id': 'NCT01543594',\n",
       "  'inclusion': ['Clinical diagnosis of Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis',\n",
       "   'Patients with active disease refractory to traditional disease modifying drugs (methotrexate, leflunomide, sulphasalazine, cyclosporine, hydrossiclorochine)',\n",
       "   'Patients eligible to begin conventional biologic therapy'],\n",
       "  'exclusion': ['Any criteria excluding treatment with biologic drugs according to international guidelines']},\n",
       " {'nct_id': 'NCT01543503',\n",
       "  'inclusion': ['Adult patients, >/=18 years of age',\n",
       "   'Diagnosis of rheumatoid arthritis',\n",
       "   'Non-respondent or intolerant to non-biologic disease-modifying anti-rheumatic drug (DMARD) therapy',\n",
       "   'Patient has been prescribed a first biologic therapy up to 6 weeks prior to the inclusion visit, irrespective of the treatment prescribed'],\n",
       "  'exclusion': ['Patients whose first biologic therapy is given as part of a clinical trial studying rheumatoid arthritis (RA) treatment',\n",
       "   'Patients who are receiving or have received experimental DMARDs as part of a clinical trial studying RA treatment in the last 12 months',\n",
       "   'Patients whose first biologic is rituximab, abatacept or anakinra.',\n",
       "   'Patients who have received any biologic therapy for more than 6 weeks prior to the inclusion visit']},\n",
       " {'nct_id': 'NCT01544101',\n",
       "  'inclusion': ['A diagnosis of rheumatoid arthritis, as defined below. A diagnosis of rheumatoid arthritis is based on 2010 ACR / EULAR Rheumatoid Arthritis Classification Criteria. Classification as \"definite RA\" is based on the confirmed presence of synovitis in at least 1 joint, absence of an alternative diagnosis that better explains the synovitis, and achievement of a total score of 6 or greater (of a possible 10): 24 Joint involvement, designating the metacarpophalangeal joints, proximal interphalangeal joints, the interphalangeal joint of the thumb, second through third metatarsophalangeal joint and wrist as small joints, and elbows, hip joints and knees as large joints:',\n",
       "   'Involvement of 1 large joint gives 0 points',\n",
       "   'Involvement of 2-10 large joints gives 1 point',\n",
       "   'Involvement of 1-3 small joints (with or without involvement of large joints) gives 2 points',\n",
       "   'Involvement of4-10 small joints (with or without involvement of large joints) gives 3 points',\n",
       "   'Involvement of more than 10 joints (with involvement of at least 1 small joint) gives 5 points Serological parameters',\n",
       "   'including the rheumatoid factor as well as anti-citrullinated protein antibody (ACPA):',\n",
       "   'Negative RF and negative ACPA gives 0 points',\n",
       "   'Low-positive RF or low-positive ACPA gives 2 points',\n",
       "   'High-positive RF or high-positive ACPA gives 3 points Acute phase reactants: 1 point for elevated erythrocyte sedimentation rate (ESR) or elevated C-reactive protein (CRP) value Duration of arthritis: 1 point for symptoms lasting six weeks or longer',\n",
       "   'Continuing or recurring pain (i.e., joint pain daily, unless on pain medication).',\n",
       "   'Age at least 18 years',\n",
       "   'Ability and willingness to participate in all components of the study',\n",
       "   'Willingness to be assigned to either the diet group or supplement group',\n",
       "   'Pain medications unchanged within last 6 weeks.'],\n",
       "  'exclusion': ['< 18 years of age',\n",
       "   'Rheumatoid arthritis for more than 6 years',\n",
       "   'Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use',\n",
       "   'Use of recreational drugs in the past 6 months (past drug use, if fully recovered, is not a criteria for exclusion)',\n",
       "   'Pregnancy',\n",
       "   'Unstable medical or psychiatric illness',\n",
       "   'Likely to be disruptive in group sessions (as determined by research staff)',\n",
       "   'Already following a low-fat, vegan diet',\n",
       "   'Lack of English fluency',\n",
       "   'Inability to maintain current medication regimen',\n",
       "   'Inability or unwillingness to participate in all components of the study']},\n",
       " {'nct_id': 'NCT01548768',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis by 2010 American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) diagnostic criteria',\n",
       "   'Age>18 years old',\n",
       "   'Moderate to high RA disease activity defined by a Clinical Disease Activity Index (CDAI) of >10',\n",
       "   'Stable dose of Methotrexate for 6 weeks prior to enrollment',\n",
       "   'Stable doses of Nonsteroidal anti-inflammatory drug (NSAID) and prednisone (if already taking these medications) for 2 weeks prior to study EXCLUSION CRITERIA',\n",
       "   'Prior self reported or physician diagnosed CV event (MI; angina; stroke or Transient Ischemic Attach (TIA); Heart Failure (HF); prior CV procedure (e.g., coronary artery bypass graft, angioplasty, valve replacement, pacemaker)',\n",
       "   'Contraindications to having a PET-CT scan or receive adenosine or Fludeoxyglucose (FDG)',\n",
       "   'Active treatment for Cancer',\n",
       "   'Uncontrolled hypertension',\n",
       "   'Diabetes',\n",
       "   'Smoking',\n",
       "   'Treatment with a TNF inhibitor or other biologic currently or within the last 6 months',\n",
       "   'Current treatment with \"Triple Therapy\" or within the last 2 months',\n",
       "   'Untreated positive purified protein derivative (PPD) tuberculosis skin test or active tuberculosis',\n",
       "   'History of Lymphoma and Melanoma',\n",
       "   'Ejection Fraction (EF) < 40% (if not known in advance then the Study Visit I Echocardiogram results will be used to exclude the patient from randomization and follow up)',\n",
       "   'Change in NSAID/Prednisone dosage in last 2 weeks',\n",
       "   'Participation in other research studies involving imaging/radiation exposure For non-RA subjects (25 controls): INCLUSION CRITERIA',\n",
       "   'Age>18 years old',\n",
       "   'Absence of diagnosis of RA'],\n",
       "  'exclusion': ['Prior self reported or physician diagnosed CV event (MI; angina; stroke or Transient Ischemic Attach (TIA); Heart Failure (HF); prior CV procedure (e.g., coronary artery bypass graft, angioplasty, valve replacement, pacemaker)',\n",
       "   'Contraindications to having a PET-CT scan or receive adenosine or FDG',\n",
       "   'Uncontrolled hypertension',\n",
       "   'Participation in other research studies involving imaging/radiation exposure']},\n",
       " {'nct_id': 'NCT00650390',\n",
       "  'inclusion': ['Males and females >= 18 years of age',\n",
       "   'ACR criteria for RA diagnosis for at least 6 months',\n",
       "   'Active RA defined as a DAS 28 >3.2 at study entry',\n",
       "   'Unsatisfactory response, loss of response or intolerance to prior infliximab treatment',\n",
       "   'A negative pregnancy test for females of childbearing potential'],\n",
       "  'exclusion': ['Patient who had previous treatment with cyclophosphamide and chlorambucil',\n",
       "   'Treatment within the last 8 weeks with infliximab',\n",
       "   'Prior treatment with more than one DMARD or DMARD combination following infliximab treatment',\n",
       "   'Prior treatment with biologics (Investigational or Commercial) RA therapies other than infliximab',\n",
       "   'History of cancer, other than successfully treated squamous cell or basal cell carcinoma or lymphoproliferative disease',\n",
       "   'Prior treatment with total lymphoid irradiation']},\n",
       " {'nct_id': 'NCT00654368',\n",
       "  'inclusion': ['18 years of age or older at the baseline visit',\n",
       "   'An American College of Rheumatology(ACR) diagnosis of rheumatoid arthritis with onset of symptoms of at least 6 months',\n",
       "   'Active disease of at least 3 swollen joints from the Disease Activity Severity 28 at the baseline visit',\n",
       "   'A Disease Activity Severity 28 score of ≥ 3.2 at the baseline visit',\n",
       "   'Have not previously received etanercept therapy',\n",
       "   'Able to start etanercept therapy per the approved product monograph',\n",
       "   'Able to continue methotrexate therapy per the approved product monograph and have received a dose of at least 15 mg/wk (or 10 mg/wk in the case of documented intolerance to higher doses) for at least 12 weeks and this dose has been stable at least 4 weeks before the baseline visit',\n",
       "   'The patient or legally acceptable representative must provide written informed consent for participation in the study before any study specific procedures are performed'],\n",
       "  'exclusion': ['Patients who have a positive purified protein derivative (PPD) skin test and who do not have a documented course of anti-tuberculosis therapy. Patients with a positive PPD skin test (equal to or greater than 5 mm), a negative chest x-ray at screening which should be repeated if indicated during of the study, at low risk based on exposure and travel and have initiated a course of anti-tuberculosis therapy of which at least 8 weeks have been completed would be eligible for the study. The full course of anti-tuberculosis therapy must be completed',\n",
       "   'Patients who have previously received infliximab or adalimumab',\n",
       "   'Active infections within 2 weeks of the baseline visit or during the study period',\n",
       "   'Any history of human immunodeficiency (HIV) infection, untreated tuberculosis, multiple sclerosis, congestive heart failure, hepatitis B, hepatitis C, cytopenia, prior or current use of cyclophosphamide or malignancy (other than basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix) in the past 5 years',\n",
       "   'Women who are pregnant or lactating or of childbearing potential who are not using adequate contraception',\n",
       "   'Receipt of any investigational therapy within 4 weeks of the initiation of study medication or during the study period',\n",
       "   \"Presence of any significant and uncontrolled medical condition, which in the investigator's opinion precludes the use of etanercept, as outlined in the product monograph\",\n",
       "   'Participants not available for follow-up assessment or unable to comply with study procedures']},\n",
       " {'nct_id': 'NCT00650767',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis, based on the American College of Rheumatology (ACR) 1987 Revised Criteria, prior to first dose of study drug.',\n",
       "   'Patient has received a stable dose of methotrexate for ≥ 6 weeks prior to first dose of study drug and is willing to continue on this regimen for the duration of the study.',\n",
       "   'Patient has received a stable dose of folate for ≥ 6 weeks and is willing to continue on this regimen for the duration of the study.',\n",
       "   'No prior use of biological agents for the treatment of rheumatoid arthritis.',\n",
       "   'Additional criteria exist. Key'],\n",
       "  'exclusion': ['Diagnosis of any other inflammatory or non-inflammatory arthritis that may interfere with disease activity assessments or clinically apparent osteoarthritis which would affect subsequent efficacy measures.',\n",
       "   'A history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological disease or severe systemic involvement with rheumatoid arthritis.',\n",
       "   'Additional criteria exist.']},\n",
       " {'nct_id': 'NCT00650026',\n",
       "  'inclusion': ['Eighteen years or older',\n",
       "   'Females',\n",
       "   'post-menopausal for at least 1 year, surgically sterile or practicing an acceptable method of birth control',\n",
       "   'Females',\n",
       "   'negative pregnancy test at screening',\n",
       "   'Confirmed diagnosis of active RA >= 6 swollen joints and >= 9 tender joints',\n",
       "   'Met ACR criteria for diagnosis of RA for at least 3 months',\n",
       "   'Active RA defined by a DAS >= 3.2 at study entry'],\n",
       "  'exclusion': ['Subject had prior treatment with cyclophosphamide or chlorambucil',\n",
       "   'Subjects previously treated with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in CD4 lymphopenia',\n",
       "   'Prior treatment with intravenous immunoglobulin or investigational agent in with 30 days or 5 half-lives of adalimumab',\n",
       "   'Subject with history of cancer within the past 10 years other than resected basal cell or squamous cell carcinoma of the skin']},\n",
       " {'nct_id': 'NCT00650078',\n",
       "  'inclusion': ['Documented history of RA in agreement with ACR criteria',\n",
       "   'DMARD treatment for RA greater than or equal to 6 months, with a stable dose greater than or equal to 6 weeks prior to screening visit',\n",
       "   'Duration of morning stiffness greater than or equal to 45 minutes',\n",
       "   'greater than or equal to 4 swollen joints (out of 28)',\n",
       "   'greater than or equal to 4 tender joints (out of 28)'],\n",
       "  'exclusion': ['Suffering from another disease, which requires glucocorticoid treatment during the study period',\n",
       "   'Synovectomy within 4 months prior to study start',\n",
       "   'Use of glucocorticoids:',\n",
       "   'Continued use of systemic glucocorticoids within 4 weeks prior to screening visit',\n",
       "   'Intermittent use of glucocorticoids within 2 weeks prior to screening visit.',\n",
       "   'Joint injections within 6 weeks prior to screening visit',\n",
       "   'Topical glucocorticoids must be stopped at screening visit',\n",
       "   'Use of biologicals such as: tumor necrosis factor α (TNFα) inhibitors and other compounds within 5 serum half lives prior to screening visit',\n",
       "   'Pregnancy or nursing']},\n",
       " {'nct_id': 'NCT00650156',\n",
       "  'inclusion': ['Male or Female ages 18 years and older.',\n",
       "   'Mild',\n",
       "   '- Body weight less than 100',\n",
       "   ''],\n",
       "  'exclusion': ['Wheelchair-bound or bedridden.',\n",
       "   'Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit.',\n",
       "   'Intra-articular, intramuscular or intravenous (IV) administration of corticosteroids within 28 days prior to the Screening visit.',\n",
       "   'Prior treatment with any TNF antagonist, including adalimumab.',\n",
       "   'Positive tuberculin PPD',\n",
       "   '- Female subjects who are pregnant or breast-feeding.',\n",
       "   'History of HIV or of being immuno-compromised.',\n",
       "   'History of malignancy.',\n",
       "   'Poorly controlled medical condition.']},\n",
       " {'nct_id': 'NCT00941707',\n",
       "  'inclusion': ['Participants diagnosed with rheumatoid arthritis (RA) according to the revised 1987 criteria of the ARA (Arnett et al, 1988) for at least 6 months at Screening',\n",
       "   'Participants who have been treated with and tolerated methotrexate (MTX) treatment at dosages from 7.5 to 25 milligram (mg) per week inclusive, for a minimum of 4 months before Screening',\n",
       "   'Participants if using non-steroidal anti-inflammatory drugs (NSAIDs) or other analgesics (drug used to control pain) regularly for RA, participants must have been on a stable dose for at least 2 weeks before the first dose of study medication',\n",
       "   'Participants if using oral corticosteroids (compounds, usually hormonal, taken orally [by mouth] in order to block ovulation [discharge of an egg from the ovary] and prevent the occurrence of pregnancy [carrying an unborn baby]), must be on a stable dose of less than or equal to 10 mg per day of prednisone or another oral corticosteroid for at least 4 weeks before the first dose of study medication and continue with the same dose throughout the study. If not using corticosteroids at study initiation, the participant must have not received any oral corticosteroids for at least 4 weeks before the first dose of study medication',\n",
       "   'Participants currently treated with folic acid at a minimum dose of 5 mg per week'],\n",
       "  'exclusion': ['Participants having inflammatory disease other than RA',\n",
       "   'Participant who have used any of the following medications: D-penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold salts, sulfasalazine, leflunomide, azathioprine, cyclosporine, tacrolimus, and mycophenolatemofetil',\n",
       "   'Participant who have received intra-articular, intramuscular (into the muscle), or intravenous (into the vein) corticosteroids, including adrenocorticotropic hormone (hormone made by the brain that activates the adrenal glands) within 4 weeks before the first dose of the study medication',\n",
       "   'Participants who have been treated with any other investigational drug or medical device within 4 weeks or 5 half-lives of the drug, whichever is longer before the first dose of study medication',\n",
       "   'Participants who have undergone surgical treatments for RA including synoviectomy (surgical removal of a part of the synovial membrane of a joint) and arthroplasty (surgery to fix a joint) within 3 months before the first dose of study medication']},\n",
       " {'nct_id': 'NCT00947492',\n",
       "  'inclusion': ['Rheumatoid arthritis patients',\n",
       "   'treated with new immunosuppressive drugs : Orencia* (abatacept) and RoActemra* (tocilizumab)',\n",
       "   'Disease longer than one year'],\n",
       "  'exclusion': ['Rheumatoid arthritis patients treated with ciclosporin in two years preceding the study',\n",
       "   'Transplanted patients',\n",
       "   'Disease shorter than one year',\n",
       "   'Histories of lymphoma']},\n",
       " {'nct_id': 'NCT00944320',\n",
       "  'inclusion': ['Male/female age >18',\n",
       "   'Clinical diagnosis of Rheumatoid Arthritis'],\n",
       "  'exclusion': ['Must not be pregnant/breastfeeding',\n",
       "   'Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitis, malignant melanoma, cardiac conduction disorders, hepatic/renal insufficiency.']},\n",
       " {'nct_id': 'NCT00944255',\n",
       "  'inclusion': ['Male/female age >18', 'RA diagnosed'],\n",
       "  'exclusion': ['Must not be pregnant/breastfeeding',\n",
       "   'Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitus, malignant melanoma, cardiac conduction disorders, hepatic/renal insufficiency.']},\n",
       " {'nct_id': 'NCT00948610',\n",
       "  'inclusion': ['Rheumatoid arthritis patients will meet American College of Rheumatology revised criteria (Arnett, Edworthy et',\n",
       "   '1988). This requires at least four of the following seven criteria: 1) morning joint stiffness; 2) arthritis in 3 or more joint areas; 3) arthritis of hand joints; 4) symmetric arthritis; 5) rheumatoid nodules; 6) presence of serum rheumatoid factor and 7) changes on posteroanterior hand and wrist radiographs. In addition, criteria 1-4 must be present for at least four weeks. Subjects must be between 18 and 85 years of age.',\n",
       "   'If rheumatoid arthritis patients are receiving treatment with traditional disease modifying antirheumatic drugs (DMARD), such as methotrexate, sulfasalazine or hydroxychloroquine, they must be on a stable regime for one month before study and stable throughout study.',\n",
       "   'If rheumatoid arthritis patients have received treatment with a TNF antagonist or other biologic medication, they must be drug free for greater than 3 months.'],\n",
       "  'exclusion': ['Steroids',\n",
       "   'Individuals currently taking greater than an equivalent of 10 mg of prednisone will be excluded given the potent anti-inflammatory effects of such medications.',\n",
       "   'Opioids',\n",
       "   'Individuals using multiple daily dosage schedule of opioid agents such as oxycodone (Percocet), hydrocodone (Vicodin), morphine, Dilaudid will be excluded.',\n",
       "   'Co-morbid medical disorders',\n",
       "   \"the presence of active unstable and uncontrolled co-morbid medical conditions such as diabetes, cardiovascular diseases, and cancer will be exclusionary criteria. In particular, individuals with co-morbid inflammatory disorders such as Crohn's disease and ulcerative colitis and other autoimmune disorders will be excluded. Any uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or put the study participant at undue risk will also be considered exclusionary criteria.\",\n",
       "   'Chronic infections',\n",
       "   'individuals with chronic infections will also be excluded because of effects on immune markers measured in study.',\n",
       "   'Co-morbid pain disorders',\n",
       "   'individuals with co-morbid pain disorders such as fibromyalgia will also be excluded. Individuals with fibromyalgia have been found to have sleep abnormalities as well as daytime fatigue and pain and thus could confound findings.',\n",
       "   'Psychiatric disorders',\n",
       "   'current conditions such as major depressive disorder, bipolar disorder and risk for suicide will also be considered exclusionary criteria.',\n",
       "   'Gender-based criteria',\n",
       "   'pregnant or breast-feeding women will also be excluded because of their effects on neuroendocrine systems and sleep']},\n",
       " {'nct_id': 'NCT00819481',\n",
       "  'inclusion': ['This must be a primary knee replacement on this knee.',\n",
       "   'Patient is over 18 years of age or older',\n",
       "   'Have knee joint disease related to one or more of the following',\n",
       "   'degenerative joint disease, including osteoarthritis or traumatic arthritis',\n",
       "   'Avascular necrosis of the femoral condyles',\n",
       "   'Post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy',\n",
       "   'Moderate valgus, varus, or flexion deformities',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Patient is likely to be available for evaluation for the duration of the study',\n",
       "   'Able and willing to sign the informed consent and follow study procedures',\n",
       "   'Patient is not pregnant'],\n",
       "  'exclusion': ['Is younger than 18 years of age',\n",
       "   'If there has been a total knee replacement on this knee in the past (no revisions allowed in study)',\n",
       "   'Infection, or history of infection, acute or chronic, local or systemic',\n",
       "   'Alcoholism or other addictions',\n",
       "   'Muscular, neurological or vascular deficiencies which compromise the affected extremity',\n",
       "   'Obesity',\n",
       "   'Insufficient bone quality',\n",
       "   'Loss of ligamentous structures',\n",
       "   'High levels of physical activity',\n",
       "   'Materials sensitivity',\n",
       "   'Prisoner',\n",
       "   \"Mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements\",\n",
       "   'Patient is pregnant']},\n",
       " {'nct_id': 'NCT00810199',\n",
       "  'inclusion': ['adult patients, ≥ 18 years of age;',\n",
       "   'moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) > 4.4);',\n",
       "   'inadequate response to methotrexate;',\n",
       "   'on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.'],\n",
       "  'exclusion': ['prior treatment with a biologic;',\n",
       "   'Rheumatoid arthritis (RA) functional class IV;',\n",
       "   'known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;',\n",
       "   'evidence of active malignant disease.']},\n",
       " {'nct_id': 'NCT00815425',\n",
       "  'inclusion': ['Rheumatoid arthritis', 'Self-declared as African American'],\n",
       "  'exclusion': ['Lupus']},\n",
       " {'nct_id': 'NCT00810277',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'moderate to severe rheumatoid arthritis;',\n",
       "   'inadequate response to current non-biologic DMARDs'],\n",
       "  'exclusion': ['rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;',\n",
       "   'previous treatment with other biologics.']},\n",
       " {'nct_id': 'NCT00818064',\n",
       "  'inclusion': ['For healthy volunteers (HV) the following applies:',\n",
       "   'Subjects who are considered to be generally healthy based on assessment of medical history, physical examination and clinical laboratory data at screening, as judged by the Investigator',\n",
       "   'Females who are post-menopausal, surgically sterile or of non-child-bearing potential',\n",
       "   'For rheumatoid arthritis (RA) patients the following applies:',\n",
       "   \"A diagnosis of rheumatoid arthritis according to the American College of Rheumatology (ACR1987 classification) of at least three months' duration prior to dosing\",\n",
       "   'Active RA, characterised by a Disease Activity Score 28 (DAS28) greater than 3.2',\n",
       "   'Methotrexate treatment (stable doses of maximally 25.0 mg/week for at least 4 weeks) and concomitant intake of folic acid 1 mg/day or 5 mg/week',\n",
       "   'Females who are post-menopausal, surgically sterile or of non-child-bearing potential'],\n",
       "  'exclusion': ['For healthy volunteers (HV) the following applies:',\n",
       "   'Male subjects who do not accept to use double barrier methods of birth control from first dosing until 3 moths after their last visit',\n",
       "   'Body mass index (BMI) below 18.5 or above 35.0 kg/m2',\n",
       "   'Clinically significant cardiac or cardiovascular disease',\n",
       "   'Abnormal blood pressure and heart rate',\n",
       "   'Hepatic insufficiency',\n",
       "   'Renal insufficiency',\n",
       "   'Positive for humane immunodeficiency virus (HIV)',\n",
       "   'Positive for hepatitis B (HBV) or hepatitis C (HCV)',\n",
       "   'Lymphoproliferative disease',\n",
       "   'History or signs of malignancy (except adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to dosing)',\n",
       "   'History of any autoimmune or current inflammatory conditions including rheumatoid arthritis or any other joint disease',\n",
       "   'Active or latent tuberculosis: For tuberculosis unvaccinated subjects detected as a positive Mantoux test. For subjects vaccinated against tuberculosis detected as a positive QuantiFeron-test',\n",
       "   'Chronic or ongoing infectious disease requiring systemic anti-infectious treatment within the last 2 weeks prior to administration of trial drug',\n",
       "   'Any vaccination within the last month before dosing',\n",
       "   'Known active viral, bacterial or fungal infection, including herpes, herpes zoster or cold sores 14 days prior to dosing',\n",
       "   'Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 2 weeks prior to dosing, unless in the opinion of the Investigator the medication will not interfere with the trial procedures or compromise the safety of the subject',\n",
       "   'History of or current drug and/or alcohol abuse',\n",
       "   'Blood donation within the last 3 months (more than 0.45 L)',\n",
       "   'For rheumatoid arthritis (RA) patients the following applies:',\n",
       "   'Male subjects who do not accept to use double barrier methods of birth control from first dosing until 3 months after their last visit',\n",
       "   'Body mass index (BMI) below 18.5 or above 35.0 kg/m2',\n",
       "   \"Subjects with chronic inflammatory autoimmune disease other than rheumatoid arthritis (except secondary Sjögren's syndrome)\",\n",
       "   \"History of or current inflammatory joint disease other than rheumatoid arthritis (e.g. gout, psoriatic or reactive arthritis, Lyme's disease, juvenile arthritis)\",\n",
       "   'Chronic or ongoing infectious disease requiring systemic anti-infectious treatment within the last 2 weeks prior to dosing',\n",
       "   'Any vaccination within the last month before dosing',\n",
       "   'Known active viral, bacterial or fungal infection, including herpes, herpes zoster or cold sores 14 days prior to administration of trial product',\n",
       "   'Lymphoproliferative disease',\n",
       "   'History or signs of malignancy (except adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to dosing)',\n",
       "   'Use of selective cyclooxygenase-2 (COX-2) inhibitors within the last 2 weeks prior to randomisation',\n",
       "   'Concomitant medication']},\n",
       " {'nct_id': 'NCT00814866',\n",
       "  'inclusion': ['Patients satisfying the ACR criteria for Rheumatoid arthritis and having received a prescription of Adalimumab at the Centre Hospitalier Universitaire de Sherbrooke.'],\n",
       "  'exclusion': ['Patients under 18 years old',\n",
       "   'Patients unwilling or unable to sign an informed consent',\n",
       "   'Patients starting Adalimumab less than five half-lifes after the interruption of a previous anbti-TNF therapy']},\n",
       " {'nct_id': 'NCT00538902',\n",
       "  'inclusion': ['Met ACR criteria for diagnosis of active rheumatoid arthritis (RA) and have had at both the Screening visit and Week 0 visit at least four swollen joints (out of 66 assessed) and at least six tender joints(out of 68 assessed)',\n",
       "   'Subjects must have failed prior treatment with one or more disease-modifying antirheumatic drugs (DMARDs)',\n",
       "   'DMARDs (other than methotrexate [MTX]) must have been discontinued for >= 28 days or at least 5 half-lives, whichever is greater, before the Week 0 visit',\n",
       "   'Traditional Chinese Medicines must have been discontinued for >= 28 days before the Week 0 visit',\n",
       "   'Subjects must have received at least three months of treatment with MTX (minimum 7.5 mg/week) and remained on a stable dose of MTX for >= 28 days prior to the Screening visit',\n",
       "   'Glucocorticoids equivalent to <= 10 mg of prednisone and prednisone equivalent must have remained unchanged for at least 28 days prior to the Week 0 visit',\n",
       "   'Must have been able and willing to give written informed consent and to comply with the requirements of this study protocol'],\n",
       "  'exclusion': [\"A history of, or current, acute inflammatory joint disease of different origin (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus, fibromyalgia or any arthritide with onset prior to age 16 years\",\n",
       "   'Wheelchair-bound or bedridden',\n",
       "   'Joint surgery involving joints to be assessed within this study, within two months prior to the Screening visit',\n",
       "   'Intra-articular, intramuscular or intravenous administration of corticosteroids within 28 days prior to the Screening visit',\n",
       "   'Prior treatment with any TNF antagonist, including adalimumab',\n",
       "   'Subject considered by the investigator, for any reason, to be an unsuitable candidate',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT00533897',\n",
       "  'inclusion': ['Clinical diagnosis of Rheumatoid Arthritis',\n",
       "   'Disease Activity Score (DAS)28-C-Reactive Protein (CRP) score ≥ 3.2 and ≤5.1',\n",
       "   'On background methotrexate at least 3 months (≥10mg weekly)',\n",
       "   'Must be able to self injection or allow a care giver to do it for them',\n",
       "   'Discontinue all Biologics and Disease-Modifying Anti-rheumatic Drugs (DMARDs) except for methotrexate'],\n",
       "  'exclusion': ['Participants who had prior exposure to abatacept or CTLA-4 Ig',\n",
       "   'Received treatment with rituximab.',\n",
       "   'Participants who have received treatment with leflunomide within 1 year of screening',\n",
       "   'Participants who have received treatment with immunoadsorption columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine.']},\n",
       " {'nct_id': 'NCT00537667',\n",
       "  'inclusion': ['Diagnosed with RA as determined by American College of Rheumatology (ACR) criteria (Appendix C)',\n",
       "   'Disease duration of no less than 12 weeks of diagnosis confirmed by physician and source documentation',\n",
       "   'Disease duration < 10 years',\n",
       "   'Active RA at baseline as defined by a minimum of 6 or more swollen joints and 9 or more tender/painful joints (based on a 66/68-joint count excluding distal interphalangeal joints) at screening and baseline, And',\n",
       "   'C-reactive protein (CRP) > 2 mg/dL at screening.',\n",
       "   'Have active clinical synovitis in the knee as determined by the investigator based on clinical evaluation',\n",
       "   '18 years of age or older',\n",
       "   'Men or non-pregnant (negative serum HCG at screening unless surgically sterile or postmenopausal), non-breast-feeding women may be enrolled. Females of childbearing potential and males must use adequate contraceptive precautions as determined by the principal investigator.',\n",
       "   'Subjects that have taken any DMARD for less than 3 months must not have taken DMARDs within 4 weeks prior to screening. Subjects that have taken any DMARD for longer than 3 months must not have taken DMARDs within 6 months of screening.',\n",
       "   \"Subject's doses of NSAIDs and oral corticosteroids (10 mg/day of prednisone or equivalent) must have been kept stable for 4 weeks before screening\",\n",
       "   'Subjects must not have had intrarticular injections in the joint that will be arthroscoped for at least 3 months prior to screening. Before any study specific procedure or screening is done, the subject or legally acceptable representative must give informed consent for participation in the study (see Section 12.2). Before buccal smears and blood samples are taken for genetic testing, the subject or legally acceptable representative must give informed consent for use of those samples for genetic testing (see Section 12.2).'],\n",
       "  'exclusion': ['ACR functional class IV or American Rheumatology Association anatomical stage IV (see Appendix C)',\n",
       "   'Disease duration >10 years',\n",
       "   \"Diagnosed with the following: Felty's syndrome Advanced or uncontrolled Diabetes Mellitus (defined as: HbA1c > 8%, peripheral neuropathy, renal/retinal involvement, or vascular disorders) Malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix, within the past five years Any other major chronic inflammatory disease or syndrome (e.g., psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease, fibromyalgia that required treatment in the last year)\",\n",
       "   'Any uncontrolled, clinically significant systemic disease',\n",
       "   'Pre-existing or recent onset central nervous system demyelinating disorders',\n",
       "   'Significant hematologic abnormalities',\n",
       "   'A history of drug or alcohol abuse within the previous 24 weeks',\n",
       "   'Known to be hepatitis B surface antigen, hepatitis C virus or Human Immunodeficiency Virus positive',\n",
       "   'Any disorder that compromises ability to give informed consent for participation in this study',\n",
       "   'Is expected to require a major surgical operation while on study that would interfere with the collection of the required assessments.',\n",
       "   'Has an infection requiring systemic anti-infective therapy, open wounds, or has developed frequent acute or chronic infections during the past 12 weeks.',\n",
       "   'Prior active tuberculosis.',\n",
       "   'Total white blood cell count < 3.5 x 109/L at screening',\n",
       "   'Neutrophil count of < 2.5 x 109/L at screening',\n",
       "   'Platelet count of < 125 x 109/L at screening',\n",
       "   'Hemoglobin < 8.0 g/dL at screening',\n",
       "   'Abnormal liver function tests (AST/ALT > 1.5 x the upper limits of normal) at screening',\n",
       "   'Abnormal renal function (serum creatinine > 1.5 x the upper limits of normal) at screening',\n",
       "   'Prior treatment with any protein-based TNF inhibitor (e.g. etanercept, infliximab, PEG sTNF-RI, D2E7)',\n",
       "   'Prior treatment with anakinra',\n",
       "   'Receiving or has received any investigational drug within the previous 16 weeks or within at least 5 half-lives of any investigational drug, whichever is greater (or is currently using an investigational device)',\n",
       "   'Received any intra-articular injections (e.g.. corticosteroids, hyaluronate preparations) or systemic corticosteroid injections within 4 weeks before the screening visit',\n",
       "   'Requires analgesia other than paracetamol, NSAIDs, codeine, oxycodone, propoxyphene, tramadol, hydrocodone, or the combinations of these products (or equivalents)',\n",
       "   'Subject (men or women of childbearing potential) is not using adequate contraceptive precautions as determined by the principal investigator',\n",
       "   'Known allergy to E coli-derived products',\n",
       "   'Not available for follow-up assessments',\n",
       "   \"Concerns for the subject's compliance with the protocol procedures\"]},\n",
       " {'nct_id': 'NCT00535782',\n",
       "  'inclusion': ['adult patients, 18-75 years of age',\n",
       "   'rheumatoid arthritis (RA) of >6 months duration',\n",
       "   'able to receive outpatient treatment',\n",
       "   'on methotrexate for at least 12 weeks before entering study, at a stable dose of 7.5-25 mg/week for the last 8 weeks',\n",
       "   'oral corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDS) permitted, if at a stable dose for 4 weeks before study start'],\n",
       "  'exclusion': ['major surgery (including joint surgery) within 8 weeks prior to screening, or planned surgery within 6 months after entering study',\n",
       "   'history of, or current inflammatory joint disease or rheumatic autoimmune disease other than RA',\n",
       "   'inadequate response to anti-tumor necrosis factor (TNF) agent during the 6 months prior to baseline, or inadequate response to >2 anti-TNF agents',\n",
       "   'initiation of treatment with lipid lowering agents within 12 weeks prior to baseline']},\n",
       " {'nct_id': 'NCT00531817',\n",
       "  'inclusion': ['Adult patients, ≥18 years of age',\n",
       "   'Active rheumatoid arthritis of >6 months duration',\n",
       "   'Received permitted DMARDs each at a stable dose for at least 7 weeks prior to baseline'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Major surgery within 8 weeks prior to screening or planned within 6 months following randomization',\n",
       "   'Unsuccessful treatment with a biologic agent, including an anti-TNF agent',\n",
       "   'Previous treatment with tocilizumab']},\n",
       " {'nct_id': 'NCT00042406',\n",
       "  'inclusion': ['A diagnosis of rheumatoid arthritis according to the American College of Rheumatology 1987 revised criteria (ACR) of at least 6 months duration.',\n",
       "   'Active disease at the time of screening.',\n",
       "   'Failure to tolerate MTX, or lack of efficacy after a minimum of 6 months treatment with MTX. Exclusion Criteria:',\n",
       "   \"Active autoimmune disease requiring therapy (other than rheumatoid arthritis and secondary Sjögren's disease).\",\n",
       "   'Syndromes such as Fibromyalgia which require chronic pain treatment.',\n",
       "   'Most past or current cancers.',\n",
       "   'Chronic or current infectious disease such as, but not limited to, chronic renal infection, chronic chest, nasal or throat infections, tuberculosis, hepatitis B and',\n",
       "   '- History of infected joint prosthesis within 5 years.',\n",
       "   'Most active medical conditions such as heart disease, kidney disease, liver disease, blood diseases, hormonal disturbances, lung disease, psychiatric disease.',\n",
       "   'Drug or alcohol abuse.',\n",
       "   'Pregnant or breast-feeding women may not participate. Women of childbearing potential must use either contraceptive pills or an intra-uterine device for the entire study period. Note: Other protocol defined Inclusion and'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00048321',\n",
       "  'inclusion': ['Age >/= 18 years.',\n",
       "   'Rheumatoid arthritis for >/= 6 months.',\n",
       "   'Active disease as defined by >/= 6 swollen and >/= 9 tender joints, AND an abnormal C-reactive protein or Westergren Erythrocyte Sedimentation Rate lab test, OR Morning Stiffness >/= 1 hour.',\n",
       "   'Use of at least one DMARD, and ability to discontinue any current DMARD.'],\n",
       "  'exclusion': ['Onset of rheumatoid arthritis before the 16th birthday.',\n",
       "   'Wheelchair or bed-bound functional level.',\n",
       "   'No previous infliximab or etanercept treatment, or investigational therapy (not placebo) with other TNF-alpha inhibitors.',\n",
       "   'Prednisone > 10 mg per day or more than one nonsteroidal anti-inflammatory drug.',\n",
       "   'Patients with an active infection, a history of tuberculosis, multiple sclerosis, other poorly controlled medical illness, or a malignancy within the last 5 years.',\n",
       "   'Patients who require intravenous heparin therapy or with a history of a bleeding problem.']},\n",
       " {'nct_id': 'NCT00043732',\n",
       "  'inclusion': ['Patients who have active rheumatoid arthritis and are receiving methotrexate',\n",
       "   'meet the revised 1987 American Rheumatism Association (ARA) criteria for rheumatoid arthritis',\n",
       "   'has active RA as demonstrated by 9 tender and 6 swollen joints and one of the following: C-reactive protein 1.0 mg/dL, Erythrocyte sedimentation rate (ESR) 28 mm/hour, or Morning stiffness = 45 minutes. .'],\n",
       "  'exclusion': ['Patient used etanercept, infliximab, anakinra, or an experimental biologic agent within past 3 months',\n",
       "   'Had elevation of liver enzymes within past 6 months',\n",
       "   'Has a history of Tuberculosis',\n",
       "   'Vertigo, inner ear, or vestibular abnormalities',\n",
       "   'Cancer',\n",
       "   'HIV-positive',\n",
       "   'Abnormal electrocardiogram',\n",
       "   'patient has chronic or acute infection',\n",
       "   'Multiple sclerosis, neuropathy or encephalopathy']},\n",
       " {'nct_id': 'NCT00213538',\n",
       "  'inclusion': ['Is age 18 years old or older Satisfies the 1987 American College of Rheumatology revised criteria for Rheumatoid arthritis Has active disease at the time of randomization as indicated by a DAS28> 5.1 Has a disease at least refractory to DMARDs whose methotrexate or leflunomide Is capable of understanding and signing an informed consent form Agrees to use a medically accepted form of contraception during the study'],\n",
       "  'exclusion': ['Is pregnant or breast-feeding or without contraception Has significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the study, uncompensated congestive heart failure, significant active infection or any underlying diseases that could predispose subjects to infections (whose tuberculosis) Has renal disease (creatinin clearance level < 30 ml/min) Has allergy to anakinra Has leukopenia (white blood cells < 1.5 x 109 /l']},\n",
       " {'nct_id': 'NCT00213564',\n",
       "  'inclusion': ['Is age 18 years old or older Satisfies the 1987 American College of Rheumatology revised criteria for Rheumatoid arthritis Has active disease at the time of randomization as indicated by a DAS28> 5.1 Has a disease at least refractory to DMARDs whose methotrexate or leflunomide Is capable of understanding and signing an informed consent form Agrees to use a medically accepted form of contraception during the study'],\n",
       "  'exclusion': ['Is pregnant or breast-feeding or without Has significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the study, uncompensated congestive heart failure, significant active infection or any underlying diseases that could predispose subjects to infections (whose tuberculosis) Has allergy to infliximab']},\n",
       " {'nct_id': 'NCT00796705',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis',\n",
       "   'Current treatment with either etanercept or adalimumab for at least 12 weeks prior to randomization',\n",
       "   'Disease Activity Score (DAS) C-reactive Protein (CRP) 28 ≥ 4.4',\n",
       "   'Treatment with concomitant Disease-Modifying Anti-Rheumatic Drugs (DMARDs) is permitted but not required as described below:',\n",
       "   'Methotrexate',\n",
       "   'maximum dose of 25 mg per os (PO), intra-muscular (IM), or SQ weekly.',\n",
       "   'Leflunomide',\n",
       "   'maximum dose of 20 mg PO daily.',\n",
       "   'Sulfasalazine',\n",
       "   'maximum dose of 1,500 mg PO twice daily.',\n",
       "   'Hydroxychloroquine',\n",
       "   'maximum dose of 400 mg PO daily.',\n",
       "   'If taking DMARD(s), subjects must be on stable doses for at least 12 weeks prior to randomization.',\n",
       "   'If treated with prednisone (or equivalent corticosteroid), on a stable dose of <= 10 mg/day for 28 days prior to randomization.',\n",
       "   'Agree to use appropriate form of contraception. More information on this criterion can be found in the protocol.'],\n",
       "  'exclusion': ['Diagnosis of another autoimmune disease likely to require immunosuppression. More information on this criterion can be found in the protocol.',\n",
       "   'Failing treatment with etanercept if previously treated with adalimumab',\n",
       "   'Failing treatment with adalimumab if previously treated with etanercept',\n",
       "   'Intraarticular injection within 4 weeks prior to randomization',\n",
       "   'Concomitant use of DMARDs other than those described in Inclusion Criteria within 12 weeks of randomization.',\n",
       "   'Concurrent use of any biologic agent other than etanercept or adalimumab',\n",
       "   'Concomitant immunosuppressive therapy other than the Disease-Modifying Anti-Rheumatic Drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs), or corticosteroids specified in the protocol',\n",
       "   'Presence of open leg ulcers',\n",
       "   'Chronic or persistent infection that may be worsened by immunosuppressive treatment. More information on this criterion can be found in the protocol.',\n",
       "   'Active infection or severe infections requiring hospitalization or treatment with intravenous antibiotics, antivirals, or antifungals within 30 days prior to randomization',\n",
       "   'History of positive Purified Protein Derivative (PPD) or chest x-ray findings indicative of prior tuberculosis infection',\n",
       "   'Any medical condition or treatment that, in the opinion of the investigator, would put the subject at risk by participation in the study',\n",
       "   'History of malignancy. More information on this criterion can be found in the protocol.',\n",
       "   'Certain abnormal laboratory values. More information on this criterion can be found in the protocol.',\n",
       "   'Investigational biological or chemical agents within 4 weeks prior to randomization.',\n",
       "   'History of drug or alcohol abuse within a year prior to randomization',\n",
       "   'Treatment with natalizumab, rituximab, or another B-cell depleting therapy within a year prior to randomization',\n",
       "   'Treatment with infliximab, abatacept, tocilizumab, golimumab, or certolizumab pegol within 12 weeks prior to randomization.',\n",
       "   'Known allergy or hypersensitivity to study products',\n",
       "   'Any psychiatric disorder that prevents the participant from providing informed consent',\n",
       "   'Inability to follow protocol instructions',\n",
       "   'Pregnant or breastfeeding']},\n",
       " {'nct_id': 'NCT00791921',\n",
       "  'inclusion': ['Subjects must have a diagnosis of adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria.',\n",
       "   'Subjects must have active RA disease as defined by:',\n",
       "   'At least 6 tender joints and 6 swollen joints',\n",
       "   'ESR of 28 mm/hour or CRP of 2.0 mg/dL',\n",
       "   'Subjects who have failed to respond or have been resistant to at least one DMARD (including MTX)',\n",
       "   'Subjects in whom MTX cannot be administered for any of the reasons(incomplete response/safety concerns)'],\n",
       "  'exclusion': ['Patients who have a diagnosis of any other inflammatory arthritis',\n",
       "   'Patients who have a secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)',\n",
       "   'Patients who currently have, or who have a history of, a demyelinating or convulsive disease of the central nervous system (eg, multiple sclerosis, epilepsy)',\n",
       "   'Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure',\n",
       "   'Patients who currently have, or who have a history of, tuberculosis',\n",
       "   'Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)',\n",
       "   'Patients who currently have, or who have a history of, malignancy',\n",
       "   'Female patients who are breastfeeding or pregnant, who are of childbearing potential',\n",
       "   'Patients who previously received treatment with 2 or more anti-TNFα drugs or who previously failed to respond to treatment with 1 or more aint-TNFα drugs.']},\n",
       " {'nct_id': 'NCT00792675',\n",
       "  'inclusion': ['a diagnosis of RA according to the ACR 1989 Criteria at least 6 months prior to enrollment in the study, but not longer than 12 years',\n",
       "   'age 19 to 65 years old',\n",
       "   'stable regimen of medication for 2 months with less than 10 mg/day of oral corticosteroids',\n",
       "   'currently exercise < 2x/week for less than 30 minutes at less than 60% of his/her age predicted maximum heart rate',\n",
       "   'Subjects must pass the Physical Activity Readiness Scale Questionnaire (PAR-Q)'],\n",
       "  'exclusion': ['other serious health problems',\n",
       "   'intra-articular injection within 6 weeks',\n",
       "   'total joint replacement of the large joints',\n",
       "   'use of beta-blockers',\n",
       "   'inability to complete the submaximal exercise test']},\n",
       " {'nct_id': 'NCT00794118',\n",
       "  'inclusion': ['Eighteen years of age or older',\n",
       "   'Diagnosis of RA in accordance with ARA 1987 classification has satisfied at least 4 of the following 7 criteria:',\n",
       "   'Morning stiffness in and around the joints lasting at least 1 hour;',\n",
       "   'Arthritis of 3 or more joint areas;',\n",
       "   'Arthritis of hand joints;',\n",
       "   'Symmetric arthritis. simultaneous involvement of the same joint areas on both sides of the body;',\n",
       "   'Rheumatoid nodules;',\n",
       "   'Serum Rheumatoid Factor (RF)',\n",
       "   'Radiographic changes. Criteria 1 through 4 must have been present for at least 6 weeks.',\n",
       "   'Patients refractory or without complete response to DMARDs according to the Italian Guidelines for the clinical practice established by Italian Society of Rheumatology',\n",
       "   'Patients naive to anti-TNF drugs',\n",
       "   'Outpatients'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00791999',\n",
       "  'inclusion': ['Subjects must have a diagnosis of adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria.',\n",
       "   'Subjects must have active RA disease as defined by:',\n",
       "   'At least 9 tender joints and 9 swollen joints',\n",
       "   'ESR of 30 mm/hour or CRP of 1.5 mg/dL',\n",
       "   'Subjects must have received treatment with MTX for at least 6 months prior to the start of study drug administration. The dose of MTX must have remain fixed for at least 2 months prior to the study and the dose of MTX should be within 6 to 8 mg/week.'],\n",
       "  'exclusion': ['Patients who have a diagnosis of any other inflammatory arthritis',\n",
       "   'Patients who have a secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)',\n",
       "   'Patients who currently have, or who have a history of, a demyelinating or convulsive disease of the central nervous system (eg, multiple sclerosis, epilepsy)',\n",
       "   'Patients who have NYHA (New York Heart Association) Class III or IV congestive heart failure',\n",
       "   'Patients who currently have, or who have a history of, tuberculosis',\n",
       "   'Patients who have a high risk of infection (with a current infectious disease, a chronic infectious disease, a history of serious infectious disease)',\n",
       "   'Patients who currently have, or who have a history of, malignancy',\n",
       "   'Female patients who are breastfeeding or pregnant, who are of childbearing potential',\n",
       "   'Patients who previously received treatment with 2 or more anti-TNFα drugs or who previously failed to respond to treatment with 1 or more aint-TNFα drugs.']},\n",
       " {'nct_id': 'NCT00793403',\n",
       "  'inclusion': ['Eighteen years of age or older with diagnosis of RA based on the 1987 American College of Rheumatology (ACR) criteria and in accordance with local guidelines.',\n",
       "   'Patients eligible to anti-TNF therapy',\n",
       "   'Patients naïve to anti-TNFa drugs',\n",
       "   'Patients with radiography (hands and feet) executed by 6 months before the baseline or at baseline according to modified Sharp Van der Hejde method [Sharp JT et',\n",
       "   '1985; Sharp',\n",
       "   'Et',\n",
       "   '1989; Van der Heijde DM et',\n",
       "   '1989] Patients capable of understanding and completing the questionnaire Patients capable of understanding and signing an informed consent form'],\n",
       "  'exclusion': ['Patients with tumors',\n",
       "   'Patients already included in clinical trials']},\n",
       " {'nct_id': 'NCT00205478',\n",
       "  'inclusion': ['Adults with active rheumatoid arthritis for greater than 6 months and evidence of inflammation.'],\n",
       "  'exclusion': ['Subjects who have conditions precluding the use of cytokine inhibitors or subjects who require DMARDs other than hydroxychloroquine or sulfasalazine are excluded.']},\n",
       " {'nct_id': 'NCT00209859',\n",
       "  'inclusion': ['Synovitis in at least 2 joints.',\n",
       "   'Compliance with the ACR criteria for',\n",
       "   \"- Duration of no more than 6 months (from the first anamnestic non-traumatic synovitis of at least 6 weeks' duration).\",\n",
       "   'Informed consent.'],\n",
       "  'exclusion': ['Age less than 18 years or more than 75 years',\n",
       "   'Lack of co-operability.',\n",
       "   'Previous treatment with DMARD',\n",
       "   'Corticosteroid treatment during the preceding 4 weeks.',\n",
       "   'Contra indications for the treatments (awaiting the recommendations from Novartis)',\n",
       "   'Previous or present malignant or premalignant disease',\n",
       "   'Poorly regulated hypertension',\n",
       "   'Impaired renal function',\n",
       "   'Immuno defective diseases, including HIV',\n",
       "   'Cardiac or pulmonary insufficiency',\n",
       "   'Serious arteriosclerosis',\n",
       "   'Serious granulocytopenia or thrombocytopenia',\n",
       "   'Impaired liver function (liver enzymes more than twice the highest normal limit).',\n",
       "   'Alcohol consumption of more than 3 drinks a week.',\n",
       "   'Poorly controlled epilepsy',\n",
       "   'Lack of contraception in fertile patients',\n",
       "   'Pregnancy and lactation',\n",
       "   'Psoriasis',\n",
       "   'Poorly regulated diabetes',\n",
       "   'Anticoagulant treatment',\n",
       "   'Known allergy to the medicine',\n",
       "   'Medicamental interactions',\n",
       "   'Other inflammatory rheumatic diseases']},\n",
       " {'nct_id': 'NCT00207714',\n",
       "  'inclusion': ['Diagnosis of RA according to the American College of Rheumatology criteria for at least 3 months prior to screening',\n",
       "   'Have active Rheumatoid Arthritis at the time of screening and at baseline, as defined by 6 or more swollen joints and 6 or more tender joints and additional laboratory criteria'],\n",
       "  'exclusion': ['Have other inflammatory diseases, including but not limited to ankylosing spondylitis, systemic lupus erythematosus, Lyme disease',\n",
       "   'Received disease-modifying antirheumatic drugs ([DMARDs] eg, D penicillamine, hydroxychloroquine, chloroquine, oral or parenteral gold, interleukin [IL]-1 receptor antagonist [anakinra], azathioprine, sulphasalazine, agents other than MTX) within 4 weeks prior to the first study dose']},\n",
       " {'nct_id': 'NCT00422942',\n",
       "  'inclusion': ['adult patients 18-80 years of age;',\n",
       "   'RA for >=3 months;',\n",
       "   'receiving outpatient treatment;',\n",
       "   'failed treatment with >=1 DMARD (but not anti TNF or other biologic therapy);',\n",
       "   'inadequate response to methotrexate, having taken and tolerated it for >=12 weeks, with a stable dose for >=4 weeks.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;',\n",
       "   'history of, or current, inflammatory joint disease other than RA, or other systemic autoimmune disorder;',\n",
       "   'diagnosis of RA before the age of 16;',\n",
       "   'bone/joint surgery within 12 weeks of study;',\n",
       "   'prior use of anti-TNF or other biologic therapy, an anti-alpha 4 integrin, or any cell-depleting therapies.']},\n",
       " {'nct_id': 'NCT00424502',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'diagnosed RA for >=3 months prior to first administration of study medication;',\n",
       "   'inadequate response or intolerance to >=1 anti-TNF therapies, alone or in combination with methotrexate;',\n",
       "   'if using NSAIDS, analgesics or oral corticosteroids, must be on a stable dose for >=2 weeks prior to start of study.'],\n",
       "  'exclusion': ['other chronic inflammatory diseases;',\n",
       "   'use of parental corticosteroids within 4 weeks prior to screening;',\n",
       "   'severe heart failure, or severe, uncontrolled cardiac disease.']},\n",
       " {'nct_id': 'NCT00424346',\n",
       "  'inclusion': ['Cooperative male or non-pregnant, non-lactating female patients at least 18 years of age who signed an informed consent before the initiation of any study procedure.',\n",
       "   'Diagnosis of rheumatoid arthritis (RA) classified by American College of Rheumatology (ACR) 1987 revised criteria and with symptoms for at least 3 months before randomization.',\n",
       "   'Functional status class I, II or III classified according to the ACR 1991 revised criteria.',\n",
       "   'Patients treated with methotrexate (MTX) at the maximum tolerated (≤25 mg/week) and stable dose of ≥7.5 mg/week for at least 12 weeks before randomization.',\n",
       "   'Patients who had failed any disease-modifying antirheumatic drugs (DMARDs) (including biologic agents and any DMARD used in combination with MTX) were allowed.',\n",
       "   'For patients with previous treatment of biological therapy, the following wash-out periods were required before randomization:',\n",
       "   '3 days for Kineret™ (anakinra)',\n",
       "   'with a terminal half-life of 4 to 6 hours (s.c. route).',\n",
       "   '4 weeks for Enbrel® (etanercept)',\n",
       "   'with a terminal half-life of 102 ± 30 hours (s.c. route).',\n",
       "   '8 weeks for Remicade® (infliximab)',\n",
       "   'with a terminal half-life of 8.0-9. 5 days (intravenous (i.v.) infusion).',\n",
       "   '12 weeks for Humira® (adalimumab)',\n",
       "   'with a terminal half-life of 10-20 days (average 2 weeks) (subcutaneous (s.c.) route).',\n",
       "   '12 weeks for Orencia® (abatacept)',\n",
       "   'with a terminal half-life of 13.1 (8-25) days (i.v. infusion).',\n",
       "   '26 weeks for any other biologic',\n",
       "   'or 10 half-lives, whichever was longer.',\n",
       "   'Patients who took systemic corticosteroids had to be on a stable dose of ≤10 mg/d prednisone or equivalent for at least 4 weeks before randomization.',\n",
       "   'Patients who were regularly taking non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors or paracetamol/ acetaminophen as part of their RA therapy must have been on a stable dose for at least 4 weeks before randomization. Patients taking NSAIDs or COX-2 inhibitors or paracetamol/acetaminophen as needed within 2 weeks before randomization had to stop their medication at least 24 hours before an ACR visit (i.e. Visits 3, 7, 8, 10 and 12 [End of Study]). Patients taking folic acid supplementation had to be on stable dose for at least 4 weeks before randomization.',\n",
       "   'Patients with a history of immunization for Influenza (within past 12 months) and Pneumococcal vaccination (within 4 years) were included. If not already immunized, vaccination was completed when medically indicated (only during flu season for influenza) and such patients were included after approximately a 3 week window post-immunization to allow immunity to develop for vaccine.',\n",
       "   'Weight ≥45 kg and body mass index (BMI) <34.0',\n",
       "   'Women of non-child-bearing potential, defined as all women physiologically not capable of becoming pregnant. Core Study Inclusion criteria At Baseline (Visit 3)',\n",
       "   'Disease activity criteria of ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints.',\n",
       "   'One of the following also had to be present:',\n",
       "   'High-sensitive C-Reactive Protein (hsCRP) concentration ≥10 mg/L',\n",
       "   'Erythrocyte Sedimentation Rate (ESR) ≥28 mm/1st hr',\n",
       "   'a. +',\n",
       "   'based on screening values. EXCLUSION',\n",
       "   'History of hypersensitivity to study drug or to molecules with similar structures.',\n",
       "   'Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization.',\n",
       "   'Current use of DMARDs other than MTX. DMARDs included but were not limited to: biologic agents, thiolates (D-penicillamine, thiopronine), sulfasalazine, gold compounds, antimalarials, cyclosporine A, azathioprine, leflunomide, and alkylating agents such as cyclophosphamide.',\n",
       "   'If a patient had been discontinued from DMARDs, the patient should have been off the agent for at least 4 weeks, except leflunomide which was 8 weeks.',\n",
       "   'Patients with evidence of active pulmonary disease (e.g. tuberculosis, fungal diseases).',\n",
       "   'Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.',\n",
       "   'Who had a live vaccination within 12 weeks before randomization, or were planning to have one during the study and were not willing/able to postpone until study completion.',\n",
       "   'a) With bacterial, fungal or viral infections at the time of enrollment, including patients with evidence of human immunodeficiency virus (HIV) infection, hepatitis B and hepatitis C infection. b) History of a positive purified protein derivative (PPD) of tuberculin skin test without a follow-up of a negative chest X-ray. c) Patients requiring administration of antibiotics against latent tuberculosis, e.g. isoniazide.',\n",
       "   \"Underlying metabolic, hematologic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromised the patient and/or placed the patient at unacceptable risk for participation in an immunomodulatory therapy. In particular, clinical evidence or history of multiple sclerosis or other demyelinating diseases, or Felty's syndrome.\",\n",
       "   'With significant medical problems, including but not limited to the following: uncontrolled hypertension (≥160/95 mmHg), congestive heart failure, type-I-diabetes(well controlled type-II-diabetes was allowed even when requiring insulin), thyroid disease (unless the patient was taking a stable dose of thyroid hormone for at least 12 weeks before randomization).',\n",
       "   \"Other rheumatic diseases that could confound the evaluation of efficacy, including but not limited to primary fibromyalgia, ankylosing spondylitis, Lyme disease, adult juvenile RA, systemic lupus erythematosus, gout and pseudo gout, vasculitis, psoriatic arthritis, reactive arthritis, primary Sjoegren's Syndrome, and Behcet's Syndrome.\",\n",
       "   \"Any medical or psychiatric condition which, in the Investigator's opinion, would preclude the participant from adhering to the protocol or completing the study per protocol.\",\n",
       "   'History of malignancy of any organ system, treated or untreated, within the past 5 years (with the exception of adequately treated basal cell carcinoma or squamous-cell carcinoma of the skin, carcinoma in situ of the cervix, colon polyps with non-invasive malignancy that have been removed).',\n",
       "   'Use of any investigational drug other than RA therapy and/or devices at the time of randomization, or within 30 days or 5 half- lives of randomization, whichever was longer. STUDY EXTENSIONS Extension Studies Inclusion Criteria:',\n",
       "   'Patients who completed the core CACZ885A2201 study may enter the first extension study upon signing informed consent. A patient is defined as completing the study if he/she completed the core CACZ885A2201 study up to and including Visit',\n",
       "   '2. Patients who completed the first extension study, may enter the second. Extension Studies'],\n",
       "  'exclusion': ['Patients for whom continued treatment in the extension is not considered appropriate by the treating physician.',\n",
       "   'Patients who were non-compliant or who demonstrated a major protocol violation in the core CACZ885A2201 study.',\n",
       "   'Patients who discontinued from the core CACZ885A2201 study before Visit',\n",
       "   '']},\n",
       " {'nct_id': 'NCT00427804',\n",
       "  'inclusion': ['Males',\n",
       "   'Age 18 to 50',\n",
       "   \"History of Crohn's disease or Rheumatoid Arthritis (cases) or healthy individuals (controls)\"],\n",
       "  'exclusion': ['Subjects already taking activated vitamin D medications such as calcitriol, Zemplar®, Hectoral®',\n",
       "   'Vitamin D deficiency defined as 25(OH)D ≤ 20 ng/ml',\n",
       "   'Post-menopausal women (absence of menses for greater than 6 months by history or FSH level >20)',\n",
       "   'History of nephrolithiasis',\n",
       "   'History of hypercalcemia or hypercalciuria',\n",
       "   'Short bowel disease',\n",
       "   'Glucocorticoid use',\n",
       "   'Use of osteoporosis medication (bisphosphonate, calcitonin or teriparatide)',\n",
       "   'Chronic kidney disease (calculated GFR <60 ml/min/1.73 m2)',\n",
       "   'History of hyperparathyroidism (PTH greater than upper limit of normal) or',\n",
       "   'Hypoparathyroidism (PTH below lower limit of normal)']},\n",
       " {'nct_id': 'NCT00422383',\n",
       "  'inclusion': ['adult patients >=18 years of age;',\n",
       "   'RA for >=6 months;',\n",
       "   'receiving outpatient treatment;',\n",
       "   'inadequate response to methotrexate, having received and tolerated it for >=12 weeks, with a stable dose for >=4 weeks.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;',\n",
       "   'inflammatory joint disease other than RA, or other systemic autoimmune disorder;',\n",
       "   'diagnosis of juvenile arthritis, or RA before the age of 16;',\n",
       "   'previous treatment with >1 biologic agent, any cell-depleting therapies, or concurrent treatment with any biologic agent or DMARD other than methotrexate.']},\n",
       " {'nct_id': 'NCT00425321',\n",
       "  'inclusion': ['Patients diagnosed with rheumatoid arthritis for at least 6 months with at least 8 tender and 8 swollen joints',\n",
       "   'methotrexate treatment for 6 months',\n",
       "   'at least 10mg/wk and stable dose for at least 8 weeks',\n",
       "   'negative TB screening'],\n",
       "  'exclusion': ['Use of other disease-modifying anti-rheumatic drugs (DMARDs) (other than Methotrexate MTX)',\n",
       "   'previous use of more than 1 anti-TNF (tumor necrosis factor) agent',\n",
       "   'previous use of cytotoxics, p38 MAPkinase inhibitor, anti-CD4 antibody',\n",
       "   'receipt of live vaccine within 1 month of study drug',\n",
       "   'serious infection in previous 2 months or history of chronic or recurrent infectious disease or history of opportunistic infection',\n",
       "   'other clinically significant disease of other organ system']},\n",
       " {'nct_id': 'NCT00420927',\n",
       "  'inclusion': ['Subject must be 18 or older and in good health',\n",
       "   'Subject must meet the definition of early rheumatoid arthritis (RA) defined by the 1987-revised American College of Rheumatology (ACR) classification criteria and had disease duration of less than 1 year from diagnosis',\n",
       "   'Subject must have a Disease Activity Score (DAS28, based on C-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed',\n",
       "   'Subject must fulfill at least one of the following three criteria:',\n",
       "   'Rheumatoid factor positive',\n",
       "   'Greater than 1 joint erosion',\n",
       "   'Anti-cyclic citrullinated peptide (CCP) antibody positive.'],\n",
       "  'exclusion': ['Subject has previously received systemic anti-tumor necrosis factor (TNF) therapy',\n",
       "   'Subject has received any biologic or investigational therapy within 6 weeks prior to Baseline',\n",
       "   'Subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (DMARDs) or MTX, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.']},\n",
       " {'nct_id': 'NCT00422227',\n",
       "  'inclusion': ['Diagnosis of RA',\n",
       "   'Currently receiving an adequate dose of methotrexate (MTX) for treatment of RA',\n",
       "   'Active RA at time of screening and baseline'],\n",
       "  'exclusion': ['Previous or current treatment with etanercept (ETN), other tumor necrosis factor-alpha inhibitors, or other biologic agents',\n",
       "   'Concurrent treatment with a DMARD, other than MTX, at screening',\n",
       "   'Receipt of any DMARD, other than MTX, within 3 months before screening']},\n",
       " {'nct_id': 'NCT00425932',\n",
       "  'inclusion': ['Able and willing to give written informed consent',\n",
       "   'Age 18-80 years',\n",
       "   'Must have active rheumatoid arthritis for at least 12 weeks, but no more than 5 years.',\n",
       "   'Must be receiving treatment on an outpatient basis',\n",
       "   'Must have > 8 tender and swollen joints',\n",
       "   'Must have negative serum pregnancy test',\n",
       "   'Must have an inadequate response to MTX',\n",
       "   'Must have elevated serology parameters',\n",
       "   'Must have Positive RF or anti-CCP antibody, or radiographic evidence of at least one joint with definite erosion attributable to',\n",
       "   '- Stable use of Corticosteroids is permitted',\n",
       "   'Stable use of NSAIDs is permitted'],\n",
       "  'exclusion': ['History of or current inflammatory joint disease',\n",
       "   'Functional class IV',\n",
       "   'Any surgical procedure within 12 weeks',\n",
       "   'Lack of peripheral venous access.',\n",
       "   'Pregnancy or breast feeding.',\n",
       "   'Significant cardiac or pulmonary disease.',\n",
       "   'Evidence of significant uncontrolled concomitant disease',\n",
       "   'Positive HIV',\n",
       "   'Known active infection of any kind',\n",
       "   'History of deep space/tissue infection',\n",
       "   'History of recurrent significant infection',\n",
       "   'Concomitant malignancies or previous malignancies',\n",
       "   'Any neurological, vascular or systemic disorder',\n",
       "   'History of drug, alcohol, or chemical abuse',\n",
       "   'Inability to comply with study and follow-up procedures',\n",
       "   'History of a severe allergic or anaphylactic reaction to a biologic agent',\n",
       "   'Previous treatment with more than one biologic agent for',\n",
       "   'Patients must not have received a biologic agent within 2 months prior to the Baseline visit, except for etanercept, abatacept and anakinra for which a one month washout prior to Baseline visit is acceptable',\n",
       "   'Previous treatment with an anti-alpha 4 integrin antibody or co-stimulation modulator.',\n",
       "   'Previous treatment with any cell depleting therapies.',\n",
       "   'Treatment with any investigational agent within 28 days',\n",
       "   'Receipt of a live/attenuated vaccine within 28 days',\n",
       "   'Ongoing use of high dose steroids (>10mg/day)',\n",
       "   'Inra-articular or parental glucocorticoids within 4 weeks prior to baseline.',\n",
       "   'Intolerance or contraindications to i.v. glucocorticoids.']},\n",
       " {'nct_id': 'NCT00069472',\n",
       "  'inclusion': ['Adult onset RA',\n",
       "   'Diagnosis of RA made between 18 and 60 years old',\n",
       "   'Both parents alive and willing to participate',\n",
       "   'Parents may have diagnosis of RA (affected) or be unaffected'],\n",
       "  'exclusion': ['Inflammatory bowel disease', 'Lupus', 'Psoriatic arthritis']},\n",
       " {'nct_id': 'NCT00062465',\n",
       "  'inclusion': ['Subjects must be either DMARD or biological anti-RA agent naive or have failed a DMARD/biological RA agent, other than sulfasalazine, and have stopped this DMARD/biological one (1) month prior to randomization unless they have a flare in disease activity upon discontinuing DMARD/biological therapy as part of this protocol. DMARDs include but are not limited to methotrexate, leflunomide, minocycline, hydroxychloroquine, gold, cyclosporine, and biologics include anti-TNF and anti-IL-1 agents.',\n",
       "   'Subjects may be taking NSAIDs, provided the dose and frequency have been stable for 30 days prior to randomization. However if the patient meets the flare criteria they can be enrolled even if they have not fulfilled the criteria of being on a stable dose of NSAIDs and steroids for 30 days prior to randomization. At the time of flare neither steroids nor NSAIDs can be increased.',\n",
       "   'Subjects may be taking corticosteroid therapy equivalent to prednisone less than or equal to 7.5 mg/day. This dose must be stable for at least 1 month prior to randomization. Subjects may not change the dose of their corticosteroid or receive intra-articular or intra-muscular injections of corticosteroids, within 1 month of randomization or during the study. Note section 9.3 of the protocol, Concomitant Medication, has been amended to read: If it is medically necessary a one joint steroid injection is acceptable. This must be noted on the CRF and the joint excluded from the joint count.',\n",
       "   'Subjects may not be taking other complementary and/or alternative medications for RA for the last 1-month prior to randomization. Subjects must provide written informed consent prior to any study-related screening tests.'],\n",
       "  'exclusion': ['Liver function tests: Total bilirubin above the upper limit of normal (ULN). AST, ALT, 1.5 X greater than ULN',\n",
       "   'Hematology: Total white blood count (WBC) less than 3500mm3. Hemoglobin and hematocrit less than 10 g/dl or 30%, unless stable for at least 3 months), and platelet count less than 100K or greater than 750',\n",
       "   '- Renal function tests: BUN or creatinine greater than 1.2 X above the ULN',\n",
       "   'Urinalysis: On dipstick',\n",
       "   'Proteinuria / hematuria / leukocytes greater than trace. Subjects with serological evidence of chronic hepatitis B (positive HbsAG) or hepatitis C (positive C Ab), HIV Subjects with evidence of active peptic ulcer disease or who have a reliable positive history of gastrointestinal bleeding within the past five (5) years. Any recurrent or history of an intestinal disorder that may interfere with the proper absorption of the drug Pregnant women or nursing mothers Subjects who plan to donate blood or blood products during the study or within 30 days following the last study visit. One re-screening to meet criterion 6.1.5 will be allowed. Multiple screenings, beyond one for failure to meet criterion 6.1.5 are not allowed (at either screening or baseline). Abuse of alcohol or drugs. The subject should not consume more than 2 units of alcohol per day. (A unit of alcohol is considered: 12 oz of beer, 6 oz of wine or 1 oz of spirits). This is on a per day basis and not the average for the week. Subjects with a sulfonamide allergy Subjects who have known G6PD deficiency Subjects who are unable or unwilling to follow the protocol Recent major trauma or major surgery or serious infection Subjects who started but left, or were dropped out of this study, for any reason (subjects who left or are dropped will not be replaced).']},\n",
       " {'nct_id': 'NCT00995449',\n",
       "  'inclusion': ['At least 6 swollen and at least 6 tender joints',\n",
       "   'C-reactive Protein (CRP) > Upper Limit Normal (ULN)',\n",
       "   'Prior inadequate response from biologic therapy',\n",
       "   'Stable regimens of concomitant RA therapies'],\n",
       "  'exclusion': ['Unstable medical conditions']},\n",
       " {'nct_id': 'NCT00996606',\n",
       "  'inclusion': ['Moderate to severe active RA of ≥6 months duration',\n",
       "   'DAS28 >3.2',\n",
       "   'Inadequate response to a stable dose of non-biologic DMARD for ≥2 months',\n",
       "   'Those receiving oral corticosteroids must have been at stable dose for ≥25 days in the 28 days prior to first study treatment'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'History of or current inflammatory joint disease other than RA',\n",
       "   'Previous treatment with alkylating agents or total lymphoid irradiation',\n",
       "   'Intra-articular or parenteral corticosteroids within 6 weeks prior to Baseline',\n",
       "   'Previous treatment with any cell-depleting therapies',\n",
       "   'American College of Rheumatology (ACR) Functional Class IV']},\n",
       " {'nct_id': 'NCT00990730',\n",
       "  'inclusion': ['Diagnosis of RA by ACR criteria',\n",
       "   'Age 18-80',\n",
       "   'Enrolled in UCSF RA cohort already'],\n",
       "  'exclusion': ['Diabetes (on meds or in medical history)',\n",
       "   'Pregnant or Lactating',\n",
       "   'Renal failure (Creatinine > 2mg/dL or on dialysis)',\n",
       "   'History of MI or CAD',\n",
       "   'History of ischemic CVA',\n",
       "   'Symptomatic PVD',\n",
       "   'Current uncontrolled hypertension (blood pressure > 160/100mmHg)',\n",
       "   'Daily prednisone > 10mg daily',\n",
       "   'Current smoker',\n",
       "   'New BP med within 3 months',\n",
       "   'New statin within 3 months',\n",
       "   'Change in RA meds: new or increase in prednisone within 1 month, new TNF inhibitor within 2 months, titration of methotrexate, leflunomide or sulfasalazine within 3 months.']},\n",
       " {'nct_id': 'NCT00993668',\n",
       "  'inclusion': ['Subjects must be at least 18 years old at the screening visit',\n",
       "   'Subjects must be able to understand the information provided to them and to give written informed consent, and be able and willing to comply with the study requirements',\n",
       "   'Female subjects must be either postmenopausal for at least 1 year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (either oral/parenteral/implantable hormonal contraceptives, intrauterine device or barrier and spermicide. Abstinence only is not an acceptable method. Subjects must agree to use adequate contraception during the study and for 10 weeks after the last dose of CZP. Male subjects must agree to ensure they or their female partner(s) use adequate contraception during the study and for 10 weeks after the subject receives their last dose of CZP',\n",
       "   'Subjects must have a diagnosis of adult-onset Rheumatoid Arthritis (RA) of at least 6-months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria',\n",
       "   'Subjects must have active RA disease as defined by: ≥ 4 tender joints (28 joint count) at Screening and Week 0; and ≥ 4 swollen joints (28 joint count) at Screening and Week 0'],\n",
       "  'exclusion': ['Subjects who have a diagnosis of any other inflammatory arthritis (eg., psoriatic arthritis or ankylosing spondylitis)',\n",
       "   'Subjects who have a history of an infected joint prosthesis at any time with that prosthesis still in situ',\n",
       "   'Subjects must be free of defined prohibited medication and biological therapy',\n",
       "   'Subjects who have received any experimental nonbiological therapy, within or outside of a clinical trial in the 3 months prior to Week 0',\n",
       "   'Subjects who have received any experimental biological agent in the past 3 months or within 5 half-lives prior to Week 0 (whichever is longer)',\n",
       "   'Subjects who have received previous treatment with biological response modifier therapy for RA that resulted in a severe hypersensitivity reaction or an anaphylactic reaction.',\n",
       "   'Subjects with a history of pneumococcal or influenza infection in the last 3 months',\n",
       "   'Subjects with a history of pneumococcal vaccination in the last 5 years',\n",
       "   'Subjects with a history of influenza vaccination within the last 6 months',\n",
       "   'Female subjects who are breast-feeding, pregnant, or plan to become pregnant during the trial or within 3 months following last dose of study drug',\n",
       "   'Subjects with a history of chronic or recurrent infections (more than 3 episodes requiring antibiotics/antivirals during the preceding year), recent serious or life-threatening infection within 6 months (including herpes zoster), or any current sign or symptom that may indicate an infection',\n",
       "   'Subjects who have had a splenectomy',\n",
       "   'Subjects who have had a hypersensitivity reaction to previous pneumococcal or influenza vaccination',\n",
       "   'Subjects who have a known hypersensitivity to eggs and egg products or to other components of the vaccine',\n",
       "   'Subjects with a history of Guillain-Barre syndrome',\n",
       "   'Subjects with a history of tuberculosis, active tuberculosis, positive chest x-ray for tuberculosis, or positive purified protein derivative (PPD) skin test (defined as induration of ≥5 mm). Subjects who are not candidates for PPD testing due to prior severe reaction to the PPD test or a history of PPD positivity must undergo an Elispot test instead for tuberculosis evaluation. Subjects testing positive via the PPD or having an indeterminate or positive Elispot test, or for which latent tuberculosis cannot be ruled out, may be enrolled in the study provided that they are treated (eg., isoniazid for 9 months) and that their treatment has been initiated at least 4 weeks prior to the first administration of CZP',\n",
       "   'Subjects at high risk of infection (eg., presence of leg ulcers or an indwelling urinary catheter, persistent or recurrent chest infections, bedridden or wheelchair bound subjects)',\n",
       "   'Subjects with a history of a lymphoproliferative disorder including lymphoma or signs and symptoms suggestive of lymphoproliferative disease',\n",
       "   'Subjects with known concurrent acute or chronic viral hepatitis B or C or positive hepatitis B surface antigen (HBs-Ag) or hepatitis C virus antibody (HCV-Ab)',\n",
       "   'Subjects with known human immunodeficiency virus (HIV) infection',\n",
       "   'Subjects receiving any live or attenuated vaccination within 12 weeks prior to Week 0',\n",
       "   'Concurrent malignancy or a history of malignancy (other than carcinoma of the cervix or basal cell carcinoma successfully treated more than 5 years prior to screening)',\n",
       "   'Subjects with Class III or Class IV congestive heart failure according to the New York Heart Association (NYHA) 1964 classification criteria',\n",
       "   'Subjects with a history of, or suspected, demyelinating disease of the central nervous system (eg., multiple sclerosis or optic neuritis)',\n",
       "   'Subjects with a current or recent history of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological or cerebral disease',\n",
       "   \"Subjects with any other condition (eg., clinically significant laboratory values) which in the Investigator's judgement would make the subject unsuitable for inclusion in the study\",\n",
       "   'Subjects with a history of an adverse reaction to polyethylene glycol (PEG)']},\n",
       " {'nct_id': 'NCT00993317',\n",
       "  'inclusion': ['Adult-onset RA of at least 6 months but not longer than 15 years in duration as defined by the 1987 American College of Rheumatology classification criteria',\n",
       "   'Active RA disease as defined by at least 9 tender joints and 9 swollen joints, ESR of 30 mm/hour or CRP of 1.5 mg/dL',\n",
       "   'MTX (with or without folic acid) for at least 24 weeks prior to the Baseline visit, The dose of MTX and route of administration must have been stable for at least 8 weeks prior to the baseline visit. The minimum stable dose of MTX allowed is 10 mg weekly.'],\n",
       "  'exclusion': ['Any other inflammatory arthritis (e.g., psoriatic arthritis, ankylosing spondylitis or reactive arthritis)',\n",
       "   'Secondary, non-inflammatory type of arthritis (eg, osteoarthritis, fibromyalgia)',\n",
       "   'NYHA (New York Heart Association) Class III or IV congestive heart failure',\n",
       "   'current or history of, tuberculosis',\n",
       "   'history of chronic infection, recent serious or life-threatening infection (within 24 weeks , including herpes zoster), or any current sign or symptom that may indicate an infection (e.g., fever, cough)',\n",
       "   'High risk of infection',\n",
       "   'Have received any experimental non-biological therapy, within or outside a clinical trial in the 12 weeks prior to Baseline',\n",
       "   'Have received previous B-cell therapy (eg. Rituximab)',\n",
       "   'Have received any other biological therapy for RA within 24 weeks prior to Baseline visit, except for etanercept where a three month washout prior to baseline visit is acceptable',\n",
       "   'Have received previous treatment with a biological therapy for RA that resulted in a severe hypersensitivity reaction or an anaphylactic reaction',\n",
       "   'Failed to respond to previous treatment with an anti-TNF drug',\n",
       "   'Female breast feeding, pregnant or plan to become pregnant during the trial or for 12 weeks following the last dose of study drug']},\n",
       " {'nct_id': 'NCT00996203',\n",
       "  'inclusion': ['adult patients, >/= 18 years of age',\n",
       "   'moderate to severe active rheumatoid arthritis of >/=6 months duration',\n",
       "   'inadequate clinical response to current non-biologic DMARDs',\n",
       "   'current DMARDs must be at stable dose for 8 weeks prior to study entry',\n",
       "   'oral corticosteroids (</=10mg/day prednisone or equivalent) and NSAIDs must be at stable dose for >/=4 weeks prior to screening'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA',\n",
       "   'history of or current inflammatory joint disease other than RA',\n",
       "   'previous treatment with any biologic DMARD',\n",
       "   'functional class IV as defined by the ACR classification',\n",
       "   'intra-articular or parenteral corticosteroids within 6 weeks prior to screening']},\n",
       " {'nct_id': 'NCT00555230',\n",
       "  'inclusion': ['Men or women, 18 years of age or older',\n",
       "   'Clinical diagnosis of RA with a duration of at least 6 month',\n",
       "   'Prednisolone < =10 mg/day',\n",
       "   'NSAID or DMARD',\n",
       "   'Informed consent'],\n",
       "  'exclusion': ['Little or no ability for self-care',\n",
       "   'Type 1 diabetes mellitus',\n",
       "   'Uncontrolled hypertension(> 160/95 mmHg)',\n",
       "   'Total cholesterol > 240 mg/dl, current or recent (within the past 3 months)',\n",
       "   'History of coronary bypass grafting, myocardial infraction within 28days, left ventricular dysfunction (ejection fraction < 40%), significant valvular heart disease',\n",
       "   'Current treatment with ACE inhibitor, angiotensin II receptor blockers or beta-blockers, lipid lowering drug, or contra-indication to statins',\n",
       "   'Current treatment of oral contraceptives, estrogen and progestin was allowed but patient not willing to stop during study',\n",
       "   'Current treatment with antioxidant therapy (Vitamin C or multivitamin)',\n",
       "   'Received intra-articular, intramuscular, or intravenous corticosteroids in the past 4 weeks before screening',\n",
       "   'Clinically significant renal disease(serum creatinine level ≥ 270 µmol/L) or aspartate aminotransferase(AST), alanine aminotransferase ALT), or creatine kinase (CK)≥ 2 X ULN',\n",
       "   'Female of childbearing potential, unwilling to use adequate contraception during the study',\n",
       "   'Current or recent (within the past 3 months) pregnancy and cancer']},\n",
       " {'nct_id': 'NCT00556894',\n",
       "  'inclusion': ['Males and females ages 18-75 years',\n",
       "   'Meet the criteria of the American College of Rheumatology for RA (Arnett FC et',\n",
       "   'Arthritis Rheum 1988;31:315-324; refer to Appendix',\n",
       "   'diagnostic criteria for Rheumatoid Arthritis)',\n",
       "   'Not bed- or wheelchair-bound',\n",
       "   'Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory',\n",
       "   'Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline',\n",
       "   'Methotrexate route of administration has been unchanged for >=2 months prior to baseline',\n",
       "   'Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose',\n",
       "   'If taking hydroxychloroquine or chloroquine, administration duration has been for >=3 months and dose has been stable for >=2 months prior to baseline',\n",
       "   'If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation',\n",
       "   'If taking an oral corticosteroid, dose is <10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the stabilization period, and will remain stable through the stabilization and entire treatment and follow-up period',\n",
       "   'Negative screening serum pregnancy test for female patients of childbearing potential',\n",
       "   'Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)'],\n",
       "  'exclusion': ['Receipt of any of the following for at least a 1 month stabilization period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra',\n",
       "   'Receipt of etanercept for at least a 6 week period prior to dosing',\n",
       "   'Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing',\n",
       "   'Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing',\n",
       "   'Receipt of cyclophosphamide for at least a 6 month period prior to dosing',\n",
       "   'Receipt of rituximab at any previous time',\n",
       "   'Participation in a previous trial CF101 trial',\n",
       "   'Use of oral corticosteroids >10 mg of prednisone, or equivalent, per day',\n",
       "   'Change in NSAID dose level for 1 month prior to dosing',\n",
       "   'Change in oral corticosteroid dose level during the 1 month prior to, or during, the stabilization period vChange in hydroxychloroquine or chloroquine dose level during the 2 months prior to, or during, the stabilization period',\n",
       "   'Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the stabilization period',\n",
       "   'Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)',\n",
       "   'Hemoglobin level <9.0 gm/dL at the screening visit',\n",
       "   'Platelet count <125,000/mm3 at the screening visit',\n",
       "   'White blood cell count <3000/mm3 at the screening visit',\n",
       "   \"Serum creatinine level outside the central laboratory's normal limits at the screening visit\",\n",
       "   \"Liver aminotransferase (ALT and/or AST) levels greater than 1.25 times the central laboratory's upper limit of normal at the screening visit\",\n",
       "   \"Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study\"]},\n",
       " {'nct_id': 'NCT00551707',\n",
       "  'inclusion': ['Subject must voluntarily give written informed consent',\n",
       "   'Subject must be ≥ 18 years of age',\n",
       "   'Subject must have RA (ACR criteria)',\n",
       "   'Subject must have at least 4 swollen joints and at least 6 tender joints at screening and baseline (28 joint count)',\n",
       "   'Subject must have a CRP > Upper Limit of Normal at screening',\n",
       "   'Subject must have been on DMARD or DMARD combination (e.g. MTX + hydroxychloroquine) for at least 3 months and be on a stable dose of DMARD(s) for at least 6 weeks prior to screening.',\n",
       "   'For MTX subjects: MTX ≥ 7.5 mg weekly (po/sc/im) and willing to take folic acid or folinic acid supplementation',\n",
       "   'Subject willing to take concomitant multivitamin or the equivalent of 400 I.U. vitamin D and the equivalent of 1000 mg of elemental calcium daily'],\n",
       "  'exclusion': ['History of clinically significant (as determined by the Investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease',\n",
       "   'Wheelchair or bed bound',\n",
       "   'History of osteoporotic fracture',\n",
       "   'History of malignancy within the past 10 years. However, subjects with a history of treated or excised basal cell carcinoma or fewer than 3 squamous cell carcinomas are eligible to participate',\n",
       "   'History of lymphoma or chronic leukemia',\n",
       "   'Moles or lesions that are currently undiagnosed, but are suspicious for malignancy',\n",
       "   'Surgery within the previous 3 months (except for minor dental and cosmetic)',\n",
       "   'History of drug or alcohol abuse (as defined by the Investigator)',\n",
       "   'History of bleeding disorder',\n",
       "   'History of gastrointestinal bleeding within 5 years of screening',\n",
       "   'History of severe migraines or headaches',\n",
       "   'History of glaucoma',\n",
       "   'Active diabetic retinopathy',\n",
       "   'Visually compromising cataract',\n",
       "   'History of opportunistic infection within the previous 12 months',\n",
       "   'Active Tuberculosis (TB)',\n",
       "   'Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., septicemia) within 3 months prior to screening',\n",
       "   'Fever or symptomatic viral or bacterial infection within 2 weeks prior to screening',\n",
       "   'Positive for Hepatitis C virus (HCV) antibody',\n",
       "   'Positive for HBsAg',\n",
       "   'Known positive HIV antibody',\n",
       "   'Has a history of hypersensitivity to glucocorticoids and/or dipyridamole',\n",
       "   'Treatment with oral, intra-articular, intramuscular, or intravenous glucocorticoids within 6 weeks prior to screening; inhaled glucocorticoid is permitted',\n",
       "   'Treatment with any tumor necrosis factor-alpha (TNFα) biologic, anakinra or abatacept within 2 months prior to screening',\n",
       "   'Treatment with rituximab',\n",
       "   'Treatment with another investigational drug 3 months prior to screening',\n",
       "   'Treatment with anticoagulants including: dipyridamole, warfarin, clopidogrel, ticlopidine; Acetylsalicylic acid > 150 mg per day',\n",
       "   'Treatment with any concomitant medications that have not been at a stable dose for at least 28 days prior to screening',\n",
       "   'Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) laboratory values that exceed 1.5 x ULN',\n",
       "   'HbA1C value of > 7.0%',\n",
       "   'Current enrollment in any other study with investigational drug or device',\n",
       "   'Female subject who is pregnant or lactating or of child bearing potential and not using acceptable methods of contraception (birth control pills, barriers or abstinence)',\n",
       "   \"Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's return for follow-up visits on schedule\",\n",
       "   'Other unspecified reasons that, in the opinion of the Investigator or sponsor make the subject unsuitable for enrollment']},\n",
       " {'nct_id': 'NCT00554853',\n",
       "  'inclusion': ['Women on adequate contraception if they are of child-bearing age.',\n",
       "   'Meet revised ACR criteria for',\n",
       "   '- Stable doses of DMARDS,biologic agents and or corticosteroids for at least 3 months.'],\n",
       "  'exclusion': ['Pregnant or lactating women.',\n",
       "   'Current smokers or individuals who smoked in the last 6 months.',\n",
       "   'Diagnosis of Diabetes, heart failure, or infection.',\n",
       "   'Current diagnosis of malignant disease except for basal cell or squamous cell carcinoma of the skin.',\n",
       "   'No active liver disease.',\n",
       "   'No cholesterol-lowering medications or oral hypoglycemic agents.']},\n",
       " {'nct_id': 'NCT00555542',\n",
       "  'inclusion': ['Age 21 or above',\n",
       "   'Fulfilled the 1978 American college of Rheumatology(ACR) criteria for RA',\n",
       "   'Seropositive for RF with RF>20 IU/ml',\n",
       "   'Active disease despite treatment with at least 2 stable dose of DMARDs for at least 16 weeks, including MRX>10mg weekly',\n",
       "   '4 or more swollen and/or tender joints',\n",
       "   'Stable dose of prednisolone<=12.5mg/day or NASID for at lease 4 weeks',\n",
       "   'MTX>10mg/wk and folic acid>10 mg/wk for at lease 4 weeks'],\n",
       "  'exclusion': ['Little or no ability for self-care',\n",
       "   'Used a DMARD other than MTX(Leflunomide should be wash-out with cholestyramine 4 weeks prior screening)',\n",
       "   'Received intra-articular,intramuscular, or intravenous corticosteroids in the last 4 weeks',\n",
       "   'Concurrent treatment with any biologics within 8 weeks',\n",
       "   'Infected joint prosthesis during the previous 5 years',\n",
       "   \"Autoimmune disease other than RA(except concurrent Sjogren's syndrome), active rheumatoid vasculitis, and history of systemic disease associated with arthritis, chronic fatigue syndrome.\",\n",
       "   'Serious infections, such as hepatitis, pneumonia, pyelonephritis in the previous 3 months',\n",
       "   'Any chronic infectious disease such as renal infection, chest infection with bronchiectasis or sinusitis',\n",
       "   'Recurrent bacterial infections with encapsulated organisms, primary or secondary immunodeficiency',\n",
       "   'Active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'Opportunistic infection such as herpes zoster within the previous 2 months',\n",
       "   'Any evidence of active cytomegalovirus;active Pneumocystis Jirovecl;or drug-resistant atypical mycobacterial infection',\n",
       "   'Known hypersensitivity to murine proteins',\n",
       "   'Current signs or symptoms of severe,progressive,or uncontrolled renal,hepatic,haematological,gastrointestinal,endocrine,pulmonary,cardias,neurological ,or cerebral disease',\n",
       "   'A history of lymphoproliferative disease including lymphoma or signs suggestive of disease,such as lymphadenopathy of unusual size or location(ie,lymphadenopathy nodes,in the posterior tangle of the neck,infraclavicular epitrochlear,or periaortic areas);splenomegaly',\n",
       "   'Any know malignant disease except basal cell carcinoma currently or in the last 5 years']},\n",
       " {'nct_id': 'NCT00550043',\n",
       "  'inclusion': ['Established diagnosis of rheumatoid arthritis',\n",
       "   'Patients receiving methotrexate must be treated with for at least 6 months and receiving a stable weekly dose between 10 and 25 mg for at least 8 consecutive weeks prior to study entry.'],\n",
       "  'exclusion': ['Patients who have taken the following drugs within the timeframe below:',\n",
       "   'Leflunomide, infliximab, etanercept, adalimumab, abatacept, or other biological therapies (except rituximab)',\n",
       "   'Within 12 weeks prior to the first dose of study medication;',\n",
       "   'Rituximab',\n",
       "   'Within 12 months prior to the first dose of study medication;',\n",
       "   'Disease-modifying anti-rheumatic drugs (DMARDs) or other anti-rheumatic therapies not specified above including but not limited to: gold, penicillamine, dapsone, azathioprine, 6-mercaptopurine, chlorambucil, cyclophosphamide, cyclosporin, mycophenolate mofetil',\n",
       "   'Within 12 weeks prior to the first dose of study medication;',\n",
       "   'Treatment with any investigational medication within 12 weeks prior to the first dose of study medication.']},\n",
       " {'nct_id': 'NCT00146393',\n",
       "  'inclusion': ['Adults over age 18',\n",
       "   'Have some form of arthritis (examples: osteoarthritis, rheumatoid arthritis, lupus, fibromyalgia, gout, etc.)',\n",
       "   'Be able to move independently without assistance',\n",
       "   'Currently exercising less than 3 times per week'],\n",
       "  'exclusion': ['Inability to walk without assistance',\n",
       "   'Severe health condition where exercise is contraindicated']},\n",
       " {'nct_id': 'NCT00141830',\n",
       "  'inclusion': ['Clinical diagnosis of active rheumatoid arthritis for at least 6 months and on a stable dose of methotrexate for at least 12 weeks',\n",
       "   'Rheumatoid arthritis onset after 16 years of age'],\n",
       "  'exclusion': ['Any significant health problem other than rheumatoid arthritis',\n",
       "   'History of male or female reproductive system cancer',\n",
       "   'Clinically significant laboratory abnormalities']},\n",
       " {'nct_id': 'NCT00141934',\n",
       "  'inclusion': ['Male/female age 18 -75',\n",
       "   'RA diagnosed for at least 6 months',\n",
       "   'Taking methotrexate for at least 6 months',\n",
       "   'Must have at least 4 swollen/tender joints'],\n",
       "  'exclusion': ['Must not be pregnant/breastfeeding',\n",
       "   'Must not have history of other inflammatory disorders',\n",
       "   'Other conditions may lead to exclusion from the trial (e.g. Diabetes mellitus, malignant melanoma, HIV, active infection, hepatitis B/C, cardiac conduction disorders, hepatic/renal insufficiency, active depression/anxiety/psychosis/schizophrenia or convulsions.']},\n",
       " {'nct_id': 'NCT00147966',\n",
       "  'inclusion': ['Active rheumatoid arthritis',\n",
       "   'Use of concomitant methotrexate'],\n",
       "  'exclusion': ['Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than methotrexate',\n",
       "   'Serious medical conditions that would preclude the use of the treating agent']},\n",
       " {'nct_id': 'NCT00144586',\n",
       "  'inclusion': ['RA patients who participated in the previous studies',\n",
       "   'Patients who completed the last observation in the previous studies',\n",
       "   'Patients who were confirmed to have no problems with safety in the previous studies.'],\n",
       "  'exclusion': ['Patients with Class IV Steinbrocker functional disorder at evaluation within 4 weeks before treatment with the investigational product',\n",
       "   'Patients who were not enrolled by 3 months after the last observation day of the previous study']},\n",
       " {'nct_id': 'NCT00144547',\n",
       "  'inclusion': ['Patients must suffer from RA, and must have participated in the preceding study.',\n",
       "   'Patients must have been confirmed to be appropriate on week 52 of the preceding study by X radiography.'],\n",
       "  'exclusion': [\"Patients evaluated as belonging to Steinbrocker's class IV within 4 weeks before administration of the study drug\",\n",
       "   'Patients who have not been registered by 3 months after week 52 of the preceding study']},\n",
       " {'nct_id': 'NCT00144560',\n",
       "  'inclusion': ['Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria',\n",
       "   'Patients who contracted RA at least 6 months prior'],\n",
       "  'exclusion': ['Patients with Class IV Steinbrocker functional impairment at enrollment.',\n",
       "   'Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug']},\n",
       " {'nct_id': 'NCT00144521',\n",
       "  'inclusion': ['Diagnosis of RA based on the 1987 classification criteria of the American College of Rheumatology (ACR)',\n",
       "   'Disease duration of 6 months or more',\n",
       "   'Treated with 8 mg/week of MTX for at least 8 weeks immediately preceding enrollment, and continued on this treatment up to initiation of the study drug',\n",
       "   \"Active disease at enrollment (less than 2 weeks before initiating treatment with a study drug), Which is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL\"],\n",
       "  'exclusion': ['Assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding treatment with the study drug',\n",
       "   'Treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment with the study drug',\n",
       "   'Received any of the following therapies in the 2 weeks preceding initiation of treatment with the study drug.',\n",
       "   'Administration of any DMARD or immunosuppressant other than MTX',\n",
       "   'Administration of corticosteroids exceeding 10 mg/day as prednisolone',\n",
       "   'Dose escalation or initiation of corticosteroids',\n",
       "   'Received any of the following therapies in the 4 weeks preceding treatment with the study drug',\n",
       "   'Plasma exchange therapy',\n",
       "   'Surgical treatment (operation, etc.)']},\n",
       " {'nct_id': 'NCT00144573',\n",
       "  'inclusion': ['Patients who are diagnosed with RA according to the 1987 ACR (American College of Rheumatology) classification criteria',\n",
       "   'Patients with RA at least 6 months prior to enrollment',\n",
       "   'Patients with a creatinine clearance not less than 10 mL/min but no higher than 80 mL/min'],\n",
       "  'exclusion': ['Patients with Class IV Steinbrocker functional impairment at enrollment',\n",
       "   'Patients who are undergoing dialysis',\n",
       "   'Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept, and have been receiving treatment with leflunomide, within 12 weeks before treatment with the investigational product']},\n",
       " {'nct_id': 'NCT00144508',\n",
       "  'inclusion': ['Diagnosed as having RA, on the basis of the criteria stipulated by the American Conference on Rheumatism (ACR) in 1987.',\n",
       "   'With RA that has continued for at least 6 months but less than 5 years, with the date of first appearance being taken as the date of RA diagnosis.',\n",
       "   \"Active RA despite at least one DMARD or immunosuppressant. Active disease is defined as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30 mm/hr and CRP not less than 2.0mg/dL.\"],\n",
       "  'exclusion': [\"Shown to have class-IV Steinbrocker's functional activity in an evaluation carried out within 4 weeks before administration of the study drug.\",\n",
       "   'Treated with drugs that delay joint destruction (infliximab, etanercept, leflunomide, etc.) within 3 months before administration of the study drug.',\n",
       "   'The oral corticosteroid dose (prednisolone equivalent of up to 10 mg/day)has not been fixed 2 weeks before administration of the study drug.',\n",
       "   'Subjected to any of the following within 4 weeks before administration of the study drug: (i) Change in dosage of currently administered DMARDs and/or immunosuppressive agents. (ii) Plasma exchange method. (iii) Surgical treatment (operations, etc.).']},\n",
       " {'nct_id': 'NCT00717808',\n",
       "  'inclusion': ['Adult men and non-pregnant, non-lactating women between 18 and 75 years of age. Sexually active females must be of either non-childbearing potential or willing to comply with the contraceptive requirements.',\n",
       "   'Body weight greater >40 kg and <120 kg with a body mass index (BMI) between 19-31 kg/m2',\n",
       "   'Clinical history of rheumatoid arthritis as defined by ACR criteria and currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as their only DMARD (no changes in dosing regimen for 4 weeks prior to screening).',\n",
       "   'Negative urine pregnancy test (for all women except those with documented proof of hysterectomy or bilateral oophorectomy)',\n",
       "   'Subjects who are able and willing to give written consent'],\n",
       "  'exclusion': ['Any clinically relevant abnormality identified on the screening history, physical exam, clinical laboratory evaluations or ECG, with the exception of values related to rheumatoid arthritis.',\n",
       "   'Estimated Glomerular Filtration rate <60mL/min.',\n",
       "   'Significant hepatic insufficiency as defined by total bilirubin greater than 25.7umol/L or transaminase(ALT, AST) elevations greater than 2 times the upper limit of the clinical laboratory range. Also any patient with documented cirrhosis or a history consistent with a diagnosis of cirrhosis or hepatitis.',\n",
       "   'Patients not on a stable DMARD and/or NSAID drug regimen, or expecting to remain on a stable drug regimen, as defined by starting a new drug or changing dosage within 14 days prior to administration of study medication.',\n",
       "   'Patients taking any drugs known to be substrates of CYP2C9 or taking digoxin, or cerivastatin within 14 days prior to Session 1, or taking any drugs known to inhibit or induce CYP2C9.',\n",
       "   'Known or suspected hypersensitivity to tranilast or to structurally similar compounds.',\n",
       "   'History of recurrent urinary tract infections or kidney stones.',\n",
       "   'History of an acute illness within 2 weeks prior to the first dose of study medication.',\n",
       "   'History of alcohol abuse within 2 years preceding the first dose of study medication.',\n",
       "   'History of gout or hyperuricaemia.',\n",
       "   'History of drug abuse within 2 years preceding the first dose of study medication.',\n",
       "   'Use of an investigational drug within 30 days preceding the first dose of study medication.',\n",
       "   'Donation of blood in excess of 500 mL within 56 days prior to the first dose of study medication.']},\n",
       " {'nct_id': 'NCT00713544',\n",
       "  'inclusion': ['Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6 tender/painful joints, and either have (blood tests) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).',\n",
       "   'At least one of the following: documented history of positive rheumatoid factor (blood test), current presence of positive rheumatoid factor (blood test), baseline radiographic erosion, presence of serum anti-cyclic citrullinated peptide antibodies (bloo',\n",
       "   'Be receiving either: Oral (tablets) or subcutaneous (injection) methotrexate for at least 6 months prior to randomisation.'],\n",
       "  'exclusion': ['Any other inflammatory disease in addition to RA that may interfere with the study (e.g. polymyalgia rheumatica, giant cell arteritis, reactive arthritis, etc).',\n",
       "   'Current chronic pain disorders including fibromyalgia and chronic fatigue syndromes.']},\n",
       " {'nct_id': 'NCT00716248',\n",
       "  'inclusion': ['RA according to American College of Radiology (ACR) classification criteria',\n",
       "   'Age of 20 or greater',\n",
       "   'DAS28-ESR < 3.2 or DAS28-CRP < 2.6 for more than 6 months'],\n",
       "  'exclusion': ['Previously teated with bucillamine',\n",
       "   'Pregnancy or lactation']},\n",
       " {'nct_id': 'NCT00718588',\n",
       "  'inclusion': ['SAD Stage',\n",
       "   'RA diagnosed according to the ACR',\n",
       "   'For patients taking anti-rheumatic therapies, receipt of a stable regimen prior to randomization',\n",
       "   'Previous treatment with biologic agents, including anti-TNF agents, permitted but discontinued for an appropriate washout period',\n",
       "   'MAD Stage (same as above with the addition of the following)',\n",
       "   'Failure of at least one biologic agent, defined as lack of or loss of response or intolerance',\n",
       "   'Active disease defined by swollen and tender count'],\n",
       "  'exclusion': [\"Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty's syndrome\",\n",
       "   'Malignancy, or prior malignancy, other than non-melanoma skin cancer or cervical carcinoma in situ that has been resected',\n",
       "   'History of treatment with any T cell-directed therapy']},\n",
       " {'nct_id': 'NCT00714493',\n",
       "  'inclusion': ['Patients must have rheumatoid arthritis',\n",
       "   'Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints',\n",
       "   'Patients must have inadequate disease response to etanercept or adalimumab',\n",
       "   'Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.'],\n",
       "  'exclusion': ['Patients who have a history of latent or active TB',\n",
       "   'Have inflammatory disease other than rheumatoid arthritis',\n",
       "   'Have had a chronic or recurrent infectious disease.']},\n",
       " {'nct_id': 'NCT00717236',\n",
       "  'inclusion': ['Adult patient with established moderate to severe rheumatoid arthritis'],\n",
       "  'exclusion': ['All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment',\n",
       "   'Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trials']},\n",
       " {'nct_id': 'NCT00132769',\n",
       "  'inclusion': ['Rheumatoid arthritis, according to the American College of Rheumatology criteria, with active disease despite current medications',\n",
       "   'Other criteria also apply'],\n",
       "  'exclusion': ['Other major illnesses',\n",
       "   'Past history of certain other disorders',\n",
       "   'Certain prohibited medications']},\n",
       " {'nct_id': 'NCT00989677',\n",
       "  'inclusion': ['Diagnosed with Rheumatoid Arthritis',\n",
       "   'Inflamed PIP joint of at least one index finger (moderate or severe)',\n",
       "   'Disease activity of specific joints known (swelling, tenderness)',\n",
       "   'No significant deformations of the hand or fingers',\n",
       "   'More than 18 years old'],\n",
       "  'exclusion': ['Recent surgery or operation, in the last three months, on the arm or fingers that will be tested with the RADAM RRC',\n",
       "   'Inability to give informed consent']},\n",
       " {'nct_id': 'NCT00984815',\n",
       "  'inclusion': ['Patient is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.',\n",
       "   'Patient is male or female, aged 40 to 80 years of age.',\n",
       "   'Patient is expected to require daily administration of an NSAID for at least the coming year for conditions including but not limited to: osteoarthritis, rheumatoid arthritis, chronic low back pain, chronic regional pain syndrome, chronic soft tissue pain.',\n",
       "   'Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use medically acceptable methods of contraception throughout the entire study period.',\n",
       "   'Patient is willing and able to comply with the prescribed treatment protocol and evaluations.'],\n",
       "  'exclusion': ['Patient has a history of or experienced any of the following:',\n",
       "   'NSAID-associated and/or primary peptic ulcer disease-associated serious gastrointestinal complications such as perforation of ulcers, gastric outlet obstruction due to ulcers, and/or acute gastrointestinal bleeding',\n",
       "   'NSAID-induced asthma exacerbation, acute renal failure, interstitial nephritis, and/or hepatitis',\n",
       "   'Malignant disease of the gastrointestinal tract',\n",
       "   'Erosive esophagitis',\n",
       "   'Coronary artery bypass graft (CABG) surgery within the 14 days prior to study Day 0',\n",
       "   'Uncontrolled diabetes mellitus as evidenced by Hemoglobin A1c > 7%',\n",
       "   'Known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C',\n",
       "   'Patient has active cardiac, renal, and/or hepatic disease, as evidenced by:',\n",
       "   'Creatinine clearance < 45 mL/min (based on the Cockroft-Gault formula) at Screening',\n",
       "   'Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) > 2.5 times the upper limit of normal at Screening',\n",
       "   'History of acute myocardial infarction, unstable cardiac arrhythmias, and/or stroke within the 6 months prior to study entry',\n",
       "   'Uncontrolled congestive heart failure',\n",
       "   'Uncontrolled hypertension',\n",
       "   'Patient currently is participating in an investigational drug study, or patient participated in an investigational drug study within the 30 days prior to study entry.',\n",
       "   'Female patient has a positive urine pregnancy test at Screening and/or Study Day',\n",
       "   '- Patient has a concomitant disease or condition that, in the opinion of the Investigator, could interfere with the conduct of the study or could put the patient at unacceptable risk.']},\n",
       " {'nct_id': 'NCT00984711',\n",
       "  'inclusion': ['Subjects with active rheumatoid arthritis as defined by ACR criteria',\n",
       "   '> 18 years of age at time of consent',\n",
       "   'Able to start RITUXAN therapy per the approved product monograph within approximately 30 days of confirmed enrollment'],\n",
       "  'exclusion': ['Known Type 1 hypersensitivity or anaphylactic reactions to murine proteins, Chinese Hamster Ovary cell proteins or to any component of RITXAN as per approved Product monograph',\n",
       "   \"Presence of any significant and or uncontrolled medical condition, which in the Investigator's opinion, precludes the use of RITUXAN as outlined in the Product Monograph\"]},\n",
       " {'nct_id': 'NCT00056602',\n",
       "  'inclusion': ['A diagnosis of RA;',\n",
       "   'Age 18 years or older;',\n",
       "   'Onset of arthritis after the age of 16 years;',\n",
       "   'Active arthritis, as evidenced by six or more tender joints EXCLUSION CRITERIA:'],\n",
       "  'exclusion': ['Inability to provide informed consent.',\n",
       "   'Children will necessarily be excluded from this protocol.']},\n",
       " {'nct_id': 'NCT00055055',\n",
       "  'inclusion': ['Children (< 18 years of age) or adults (18 or more years of age) require a diagnosis of a systemic rheumatic disorder (by American College of Rheumatology (ACR) or other criteria for the adult or juvenile forms of RA, SLE, SSc, or IIM (per (92;93)). Regarding the childhood-onset diseases: JRA will be defined by age of onset <17 years of age; for other diseases age of onset will be < 18 years. Probands will be diagnosed within 5 years of enrollment in the study, with at least one twin or other sibling of the same gender within 5 years of age and without a recognized systemic rheumatic disorder or other autoimmune disease available for study. Twin-sibling inclusion criteria: -Children or adults who are twins or other siblings of a proband sharing the same biological parents, but without a recognized systemic rheumatic or autoimmune disorder, of the same gender and within 5 years of age of the proband. If monozygotic twins are enrolled from a family, another unaffected non-twin sibling sharing the same biological parents will be enrolled for each proband if available to allow for log-linear genetic analyses. All probands and unaffected siblings need to be at least one year of age at the time of autoimmune disease diagnosis. In the case of triplets or greater multiples, all such siblings are eligible for enrollment. Parent inclusion criteria: -Individuals who are the genetic father and mother of the proband and twin-sib. Both parents will be enrolled whenever possible. Healthy volunteer inclusion criteria: Healthy controls, recruited in part via the NIH Healthy Volunteers program, and as reasonably as possible, matched to a subset of probands based on age (within 5 years), gender, and race (when feasible). Healthy volunteers should be in good health, without a recognized systemic rheumatic disorder or other autoimmune disease, and should not be taking antiinflammatory medicines, including nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. For all subjects: ability of the subject or parents/legal guardians to provide informed consent to all aspects of the study after full protocol information is provided. Should a participant enroll at a time when his/her twin/sibling is willing and able to give informed consent, but his/her twin/sibling never enrolls (eg. Due to no longer being willing or able to give informed consent), the enrolled participant will remain in the study and his/her data will be used in the analyses not pertinent to his/her twin/sibling. Data analysis will also occur in this manner should the enrolled participant s sibling enroll, but never send in blood samples and/or questionnaires. EXCLUSION CRITERIA: Exclusion criteria for all protocol subjects:',\n",
       "   'severe trauma or vaccinations within 8 weeks of enrollment;',\n",
       "   'Still s disease/systemic-onset or pauciarticular JRA;',\n",
       "   'medical illness that in the judgment of the investigators does not allow safe blood draws or other clinical evaluations needed for study participation;',\n",
       "   'cognitive impairment;',\n",
       "   'inability to give informed assent or consent. Exclusion criteria for twin-sibs: Not sharing the same biological parents (being half-brothers or half-sisters). Known criteria for systemic rheumatic disease or autoimmune disease (for example: RA/JRA, SLE/JSLE, SSc/JSSc, IIM/JIIM, Type 1 diabetes, Psoriasis, Still s disease/systemic-onset or pauciarticular JRA, Celiac sprue, Autoimmune thyroid disease, Idiopathic Thrombocytopenia Purpura, Multiple sclerosis, Myasthenia gravis, Systemic vasculitis or Vitiligo).'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00056667',\n",
       "  'inclusion': ['RA as defined by the American College of Rheumatology',\n",
       "   'English literacy and fluency'],\n",
       "  'exclusion': ['Major medical condition or illness which limits life expectancy or results in severe symptoms or functional disability (Duke Severity of Illness score > 0.85)',\n",
       "   'Fibromyalgia',\n",
       "   'Received or currently receiving psychosocial treatment for RA',\n",
       "   'Unavailability for Month 12 follow-up']},\n",
       " {'nct_id': 'NCT00056394',\n",
       "  'inclusion': ['Meet at least 4 of the 7 criteria for RA classification based on the 1987 American College of Rheumatology criteria',\n",
       "   'Onset of RA symptoms within 2 years of study entry'],\n",
       "  'exclusion': ['Known organic disease that significantly affects function',\n",
       "   'Rheumatic disorders in addition to RA that significantly affect function']},\n",
       " {'nct_id': 'NCT00055133',\n",
       "  'inclusion': ['≥6 swollen and ≥9 tender joints',\n",
       "   'CRP ≥0.8 mg/dL or morning stiffness ≥45 minutes (vi) If female and of child bearing potential, she must:',\n",
       "   'have a negative serum pregnancy test, and',\n",
       "   'be using two forms of an effective method of contraception (one form being a barrier method) or be surgically incapable of bearing children or abstinent. If male and heterosexual, he must:',\n",
       "   'agree to use condoms with spermicide throughout the study and for at least 12 weeks following the last infusion.',\n",
       "   'vasectomy is an acceptable form of contraception for males and partners of females (vii) Adequate venous access as defined by the Principal Investigator (viii) If taking non-steroidal anti-inflammatory medications, must be on stable regimen for four weeks prior to the Screening visit (ix) If taking prednisone (≤ 10 mg) or equivalent, must be on stable regimen for four weeks prior to Screening visit'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00853385',\n",
       "  'inclusion': ['The patient has a diagnosis of RA based upon the American College of Rheumatology (ACR) 1987 Revised Criteria.',\n",
       "   'The patient must have had an inadequate response to methotrexate and have active disease, as defined by both: ≥6 joints tender or painful on motion; and ≥6 joints swollen; and fulfills 1 of the following 2 criteria at Screening: 1.ESR (Westergren method) >28 mm in the local laboratory.',\n",
       "   'CRP >7 mg/L in the central laboratory.',\n",
       "   'No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.',\n",
       "   'The patient must have been on a stable dose of 7.5 mg to 25 mg weekly of methotrexate and washed out of all other DMARDs.'],\n",
       "  'exclusion': ['Blood dyscrasias including confirmed:',\n",
       "   'Hemoglobin <9 g/dL or Hematocrit <30%;',\n",
       "   'White blood cell count <3,000 cu.mm. Absolute neutrophil count <1,200 cu.mm;',\n",
       "   'Platelet count <100,000/L',\n",
       "   \"History of any other autoimmune rheumatic disease other than Sjogren's syndrome\",\n",
       "   'No malignancy or history of malignancy.',\n",
       "   'History of infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator, within the 6 months prior to the first dose of study drug',\n",
       "   'Patients who have failed any TNFi for either lack of efficacy or a TNFi mechanism related adverse event.',\n",
       "   'Patients who have previously received adalimumab therapy for any reason.',\n",
       "   'Patients who are contraindicated for treatment with adalimumab in accordance with the approved local label.',\n",
       "   'Patients meeting the New York Heart Association Class III and Class IV Congestive Heart failure']},\n",
       " {'nct_id': 'NCT00854243',\n",
       "  'inclusion': ['Adults: age at disease onset >18 years and < 50 years',\n",
       "   'Disease duration < 3 month',\n",
       "   'Fulfilling ARA criteria for classification of RA',\n",
       "   'DMARD naive'],\n",
       "  'exclusion': ['Age at diagnosis < 18 years',\n",
       "   'Disease duration > 3 month',\n",
       "   'Previous use of DMARDS',\n",
       "   'Previous use of biologics']},\n",
       " {'nct_id': 'NCT00854321',\n",
       "  'inclusion': ['active RA without response to earlier treatment'],\n",
       "  'exclusion': ['contraindications to rituximab']},\n",
       " {'nct_id': 'NCT00858169',\n",
       "  'inclusion': ['Patients who fulfill the 1987 ARA criteria for RA',\n",
       "   'Patients with at least one painful swollen wrist or knee joint observed by a rheumatologist',\n",
       "   'Patients who will receive a new medicine, including oral corticosteroid, intravenous methylprednisolone pulse therapy, intraarticular injection with steroid or methotrexate, DMARDs, or biologic agent'],\n",
       "  'exclusion': ['Patients with active infection',\n",
       "   'Patients with concurrent malignant disease',\n",
       "   'Patients with a history of traumatic, septic, or cystal arthritis, previous joint surgery, or arthroscopic synovectomy of any wrist or kneejoint within the past 12 months before the study',\n",
       "   'Patients who have severe wrist or knee joint deformity that makes the US assessment protocol unable to complete']},\n",
       " {'nct_id': 'NCT00851240',\n",
       "  'inclusion': ['adult-onset rheumatoid arthritis'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT00859859',\n",
       "  'inclusion': ['Patients with a diagnosis of RA based on the ACR guidelines. Disease activity measured as activity score (DAS-28 CRP) will be used',\n",
       "   'None of the exclusion criteria (see below).'],\n",
       "  'exclusion': ['Minors (<18 years of age) and mentally incompetent individuals',\n",
       "   'One or more of the following conditions: immunosuppressive condition (which includes malignancy, chronic alcoholism, diabetes), severe chronic dementia, psychiatric illness with active psychosis, current intravenous or other serious illicit drug use',\n",
       "   'Pregnancy',\n",
       "   'Terminal status referred for palliative care only',\n",
       "   'Homeless status',\n",
       "   'IDDM and NIDDM patients will not be enrolled in this study',\n",
       "   'Previous history of ischemic cardiovascular disease including myocardial infarction, unstable angina, and bradytachyarrythmias',\n",
       "   'Moderate or severe anemia. Hemoglobin levels will be determined at screening. A cut-off level of < 10 mg/dL in women and < 11 mg/dL in men is selected.',\n",
       "   'Smoking',\n",
       "   'Subjects taking concomitant medications potentially affecting autonomic function such as anti-cholinergic medications and beta-blockers.']},\n",
       " {'nct_id': 'NCT00854685',\n",
       "  'inclusion': ['Patients who are willing to give signed informed consent..',\n",
       "   'Male or female subjects at least 18 years of age and no more than 80 years of age.',\n",
       "   \"Women of childbearing potential, or men of reproductive potential, must be using adequate (in the investigator's opinion) birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilisation) during the study. Female subjects of childbearing potential must test negative for pregnancy prior to enrolling in the study. Post menopausal (cessation of menses for more than 2 years) women are eligible for this study.\",\n",
       "   'Diagnosis of RA according to the revised (1987) American College of Rheumatology criteria for at least 6 months prior to screening.',\n",
       "   'Meet ACR functional class criteria I, II or III.',\n",
       "   'Have active RA at the time of screening and at baseline, defined as ≥ 6 swollen joints and ≥ 6 tender joints (from 68 joint count) together with at least 2 of the following 3 criteria:',\n",
       "   'CRP level ≥ 1.5 mg/dl;',\n",
       "   'ESR by Westergren method ≥ 28 mm in the first hour; or',\n",
       "   'morning stiffness ≥ 45 minutes.',\n",
       "   'At least one of the following should be present at screening:',\n",
       "   'documented history or current presence of positive rheumatoid factor;',\n",
       "   'presence of serum anti-CCP antibodies; or',\n",
       "   'screening radiographic erosion.',\n",
       "   'Have been tolerating concomitant methotrexate (oral or subcutaneous) for at least 3 months prior to screening and on a stable dose between 10-25 mg per week for at least 6 weeks prior to the first study dose. The route of administration must also be stable. Use of methotrexate dose of 25-50 mg every 2 weeks is also acceptable. (Other DMARDs taken concomitantly with methotrexate are not allowed. Those subjects concomitantly receiving additional DMARDs with methotrexate may enter the study by stopping the additional DMARD at least 4 weeks prior to first study dose).',\n",
       "   'If using the following medication, the subject must be on a stable dose for the 4 weeks prior to the first study dose and maintain that dose throughout the study:',\n",
       "   'oral corticosteroids, equivalent to ≤ 10 mg of prednisone/day.',\n",
       "   'one nonsteroidal anti-inflammatory drug (NSAID).',\n",
       "   '3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates (see Section 7.1 for acceptable doses).',\n",
       "   'Does not have active or latent TB according to eligibility assessment and screening tests.',\n",
       "   'Is willing and able to comply with study visits and other protocol requirements.'],\n",
       "  'exclusion': ['Body weight >98',\n",
       "   '- Pregnant, nursing, or planning a pregnancy (both men and women) within 9 months of enrolment.',\n",
       "   'Screening laboratory tests:',\n",
       "   'haemoglobin ≤ 8.0 gm/dl',\n",
       "   'white blood cells ≤ 3.0 x103 cells/µl',\n",
       "   'neutrophils ≤ 1.5 x 103 cells/µl',\n",
       "   'platelets ≤100 x 103 cells/µl',\n",
       "   'serum transaminase level (AST and ALT) ≥ 2 times upper limit of normal (ULN)',\n",
       "   'serum creatinine ≥ 0.15 mmol/l',\n",
       "   'Subjects with a diagnosis of juvenile arthritis or other inflammatory or autoimmune diseases that might confound the evaluations of benefit from ART621 such as ankylosing spondylitis, systemic lupus erythematosus and Lyme disease.',\n",
       "   'Subjects who have previously failed to respond to any oral or injectable anti-TNFα therapy or subjects who have had to stop anti-TNFα therapy for safety reasons. Subjects who have successfully responded to anti-TNF therapy in the past (but discontinued for reasons other than safety or lack of efficacy) > 6 months prior to study day one may enrol. Patients who have participated in a previous anti-TNF therapy study are eligible if they are confirmed to have received placebo.',\n",
       "   'Subjects who have previously received the following anti-rheumatic drugs: interleukin-1 receptor antagonist [anakinra], rituximab, anti-CD4 antibody, abatacept, thalidomide, p38 MAP kinase inhibitor and other agents (other than those listed in Section 7.3).',\n",
       "   'Subjects who have undergone plasmapheresis within 6 months prior to randomisation.',\n",
       "   'Have received intraarticular, intramuscular, or intravenous corticosteroids, including intramuscular adrenocorticotropic hormone, during the 4 weeks prior to the first study dose, or non-stable doses of oral steroids.',\n",
       "   'Subjects with a history of any clinically significant adverse reaction to murine or chimeric proteins, including serious allergic reactions.',\n",
       "   \"Subjects with Felty's syndrome or a history of Felty's syndrome.\",\n",
       "   'Subjects who have received or are expecting to receive any live virus or bacterial vaccinations within 1 month before first study dose, during the study, or up to 3 months after the study dose.',\n",
       "   'Subjects with a history of, presence of, or at high risk of serious infection including:',\n",
       "   'history of active TB, or positive Mantoux test or QuantiFERON Gold test or chest x-ray suggestive of active or healed TB or positive contact history with a subject with active TB within the past 3 months. If patients have a positive Mantoux test but a negative QuantiFERON Gold test, they may be enrolled.',\n",
       "   'a serious infection during the 3 months prior study entry (hospitalised or received IV antibiotics for an infection).',\n",
       "   'chronic or recurrent infectious disease.',\n",
       "   'systemic fungal infections',\n",
       "   'opportunistic infection within 3 months prior to screening (refer to 1993 CDC Classification System for HIV Infection).',\n",
       "   'subjects known, or suspected, to be infected with HIV, hepatitis B, or hepatitis',\n",
       "   '- subjects with planned joint replacement surgery or a history of infected joint prosthesis or who have received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.',\n",
       "   'Subjects with a known history of demyelinating diseases such as multiple sclerosis or optic neuritis.',\n",
       "   'Subjects with evidence of severe, progressive, or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease.',\n",
       "   'Concurrent CHF, including medically controlled, asymptomatic CHF or ECG findings suggestive of CHF.',\n",
       "   'Subjects receiving cytotoxic drugs including cyclophosphamide, cyclosporine, or alkylating agents within 6 months prior to first study dose.',\n",
       "   'Known history or evidence of malignancy, lymphoproliferative or neoplastic disease with the exception of successfully treated basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.',\n",
       "   'Subjects who have undergone organ transplant (with exception of a corneal transplant more than 3 months prior to screening).',\n",
       "   'Subjects previously enrolled in this study, currently participating in another investigational study or treated with any investigational drug within the previous 3 months or within 5 half-lives, whichever is greater, prior to first study dose.',\n",
       "   'Any other clinically significant disease or disorder or factors such as substance abuse which in the opinion of the investigator make the subject ineligible for participation in this study.']},\n",
       " {'nct_id': 'NCT00430495',\n",
       "  'inclusion': ['Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic criteria with a disease history of at least one year',\n",
       "   'Male or female greater than or equal to (>=)18-years of age at time of informed consent',\n",
       "   'Active RA as defined by:',\n",
       "   '>=8 swollen joints (66-joint count),',\n",
       "   '>=8 tender joints (68-joint count), and',\n",
       "   'C-reactive protein (CRP) >=10 milligram per liter (mg/L) (central laboratory) and/or erythrocyte sedimentation rate (ESR) >= to 28 millimeter per hour (mm/h)',\n",
       "   'Failure of at least one TNFa antagonist therapy (previously or at the time of screening) as specified in the protocol',\n",
       "   'Other protocol defined inclusion criteria could apply Exclusion Criteria:',\n",
       "   \"Any condition, including laboratory findings or findings in the medical history or pre-trial assessments, that in the opinion of the Investigator constitutes a risk or a contraindication for the subject's participation in the trial or that could interfere with the trial objectives, conduct or evaluation\",\n",
       "   'Treatment with biologics aiming at B cell modulation such as rituximab or belimumab within 2 years before study Day 1',\n",
       "   'Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab within 3 months before study Day 1',\n",
       "   'Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab (Remicade) or adalimumab (Humira) within 60 days before study Day 1',\n",
       "   'Participation in any interventional clinical trial with an unapproved investigational therapy within the 3 months before the start of this study (or within 5 half-lives of the investigated compound before study Day 1, whichever is longer)',\n",
       "   'Other protocol defined'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00432484',\n",
       "  'inclusion': ['Fulfilled the 1987 American College of Rheumatology (ACR) criteria for',\n",
       "   '- The presence of 2 or more swollen or tender joints, based on 28-joint count.',\n",
       "   'Morning stiffness lasting for 30 minutes.',\n",
       "   'Erythrocyte sedimentation rate (ESR) of 28 mm/hour, despite treatment with disease modifying agent including MTX, sulphasalazine, hydroxychloroquine, auranofin or azathioprine were recruited into the study.',\n",
       "   'Patients taking glucocorticoids (prednisone < 7.5 mg/day) and/or nonsteroidal antiinflammatory drugs must have been taking a stable dosage for at least 4 weeks before entering the trial and were required to take the same dosage throughout the trial.',\n",
       "   'Patients had radiographic erosive diseases.'],\n",
       "  'exclusion': ['Patients who are pregnant or nursing mothers.',\n",
       "   'Severe liver disease (e.g cirrhosis, chronic active hepatitis)',\n",
       "   'Renal impairment (serum creatinine level > 150mmol/L)',\n",
       "   'Known hypersensitivity to herbal medicine']},\n",
       " {'nct_id': 'NCT00434200',\n",
       "  'inclusion': ['Rheumatoid arthritis'],\n",
       "  'exclusion': ['Prosthesis of a weight bearing joint']},\n",
       " {'nct_id': 'NCT00617032',\n",
       "  'inclusion': ['Rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis, diagnosed according to published criteria',\n",
       "   'Persistent moderate (grade 2) or sever (grade 3) swelling due to inflammatory arthritis in at least one peripheral joint eligible for injection',\n",
       "   'For subjects with rheumatoid arthritis, an adequate trial of at least one disease-modifying antirheumatic drug (DMARD) prior to screening',\n",
       "   'For subjects currently on DMARD(s), a stable regimen for inflammatory arthritis for the previous three months, with no changes in doses in the four weeks prior to screening',\n",
       "   'Age greater than 18 years',\n",
       "   'Be willing to practice effective birth control measures during the study, if of reproductive ability',\n",
       "   'Able to give written informed consent'],\n",
       "  'exclusion': ['Current use of a TNF-alpha antagonist',\n",
       "   'Disease severe enough to warrant use of a systemic TNF-alpha antagonist in the next three months',\n",
       "   'Discontinuation of TNF-alpha antagonists in the past because of safety concerns',\n",
       "   'Current use of anakinra',\n",
       "   'Poor functional status, defined as being bed-bound or wheelchair-bound',\n",
       "   'Corticosteriod therapy at doses higher than the equivalent of 10 mg prednisone per day',\n",
       "   'Any of the following laboratory values: Hemoglobin <8.5 gm/dL, white blood cell count <3500 per mm^3, platelet <100 K/microL, creatinine >2 mg/dL, bilirubin >2 mg/dL, AST or ALT >2 times the upper limit of normal, or abnormal coagulation profiles',\n",
       "   'Known HIV infection, known hepatitis C infection, or known positive serologic test for hepatitis B surface antigen',\n",
       "   'Positive PPD, unless previously treated with appropriate prophylaxis',\n",
       "   'Pregnancy or lactation, either at the time of screening or planned in the next six months',\n",
       "   \"Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis\",\n",
       "   'Serious medical disease, such as sever liver or kidney disease, uncompensated congestive heart failure, myocardial infarction within six months, unstable angina, uncontrolled hypertension, severe pulmonary disease or active asthma, demyelinating neurological disease, history of cancer (other than cutaneous basal and squamous cell carcinoma) with less than five years documentation of a disease free state, insulin-dependent diabetes, recurrent opportunistic infections or other concurrent medical condition that, in the opinion of the investigator, would make the subject unsuitable for the study',\n",
       "   'Unlikely to comply with the protocol']},\n",
       " {'nct_id': 'NCT00619905',\n",
       "  'inclusion': ['Male and female patients aged 18.5',\n",
       "   '65/75 years (depending on the dose group).',\n",
       "   'Diagnosis of rheumatoid arthritis (ACR 1987 revised classification for criteria for RA) with a disease duration of at least 6 months prior to randomization.',\n",
       "   'Active disease at screening and baseline evaluation (same evaluator) ) with more than 6 tender and 6 swollen joints of 28 examined (including any effused joint) and either a) Westergren erythrocyte sedimentation (ESR) ≥ 28 mm/hour, or b) CRP ≥ 6 mg/L.',\n",
       "   'Patients should have failed at least 1 DMARD in the past, but should not be deemed \"refractory to all therapies\"',\n",
       "   'Patients should have a current treatment regimen of ≥ 15 mg methotrexate/week and with the current dose stable for approximately 3 months.',\n",
       "   'Patients were required to have an otherwise stable RA therapeutic regimen, consisting of either a stable dose of NSAIDs and/or a stable dose of oral corticosteroids (prednisone or equivalent < 10 mg daily) for at least 4 weeks prior to randomization. Exclusion Criteria:',\n",
       "   'Previous treatment with anti-TNF-α antibody therapy (or other biological therapy) within appropriate timeframe (considering the half life of the compound)',\n",
       "   'Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization OR require narcotic analgesics other than those accepted by the investigator for analgesia (e.g., codeine, tramadol, dextropropoxyphene) Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00845949',\n",
       "  'inclusion': ['patients with rheumatoid arthritis fulfills ACR 1987 classification criteria for rheumatoid arthritis'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT00843778',\n",
       "  'inclusion': ['Patients with established adult rheumatoid arthritis on Disease Modifying Anti-Rheumatic Drugs (DMARDs) therapy who were included in C87076 protocol and:',\n",
       "   'either failed to achieve remission after 6 months of study treatment',\n",
       "   'or flared after the 6 months of study treatment and completed the study (C87076 [NCT00674362])'],\n",
       "  'exclusion': ['All the concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment',\n",
       "   'Previous clinical trials and previous biological therapy that could interfere with the results in the present clinical trial']},\n",
       " {'nct_id': 'NCT00848120',\n",
       "  'inclusion': ['adult patients,>=18 years of age;',\n",
       "   'rheumatoid arthritis diagnosed >8 weeks and <4 years prior to baseline;',\n",
       "   'naive to, or not responding well to, methotrexate;',\n",
       "   'swollen joint count >=8 (66 joint count) and tender joint count>=8 (68 joint count) at screening and baseline.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than rheumatoid arthritis;',\n",
       "   'patients with functional class IV rheumatoid arthritis;',\n",
       "   'history of, or current, inflammatory joint disease other than rheumatoid arthritis, or other systemic autoimmune disorder.']},\n",
       " {'nct_id': 'NCT00840957',\n",
       "  'inclusion': ['Rheumatoid arthritis according to ACR criteria',\n",
       "   'Patient already receiving infliximab for more than 14 weeks',\n",
       "   'No modification of the dose regimen of infliximab since the last infusion',\n",
       "   'No modification of disease modifying anti rheumatic drugs since the last 4 weeks'],\n",
       "  'exclusion': ['Surgery scheduled during the duration of the study',\n",
       "   'Pregnancy',\n",
       "   'infection, malignancy, immune reaction to infliximab or demyelinating diseases']},\n",
       " {'nct_id': 'NCT00848354',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis (RA)',\n",
       "   'Currently receiving a suboptimal response to a stable dose of methotrexate for treatment of Rheumatoid Arthritis (RA)',\n",
       "   'Active Rheumatoid Arthritis (RA) at time of screening and baseline'],\n",
       "  'exclusion': ['Previous or current treatment with etanercept, other tumor necrosis factor-alpha inhibitors, or other biologic agents',\n",
       "   'Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, at screening',\n",
       "   'Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, within 3 months before screening']},\n",
       " {'nct_id': 'NCT00845832',\n",
       "  'inclusion': ['adult patients, 18-65 years of age;',\n",
       "   'rheumatoid arthritis, functional status I-III;',\n",
       "   'SJC>=4 (28 joint count) and TJC>=4 (28 joint count) at screening and baseline;',\n",
       "   'RF and/or anti-CCP positive;',\n",
       "   'may have failed up to 1 approved anti-TNF agent (infliximab, etanercept or adalimumab);',\n",
       "   'inadequate response to methotrexate, at a dose of 7.5-25mg weekly for at least 12 weeks, at a stable dose for past 4 weeks.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than rheumatoid arthritis, or significant systemic involvement secondary to rheumatoid arthritis;',\n",
       "   'history of, or current, inflammatory joint disease other than rheumatoid arthritis;',\n",
       "   'diagnosis of juvenile idiopathic arthritis and/or rheumatoid arthritis before age 16;',\n",
       "   'significant cardiac or pulmonary disease;',\n",
       "   'previous treatment with any biologic agent for rheumatoid arthritis (other than infliximab, etanercept or adalimumab).']},\n",
       " {'nct_id': 'NCT00847886',\n",
       "  'inclusion': ['Males and females ≥ 18 years old',\n",
       "   'Must be willing to practice 2 adequate methods of contraception for the duration of the study',\n",
       "   'Rheumatoid arthritis present for at least 3 months; functional class I, II, or III as defined by ACR criteria',\n",
       "   'Treatment with methotrexate (7.5 to 25 mg per week) for at least the last 3 months, and currently receiving stable dose methotrexate for at least one month prior to the start of the study',\n",
       "   'Ability to provide written informed consent'],\n",
       "  'exclusion': ['Women who are pregnant or nursing',\n",
       "   'History of other current inflammatory arthritis',\n",
       "   'History of opportunistic infection',\n",
       "   'History of recurrent infections or current infection 2 weeks prior to start of study',\n",
       "   'Presence of significant, uncontrolled medical problems',\n",
       "   'Treatment with any disease-modifying anti-rheumatoid drugs other than methotrexate within 4 weeks prior to start of study',\n",
       "   'Use of chondroitin sulfate, glucosamine sulfate, minocycline, or matrix metalloproteinase inhibitors, H-2 blockers, proton pump inhibitors, or misoprostol within 4 weeks prior to study start',\n",
       "   'Receipt of live vaccine within 8 weeks prior to study start',\n",
       "   'Rheumatoid arthritis, functional class IV as defined by ACR criteria']},\n",
       " {'nct_id': 'NCT00586781',\n",
       "  'inclusion': ['Moderate or severe pain, loss of mobility and function of the ankle',\n",
       "   'Primary arthrosis, post traumatic arthrosis or rheumatoid arthrosis',\n",
       "   'At least six months of conservative treatment for severe ankle conditions',\n",
       "   'Bilateral ankle disease that have not been enrolled in the pivotal study or single ankle disease and enrolled in the pivotal study but have subsequently developed ankle disease in the contralateral ankle and require surgical intervention',\n",
       "   'Willing and able to give informed consent'],\n",
       "  'exclusion': ['Patients who have not reached skeletal maturity',\n",
       "   'Active or prior deep infection in the ankle joint or adjacent bones',\n",
       "   'Prior arthrodesis at the involved site',\n",
       "   'History of prior mental illness or patient demonstrates that their mental capacity may interfere with their ability to follow the study protocol',\n",
       "   'Obesity (weight greater than 250 lbs)',\n",
       "   'History of current or prior drug abuse or alcoholism',\n",
       "   'Any physical condition precluding major surgery',\n",
       "   'Prior surgery and/or injury that has adversely affected the ankle bone stock',\n",
       "   'Severe osteoporotic or osteopenic condition or other conditions that may lead to inadequate implant fixation in the bone',\n",
       "   'Insufficient ligament support']},\n",
       " {'nct_id': 'NCT00580840',\n",
       "  'inclusion': ['Patients with established adult rheumatoid arthritis currently on Methotrexate for at least 3 months'],\n",
       "  'exclusion': ['All concomitant diseases or pathological conditions that could interfere and impact the assessment of the study treatment',\n",
       "   'Previous clinical trials participation and previous biological therapy that could interfere with the results of the present clinical trial']},\n",
       " {'nct_id': 'NCT00588887',\n",
       "  'inclusion': ['Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.',\n",
       "   'Patients requiring correction of varus, valgus, or posttraumatic deformity.',\n",
       "   'Patients requiring correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.'],\n",
       "  'exclusion': ['Patients with infection, sepsis, or osteomyelitis.']},\n",
       " {'nct_id': 'NCT00589485',\n",
       "  'inclusion': ['Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved',\n",
       "   'Patients requiring correction of varus, valgus, or posttraumatic deformity',\n",
       "   'Patients requiring correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure'],\n",
       "  'exclusion': ['Infection, sepsis, and osteomyelitis']},\n",
       " {'nct_id': 'NCT00588783',\n",
       "  'inclusion': ['Patients with painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartment are involved.',\n",
       "   'Patients requiring correction of varus, valgus, or posttraumatic deformity',\n",
       "   'Patients requiring correction of revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure.'],\n",
       "  'exclusion': ['Patients with infection, sepsis, or osteomyelitis.']},\n",
       " {'nct_id': 'NCT00588393',\n",
       "  'inclusion': [\"Study will include 40 subjects with rheumatoid arthritis (active or inactive disease, defined as no swollen joints) and 5 patients in each of the following diagnosis: osteoarthritis, multiple sclerosis, Crohn's disease, systemic lupus erythematosus, interstitial lung disease and no autoimmune disease (healthy).\",\n",
       "   'Subjects must have disease duration of at least 6 months and creatinine level may not be greater than 1.5 mg/dL.'],\n",
       "  'exclusion': ['Subjects will be excluded if they are pregnant, have an active infection, received an investigational therapy in the past month or previous malignancy within the past 5 years.']},\n",
       " {'nct_id': 'NCT00754559',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'rheumatoid arthritis of >=6 months duration diagnosed according to the revised 1987 ACR criteria;',\n",
       "   'DAS28 of >3.2;',\n",
       "   'At screening either ESR >=28 mm/h or CRP >=1 mg/dL;',\n",
       "   'Having received permitted DMARDs, 1 or more; current DMARD therapy must have been at a stable dose for at least 8 weeks prior to baseline.'],\n",
       "  'exclusion': ['major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following screening;',\n",
       "   'functional class IV as identified by the ACR classification of functional status in RA;',\n",
       "   'rheumatoid autoimmune disease other than RA;',\n",
       "   'prior history of or current inflammatory joint disease other than',\n",
       "   '']},\n",
       " {'nct_id': 'NCT00752154',\n",
       "  'inclusion': ['Age ≥ 18 years; read and understand English',\n",
       "   'Stable dose of non-steroidal anti-inflammatory agents (NSAID) for ≥ 2 weeks.',\n",
       "   'Oral prednisone or equivalent ≤ 10 mg daily and stable dose for ≥ 2 weeks(and must be kept stable throughout the duration of the protocol).',\n",
       "   'ESR > 20 mm/hr, or CRP > 0.8 mg/dl',\n",
       "   'May be using any of the following DMARDs: methotrexate, sulfasalazine, hydroxychloroquine or leflunomide. If using any of these DMARDs must be using them for ≥ 12 weeks and stable dose for ≥ 4 weeks. If using other DMARD, or DMARD combinations, these additional or other DMARDs must be stopped for ≥ 4 weeks before baseline visit. May also participate if patient not on DMARD,',\n",
       "   'Subjects must be diagnosed with rheumatoid arthritis based on the revised American College of Rheumatology criteria:Presence of > swollen and > 6 tender joint count (28 joint count), and either ESR > 20 mm/hr or CRP > 0.8 mg/dl'],\n",
       "  'exclusion': ['Acute medical conditions deemed as inappropriate by the investigators (acute heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension)',\n",
       "   'AST/ALT > 1.5 upper limit of normal (ULN)',\n",
       "   'Serum creatinine > 1.6 mg/dl',\n",
       "   'Hemoglobin/Hematocrit < 10.0 gram/dl/ 30.0',\n",
       "   'Platelet count < 100,000',\n",
       "   'Current use of warfarin (as there is a drug interaction between curcumin and warfarin).',\n",
       "   'Currently on biologic therapy (must have stopped etanercept for ≥ 4 weeks or adalimumab or infliximab for ≥ 8 weeks at time of Time 1 visit),',\n",
       "   'Women who are pregnant,',\n",
       "   'Subjects who are taking digoxin, warfarin and/or heparin,',\n",
       "   'Subjects with a history of antiphospholipid syndrome and other thrombophilic states,',\n",
       "   'Subjects who have an INR >= 1.5 at baseline,',\n",
       "   'Subjects with acute episode(s) of cholecystitis within the last 6 months,',\n",
       "   'Subjects with active peptic ulcer disease within the last 6 weeks']},\n",
       " {'nct_id': 'NCT00754572',\n",
       "  'inclusion': ['patients >=18 years with moderate to severe active RA for at least 6 months;',\n",
       "   'swollen joint count >=6 (66 joint count) and tender joint count >=8 (68 joint count) at screening;',\n",
       "   'inadequate response to stable dose of MTX;',\n",
       "   'patients of reproductive potential must be using a reliable means of contraception.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than RA;',\n",
       "   'patients with functional class IV RA;',\n",
       "   'diagnosis of juvenile idiopathic or rheumatoid arthritis before age 16 or a history of current inflammatory joint disease other than RA;',\n",
       "   'prior treatment failure with anti-tumor necrosis factor agent;',\n",
       "   'pregnant or breastfeeding women.']},\n",
       " {'nct_id': 'NCT00750880',\n",
       "  'inclusion': ['male and non-pregnant or nursing female patients >=18 years of age;',\n",
       "   'body weight <=150kg;',\n",
       "   'moderate to severe active RA (DAS28 >=3.2) of >=6 months duration;',\n",
       "   'on >=1 non-biologic DMARDs at a stable dose for a period of >= 8 weeks prior to start of treatment;',\n",
       "   'inadequate clinical response to a stable dose of non-biologic DMARD or anti-TNF therapy;',\n",
       "   'if receiving oral corticosteroids, the dose must have been stable for at least 25 of 28 days prior to start of treatment.'],\n",
       "  'exclusion': ['major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment;',\n",
       "   'rheumatic autoimmune disease other than RA;',\n",
       "   'prior history of, or current inflammatory joint disease other than RA;',\n",
       "   'functional class IV as defined by the ACR Classification of Functional Status in',\n",
       "   '']},\n",
       " {'nct_id': 'NCT00757354',\n",
       "  'inclusion': ['Subjects selected for this Evaluation will be grouped by initial diagnosis into one of the following diagnostic groups:',\n",
       "   'Non-inflammatory degenerative joint disease including osteoarthritis, avascular necrosis and traumatic arthritis.',\n",
       "   'Rheumatoid arthritis.',\n",
       "   'Selection of subjects for this Evaluation should include the following considerations:',\n",
       "   'Patients under 70 years of age.',\n",
       "   'Willing to return for follow-up evaluations.',\n",
       "   'No bias to sex.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00474877',\n",
       "  'inclusion': ['Clinical diagnosis of RA, less than 5 years duration'],\n",
       "  'exclusion': ['Patients with previous wrist and hand surgery, non-addressable fixed hand or wrist deformity, those from vulnerable group']},\n",
       " {'nct_id': 'NCT00476996',\n",
       "  'inclusion': ['Adult patients, ≥ 18 years of age',\n",
       "   'Rheumatoid arthritis for at least 3 months',\n",
       "   'Inadequate response to previous or current treatment with at least one anti-TNF-alpha agent',\n",
       "   'Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for the last 4 weeks',\n",
       "   'Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68 joint count) at screening and baseline.',\n",
       "   'CRP ≥ 0.6 mg/dL using a high-sensitivity assay.',\n",
       "   'Positive rheumatoid factor or positive anti-CCP antibody or both.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease or inflammatory joint disease, other than RA',\n",
       "   'Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline']},\n",
       " {'nct_id': 'NCT00471874',\n",
       "  'inclusion': ['Male or female patient with clinically defined rheumatoid arthritis diagnosed for at least 3 months',\n",
       "   'Age 18 years or older',\n",
       "   'Ability to complete the study documents in English'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00475111',\n",
       "  'inclusion': ['Diagnosis of RA'],\n",
       "  'exclusion': ['Currently taking cyclical estrogen replacement therapy',\n",
       "   'Diagnosis of lupus']},\n",
       " {'nct_id': 'NCT00785928',\n",
       "  'inclusion': ['Have given written informed consent',\n",
       "   'Women must not be at risk to become pregnant during study participation',\n",
       "   'Diagnosis of Rheumatoid Arthritis (RA)',\n",
       "   'Current, regular use of Methotrexate, at a stable dose',\n",
       "   'Other criteria to be reviewed by study doctor'],\n",
       "  'exclusion': ['Use of excluded medications(reviewed by study doctor)',\n",
       "   'Have not failed biologic tumor necrosis factor-alpha (TNF-α) inhibitor therapy',\n",
       "   'Have had recent or ongoing infection which, in the opinion of the study doctor put patient at an unacceptable risk for participation in the study',\n",
       "   'Evidence of tuberculosis',\n",
       "   \"Have systemic inflammatory condition other than RA, such as juvenile RA, Crohn's disease, ulcerative colitis, psoriatic arthritis or seronegative spondyloarthropathy\",\n",
       "   'Other criteria to be reviewed by study doctor']},\n",
       " {'nct_id': 'NCT00781469',\n",
       "  'inclusion': ['Adult men and non-pregnant, non-lactating women between 18 and 75 years of age. Sexually active females must be of either non-childbearing potential or willing to comply with the contraceptive requirements',\n",
       "   'Body weight greater >40 kg and <120 kg with a body mass index (BMI) between 19-31 kg/m2',\n",
       "   'Clinical history of rheumatoid arthritis as defined by ACR criteria',\n",
       "   'Negative urine pregnancy test for women of child bearing age (except those with documented proof of hysterectomy or bilateral oophorectomy) For populations B and C only',\n",
       "   'Currently on a stable dosing regimen of methotrexate 7.5 to 25 mg once weekly, as their only DMARD (no changes in dosing regimen for 4 weeks prior to screening).'],\n",
       "  'exclusion': ['History of an acute illness within 2 weeks prior to the study',\n",
       "   'History of drug abuse within 2 years',\n",
       "   'Donation of blood in excess of 500 mL within 56 days prior to the first dose of study medication For group A only',\n",
       "   'Prior treatment with disease modifying anti-rheumatic agents or biologicals.']},\n",
       " {'nct_id': 'NCT00786227',\n",
       "  'inclusion': ['Rheumatologist-diagnosed RA',\n",
       "   'Meets one of the conditions for treatment intensification as described in the protocol',\n",
       "   'Ability to read, write, and speak English',\n",
       "   'Ability to understand and provide informed consent'],\n",
       "  'exclusion': ['Unable or unwilling to complete questionnaires']},\n",
       " {'nct_id': 'NCT00780793',\n",
       "  'inclusion': ['Patients aged 18 or more, diagnosed with RA according to the 1987 ACR classification criteria;',\n",
       "   'RA treated with subcutaneous TNF-blockers (étanercept or adalimumab) at stable and standard dosage for 1 year or more, as monotherapy or associated with stable conventional DMARD;',\n",
       "   'RA in clinical remission, defined as a stable DAS28 ≤ 2.6 for 6 months or more, without any structural damage progression on X-rays (local reading by the treating rheumatologist);'],\n",
       "  'exclusion': ['Treatment with steroids;',\n",
       "   'progressing disease on X-rays during the year preceding the trial;',\n",
       "   'surgery planed in the 18 coming months;',\n",
       "   'pregnancy;',\n",
       "   'on-going neoplastic disease;',\n",
       "   'other auto-immune disorders different from RA;',\n",
       "   'inability to speak or understand French;',\n",
       "   'absence of signed informed consent;',\n",
       "   'absence of medical insurance coverage.']},\n",
       " {'nct_id': 'NCT00781989',\n",
       "  'inclusion': ['Male and female adults aged 18 years or greater.',\n",
       "   'The subject has a diagnosis of RA according to the revised 1987 criteria of the American College of Rheumatology (ACR) with onset of symptomatology of less than 3 years.',\n",
       "   'The patient is seropositive for rheumatoid factor (IgM RF measured by agglutination assay) and / or anti-cyclic citrullinated peptides (measured by ELISA).',\n",
       "   'The subject has provided signed and dated written informed consent prior to admission to the study',\n",
       "   'The subject is able to understand and comply with protocol requirements, instructions and restrictions.'],\n",
       "  'exclusion': [\"Past or present disease, which as judged by the investigator, may affect both the subject's participation in the study or outcome of the study. These diseases include but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease.\",\n",
       "   'Current or prior use of biologic drugs ( anti- tumour necrosis factor alpha drugs or rituximab)',\n",
       "   'As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the subject unfit for the study.',\n",
       "   \"The subject's RA does not have a clearly recordable time of onset (within a 6 month period) as determined by either the notes or from the history taken from the patient by the physician responsible\"]},\n",
       " {'nct_id': 'NCT00895050',\n",
       "  'inclusion': ['Patients, male or female, over 18 years old.',\n",
       "   'Patients diagnosed with RA according to investigator criteria',\n",
       "   'Patients with a disease evolution >= 1 year',\n",
       "   'Patients with > = 5 affected joints Exclusion Criteria:'],\n",
       "  'exclusion': ['Patients with other muscle skeletal, rheumatic and/or degenerative diseases different from',\n",
       "   \"- Patients who are taking part or have taken part in a clinical trial or in a study with drugs within the last 12 months. Any condition that, in the investigator's judgment would interfere with the subject's ability to comply with protocol requirements or give informed consent.\"]},\n",
       " {'nct_id': 'NCT00891020',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'moderate to severe active rheumatoid arthritis for >6 months;',\n",
       "   'inadequate clinical response or unable to tolerate current or prior biologic or non-biologic Disease-modifying antirheumatic drug (DMARD) therapy;',\n",
       "   'Swollen joint count (SJC) >/=4 and Tender joint count (TJC) >/=4',\n",
       "   'body weight </=150kg',\n",
       "   'current permitted non-biologic DMARDs must be on stable dose for >/= 7 weeks prior to baseline;'],\n",
       "  'exclusion': ['history of autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;',\n",
       "   'functional class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in rheumatoid arthritis;',\n",
       "   'treatment with rituximab within 6 months before screening;',\n",
       "   'intraarticular corticosteroids within 8 weeks or intramuscular (im)/ intravenous (iv) corticosteroids within 12 weeks prior to screening;',\n",
       "   'known active current or history of recurrent infections, or any major episode of infection requiring hospitalization or treatment with iv antibiotics within 4 weeks of screening, or oral antibiotics within 2 weeks prior to screening.']},\n",
       " {'nct_id': 'NCT00162292',\n",
       "  'inclusion': ['Age 18-70 years',\n",
       "   'Diagnosis of RA for ≥6 months',\n",
       "   'Swollen or tender joint or ESR >ULN. Subject must be on stable doses of MTX',\n",
       "   'Women of Childbearing Potential'],\n",
       "  'exclusion': ['Serum transaminase levels >ULN',\n",
       "   'CK>ULN',\n",
       "   'Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline',\n",
       "   'Use of H2 blockers or Proton Pump inhibitors while on study']},\n",
       " {'nct_id': 'NCT00160602',\n",
       "  'inclusion': ['Patients must be at least 18 years old at the screening visit.',\n",
       "   'Patients must have a diagnosis of adult-onset RA of at least six months duration but not longer than fifteen years as defined by the 1987 American College of Rheumatology classification criteria.',\n",
       "   'Patients must have active RA disease as defined by:',\n",
       "   '9 tender joints at Screening and Baseline.',\n",
       "   '9 swollen joints at Screening and Baseline. and fulfilling 1 of the following 2 criteria during the screening period:',\n",
       "   '30 mm/hour ESR (Westergren), or CRP >15 mg/L.',\n",
       "   'Patients must have received treatment with MTX (with or without folic acid) for at least 6 months prior to the Baseline visit. The dose of MTX and route of administration must have been stable for at least 2 months prior to the baseline visit. The minimum stable dose of MTX allowed is 10 mg weekly.',\n",
       "   'Patients must be willing to complete an X-ray of the hands and feet 24 weeks after randomization even if they are no longer receiving study treatment in the present study, provided they have not withdrawn their informed consent.'],\n",
       "  'exclusion': ['Patients must not have a diagnosis of any other inflammatory arthritis (e.g., psoriatic arthritis or ankylosing spondylitis).',\n",
       "   'Patients must not have a secondary, non-inflammatory type of arthritis (e.g. OA or fibromyalgia)',\n",
       "   'Female patients who are breast feeding, pregnant, or plan to become pregnant during the trial or for three months following last dose of study drug.',\n",
       "   'Patients with a history of tuberculosis or positive chest X-ray for tuberculosis or positive',\n",
       "   'Patients at a high risk of infection (e.g. leg ulcers, indwelling urinary catheter and persistent or recurrent chest infections and patients who are permanently bed ridden or wheelchair bound).',\n",
       "   'Patients with known human immunodeficiency virus (HIV) infection.',\n",
       "   'Patients with an active malignancy of any type or a history of malignancy (except basal cell carcinoma of the skin that has been excised prior to study start).',\n",
       "   \"Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the trial.\",\n",
       "   'Patients with a history of, or suspected, demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis).']},\n",
       " {'nct_id': 'NCT00162201',\n",
       "  'inclusion': ['RA for at least 1 year',\n",
       "   'Clear clinical signs of active RA in 1 knee joint',\n",
       "   'Meet ARA (1987) criteria for diagnosis of RA and ACR (1991) criteria for RA functional classes I, II, or III',\n",
       "   'Inadequate clinical response to a minimum of 3 months of therapy with anti-TNF-blocking agents',\n",
       "   'Taking background DMARDs for a minimum of 3 months and at stable doses for at least 28 days'],\n",
       "  'exclusion': ['Serious bacterial infection in last 3 months',\n",
       "   'History of TB',\n",
       "   'History of cancer within 5 years',\n",
       "   'Evidence of latent or active bacterial or viral infection',\n",
       "   'Intra-articular corticosteroids within 3 months',\n",
       "   'Exposure to live vaccines',\n",
       "   'Exposure to CTLA4Ig or BMS-188667',\n",
       "   'Treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, D-penacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents']},\n",
       " {'nct_id': 'NCT00162266',\n",
       "  'inclusion': ['Males or females (not nursing and not pregnant), at least 18 years of age. Women of child bearing potential (WOCBP) are eligible if they are practicing effective contraceptive measures',\n",
       "   'Subjects must meet the criteria of the American Rheumatism Association (1987) for the diagnosis of rheumatoid arthritis and the American College of Rheumatology (1991) functional classes I, II, or III',\n",
       "   'Subjects have been taking Methotrexate (10-30 mg weekly) for at least 6 months, and at a stable dose for 28 days prior to treatment',\n",
       "   'Washout/drug stabilization requirements (except Methotrexate) [Informed consent must be signed before making any changes in RA therapy if those changes are solely for the purpose of this study].',\n",
       "   'Leflunomide or Infliximab have already been discontinued at least 60 days prior to enrollment (prior to signing of informed consent) and a total of 90 days prior to treatment. All other Disease Modifying Anti-Rheumatic Drugs (DMARDs) (except Methotrexate) have been withdrawn at least 28 days prior to treatment',\n",
       "   'Oral corticosteroid treatment has been reduced to the equivalent of 10 mg or less prednisone daily and stabilized for at least 28 days prior to enrollment',\n",
       "   'Eligibility of subjects for the study is based on their disease activity and anti-rheumatic treatment at the initial visit:',\n",
       "   'Methotrexate monotherapy: Subject is receiving only Methotrexate, steroids, Non-steroidal anti-inflammatory drugs (NSAIDs) and will not require washout',\n",
       "   'Combination therapy: Subject is receiving Methotrexate in combination with another DMARD(s) and will require washout At entry, Methotrexate monotherapy must have a disease activity:',\n",
       "   '10 or more swollen joints (66 joint count)',\n",
       "   '12 or more tender joints (68 joint count)',\n",
       "   'C reactive protein (CRP) ≥.1 mg/dL (10 mg/L) at \"Screening\" visit At entry, combination therapy must have a disease activity (if subject does not satisfy the above):',\n",
       "   '6 or more swollen joints (66 joint count)',\n",
       "   '8 or more tender joints (68 joint count)',\n",
       "   'No restriction on C-reactive protein (CRP) In addition All subjects who were on combination therapy at entry must undergo a 28 day washout period of DMARDs other than Methotrexate. After the washout/drug stabilization and prior to randomization such subjects must have:',\n",
       "   '10 or more swollen joints (66 joint count)',\n",
       "   '12 or more tender joints (68 joint count)',\n",
       "   'C reactive protein (CRP) ≥ 1 mg/dL (10 mg/L)',\n",
       "   'Subject is willing to participate in the study and willing to sign the informed consent Open label study phase:',\n",
       "   'Participants that have completed the initial short term portion (double blind) of the study Exclusion Criteria: Double blind study phase:',\n",
       "   'Subjects who have at any time received treatment with BMS-188667 (Abatacept)',\n",
       "   'Subjects who within 30 days of the Day 1 visit have received treatment with any investigational drug',\n",
       "   'Subjects with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules)',\n",
       "   'Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease. Concomitant medical conditions that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study',\n",
       "   'Mammogram requiring further investigation or biopsies leading to the diagnosis of a clinically significant abnormality. Complete evaluation of lesion is required before initiation of dosing',\n",
       "   'Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection)',\n",
       "   'Subjects who have a history of clinically significant drug or alcohol abuse, or admit to consumption of more than 1 alcoholic drink per day',\n",
       "   'Subjects with evidence (as assessed by the investigator) of active or latent bacterial or viral infections at the time of potential enrollment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection, or hepatitis B or C infection',\n",
       "   'Subjects with any serious or chronic infections such as pneumonia, pyelo-nephritis, renal infection, chest infection with bronchiectasis, or sinusitis in the previous 3 months',\n",
       "   'Subjects with active tuberculosis requiring treatment within the previous 3 years',\n",
       "   'Subjects with any opportunistic infections such as herpes zoster or cytomegalovirus (CMV) within the previous 2 months',\n",
       "   'Subjects with severe asthma defined as > 3 emergency room admissions in the last year or > 3 treatments with oral steroids for asthma in the last year',\n",
       "   'A history of either angioedema or anaphylaxis that was associated with a reaction to a drug',\n",
       "   'Subjects with the following laboratory values:',\n",
       "   'Hemoglobin < 8.5 g/dL',\n",
       "   'White blood cells < 3000/mm3',\n",
       "   'Platelets < 100,000/mm3',\n",
       "   'Serum creatinine > 2 times upper limit of normal',\n",
       "   'Serum Alanine aminotransferase (ALAT) or Aspartate aminotransferase (ASAT) > 2 times upper limit of normal',\n",
       "   'Any other lab values that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study Open label study phase:',\n",
       "   'Participants must continue to meet inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00235859',\n",
       "  'inclusion': ['Meet ACR criteria for diagnosis of active RA and have at >6 swollen joints and >9 tender joints',\n",
       "   'Subjects must have received at least one prior DMARD besides MTX, but may have had efficacy failures on no more than four standard DMARDs other than MTX',\n",
       "   'Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX for at least 4 weeks prior to screening visit',\n",
       "   'Age 18 years and older'],\n",
       "  'exclusion': ['Prior treatment with any TNF antagonist, including adalimumab',\n",
       "   'History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin.',\n",
       "   'Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide.',\n",
       "   'Chest X-ray with calcified granuloma and/or pleural scarring',\n",
       "   'Positive TB skin test, RT23 dose skin test, >5 mm at 48 to 72 hours',\n",
       "   'Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months of the screening evaluation) or any poorly controlled medical condition',\n",
       "   'Intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks prior to screening evaluation',\n",
       "   'Female who is pregnant or breast-feeding.']},\n",
       " {'nct_id': 'NCT00234897',\n",
       "  'inclusion': ['Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.',\n",
       "   'Subject, based on assessment of investigator, meets the definition of active RA'],\n",
       "  'exclusion': ['Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT00233558',\n",
       "  'inclusion': ['Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history',\n",
       "   'Subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised ACR criteria'],\n",
       "  'exclusion': ['Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT00234936',\n",
       "  'inclusion': ['Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history',\n",
       "   'Subject has a diagnosis of rheumatoid arthritis as defined by the 1987 ACR criteria',\n",
       "   'Subjects with treatment failure criteria to Mtx or Mtx + another DMARD'],\n",
       "  'exclusion': ['Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant',\n",
       "   'Previous treatment with approved biological agents (etanercept, infliximab, anakinra) in the last 2 months']},\n",
       " {'nct_id': 'NCT00234845',\n",
       "  'inclusion': ['Subject is age 18 or older and in good health (Investigator discretion) with a recent stable medical history',\n",
       "   'Subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised ACR criteria',\n",
       "   'Subject must be in paid employment',\n",
       "   'Subject has self-reported work impairment since onset of symptoms'],\n",
       "  'exclusion': ['A subject has chronic arthritis diagnosed before age 16 years.',\n",
       "   'Subject has been on preceding treatment with methotrexate Subject unable to withdraw from current DMARDs',\n",
       "   'Subject has preceding treatment with any biological TNF antagonist',\n",
       "   'Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT00234234',\n",
       "  'inclusion': ['ACR classification criteria of RA',\n",
       "   'DAS 28 > 5.1',\n",
       "   'inadequately controlled by at least one DMARD',\n",
       "   'biologics naïve Exclusion Criteria:',\n",
       "   ''],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00236678',\n",
       "  'inclusion': ['Patients must have rheumatoid arthritis with chronic anemia. Patients must have signed an informed consent',\n",
       "   'women must be postmenopausal for at least one year, surgically sterile, or practicing an effective method of birth control, or have a negative serum pregnancy test',\n",
       "   'women must not be breast feeding during this study period.'],\n",
       "  'exclusion': ['Uncontrolled hypertension',\n",
       "   'elective surgery, including joint replacement, anticipated to require transfusion during the extension study period',\n",
       "   'thromboembolic event during the double-blind study including acute myocardial infarction, cerebrovascular accident and/or transient ischemic attack',\n",
       "   'deep vein thrombosis and/or pulmonary embolism',\n",
       "   'uncontrolled psychiatric disease',\n",
       "   'planning to be enrolled in any other clinical trial during the course of this study']},\n",
       " {'nct_id': 'NCT00236028',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis for at least 3 months and less than or equal to 3 years before screening',\n",
       "   'Active disease at the time of screening and pre-infusion of the drug'],\n",
       "  'exclusion': ['Pregnant, nursing, or planning a pregnancy within 18 months of enrollment',\n",
       "   'Incapacitated, largely or wholly bedridden, or confined to a wheelchair, or had little or no ability for self care',\n",
       "   'Rheumatic disease other than rheumatoid arthritis or any current systemic inflammatory condition']},\n",
       " {'nct_id': 'NCT00737087',\n",
       "  'inclusion': ['Male or female subjects, aged less than 85 years inclusive.',\n",
       "   'Subjects who have cuff tear arthropathy, osteoarthritis with cuff deficiency, rheumatoid arthritis, post traumatic injury, or a need for revision surgery of a failed anatomic prosthesis in the left or right shoulder, which requires (total) shoulder arthroplasty.',\n",
       "   'Subjects with radiographic evidence of sufficient bone stock to seat and support the Delta XtendÔ Reverse Total Shoulder System.',\n",
       "   'Subjects who in the opinion of the Clinical Investigator are considered suitable for treatment with the Delta Xtend Reverse Total Shoulder System.',\n",
       "   'Patients with a life expectancy of greater than 12 months.',\n",
       "   'Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.',\n",
       "   'Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.'],\n",
       "  'exclusion': ['Male and female subjects aged 86 years or older.',\n",
       "   'Subjects with complete deltoid muscle palsy in the target joint as determined by clinical evaluation.',\n",
       "   'Subjects with active local or systemic infection or with a history of general or local infections in the target joint over the past 12 months.',\n",
       "   'Subjects with severe deformities, or tumours, that would impair fixation or proper positioning of the implant.',\n",
       "   'Subjects with no significant muscle, nerve or vascular disease.',\n",
       "   'Subjects with a pathology that, in the opinion of the Clinical Investigator, will adversely affect healing.',\n",
       "   'Known allergic reactions to implant materials (e.g. bone cement, metal, polyethylene) implant corrosion or implant wear debris.',\n",
       "   'Subjects with a known history of poor compliance to medical treatment.',\n",
       "   'Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.',\n",
       "   'Women who are pregnant.',\n",
       "   'Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.',\n",
       "   'Subjects who have participated in a clinical investigation with an investigational product in the last month.',\n",
       "   'Subjects who are currently involved in any injury litigation claims.']},\n",
       " {'nct_id': 'NCT00913458',\n",
       "  'inclusion': ['Diagnosis of early rheumatoid arthritis.',\n",
       "   'Methotrexate (MTX) naive.',\n",
       "   'Active early rheumatoid arthritis at the time of enrollment.'],\n",
       "  'exclusion': ['Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.',\n",
       "   'Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), within 4 weeks before baseline.',\n",
       "   'Concurrent treatment with more than 1 non-steroidal anti-inflammatory drug (NSAID) at baseline.']},\n",
       " {'nct_id': 'NCT00913432',\n",
       "  'inclusion': ['Disease duration of at least 6 months Meet American College of Rheumatology (ACR) criteria for',\n",
       "   '2. ACR functional class I-III',\n",
       "   'Have active RA',\n",
       "   'Failed (defined as active RA with stable dose during 3 months)',\n",
       "   'methotrexate or',\n",
       "   'any DMARD including anti TNF alpha if patients previously failed methotrexate or iii. methotrexate in combination with any DMARD including anti TNF alpha'],\n",
       "  'exclusion': ['Patient had a major surgery within 2 weeks prior to study entry.',\n",
       "   'Life expectancy < 6 months.']},\n",
       " {'nct_id': 'NCT00665626',\n",
       "  'inclusion': ['Patients must give written informed consent by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.',\n",
       "   'Males and females, 18 years of age or older, with active RA for at least 12 months prior to Day 1 dosing',\n",
       "   'Are currently receiving or previously had received a biologic therapy with an inhibitor of TNF, rituximab, abatacept, or anakinra at an approved labeled dose for ≥3 months prior to Day 1 dosing and are designated as biologic therapy failures for lack of efficacy, safety, or tolerability.',\n",
       "   'Patients may receive stable doses of methotrexate (MTX), azathioprine (not in combination with MTX), leflunomide (not in combination with MTX), sulfasalazine, chloroquine, hydroxychloroquine, gold, NSAIDs (including COX2 inhibitors), minocycline, or doxycycline. The dose must have been stable for at least 30 days prior to Day 1 dosing and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements. Patients who are taking MTX must have been receiving weekly MTX doses (7.5-25 mg/week) for a minimum of 3 months prior to Day 1 dosing and must be receiving a stable MTX dose, with no change in route, for the previous 6 weeks prior to Day 1 dosing. Patients who are receiving MTX must also be receiving folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing.',\n",
       "   'Females of childbearing potential must be fully informed of the potential for R788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.',\n",
       "   'The patient must otherwise be in good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. See exclusion criteria for specific exclusions.',\n",
       "   \"In the Investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.\"],\n",
       "  'exclusion': [\"The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study. Specifically, excluded are patients with the following:\",\n",
       "   'uncontrolled or poorly controlled hypertension;',\n",
       "   \"other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, Lyme disease, Reiter's syndrome);\",\n",
       "   'recent serious surgery or infectious disease;',\n",
       "   'recent history ( of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;',\n",
       "   'Hepatitis B;',\n",
       "   'Hepatitis C;',\n",
       "   'interstitial pneumonitis or active pulmonary infection on chest x-ray',\n",
       "   'Tuberculosis (TB)',\n",
       "   'known laboratory abnormalities',\n",
       "   'The patient has a history of substance abuse, drug addiction or alcoholism. Patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. Patients who cannot reliably comply with this should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355 mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled spirits= 1.5 oz or 44',\n",
       "   '- The patient has been treated previously treated with R788 under a different protocol.',\n",
       "   'The patient has a pacemaker, aneurysm clip or other contraindication to MRI.']},\n",
       " {'nct_id': 'NCT00665925',\n",
       "  'inclusion': ['Patients must give written informed consent by signing an IRB/EC-approved Informed Consent Form (ICF) prior to admission to this study.',\n",
       "   'Males and females, 18 years of age or older, with active RA for at least 6 months prior to Day 1 dosing.',\n",
       "   \"Patients must have been receiving weekly methotrexate doses (7.5-25 mg/week) for a minimum of 3 months prior to Day 1 dosing and must be receiving a stable MTX dose, with no change in route, for the previous 6 weeks prior to Day 1 dosing. 'Patients must be receiving a folic or folinic acid supplementation at a stable dose for at least 6 weeks prior to Day 1 dosing.\",\n",
       "   'Females of childbearing potential must be fully informed of the potential for R788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.',\n",
       "   'The patient must otherwise be in good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period. See exclusion criteria for specific exclusions.',\n",
       "   \"In the Investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol.\"],\n",
       "  'exclusion': [\"The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study. Specifically, excluded are patients with the following:\",\n",
       "   'uncontrolled or poorly controlled hypertension;',\n",
       "   \"other autoimmune disease (psoriatic arthritis, lupus, mixed connective disorder) or arthritis syndromes (gout, Lyme disease, Reiter's syndrome);\",\n",
       "   'recent (within past 2 months prior to Day 1 dosing) serious surgery or infectious disease;',\n",
       "   'recent history (past 5 years prior to Day 1 dosing) of, or treatment for, a malignancy other than nonmelanomatous skin cancer, or any history of lymphoma;',\n",
       "   'Hepatitis B ;',\n",
       "   'Hepatitis C ;',\n",
       "   'interstitial pneumonitis or active pulmonary infection on chest x-ray;',\n",
       "   'Tuberculosis (TB): the TB skin test should be negative.',\n",
       "   'known laboratory abnormalities.',\n",
       "   'The patient has a history of substance abuse, drug addiction or alcoholism. Patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. Patients who cannot reliably comply with this should be excluded. A unit of alcohol is defined as the following: Beer=12 oz or 355 mL; wine = 5 oz or 148 mL; sweet dessert wine=3 oz or 89 mL; 80 proof distilled spirits= 1.5 oz or 44',\n",
       "   '- The patient has been treated previously treated with R788 under a different protocol.']},\n",
       " {'nct_id': 'NCT00664521',\n",
       "  'inclusion': ['Male and female subjects',\n",
       "   'Greater than and equal to (>=) 18 years of age at the time of Informed Consent',\n",
       "   'Who have rheumatoid arthritis satisfying American College of Rheumatology (ACR) criteria with a disease history of at least 12 months',\n",
       "   'Subjects must have active disease defined by DAS28 >3.2',\n",
       "   'Subjects must have received previous treatment with rituximab and must be candidates for re-treatment with rituximab',\n",
       "   'Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for 4 weeks before study day 1 (SD1), during the treatment period and for 12 months after the last dose of rituximab, and must have a negative urine pregnancy test at the screening visit and SD1',\n",
       "   'Other protocol defined inclusion criteria could apply Exclusion Criteria:',\n",
       "   'Current neurological disease excluding migraine',\n",
       "   'Inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'Any contraindication to rituximab as per national label',\n",
       "   'Use of disease-modifying anti-rheumatic drugs (DMARDs; including methotrexate) for less than 3 months or change in dosing regimen within 28 days before SD1, or methotrexate dose regimen >25 mg/week',\n",
       "   'Participation in any interventional clinical trial within 1 month before SD1 (or within 5 half-lives of the investigated compound before SD1, whichever is longer)',\n",
       "   'Prednisone dose regimen >10 mg/day (or equivalent), or change in steroid dosing regimen within 28 days before SD1',\n",
       "   'Active or latent tuberculosis within the year before screening or major infection requiring hospitalization or intravenous anti-infectives within 28 days before SD1',\n",
       "   'Serum Immunoglobulin G (IgG) below 6 gram per liter (g/L)',\n",
       "   'Known hypersensitivity to atacicept or to any of the components of the formulated atacicpet',\n",
       "   'Known hypersensitivity to rituximab, to any of the components of the formulated rituximab or to murine proteins',\n",
       "   'Breastfeeding or pregnancy',\n",
       "   'Other protocol defined'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00664716',\n",
       "  'inclusion': ['Diagnosis of RA (functional class I',\n",
       "   'III)',\n",
       "   'Stable dose of MTX',\n",
       "   'Inadequate response to at least one conventional DMARD therapy Key Exclusion Criteria:',\n",
       "   'Serious local infection or systemic infection',\n",
       "   'History (Hx) of recurrent infections requiring oral or parenteral anti-infective treatment',\n",
       "   'Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period',\n",
       "   'Clinical significant lab tests at screening',\n",
       "   'Positive for Hep C or Hep B at screening NOTE: Other protocol defined Inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00664820',\n",
       "  'inclusion': ['Are between the ages of 18 to 80',\n",
       "   'Are clinically diagnosed with RA (according to ACR criteria)',\n",
       "   'Have been on stable RA treatment and are expected to stay on stable RA treatment during the time of the study (i.e. ongoing medication and/or other therapy, such as physiotherapy are permitted, except immunotherapy).',\n",
       "   'Have at least 4 swollen and tender joints on a 64/66 scale',\n",
       "   'Women of childbearing capacity and who agree to an acceptable method of birth control. Acceptable methods of birth control will include: hormone therapy (oral birth control pills, injectable or skin patches), barrier contraceptive with spermacide, an intra uterine device (IUD) or complete abstinence (no sexual intercourse).',\n",
       "   'Patients who did not meet any of the exclusion criteria stated below.'],\n",
       "  'exclusion': ['Receiving ongoing immunotherapy for RA',\n",
       "   'Has inflammatory bowel disease or leaky gut',\n",
       "   'Currently consuming probiotics and refuse to have a two week washout period',\n",
       "   'Have known allergies to any component in the study product or placebo',\n",
       "   'Plan to have surgery during the time of the study',\n",
       "   'Mental illness impairing ability to comply with study',\n",
       "   'Women who are pregnant or plan to get pregnant during the study period',\n",
       "   'Women who are breastfeeding',\n",
       "   'Consumption of probiotic-containing products during study treatment',\n",
       "   'Patients participating in another NHP clinical trial',\n",
       "   'Patients enrolled in another clinical trial in the past 3 month',\n",
       "   'Women who are breastfeeding']},\n",
       " {'nct_id': 'NCT00661661',\n",
       "  'inclusion': ['Subjects who have completed their participation in a randomized \"qualifying\" study of CP-690,550 for the treatment of rheumatoid arthritis'],\n",
       "  'exclusion': ['Serious medical conditions that would make treatment with CP-690,550 potentially unsafe']},\n",
       " {'nct_id': 'NCT00669942',\n",
       "  'inclusion': ['Male and female patients with active rheumatoid arthritis in combination with a stable dose of methotrexate aged 18-75 years may participate in this trial.',\n",
       "   'Post menopausal or surgically sterile female patients are allowed. Women of child-bearing potential may participate if they are on a stable dose of methotrexate and if they are practicing effective contraception for at least 6 months prior to screening, willing to use 2 forms of contraception, including at least 1 barrier method during the study and for at least 2 months following the completion/discontinuation of the study.',\n",
       "   'Patients must have a diagnosis of active rheumatoid arthritis of stages I, II or III (ACR 1987 revised classification for criteria for RA). Disease duration of at least 6 months prior to randomization is essential; Exclusion Criteria:',\n",
       "   'Current treatment with anti-TNF-α or anti IL-1 therapy (or other biological therapy).',\n",
       "   'Patients with congestive heart failure or poorly controlled diabetes mellitus (HbA1c value ≥10%).',\n",
       "   'Presence of any major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or SLE that can mimic rheumatoid arthritis diagnosis or that can interfere with efficacy evaluation in the study.',\n",
       "   'History of renal trauma, glomerulonephritis or patient with one kidney.',\n",
       "   'Pregnant or breastfeeding women will be excluded.',\n",
       "   'A positive tuberculin skin test. Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00808210',\n",
       "  'inclusion': ['Age >= 18 years',\n",
       "   'Current treatment for RA on an outpatient basis',\n",
       "   'Active disease',\n",
       "   'Currently receiving 50 mg etanercept subcutaneously (SC) every week or 40 mg adalimumab SC every other week.',\n",
       "   'Considered by Investigator to be a primary non-responder to their first anti-TNFÎ± treatment for efficacy reasons'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA',\n",
       "   'History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)',\n",
       "   'Previous treatment with a any biologic therapy for RA (including investigational products with the exception of etanercept or adalimumab',\n",
       "   'Treatment with more than one prior anti-TNFÎ± therapy']},\n",
       " {'nct_id': 'NCT00805116',\n",
       "  'inclusion': ['Rheumatoid arthritis patients according to American College of Rheumatology criteria (with active disease and in remission). Intensity of joint pain last week (30 mm or more on 100 mm Visual analogue scale). Stable use of DMARDS and no corticosteroid injections last 4 weeks before study and during study.'],\n",
       "  'exclusion': ['Non-Norwegian speaking/reading or not understanding study design or non-compliance. Pregnant/lactating women. Bleeder disease, known HIV or hepatitis, medication with Marevan (blood thinner). Not willing or possible to stop taking regular omega-3 supplements during study.']},\n",
       " {'nct_id': 'NCT00777816',\n",
       "  'inclusion': ['American College of Rheumatology (ACR) diagnostic criteria for RA',\n",
       "   'Moderate to severe disease, defined as follows',\n",
       "   'At least six tender and six swollen joints (28 joint count) AND ESR > 28 mm/hr or CRP > 1.0 mg/dL',\n",
       "   'Current duration of RA at Screening ≥ 6 months and ≤ 20 years',\n",
       "   'RA and other medical conditions must be stable.',\n",
       "   'Age ≥ 18 and ≤ 75 at Screening',\n",
       "   'Weight ≥ 80 lbs (36.3 kg) and ≤ 275 lbs (125.0 kg)',\n",
       "   'For females with child-bearing potential, a negative serum pregnancy test'],\n",
       "  'exclusion': ['Major surgery within 28 days prior to Day 0',\n",
       "   'Joint replacement surgery within 60 days prior to Day 0 or joint replacement surgery planned within 9 months following Day 0',\n",
       "   'Known HIV antibody, or hepatitis B surface antigen',\n",
       "   'History of malignancy within 5 years prior to Screening other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin',\n",
       "   'Immunodeficiency',\n",
       "   'History or symptoms of a demyelinating disease',\n",
       "   'History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies. Respiratory distress (dyspnea, oxygen desaturation with pO2 < 90% or onset of acute respiratory distress syndrome), flank or back pain, and/or hypotension may be signs of anaphylaxis.',\n",
       "   'History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma. A subject who has had a positive PPD test but has completed a course of treatment for tuberculosis, had a documented vaccination against tuberculosis, or had a negative QuantiFERON -TB test result is eligible.',\n",
       "   'Chronic obstructive pulmonary disease (COPD), asthma, or other pulmonary disease requiring more therapy than using one inhaler 4× daily',\n",
       "   'Significant systemic involvement secondary to RA (e.g. vasculitis, pulmonary fibrosis)',\n",
       "   'Liver disease (e.g., hepatitis, cirrhosis) or abnormal hepatic function. If the diagnosis of liver disease was based on positive Hep C serology due to prior vaccination, the subject is eligible.',\n",
       "   'Pregnant or planning to become pregnant during the course of the study, or breast-feeding']},\n",
       " {'nct_id': 'NCT00773461',\n",
       "  'inclusion': ['adult patients, 18-70 years of age;',\n",
       "   'rheumatoid arthritis for >= 6 months;',\n",
       "   'receiving permitted DMARDs, at a stable dose, for >= 8 weeks prior to baseline;',\n",
       "   'current inadequate clinical response to DMARDs.'],\n",
       "  'exclusion': ['major surgery, including joint surgery, within 8 weeks before entering study, or planned major surgery within 6 months following randomization;',\n",
       "   'rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis;',\n",
       "   'unsuccessful treatment with an anti-TNF agent;',\n",
       "   'previous treatment with tocilizumab.']},\n",
       " {'nct_id': 'NCT00771420',\n",
       "  'inclusion': ['Signed and dated informed consent, prior to any study related procedures',\n",
       "   'Male and female patients aged 18-70 years at the screening visit',\n",
       "   'Use of an appropriate method of contraception',\n",
       "   'A diagnosis of adult onset rheumatoid arthritis of at least 6 months duration as defined by the 1987 ACR classification criteria',\n",
       "   'ACR functional class I, II or III',\n",
       "   'Treatment with methotrexate for at least 3 months and stable dose 10mg',\n",
       "   '25mg / week for ≥ 8 weeks prior to the baseline visit',\n",
       "   'Availability of clear chest X-ray (i.e. no evidence of TB, chest infection or cardiac failure). Patients who are clinically asymptomatic with minor changes consistent with rheumatoid lung are acceptable.',\n",
       "   \"Stable mild or inactive rheumatoid arthritis where in the opinion of the investigator it is unlikely that a change in the patient's therapeutic regimen would be required during the subsequent 3 months.\",\n",
       "   'DAS28 ≤ 4.8 for at least 3 months prior to the baseline visit'],\n",
       "  'exclusion': ['Relating to RA',\n",
       "   \"Diagnosis of any other inflammatory arthritis (e.g. psoriatic arthritis or ankylosing spondylitis), or a diagnosis of a secondary, non-inflammatory type of arthritis (e.g. osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with the evaluation of the effect of CAM-3001 on the patient's primary diagnosis of rheumatoid arthritis Relating to Previous Clinical Trials and Biologic Therapies\",\n",
       "   'Administration of any investigational or experimental non-biologic therapy in the 12 weeks prior to the baseline visit',\n",
       "   'Administration of any biologic therapy within 6 months prior to the baseline visit Relating to Concomitant Medications',\n",
       "   'Use of prohibited concomitant medications, which might confound the interpretation of the study data Relating to Medical History',\n",
       "   'Female patients who are pregnant or breast-feeding, or who plan to become pregnant during the trial or during the 24 weeks after administration of CAM-3001',\n",
       "   'Male or female patients not willing to use reliable methods of birth control for the duration of the study',\n",
       "   'A history of TB, or clinical/radiographic evidence of TB, or positive TB test',\n",
       "   'A history or current symptoms and signs of chronic infection, or recent (within 6 months prior to screening visit) serious infection including herpes zoster',\n",
       "   'Patients at a high risk of infection e.g. a history of an infected joint prosthesis at any time with that prosthesis still in situ, leg ulcers, indwelling urinary catheter, persistent or recurrent chest infections',\n",
       "   'Neutrophil count < 1000 x 106 cells/L',\n",
       "   'A positive hepatitis B surface antigen test and/or hepatitis C antibody test result',\n",
       "   'A positive test for human immunodeficiency virus (HIV) infection',\n",
       "   'Receipt of live (attenuated) vaccine within the 4 weeks prior to baseline or during the study',\n",
       "   \"Current or recent history of significant renal, hepatic, haematological, immunological (other than RA), gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the trial. Patients with mild and stable asthma or mild and stable Chronic Obstructive Pulmonary Disease (COPD) may be included at the discretion of the Investigator\",\n",
       "   'Active malignancy or lymphoproliferative disorder of any type, or a history of malignancy except for basal cell carcinoma of the skin that has been excised prior to the screening visit',\n",
       "   'Suspected alcohol or substance abuse',\n",
       "   'Donation of ≥ 400mL of blood within 8 weeks prior to baseline',\n",
       "   'Any other significant medical condition which in the opinion of the investigator might increase the risk to the patient or confound the interpretation of the data',\n",
       "   'Individuals who are legally institutionalised']},\n",
       " {'nct_id': 'NCT00771251',\n",
       "  'inclusion': ['Patients diagnosed with rheumatoid arthritis at least 3 months prior to registration and who are definitely identified as having rheumatoid arthritis, at the time of informed consent, according to the criteria for classification established by the American College of Rheumatology (1987)',\n",
       "   'Patients who have previously not responded to at least one DMARD (before informed consent is obtained)',\n",
       "   'Patients who, if they are on the treatment with a DMARD, the DMARD can be washed out for at least 4 weeks before the first administration',\n",
       "   'Patients having at least 6 swollen joints and 6 tender joints at the time of registration and immediately before the first injection'],\n",
       "  'exclusion': ['Patients with a history of hypersensitivity to human immunoglobulin proteins or other ingredients of golimumab',\n",
       "   'Patients who have previously experienced or are suffering from any of the following diseases: (i) Collagen diseases other than rheumatoid arthritis, (ii) Latent or active granulomatous infections such as histoplasmosis and coccidioidomycosis, (iii) Felty syndrome, etc',\n",
       "   'Patients with a severe, advanced, or poorly controlled disease in any of the kidney, liver, blood, gastrointestinal system, endocrine system, lung, heart, nervous system, psychiatric system, and brain']},\n",
       " {'nct_id': 'NCT00771329',\n",
       "  'inclusion': ['Diagnosis of adult onset RA (functional class I-III) for at least 6 months',\n",
       "   'Must have been treated with and be tolerating Methotrexate (5-25 mg/week) for 3 months, at a stable dose for at least 4 weeks',\n",
       "   'Must have at least 4 swollen and tender joints due to rheumatoid arthritis'],\n",
       "  'exclusion': ['History of recurrent infections requiring antibiotic treatment within 12 months',\n",
       "   'Serious local infection or systemic infection within 3 months',\n",
       "   'Suffering from rheumatic or autoimmune disease other than RA',\n",
       "   'History of cancer, heart failure, kidney disease, liver disease, HIV infection, tuberculosis or other serious illness']},\n",
       " {'nct_id': 'NCT00771030',\n",
       "  'inclusion': ['Male or female between 18 to 70 years of age, inclusive at the time of screening',\n",
       "   'Diagnosed with RA as determined by meeting 1987 American College of Rheumatology (ACR) classification criteria',\n",
       "   'Active RA defined as ≥ 6 swollen joints (out of 66 joints examined) and ≥ 8 tender/painful joints (out of 68 joints examined) and at least 1 of the following:',\n",
       "   'Erythrocyte sedimentation rate (ESR) ≥ 28 mm, or',\n",
       "   'C-reactive protein (CRP) > 15 mg/L, or',\n",
       "   'Morning stiffness > 45 minutes (applicable to subjects in Part A ONLY)',\n",
       "   'Duration of RA for at least 6 months',\n",
       "   'Currently taking methotrexate (MTX) consecutively for ≥ 12 weeks and on a stable dose of oral or SC MTX at 15-25 mg weekly for ≥ 4 weeks at day -1. A lower MTX dose is acceptable if it is the highest tolerated dose, however, toxicity documentation by the Investigator is required. All subjects will take folic acid to minimize toxicity, according to local guidelines.',\n",
       "   'Additional Inclusion Criteria Apply Exclusion Criteria:',\n",
       "   'History or evidence of a clinically significant disorder other than RA (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric), condition or disease that, in the opinion of the Investigator and Amgen physician would pose a risk to subject safety or interfere with the study evaluation, procedures or completion',\n",
       "   'Uncontrolled, clinically significant systemic disease other than RA such as diabetes mellitus, liver disease, asthma, cardiovascular disease or hypertension',\n",
       "   'Malignancy within 5 years (except successfully treated in situ cervical cancer or squamous or basal cell carcinoma of the skin)',\n",
       "   'Presence of a serious or chronic infections',\n",
       "   'Subject (male or female) is not willing to use highly effective contraception, defined as a double barrier method (ie, spermicidal jelly and condom, or condom and diaphragm) during treatment and up to end of study',\n",
       "   'Additional'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00779220',\n",
       "  'inclusion': ['Diagnosis of RA for ≧6 months according to the revised 1987 ACR criteria for the classification of',\n",
       "   '- Adult patients, ≧20 years of age.',\n",
       "   'Receiving methotrexate at a dose of 6 to 8mg/week（oral）for ≧12 weeks, with a stable dose for the last 4 weeks before treatment.',\n",
       "   'Positive serum',\n",
       "   ''],\n",
       "  'exclusion': [\"Rheumatic autoimmune disease other than RA, or Significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome).Patients with secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA are eligible.\",\n",
       "   'Functional Class Ⅳ as defined by the ACR Classification of Functional Status in',\n",
       "   '- History of or current inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome).',\n",
       "   'Any surgical procedure (except for minor surgeries requiring local or no anaesthesia and without any complications or sequelae) within 12 weeks prior to or planned within 24 weeks after baseline.']},\n",
       " {'nct_id': 'NCT00458861',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis (functional class I',\n",
       "   'III) at least 6 months prior to baseline',\n",
       "   'Methotrexate (10 mg/week to 25 mg/week) > 3 months prior to Day 0 (stable dose > 4 weeks prior to Day 0)',\n",
       "   'Must have had an inadequate response to anti-TNF therapy due to inadequate efficacy Key Exclusion Criteria: Medical History',\n",
       "   'Serious local infection or systemic infection within 3 months of Day 0',\n",
       "   'History (Hx) of recurrent infections requiring oral or parental anti-infective treatment',\n",
       "   'Hx of tuberculosis (TB) or positive purified protein derivative (PPD) test during the screening period Laboratory Tests',\n",
       "   'Clinically significant lab tests at screening; or',\n",
       "   'Positive for hepatitis C antibody or hepatitis B at screening NOTE: Other protocol defined Inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00455208',\n",
       "  'inclusion': ['Having a diagnosis of rheumatoid arthritis and osteoarthritis at active stage',\n",
       "   'Able and willing to comply with study visits and procedures specified in this protocol for at least six months period',\n",
       "   'Able to understand and willing to sign and date the written informed consent form prior to admission of the study',\n",
       "   'Able and willing to provide adequate information for locator purposes',\n",
       "   'Able and willing to provide self evaluation information and diagnostic report of arthritis as required for efficacy evaluation'],\n",
       "  'exclusion': ['Pregnant women',\n",
       "   'Over-weighted',\n",
       "   'Hypertension, or diabetes, or a history of cardiovascular disease or kidney disease, or serious skin allergy or other concurrent clinically significant illness or medical condition (other than arthritis) which, in the viewpoint of the study doctor, may put the subject at a possible risk for participation',\n",
       "   'Patients used biologic modifier therapy or currently taking immunosuppressive agents might be excluded',\n",
       "   'Unable to spend 3 hours for treatment at the study center']},\n",
       " {'nct_id': 'NCT00458146',\n",
       "  'inclusion': ['Meet American College of Rheumatology (ACR) criteria for',\n",
       "   '- Have active RA consisting of > or equal to 6 tender joints and > or equal to 6 swollen joints and one of the following:CRP or ESR levels of ULN',\n",
       "   'Have an ACR functional class of I-III.',\n",
       "   'Have had RA for at least 6 months.',\n",
       "   'Had disease onset at > 16 years of age.',\n",
       "   'Aged 18',\n",
       "   '80 years.',\n",
       "   'Currently being treated with a stable, well tolerated weekly dose of MTX between 10-25 mg for at least 6 consecutive prior to screening visit.',\n",
       "   'Currently being treated with folic/folinic acid in conjunction with their MTX treatment. (Note: Patients may begin folic/folinic acid treatment after their screening visit, but must remain on stable dose for two weeks before undergoing the Day 1 assessments.)',\n",
       "   'Willing to remain on a constant, weekly dose of MTX and folic/folinic acid through out the duration of the study.',\n",
       "   'Understand, sign, and date the written, voluntary informed consent form at the screening visit prior to any protocol',\n",
       "   'specific procedures being performed.',\n",
       "   'Be able and willing to comply with study visits and procedures per protocol.',\n",
       "   'Women of childbearing potential must use a medically acceptable means of birth control in an effective manner and agree to continue its use during the study and for 4 weeks after the last dose of study drug. Women who have had a complete surgical hysterectomy or are postmenopausal (absence of menstrual period for at least one year or > 52 years old) are exempt from this requirement. Medically acceptable forms of birth control include oral contraceptives, injectable or implantable methods, intrauterine devices, tubal ligation (if performed more than 1 year before screening), or properly used barrier contraception. Additionally, the use of condoms is suggested as an adjunct to the methods previously addressed to protect against sexually transmitted diseases and to provide additional protection against accidental pregnancy.',\n",
       "   'Sexually active men must agree to use a medically acceptable form of contraception during the study and continue for 4 weeks after the last dose of study drug.',\n",
       "   'Able to store patient kit/cooler containing drug in a refrigerator at home.'],\n",
       "  'exclusion': ['Patient will be excluded if any of the following prior medications are currently being used or have used within the designated time interval before the screening visit:',\n",
       "   'Any B',\n",
       "   'cell or antibody depleting therapy , including plasmaphoresis or Prosorba columns (6 months)',\n",
       "   'Leflunomide, Adalimumab (Humira)(3 months)',\n",
       "   'Investigational biologics (2 months)',\n",
       "   'Infliximab (Remicade) (2 months)',\n",
       "   'Cyclosporine, sulphasalazine, auranofin, intramuscular gold, azathioprine, D-penicillamine, tacrolimus (6 weeks)',\n",
       "   'Investigational small molecules (e.g. NSAIDS or Cox-2 inhibitors)(4 weeks)',\n",
       "   'Use more than 10mg/day of prednisone or equivalent (4 weeks)',\n",
       "   'Bolus intramuscular/intravenous (IM/IV) treatment with corticosteroids (>20 mg prednisone or equivalent)(4 weeks)',\n",
       "   'Intra-articular corticosteroid injection (4 weeks)',\n",
       "   'Etanercept (Enbrel) (4 weeks)',\n",
       "   'Anakinra (Kineret) (2 weeks)',\n",
       "   'Use of more than one NSAID (current)',\n",
       "   'Dose of NSAID greater than maximum recommended dose in the product information (current)',\n",
       "   'Significant concurrent medical diseases including:',\n",
       "   'Cancer, or a history of cancer (other than successfully resected cutaneous basal and squamous cell carcinoma) within 5 years before the screening visit.',\n",
       "   'Any condition for which participation in this study is judged by the physician to be detrimental to the patient, such as history of significant or unstable cardiac, pulmonary, gastrointestinal, neurological, or psychiatric disease, or a DMARD-related severe, potentially life threatening',\n",
       "   '3. Significant ongoing infection requiring systemic antibiotic, antifungal, antiviral, or anti-myobacterial therapy.',\n",
       "   'Autoimmune or connective tissue disorder other than rheumatoid arthritis (e.g. Systemic Lupus Erythematosis, Scleroderma, or Psoriatic Arthritis)',\n",
       "   'Grade 2 or above leukopenia (i.e. white blood cells < 3000/mm^3 [SI units: < 3.0 x 10^9/L)',\n",
       "   'Thrombocytopenia or thrombocytosis (platelets > 125,000/mm^3 or > 1,000,000/mm^3 [SI units: < 125 x 10^9/L or > 1,000 x 10^9/L]), respectively.',\n",
       "   'Grade 2 or above liver function abnormality(i.e. total bilirubin .1.5 x the upper limit of normal; or aspartate aminotransfersate [AST/SGOT] or alanine aminotransferase [ALT/SGPT]> 2.5 x upper limit of normal.',\n",
       "   'Renal disease (including serum creatinine level > 1.5 x the upper limit of normal).',\n",
       "   'Any history of immunodeficiency syndromes or infection with human immunodeficiency virus (HIV), or a history of hepatitis C or chronic hepatitis',\n",
       "   '- Pregnant or breastfeeding women or women planning to become pregnant during the study or within 4 weeks after the last dose of study drug.',\n",
       "   'Any major surgery, including joint surgery, within 3 months before the screening visit.',\n",
       "   'Scheduled elective surgery during the study participation.',\n",
       "   'Participated in any previous clinical trial using MM-093 or have any prior exposure to MM-093.',\n",
       "   'History of severe hypersensitivity to goat, sheep, or cow milk. (Patients who are lactose intolerant are not excluded).',\n",
       "   'Any other condition that the investigator feels would jeopardize the integrity of the study (e.g. a CTCAE grade 2 or above clinical finding or laboratory result).']},\n",
       " {'nct_id': 'NCT00122382',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis (RA) <=2 years; MTX naive or <=10 mg/wk for <=3 weeks. No dose within 3 months prior to informed consent.',\n",
       "   'C-Reactive Protein (CRP) >= 4.5 mg/L (after amendment)',\n",
       "   'Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive',\n",
       "   'Tender joints >=12 and swollen joints >=10'],\n",
       "  'exclusion': ['Women and men who are not willing to use birth control',\n",
       "   'Diagnosed with other rheumatic disease',\n",
       "   'History of cancer within 5 years',\n",
       "   'Active tuberculosis',\n",
       "   'Treatment with another investigation drug within 28 days',\n",
       "   'Active bacterial or viral infection']},\n",
       " {'nct_id': 'NCT00124982',\n",
       "  'inclusion': ['Completed double-blind portion of the IM101064 study.',\n",
       "   'Rheumatoid arthritis (RA) for greater than 1 year from the time of initial diagnosis',\n",
       "   'American College of Rheumatology (ACR) functional class I, II, III',\n",
       "   'Subjects currently or previously received an anti-TNF therapy at an approved labeled dose for at least 3 months'],\n",
       "  'exclusion': ['Subjects with active vasculitis of a major organ system (except subcutaneous rheumatoid nodules)',\n",
       "   'History of cancer within the last 5 years (other than non-melanoma skin cell cancers cured by local resection)']},\n",
       " {'nct_id': 'NCT00088764',\n",
       "  'inclusion': ['Meet American College of Rheumatology (ACR) 1987 criteria for RA'],\n",
       "  'exclusion': ['Other disorders that would significantly affect function (e.g., lupus, chronic obstructive pulmonary disease [COPD], congestive heart failure [CHF], cancer)',\n",
       "   'Judged by the physician to have cognitive impairment (dementia, retardation, psychosis) or illiteracy',\n",
       "   'Has experienced recent (last 6 months) significant stressor resulting in substantial emotional instability',\n",
       "   'Currently in psychotherapy or a formal behavioral pain management program',\n",
       "   'Unable to walk. Participants who use walking aids are not excluded.',\n",
       "   'Physically unable to write']},\n",
       " {'nct_id': 'NCT00083759',\n",
       "  'inclusion': ['Subject is able to read, understand, and voluntarily sign the approved Informed Consent form prior to the performance of any study-specific procedures;',\n",
       "   'Male or female subjects, ≥18 to ≤75 years of age, who has a diagnosis of rheumatoid arthritis Functional Class 1 to 3 by the 1987 Revised American Rheumatism Association Criteria for the Classification of Rheumatoid Arthritis for at least 6 months prior to screening;',\n",
       "   'Subject is on a stable dose of MTX of at least 10 mg/week for ≥3 months prior to randomization (Month 0) without an adequate response;',\n",
       "   'Female subjects of childbearing potential agree to use adequate, contraceptive methods (either intrauterine device [IUD], oral or depot contraceptive, or barrier plus spermicide). Female subjects of childbearing potential use adequate contraception for at least 2 months prior to study entry and continue contraception for at least 3 months after their last infusion of study drug;',\n",
       "   'Subject is willing and able to complete all planned study procedures;',\n",
       "   'Subject has at least 10 painful/tender and 6 swollen joints at the Month 0 (Baseline) visit;',\n",
       "   'Subject has an elevated CRP level (defined as >2.87 mg/L) at Screening.'],\n",
       "  'exclusion': ['Subject is pregnant or lactating;',\n",
       "   'Subject who has experienced an inadequate therapeutic response after at least 3 months of treatment with at least one TNF-alpha inhibitor;',\n",
       "   'Subject who has received treatment with anakinra;',\n",
       "   'Subject who has received prior treatment with natalizumab;',\n",
       "   'Subject does not meet the following criteria regarding concomitant medications for RA:',\n",
       "   'Use of any oral steroid exceeding 10 mg/day of prednisone (or equivalent dose) and not administered at a stable dose for at least 1 month prior to randomization (Month 0);',\n",
       "   'Use of any NSAIDs unless stable for at least 1 month prior to randomization (Month 0);',\n",
       "   'Use of other anti-arthritic treatments, including approved or experimental oral, topical, or injectable biologics or drugs, or devices within 1 month prior to randomization (Month 0);',\n",
       "   'Intra-articular corticosteroid injections within 1 month prior to randomization (Month 0);',\n",
       "   'Treatment with any TNF-alpha inhibitor within 2 months prior to randomization (Month 0);',\n",
       "   'Subject who is expected to be unavailable for the duration of the trial, likely to be noncompliant with the Protocol, or felt to be unsuitable by the Investigator for any other reason;',\n",
       "   'Subject who has a history of a malignancy (other than basal cell carcinoma of the skin);',\n",
       "   'Subject who has a history of clinically significant and/or persistent gastrointestinal, pulmonary, chronic infection, cardiovascular, renal, hepatic, neurological, dermatological, immunological, major psychiatric (including drug or alcohol abusers) or hematological illness, which, in the opinion of the Investigator placed the subject at unacceptable risk for participation in the study;',\n",
       "   'Subject who has any laboratory test at Screening considered significantly abnormal. An alanine transaminase (ALT) or aspartate transaminase (AST) ≥1.5 x upper limits of normal (ULN) and cytopenia (included any of the following: WBC <3.5 x 1000/uL; hemoglobin [Hb] <8 g/dL; platelets <100 x 1000/uL; and/or neutrophils absolute <1.0 x 1000/uL) were considered significantly abnormal;',\n",
       "   'Subject who intends to donate blood or blood products during the period of the study or within 1 month following completion of the study;',\n",
       "   'Subject who has a positive tuberculosis (TB) skin test at Screening or within the 30 days prior to Screening (defined as ≥10 mm induration);',\n",
       "   'Subject who plans or requires any surgical procedure during the study treatment period.']},\n",
       " {'nct_id': 'NCT00691028',\n",
       "  'inclusion': ['Patients with active RA in spite of stable dose of MTX'],\n",
       "  'exclusion': ['Having received infliximab in the past',\n",
       "   'Having a history of serious infection which caused hospitalization within 6 months before the registration',\n",
       "   'Having an active tuberculosis',\n",
       "   'Having a complication or a history of malignancy within 5 years before the registration']},\n",
       " {'nct_id': 'NCT00695188',\n",
       "  'inclusion': ['MTX-naive',\n",
       "   'Age > 18 years',\n",
       "   'DAS-28 > 3.2',\n",
       "   'American College of Rheumatology-criteria for RA',\n",
       "   'Chest-X-ray',\n",
       "   'Informed consent',\n",
       "   'Prednisolon < 10 mg a day'],\n",
       "  'exclusion': ['Pregnancy',\n",
       "   'Lactation',\n",
       "   'Renal and hepatic impairment',\n",
       "   'Malignant diseases (last 5 years)',\n",
       "   'Contraindications',\n",
       "   'Human Immunodeficiency Virus (HIV), Hepatitis B and C']},\n",
       " {'nct_id': 'NCT00699088',\n",
       "  'inclusion': ['Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid arthritis.',\n",
       "   'Correction of functional deformity.',\n",
       "   'Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques.',\n",
       "   'Revision of previously failed femoral head resurfacing component'],\n",
       "  'exclusion': ['infection,',\n",
       "   'sepsis,',\n",
       "   'osteomyelitis. Relative contraindications include:',\n",
       "   'uncooperative patient or patient with neurologic disorders who are incapable of following directions,',\n",
       "   'osteoporosis,',\n",
       "   'metabolic disorders which may impair bone formation,',\n",
       "   'osteomalacia,',\n",
       "   'distant foci of infections which may spread to the implant site,',\n",
       "   'rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,',\n",
       "   'vascular insufficiency, muscular atrophy, or neuromuscular disease.']},\n",
       " {'nct_id': 'NCT00699270',\n",
       "  'inclusion': ['Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid Arthritis',\n",
       "   'Correction of functional deformity'],\n",
       "  'exclusion': ['Infection, Sepsis, and Osteomyelitis Relative contraindications:',\n",
       "   'Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone function',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram']},\n",
       " {'nct_id': 'NCT00699309',\n",
       "  'inclusion': ['Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid arthritis.',\n",
       "   'Correction of functional deformity.',\n",
       "   'Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques.',\n",
       "   'Revision of previously failed femoral head resurfacing component'],\n",
       "  'exclusion': ['infection,',\n",
       "   'sepsis, and',\n",
       "   'osteomyelitis. Relative contraindications include:',\n",
       "   'uncooperative patient or patient with neurologic disorders who are incapable of following directions,',\n",
       "   'osteoporosis,',\n",
       "   'metabolic disorders which may impair bone formation,',\n",
       "   'osteomalacia,',\n",
       "   'distant foci of infections which may spread to the implant site,',\n",
       "   'rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,',\n",
       "   'vascular insufficiency, muscular atrophy, or neuromuscular disease.']},\n",
       " {'nct_id': 'NCT00696059',\n",
       "  'inclusion': ['Diagnosis of rheumatoid arthritis according to the American College of Rheumatology 1987 criteria',\n",
       "   'Moderate or severely active RA, defined as a DAS28(CRP)> 3.2',\n",
       "   'Moderate radiographic structural joint damage, defined as Larsen grade 2-3, in ≥ 2 wrist and/or MCP joints',\n",
       "   'No previous biological therapy',\n",
       "   'Clinical indication for biological therapy, according to the treating physician',\n",
       "   'Treatment with methotrexate and folic acid for at least 4 weeks prior to inclusion',\n",
       "   'No history of tuberculosis, and no signs of tuberculosis at chest radiograph or Mantoux test.',\n",
       "   'No contra-indications for TNF-alpha antagonist treatment',\n",
       "   'Co-operability of the patient, including that the patient is willing and able to comply with the treatment and scheduled follow-up visits and examinations',\n",
       "   'Oral and signed informed consent by the patient'],\n",
       "  'exclusion': ['Acute infection, and known chronic viral infection such as HIV or hepatitis B and C',\n",
       "   'Other DMARDs than methotrexate within last 4 weeks before inclusion',\n",
       "   'Intramuscular or intraarticular glucocorticoids within last 4 weeks before inclusion',\n",
       "   'Oral treatment with prednisolone >10 mg per day',\n",
       "   'Malignant lymphoma and other malignant disease',\n",
       "   'Other serious concomitant diseases (uncontrolled/severe kidney, liver, haematological, gastrointestinal, endocrine, cardiovascular, pulmonary, neurological or cerebral disease (including demyelinating disease))',\n",
       "   'Pregnancy and lactation. Patients must use safe anti-conception during the treatment.',\n",
       "   'Development of SLE-like disease. Occurrence of positive ANA and/or anti-DNA antibodies without clinical symptoms is not considered a contra-indication.',\n",
       "   'Contra-indications for MRI']},\n",
       " {'nct_id': 'NCT00698750',\n",
       "  'inclusion': ['Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Correction of functional deformity',\n",
       "   'Reconstructable Rotator Cuff',\n",
       "   'Treatment of acute fracture of the humeral head',\n",
       "   'Traumatic arthritis'],\n",
       "  'exclusion': ['Patients less than 18 years.',\n",
       "   'Patients with rapid joint destruction, osteomalacia, osteoporosis, or marked bone loss, which would preclude proper fixation of the prosthesis.',\n",
       "   'Patients with marked bone loss apparent on roentgenogram.',\n",
       "   'Metabolic disorders, which may impair bone formation.',\n",
       "   'Patients who are pregnant.',\n",
       "   'Patients with an active or suspected infection in or around the shoulder or distant foci of infections, which may spread to the implant site.',\n",
       "   'Patients with severe instability or deformity of the ligaments and/or surrounding soft tissue, which would prelude stability of the prosthesis.',\n",
       "   'Patients who have had revision procedures where other devices or treatments have failed.',\n",
       "   'Patients with a highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, neoplastic disease, etc).',\n",
       "   'Patients unwilling or unable to comply with a rehabilitation program for a cemented or cementless partial or total shoulder replacement or who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol.',\n",
       "   \"Patients with previous shoulder surgery or conditions that may interfere with the partial or total shoulder replacement's survival or outcome.\",\n",
       "   'Patients who qualify for inclusion in the study, but refuse consent to participate in the study.',\n",
       "   'Patients who have had a partial or total shoulder arthroplasty on the contralateral shoulder within the last year.']},\n",
       " {'nct_id': 'NCT00698854',\n",
       "  'inclusion': ['Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.',\n",
       "   'Correction of varus, valgus, or posttraumatic deformity',\n",
       "   'Correction or revision of unsuccessful osteotomy, or arthrodesis Patient selection factors to be considered include:',\n",
       "   'Need to obtain pain relief and improve function',\n",
       "   'Ability and willingness of the patient to follow instructions',\n",
       "   'Including control of weight and activity level',\n",
       "   'Good nutritional state of the patient',\n",
       "   'Patient must have reached full skeletal maturity Exclusion criteria: Absolute contraindications include:',\n",
       "   'Infection',\n",
       "   'Sepsis',\n",
       "   'Osteomyelitis',\n",
       "   'Failure of a previous joint replacement Relative contraindications include:',\n",
       "   'Uncooperative patient or patient with neurologic disorders who are incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, Muscular atrophy, Neuromuscular disease',\n",
       "   'Incomplete or deficient soft tissue surrounding the knee Additional'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00698152',\n",
       "  'inclusion': ['Non inflammatory degenerative joint disease including osteoarthritis and avascular necrosis',\n",
       "   'Rheumatoid Arthritis',\n",
       "   'Correction of Functional Deformity',\n",
       "   'Treatment of non-union, femoral neck fractures, trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques',\n",
       "   'Revision of previously failed total hip arthroplasty',\n",
       "   'Uncemented applications'],\n",
       "  'exclusion': ['Infection, sepsis and osteomyelitis Relative contraindications',\n",
       "   'Uncooperative patient or patient with neurologic disorders who are incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may be spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy or neuromuscular disease']},\n",
       " {'nct_id': 'NCT00698347',\n",
       "  'inclusion': ['Non-inflammatory degenerative joint disease including: Avascular Necrosis, Diastrophic Variant, Fracture of the Pelvis, Fused Hip, Leg Perthes, Osteoarthritis, Slipped Capital Epiphysis, Subcapital Fractures, Traumatic Arthritis',\n",
       "   'Rheumatoid Arthritis',\n",
       "   'Correction of Functional Deformity',\n",
       "   'Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable by other techniques',\n",
       "   'Revision of previously failed total hip arthroplasty'],\n",
       "  'exclusion': ['Infection, Sepsis, and Osteomyelitis Relative contraindications include:',\n",
       "   'Uncooperative patient or patient with neurologic disorders that are incapable of following directions',\n",
       "   'Osteoporosis',\n",
       "   'Metabolic disorders which may impair bone formation',\n",
       "   'Osteomalacia',\n",
       "   'Distant foci of infections which may spread to the implant site',\n",
       "   'Rapid joint destruction, marked bone loss, or bone resorption apparent on roentgenogram',\n",
       "   'Vascular insufficiency, muscular atrophy, or neuromuscular disease']},\n",
       " {'nct_id': 'NCT00177320',\n",
       "  'inclusion': ['Has Fibromyalgia, Osteoarthritis, or Rheumatoid arthritis; between 18-65; in the UPMC Arthritis Network Disease REgistry'],\n",
       "  'exclusion': ['']},\n",
       " {'nct_id': 'NCT00170872',\n",
       "  'inclusion': ['Requirement of regular NSAID therapy',\n",
       "   'With primary osteoarthritis of the target knee (by ACR Criteria) or with a diagnosis of rheumatoid arthritis (by ACR Criteria) Exclusion Criteria:',\n",
       "   'Evidence of active ulceration of the UGI tract within 6 months prior to the screening visit or history of active bleeding of the UGI tract within the previous 5 years. As well as with pyloric or duodenal obstruction or with history of gastrointestinal parasites.',\n",
       "   'History of cardiac and cerebral thrombotic/ischemic diseases and/or events',\n",
       "   'Patients taking additional NSAIDs (including COX-2 inhibitors) during the course of the study. Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00832910',\n",
       "  'inclusion': ['The RA group included patients between 18 and 70 years of age, of either gender, with an established diagnosis of RA based ACR criteria and belonging to functional classes I, II and III. The control group was made up of individuals from the community paired for gender, age and body mass index with RA group.'],\n",
       "  'exclusion': ['Individuals with fibromyalgia, neurological disease, psychiatric disorders or other severe co-morbidity were excluded from the study.']},\n",
       " {'nct_id': 'NCT00831922',\n",
       "  'inclusion': ['Meet American College of Rheumatology (ACR) criteria for RA',\n",
       "   'Have active RA',\n",
       "   'ACR functional class I-III',\n",
       "   'Disease onset at > 16 years of age',\n",
       "   'Disease duration of at least 6 months',\n",
       "   'Failure to one DMARD including methotrexate and anti-TNF alpha'],\n",
       "  'exclusion': ['Pregnant or breastfeeding women',\n",
       "   'Inadequate bone marrow function',\n",
       "   'Current use of a DMARD within 4 weeks (or 5 half-lives, whichever is longer) of screening except for leflunomide which requires a specific wash-out',\n",
       "   'Any previous use of recombinant IL1-Ra',\n",
       "   'Current use of more than 1 non steroidal anti-inflammatory drug (NSAID) or change of dose of the NSAID within 4 weeks of baseline or NSAID use greater than the maximum recommended dose',\n",
       "   'Within 4 weeks before baseline, use of more than 10 mg/day of prednisone or equivalent or change in the dose of prednisone or equivalent, or having intra-articular corticosteroid injection or bolus intramuscular or intravenous treatment with corticosteroids (>20 mg prednisone or equivalent']},\n",
       " {'nct_id': 'NCT00837434',\n",
       "  'inclusion': ['Diagnosis of RA*',\n",
       "   'Disease duration as defined from the onset of symptoms of at least 3 months prior to study entry',\n",
       "   'Active RA with DAS28 > 4.4, clinically requiring the addition of anti-TNF therapy',\n",
       "   'Stable dose of MTX between 7.5 mg and 25 mg weekly for at least 8 weeks prior to study entry',\n",
       "   'Able and willing to self-administer subcutaneous injections or have available qualified person(s) or caregiver to administer subcutaneous injections',\n",
       "   'For females, agree to use accepted methods of contraception during the duration of the study and for 150 days after study completion*. *More information on these criterion can be found in the protocol.'],\n",
       "  'exclusion': ['Positive PPD test',\n",
       "   'a tuberculosis (TB) skin test: (> 5 mm induration regardless of prior Bacille Calmette-Guerin [BCG] vaccine administration) without evidence of ongoing treatment for at least 30 days or completed treatment',\n",
       "   'History of positive PPD or chest x-ray findings indicative of prior TB infection, without documentation of either treatment for TB infection or chemoprophylaxis for TB exposure',\n",
       "   'Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 30 days prior to study entry',\n",
       "   'Definitive diagnosis of another autoimmune disease that may require immunosuppression for treatment*',\n",
       "   'Concomitant use of DMARDSs (e.g., disease-modifying antirheumatic drugs)*',\n",
       "   'Any immunosuppressive therapy other than MTX, NSAIDs, or corticosteroids*',\n",
       "   'Current or previous use of any biologic agent',\n",
       "   'Presence of open leg ulcers',\n",
       "   'Chronic or persistent infection that might be worsened by immunosuppressive treatment*',\n",
       "   'Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to study entry',\n",
       "   'Received oral antibiotics, antivirals, or antifungals within 14 days prior to study entry',\n",
       "   'Certain abnormal laboratory values*',\n",
       "   'Any medical condition that, in the opinion of the investigator, would interfere with the study',\n",
       "   'History of malignancy other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma within 10 years prior to study entry',\n",
       "   'Any Investigational agent within the earlier of 4 weeks or 5 half-lives prior to study entry',\n",
       "   'History of drug or alcohol abuse within 6 months prior to study entry',\n",
       "   'Known allergy or hypersensitivity to study products',\n",
       "   'Inability or unwillingness to follow the protocol',\n",
       "   'Any condition or treatment that, in the opinion of the investigator, places the participant at an unacceptable risk',\n",
       "   'Pregnant or breastfeeding *More information on these criterion are in the protocol.']},\n",
       " {'nct_id': 'NCT00838565',\n",
       "  'inclusion': ['Rheumatoid Arthritis on a stable dose of methotrexate',\n",
       "   'Rheumatoid Arthritis disease activity as assessed by blood tests'],\n",
       "  'exclusion': ['Serious or uncontrolled medical conditions',\n",
       "   'Current or recent treatment with disease-modifying drugs other than methotrexate including but not limited to leflunomide, sulfasalazine, etanercept, infliximab, adalimumab, abatacept, rituximab',\n",
       "   'Current oral glucocorticoid dose of more than 10 mg/d prednisone equivalent']},\n",
       " {'nct_id': 'NCT00484809',\n",
       "  'inclusion': ['Inclusion in this study will be as per the approved indications in the package insert.',\n",
       "   'Patients with moderately to severely active',\n",
       "   '- Children with JRA who have had an inadequate response to one or more DMARDs.'],\n",
       "  'exclusion': ['Known hypersensitivity to etanercept or any of its components.',\n",
       "   'Known significant concurrent medical disease, including:',\n",
       "   'Congestive heart failure, uncontrolled angina pectoris, recent history of myocardial infarction',\n",
       "   'Cancer or history of cancer',\n",
       "   'Active infection',\n",
       "   'Sepsis or risk of sepsis',\n",
       "   'Active tuberculosis or a past history of tuberculosis',\n",
       "   'Pancytopenia',\n",
       "   'Females who are pregnant, breast feeding or at risk of pregnancy and not using a medically acceptable form of contraception.',\n",
       "   'Patients who are planning to undergo elective surgery during the study period.']},\n",
       " {'nct_id': 'NCT00484289',\n",
       "  'inclusion': ['The participants who completed the 169 days, full study period of Phase II (IM101-071) and were not administered other biologics between completion of IM101-071 and registration of this long-term study.',\n",
       "   'The participants of the Phase I study (IM101-034), who received abatacept, except participants who were withdrawn from the study due to safety problems related to abatacept.',\n",
       "   'New subjects with MTX intolerance: rheumatoid arthritis (RA) patients to whom MTX cannot be administered for safety reasons and who present an inadequate response to disease-modifying antirheumatic drugs (DMARDs;excluding MTX) or biologics (new subjects with MTX intolerance: RA patients who present an inadequate response to DMARDs).'],\n",
       "  'exclusion': ['Women of childbearing potential (WOCBP) who were unwilling or unable to use an acceptable method of contraception.',\n",
       "   'Participants who have received non approved or investigational biologics (other than abatacept from previous or ongoing studies in Japan) at registration.',\n",
       "   'Participants who have received treatment with any investigational drug within 56 days before registration or five half-lives (whichever is the longest).',\n",
       "   'Participants currently receiving treatment with leflunomide, mycophenolate mofetil, calcineurine inhibitors such as cyclosporine and tacrolimus, D-Penicillamine, Cyclophosphamide, or immunoadsorption columns.',\n",
       "   'The participants who completed Phase II (IM101-071) are not applicable in the following instances at time of registration: with active vasculitis, symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral disease, breast cancer, or a history of cancer within the last 5 years, evidence of active or latent bacterial , viral infections, any serious or chronic, at risk of tuberculosis (TB), with any opportunistic infections, laboratory values of hemoglobin < 8.5 g/dL, white blood cells (WBC) < 3,000/mm^3, Platelets < 100,000/mm^3, Serum creatinine > 2 times upper limit of normal (ULN), Serum alanine transaminase or aspartate aminotransferase > 2 times ULN.']},\n",
       " {'nct_id': 'NCT00485589',\n",
       "  'inclusion': ['Age ≥ 18',\n",
       "   'Rheumatoid arthritis for 3 months-5 years',\n",
       "   'Naive to methotrexate',\n",
       "   'If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to baseline'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease or inflammatory joint disease other than RA',\n",
       "   'Prior receipt of any biologic therapy for RA',\n",
       "   'Concurrent treatment with any DMARD']},\n",
       " {'nct_id': 'NCT00488475',\n",
       "  'inclusion': ['Clinical diagnosis of rheumatoid arthritis'],\n",
       "  'exclusion': ['Sepsis or risk for sepsis,',\n",
       "   'Acute infection,',\n",
       "   'Hypersensitivity against Etanercept']},\n",
       " {'nct_id': 'NCT00485914',\n",
       "  'inclusion': ['Rheumatoid arthritis or osteoarthritis diagnosed by a rheumatologist',\n",
       "   'Competitively employed; full or part time',\n",
       "   'Reporting arthritis-related employment difficulties',\n",
       "   'Agree to participate in a work site evaluation'],\n",
       "  'exclusion': ['Systemic complications of RA (e.g., vasculitis)',\n",
       "   'Organic Brain Syndrome',\n",
       "   'Uncontrolled psychiatric disorders',\n",
       "   'Uncontrolled medical conditions (e.g., active cancer)']},\n",
       " {'nct_id': 'NCT00480272',\n",
       "  'inclusion': ['Active rheumatoid arthritis diagnosed for at least 6 weeks, but no more than 1 year, according to the revised 1987 ACR criteria',\n",
       "   'Naïve to treatment with MTX',\n",
       "   'Swollen joint count (SJC) > 8 tender joint count (TJC) > 8',\n",
       "   'At screening CRP > 1.5 mg/dL (15 mg/L) or ESR ≥ 28 mm/h',\n",
       "   '≥ 1 joint erosion or RF positivity or anti-CCP positivity',\n",
       "   'Age 18-70 years.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA',\n",
       "   'Functional class IV',\n",
       "   'Any surgical procedure within 12 weeks prior to baseline or planned during the study.',\n",
       "   'Pregnancy or breast feeding.',\n",
       "   'Evidence of significant concomitant disease',\n",
       "   'Primary or secondary immunodeficiency',\n",
       "   'active infection of any kind',\n",
       "   'History of previously untreated infection with mycobacterium tuberculosis or current treatment for same.',\n",
       "   'History of cancer',\n",
       "   'Any history or presence of congestive heart failure (CHF) (New York Heart Association classification for CHF: Class III or IV).',\n",
       "   'Any history of myocardial infarction within 5 years.',\n",
       "   'History of a severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of adalimumab or methotrexate.',\n",
       "   'Positive serology for hepatitis B or C indicating active infection.',\n",
       "   'Hemoglobin < 8.0 g/dL.',\n",
       "   'Absolute neutrophil count (ANC) < 1.5 x 103/L.',\n",
       "   'Liver function abnormality']},\n",
       " {'nct_id': 'NCT00482417',\n",
       "  'inclusion': ['You are 18-65 years of age and have Rheumatoid Arthritis',\n",
       "   'You must be able to read and understand patient questionnaires'],\n",
       "  'exclusion': ['You have had certain types of surgery, certain types of cancer or history of Tuberculosis (TB) or HIV.']},\n",
       " {'nct_id': 'NCT00487825',\n",
       "  'inclusion': ['Male and female patients of 18 to 75 years of age (inclusive)',\n",
       "   'Recent definite diagnosis of rheumatoid arthritis (RA) (<3 years since diagnosis), classified by American Rheumatism Association 1987 revised criteria.',\n",
       "   'Candidate for methotrexate (MTX) or biologic due to erosive arthritis, with no contraindications to such therapy, including:',\n",
       "   'Negative tuberculin skin test reaction',\n",
       "   'Normal chest X-ray (within the last year) prior to possibility of receiving MTX (r/o lung fibrosis).',\n",
       "   'Active disease: at least 6 swollen and 6 painful tender joints of 28 joint count,',\n",
       "   'Vital signs should be within the following ranges:',\n",
       "   '18-59 years of age: oral temperature between 35.0-37.5 °C systolic blood pressure, 90-140 mm Hg diastolic blood pressure, 50-90 mm Hg pulse rate, 40',\n",
       "   '90 beats per minute',\n",
       "   '60-75 years of age: oral temperature between 35.0-37.5 °C systolic blood pressure, 100-160 mm Hg diastolic blood pressure, 50-100 mm Hg pulse rate, 50',\n",
       "   '100 beats per minute',\n",
       "   'Women of child-bearing potential willing to practice double-barrier contraception during the study for at least 3 months following last study drug administration. Postmenopausal women must have no regular menstrual bleeding for at least 1 year prior to inclusion. Surgically sterilized women at least 6 months prior to screening. Male patients must be using a double-barrier local contraception and refrain from fathering a child in the 3 months following last study drug administration.',\n",
       "   'Weight: at least 45 kg; body mass index (BMI) within the range of 18 to',\n",
       "   '- Oral corticosteroids are permitted as long as patients are on a stable dose (up to 10 mg) for at least 4 weeks before study start.'],\n",
       "  'exclusion': ['Unable to have Magnetic Resonance Imaging (MRI) of wrist.',\n",
       "   'Patients with magnetizable metal parts/devices on and in the body that could interfere with the MRI',\n",
       "   'Patients with an unstable active medical condition that could impair evaluation of study results.',\n",
       "   'Previous treatment with biological therapy or MTX.',\n",
       "   'Limited kidney function (creatinine clearance under 60 ml/min)',\n",
       "   'Previous treatment with other disease-modifying anti-rheumatic drugs such as sulfasalazine, hydroxychloroquine within 4 weeks of screening.',\n",
       "   'Corticosteroids injections into joints within 4 weeks prior to screening.',\n",
       "   'Participation in any clinical investigation within 4 weeks prior to study start or longer if required by local regulations, and for any other limitation of participation based on local regulations.',\n",
       "   'Blood donation or loss of > 400 mL within 8 weeks before study start, or longer if required by local regulation.',\n",
       "   'Significant illness within 2 weeks of study start.',\n",
       "   'Past personal or family medical history of clinically significant ECG abnormalities or cardiac issues.',\n",
       "   'History of:',\n",
       "   'fainting, orthostatic hypotension, sinus arrhythmia asthma and chronic obstructive pulmonary disease, clinically significant drug allergy or urticaria, eczematous dermatitis, and/or known hypersensitivity to the study drug or drugs similar to the study drug.',\n",
       "   'disease of the blood building system, serious or active infections, gastric ulcers.',\n",
       "   'surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the patient in case of participation in the study.',\n",
       "   'immunodeficiency diseases, including a positive Human Immunodeficiency Virus (HIV) (ELISA and Western blot) test result.',\n",
       "   'positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.',\n",
       "   'drug or alcohol abuse within the 12 months prior to dosing or evidence of such abuse.']},\n",
       " {'nct_id': 'NCT00116727',\n",
       "  'inclusion': ['Fulfillment of the 1987 American Rheumatism Association criteria for RA',\n",
       "   'Currently requiring the addition of ENBREL® therapy (to be taken alone or in addition to their current DMARD therapy)'],\n",
       "  'exclusion': ['Currently or previously enrolled in RADIUS 1',\n",
       "   'Currently enrolled in a clinical trial where treatments or patient visits are imposed by a protocol',\n",
       "   'Active infections',\n",
       "   'Known allergy to ENBREL® or any of its components',\n",
       "   'Current treatment with ENBREL®',\n",
       "   'Patients who have previously been demonstrated to be intolerant of or refractory to ENBREL® therapy',\n",
       "   'Nursing or pregnant women']},\n",
       " {'nct_id': 'NCT00111410',\n",
       "  'inclusion': ['Diagnosed with RA by American College of Rheumatology (ACR) criteria for greater than or equal to 12 weeks',\n",
       "   'Active RA with at least 3 swollen joints and 3 tender/painful joints and at least one of the following:',\n",
       "   'Morning stiffness greater than or equal to 45 minutes;',\n",
       "   'C-reactive protein (CRP) greater than or equal to 1.5 mg/dL;',\n",
       "   'Erythrocyte sedimentation rate greater than or equal to 28 mm/hr;',\n",
       "   'Stable methotrexate dose of less than or equal to 20 mg/week for 8 weeks prior to randomization;',\n",
       "   'Stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral corticosteroids (less than or equal to 10 mg/day of prednisone or equivalent) for 4 weeks prior to randomization.'],\n",
       "  'exclusion': ['Pregnant or breast-feeding women',\n",
       "   'Any uncontrolled, clinically significant systemic disease',\n",
       "   'Has total white cell count less than 3.5 x 10^9/L, a neutrophils count less than 2.0 x 10^9/L, platelet count less than 125 x 10^9/L or hemoglobin (Hgb) less than 8.0 g/dL at screening',\n",
       "   'Abnormal liver function tests (AST/ALT greater than or equal to 1.5 x the upper limit of normal at screening)',\n",
       "   'Serum creatinine greater than 1.5 x the upper limit of normal at screening',\n",
       "   'Subject recall of having tetanus toxoid or diphtheria vaccination less than 10 years prior to randomization',\n",
       "   'Has never received a primary tetanus vaccination',\n",
       "   'Any other vaccination within 12 weeks of randomization',\n",
       "   'Disease-modifying antirheumatic drugs (DMARDs) other than methotrexate',\n",
       "   'Biologics to treat RA within the previous 8 weeks of screening (e.g., etanercept, infliximab)',\n",
       "   'Subjects were treated with anakinra within 4 weeks prior to randomization']},\n",
       " {'nct_id': 'NCT00115219',\n",
       "  'inclusion': ['Diagnosis of Rheumatoid Arthritis',\n",
       "   'RA with a disease duration > 6 months',\n",
       "   'Current and prior but continuous etanercept (50 mg weekly) treatment for at least 5 months prior to screening',\n",
       "   'Subjects must be receiving methotrexate (MTX) at a stable dose > 15 mg/week at least 4 weeks prior to screening',\n",
       "   'Sub-optimal response to etanercept defined by the presence of the following criteria (based on 28 joint count) at screening: 5 or more swollen joints and 5 or more tender joints',\n",
       "   'Subjects who are currently receiving oral corticosteroids must be on a dose equivalent to prednisone less than or equal to 10 mg/day at screening',\n",
       "   'Subjects who are currently receiving non-steroidal anti-inflammatory drugs (NSAIDs), must be on a stable dose for at least 2 weeks prior to screening',\n",
       "   'Subjects who are currently receiving DMARD therapy (including sulfasalazine, hydroxy-chloroquine and leflunomide), must be on a stable dose for at least 4 weeks prior to screening'],\n",
       "  'exclusion': ['Nursing mothers, female subjects planning on becoming pregnant, or male subjects planning a pregnancy with their spouse/partner while in the study',\n",
       "   'ACR functional class IV',\n",
       "   'Receipt of any investigational drug or biologic within 4 weeks of study drug initiation',\n",
       "   'Concurrent or history of psychiatric disease that would interfere with ability to comply with study protocol or give informed consent',\n",
       "   'History of alcohol or drug abuse within 12 months of screening visit',\n",
       "   'Severe comorbidities including: History of cancer (other than resected cutaneous basal and squamous cell carcinoma, and in situ cervical cancer) within 5 years of screening visit. Documentation of disease-free state since treatment required; Diagnosis of Class III or IV congestive heart failure (CHF) or myocardial infarction (MI) within 12 months of screening; Unstable or stable angina pectoris; Uncontrolled hypertension (defined as systolic blood pressure measurement of greater than 180 mm Hg or a diastolic blood pressure of greater than 110 mm Hg); Oxygen-dependent pulmonary disease; Known HIV-positive status or other immunodeficiency syndromes; Chronic hepatitis B (HbsAg) or C (HCV); Systemic lupus erythematosus (SLE); CNS demyelinating events suggestive of multiple sclerosis; Presence of active infection or any underlying diseases that could predispose subjects to infection (e.g., history of recurrent infections, non-healing leg ulcers, advanced or poorly controlled diabetes); Active or prior history of tuberculosis (or known exposure).',\n",
       "   'Concurrent treatment with cyclophosphamide']},\n",
       " {'nct_id': 'NCT00110903',\n",
       "  'inclusion': ['Fulfill the 1987 American Rheumatism Association (ARA) criteria for RA',\n",
       "   'Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of up to 25 mg a week is permitted',\n",
       "   'Screening lab results must demonstrate:',\n",
       "   'AST and ALT less than or equal to 2 times the upper limit of normal hemoglobin greater than or equal to 8.5 g/dL;',\n",
       "   'Platelet count greater than or equal to 125,000/cm3;',\n",
       "   'White blood cell count (WBC) greater than or equal to 3500 cells/cm3;',\n",
       "   'Serum creatinine less than or equal to 2 mg/dL',\n",
       "   'Before any study specific procedure is performed, the subject must provide informed consent for participation in the study'],\n",
       "  'exclusion': ['Previous receipt of etanercept',\n",
       "   'Receipt of antibody to (tumor necrosis factor) TNF alpha or other TNF inhibitors within 90 days of Day 1',\n",
       "   'Currently enrolled in other investigational device or drug trials, or participation in investigational trial within the past 30 days',\n",
       "   'Receipt of intra-articular corticosteroids within 14 days prior to Day 1',\n",
       "   'Receipt of any disease-modifying anti-rheumatic drugs (DMARDs) within 28 days of Day 1',\n",
       "   'Receipt of cyclophosphamide within 6 months of Day 1',\n",
       "   'Concomitant corticosteroids greater than 10 mg/day of prednisone (or equivalent) during 14 days prior to Day 1',\n",
       "   'Dose of nonsteroidal anti-inflammatory drug (NSAID) must be stable for 14 days prior to Day 1 and must not exceed the recommended dose in the product information sheet',\n",
       "   'Subject is not using adequate contraception',\n",
       "   'Subject is pregnant or breast-feeding',\n",
       "   'Subject has significant concurrent medical disease']},\n",
       " {'nct_id': 'NCT00117091',\n",
       "  'inclusion': ['Subjects diagnosed with RA as determined by American College of Rheumatology (ACR) criteria with a disease duration of at least 24 weeks prior to enrollment',\n",
       "   'Active RA at screening as defined by EITHER: (1) At least 6 swollen joints (using a 66 joint count) and at least 6 tender joints (using a 68 joint count) OR (2) 4 non-hand joints and at least 1 of the following: *Morning stiffness of at least 45 minutes; *CRP greater than 1.5 mg/dL (15.0 mg/L); *ESR greater than 28 mm/h; *DAS28 greater than 3.2',\n",
       "   'Subjects must have failed an adequate trial of at least 3 disease-modifying antirheumatic drugs (DMARDS) alone or in combination (one of which must be MTX) and have been on the same treatment and doses for 4 weeks prior to enrollment (i.e., an adequate trial is defined as 12 weeks unless limited by toxicity or intolerance)',\n",
       "   \"Subjects' doses of nonsteroidal antiinflammatory drugs (NSAIDs) and oral corticosteroids (less than or equal to 10 mg/day of prednisone or equivalent) must have been kept stable for 4 weeks prior to enrollment. Doses of 10 mg/day prednisone or equivalent should not be exceeded during the study\"],\n",
       "  'exclusion': ['ACR functional class IV or ARA anatomical stage IV',\n",
       "   'Subjects that are scheduled for surgery or being evaluated for surgery for hands, wrist and feet',\n",
       "   \"Felty's syndrome\",\n",
       "   'Any poorly controlled, clinically significant systemic disease (e.g., chronic obstructive pulmonary disease, congestive heart failure, stroke, chronic renal failure, liver disease)',\n",
       "   'Poorly controlled diabetes mellitus (e.g., diabetics with HbA1C greater than 8%, peripheral neuropathy, renal/retinal involvement, or vascular disorders)',\n",
       "   'Malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix within the past 5 years',\n",
       "   'Abnormal chest x-ray that is clinically significant or bronchiectasis',\n",
       "   'Within 12 weeks before date of enrollment any of the following occurrences: presence of serious infection (e.g., requiring hospitalization and/or IV antibiotics), frequent, acute, or chronic infections',\n",
       "   'History of chronic infection',\n",
       "   'Recent history (within 24 weeks of enrollment) of drug or alcohol abuse',\n",
       "   'Known to be positive for hepatitis B surface antigen, hepatitis C virus, or human immunodeficiency virus',\n",
       "   'Presence of any condition that may compromise the ability of the subject to give informed consent',\n",
       "   'Planned events (e.g., planned hospitalizations, vacations, etc.) that would interfere with the collection of the required assessments and/or may prevent the subject from completing the study according to protocol',\n",
       "   'White cell count less than or equal to 3.5 x 10^9/L, a neutrophil count of less than or equal to 2.5 x 10^9/L, or platelet count of less than or equal to 125 x 10^9/L at screening',\n",
       "   'Hemoglobin less than or equal to 8.0 g/dL at screening',\n",
       "   'Elevated AST or ALT greater than or equal to 1.5 x the upper limit of normal at screening',\n",
       "   'Elevated serum creatinine greater than or equal to 1.5 x the upper limit of normal at screening',\n",
       "   'Received intra-articular or systemic corticosteroid injections within 4 weeks before enrollment',\n",
       "   'Subjects who have received previous treatment with anti-IL-1ra or anti-TNF therapies (e.g., anakinra, etanercept or infliximab) within 4 weeks prior to enrollment',\n",
       "   'Subjects who are pregnant or breast-feeding, or plan to become pregnant during the course of the study',\n",
       "   'Subject (man or woman) is of child bearing potential and not using adequate contraceptive precautions',\n",
       "   'Known allergy to',\n",
       "   'coli derived products',\n",
       "   'Receiving or has received any investigational drug within the previous 30 days or within 5 half-lives of any investigational drug, whichever is greater (or is currently using an investigational device)']},\n",
       " {'nct_id': 'NCT00110565',\n",
       "  'inclusion': ['Diagnosis of RA',\n",
       "   'Postmenopausal, defined by no menstrual period in at least 2 years prior to study entry or a hysterectomy',\n",
       "   'Average pain of 2 or greater on a 0 to 10 pain scale',\n",
       "   'Sleep difficulty',\n",
       "   'Stable medication use related to RA for at least 4 weeks prior to study entry'],\n",
       "  'exclusion': ['Diagnoses of lupus, sleep apnea, or restless leg syndrome',\n",
       "   'High-dose prednisone (more than 10 mg/day) or equivalent',\n",
       "   'Pacemakers or other implanted devices',\n",
       "   'Epilepsy',\n",
       "   'Currently undergoing treatment for cancer']},\n",
       " {'nct_id': 'NCT00116714',\n",
       "  'inclusion': ['Fulfillment of the 1987 American Rheumatism Association criteria for RA',\n",
       "   'Currently requiring a new DMARD (change or addition)'],\n",
       "  'exclusion': ['Currently enrolled in a clinical trial with treatments or patient visits imposed by a protocol',\n",
       "   'Nursing or pregnant women',\n",
       "   'Patients with active infection']},\n",
       " {'nct_id': 'NCT00883896',\n",
       "  'inclusion': ['Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening',\n",
       "   'Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h',\n",
       "   'Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.'],\n",
       "  'exclusion': ['Subjects with other rheumatic diseases',\n",
       "   'Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)',\n",
       "   'Any prior use of B cell-depleting therapy']},\n",
       " {'nct_id': 'NCT00888745',\n",
       "  'inclusion': ['RA diagnosed according to the American College of Rheumatology (ACR)'],\n",
       "  'exclusion': ['Female patients who are pregnant, plan to become pregnant during the study, or are breastfeeding',\n",
       "   'Clinically significant abnormal ECG',\n",
       "   'History of anaphylactic reactions',\n",
       "   'Positive hepatitis C antibody or hepatitis B surface antigen',\n",
       "   'Positive serology for human immunodeficiency virus (HIV) by quantitative polymerase chain reaction',\n",
       "   'A history of an autoimmune disease other than RA (other than secondary Sjogren syndrome)',\n",
       "   'Significant systemic involvement of RA, including vasculitis, pulmonary fibrosis, or Felty syndrome',\n",
       "   'Malignancy, or prior malignancy, other than non-melanoma skin cancer, or cervical carcinoma in situ that has been resected',\n",
       "   'Recent administration of a live, attenuated vaccine, or anticipation that such a live attenuated vaccine will be required during the study or within 60 days after the last dose',\n",
       "   'Concomitant therapy with a biologic agent',\n",
       "   'Recent exposure to any investigational agent',\n",
       "   'Any current or recent signs or symptoms of infection requiring parenteral antibiotic administration',\n",
       "   'Hospitalization for a clinically relevant event within the 4 weeks prior to screening']},\n",
       " {'nct_id': 'NCT00887341',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'active moderate or severe rheumatoid arthritis;',\n",
       "   'active disease for >6 months;',\n",
       "   'inadequate response to a stable dose of non-biologic DMARDs or antiTNFs.'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than rheumatoid arthritis;',\n",
       "   'prior history of, or current inflammatory joint disease other than rheumatoid arthritis;',\n",
       "   'major surgery (including joint surgery) within 8 weeks prior to screening, or planned major surgery within 6 months following enrollment.']},\n",
       " {'nct_id': 'NCT00881881',\n",
       "  'inclusion': ['Group 1: early RA : patients with disease lasting 2 years or less, considered by the investigator as an early RA',\n",
       "   'Group 2: established RA: patients with disease lasting more than 2 years who meet the ACR criteria for RA'],\n",
       "  'exclusion': ['Patients with any rheumatic disease different from RA',\n",
       "   'Participation in any clinical trial or study in the last 12 months']},\n",
       " {'nct_id': 'NCT00361335',\n",
       "  'inclusion': ['Must have a diagnosis of active rheumatoid arthritis (RA) (according to the revised 1987 criteria of the ARA (American Rheumatism Association) with at least 4 swollen and 4 tender joints for at least 3 months prior to screening',\n",
       "   'Have been treated with and tolerated methotrexate (MTX) at a dose of at least 15 mg per week for at least 3 months prior to screening',\n",
       "   'Have been on a stable MTX dose of greater than or equal to 15 mg per week and less than or eual to 25 mg per week for at least 4 weeks prior to screening',\n",
       "   'If using non steroidal anti-inflammatory agents (such as naproxen) or other pain relievers for RA, must be on a stable dose for at least 2 weeks prior to the first administration of study agent'],\n",
       "  'exclusion': ['Participants having known hypersensitivity (severe allergy) to human immunoglobulin proteins or other components of golimumab',\n",
       "   'Having known clinically serious adverse reaction to a biologic anti-TNF agent',\n",
       "   'Have had history of latent or active granulomatous infection, including tuberculosis, histoplasmosis, or coccidioidomycosis, prior to screening']},\n",
       " {'nct_id': 'NCT00367211',\n",
       "  'inclusion': ['Male or non-pregnant female subjects with a history of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical conditions expected to require daily NSAID therapy for at least 6 months who are 18-49 years of age and have a history of a documented, uncomplicated gastric or duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without any concurrent bleeding, clot or perforation) within the past 5 years OR, who are 50 years of age and older (these subjects do not require a history of a documented, uncomplicated gastric or duodenal ulcer within the past 5 years).',\n",
       "   'Female subjects are eligible for participation in the study if they are of:',\n",
       "   'Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,',\n",
       "   'Childbearing potential, have a negative pregnancy test (urine) at screening, and at least one of the following applies or is agreed to by the subject:',\n",
       "   'Complete abstinence from intercourse for at least 14 days prior to first dose of study drug, throughout the study, and for 30 days after completion of the study',\n",
       "   'Female sterilization or sterilization of male partner; or,',\n",
       "   'Hormonal contraception by oral route, implant, injectable, vaginal ring; or,',\n",
       "   'Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year;',\n",
       "   'Double barrier method (2 physical barriers or 1 physical barrier plus spermicide); or',\n",
       "   'Any other method with published data showing that the lowest expected failure rate is less than 1% per year.',\n",
       "   'Each subject must be able to understand and comply with study procedures required of a subject and is able and willing to provide written informed consent prior to any study procedures being performed.'],\n",
       "  'exclusion': ['History of hypersensitivity to omeprazole or to another proton-pump inhibitor.',\n",
       "   'History of allergic reaction or intolerance to any NSAID (including aspirin) and/or subject has a history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps.',\n",
       "   'Participation in any study of an investigational treatment in the 4 weeks before screening.',\n",
       "   'Presence of uncontrolled acute or chronic medical illness, e.g. gastrointestinal disorder, diabetes, hypertension, thyroid disorder, depression and/or infection that would endanger a subject if they were to participate in the study.',\n",
       "   'Gastrointestinal disorder or surgery leading to impaired drug absorption.',\n",
       "   \"Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in the investigator's opinion would endanger a subject if they were to participate in the study.\",\n",
       "   'Schizophrenia or bipolar disorder.',\n",
       "   'Use of any excluded concomitant medication (see Section 9.2).',\n",
       "   'A recent history (in the past 3 months) suggestive of alcohol or drug abuse or dependence, including overuse/abuse of narcotics for management of pain.',\n",
       "   'Serious blood coagulation disorder including use of systemic anticoagulants.',\n",
       "   'Positive test result for',\n",
       "   'pylori at screening.',\n",
       "   'Baseline endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter with depth.',\n",
       "   'Screening laboratory value for ALT, AST >2 times the upper limit of normal.',\n",
       "   'Estimated creatinine clearance < 30 ml/min.',\n",
       "   \"Other than noted specifically, any screening laboratory value that is clinically significant in the investigator's opinion and would endanger a subject if they were to participate in the study.\",\n",
       "   'History of malignancy, treated or untreated, within the past 5 years, with the exception of successfully treated basal cell or squamous cell carcinoma of the skin.']},\n",
       " {'nct_id': 'NCT00364728',\n",
       "  'inclusion': ['SLE, RA, healthy'],\n",
       "  'exclusion': ['nil']},\n",
       " {'nct_id': 'NCT00361634',\n",
       "  'inclusion': ['Fulfillment of the 1987 American College of Rheumatology (ACR) criteria for RA with a disease duration > 6 months',\n",
       "   'Presence of active disease (defined as both tender and swollen joints) in at least one wrist',\n",
       "   'Sub-optimal response to methotrexate (MTX) defined by the presence of the following criteria (based on 68/66 joint count): 8 or more swollen joints AND 8 or more tender joints (with involvement of the wrist, fingers and at least one region outside the hands) at screening',\n",
       "   'Must be receiving MTX at a stable dose > 15 mg/week at least 12 weeks prior to baseline',\n",
       "   'a lower dose is acceptable if otherwise not tolerated (toxicity documentation required).'],\n",
       "  'exclusion': ['Patients who are currently receiving disease modifying anti-rheumatic drug (DMARD) therapy (other than MTX, hydroxychloroquine or sulfasalazine) including tumor necrosis factor (TNF) antagonists (etanercept, infliximab, and adalimumab), abatacept, rituximab, leflunomide, cyclosporine, and gold (oral and intramuscular injection) within 8 weeks or 5.5 half-lives, whichever is longer, of screening',\n",
       "   'Co-existing condition requiring medications that alter vascular flow (e.g., nitrates, calcium channel blockers, ergot containing drugs) [Potential effects of antihypertensive and migraine medications will be discussed with the Sponsor]',\n",
       "   'Comorbid autoimmune disorders including systemic lupus erythematosus',\n",
       "   'Unable to undergo an MRI examination (e.g., presence of a pacemaker, defibrillator, or other implanted device such as anterior interbody cages, aneurysm clip or pedicle screws',\n",
       "   'allergic to contrast agent',\n",
       "   'tattoos [in area of examination if contains metallic pigment])',\n",
       "   'or will likely require sedation for the procedure']},\n",
       " {'nct_id': 'NCT00369928',\n",
       "  'inclusion': ['Meet American College of Rheumatology (ACR) criteria for Rheumatoid Arthritis',\n",
       "   'Disease duration of at least 6 months',\n",
       "   'Must be treated with Methotrexate for at least 24 weeks',\n",
       "   'At least 6 swollen joints and 6 tender joints',\n",
       "   'Washout required for other Disease Modifying Anti-rheumatic Drugs (DMARDs)',\n",
       "   'Women of childbearing age and all males must use acceptable method of birth control'],\n",
       "  'exclusion': ['Tuberculosis',\n",
       "   'Malignancies',\n",
       "   'Abnormal electrocardiograms as described in the protocol',\n",
       "   'Current infection or recurrent infections or immunodeficiency',\n",
       "   'Liver diseases and abnormalities in liver function tests as described in the protocol',\n",
       "   \"Autoimmune diseases other than RA except Sjogren's syndrome secondary to RA;\",\n",
       "   'History of demyelization diseases',\n",
       "   'Any condition that in the opinion of the investigator could be detrimental to patients enrolling in the study including clinically important changes in laboratory values and other diseases described in the protocol']},\n",
       " {'nct_id': 'NCT00369187',\n",
       "  'inclusion': ['Males or females at least 18 years of age with RA treated with MTX who have been treated with:',\n",
       "   'co-injected large molecule protein for at least two cycles, and',\n",
       "   'have had stable disease with no symptom flares in the previous 30 days.',\n",
       "   'AST (SGOT) and ALT (SGPT) within normal range within 7 days prior to entry in the study.',\n",
       "   'Adequate venous access in at least one extremity.',\n",
       "   'A negative pregnancy test (if female of child-bearing potential) within 7 days prior to entry in the study.',\n",
       "   'Decision-making capacity.',\n",
       "   'Signed, written IRB-approved informed consent.'],\n",
       "  'exclusion': ['Unacceptable toxicity to the large molecule protein, or contraindication to or other reason to not continue the large molecule protein per the package insert (e.g., active or latent tuberculosis, chronic or localized infections, or concurrent treatment with anakinra).',\n",
       "   'History of active tuberculosis, or known positive tuberculin skin test unless the patient has successfully completed a nine-month course of isoniazid therapy.',\n",
       "   'Concurrent use of any disease-modifying anti-rheumatic drug except the large molecule protein and MTX.',\n",
       "   'Any anticipation that the dose of the large molecule protein or MTX would be changed within 4 weeks following entry in the study.',\n",
       "   'Known allergy to hyaluronidase or any hyaluronidase product.',\n",
       "   'Known allergy to bee or vespid venom.',\n",
       "   'Contraindication to IV heparin lock or known hypersensitivity to heparin.',\n",
       "   'Edema, infection, or any other lower extremity or pelvic disorder that might affect subcutaneous absorption from the thigh.',\n",
       "   'Presence of any other medical condition that would present an unacceptable safety risk to the patient.',\n",
       "   'Participation in a study of any investigational drug or device within 30 days of enrollment in this study.']},\n",
       " {'nct_id': 'NCT00365001',\n",
       "  'inclusion': ['adult patients, 18-75 years of age;',\n",
       "   'rheumatoid arthritis for >=6 months;',\n",
       "   'methotrexate for >=12 weeks prior to day 1 (stable at 10-25mg/week for 8 weeks).'],\n",
       "  'exclusion': ['history of, or current inflammatory joint disease or rheumatic autoimmune disease other than RA;',\n",
       "   'concurrent treatment with any DMARD other than methotrexate;',\n",
       "   'prior treatment with tocilizumab.']},\n",
       " {'nct_id': 'NCT00639834',\n",
       "  'inclusion': ['Must have met ACR criteria for the diagnosis of rheumatoid arthritis (RA)',\n",
       "   'Must have active RA',\n",
       "   'Must be treated with Methotrexate (MTX) (10 to 25 mg weekly) for at least 3 months and have received a stable dose for at least 28 days prior to the anticipated study drug administration date.',\n",
       "   'All other DMARDs or biologics must be discontinued at least 28 days prior to study drug administration and: 1) Leflunomide, which must be discontinued at least 60 days before study drug administration, 2) infliximab, adalimumab, and abatacept must be discontinued at least 56 days prior to study drug administration'],\n",
       "  'exclusion': ['Both Rheumatoid factor and anti-CCP negative',\n",
       "   'Prior treatment with any B-cell depleting therapy',\n",
       "   'Any other mAb or Ig-based fusion proteins 56 days or less prior to Visit',\n",
       "   'History of or current inflammatory joint disease other than RA',\n",
       "   'Neuropathies or neurovasculopathies that might interfere with pain evaluation',\n",
       "   'Complications of RA or other disease',\n",
       "   'Any other autoimmune disease other than RA',\n",
       "   'Acute or chronic infection',\n",
       "   'Clinically significant disease requiring']},\n",
       " {'nct_id': 'NCT00638950',\n",
       "  'inclusion': ['Clear diagnosis of Rheumatoid Arthritis',\n",
       "   'Patients receiving nonsteroidal anti-inflammatory drugs (NSAID) or corticosteroids (max. 15 mg/d) or both were eligible if dosage had been stable for at least 4 weeks before day 1 of the study and remained below this limit throughout the study',\n",
       "   'Patients on disease-modifying antirheumatic drugs (DMARD) had to be on a constant dosage for at least 8 weeks before and throughout the study'],\n",
       "  'exclusion': ['Subjects with gastrointestinal or metabolic diseases, alcohol abuse, taking dietary supplements (e.',\n",
       "   'fish oil capsules), known allergies or foodstuff indigestibility',\n",
       "   \"patient's request, serious infections, inadequate control of arthritis symptoms (over 50% increase of the number of swollen or tender joints), reinstitution of therapy with DMARD, or if patient compliance with the study protocol was doubtful.\"]},\n",
       " {'nct_id': 'NCT00632710',\n",
       "  'inclusion': ['patients with RA',\n",
       "   'inflammatory condition of at least two hand joints among the wrists, proximal interphalangeal (PIP) joint and metacarpophalangeal (MCP) joint',\n",
       "   'visual analogue scale (VAS) for pain between 3 and 8 cm during activities of daily living',\n",
       "   'and being of either gender'],\n",
       "  'exclusion': ['skin lesions at the application site',\n",
       "   'other illnesses affecting the hands; physiotherapy for the hands in the previous three months',\n",
       "   'joint injections in the previous three months',\n",
       "   'change in disease-modifying anti-rheumatic drugs in the previous three months',\n",
       "   'and change in corticosteroids in the previous month.']},\n",
       " {'nct_id': 'NCT00513591',\n",
       "  'inclusion': ['18 years of age or older',\n",
       "   'Desire for pregnancy within 6 months or currently pregnant',\n",
       "   'Women with systemic autoimmune disease, including:',\n",
       "   'Lupus (systemic lupus erythematosus or cutaneous lupus)',\n",
       "   'Antiphospholipid Syndrome or positive antiphospholipid antibodies',\n",
       "   'Rheumatoid Arthritis',\n",
       "   'Scleroderma (systemic sclerosis)',\n",
       "   \"Sjogren's Syndrome\",\n",
       "   'Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)',\n",
       "   'Undifferentiated Connective Tissue Disease (UCTD)',\n",
       "   'Vasculitis',\n",
       "   'Myositis (Polymyositis or Dermatomyositis)',\n",
       "   'Positive Ro/SSA or La/SSB antibodies'],\n",
       "  'exclusion': ['Unable to speak English',\n",
       "   'Unable to provide informed consent',\n",
       "   'Unable to travel to Duke University for follow-up visits']},\n",
       " {'nct_id': 'NCT00512239',\n",
       "  'inclusion': ['Early Rheumatoid arthritis', 'Early Inflammatory Arthritis'],\n",
       "  'exclusion': ['Refusal or inability to consent',\n",
       "   'Infectious arthritis',\n",
       "   'Microcrystalline arthritis']},\n",
       " {'nct_id': 'NCT00221000',\n",
       "  'inclusion': ['Patients must have a history of RA per the ACR criteria for the classification of',\n",
       "   '- Patients must have moderately to severely active',\n",
       "   'Moderately to severely active RA patients are defined as those patients meeting the following classification criteria, upon review by a physician, during screening: At least nine tender joints; At least six swollen joints; PLUS (at least one of the following): Morning stiffness, lasting greater than or equal to 45 minutes; Erythrocyte Sedimentation Rate greater than or equal to 28 mm/hour (ESR, to be evaluated at a local laboratory) or C reactive protein (CRP) greater than or equal to 15 mg/dL (to be evaluated at a central laboratory).',\n",
       "   'Patients must have an inadequate response and continue to have moderately to severely active disease while on current or previous treatment with at least one agent from both of the following groups: methotrexate (greater than or equal to 15 mg/week, or maximum tolerated dose) or leflunomide (20 mg/day, or maximum tolerated dose) for at least 12 weeks prior to screening; etanercept ( greater than or equal to 25 mg/2 x week SC, or maximum tolerated dose) for at least 12 weeks prior to screening, infliximab (greater than or equal to 3 mg/kg IV, or maximum tolerated dose) for at least 14 weeks duration prior to screening, or adalimumab (greater than or equal to 40 mg SC every 2 weeks, or maximum tolerated dose) for at least 12 weeks prior to screening. Note: In individual cases or in a country where access to anti TNF agents is limited or anti TNF agents are unavailable, the Investigator should document the reason for lack of availability of this treatment. Those patients who have not been treated with an anti-TNF agent would still be eligible for the study if they have failed treatment with at least two additional DMARDs, besides MTX and/or leflunomide. All patients may have also failed treatment with other biological agents or a protein A column.',\n",
       "   'Patients who are not on oral corticosteroids. OR Patients who have been on a stable dose of oral corticosteroids at a prednisone equivalent dosage greater than or equal to 15 mg/day for at least 4 weeks prior to screening.',\n",
       "   'Patients must have a platelet count greater than or equal to 100,000/cmm.',\n",
       "   \"Female patients must be one of the following: postmenopausal, surgically incapable of bearing children, practicing an acceptable method of birth control (acceptable methods may include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of childbearing potential, she must have a negative urine pregnancy test at screening.\",\n",
       "   'Patients must be able and willing to comply with all study procedures.',\n",
       "   'Patients must be willing to sign an ICF.',\n",
       "   'Patients must be greater than or equal to 18 years of age.',\n",
       "   'Patients must have a body weight greater than or equal to 40 kg (88 lb).'],\n",
       "  'exclusion': ['Patients who have a form of arthritis or arthropathy, other than RA, or any current inflammatory condition that might confound the assessments (e.g., other connective tissue diseases or Lyme disease).',\n",
       "   'Patients who have been enrolled in any investigational therapy study for the treatment of RA within 4 weeks prior to the start of the Treatment Period, or patients who are scheduled to receive investigational therapies or a plasma based apheresis procedure (e.g., a protein A column) for the treatment of RA during the course of the study.',\n",
       "   'Patients unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe chronic obstructive pulmonary disease, severe asthma, renal failure, or hepatic failure.',\n",
       "   'Patients with a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling. Note: Every attempt should be made to enroll patients who have adequate peripheral venous access.',\n",
       "   'Patients who have a known hypersensitivity or allergy to psoralen (methoxsalen).',\n",
       "   'Patients who have a known hypersensitivity or allergy to both heparin and citrate products.',\n",
       "   'Patients who are taking any of the following permitted DMARDs and biological agents and have not been on a stable dose for the specific indicated periods of time prior to screening: MTX for at least 8 weeks; leflunomide for at least 8 weeks; infliximab for at least 14 weeks; etanercept for at least 12 weeks; adalimumab for at least 12 weeks.',\n",
       "   'Patients who are taking any of the following permitted medications and have not been on a stable dose for at least 4 weeks prior to screening: NSAIDs; anakinra; hydroxychloroquine; chloroquine; sulfasalazine; D-penicillamine; gold salts; azathioprine; oral corticosteroids (greater than or equal to 15 mg/day, prednisone equivalent dose).',\n",
       "   'Patients whom the Investigator believes cannot be maintained on stable doses of permitted concomitant RA medications throughout the Treatment Period.',\n",
       "   'Patients who are taking any of the following prohibited medications: cyclophosphamide; chlorambucil; intramuscular (IM) or intravenous (IV) corticosteroid injection(s), within 4 weeks of screening; intra-articular corticosteroid injection(s) > 60 mg prednisone equivalent total dose, within 4 weeks of screening.',\n",
       "   'Patients who have any known malignant disease (other than basal cell carcinoma) currently or within the last 5 years.',\n",
       "   'Patients who have a pre-existing blood dyscrasia such as bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia, or a coagulation disorder.',\n",
       "   'Patients with a persistent or severe infection within 12 weeks of screening.',\n",
       "   'Patients with a history of drug or alcohol abuse within 12 weeks of screening.',\n",
       "   'Patients with impaired hepatic function at screening as shown by abnormal liver function tests (LFT; i.e., aspartate transaminase [AST] or alanine transaminase [ALT] levels > 2 x the upper limit of normal [ULN]).',\n",
       "   'Women who are pregnant or lactating.']},\n",
       " {'nct_id': 'NCT00229541',\n",
       "  'inclusion': ['Rheumatoid arthritis / psoriatic arthritis (expert decision, ACR criteria)',\n",
       "   'Insurant of co-operating health insurance and pension insurance',\n",
       "   'Gainfully employed',\n",
       "   'Eligible to receive a medical in-patient rehabilitation'],\n",
       "  'exclusion': ['Polyarthritis, inflammatory intestinal diseases and diseases of connective tissue',\n",
       "   'Currently work disabled',\n",
       "   'Not able / not willing to co-operate',\n",
       "   'Medical in-patient rehabilitation within past 48 months']},\n",
       " {'nct_id': 'NCT00224562',\n",
       "  'inclusion': ['past or current treatement with TNF-a antagonists',\n",
       "   'either lymphoma severe bacterial infection opportunistic infection Inclusion Criteria for controls:',\n",
       "   \"matched with cases by gender, age (+/- 5 years), underlying disease (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, or psoriasis)\",\n",
       "   'past or current treatement with TNF-a antagonists',\n",
       "   'no lymphoma, severe bacterial infection, opportunistic infection (same as case)'],\n",
       "  'exclusion': ['none']},\n",
       " {'nct_id': 'NCT00928512',\n",
       "  'inclusion': ['Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should have been on MTX for at least 3 months and must currently be treated with a stable dose of MTX (> or =7.5 mg/week',\n",
       "   '< or = 25 mg/week) for at least 4 weeks',\n",
       "   'At Baseline: Disease activity criteria defined by > or = 6 out of 28 tender joints and > or = 6 out of 28 swollen joints WITH either Screening value of hsCRP > or = 10 mg/L OR ESR > or = 28 mm/1st hr Exclusion Criteria:',\n",
       "   'RA patients functional status class IV classified according to the ACR 1991 revised criteria',\n",
       "   'Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)',\n",
       "   'Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00928317',\n",
       "  'inclusion': ['Provision of a valid written informed consent.',\n",
       "   'Male or female subjects ≥ 18 and ≤ 80 years old.',\n",
       "   \"Women of childbearing potential, or men of fathering potential, must be using adequate (in the investigator's opinion) birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilisation) during the study. Female subjects of childbearing potential must test negative for pregnancy prior to enrolling in the study. Post menopausal (cessation of menses for more than 2 years) women are eligible for this study.\",\n",
       "   'Diagnosis of RA according to the revised (1987) American College of Rheumatology criteria for at least 6 months and no longer than 3 years prior to screening.',\n",
       "   'Meet ACR functional class criteria I, II or III.',\n",
       "   'Have active RA at the time of screening and at baseline, defined as ≥ 6 swollen joints and ≥ 6 tender joints (from 68 joint count) together with at least 2 of the following 3 criteria:',\n",
       "   'CRP level ≥ 1.5 mg/dl;',\n",
       "   'ESR by Westergren method ≥ 28 mm in the first hour; or',\n",
       "   'morning stiffness ≥ 45 minutes.',\n",
       "   'At least one of the following should be present at screening:',\n",
       "   'documented history or current presence of positive rheumatoid factor;',\n",
       "   'presence of serum anti-CCP antibodies; or',\n",
       "   'screening radiographic erosion',\n",
       "   'Have been tolerating concomitant methotrexate (oral or subcutaneous) for at least 3 months prior to screening and on a stable dose between 10-25 mg per week for at least 6 weeks prior to the first study dose. The route of administration must also be stable. Use of methotrexate dose of 25-50 mg every 2 weeks is also acceptable. (Other DMARDs taken concomitantly with methotrexate are not allowed. Those subjects concomitantly receiving additional DMARDs with methotrexate may enter the study by stopping the additional DMARD at least 4 weeks prior to first study dose).',\n",
       "   'If using the following medication, the subject must be on a stable dose for the 4 weeks prior to the first study dose and maintain that dose throughout the study:',\n",
       "   'oral corticosteroids, equivalent to ≤ 10 mg of prednisone/day.',\n",
       "   'one nonsteroidal anti-inflammatory drug (NSAID).',\n",
       "   '3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) or fibrates (see Section 7.1 for acceptable doses).',\n",
       "   'Does not have active or latent TB according to eligibility assessment and screening rules (see Section 8.3.1).',\n",
       "   'Is willing and able to comply with study visits and other protocol requirements.'],\n",
       "  'exclusion': ['Pregnant, nursing, or planning a pregnancy (both men and women) within 9 months of enrolment.',\n",
       "   'Subjects weighing > 100 kgs.',\n",
       "   'Screening laboratory tests:',\n",
       "   'hemoglobin ≤ 8.0 gm/dl',\n",
       "   'white blood cells ≤ 3.0 x103 cells/µl',\n",
       "   'neutrophils ≤ 1.5 x 103 cells/µl',\n",
       "   'platelets ≤100 x 103 cells/µl',\n",
       "   'serum transaminase level (AST and ALT) ≥ 2 times upper limit of normal (ULN)',\n",
       "   'serum creatinine ≥ 0.15 mmol/l',\n",
       "   'Subjects with diagnosis of juvenile arthritis or other inflammatory or autoimmune diseases that might confound the evaluations of benefit from ART621 such as ankylosing spondylitis, systemic lupus erythematosus and Lyme disease.',\n",
       "   'Subjects who have previously failed to respond to any oral or injectable anti-TNFα therapy or subjects who have had to stop anti-TNFα therapy for safety reasons. Subjects who have successfully responded to anti-TNFα therapy in the past (but discontinued for reasons other than safety or lack of efficacy) > 6 months prior to study day one may enrol. Patients who have participated in a previous anti-TNFα therapy study are eligible if they are confirmed to have received placebo.',\n",
       "   'Subjects who have previously received the following anti-rheumatic drugs: interleukin-1 receptor antagonist [anakinra], rituximab, anti-CD4 antibody, abatacept, thalidomide, p38 MAP kinase inhibitor and other agents (other than those listed in Section 7.3).',\n",
       "   'Subjects who have undergone plasmapheresis within 6 months prior to randomisation.',\n",
       "   'Have received intraarticular, intramuscular, or intravenous corticosteroids, including intramuscular adrenocorticotropic hormone, during the 4 weeks prior to the first study dose, or non-stable doses of oral steroids.',\n",
       "   'Subjects with a history of any clinically significant adverse reaction to murine or chimeric proteins, including serious allergic reactions.',\n",
       "   \"Subjects with Felty's syndrome or a history of Felty's syndrome.\",\n",
       "   'Subjects who have received or are expecting to receive any live virus or bacterial vaccinations within 1 month before first study dose, during the study, or up to 3 months after the study dose.',\n",
       "   'Subjects with a history of, presence of, or at high risk of serious infection including:',\n",
       "   'history of active TB, or positive Mantoux test or QuantiFERON Gold test or chest x-ray suggestive of active or healed TB or positive contact history with a subject with active TB within the past 3 months. If subjects have a positive Mantoux test but a negative QuantiFERON Gold test, they may be enrolled.',\n",
       "   'a serious infection during the 3 months prior study entry (hospitalised or received IV antibiotics for an infection).',\n",
       "   'chronic or recurrent infectious disease.',\n",
       "   'systemic fungal infections',\n",
       "   'opportunistic infection within 3 months prior to screening (refer to 1993 CDC Classification System for HIV Infection).',\n",
       "   'subjects known, or suspected, to be infected with HIV, hepatitis B, or hepatitis',\n",
       "   '- subjects with planned joint replacement surgery or a history of infected joint prosthesis or who have received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.',\n",
       "   'Subjects with a known history of demyelinating diseases such as multiple sclerosis or optic neuritis.',\n",
       "   'Subjects with evidence of severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatric, or cerebral disease.',\n",
       "   'Concurrent CHF, including medically controlled, asymptomatic CHF or ECG findings suggestive of CHF.',\n",
       "   'Subjects receiving cytotoxic drugs including cyclophosphamide, cyclosporine, or alkylating agents within 6 months prior to first study dose.',\n",
       "   'Known history or evidence of malignancy, lymphoproliferative or neoplastic disease with the exception of successfully treated basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.',\n",
       "   'Subjects who have undergone organ transplant (with exception of a corneal transplant more than 3 months prior to screening).',\n",
       "   'Subjects previously enrolled in this study, currently participating in another investigational study or treated with any investigational drug within the previous 3 months or within 5 half-lives, whichever is greater, prior to first study dose.',\n",
       "   'Any other clinically significant disease or disorder or factors such as substance abuse which in the opinion of the investigator make the subject ineligible for participation in this study.']},\n",
       " {'nct_id': 'NCT00920478',\n",
       "  'inclusion': ['Patients attending Early RA clinics with newly diagnosed RA or anti-CCP +ve Undifferentiated Arthritis (UA)',\n",
       "   'Active disease (DAS28 > 3.2)',\n",
       "   'DMARD naïve or DMARD monotherapy for less than 6 weeks',\n",
       "   'Aged 18 or more'],\n",
       "  'exclusion': ['Significant liver disease and/or abnormality of liver function tests',\n",
       "   'AST / ALT > x2 normal, Alkaline Phosphatase > x2.5 normal',\n",
       "   'Renal impairment',\n",
       "   'serum creatinine > 200 μmol/l, eGFR < 30',\n",
       "   'Cytopenias',\n",
       "   'white cell count < 4.0, haemoglobin < 10, platelet < 150',\n",
       "   'Pregnancy or planned pregnancy',\n",
       "   'Contraindication to MRI',\n",
       "   'Other co-morbid condition that in the opinion of the investigator would preclude the use of sequential or combination DMARD therapy']},\n",
       " {'nct_id': 'NCT00927927',\n",
       "  'inclusion': ['Active rheumatoid arthritis, characterized by a Disease Activity Score (DAS28) above 3.2, and a diagnosis of at least three months duration',\n",
       "   'Aged between 18 and 75 years (both inclusive)',\n",
       "   'Subjects on stable doses of methotrexate for at least 4 weeks prior to dosing',\n",
       "   'Use of highly effective contraception during the trial (both males and females)'],\n",
       "  'exclusion': ['A chronic inflammatory autoimmune or joint disease other than RA (rheumatoid arthritis)',\n",
       "   'An active or latent tuberculosis',\n",
       "   'Any investigational or experimental therapy within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit',\n",
       "   'A known significant cardio-vascular disease',\n",
       "   'Vaccination against live virus or bacteria within 4 weeks prior to randomization',\n",
       "   'The use of concomitant medications that are prohibited in the trial (e.g., certain DMARDs (antirheumatic therapies that are disease modifying), biologics (here: biotechnologically produced antibodies), intra-articular corticoid-injections, etc.)',\n",
       "   'A positive test result for human immunodeficiency virus (HIV) infection, hepatitis B and/or hepatitis C, or tuberculosis skin test',\n",
       "   'Donation of greater than or equal to 400 ml of blood within 8 weeks prior to trial entry']},\n",
       " {'nct_id': 'NCT00925249',\n",
       "  'inclusion': ['Any patient 18 years or older who has been diagnosed with RA (American College of Rheumatology (ACR) criteria) and is being considered for de novo anti-TNF alpha therapy will be invited to participate in this study. Control group:',\n",
       "   'Control subjects will be any patient 18 years or older presenting to the Allergy/Immunology clinic for routine TST.'],\n",
       "  'exclusion': ['We will exclude any individual with a previous history of known immuno-compromising disease state or unstable medical condition other than RA resulting in overall poor health and/or protein calorie deprivation to include:',\n",
       "   'any other autoimmune disease',\n",
       "   'oral steroid use in the past 3 days (4 half-lives of prednisone is 14 hours)',\n",
       "   'inhaled steroid use at a dose of > 2000 mg beclomethasone equivalent/day',\n",
       "   'any cancer [solid organ or blood]',\n",
       "   'radiation therapy in prior three months',\n",
       "   'any bleeding disorders',\n",
       "   'chemotherapeutic agents',\n",
       "   'transfusion or blood products in past 1 year',\n",
       "   'history of HIV',\n",
       "   'chronic hepatitis',\n",
       "   'malignancy',\n",
       "   'transplant history',\n",
       "   'chronic infection',\n",
       "   'chronic renal failure',\n",
       "   'current allergy treatment (shots, antihistamines)',\n",
       "   'uncontrolled diabetes, or the inability to provide informed consent',\n",
       "   'we will also exclude individuals with immediate hypersensitivity to the TST/PPD or PHA antigens',\n",
       "   'a previous severe local ulceration with TST/PPD',\n",
       "   'suspected active TB, previous TB treatment Control group:',\n",
       "   'We will exclude any individual with known history of anti-TNF alpha therapy.',\n",
       "   'We will also exclude any patient with a history of any immune-modulatory (DMARD) therapy (steroids, anti-TNF agents, methotrexate, azathioprine, sulfasalazine, etc.) within the previous 12 months.',\n",
       "   'Additionally we will exclude all those individuals with previous history of TB or TB therapy, diabetes mellitus, HIV, malignancy, or hepatitis that may influence the dermal reaction to PHA antigen or ex vivo CMI activity.']},\n",
       " {'nct_id': 'NCT00924625',\n",
       "  'inclusion': ['English-speaking',\n",
       "   'Age 21 or older',\n",
       "   'Diagnosed with RA for at least 5 years according to the criteria of the American College of Rheumatology',\n",
       "   'Independent ambulator'],\n",
       "  'exclusion': ['History of cardiovascular disease or uncontrolled hypertension (above 140/90 mmHg);',\n",
       "   'History of a quadriceps tendon or patellar tendon rupture;',\n",
       "   'History of previous adverse reaction associated with electrical stimulation treatment;',\n",
       "   'Surgery to the dominant lower extremities within the past 6 months.',\n",
       "   \"History of a neurological disorder that may affect lower extremity function, such as cerebrovascular accident or neuropathy, parkinson's disease, multiple sclerosis, etc.;\",\n",
       "   'History of muscle disease such as muscular dystrophy;',\n",
       "   'Change in medication regimen (excluding NSAID change) during the month prior to treatment;',\n",
       "   'Current use of cholesterol-lowering medication;',\n",
       "   'History of malignancy during the last 5 years, excluding skin cancers other than melanoma;',\n",
       "   'Current or anticipated pregnancy;',\n",
       "   'Less than 70º of passive knee flexion;',\n",
       "   'Are not willing to undergo needle biopsy.',\n",
       "   'Participated in progressive resistance training or NMES training in the prior year;',\n",
       "   'Prior adverse effects with local anesthesia.']},\n",
       " {'nct_id': 'NCT00920608',\n",
       "  'inclusion': ['Patients diagnosed with rheumatoid arthritis',\n",
       "   'Currently on Methotrexate treatment',\n",
       "   'Provision of informed consent'],\n",
       "  'exclusion': ['History of malignancy (except for treated squamous and basal cell carcinoma of the skin more than 5 years prior to entry)',\n",
       "   'Patients who were taking prescription of medications listed below: Medications that are hepatic enzyme inducers and that were inhibitors of cytochrome P450, Lovastatin',\n",
       "   'Leflunomide, hydroxychloroquine, cyclosporin or anti-tumour necrosis factor therapies within 90 days of Visit 1, or treatment with rituximab within 1 year before Visit 1']},\n",
       " {'nct_id': 'NCT00929864',\n",
       "  'inclusion': ['Moderate to severe Rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) criteria',\n",
       "   'Methotrexate failure',\n",
       "   'Naive to RA biologics',\n",
       "   '≤5 years duration of disease',\n",
       "   'Disease Activity Score-28 C-reactive protein (DAS28 CRP) ≥ 3.2',\n",
       "   'Willingness to self-inject subcutaneous (SC) drug'],\n",
       "  'exclusion': ['Previous or current medical conditions that are warnings against the use of tumor necrosis factor (TNF)-blocking agents',\n",
       "   'History of active or chronic hepatitis',\n",
       "   'Cancer in the last 5 years',\n",
       "   'History of severe chronic or recurrent bacterial or viral infections',\n",
       "   'Risk of tuberculosis',\n",
       "   'Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic, Gastro-intestinal, pulmonary, cardiac, neurologic, or cerebral disease']},\n",
       " {'nct_id': 'NCT00929357',\n",
       "  'inclusion': ['Secure diagnosis of rheumatoid arthritis',\n",
       "   'Older than 18 years',\n",
       "   'Two consecutive plain radiographs of the hands and feet with a time interval of 12 to 36 months are available. The radiographs are recorded 2003 or later and are in accordance with a defined X-ray protocol.'],\n",
       "  'exclusion': ['Patients who receive Anakinra, Rituximab or Abatacept']},\n",
       " {'nct_id': 'NCT00965757',\n",
       "  'inclusion': ['Subjects who have a diagnosis of Rheumatoid Arthritis by the ACR criteria',\n",
       "   'Age greater or 20 years and less than 70 years old'],\n",
       "  'exclusion': ['Subject who is considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Women of childbearing potential who are not practicing a successful method of contraception, or wish to become pregnant']},\n",
       " {'nct_id': 'NCT00965653',\n",
       "  'inclusion': ['adults 18',\n",
       "   '75 years of age',\n",
       "   'active rheumatoid arthritis of >/= 6 months duration',\n",
       "   'inadequate response to at least 12 weeks of methotrexate, the last 8 prior to baseline on stable dose',\n",
       "   'swollen joint count (SJC)>/=4, tender joint count (TJC)>/=6 at screening and baseline',\n",
       "   'DMARDs and anti-TNFs, other than methotrexate, withdrawn prior to baseline',\n",
       "   'oral corticosteroids (</= 10mg/day prednisone or equivalent) and NSAIDS on stable dose </= 4 weeks prior to baseline'],\n",
       "  'exclusion': ['rheumatic autoimmune disease other than rheumatoid arthritis',\n",
       "   'prior history or current inflammatory joint disease other than rheumatoid arthritis',\n",
       "   'major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment',\n",
       "   'functional class IV by ACR classification']},\n",
       " {'nct_id': 'NCT00968266',\n",
       "  'inclusion': ['RA according to the 1986 ACR criteria for at least 1 year',\n",
       "   'Prescription of anti-rheumatic medication (DMARDs)',\n",
       "   'Non-adherent patients (Compliance Questionnaire Rheumatology)'],\n",
       "  'exclusion': ['Co-morbidity (physical or psychological) that unables patient to participate in the intervention',\n",
       "   'Illiteracy',\n",
       "   'Inability to communicate in Dutch',\n",
       "   'Participation in other studies with significant burden']},\n",
       " {'nct_id': 'NCT00963703',\n",
       "  'inclusion': ['Patients with documented rheumatoid arthritis by ACR criteria',\n",
       "   'Disease duration < 5 years',\n",
       "   'May have previously been treated with methotrexate,hydroxychloroquine or sulfasalazine, either as a single DMARD or in combination',\n",
       "   'Tender joint count >= 6, swollen joint count >= 6, and one must be a knee',\n",
       "   'Corticosteroids <= 10 mg per day permitted on stable doses for at least 4 weeks',\n",
       "   'Patients must consent to 2 arthroscopic synovial biopsy procedures'],\n",
       "  'exclusion': ['History of severe allergic or anaphylactic reactions to monoclonal antibodies',\n",
       "   'Previous treatment with Rituximab',\n",
       "   'Previous treatment with Arava',\n",
       "   'Injected with steroids within 4 weeks of day 1 of study',\n",
       "   'Treatment with any investigational agent within 4 weeks of day of study',\n",
       "   'Any severe or significant medical condition or disease or known active infection',\n",
       "   'Pregnancy or nursing at present']},\n",
       " {'nct_id': 'NCT00967395',\n",
       "  'inclusion': ['Patients with rheumatoid arthritis in a stable medication the past 3 months written informed consent'],\n",
       "  'exclusion': ['Not able to arrange own transport, language problems']},\n",
       " {'nct_id': 'NCT00969527',\n",
       "  'inclusion': ['Treatment-naive subjects with recent onset rheumatoid arthritis',\n",
       "   'Signed informed consent'],\n",
       "  'exclusion': ['Subjects with rheumatoid arthritis symptoms other than those associated with joints at disease onset',\n",
       "   'Subjects with joint function impairment secondary to other conditions not associated with rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT00966875',\n",
       "  'inclusion': ['You must be between the ages of 18 and 75',\n",
       "   'You must have active RA Qualifications Specific to the bDMARD-naive Population: You must be regularly using methotrexate (MTX) for at least 12 weeks before your participation in this study Qualifications Specific to the TNFα-IR Population:',\n",
       "   'You must have been treated with at least 1 biologic TNFα inhibitor therapy and either had an insufficient response to at least 3 months of treatment OR have been intolerant of such treatment',\n",
       "   'You must be regularly using at least 1 conventional DMARD in a stable treatment regimen'],\n",
       "  'exclusion': ['You are concomitantly using non-steroidal anti-inflammatory drugs (NSAIDS), unless you are on a stable dose within the last 2 weeks',\n",
       "   'You are a woman who is lactating or breast feeding',\n",
       "   'You have donated more than 300 milliliters (mL) of blood within the last month',\n",
       "   'You have received glucocorticoid administered by intra-articular, intramuscular, or intravenous injection or oral corticosteroids at an average daily dose of greater than 10 mg per day of prednisone or its equivalent within the last 4 weeks',\n",
       "   'You had surgery on a joint that is to be assessed in the study within 2 months of study enrollment, or will require such during the study',\n",
       "   'You have another serious disorder or illness',\n",
       "   'You suffered a serious bacterial infection (for example, pneumonia, cellulitis, or bone or joint infections) within the last 3 months',\n",
       "   'You have a history of uncontrolled high blood pressure',\n",
       "   'You have clinical laboratory test results at entry that are outside the normal reference range',\n",
       "   'You are an employee of the clinic or you are an immediate family member of an employee of the clinic. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted',\n",
       "   'You are currently participating in or were discontinued within the last 30 days from another clinical trial involving an investigational drug',\n",
       "   'If you are a woman and you could become pregnant during this study, you must talk to the study doctor about the birth control that you will use to avoid getting pregnant during the study.',\n",
       "   'If you are a post-menopausal woman, you must be at least 45 years of age and have not menstruated for the last 12 months',\n",
       "   'If you are a post-menopausal woman between 40 and 45 years of age, test negative for pregnancy, and have not menstruated during the last 12 months only, you must have an additional blood test to see if you can participate.',\n",
       "   'If you are male, you must agree to reduce the risk of your female partner becoming pregnant during the study. Exclusions Specific to the bDMARD-naive Population:',\n",
       "   'You have received any prior bDMARD therapy such as TNFα, Interleukin (IL)-1, IL-6, T-cell, or B-cell targeted therapies',\n",
       "   'You have had an inadequate response to a minimum of 3 months of treatment with 5 or more conventional DMARDs [such as leflunomide, azathioprine, cyclosporine, etcetera (etc.)]',\n",
       "   'You have used DMARDs other than MTX, hydroxychloroquine, or sulfasalazine within the last 8 weeks',\n",
       "   'You have used leflunomide within the last 12 weeks and have not received cholestyramine to speed up the elimination of leflunomide from your body. Exclusions Specific to the TNFα-IR Population:',\n",
       "   'You are currently using or recently used a bDMARD or a biologic TNFα inhibitor therapy within specified periods',\n",
       "   \"You have had a serious reaction to other biologic DMARDs that, in the study doctor's opinion, puts you at serious risk\",\n",
       "   'You have used cyclosporine or any other immunosuppressive in the 8 weeks before your participation in this study']},\n",
       " {'nct_id': 'NCT00647270',\n",
       "  'inclusion': ['Subject > 18 years of age',\n",
       "   'Subject has a diagnosis of RA as defined by the 1987-revised ACR-classification criteria and has a disease duration for a minimum of three months',\n",
       "   'Subject must meet the following two criteria: a) At least 6 swollen joints out of 66 assessed, or b) At least 6 tender joints out of 68 assessed',\n",
       "   'If a subject is on MTX, the doses must be stable for at least 4 weeks prior to Screening blood draw and follow standard recommendations for MTX treatment',\n",
       "   'Subject is judged to be in generally good health as determined by the principal investigator'],\n",
       "  'exclusion': ['Subject has previous exposure to any systemic anti-TNF therapy (eg, infliximab, etanercept, certolizumab pegol or golimumab) including adalimumab',\n",
       "   'Subject has a history of acute inflammatory joint disease of different origin other than RA',\n",
       "   'Subject has been treated with any investigational biologic agents',\n",
       "   'Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study',\n",
       "   'Female subject who is pregnant or breast-feeding or considering becoming pregnant']},\n",
       " {'nct_id': 'NCT00647920',\n",
       "  'inclusion': ['Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits 6 swollen joints and 9 tender joints.'],\n",
       "  'exclusion': [\"A history of, or current, acute inflammatory joint disease of different origin than RA (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus or any arthritide with onset prior to age 16 years).\"]},\n",
       " {'nct_id': 'NCT00649922',\n",
       "  'inclusion': ['Male/Females at least 20 years of age.',\n",
       "   'Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control.',\n",
       "   'Females have a negative pregnancy test at screening.',\n",
       "   'Diagnosis of RA and met ACR criteria.',\n",
       "   'Must discontinue any TNF at least 2 months prior to baseline.',\n",
       "   'In condition of general good health.'],\n",
       "  'exclusion': ['History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix.',\n",
       "   'History of current acute inflammatory joint disease.',\n",
       "   'Use of TAMIFLU or Symmetrel within 3 months of study drug administration.',\n",
       "   'Recent (3 month) history of influenza or pneumococcal bacterial infection.',\n",
       "   'Known positive human immunodeficiency virus (HIV) status.',\n",
       "   'Positive hepatitis B or hepatitis C virus.',\n",
       "   'Positive PPD >5',\n",
       "   '- Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.']},\n",
       " {'nct_id': 'NCT00641225',\n",
       "  'inclusion': ['Man or nonlactating and nonpregnant woman, aged 18 to 70 years, inclusive, at the screening visit.',\n",
       "   'Must meet criteria for rheumatoid arthritis with functional class I to III.',\n",
       "   'Diagnosis of rheumatoid arthritis more than 6 months before study day 1 and rheumatoid arthritis onset after 16 years of age'],\n",
       "  'exclusion': ['Any significant health problems other than rheumatoid arthritis.',\n",
       "   'Treatment of greater than 10 mg of prednisone per day.',\n",
       "   'Treatment with cyclophosphamide.']},\n",
       " {'nct_id': 'NCT00642629',\n",
       "  'inclusion': ['Male or female 18 years of age or older.',\n",
       "   'Has a diagnosis of RA in conformance with the American College of Rheumatology (ACR) criteria for at least 6 months.',\n",
       "   'Has at least one knee, wrist, or ankle that has active synovitis and is amenable to arthroscopic procedures for the acquisition of synovial tissue via biopsy.',\n",
       "   'Must be taking methotrexate for a minimum of 4 months prior to Day 1, with a stable dose regimen for at least 2 months, and',\n",
       "   'have plans to remain on the stable dose regimen of methotrexate for the duration of this study.',\n",
       "   'If female of childbearing potential, must be neither pregnant nor breast feeding, and',\n",
       "   'must have a negative pregnancy test (serum β-hCG) within 1 week of Day',\n",
       "   'Must be willing to use \"double-barrier\" contraception methods for the duration of the study.'],\n",
       "  'exclusion': ['Is taking any disease-modifying anti-rheumatic drug (DMARD) other than MTX concomitantly or within 1 month prior to Day',\n",
       "   '- A positive (≥10 mm) tuberculin (PPD) skin test, unless the patient has had prior BCG immunization or has received prior suppressive treatment such as 1 year of INH.',\n",
       "   'Has received any investigational drug or experimental procedure for the treatment of RA within 3 months of Day 1 for a biologic compound or within 1 month of Day 1 for a non-biologic compound.',\n",
       "   'Has any clinically significant disease (e.g., renal, hepatic, neurological, cardiovascular, pulmonary, endocrine, psychiatric, hematologic, urologic, or other acute or chronic illness) that, in the opinion of the investigator, would make the patient an unsuitable candidate for this trial.']},\n",
       " {'nct_id': 'NCT00649545',\n",
       "  'inclusion': ['Patient has completed (i.e. not dropped out of) the DE013 study or fulfills criteria 2-12',\n",
       "   'Patients 18 years of age or older',\n",
       "   'Female is either not childbearing, defined as post-menopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or if childbearing potential, practicing an acceptable method of birth control',\n",
       "   'Female of childbearing potential must have a negative serum pregnancy test prior to first dose of adalimumab',\n",
       "   'Diagnosis of active RA defined by >= 5 swollen joints and one of the following:',\n",
       "   'Positive RF',\n",
       "   'One or more joint erosions present of x-ray',\n",
       "   'HAQ score > 1'],\n",
       "  'exclusion': ['Patient has failed 2 or more biologics',\n",
       "   'Patient who had previous treatment with cyclophosphamide and chlorambucil',\n",
       "   'Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibody resulting in presistent CD4 lymphopenia (CD4 lymphocytes +< 500/mm3)',\n",
       "   'History of cancer within the past 10 years unless successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix',\n",
       "   'History of malignant lymphoma or leukemia regardless of treatment']},\n",
       " {'nct_id': 'NCT00647491',\n",
       "  'inclusion': ['Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits >10 swollen joints, >12 tender joints.',\n",
       "   'Subjects must have failed prior treatment with one or more DMARDs.',\n",
       "   'A negative (serum) pregnancy test for all female subjects of child-bearing potential at screening and a negative (urine) pregnancy test prior to study drug administration.',\n",
       "   'Body weight less than or equal to 100 kg'],\n",
       "  'exclusion': ['A history of, or current, acute inflammatory joint disease of different origin from',\n",
       "   '- Prior treatment with any TNF antagonist, including adalimumab.',\n",
       "   'Any ongoing chronic or active infection or any major episode of infection requiring hospitalization or treatment with IV antibiotics.',\n",
       "   'Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke or any poorly controlled medical condition.']},\n",
       " {'nct_id': 'NCT00036153',\n",
       "  'inclusion': ['Willing to discontinue DMARDs, other than methotrexate',\n",
       "   'Has a diagnosis of Rheumatoid Arthritis using American College of Rheumatology Criteria, of at least 6 months duration',\n",
       "   'Have been receiving oral or parenteral methotrexate for at least 3 months'],\n",
       "  'exclusion': ['Has received tacrolimus for any indication',\n",
       "   'Has moderate or severe liver disease',\n",
       "   'Has a known history of HIV infection',\n",
       "   'Has serum creatinine outside the normal range']},\n",
       " {'nct_id': 'NCT00034060',\n",
       "  'inclusion': ['General: Healthy women, or women with RA, 18-55 year old, with a history of regular menses or who are perimenopausal, have a BMI less than 30, able to provide informed consent to all aspects of the study after full information is provided. Women must have a negative pregnancy test at screening. Study participants will be allowed to continue taking medications for chronic, stable conditions, such as hypertension and hypercholesteremia, while in the study. INCLUSION CRITERIA',\n",
       "   \"for RA Patients: Active RA as defined by 9 tender and 6 swollen joints; ESR greater than 35 mm/hr OR CRP greater than 2.0 mg/dL; and, morning stiffness greater than 45 min. Actively menstruating with a normal estrogen level or who are perimenopausal. Women must be practicing, or willing to practice, an acceptable method of birth control that does not involve use of prescription or OTC estrogen/progesterone preparations during the two weeks prior to screening. Acceptable means of contraception include: abstinence, barrier methods with spermicides, intrauterine devices (IUD's) or surgical sterilization. (phase 2 of the study only) Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or hydroxychloroquine are permitted. Drug doses must have been stable for at least one month prior to enrollment, and must be held constant during the study unless toxicity requires dose reduction. Past use of a disease modifying agent (DMARD) such as methotrexate, sulfasalazine and cyclosporine is allowed. EXCLUSION CRITERIA\",\n",
       "   'General: Patients or control subject will be excluded if they exhibit any medical condition that has the potential of placing the candidate at unnecessary risk during the study. Additionally, patients with impaired renal, hepatic, cardiovascular or endocrine-metabolic function, or any immunodeficiency syndrome including HIV infection, will be excluded Use of systemic corticosteroids in the two weeks before screening and study entry. Women with a history of cancer, with the exception of limited, resolved skin cancer. Women who are menopausal. Clinical menopause is defined as the absence of spontaneous menses during the preceding 12 months. Pregnant women or women who are nursing. Use of prescription or OTC estrogen/progesterone preparations during the two weeks prior to screening The patient or control subject has received any investigational drug within 30 days of the start of the study. History of autoimmune endocrinopathy. Serious medical illnesses or abnormal laboratory values that would, in the opinion of the P.I., preclude study participation.'],\n",
       "  'exclusion': ['For RA Patients: BMI greater than or equal to',\n",
       "   'Active infection or other contraindication to use of an anti-TNF agent (phase 2 of the study only). History of untreated tuberculosis, or of a positive PPD without completion of adequate treatment. (phase 2 of the study only) Live vaccinations in the 3 months prior to study (phase 2 of the study only).']},\n",
       " {'nct_id': 'NCT00034203',\n",
       "  'inclusion': ['Clinical diagnosis of moderate to severe rheumatoid arthritis.',\n",
       "   'On stable dose of methotrexate.',\n",
       "   '18 to 80 years of age.',\n",
       "   'Less than 275 lbs.'],\n",
       "  'exclusion': ['Joint replacement surgery within 60 days of the start of drug dosing.',\n",
       "   'Intra-articular cortisone injections within 28 days of the start of drug dosing.',\n",
       "   'Pregnancy.',\n",
       "   'History of severe allergic or anaphylactic reactions.',\n",
       "   'Active bacterial, viral, fungal, mycobacterium tuberculosis.',\n",
       "   'Positive PPD test.',\n",
       "   'History of any opportunistic infection.',\n",
       "   'Serious persisting local or systemic infection.',\n",
       "   'History of malignancy within the past five years.',\n",
       "   'Received any vaccine within 28 days of the start of study drug dosing.',\n",
       "   'Joint replacement therapy planned within nine months of the start of study drug dosing.',\n",
       "   'Chronic disorders apart from RA affecting the joints.',\n",
       "   'Significant systemic involvement secondary to',\n",
       "   '- COPD, asthma, or other pulmonary disease.',\n",
       "   'Received any DMARD other than methotrexate in the 28 days prior to the start of study drug dosing.',\n",
       "   'Approved biologic RA therapy during the 28 days or 7 half-lives of the drug prior to the start of drug dosing.',\n",
       "   'Investigational drug and/or treatment during the 28 days or seven half-lives of the investigational drug prior to the start of study drug dosing.',\n",
       "   'Liver disease or abnormal hepatic function.',\n",
       "   'Serum creatinine level > 1.5 mg/dL.',\n",
       "   'Platelet count < 125,000 cells/mm3.',\n",
       "   'WBC count < 3,500 cells/mm3.',\n",
       "   'Seropositive for hepatitis B surface antigen.',\n",
       "   'Seropositive for hepatitis C antibody.',\n",
       "   'Known seropositivity for HIV.']},\n",
       " {'nct_id': 'NCT00413452',\n",
       "  'inclusion': ['Men and women 18 years of age or older who have RA, as defined by the ACR criteria for classification of RA',\n",
       "   'Naïve to etanercept therapy',\n",
       "   'Able to self-inject investigational product or have a designee who can do so',\n",
       "   'Ethical',\n",
       "   'Before any study-specific procedure, the appropriate written informed consent must be obtained'],\n",
       "  'exclusion': ['Receipt of Corticosteroids> 10 mg/day of prednisone (or its equivalent) during 14 days befor 1st dose of investigational product',\n",
       "   'Receipt of MTX witin 30 days of 1st dose of investigational product',\n",
       "   'Receipt of an other investigational drug within 30 days of 1st dose',\n",
       "   'Receipt of TNF inhibitor therapy within 90 days of 1st dose',\n",
       "   'Receipt of cyclophosphamide within 6 mo of 1st dose',\n",
       "   'Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) greather than the maximum recommended dose in the product info sheet',\n",
       "   'Current use of insulin',\n",
       "   'gnificant concurrent medical condition']},\n",
       " {'nct_id': 'NCT00412256',\n",
       "  'inclusion': ['written informed consent',\n",
       "   'RA according to the ACR criteria',\n",
       "   'active RA (DAS28 > 4.0) at the screening visit',\n",
       "   'insignificant DAS28-change (<0.6) between screening and the first intervention'],\n",
       "  'exclusion': ['age lower than 18 yrs.',\n",
       "   'pregnancy and insufficient birth control',\n",
       "   'lactation',\n",
       "   'army service',\n",
       "   'lack of independence',\n",
       "   'relevant therapeutic or dietary changes during the last three months',\n",
       "   'relevant therapeutic or dietary changes foreseen for the study duration (including surgery)',\n",
       "   'application of Omega-3 fatty acids during the last three months',\n",
       "   'application of Omega-3 fatty acids intended for the study duration',\n",
       "   'prednisolone > 10 mg/day',\n",
       "   'contraindication for Omegaven or Lipovenös (according to the label)']},\n",
       " {'nct_id': 'NCT00411424',\n",
       "  'inclusion': ['meet the American Rheumatism Association (ARA) 1987 revised criteria for the classification of RA (also referred to as the American College of Rheumatology [ACR] criteria);',\n",
       "   'being treated with an adequate dose (to the discretion of the local physicians) of either MTX or leflunomide (LEF)or sulfasalazine (SS2) for at least 4 months prior to baseline of which the last 6 weeks before baseline were at a stable dose;',\n",
       "   'have active poly-arthritis (i.e. active rheumatoid arthritis as defined in detail in the protocol)'],\n",
       "  'exclusion': ['have been treated with any registered or non-registered investigational drug in the context of a clinical intervention study during the last 3 months before baseline;',\n",
       "   'have been treated with TNFα-blockers within a certain period of time (defined for each medication) before baseline;',\n",
       "   'have been treated with any DMARD other than MTX, LEF or SS2 during the last month before baseline;',\n",
       "   'documented evidence for the presence of clinically severe, unstable, or uncontrollable renal, hepatic, respiratory, hematological, genitourinary, cardiovascular, endocrine, neurological, psychiatric, or other medical illness which would, in the opinion of the investigator, put the patient at safety risk or mask measures of efficacy.']},\n",
       " {'nct_id': 'NCT00412399',\n",
       "  'inclusion': ['Patients are eligible if they are:',\n",
       "   'over age 18;',\n",
       "   'meet American Rheumatism Association criteria for rheumatoid arthritis; and',\n",
       "   'are employed for salary or monetary reimbursement.',\n",
       "   'Controls are eligible if they are:',\n",
       "   'over age 18;',\n",
       "   'have no major comorbidity; and',\n",
       "   'are employed for salary or monetary reimbursement.'],\n",
       "  'exclusion': ['Patients and controls are excluded if they:',\n",
       "   'have cognitive deficits and cannot provide informed consent;',\n",
       "   'do not speak English or Spanish; or',\n",
       "   'their physicians do not grant permission to enroll them.']},\n",
       " {'nct_id': 'NCT00609830',\n",
       "  'inclusion': ['Meet American College of Rheumatology criteria for rheumatoid arthritis',\n",
       "   'Taking an oral glucocorticoid equivalent to 5 mg/day of prednisone for at least one month prior to study entry',\n",
       "   'Age 18 or older'],\n",
       "  'exclusion': ['Existing osteoporosis',\n",
       "   'Pregnancy',\n",
       "   'Breast feeding',\n",
       "   'History of breast cancer',\n",
       "   'Physician recommendation to limit calcium intake',\n",
       "   'Class IV rheumatoid arthritis']},\n",
       " {'nct_id': 'NCT00605735',\n",
       "  'inclusion': ['Must have a diagnosis of RA for at least 6 months',\n",
       "   'Must be taking methotrexate for at least 3 months & on a stable dose of 7.5-30 mg weekly) for 4 weeks before dosing with study medication',\n",
       "   'Must have at least 6 swollen and at least 8 tender joints',\n",
       "   'CRP above upper limit of normal or ESR > 28 mm/hr',\n",
       "   'Must wash-out (stop taking) other immunosuppressant medications to treat RA (except for methotrexate) before dosing with study medication'],\n",
       "  'exclusion': ['Any infection including TB, HIV, Hepatitis B or C',\n",
       "   'Recent infection requiring antibiotics within 4 weeks',\n",
       "   'History of gastrointestinal disease (such as GERD, gastrointestinal ulcers, heartburn) requiring medical or surgical treatment within 3 months',\n",
       "   'Chronic use of proton pump inhibitors (such as Losec, Prilosec, Prevacid, Nexium), H2 blockers (such as Tagamet, Pepcid, Zantac, Axid) or antacids (such as Mylanta, Maalox)']},\n",
       " {'nct_id': 'NCT00938587',\n",
       "  'inclusion': ['Patients ≥ 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months',\n",
       "   'On stable dose of methotrexate for at least 6 weeks prior to screening',\n",
       "   'Patient must have minimum disease activity level of ≥ 6 tender/painful joints, ≥ 6 swollen joints and CRP ≥ 0.7 mg/dL',\n",
       "   'Not currently receiving steroid medication'],\n",
       "  'exclusion': ['Pregnant or nursing women',\n",
       "   'Patients that have active infections, TB, HIV and/or Hepatitis B or C',\n",
       "   'Patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids']},\n",
       " {'nct_id': 'NCT00289094',\n",
       "  'inclusion': ['Osteoarthritis',\n",
       "   'Rheumatoid Arthritis',\n",
       "   'Other inflammatory arthritis',\n",
       "   'Avascular necrosis of bone'],\n",
       "  'exclusion': ['Prior ipsilateral TKA',\n",
       "   'Metabolic disorders',\n",
       "   'Joint replacement due to autoimmune disorders']},\n",
       " {'nct_id': 'NCT00289081',\n",
       "  'inclusion': ['Osteoarthritis',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Avascular necrosis (AVN) of bone',\n",
       "   'Other inflammatory arthritis',\n",
       "   'Post-traumatic arthritis',\n",
       "   'Juvenile rheumatoid arthritis'],\n",
       "  'exclusion': ['Prior ipsilateral TKA',\n",
       "   'Metabolic disorders',\n",
       "   'Joint replacement due to autoimmune disorders',\n",
       "   'History of recent/active joint sepsis',\n",
       "   'Charcot neuropathy',\n",
       "   'Psycho-social disorders that would limit rehabilitation',\n",
       "   'Greater than 75 years of age at the time of surgery',\n",
       "   'Severe diabetes mellitus',\n",
       "   'Skeletal immaturity']},\n",
       " {'nct_id': 'NCT00289107',\n",
       "  'inclusion': ['Osteoarthritis',\n",
       "   'Rheumatoid arthritis',\n",
       "   'Other inflammatory arthritis',\n",
       "   'Avascular necrosis (AVN) of bone',\n",
       "   'Post-Traumatic Arthritis',\n",
       "   'Juvenile Rheumatoid Arthritis'],\n",
       "  'exclusion': ['History of recent/active joint sepsis.',\n",
       "   'Charcot neuropathy.',\n",
       "   'Psycho-social disorders that would limit rehabilitation.',\n",
       "   'Greater than 75 years of age at the time of surgery.',\n",
       "   'Prior ipsilateral knee arthroplasty.',\n",
       "   \"Metabolic disorders of calcified tissues, such as Paget's disease.\",\n",
       "   'Severe diabetes mellitus.',\n",
       "   'Joint replacement due to autoimmune disorders.',\n",
       "   'Skeletal immaturity']},\n",
       " {'nct_id': 'NCT00280917',\n",
       "  'inclusion': ['Males and females ages 18-75 years',\n",
       "   'Meet the criteria of the American Rheumatism Association for RA (Arnett FC et',\n",
       "   'Arthritis Rheum 1988;31:315-324, Appendix 1)',\n",
       "   'Not bed- or wheelchair-bound',\n",
       "   'Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND at least one of the following: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory; OR (e) morning stiffness for >=45 minutes',\n",
       "   'Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline',\n",
       "   'Methotrexate route of administration has been unchanged for >=2 months prior to baseline',\n",
       "   'Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose',\n",
       "   'If taking hydroxychloroquine, administration duration has been >=3 months and dose has been stable for >=2 months prior to baseline',\n",
       "   'If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation',\n",
       "   'If taking an oral corticosteroid, dose is <=10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the washout period, and will remain stable through the washout and entire treatment and follow-up period',\n",
       "   'Absence of clinically significant findings, such as interstitial pneumonitis or active pulmonary infection, on chest X-ray taken within 6 months prior to screening'],\n",
       "  'exclusion': ['Receipt of any of the following for at least a 1 month washout period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra',\n",
       "   'Receipt of etanercept for at least a 6 week period prior to dosing',\n",
       "   'Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing',\n",
       "   'Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing',\n",
       "   'Receipt of cyclophosphamide for at least a 6 month period prior to dosing',\n",
       "   'Receipt of rituximab at any previous time',\n",
       "   'Receipt of CF101 in a previous trial',\n",
       "   'Use of oral corticosteroids >10 mg of prednisone, or equivalent, per day',\n",
       "   'Change in NSAID dose level for 1 month prior to dosing',\n",
       "   'Change in oral corticosteroid dose level during the 1 month prior to, or during, the washout period',\n",
       "   'Change in hydroxychloroquine dose level during the 2 months prior to, or during, the washout period',\n",
       "   'Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the washout period',\n",
       "   'Presence or history of uncontrolled asthma',\n",
       "   'Presence or history of uncontrolled arterial hypertension or symptomatic hypotension',\n",
       "   'Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)',\n",
       "   'Hemoglobin level <9.0 gm/L',\n",
       "   'Platelet count <125,000/mm3',\n",
       "   'White blood cell count <3000/mm3',\n",
       "   \"Serum creatinine level outside the laboratory's normal limits\",\n",
       "   \"Liver aminotransferase levels greater than 1.2 times the laboratory's upper limit of normal\",\n",
       "   'Known or suspected immunodeficiency or human immunodeficiency virus positivity',\n",
       "   'Pregnancy, lactation, or inadequate contraception as judged by the Investigator']},\n",
       " {'nct_id': 'NCT00282412',\n",
       "  'inclusion': ['Age > 18 and < 60 years at time of pre-transplant evaluation.',\n",
       "   'An established clinical diagnosis of rheumatoid arthritis by American College of Rheumatology criteria.',\n",
       "   'Patients must have failed an autologous hematopoietic transplant or have failed to respond to either methotrexate or leflunomide in combination with a TNF inhibitor. Failure is defined as an inability to tolerate treatment with at least 6 swollen joints and 20 involved joints or inability to answer at least 70% of HAQ questions with \"no difficulty\" despite 2 or more months of treatment.',\n",
       "   'Ability to give informed consent.',\n",
       "   'Patient must have a HLA matched sibling donor at the A, B, C, and DR loci to proceed or HLA matched cord blood donor.',\n",
       "   'If donor is HLA matched cord blood, cord blood stem cells will be obtained from the NMDP (1-800-548-1375) and one or two units of HLA matched cord blood will be infused on day zero. Participant Exclusion Criteria',\n",
       "   'History of coronary artery disease, or documented congestive heart failure.',\n",
       "   'HIV positive.',\n",
       "   'Uncontrolled diabetes mellitus, or any other illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemoradiotherapy.',\n",
       "   'Prior history of malignancy except localized basal cell or squamous skin cancer. Other malignancies for which the patient is judged to be cured by local surgical therapy, such as head and neck cancer, or stage I breast cancer will be considered on an individual basis.',\n",
       "   'Positive pregnancy test, inability or unwillingness to pursue effective means of birth control, failure to willingly accept or comprehend irreversible sterility as a side effect of therapy.',\n",
       "   'Psychiatric illness or mental deficiency making compliance with treatment or informed consent impossible.',\n",
       "   'FEV1/FVC < 70% of predicted, DLCO < 40% of predicted.',\n",
       "   'Resting LVEF < 45 %.',\n",
       "   'Bilirubin > 2.0 mg/dl (unless due to Gilberts), transferase (AST) > 2.5 x upper limit of normal.',\n",
       "   'Serum creatinine > 2.0 mg/dl. Donor'],\n",
       "  'exclusion': ['Age < 18 years.',\n",
       "   'Positive for HIV-1, HIV-2, HTLV-I, HTLV-II.',\n",
       "   'Active hepatitis B or',\n",
       "   '- History of a malignancy except for a localized cancer such as skin cancer that is deemed cured.',\n",
       "   'History of myocardial infarction or congestive heart failure.',\n",
       "   'Inability to give informed consent.',\n",
       "   'Current pregnancy.']},\n",
       " {'nct_id': 'NCT00282308',\n",
       "  'inclusion': ['Age 18-65 years.',\n",
       "   'Diagnosis of rheumatoid arthritis (RA) for at least 6 months.',\n",
       "   'Receiving treatment for RA on an outpatient basis.',\n",
       "   'Use of methotrexate (MTX) at a dose of 10-25 mg/wk (oral [PO] or subcutaneous [SC]) for at least 12 weeks prior to Day 1, with the dose stable during the last 4 weeks prior to Day 1 (first day of the treatment period).',\n",
       "   'If taking a background corticosteroid, use of the corticosteroid must be for at least 12 weeks prior to Day 1 at a stable dose during the last 4 weeks prior to Day',\n",
       "   '- If taking one non-steroidal anti-inflammatory drug (NSAID), use of a stable dose for at least 2 weeks prior to Day',\n",
       "   ''],\n",
       "  'exclusion': [\"Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA; Sjogren's syndrome with RA is permitted.\"]},\n",
       " {'nct_id': 'NCT00287794',\n",
       "  'inclusion': ['Fulfilling the American College of Rheumatology criteria of rheumatoid arthritis'],\n",
       "  'exclusion': ['Any defined sleep disorders of International Classification of Sleep Disorders (ICSD)']},\n",
       " {'nct_id': 'NCT00283855',\n",
       "  'inclusion': ['18 or more years of age',\n",
       "   'Rheumatoid Arthritis diagnosed by a rheumatologist',\n",
       "   'Stable medication regimen for 3 months'],\n",
       "  'exclusion': ['Previous exposure to arthritis self-management programs',\n",
       "   'Uncontrolled psychiatric comorbidity',\n",
       "   'Uncontrolled medical comorbidity (e.g. active cancer)']},\n",
       " {'nct_id': 'NCT00505089',\n",
       "  'inclusion': ['Male and female patients aged 18',\n",
       "   '75 years (inclusive).',\n",
       "   'Body weight must be between 50 and 100 kg (inclusive).',\n",
       "   'Post-menopausal or surgically sterile female patients. Women of child-bearing potential if already on a stable dose of methotrexate and are practicing effective contraception for at least 3 months prior to screening, have a negative pregnancy test at screening and baseline, and are willing to use 2 forms of contraception including at least 1 barrier method during the study and for at least 2 months following the completion/discontinuation of the study. Male patients must be willing to use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study.',\n",
       "   'Diagnosis of Rheumatoid Arthritis, classified by ARA (American Rheumatism Association) 1987 revised criteria (Appendix 2). Disease duration of at least 6 months prior to randomization is essential.',\n",
       "   'Functional status class I, II or III classified according to the ACR (American College of Rheumatology) 1991 revised criteria (Appendix 3).',\n",
       "   'Active disease at screening and baseline (Day 1 predose) evaluation (same evaluator): ≥ 6 tender and ≥ 6 swollen joints of 28 examined (including any effused joint) and either a) Westergren erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour, or b) C-reactive protein (CRP) ≥ 1.0 mg/dL.',\n",
       "   'Prior treatment with 1-3 disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'Patients should have failed at least 1 DMARD but should not be deemed \"refractory to all therapies\". Patients should be on a current treatment with methotrexate ≤ 25 mg/week and with the current dose stable for at least 3 months. All patients will take folic acid 1 mg daily, or 5 mg weekly post MTX dose, to minimize toxicity, according to local guidelines. In addition to methotrexate, patients may be on either a stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) and/or a stable dose of oral corticosteroids (prednisone or equivalent ≤ 10 mg daily) for at least 4 weeks prior to randomization. Patients who failed any DMARDs will be allowed.',\n",
       "   'Negative purified protein derivative (PPD) tuberculin skin test reaction (PPD 5 tuberculin units or as according to local standard practice).',\n",
       "   'Patients with a total white cell count and platelet count clinically acceptable for patients with RA; hemoglobin must be ≥ 10 g/dL and hematocrit ≥ 30% at screening and baseline. Exclusion Criteria:',\n",
       "   'Previous treatment with anti-TNF-α or anti IL-1 therapy (or other biological therapy), immunosuppressive agents such as cyclosporine, mycophenolate or tacrolimus. The following washout period will be required for such patients to be eligible to participate in the trial.',\n",
       "   '2 months washout prior to screening for etanercept or adalimumab',\n",
       "   '3 months washout prior to screening for infliximab',\n",
       "   '3 months washout prior to screening for rituximab',\n",
       "   '1 month washout prior to screening for cyclosporine, mycophenolate and tacrolimus.',\n",
       "   'If patient has been discontinued from other DMARDs for lack of efficacy or toxicity, the patient should be at least 1 month off the agent and the effects of that agent should have dissipated according to the recognized duration of effect (e.g., sulfasalazine, hydroxychloroquine), or standard washout procedure (cholestyramine for leflunomide). Importantly, discontinuation should not be undertaken only for the purposes of participation in this study.',\n",
       "   'Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within four weeks prior to randomization.',\n",
       "   'Presence of or history of Major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or systemic lupus erythematosus. Renal trauma, glomerulonephritis or patient with one kidney. Patients with congestive heart failure (New York Heart Association class > III), QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded. A positive HIV test result, Hepatitis B surface antigen or Hepatitis C test result. Significant illness within 2 weeks prior to dosing or any active systemic infection or medical condition that may require treatment or therapeutic intervention during the study. Hypersensitivity to any biological agents, serious allergic reaction, collagen disease, neurological disease (including demyelinating disease). Any joint surgery in past 8 weeks or planned surgery within next 5 months. Cancer (other than basal cell cancer or adequately treated carcinoma-in-situ of the cervix). Drug or alcohol abuse within the 12 months prior to dosing or evidence of such indicated by the laboratory assays conducted during the screening or baseline evaluations. Underlying metabolic, endocrine, hematologic, pulmonary, cardiac, blood, renal, hepatic, infectious, psychiatric or gastrointestinal conditions which places the patient at unacceptable risk for participation in a study of an immunomodulatory therapy.',\n",
       "   'Treatment with an investigational agent within 12 weeks prior to enrollment or longer if required by local regulation.',\n",
       "   'Pregnant or breastfeeding women.',\n",
       "   'Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00503139',\n",
       "  'inclusion': ['Patients who are refractory to the treatment.',\n",
       "   'Patients who have never been treated with Enbrel and in whom its long-term therapy may be instituted.',\n",
       "   'Patients without a history of or concurrent malignant tumors.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00508768',\n",
       "  'inclusion': ['Patients with active rheumatoid arthritis',\n",
       "   'Patients on methotrexate are required to have taken a stable methotrexate dose of 15 to 25 mg/week (or lower maximum-tolerated dose level) for at least 1 month before study entry',\n",
       "   'Patients with no methotrexate are required to have taken no methotrexate for at least 1 month before study entry',\n",
       "   'Non steroidal anti inflammatory drugs (NSAIDs) and low-dose prednisone are allowed if doses had been stable for at least 1 month before study entry',\n",
       "   'Patients of childbearing potential must have agreed to practice two forms of birth control for the duration of the trial.'],\n",
       "  'exclusion': ['Have taken infliximab or experimental biological antagonists (e.g., TNF antagonists) within the 3-month period before study entry',\n",
       "   'Have used leflunomide within the 3 month period before study entry',\n",
       "   'Have taken etanercept, anakinra, and disease-modifying anti-rheumatic drugs (DMARDs) other than leflunomide (and methotrexate) within the 4-week period before study entry',\n",
       "   'Received intra-articular, intramuscular, or intravenous (IV) doses of corticosteroids or received oral doses of corticosteroids exceeding 10 mg/day within the 4-week period before study entry',\n",
       "   'Elevated levels (greater than 1.2 times the upper limit of normal) of aspartate transaminase or alanine transaminase within the 6-month period before study entry.']},\n",
       " {'nct_id': 'NCT00503425',\n",
       "  'inclusion': ['Able and willing to give written informed consent and comply with the requirements of the study protocol;',\n",
       "   'Participants with Rheumatoid Arthritis (RA) for at least 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of RA;',\n",
       "   'Receiving treatment on an outpatient basis;',\n",
       "   'Experienced an inadequate response to previous or current treatment with DMARDs because of toxicity or inadequate efficacy;',\n",
       "   'Disease activity score (DAS28) greater than or equal to (>=) 3.2 at screening and baseline visit.',\n",
       "   'Age >= 18 years;',\n",
       "   'Participants of reproductive potential (males and females) using a reliable means of contraception (for example [e.g.] contraceptive pill, intrauterine device, physical barrier);',\n",
       "   'Female participants with childbearing potential',\n",
       "   'a negative urine pregnancy test within two weeks prior to first rituximab treatment. During Re-Treatment',\n",
       "   'Achieved moderate or good response according to the EULAR response criteria during any visit including visits in the post-treatment period;',\n",
       "   'DAS28 >=3.2;',\n",
       "   'The participants has not been withdrawn into the safety follow-up at any time pre or post Week 24;',\n",
       "   \"36 weeks or more have passed since the participant's first rituximab infusion;\",\n",
       "   'No evidence of any new medical condition or laboratory test results;',\n",
       "   'In participants who were known to be positive to hepatitis B core antibody (HBcAb)',\n",
       "   'documented negative hepatitis B viral DNA (HBV-DNA) test and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to (<=) 2.5x upper limit of normal (ULN) within the last 12 weeks;',\n",
       "   'Female participants with childbearing potential',\n",
       "   'a negative urine pregnancy test immediately prior to treatment initiation. Exclusion Criteria:',\n",
       "   \"Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Sjogren's syndrome with RA was permitted;\",\n",
       "   'Functional class IV as defined by the ACR Classification of Functional Status in RA;',\n",
       "   'History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic rheumatic disorder disorder (e.g., inflammatory bowel disease, scleroderma, inflammatory myopathy); Excluded Previous/Concomitant Medications',\n",
       "   'Previous or concurrent treatment with any anti TNF-alpha therapy;',\n",
       "   'Treatment with any investigational agent within 4 weeks of screening;',\n",
       "   'Previous treatment with any cell depleting therapies excluding rituximab, including investigational agents;',\n",
       "   'Immunization with a live vaccine within 4 weeks prior to the baseline visit. Exclusions for General Safety',\n",
       "   'History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies;',\n",
       "   'Significant cardiac or pulmonary disease (including obstructive pulmonary disease).',\n",
       "   'Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders.',\n",
       "   'Known active bacterial, viral, fungal, mycobacterial or other infection (including tuberculosis, or atypical mycobacterial disease, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening;',\n",
       "   'History of recurrent significant infection or history of recurrent bacterial infections;',\n",
       "   'Primary or secondary immunodeficiency (history of, or currently active);',\n",
       "   'Active cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that have been excised and cured);',\n",
       "   'Pregnant women or nursing (breast feeding) mothers;',\n",
       "   'Participants with lack of peripheral venous access; Laboratory'],\n",
       "  'exclusion': ['Positive tests for hepatitis B surface antigen (HBsAg) and/or positive tests for HBcAb associated with detectable HBV-DNA or hepatitis C antibody (HCAb) and hepatitis C viral RNA (HCV-RNA).']},\n",
       " {'nct_id': 'NCT00502853',\n",
       "  'inclusion': ['adult patients, 18-75 years of age;',\n",
       "   'rheumatoid arthritis for >=3 months and <=10 years;',\n",
       "   'inadequate response to methotrexate (12.5-25mg/week) for >=3 months;',\n",
       "   'evidence of erosive disease and/or clinical synovitis in a signal joint.'],\n",
       "  'exclusion': ['autoimmune rheumatic diseases other than RA;',\n",
       "   'surgical operations on bones/joints in 12 weeks prior to baseline visit;',\n",
       "   'concomitant treatment with biologic agents;',\n",
       "   'previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.']},\n",
       " {'nct_id': 'NCT00506896',\n",
       "  'inclusion': ['Rheumatoid Arthritis diagnosed for more than 6 months',\n",
       "   '18 and 65 years',\n",
       "   'Functional class II or III according to the ACR criteria',\n",
       "   'VAS for knee pain higher than 5',\n",
       "   'Use of stable doses of oral corticosteroid for the last 30 days',\n",
       "   'Use of stable doses of DMARDs for the last 3 months',\n",
       "   'Active synovitis at least in one knee for at least the 30 days'],\n",
       "  'exclusion': ['Non-controlled diabetes mellitus or hypertension',\n",
       "   'Bacterial infection of any site',\n",
       "   'Blood coagulation disorders',\n",
       "   'Skin lesion on the affected knee',\n",
       "   'History of previous surgical procedure in the knee',\n",
       "   'Use of intra-muscular glucocorticoid in the last 30 days',\n",
       "   'Intra-articular injection in the last 3 months',\n",
       "   'Knee injection in the last 6 months']},\n",
       " {'nct_id': 'NCT00504777',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'active rheumatoid arthritis;',\n",
       "   'receiving outpatient treatment;',\n",
       "   'an inadequate response, or intolerance, to >=1 anti-TNF agent.'],\n",
       "  'exclusion': ['other rheumatic autoimmune disease or inflammatory joint disease;',\n",
       "   'concurrent treatment with any anti-TNF-alpha therapy;',\n",
       "   'joint or osseous surgery during 8 weeks prior to recruitment.']},\n",
       " {'nct_id': 'NCT00502996',\n",
       "  'inclusion': ['adult patients, >=18 years of age;',\n",
       "   'rheumatoid arthritis >=6 months;',\n",
       "   'lack of response to 1-5 DMARDs or biological agents;',\n",
       "   'rheumatoid factor positive.'],\n",
       "  'exclusion': ['other chronic inflammatory articular disease or systemic rheumatic disease;',\n",
       "   'joint or bone surgery during 8 weeks prior to randomization;',\n",
       "   'previous treatment with any cell-depleting therapy.']},\n",
       " {'nct_id': 'NCT00502840',\n",
       "  'inclusion': ['adult patients with rheumatoid arthritis who participated in ML19070, and have completed the week 24 visit;',\n",
       "   'eligible for re-treatment (DAS28 >2.6 after week 24, swollen joint count >=4, tender joint count >=4).'],\n",
       "  'exclusion': ['patients who have withdrawn from treatment in ML19070 pre-week 16;',\n",
       "   'patients with a previous response in DAS28 <0.6 to MabThera after week 16;',\n",
       "   'concurrent treatment with any DMARD except for methotrexate, any TNF alpha inhibitor, or other biologic or investigational agent.']},\n",
       " {'nct_id': 'NCT00502424',\n",
       "  'inclusion': ['Rheumatoid arthritis classified according to the ACR criteria.',\n",
       "   'Use of the same remissive drugs for at least 6 months before the intervention and the same doses of the same corticosteroids and nonsteroidal anti-inflammatory drugs for at least one month before the study.',\n",
       "   'A score ≥ 3 and ≤ 7 on a visual analog scale (VAS) for pain in the more aching hand.',\n",
       "   'Agreement to participate in the study, and signing of a free informed consent form.'],\n",
       "  'exclusion': ['Presented deformities in the more aching hand that did not permit fabrication of the splint.',\n",
       "   'Patients using any other type of upper limb splint.',\n",
       "   'Patients with a surgery scheduled within 6 months after the study.',\n",
       "   'Patients allergic to the splint material.',\n",
       "   'Patients with mental deficiency.',\n",
       "   'Patients who lived in inaccessible areas.']},\n",
       " {'nct_id': 'NCT00504595',\n",
       "  'inclusion': ['Male and female patients aged 18',\n",
       "   '75 years (inclusive).',\n",
       "   'Body weight between 50 and 100 kg (inclusive).',\n",
       "   'Post menopausal or surgically sterile female patients are allowed. Female patients of child-bearing potential may participate if they are already on a stable dose of methotrexate. Additional birth control details to be provided at screening. Male patients must use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study.',\n",
       "   'Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria. Disease duration of at least 6 months is essential.',\n",
       "   'Functional status class I, II or III classified according to the American College of Rheumatology 1991 revised criteria.',\n",
       "   'Active disease evaluation (≥ 6 tender and ≥ 6 swollen joints)',\n",
       "   'Prior treatment with 1-3 disease-modifying anti-rheumatic drugs (DMARDs)',\n",
       "   'Patients should have failed at least 1 DMARD but should not be deemed \"refractory to all therapies\". It is expected that patients are on a current treatment with methotrexate ≤ 25 mg/week and with the current dose stable for at least 3 months, however patients who did not tolerate MTX may also be considered. All patients will take folic acid 1 mg daily, or 5 mg weekly post MTX dose, to minimize toxicity, according to local guidelines. In addition to methotrexate, patients may be on either a stable dose of non-steroidal anti-inflammatory drugs (NSAIDs) and/or a stable dose of oral corticosteroids (prednisone or equivalent ≤ 10 mg daily) for at least 4 weeks prior to randomization. Patients who failed any DMARDs will be allowed.',\n",
       "   'Negative purified protein derivative (PPD) tuberculin skin test reaction (PPD 5 tuberculin units or as according to local standard practice). Exclusion Criteria: RA patients:',\n",
       "   'Previous treatment with anti-Tumor Necrosis Factor (TNF)-α or anti IL-1 therapy (or other biological therapy), immunosuppressive agents such as cyclosporine, mycophenolate or tacrolimus. The following washout period will be required for such patients to be eligible to participate in the trial.',\n",
       "   '2 months washout prior to screening for etanercept or adalimumab',\n",
       "   '3 months washout prior to screening for infliximab',\n",
       "   '3 months washout prior to screening for rituximab',\n",
       "   '1 month washout prior to screening for cyclosporine, mycophenolate and tacrolimus.',\n",
       "   'If patient has been discontinued from other DMARDs (disease modifying antirheumatic drugs) for lack of efficacy or toxicity, the patient should be at least 1 month off the agent.',\n",
       "   'Patients with congestive heart failure, QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded.',\n",
       "   'Patients who have received intra-articular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4 weeks prior to randomization.',\n",
       "   'Exclusion criteria 2-6 of the Health Volunteer section also applies here. Other protocol-defined inclusion/'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00296257',\n",
       "  'inclusion': ['Male or female patients aged at least 18 years, with RA for a minimum of 6 months',\n",
       "   'Has been receiving methotrexate treatment (stable for 8 weeks)',\n",
       "   'Has active disease classified as ACR functional class of I, II or III'],\n",
       "  'exclusion': ['Has previously discontinued DMARD therapy due to hepatic intolerance',\n",
       "   'Has received any DMARD in addition to methotrexate during the 4 weeks prior to randomisation',\n",
       "   'Is receiving more than 2 DMARDs in addition to methotrexate at the time of screening',\n",
       "   'Is receiving or has received Gold, leflunomide or biological agents including TNF/IL-1 inhibitors within the 8 weeks prior to randomisation',\n",
       "   'Has previously failed 2 or more DMARDS']},\n",
       " {'nct_id': 'NCT00292422',\n",
       "  'inclusion': ['Must give written informed consent. If required by local law, candidates must also authorize the release and use of protected health information (PHI).',\n",
       "   'Male or female subjects aged 18 to 75 years old, inclusive, at the time informed consent is given.',\n",
       "   'Must have a diagnosis of RA Functional Class I-III according to the 1987 Revised American Rheumatism Association Criteria for the Classification of Rheumatoid Arthritis for at least 6 months prior to baseline.',\n",
       "   'Must have been treated with MTX (>=10 mg/week to <=25 mg/week) for at least 3 months immediately prior to enrollment. The dose of MTX must be stable for at least 4 weeks prior to Day',\n",
       "   '- Must have active disease at Screening defined as SJC >=5 (66 joint count) and TJC >=5 (68 joint count).',\n",
       "   'All DMARDs, other than MTX or hydroxychloroquine sulfate, must be withdrawn at least 4 weeks prior to Day 0 (8 weeks for infliximab, adalimumab, and leflunomide).',\n",
       "   'Male and female subjects of child-bearing potential must be willing to practice effective birth control for the duration of the study. Female subjects must be: (1) postmenopausal for at least 12 months, (2) surgically sterile, or (3) willing to use 2 documented forms of birth control (e.g., barrier and spermicide, intrauterine device and barrier or spermicide, or birth control pill and barrier or spermicide).',\n",
       "   'Subjects must be willing and able to complete all planned study procedures.'],\n",
       "  'exclusion': ['Subjects with a history of a malignancy or carcinoma in situ (subjects with a history of excised or treated basal cell carcinoma are eligible to participate in this study).',\n",
       "   'Moles or lesions currently undiagnosed, but suspicious for malignancy.',\n",
       "   'Subjects with a history of clinically significant (as determined by the Investigator) cardiac, allergic, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal or hematologic insufficiency or major disease.',\n",
       "   \"Subjects with rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome is permitted.\",\n",
       "   'Serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within 3 months prior to Day',\n",
       "   '- History of recurrent significant infections.',\n",
       "   'Primary or secondary immunodeficiency (history of or currently active).',\n",
       "   'History of tuberculosis or positive purified protein derivative (PPD; positive Mantoux test defined as ³10 mm of induration [size of raised bump, not redness]) test during the screening period. Subjects whose PPD induration is >=5 mm but <10 mm are eligible for the study if they have a negative chest X-ray during the screening period.',\n",
       "   'Fever (body temperature >38°C) or symptomatic viral infection or bacterial infection within 2 weeks prior to Day',\n",
       "   '- Receipt of live vaccine within 4 weeks prior to Day',\n",
       "   '- Clinically significant chest X-ray abnormality within 3 months prior to Screening.',\n",
       "   'Current or prior treatment with more than 1 anti-TNF agent (etanercept, infliximab, or adalimumab) or other approved or investigational biologic agent for the treatment of',\n",
       "   '- Previous treatment with an anti-a4 integrin antibody within the last 6 months.',\n",
       "   'Anti-TNF therapy with infliximab or adalimumab within 8 weeks or etanercept within 4 weeks prior to Day',\n",
       "   '- Treatment with another investigational drug within the 3 months prior to Day 0 or within 5 half-lives of the agent, which ever is longer.',\n",
       "   'If the subject has previously received cell-depleting therapies, relevant cell counts must have returned to normal.',\n",
       "   'Subjects will be excluded who meet any of the following criteria regarding treatment with concomitant therapy for RA:',\n",
       "   'Concomitant use of an oral steroid exceeding 10 mg/day of prednisone (or equivalent dose) or, if 10 mg/day or less, was not administered at a stable dose for at least 4 weeks prior to Day',\n",
       "   '- Concomitant use of an NSAID that was not administered at a stable dose for at least 2 weeks prior to Day',\n",
       "   '- Concomitant use of hydroxychloroquine sulfate at >400 mg/day or not administered at a stable dose for 4 weeks prior to Day',\n",
       "   '- Concomitant use of other anti-arthritic treatments, including approved or experimental oral or topical agents, within 4 weeks prior to Day',\n",
       "   '- Intra-articular corticosteroid injections within 4 weeks prior to Day',\n",
       "   '- Previous exposure to BG9924.',\n",
       "   'Subjects will be excluded who underwent any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement), within 12 weeks prior to baseline or who are planning such a procedure within 16 weeks after randomization.',\n",
       "   'Subjects with any laboratory test result at Screening considered clinically significant (as determined by the Investigator) or',\n",
       "   'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN) established by the central laboratory',\n",
       "   'Platelet count <150,000/μL',\n",
       "   'Hemoglobin <8.5 g/dL',\n",
       "   'Neutrophil count <1.5-10^3/μL',\n",
       "   'Positive for hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV; it is recognized that HIV testing may not be permitted at all sites).',\n",
       "   'Nursing mother, pregnant women and women who are planning to become pregnant while in the study.',\n",
       "   'Blood donation (1 unit or more) within 1 month prior to screening.',\n",
       "   'History of drug or alcohol abuse (as determined by the Investigator) within 1 year prior to Day',\n",
       "   '- Current enrollment in any other investigational drug study.',\n",
       "   'Previous participation in this study.',\n",
       "   'Subjects who are expected to be unavailable for the duration of the trial, likely to be noncompliant with the protocol, or who are felt to be unsuitable by the Investigator/Sponsor for any other reason.',\n",
       "   'Other unspecified reasons that, in the opinion of the Investigator/Sponsor, make the subject unsuitable for enrollment.']},\n",
       " {'nct_id': 'NCT00298272',\n",
       "  'inclusion': ['Must give written informed consent. If required by local law, candidates must also authorize the release and use of protected health information (PHI).',\n",
       "   'Male or female participants, between 18 and 65 years of age, who have a diagnosis of active RA for at least 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis (RA).',\n",
       "   'Must have at least 5 tender and 5 swollen joints at Screening and Day',\n",
       "   '4. Must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week) or adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day',\n",
       "   '5. Must have been treated with methotrexate (MTX) greater than or equal to 15 mg per week and less than or equal to 25 mg per week (dose may be as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks.',\n",
       "   'Must be willing to receive oral folate.',\n",
       "   'Oral glucocorticoids must not exceed 10 mg per day of prednisone (or equivalent dose) and must have been administered at a stable dose for at least 4 weeks prior to Day',\n",
       "   '8. Any concomitant non-steroidal antiinflammatory drugs (NSAIDs) must be stable for at least 2 weeks prior to Day',\n",
       "   '9. For participants of reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, intrauterine device, physical barrier) throughout study participation.'],\n",
       "  'exclusion': [\"Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis, or Felty's syndrome). Secondary Sjögren's syndrome or secondary limited cutaneous vasculitis with RA is permitted.\",\n",
       "   'Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.',\n",
       "   'History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus [SLE], inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or any overlap syndrome).',\n",
       "   'Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA, and/or RA before age',\n",
       "   'Exclusions Related to General Health',\n",
       "   'Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization.',\n",
       "   'Lack of peripheral venous access.',\n",
       "   'Pregnancy or breast feeding.',\n",
       "   'Significant cardiac or pulmonary disease (including obstructive pulmonary disease).',\n",
       "   'History of chronic heart failure (CHF), SLE-like syndrome, neuropathy or myelitis, optic neuritis, or pancytopenia while on etanercept or adalimumab.',\n",
       "   \"Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the investigator's opinion, would preclude subject participation.\",\n",
       "   'Primary or secondary immunodeficiency (history of, or currently active), including known history of human immunodeficiency virus (HIV) infection.',\n",
       "   'Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV anti infectives within 4 weeks of Day 1 or completion of oral anti infectives within 2 weeks of Day',\n",
       "   '22. History of positive purified protein derivative (PPD) not adequately treated.',\n",
       "   'History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis) within 52 weeks of Day',\n",
       "   '24. History of serious infection or opportunistic infection in the last 2 years (to screen for a chest infection, a chest radiograph will be performed at Screening if one was not performed within 12 weeks prior to Screening).',\n",
       "   'History of seizures.',\n",
       "   'History of cancer, including solid tumors, hematologic malignancies, and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured).',\n",
       "   'Any neurological (congenital or acquired), vascular, or systemic disorder that might affect any of the efficacy assessments, in particular, joint pain and swelling (e.g., Parkinsons disease, cerebral palsy, diabetic neuropathy).',\n",
       "   'Currently active alcohol or drug abuse or history of alcohol or drug abuse (as determined by the Investigator) within 1 year prior to Day',\n",
       "   'Exclusions Related to Medications',\n",
       "   'History of a severe allergic or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of rituximab or to murine proteins.',\n",
       "   'Previous treatment with an anti alpha 4 integrin agent or costimulation modulator.',\n",
       "   'Concurrent treatment with any biologic agent other than etanercept or adalimumab, or disease-modifying anti-rheumatic drug (DMARD) other than MTX. Treatment with any biologic or DMARD except etanercept or adalimumab, and MTX must be discontinued 14 days prior to baseline, except for the following: azathioprine for 28 days; leflunomide for 8 weeks (or 14 days after 11 days of standard cholestyramine or activated charcoal washout).',\n",
       "   'Previous treatment with any cell depleting therapies, including investigational agents (e.g., Campath [alemtuzumab], anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti CD11a, anti-CD22, B lymphocyte stimulator/B-cell activating factor [BLys/BAFF], and anti-CD20).',\n",
       "   'Treatment with another investigational drug within 4 weeks prior to Day 1 or 5 half lives of the investigational drug (whichever is the longer).',\n",
       "   'Receipt of a live/attenuated vaccine within 4 weeks prior to Day',\n",
       "   '35. Intra-articular or parenteral glucocorticoids within 4 weeks prior to Day',\n",
       "   '36. Intolerance or contraindications to IV glucocorticoids. Exclusions Related to Laboratory Findings',\n",
       "   'For women of childbearing potential, a positive serum pregnancy test at screening and/or a positive urine pregnancy test on Day',\n",
       "   '38. Positive hepatitis B surface antigen (HBsAg).',\n",
       "   'Positive hepatitis B core antibody (HBcAb) associated with positive hepatitis B viral DNA (HBV DNA).',\n",
       "   'Positive hepatitis C antibody.',\n",
       "   'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 times upper limit of normal.',\n",
       "   'Hemoglobin <8.0 g/dL.',\n",
       "   'Levels of immunoglobulin G (IgG) and/or immunoglobulin M (IgM) below 5.0 and 0.4 mg/mL, respectively.',\n",
       "   'Absolute neutrophil count (ANC) <1500/mL. Miscellaneous Exclusions',\n",
       "   'Current enrollment in any other investigational or other drug study.',\n",
       "   'Treatment with IV Gamma Globulin or the Prosorba® Column within 6 months of the Screening visit.']},\n",
       " {'nct_id': 'NCT00299104',\n",
       "  'inclusion': ['Adult patients 18-80 years of age',\n",
       "   'RA for ≥ 2 months;',\n",
       "   'Receiving outpatient treatment',\n",
       "   'Patients naive to, and considered to be candidates for, methotrexate treatment'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA',\n",
       "   'Inflammatory joint disease other than RA, or other systemic autoimmune disorder',\n",
       "   'Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16',\n",
       "   'Surgery within 12 weeks of study',\n",
       "   'Previous treatment with any approved or investigational biologic agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy',\n",
       "   'Concurrent treatment with any biologic agent or DMARD other than methotrexate']},\n",
       " {'nct_id': 'NCT00299130',\n",
       "  'inclusion': ['Adult patients 18-80 years of age.',\n",
       "   'Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis.',\n",
       "   'Receiving outpatient treatment for',\n",
       "   '- Swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68 joint count) at screening and baseline.',\n",
       "   'At screening, either',\n",
       "   'C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or',\n",
       "   'Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour.',\n",
       "   'Inadequate response to methotrexate, having received and tolerated at a dose of 10-25 mg/week it for ≥ 12 weeks.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to',\n",
       "   '- Inflammatory joint disease other than RA, or other systemic autoimmune disorder.',\n",
       "   'Diagnosis of juvenile rheumatoid arthritis, or RA before the age of',\n",
       "   '- Surgery within 12 weeks of study or planned within 24 weeks of randomization.',\n",
       "   'Previous treatment with any approved or investigational biological agent for RA, an anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy.']},\n",
       " {'nct_id': 'NCT00293826',\n",
       "  'inclusion': ['Subjects with active rheumatoid arthritis as diagnosed by meeting ACR classification criteria for at least 6 months.',\n",
       "   'Must be taking MTX consecutively for >/= 12 weeks and at a stable dose of methotrexate at 15-25 mg weekly for at least 4 weeks prior to screening'],\n",
       "  'exclusion': ['Receipt of commercial or experimental biologic therapies for the treatment of inflammatory disease',\n",
       "   'Presence of serious infection',\n",
       "   'Class IV rheumatoid arthritis',\n",
       "   'Prior or current history of tuberculosis infection or exposure',\n",
       "   'Any other DMARDs other than methotrexate within 6 weeks of screening',\n",
       "   'Pregnant or nursing',\n",
       "   'Receipt of live vaccines within 3 months',\n",
       "   \"Felty's syndrome\"]},\n",
       " {'nct_id': 'NCT00870467',\n",
       "  'inclusion': ['Rheumatoid arthritis based on the American College of Rheumatology criteria',\n",
       "   'Methotrexate or leflunomide naïve',\n",
       "   'Disease duration less than or equal to 2 years from diagnosis'],\n",
       "  'exclusion': ['History of acute inflammatory joint disease of different origin from rheumatoid arthritis, cancer, lymphoma, leukemia or lymphoproliferative disease, active TB, HIV',\n",
       "   'Previously received anti-TNF therapy anti-IL-6 receptor antibody, CTLA4-Ig, anti-CD20 antibody, cyclophosphamide, cyclosporine, azathioprine, or tacrolimus',\n",
       "   'Joint surgery involving joints to be assessed within 8 weeks prior to Screening']},\n",
       " {'nct_id': 'NCT00706797',\n",
       "  'inclusion': ['Meet the 1987 ACR Revised Criteria for Rheumatoid Arthritis.',\n",
       "   'Documented evidence, confirmed by a blinded 3rd party assessor, of at least one erosion observed by X-ray at randomization based on X-ray taken at the screening visit.',\n",
       "   'Have received MTX as stable dose for 28 days prior to the screening visit.'],\n",
       "  'exclusion': ['Previous treatment with ETN, infliximab, adalimumab, other Tumor necrosis factor (TNF) -a inhibitors, anakinra or other biological agents.',\n",
       "   'Receipt of any DMARD, other than MTX, within 28 days before screening.']},\n",
       " {'nct_id': 'NCT00705289',\n",
       "  'inclusion': ['Subject has been diagnosed with RA',\n",
       "   \"Physician has decided, with the subject's consent, to begin treatment with infliximab\",\n",
       "   'Written informed consent form signed by both the subject and the physician.'],\n",
       "  'exclusion': ['Subjects who have previously been exposed to infliximab']},\n",
       " {'nct_id': 'NCT00579644',\n",
       "  'inclusion': ['Age over or equal to 19 years old and less than or equal to 75 years old',\n",
       "   'Diagnosis of RA as determined by fulfilling 4 of 7 ACR criteria',\n",
       "   'Positive rheumatoid factor',\n",
       "   'Duration of disease: greater than six weeks and less than one year'],\n",
       "  'exclusion': ['Allergy to tetracycline or methotrexate',\n",
       "   'Previous DMARD treatment',\n",
       "   'Doses of oral steroids greater than 7.5 mg/day',\n",
       "   'Intra-articular injections within the last four weeks',\n",
       "   'Significant liver or renal disease or active peptic ulcer disease',\n",
       "   'Patients who are not willing to abstain from alcohol consumption',\n",
       "   'Women of childbearing potential who are not practicing a successful method of contraception']},\n",
       " {'nct_id': 'NCT00579059',\n",
       "  'inclusion': ['Painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more compartments are involved.',\n",
       "   'Correction of varus, valgus, or posttraumatic deformity.',\n",
       "   'Correction or revision of unsuccessful osteotomy, arthrodesis, or failure of previous joint replacement procedure. Patient selection factors to be considered include:',\n",
       "   'need to obtain pain relief and improve function,',\n",
       "   'ability and willingness of the patient to follow instructions, including control of weight and activity level,',\n",
       "   'a good nutritional state of the patient,',\n",
       "   'the patient must have reached full skeletal maturity.',\n",
       "   'Porous coated knee joint replacement prostheses have not been approved for non-cemented applications in the United States.'],\n",
       "  'exclusion': ['infection,',\n",
       "   'sepsis',\n",
       "   'osteomyelitis. Relative contraindications include:',\n",
       "   'uncooperative patient or patient with neurologic disorders who are incapable of following directions,',\n",
       "   'Osteoporosis,',\n",
       "   'metabolic disorders which may impair bone formation,',\n",
       "   'osteomalacia,',\n",
       "   'distant foci of infections which may spread to the implant site,',\n",
       "   'rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram,',\n",
       "   'vascular insufficiency, muscular atrophy, neuromuscular disease,',\n",
       "   'incomplete or deficient soft tissue surrounding the knee.']},\n",
       " {'nct_id': 'NCT00578565',\n",
       "  'inclusion': ['Diagnosis of RA according to the revised 1987 American Rheumatism Association criteria',\n",
       "   'Absence of clinical features suggesting infection, neoplasm, sarcoidosis, interstitial lung disease other than UIP or NSIP, other collagen vascular disease, or exposure to known fibrogenic drugs or environmental factors',\n",
       "   'Diagnosis of progressive interstitial pneumonia of UIP or NSIP subtype, based on the following criteria',\n",
       "   'Clinical symptoms consistent with interstitial lung disease with onset between 3 months and 36 months prior to screening.',\n",
       "   'Worsening as demonstrated by any one of the following within the past year:',\n",
       "   '> 10% decrease in Forced Vital Capacity (FVC)',\n",
       "   'increasing infiltrates on chest X-ray or High Resolution Computed Tomography (HRCT), or worsening dyspnea at rest or on exertion',\n",
       "   'Diagnosis of UIP or NSIP by either of the following:',\n",
       "   'Open or video-assisted thoracic surgery (VATS) lung biopsy showing definite or probable UIP or NSIP',\n",
       "   'HRCT scan showing definite or probable UIP or NSIP AND abnormal pulmonary function tests (reduced FVC or decreased diffusing capacity of carbon monoxide (DLco) or impaired gas exchange at rest or with exercise) AND insidious onset of otherwise unexplained dyspnea or exertion and bibasilar, inspiratory crackles on auscultation',\n",
       "   'FVC > 50% of predicted value at Screening',\n",
       "   'DLco >30% of predicted value at Screening',\n",
       "   'No change of disease-modifying anti-rheumatic drug (DMARD) treatment within the last 3 months'],\n",
       "  'exclusion': ['History of clinically significant environmental or drug exposure known to cause pulmonary fibrosis.',\n",
       "   'Forced expiratory volume in one second (FEV1) FEV1/FVC ratio < 0.6 at screening (pre- or post-bronchodilator).',\n",
       "   'Residual volume > 120% predicted at Screening',\n",
       "   'Evidence of active infection',\n",
       "   'Any pulmonary condition other than UIP/NSIP, which, in the opinion of the site principal investigator, is likely to result in the death of the patient within the next year',\n",
       "   'History of unstable or deteriorating cardiac or neurologic disease',\n",
       "   'Pregnancy or lactation',\n",
       "   'Treatment with cyclophosphamide, cyclosporine, interferon gamma or beta, anti-tumor necrosis factor therapy, anti-interleukin 1 (IL1) therapy or with endothelin receptor blockers within the last 8 weeks; experimental therapy for rheumatoid arthritis',\n",
       "   'Creatinine > 1.5 X upper limit of normal range (ULN) at Screening',\n",
       "   'Hematology outside of specified limits: white blood cell (WBC) < 2,500/mm^3 or absolute neutrophil count (ANC) < 1500',\n",
       "   'Hematocrit < 27% or > 59%, platelets < 100,000/mm^3 at screening',\n",
       "   'Positive hepatitis B or C serology',\n",
       "   'Any medical condition, which in the opinion of the site principal investigator, may be adversely affected by the participation in this study',\n",
       "   'History of recurrent significant infection or history of recurrent bacterial infections',\n",
       "   'Known active bacterial, viral fungal mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening',\n",
       "   'Abnormal neurological examination reflective of central nervous disease, including paresis, cognitive impairment and problems with coordination',\n",
       "   'Current enrollment in another clinical trial',\n",
       "   'Fever (>99.5º F)',\n",
       "   'History of previous rituximab administration',\n",
       "   'Receipt of any vaccine, particularly live viral vaccines, within 4 weeks of first study dose',\n",
       "   'Decreased Immunoglobulin G (IgG) and Immunoglobulin M (IgM) levels (below lower limit of normal range)',\n",
       "   'Present or past malignancy',\n",
       "   'History of severe allergic or anaphylactic reaction to administration of humanized or murine monoclonal antibodies',\n",
       "   'Positive human immunodeficiency virus (HIV) serology']},\n",
       " {'nct_id': 'NCT00578305',\n",
       "  'inclusion': ['Adult patients, 18-80 years of age.',\n",
       "   'Active rheumatoid arthritis for ≥ 3 months and ≤ 10 years.',\n",
       "   'Evidence of erosive disease and/or clinical synovitis in a signal joint.',\n",
       "   'Inadequate response to 12.5-25 mg/week methotrexate for ≥ 12 weeks.'],\n",
       "  'exclusion': ['Rheumatic autoimmune disease or inflammatory joint disease other than rheumatoid arthritis.',\n",
       "   'Any surgical procedure within 12 weeks prior to baseline.',\n",
       "   'Previous treatment with a biologic agent or with a B cell modulating or cell depleting therapy.']},\n",
       " {'nct_id': 'NCT00576433',\n",
       "  'inclusion': ['adult patients, 18-80 years of age;',\n",
       "   'moderate to severe active rheumatoid arthritis;',\n",
       "   'inadequate response to previous or current treatment with 1 anti-TNF agent;',\n",
       "   'receiving methotrexate at a dose of 10-25mg/week for 12 weeks prior to start of study, at a stable dose for >=4 weeks.'],\n",
       "  'exclusion': ['previous treatment with MabThera;',\n",
       "   'use of an anti-TNF alpha agent within 8 weeks of study start;',\n",
       "   'concurrent treatment with any DMARD other than methotrexate;',\n",
       "   'active infection, or history of serious recurrent or chronic infection.']},\n",
       " {'nct_id': 'NCT00579878',\n",
       "  'inclusion': ['Age greater or 19 years and less than or 80 years old',\n",
       "   'Duration of disease greater or equal to 6 months',\n",
       "   'Diagnosis of RA with criteria',\n",
       "   'Negative urine pregnancy test',\n",
       "   'Be capable of understanding and giving written, voluntary informed consent',\n",
       "   'Must present with at least six swollen and six tender joints at the screening evaluation'],\n",
       "  'exclusion': ['Patients treated previously with leflunomide',\n",
       "   'Patients that have been treated with methotrexate in combination with any of the study drugs',\n",
       "   'Patients with a history of allergy to, or any history of significant clinical or laboratory adverse experience associated with any of the study drugs',\n",
       "   'Doses of oral steroids that are either unstable or greater than 10mg/day',\n",
       "   'Stage IV disease or other significant disease including chest x-rays that show evidence of rheumatoid lung disease. Stage IV disease is defined as x-ray evidence of cartilage/bone destruction with fibrous or bony ankylosis; creatinine greater than 2.0mg/dL, AST or ALT greater normal',\n",
       "   'Any significant liver, renal , hematologic, pulmonary, cardiovascular disease (including uncontrolled hypertension), any active peptic ulcer disease, or visual problems including a recent decrease in acuity, retinal disease, or macular degeneration',\n",
       "   'Patients who are not willing to abstain from alcohol consumption',\n",
       "   'Women of childbearing potential who are not practicing a successful method of contraception, or wish to become pregnant',\n",
       "   'Patients that are unable to understand the study procedures and/or give written informed consent.']},\n",
       " {'nct_id': 'NCT00372177',\n",
       "  'inclusion': ['Male and female subjects above 50 years of age',\n",
       "   'Suffering from joint pain which is due to active rheumatoid arthritis',\n",
       "   'Obvious signs of inflammation in at least one joint (e.g. swelling, erythema, or local elevated temperature)',\n",
       "   'Otherwise healthy',\n",
       "   'Informed consent'],\n",
       "  'exclusion': ['Patients 80 years and older',\n",
       "   'Clinically significant disease of the cardiovascular system, respiratory system, hepato-biliary system or central nervous system (CNS)',\n",
       "   'Excretory hepatic or renal insufficiency',\n",
       "   'Regular intake of any drug, except for hormone replacement therapy in females',\n",
       "   'Previous administration of xenogenous proteins',\n",
       "   'History of anaphylactic reaction to any drug administered by a parenteral pathway',\n",
       "   'Previous participation in a radiopharmaceutical drug trial (unless the effective dose acquired by participation in the current trial will remain below 10 mSv)',\n",
       "   'Participation in any clinical drug trial within 3 months prior to enrolment',\n",
       "   'Women of child-bearing potential (child-bearing potential to be ruled out by one of the following: at least 2 years past menopause, hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)',\n",
       "   'Long term medication with strong antiphlogistic agents/pain killers such as methotrexate, corticoids, or immunosuppressants prior to enrolment']},\n",
       " {'nct_id': 'NCT00326339',\n",
       "  'inclusion': ['Patients must give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study.',\n",
       "   'Males and females, 18 to 75 years of age, with active RA for at least 12 months (functional class I-III, e.g., not bed or wheelchair-bound) who have been receiving weekly doses of methotrexate (10-25 mg/week) for a minimum of 180 days, and who have been receiving a stable MTX dose of at least 15 mg without any change in route or change in folic acid supplementation for at least 30 days. Active RA is defined as the presence of (a)6 swollen joints (28 joint count); AND (b)6 tender joints (28 joint count); AND (c) CRP level > ULN for the central reference laboratory. Patient may receive up to 10 mg per day of oral prednisone or steroid equivalent, NSAID therapy, hydroxychloroquine, chloroquine, minocycline, sulfasalazine, and doxycycline. The dose(s) must have been stable for at least 30 days and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements.',\n",
       "   'Females of childbearing potential must be fully informed of the potential for methotrexate and R788 to adversely affect the fetus and must agree to use adequate (2 methods) contraception during the study. These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.',\n",
       "   'The patient is in otherwise good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period, including the absence of clinically significant findings, such as HIV, HBV or HCV, interstitial pneumonitis or active pulmonary infection, on chest X-ray taken within 6 months prior to screening and a negative TB skin test, or abnormal liver function defined as known ALT >1.2xULN within the past 90 days.',\n",
       "   \"In the investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the investigator and to participate in, and to comply with, the requirements of the entire protocol.\"],\n",
       "  'exclusion': [\"The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study (these will be included in an exclusion log).\",\n",
       "   'The patient has a history of substance abuse, drug addiction or alcoholism.',\n",
       "   'The patient is unable to abstain from alcohol during the study.',\n",
       "   'The patient has a recent (past 5 years) history of, or treatment for, a malignancy other than basal skin cancer.',\n",
       "   'The patient has received any investigational medication within 30 days prior to admission to the study.',\n",
       "   'Any patient who has received any of the following treatments must abide by the indicated washout period:',\n",
       "   'oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day washout period prior to Day 1 dosing',\n",
       "   'cyclosporine, abatacept, etanercept, infliximab or adalimumab require a 60 day washout period prior to Day 1 dosing',\n",
       "   'leflunomide requires a 60 day washout period prior to screening, unless the patient has undergone cholestyramine washout at least 30 days prior to Day 1 dosing',\n",
       "   'cyclophosphamide requires a 180 day washout period prior to Day 1 dosing',\n",
       "   'Rituxan requires a 180 day washout period and normal CD19 count prior to Day 1 dosing',\n",
       "   'parenteral or intra-articular corticosteroids require a 30 day washout period prior to Day 1 dosing',\n",
       "   'Patients with the following laboratory abnormalities: ALT > 1.2X ULN, creatinine > ULN, a neutrophil count < 2,500/mm3 or lymphocyte count < 800/mm3, Hgb < 10 g/dL, platelet count < 125,000/mm3 are excluded.',\n",
       "   'Patients should not use CYP3A4 inhibitors from within 3 days of randomization until the end of study. R406 is metabolized by CYP3A4, and ketoconazole increases the R406 AUC of a dose of R788 by approximately 2 fold.',\n",
       "   'Patients should not use CYP3A4 inducers from within 3 days of randomization until the end of the study. Although glucocorticoids are inducers, a stable dose of no more than 10 mg/day is allowed.']},\n",
       " {'nct_id': 'NCT00327275',\n",
       "  'inclusion': ['Males and females with RA',\n",
       "   'Over 18 years of age',\n",
       "   'ACR Functional Class I and II',\n",
       "   'Taking Remicade >4 months'],\n",
       "  'exclusion': ['Presence of comorbid conditions contraindicated to exercise, including, but not limited to:',\n",
       "   'heart disease',\n",
       "   'severe osteoporosis: (if >50 years): T score < -3.0 for hip or spine excluded; T score <-2.5 for hip or spine w/o current treatment)',\n",
       "   '(all potential subjects) previous non-traumatic fractures',\n",
       "   'uncontrolled BP',\n",
       "   'BMI >40',\n",
       "   'Regular use of assistive walking device which would interfere with ability to lift weights',\n",
       "   'Currently or within the last 3 months participating in aerobic exercise > 150 minutes a week',\n",
       "   'Currently or within the last 3 months participating in any regular strength training activities',\n",
       "   'Presence of neurological impairment that directly limits ability to perform exercise',\n",
       "   'Participation in concurrent exercise study',\n",
       "   \"Any reason for which the investigator deems it would not be in the patient's best interest to continue in the study\",\n",
       "   'Plans to move away from site within next 1 year']},\n",
       " {'nct_id': 'NCT00321217',\n",
       "  'inclusion': ['Patients with RA according to the ACR criteria who are treated with monoclonal anti-TNF antibodies.'],\n",
       "  'exclusion': []},\n",
       " {'nct_id': 'NCT00828997',\n",
       "  'inclusion': ['Age > 18 years',\n",
       "   'Clinical diagnosis of RA or spondylarthropathy'],\n",
       "  'exclusion': ['Pregnancy',\n",
       "   'Allergy',\n",
       "   'Has received pneumococcal vaccination within 5 years']},\n",
       " {'nct_id': 'NCT00903383',\n",
       "  'inclusion': ['Males and females aged 18-75 years old',\n",
       "   'Rheumatoid arthritis present for at least 6 months, functional class I, II, or III as defined by ACR criteria',\n",
       "   'Active disease as determined by the presence of ≥6 swollen joints, ≥6 tender joints, and serum C-reactive protein level > upper limit of normal',\n",
       "   'Receiving stable dose of MTX (≥10 mg/wk) and folate supplementation at least 8 weeks prior to Day 1',\n",
       "   'Ability to provide written informed consent'],\n",
       "  'exclusion': ['RA diagnosis prior to 16 years of age (Juvenile RA)',\n",
       "   'Lack of response to >3 disease modifying anti-rheumatic drugs (DMARDs) or exposure to >1 biologic DMARD',\n",
       "   'Use of DMARDs other than MTX within 12 weeks prior to Day 1',\n",
       "   'Intra-articular and/or parenteral corticosteroids within 4 weeks prior to study Day 1',\n",
       "   'Blood donation or receipt of live vaccine within 4 weeks prior to Day 1',\n",
       "   'Major surgical procedure within 8 weeks prior to Day 1',\n",
       "   'Any systemic inflammatory condition, recurrent infection, or current infection other than onychomycosis',\n",
       "   'History of cancer within 5 years prior to Day 1',\n",
       "   'Presence of hepatic or biliary disease',\n",
       "   'History of tuberculosis',\n",
       "   'History of human immunodeficiency virus (HIV)']},\n",
       " {'nct_id': 'NCT00902369',\n",
       "  'inclusion': ['Diagnosis of RA (class I to III)',\n",
       "   'Stable dose of methotrexate (at least 12 weeks)'],\n",
       "  'exclusion': ['Pregnant or breastfeeding',\n",
       "   'Abnormal screening laboratory test values considered to be clinically significant']},\n",
       " {'nct_id': 'NCT00902486',\n",
       "  'inclusion': ['Must have rheumatoid arthritis which has been inadequately controlled with at least one DMARD',\n",
       "   'For subjects receiving antimalarials, they must be treated with antimalarials for at least 6 months and receiving a stable daily dose',\n",
       "   'For subjects receiving sulfasalazine, they must be treated with Sulfasalazine (SSZ) for at least 6 months and receiving a stable daily dose of no more than 3 grams per day',\n",
       "   'For subjects on methotrexate, they must be treated with methotrexate for at least 6 months, and receiving a stable weekly dose of methotrexate between 7.5 and 25 mg',\n",
       "   'For subjects on leflunomide, they must be treated with leflunomide for at least 6 months, and receiving a stable dose of leflunomide between 10 to 20 mg',\n",
       "   'For subjects receiving corticosteroids, they must be on a dose not to exceed 10 mg of prednisone daily',\n",
       "   'Active rheumatoid arthritis at the time of screening defined by the following: 6 or more joints tender or painful on motion and 4 or more swollen joints and at least one of the following two: Erythrocyte sedimentation rate (ESR) greater than or equal to 28 mm/hr or C-reactive protein (CRP) greater than or equal to 7 mg/liter',\n",
       "   'Have evidence of lack of risk for tuberculosis'],\n",
       "  'exclusion': ['Current or recent viral, bacterial, fungal, parasitic or mycobacterial infection requiring systemic therapy',\n",
       "   'History of infected joint prosthesis',\n",
       "   'Subjects who have a current or recent history of severe, progressive, uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological or cerebral disease',\n",
       "   'Subjects who have received treatment with the following drugs or drug classes within the specified timeframe: prior treatment with rituximab within 12 months, prior treatment with an oral Janus kinase (JAK) inhibitor, DMARDs or other anti-rheumatic therapies not specified and allowed according to protocol, treatment with any investigational medication within 12 weeks or 5 half-lives (whichever is longer), and treatment with a biologic agent within 12 weeks prior to the first dose of study medication',\n",
       "   'Subjects with a past history of neutropenia, thrombocytopenia or anemia requiring transfusion other than at the time of trauma or surgery, and subjects that meet protocol specified laboratory measures']},\n",
       " {'nct_id': 'NCT00901550',\n",
       "  'inclusion': ['Men and women, 18 years of age or older',\n",
       "   'Clinical diagnosis of RA with a duration not more than 24 months (Fulfilled the 1987 American College of Rheumatology (ACR) criteria for RA)',\n",
       "   'Patients at risk of developing persistent or erosive arthritis',\n",
       "   'DAS 28 ≥ 3.2',\n",
       "   'Prednisolone < 10mg/day and started at least 4 weeks before baseline',\n",
       "   'Either has ESR ≥ 28, CRP ≥ 10, presence of rheumatoid factor or anti-CCP, present of HLADRB*0401 or DRB1*0404, and radiographic erosions',\n",
       "   'Informed consent'],\n",
       "  'exclusion': ['Little or no ability for self-care',\n",
       "   'Previous treatment with DMARDs other than antimalarials',\n",
       "   'Concomitant treatment with an experimental drug',\n",
       "   'Malignancy within the last 5 years',\n",
       "   'Bone marrow hypoplasia',\n",
       "   'Clinically significant renal disease ( serum creatinine level ≥ 150µmol/L) or estimated creatinine clearance > 75ml/min, alanine aminotransferase (ALT) exceeds the upper limit of normal',\n",
       "   'History of any clinically significant adverse reaction to murine or chimeric proteins',\n",
       "   'History of TB in the last 5 years',\n",
       "   'Known to have hepatitis B, or hepatitis C',\n",
       "   'Had an opportunistic infection (e.g. herpes zoster, cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months before screening',\n",
       "   'History or ongoing chronic or recurrent disease; renal infection, chest infection, urinary tract infection, ulcer or skin wound',\n",
       "   'History of infected joint prosthesis and use of antibiotics for the joint',\n",
       "   'Received intravenous antibiotics within 30 days or oral antibiotics within 14 days for screening',\n",
       "   'History of known demyelinating diseases (multiple sclerosis or optic neuritis)',\n",
       "   'Current signs or symptoms of severe diseases (renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, etc)',\n",
       "   'History or concurrent CHF',\n",
       "   'History of lymphoproliferative disease, splenomegaly',\n",
       "   'Female of childbearing potential, unwilling to use adequate contraception during the study',\n",
       "   'Current or recent ( within the past 3 months) pregnancy and cancer',\n",
       "   'Active smoker, alcohol or drug abuse']},\n",
       " {'nct_id': 'NCT00908089',\n",
       "  'inclusion': ['Diagnosis of RA fulfilling the ACR classification criteria for RA',\n",
       "   'Patients within age group of 18-60 years',\n",
       "   'Patients not permanently work disabled or retired',\n",
       "   'Duration of symptoms < 12 months, and who have not received DMARD previously',\n",
       "   'Patients with active disease (see below)',\n",
       "   'Criteria for active disease at entry:',\n",
       "   '> 6 swollen joints (66 joint count)',\n",
       "   '> 6 tender joints (68 joint count)',\n",
       "   'duration of early morning stiffness > 45 min and/or ESR > 30 mm/h and/or CRP > 20 mg/l'],\n",
       "  'exclusion': ['Previous treatment with DMARDs',\n",
       "   'Previous treatment with oral glucocorticoids during the previous 6 months',\n",
       "   'Less than 30 days from previous intra-articular injection with corticosteroids',\n",
       "   'Allergy to sulphonamides',\n",
       "   'Allergy to acetylsalicylic acid',\n",
       "   'Allergy to methotrexate',\n",
       "   'Allergy to antimalarials',\n",
       "   'Previous treatment with biologicals',\n",
       "   'Serum creatinine value > upper limit of normal (registered in 2 different blood samples)',\n",
       "   'Serum transaminase levels > 2x upper limit of normal (registered in 2 different samples)',\n",
       "   'Known/previous malignancy excluding basalioma or in situ cervical cancer >5 years previously',\n",
       "   'Cardiac failure (NYHA III-IV)',\n",
       "   'Previous history of tuberculosis and/or exposition to tuberculosis and/or typical changes of previous/active tuberculosis in chest radiology',\n",
       "   'Active infection',\n",
       "   'Pregnancy',\n",
       "   'Leukopenia (WBC < 4 x 109/l)',\n",
       "   'Thrombocytopenia (platelets < 100 x 109/l)',\n",
       "   'Active peptic ulcer',\n",
       "   'Type I or type II diabetes under poor control',\n",
       "   'Heavy use of alcohol',\n",
       "   'Fertile women not practising contraception or who are planning pregnancy',\n",
       "   'Male patients wishing to have children during the therapy',\n",
       "   'Other autoimmune rheumatic disease',\n",
       "   \"Other chronic disease which judged by the physician could influence the patient's compliance or intervene the study course\",\n",
       "   'Patient is not cooperative']},\n",
       " {'nct_id': 'NCT00902005',\n",
       "  'inclusion': ['Males and females 18-80 years',\n",
       "   'Able and willing to give written informed consent, and to comply with the requirements of the study protocol.',\n",
       "   'Fulfilling the ACR 1987 revised diagnostic criteria for the diagnosis rheumatoid arthritis, or the diagnostic criteria by Moll and Wright for the diagnosis psoriatic arthritis, or the modified New York diagnostic criteria for ankylosing spondylitis.',\n",
       "   'Clinical indication for starting treatment with methotrexate, TNFalpha- inhibitor or combination therapy.',\n",
       "   'Use of reliable method of contraception for women with childbearing potential.'],\n",
       "  'exclusion': ['Lack of cooperativity',\n",
       "   'Positive serology for hepatitis B or C',\n",
       "   'History of positive HIV status.',\n",
       "   'History of tuberculosis or untreated tuberculosis.',\n",
       "   'PPD more than 15 mm in previously BCG immunized subjects. PPD 6 mm or more if not previously BCG immunized.',\n",
       "   'Histoplasmosis or Listeriosis',\n",
       "   'Persistent or recurrent infections',\n",
       "   'Any inflammatory disease of permanence not related to RA, PSA or',\n",
       "   '- Pregnancy or breast-feeding.',\n",
       "   'Use of prednisolone more than 10 mg daily for 2 weeks at inclusion.',\n",
       "   'Use of TNFalpha-inhibitor the last 4 weeks.',\n",
       "   'History of cancer.',\n",
       "   'Uncontrolled diabetes.',\n",
       "   'Congestive heart failure (Nyha 3-4)',\n",
       "   'Recent stroke (within 3 months)',\n",
       "   'Previous diagnosis or signs of central nervous system demyelinating disease.',\n",
       "   'Previously diagnosed immunodeficiency.']},\n",
       " {'nct_id': 'NCT00626275',\n",
       "  'inclusion': ['Male and female participants between 18 and 75 years of age, inclusive',\n",
       "   'Have a documented history of rheumatoid arthritis (diagnosed according to American College of Rheumatology criteria)',\n",
       "   'Have painful rheumatoid arthritis with pain predominantly in the lower extremities (that is, hip, knees, ankles, and/or feet)',\n",
       "   'Have an evoked lower extremity pain intensity (ELEPI) score of 5 or higher on a numeric pain rating scale (NPRS) completed on Day 1 of Part A before dosing (after resting for 45 minutes and then walking for at least 10 minutes on a treadmill) and then have a minimum ELEPI score of 4 on other visits during Part A',\n",
       "   'If receiving disease modifying antirheumatic drugs, have a stable dose regimen for at least 30 days before study entry (90 days before study entry for biologic therapy)',\n",
       "   'If biologic therapy has been recently discontinued, Enbrel™ or Orencia™ must have been discontinued at least 30 days before study entry, and Humira™, Remicade™, and Rituxan™ must have been discontinued at least 60 days before study entry',\n",
       "   'For male participants, be surgically sterile or agree to use an appropriate method of contraception',\n",
       "   'For female participants of child bearing potential, be surgically sterile or using an insertable, injectable, transdermal, or combination oral contraceptive deemed highly effective by the US Food and Drug Administration (FDA) through the completion of the study and have negative findings on a urine pregnancy test before administration of study medication (women who are postmenopausal [no menses for at least 2 years] are also eligible to participate)',\n",
       "   'Have a body weight of at least 45 kilograms (kg)',\n",
       "   'Be able to understand and comply with the protocol requirements (such as repeated treadmill walking and diary completion via the interactive voice response system), instructions, and protocol-specified restrictions.'],\n",
       "  'exclusion': ['Have an overall pain intensity (OPI) score equal to 10 at screening or before the first dose of study medication in Part A',\n",
       "   'Have a pain intensity score for the upper body (that is, back, neck, fingers, wrists, elbows, and/or shoulders) above 7 on a numeric pain rating scale (NPRS) before study medication administration',\n",
       "   'Have a history of headache requiring prescription treatment within 6 months of study entry',\n",
       "   'Have significant renal disease (as indicated by blood urea nitrogen or serum creatinine ≥ 2 times the upper limit of normal) or have significant hepatic disease (as indicated by liver function test results ≥ 2 times the upper limit of normal)',\n",
       "   'Have evidence of symptomatic orthostatic hypotension',\n",
       "   'Have a history of a seizure disorder, including febrile seizures',\n",
       "   \"Have, as determined by the investigator or the sponsor's medical monitor, a history or clinical manifestations of significant renal, hepatic, cardiovascular, metabolic, neurologic, psychiatric, or other conditions that would affect study participation\",\n",
       "   'Are taking cytochrome P450 (CYP) 3A4/5 or P glycoprotein (P gp) transporter inhibitors',\n",
       "   'Have taken oral steroids within 30 days of study entry or intra articular steroids within 60 days of study entry (inhaled or topical steroids or stable oral dose ≤ 10 mg is permitted)',\n",
       "   'Have a history or presence of allergy or intolerance to nonsteroidal anti-inflammatory drugs or acetaminophen, or have a history of drug or other allergy that, in the opinion of the investigator, contraindicates participation in the study',\n",
       "   'Have a history of alcoholism or drug addiction or abuse within 5 years before the scheduled administration of study medication',\n",
       "   'Have participated in a trial of any investigational medication within 30 days before study drug administration']},\n",
       " {'nct_id': 'NCT00688103',\n",
       "  'inclusion': ['Patients had to be at least 18 years of age',\n",
       "   'fulfilled the 1987 revised classification criteria for RA by in American College of Rheumatology (ACR)',\n",
       "   'met the guidelines for the proper use of ETN in Japan (having at least 6 tender joints and 6 swollen joints',\n",
       "   'either serum C-reactive protein more than 2 mg/dl or ESR no less than 28 mm at 1 hour, with adequate safety profiles)',\n",
       "   'be ACR functional class I-III',\n",
       "   'have been receiving MTX 6 mg/week for a minimum of 3 months at a stable dose for at least 4 weeks at the time of study enrollment'],\n",
       "  'exclusion': ['Patients who required concurrent use of prednisone (PSL) >10 mg/day, or its equivalent, were excluded from study entry',\n",
       "   'the start of dose increment of PSL equivalents within 3 months of the study enrollment',\n",
       "   'experience of antirheumatic therapy except for MTX and PSL equivalents',\n",
       "   'previous treatment with ETN or any other biological treatment']},\n",
       " {'nct_id': 'NCT00546533',\n",
       "  'inclusion': ['A negative serum or urine pregnancy test at screening and a medically acceptable form of contraception starting at screening and continuing throughout the study is required for all females of childbearing potential (defined as an oral, injectable, or implantable contraceptive, intrauterine device, or barrier method combined with a spermicide).',\n",
       "   'Failed therapy with at least one DMARD (DMARD failure is defined as a discontinuation because of lack of clinical efficacy).',\n",
       "   'Meet the 1987 American Rheumatism Association (ARA) revised criteria for rheumatoid arthritis.'],\n",
       "  'exclusion': ['Uncooperative patients with a history of poor compliance.',\n",
       "   'Known hypersensitivity to etanercept or any of its components.',\n",
       "   'Known significant concurrent medical disease']},\n",
       " {'nct_id': 'NCT00547521',\n",
       "  'inclusion': ['Clinical diagnosis of Rheumatoid Arthritis',\n",
       "   'Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale',\n",
       "   'Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except for methotrexate'],\n",
       "  'exclusion': ['Received treatment with rituximab',\n",
       "   'Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine']},\n",
       " {'nct_id': 'NCT00542789',\n",
       "  'inclusion': ['Medical history of gastric and/or duodenal ulcer',\n",
       "   'A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age'],\n",
       "  'exclusion': ['Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification',\n",
       "   'History of esophageal, gastric or duodenal surgery',\n",
       "   'Having severe liver disease or chronic renal disease']},\n",
       " {'nct_id': 'NCT00548834',\n",
       "  'inclusion': ['male/female, 18-75 years old, inclusive',\n",
       "   'diagnosis of adult-onset RA',\n",
       "   'had active disease',\n",
       "   'had received methotrexate',\n",
       "   'on a stable dose of folic acid'],\n",
       "  'exclusion': ['contraindication for methotrexate or anti-TNF']},\n",
       " ...]"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "expected_output_stage1 # list of dicts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['nct_id', 'inclusion', 'exclusion'])"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "expected_output_stage1[0].keys()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# 1. Process the results and prepare for stage 2"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "# read from pickle file\n",
    "\n",
    "file_name = 'final_results.p'\n",
    "\n",
    "with open(file_name, 'rb') as file_name:\n",
    "    final_results = pickle.load(file_name)\n",
    "    \n",
    "stage1_results = pd.DataFrame(final_results)\n",
    "stage1_results = stage1_results.groupby('patient_id')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " These are the inclusion/ Exclusion criteria for the 'rheumatoid arthritis', which is shown by topic 26-30"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "# read the topic sentences.\n",
    "sentified_topics = pd.read_csv('clean_topic_sentences.csv')\n",
    "sentified_topics.sentences = sentified_topics.sentences.apply(eval) # reading the str as python lists\n",
    "\n",
    "def get_topic_sentences_from_disorder(topic_sentence_df,disorder):\n",
    "    return topic_sentence_df[(topic_sentence_df.Template == disorder)]\n",
    "\n",
    "# since our sample stage1 results are for rheumatoid arthritis\n",
    "# relevant_patient_topic = get_topic_sentences_from_disorder(sentified_topics,results[0]['condition'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "sentified_topics.loc[:,'patient_id'] = sentified_topics.loc[:,'Topic Number']\n",
    "sentified_topics.index = sentified_topics.patient_id\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "notebookRunGroups": {
     "groupValue": "2"
    }
   },
   "outputs": [],
   "source": [
    "def weighted_relevance_scoring(inclusion_matrix, exclusion_matrix=None):\n",
    "    \"\"\"Exclusion weighted more than inclusion criteria, takes the maximum value in exclusion matrix\n",
    "    and subtracts from average cosine similarities in inclusion matrix\n",
    "    Negative score indicate topic sentences matched exclusion more than inclusion.\"\"\"\n",
    "\n",
    "    # inclusion.shape: topic_sentences x inclusion_sentences\n",
    "    # exclusion.shape: topic_sentences x exclusion_sentences\n",
    "    exclusion_score = 0\n",
    "    inclusion_score = 0\n",
    "    # Average inclusion similarity\n",
    "    if inclusion_matrix is not None and inclusion_matrix.shape[1] > 0:\n",
    "        inclusion_score = inclusion_matrix.mean()\n",
    "\n",
    "    if exclusion_matrix is not None and exclusion_matrix.shape[1] > 0:\n",
    "        # Maximum exclusion similarity\n",
    "        exclusion_score = exclusion_matrix.max()\n",
    "    combined_score = inclusion_score - exclusion_score\n",
    "    return combined_score\n",
    "\n",
    "\n",
    "def balanced_relevance_scoring(inclusion_matrix, exclusion_matrix):\n",
    "    \"\"\"Negative score indicate topic sentences matched exclusion more than inclusion.\"\"\"\n",
    "    \n",
    "    \n",
    "    # inclusion.shape: topic_sentences x inclusion_sentences\n",
    "    # exclusion.shape: topic_sentences x exclusion_sentences\n",
    "    exclusion_score = 0\n",
    "    inclusion_score = 0\n",
    "    # Average inclusion similarity\n",
    "    if inclusion_matrix is not None and inclusion_matrix.shape[1] > 0:\n",
    "        inclusion_score = inclusion_matrix.mean()\n",
    "\n",
    "    if exclusion_matrix is not None and exclusion_matrix.shape[1] > 0:\n",
    "        # mean exclusion similarity\n",
    "        exclusion_score = exclusion_matrix.mean()\n",
    "    combined_score = inclusion_score - exclusion_score\n",
    "    return combined_score\n",
    "\n",
    "def naive_high_precision_scoring(inclusion_matrix, exclusion_matrix=None, threshold=0.5):\n",
    "    \"\"\"Score is computed as follows:\n",
    "    1. For each inclusion criteria, if it is satisfied by one or more topic sentence then it is considered as satisfied.\n",
    "    2. Each satisfied inclusion criteria is given a score of 1.\n",
    "    3. Final score is the normalized inclusion score (0-1) + exclusion score (if any exclusion criteria is satisfied then -1 else 0).\n",
    "    # Negative score indicates that the trial is excluded because of one or more exclusion criteria.\n",
    "    \"\"\"\n",
    "\n",
    "    # inclusion.shape: topic_sentences x inclusion_sentences\n",
    "    # exclusion.shape: topic_sentences x exclusion_sentences\n",
    "\n",
    "    exclusion_score = 0\n",
    "    inclusion_score = 0\n",
    "    if exclusion_matrix is not None and exclusion_matrix.shape[1] > 0:\n",
    "        if (exclusion_matrix > threshold).any():  # any_exclusion_matched\n",
    "            exclusion_score = -1\n",
    "    # satisfy all inclusion criteria atleast once\n",
    "    if inclusion_matrix is not None and inclusion_matrix.shape[1] > 0:\n",
    "        inclusion_satisfied_atleast_once = (inclusion_matrix > threshold).any(1)\n",
    "        inclusion_score = np.array(inclusion_satisfied_atleast_once).mean()\n",
    "\n",
    "    final_score = inclusion_score + exclusion_score\n",
    "\n",
    "    return torch.tensor([final_score])\n",
    "\n",
    "\n",
    "def compute_score_matrix(model, topic_sent, inclusion_sent, exclusion_sent):\n",
    "\n",
    "    topic_encoding = model.encode(topic_sent)\n",
    "    \n",
    "    cosine_matrix_t_e = None\n",
    "    cosine_matrix_t_i = None\n",
    "    \n",
    "    if inclusion_sent:\n",
    "        inc_encoding = model.encode(inclusion_sent)\n",
    "        cosine_matrix_t_i = util.cos_sim(topic_encoding, inc_encoding)\n",
    "        \n",
    "    \n",
    "    if exclusion_sent:  # len = 0\n",
    "        exc_encoding = model.encode(exclusion_sent)\n",
    "        cosine_matrix_t_e = util.cos_sim(topic_encoding, exc_encoding)\n",
    "    \n",
    "\n",
    "    return {'inclusion_matrix': cosine_matrix_t_i, 'exclusion_matrix': cosine_matrix_t_e}\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "### sorting does not work  fix later\n",
    "def rank_trials(model, score_functions, topic_sent, stage1_output):\n",
    "    output = {}\n",
    "    trial_scores = {func.__name__: [] for func in score_functions}\n",
    "    for item in tqdm(stage1_output):\n",
    "        # compute a score for each NCT_ID\n",
    "        nct_id, inc_sents, exc_sents,p_id =  item['ncd_id'],item['inclusion'] ,item['exclusion'],item['patient_id']\n",
    "        score_matrix = compute_score_matrix(model,topic_sent,inc_sents, exc_sents)\n",
    "        \n",
    "        scores = {func.__name__ :func(**score_matrix).item() for func in score_functions}\n",
    "        \n",
    "        \n",
    "    \n",
    "    # trial_scores.append({'nct_id': nct_id, 'topic_no':p_id}|scores)\n",
    "    for func in score_functions:\n",
    "        # trial_scores[func.__name__].append({'nct_id': nct_id, 'topic_no':p_id, f'{func.__name__}':})\n",
    "        trial_scores.sort(key=lambda x: x[func.__name__], reverse=True)\n",
    "        output[func.__name__] = trial_scores\n",
    "        \n",
    "    return output\n",
    "   \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "zero_idx = pd.DataFrame([{'inc_len': len(i['inclusion']),'exc_len':len(i['exclusion'])} for i in final_results ]).query('inc_len==0').index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([14035, 16150, 17988, 22091, 39979, 41088])"
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "zero_idx.values"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|██████████| 447/447 [00:08<00:00, 53.01it/s]\n",
      "100%|██████████| 414/414 [00:06<00:00, 62.11it/s]\n",
      "100%|██████████| 438/438 [00:06<00:00, 62.62it/s]\n",
      "100%|██████████| 409/409 [00:06<00:00, 62.96it/s]\n",
      "100%|██████████| 425/425 [00:06<00:00, 62.82it/s]\n",
      "100%|██████████| 754/754 [00:12<00:00, 60.76it/s]\n",
      "100%|██████████| 772/772 [00:12<00:00, 61.10it/s]\n",
      "100%|██████████| 603/603 [00:09<00:00, 61.38it/s]\n",
      "100%|██████████| 732/732 [00:11<00:00, 61.47it/s]\n",
      "100%|██████████| 610/610 [00:09<00:00, 61.46it/s]\n",
      "100%|██████████| 1705/1705 [00:27<00:00, 61.94it/s]\n",
      "100%|██████████| 1000/1000 [00:16<00:00, 59.14it/s]\n",
      "100%|██████████| 1742/1742 [00:28<00:00, 61.95it/s]\n",
      "100%|██████████| 1757/1757 [00:28<00:00, 62.23it/s]\n",
      "100%|██████████| 1000/1000 [00:16<00:00, 59.35it/s]\n",
      "100%|██████████| 2050/2050 [00:36<00:00, 56.53it/s]\n",
      "100%|██████████| 2113/2113 [00:35<00:00, 59.46it/s]\n",
      "100%|██████████| 1954/1954 [00:33<00:00, 57.95it/s]\n",
      "100%|██████████| 2139/2139 [00:36<00:00, 59.05it/s]\n",
      "100%|██████████| 2002/2002 [00:35<00:00, 56.78it/s]\n",
      "100%|██████████| 1529/1529 [00:23<00:00, 63.72it/s]\n",
      "100%|██████████| 1479/1479 [00:23<00:00, 63.33it/s]\n",
      "100%|██████████| 1508/1508 [00:23<00:00, 63.03it/s]\n",
      "100%|██████████| 1533/1533 [00:24<00:00, 63.03it/s]\n",
      "100%|██████████| 1822/1822 [00:31<00:00, 57.24it/s]\n",
      "100%|██████████| 1305/1305 [00:21<00:00, 60.88it/s]\n",
      "100%|██████████| 1298/1298 [00:21<00:00, 60.72it/s]\n",
      "100%|██████████| 1396/1396 [00:22<00:00, 61.29it/s]\n",
      "100%|██████████| 1343/1343 [00:22<00:00, 60.98it/s]\n",
      "100%|██████████| 1000/1000 [00:17<00:00, 56.98it/s]\n",
      "100%|██████████| 906/906 [00:17<00:00, 52.71it/s]\n",
      "100%|██████████| 974/974 [00:17<00:00, 54.55it/s]\n",
      "100%|██████████| 882/882 [00:16<00:00, 52.21it/s]\n",
      "100%|██████████| 1064/1064 [00:20<00:00, 52.42it/s]\n",
      "100%|██████████| 821/821 [00:15<00:00, 51.81it/s]\n",
      "100%|██████████| 1966/1966 [00:32<00:00, 61.02it/s]\n",
      "100%|██████████| 1947/1947 [00:31<00:00, 61.39it/s]\n",
      "100%|██████████| 1954/1954 [00:31<00:00, 61.60it/s]\n",
      "100%|██████████| 2002/2002 [00:32<00:00, 61.30it/s]\n",
      "100%|██████████| 2112/2112 [00:34<00:00, 60.70it/s]\n"
     ]
    }
   ],
   "source": [
    "score_functions_list = [weighted_relevance_scoring, balanced_relevance_scoring, naive_high_precision_scoring]\n",
    "model = SentenceTransformer('paraphrase-MiniLM-L6-v2')\n",
    "output = {func.__name__:[] for func in score_functions_list}\n",
    "\n",
    "for p_id in range(1,41):        \n",
    "    candiate_trials_stage_1 = stage1_results.get_group(p_id).to_dict('records')\n",
    "    topic_sent = sentified_topics.sentences.loc[p_id]\n",
    "    ranked_trials =  rank_trials(model= model,\n",
    "                                        score_functions= score_functions_list,\n",
    "                                        topic_sent=topic_sent, \n",
    "                                        stage1_output=candiate_trials_stage_1)\n",
    "    \n",
    "    \n",
    "    # ranked_trials by different scoring functions\n",
    "    for func in score_functions_list:\n",
    "        ranked_trials_by_score = ranked_trials[func.__name__] # lists\n",
    "        # normalization\n",
    "        for i in ranked_trials_by_score:\n",
    "            i[func.__name__]  = (i[func.__name__] + 1)/2\n",
    "\n",
    "        output[func.__name__] += ranked_trials_by_score\n",
    "    \n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Trec Submission format\n",
    "\n",
    "\n",
    "The format for run submissions follows the standard trec_eval format. Each line of the submission file should follow the form:\n",
    "\n",
    "TOPIC_NO Q0 ID RANK SCORE RUN_NAME\n",
    "\n",
    "\n",
    "\n",
    "where TOPIC_NO is the topic number (1–30), 0 is a required but ignored constant, ID is the identifier of the retrieved document (PMID or NCT ID), RANK is the rank (1–1000) of the retrieved document, SCORE is a floating point value representing the confidence score of the document, and RUN_NAME is an identifier for the run. The RUN_NAME is limited to 12 alphanumeric characters (no punctuation).\n",
    "\n",
    "The file is assumed to be sorted numerically by TOPIC_NO, and SCORE is assumed to be greater for documents that should be retrieved first. For example, the following would be a valid line of a run submission file:\n",
    "\n",
    "1 Q0 NCT00760162 1 0.9999 my-run\n",
    "The above line indicates that the run named \"my-run\" retrieves for topic number 1 document NCT00760162 at rank 1 with a score of 0.9999."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [],
   "source": [
    "output_df = pd.DataFrame(output['naive_high_precision_scoring'])\n",
    "output_df = output_df.groupby('topic_no')\n",
    "result_df = []\n",
    "for i in range(1,41):\n",
    "    result_df.append(output_df.get_group(i).sort_values(by='naive_high_precision_scoring',ascending=False))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "def format_results_for_trec(outputs,score_key,run_name):\n",
    "    ranked_df = outputs.groupby('topic_no')\n",
    "    with open(f'{run_name}.txt','a') as f:\n",
    "        for p_id in range(1,41):\n",
    "            first1000 = ranked_df.get_group(p_id).iloc[:1000]\n",
    "            for i, row in enumerate(first1000.iterrows()):\n",
    "                row = row[1]\n",
    "                line = f\"{row['topic_no']} Q0 {row['nct_id']} {i+1} {row[score_key]:f>.3} {run_name}\"\n",
    "                # f.write(line)\n",
    "                print(line,file=f)\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 68,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>topic_no</th>\n",
       "      <th>weighted_relevance_scoring</th>\n",
       "      <th>balanced_relevance_scoring</th>\n",
       "      <th>naive_high_precision_scoring</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03903588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.636710</td>\n",
       "      <td>0.636710</td>\n",
       "      <td>0.928571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT00141882</td>\n",
       "      <td>1</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00168350</td>\n",
       "      <td>1</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04864834</td>\n",
       "      <td>1</td>\n",
       "      <td>0.663815</td>\n",
       "      <td>0.663815</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00071773</td>\n",
       "      <td>1</td>\n",
       "      <td>0.639267</td>\n",
       "      <td>0.639267</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51902</th>\n",
       "      <td>NCT04151836</td>\n",
       "      <td>40</td>\n",
       "      <td>0.247894</td>\n",
       "      <td>0.447423</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51903</th>\n",
       "      <td>NCT04445181</td>\n",
       "      <td>40</td>\n",
       "      <td>0.326646</td>\n",
       "      <td>0.445102</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51904</th>\n",
       "      <td>NCT04029298</td>\n",
       "      <td>40</td>\n",
       "      <td>0.242694</td>\n",
       "      <td>0.439459</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51905</th>\n",
       "      <td>NCT01250639</td>\n",
       "      <td>40</td>\n",
       "      <td>0.218922</td>\n",
       "      <td>0.434591</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51906</th>\n",
       "      <td>NCT01101945</td>\n",
       "      <td>40</td>\n",
       "      <td>0.248646</td>\n",
       "      <td>0.405297</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>51907 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nct_id  topic_no  weighted_relevance_scoring  \\\n",
       "0      NCT03903588         1                    0.636710   \n",
       "1      NCT00141882         1                    0.680533   \n",
       "2      NCT00168350         1                    0.680533   \n",
       "3      NCT04864834         1                    0.663815   \n",
       "4      NCT00071773         1                    0.639267   \n",
       "...            ...       ...                         ...   \n",
       "51902  NCT04151836        40                    0.247894   \n",
       "51903  NCT04445181        40                    0.326646   \n",
       "51904  NCT04029298        40                    0.242694   \n",
       "51905  NCT01250639        40                    0.218922   \n",
       "51906  NCT01101945        40                    0.248646   \n",
       "\n",
       "       balanced_relevance_scoring  naive_high_precision_scoring  \n",
       "0                        0.636710                      0.928571  \n",
       "1                        0.680533                      0.785714  \n",
       "2                        0.680533                      0.785714  \n",
       "3                        0.663815                      0.785714  \n",
       "4                        0.639267                      0.785714  \n",
       "...                           ...                           ...  \n",
       "51902                    0.447423                      0.000000  \n",
       "51903                    0.445102                      0.000000  \n",
       "51904                    0.439459                      0.000000  \n",
       "51905                    0.434591                      0.000000  \n",
       "51906                    0.405297                      0.000000  \n",
       "\n",
       "[51907 rows x 5 columns]"
      ]
     },
     "execution_count": 68,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.DataFrame(output['naive_high_precision_scoring']).sort_values(\n",
    "    by=['topic_no','naive_high_precision_scoring'],\n",
    "    ascending=[True,False])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nct_id</th>\n",
       "      <th>topic_no</th>\n",
       "      <th>weighted_relevance_scoring</th>\n",
       "      <th>balanced_relevance_scoring</th>\n",
       "      <th>naive_high_precision_scoring</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03903588</td>\n",
       "      <td>1</td>\n",
       "      <td>0.636710</td>\n",
       "      <td>0.636710</td>\n",
       "      <td>0.928571</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT00168350</td>\n",
       "      <td>1</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.680533</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04864834</td>\n",
       "      <td>1</td>\n",
       "      <td>0.663815</td>\n",
       "      <td>0.663815</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT00071773</td>\n",
       "      <td>1</td>\n",
       "      <td>0.639267</td>\n",
       "      <td>0.639267</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT00069056</td>\n",
       "      <td>1</td>\n",
       "      <td>0.625819</td>\n",
       "      <td>0.625819</td>\n",
       "      <td>0.785714</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51876</th>\n",
       "      <td>NCT04702490</td>\n",
       "      <td>40</td>\n",
       "      <td>0.301562</td>\n",
       "      <td>0.497636</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51877</th>\n",
       "      <td>NCT01819597</td>\n",
       "      <td>40</td>\n",
       "      <td>0.293521</td>\n",
       "      <td>0.493993</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51878</th>\n",
       "      <td>NCT04215536</td>\n",
       "      <td>40</td>\n",
       "      <td>0.236693</td>\n",
       "      <td>0.493031</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51879</th>\n",
       "      <td>NCT00422357</td>\n",
       "      <td>40</td>\n",
       "      <td>0.221717</td>\n",
       "      <td>0.492814</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>51906</th>\n",
       "      <td>NCT01101945</td>\n",
       "      <td>40</td>\n",
       "      <td>0.248646</td>\n",
       "      <td>0.405297</td>\n",
       "      <td>0.000000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>51907 rows × 5 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "            nct_id  topic_no  weighted_relevance_scoring  \\\n",
       "0      NCT03903588         1                    0.636710   \n",
       "2      NCT00168350         1                    0.680533   \n",
       "3      NCT04864834         1                    0.663815   \n",
       "4      NCT00071773         1                    0.639267   \n",
       "5      NCT00069056         1                    0.625819   \n",
       "...            ...       ...                         ...   \n",
       "51876  NCT04702490        40                    0.301562   \n",
       "51877  NCT01819597        40                    0.293521   \n",
       "51878  NCT04215536        40                    0.236693   \n",
       "51879  NCT00422357        40                    0.221717   \n",
       "51906  NCT01101945        40                    0.248646   \n",
       "\n",
       "       balanced_relevance_scoring  naive_high_precision_scoring  \n",
       "0                        0.636710                      0.928571  \n",
       "2                        0.680533                      0.785714  \n",
       "3                        0.663815                      0.785714  \n",
       "4                        0.639267                      0.785714  \n",
       "5                        0.625819                      0.785714  \n",
       "...                           ...                           ...  \n",
       "51876                    0.497636                      0.000000  \n",
       "51877                    0.493993                      0.000000  \n",
       "51878                    0.493031                      0.000000  \n",
       "51879                    0.492814                      0.000000  \n",
       "51906                    0.405297                      0.000000  \n",
       "\n",
       "[51907 rows x 5 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "pd.concat(result_df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [],
   "source": [
    "format_results_for_trec(pd.concat(result_df),'naive_high_precision_scoring',run_name = 'nr-ema3')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Topic Number</th>\n",
       "      <th>Template</th>\n",
       "      <th>sentences</th>\n",
       "      <th>patient_id</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>patient_id</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>glaucoma</td>\n",
       "      <td>[Definitive diagnosis: The patient has primary...</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>glaucoma</td>\n",
       "      <td>[Definitive diagnosis: The patient has pigment...</td>\n",
       "      <td>2</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>glaucoma</td>\n",
       "      <td>[Definitive diagnosis: The patient has uveitic...</td>\n",
       "      <td>3</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>glaucoma</td>\n",
       "      <td>[Definitive diagnosis: The patient has primary...</td>\n",
       "      <td>4</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>5</td>\n",
       "      <td>glaucoma</td>\n",
       "      <td>[Definitive diagnosis: The patient has neovasc...</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>6</td>\n",
       "      <td>anxiety</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>6</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>7</td>\n",
       "      <td>anxiety</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>7</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>8</td>\n",
       "      <td>anxiety</td>\n",
       "      <td>[Definitive diagnosis: The patient does not ha...</td>\n",
       "      <td>8</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>9</td>\n",
       "      <td>anxiety</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>9</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>10</td>\n",
       "      <td>anxiety</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>10</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>11</td>\n",
       "      <td>COPD</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>11</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>12</td>\n",
       "      <td>COPD</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>12</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>13</td>\n",
       "      <td>COPD</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>13</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>14</td>\n",
       "      <td>COPD</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>14</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>15</td>\n",
       "      <td>COPD</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>15</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>16</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>16</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>17</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>[Definitive diagnosis: The patient is in stage...</td>\n",
       "      <td>17</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>18</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>[Definitive diagnosis: The patient is in stage...</td>\n",
       "      <td>18</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>19</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>[Definitive diagnosis: The patient is in stage...</td>\n",
       "      <td>19</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>20</td>\n",
       "      <td>breast cancer</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>20</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>21</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>[Definitive diagnosis: The patient's COVID-19 ...</td>\n",
       "      <td>21</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>22</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>[Definitive diagnosis: The patient's COVID-19 ...</td>\n",
       "      <td>22</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>23</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>[Definitive diagnosis: The patient has a confi...</td>\n",
       "      <td>23</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>24</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>[Definitive diagnosis: The patient's COVID-19 ...</td>\n",
       "      <td>24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>25</td>\n",
       "      <td>COVID-19</td>\n",
       "      <td>[Definitive diagnosis: The patient has never b...</td>\n",
       "      <td>25</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>26</td>\n",
       "      <td>rheumatoid arthritis</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>26</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>27</td>\n",
       "      <td>rheumatoid arthritis</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>27</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>28</td>\n",
       "      <td>rheumatoid arthritis</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>28</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>29</td>\n",
       "      <td>rheumatoid arthritis</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>29</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>30</td>\n",
       "      <td>rheumatoid arthritis</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>30</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>31</td>\n",
       "      <td>sickle cell anemia</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>31</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>32</td>\n",
       "      <td>sickle cell anemia</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>32</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>33</td>\n",
       "      <td>sickle cell anemia</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>33</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>34</td>\n",
       "      <td>sickle cell anemia</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>34</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>35</td>\n",
       "      <td>sickle cell anemia</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>35</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>36</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>36</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>37</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>37</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>38</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>38</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>39</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>40</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>[Definitive diagnosis: The patient has a defin...</td>\n",
       "      <td>40</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            Topic Number              Template  \\\n",
       "patient_id                                       \n",
       "1                      1              glaucoma   \n",
       "2                      2              glaucoma   \n",
       "3                      3              glaucoma   \n",
       "4                      4              glaucoma   \n",
       "5                      5              glaucoma   \n",
       "6                      6               anxiety   \n",
       "7                      7               anxiety   \n",
       "8                      8               anxiety   \n",
       "9                      9               anxiety   \n",
       "10                    10               anxiety   \n",
       "11                    11                  COPD   \n",
       "12                    12                  COPD   \n",
       "13                    13                  COPD   \n",
       "14                    14                  COPD   \n",
       "15                    15                  COPD   \n",
       "16                    16         breast cancer   \n",
       "17                    17         breast cancer   \n",
       "18                    18         breast cancer   \n",
       "19                    19         breast cancer   \n",
       "20                    20         breast cancer   \n",
       "21                    21              COVID-19   \n",
       "22                    22              COVID-19   \n",
       "23                    23              COVID-19   \n",
       "24                    24              COVID-19   \n",
       "25                    25              COVID-19   \n",
       "26                    26  rheumatoid arthritis   \n",
       "27                    27  rheumatoid arthritis   \n",
       "28                    28  rheumatoid arthritis   \n",
       "29                    29  rheumatoid arthritis   \n",
       "30                    30  rheumatoid arthritis   \n",
       "31                    31    sickle cell anemia   \n",
       "32                    32    sickle cell anemia   \n",
       "33                    33    sickle cell anemia   \n",
       "34                    34    sickle cell anemia   \n",
       "35                    35    sickle cell anemia   \n",
       "36                    36       type 2 diabetes   \n",
       "37                    37       type 2 diabetes   \n",
       "38                    38       type 2 diabetes   \n",
       "39                    39       type 2 diabetes   \n",
       "40                    40       type 2 diabetes   \n",
       "\n",
       "                                                    sentences  patient_id  \n",
       "patient_id                                                                 \n",
       "1           [Definitive diagnosis: The patient has primary...           1  \n",
       "2           [Definitive diagnosis: The patient has pigment...           2  \n",
       "3           [Definitive diagnosis: The patient has uveitic...           3  \n",
       "4           [Definitive diagnosis: The patient has primary...           4  \n",
       "5           [Definitive diagnosis: The patient has neovasc...           5  \n",
       "6           [Definitive diagnosis: The patient has a defin...           6  \n",
       "7           [Definitive diagnosis: The patient has a defin...           7  \n",
       "8           [Definitive diagnosis: The patient does not ha...           8  \n",
       "9           [Definitive diagnosis: The patient has a defin...           9  \n",
       "10          [Definitive diagnosis: The patient has a defin...          10  \n",
       "11          [Definitive diagnosis: The patient has a defin...          11  \n",
       "12          [Definitive diagnosis: The patient has a defin...          12  \n",
       "13          [Definitive diagnosis: The patient has a defin...          13  \n",
       "14          [Definitive diagnosis: The patient has a defin...          14  \n",
       "15          [Definitive diagnosis: The patient has a defin...          15  \n",
       "16          [Definitive diagnosis: The patient has a defin...          16  \n",
       "17          [Definitive diagnosis: The patient is in stage...          17  \n",
       "18          [Definitive diagnosis: The patient is in stage...          18  \n",
       "19          [Definitive diagnosis: The patient is in stage...          19  \n",
       "20          [Definitive diagnosis: The patient has a defin...          20  \n",
       "21          [Definitive diagnosis: The patient's COVID-19 ...          21  \n",
       "22          [Definitive diagnosis: The patient's COVID-19 ...          22  \n",
       "23          [Definitive diagnosis: The patient has a confi...          23  \n",
       "24          [Definitive diagnosis: The patient's COVID-19 ...          24  \n",
       "25          [Definitive diagnosis: The patient has never b...          25  \n",
       "26          [Definitive diagnosis: The patient has a defin...          26  \n",
       "27          [Definitive diagnosis: The patient has a defin...          27  \n",
       "28          [Definitive diagnosis: The patient has a defin...          28  \n",
       "29          [Definitive diagnosis: The patient has a defin...          29  \n",
       "30          [Definitive diagnosis: The patient has a defin...          30  \n",
       "31          [Definitive diagnosis: The patient has a defin...          31  \n",
       "32          [Definitive diagnosis: The patient has a defin...          32  \n",
       "33          [Definitive diagnosis: The patient has a defin...          33  \n",
       "34          [Definitive diagnosis: The patient has a defin...          34  \n",
       "35          [Definitive diagnosis: The patient has a defin...          35  \n",
       "36          [Definitive diagnosis: The patient has a defin...          36  \n",
       "37          [Definitive diagnosis: The patient has a defin...          37  \n",
       "38          [Definitive diagnosis: The patient has a defin...          38  \n",
       "39          [Definitive diagnosis: The patient has a defin...          39  \n",
       "40          [Definitive diagnosis: The patient has a defin...          40  "
      ]
     },
     "execution_count": 58,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentified_topics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Definitive diagnosis: The patient has a definitive diagnosis of anxiety.',\n",
       " 'Age: The patient is 58 years old.',\n",
       " 'Proficient languages: The patient is proficient in English and Turkish.',\n",
       " \"SSASI: The patient's SSASI score was not specified.\",\n",
       " 'HAM-A: The patient scored 12 on the HAM-A.',\n",
       " \"PHQ-9: The patient's PHQ-9 score was not specified.\",\n",
       " 'HAM-D: The patient scored 19 on the HAM-D.',\n",
       " 'GAD-7: The patient scored 9 on the GAD-7.',\n",
       " 'Beck Depression Inventory: The patient scored 8 on the Beck Depression Inventory.',\n",
       " 'Suicidal ideation: The patient does not report experiencing suicidal ideation.',\n",
       " 'Dementia: The patient has dementia']"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sentified_topics.sentences.loc[10]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 65,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'inclusion': ['Patient who have been identified as depressed or anxious by a care provider in one of the participating healthcare organizations.'],\n",
       " 'exclusion': ['None '],\n",
       " 'ncd_id': 'NCT05274620',\n",
       " 'patient_id': 6}"
      ]
     },
     "execution_count": 65,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "list(filter(lambda x: x['ncd_id'] == 'NCT05274620',final_results))[0]"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "bd_env",
   "language": "python",
   "name": "bd_env"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.6"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
